WO2010139731A1 - 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES - Google Patents

1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Download PDF

Info

Publication number
WO2010139731A1
WO2010139731A1 PCT/EP2010/057719 EP2010057719W WO2010139731A1 WO 2010139731 A1 WO2010139731 A1 WO 2010139731A1 EP 2010057719 W EP2010057719 W EP 2010057719W WO 2010139731 A1 WO2010139731 A1 WO 2010139731A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
dihydro
imidazo
pyrazol
dimethyl
Prior art date
Application number
PCT/EP2010/057719
Other languages
French (fr)
Inventor
Pascal Furet
Frank Stephan Kalthoff
Robert Mah
Christian Ragot
Frédéric STAUFFER
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010139731(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN201080034616.0A priority Critical patent/CN102574845B/en
Priority to UAA201114398A priority patent/UA106074C2/en
Priority to BRPI1010621A priority patent/BRPI1010621A2/en
Priority to KR1020127000098A priority patent/KR101445458B1/en
Priority to AU2010255727A priority patent/AU2010255727B2/en
Priority to EP10721029A priority patent/EP2438064A1/en
Priority to JP2012513613A priority patent/JP5596137B2/en
Priority to NZ596487A priority patent/NZ596487A/en
Priority to MX2011012943A priority patent/MX2011012943A/en
Priority to SG2011085487A priority patent/SG176572A1/en
Priority to EA201101704A priority patent/EA020715B1/en
Priority to CA2763821A priority patent/CA2763821A1/en
Priority to MA34404A priority patent/MA33332B1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2010139731A1 publication Critical patent/WO2010139731A1/en
Priority to ZA2011/08439A priority patent/ZA201108439B/en
Priority to IL216452A priority patent/IL216452A0/en
Priority to CU2011000221A priority patent/CU24064B1/en
Priority to TNP2011000626A priority patent/TN2011000626A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the invention relates to imidazoquinolinones, salts and prodrugs thereof, processes for their preparation, their use in the treatment of protein or liprd kinase dependent diseases and in particular phosphatidylinositol-3-kinase (PI3K) dependent diseases, their use, either alone or in combination with at least one additional therapeutic agent and optionally in combination with a pharmaceutically acceptable carrier, for the manufacture of pharmaceutical preparations, use of the pharmaceutical preparations for the treatment of protein or lipid kinase dependant diseases and in particular PI3K dependent diseases, and a method of treatment of said diseases, comprising administering the imidazoquinolinones to a warmblooded animal, especially a human
  • the invention also relates to pharmaceutical preparations comprising an imidazoquinolinone of the invention, either atone or in combination with at least one additional therapeutic agent, and optionally in combination with a pharmaceutically acceptable carrier
  • the phosphatidylinositol-3-kinases superfamily comprises 4 different PI3K related lipid or protein kinases Class 1, 11 and III are lipid kinases that differ from their substrate specificities whereas class IV PI3K also called P!3-kinase-related protein kinase (PIKK) are protein kinases Class I phosphatidylinositol-3-kinases comprise a family of lipid kinases that catalyze the transfer of phosphate to the D-3' position of inositol lipids to produce phosphoinositol-3-phosphate (PIP), phosphomositol-3,4-djphosphate (PIP 2 ) and phosphoinositol-3,4,5-triphosphate (PIP 3 ) that, in turn, act as second messengers in signaling cascades by docking proteins containing pleckstrin-homology, FYVE, Phox and other phospholipid-binding domains into a
  • Class IA PI3Ks are heterodimers composed of a catalytic p110 subunit ( ⁇ , ⁇ , ⁇ isoforms) constitutively associated with a regulatory subunit that can be ⁇ 85 ⁇ , p55 ⁇ , p50 ⁇ , p85 ⁇ or p55 ⁇ .
  • the Class IB sub-class has one family member, a heterodimer composed of a catalytic p110 ⁇ subunit associated with one of two regulatory subunits. p101 or p84 (Fruman et al , Annu Rev.
  • the modular domains of the p85/55/50 subunits include Src Homology (SH2) domains that bind phosphotyrosine residues in a specific sequence context on activated receptor and cytoplasmic tyrosine kinases, resulting in activation and localization of Class IA P!3Ks.
  • Src Homology (SH2) domains that bind phosphotyrosine residues in a specific sequence context on activated receptor and cytoplasmic tyrosine kinases, resulting in activation and localization of Class IA P!3Ks.
  • Class IB PI3K is activated directly by G protein-coupled receptors that bind a diverse repertoire of peptide and non-peptide ligands (Stephens et at., Cell 89 105 (1997)); Katso et al , Annu Rev. Cell Dev Biol.
  • Akt the product of the human homolog ⁇ e of the viral oncogene v-Akt, to the plasma membrane where it acts as a nodal point for many intracellular signaling pathways important for growth and survival
  • the tumor suppressor gene PTBN which dephosphorylates phosphoinositides at the 3 1 position of the inositol ring and in so doing antagonizes PI3K activity, is functionally deleted in a variety of tumors in other tumors, the genes for the p110 ⁇ isoform, PIK3CA, and for Akt are amplified and increased protein expression of their gene products has been demonstrated in several human cancers. Furthermore, mutations and translocation of p85 ⁇ that serve to up-regulate the p85-p110 complex have been described in human cancers, Also, somatic missense mutations in PIK3CA that activate downstream signaling pathways have been described at significant frequencies in a wide diversity of human cancers (Kang at al., Proc.
  • the mammalian target of rapamycin is a member of the class IV PI3K.
  • mTOR assembles a signaling network that transduces nutrient signals and various other stimuli to regulate a wide range of cellular functions including cell growth, proliferation, survival, autophagy, vanous types of differentiation and metabolism.
  • the mTOR protein is found complexed in two distinct entities called mTORC1 and mTORC2.
  • the mTORC1 complex that is to say mTOR associated with raptor, has been the matter of numerous studies.
  • mTORC1 that integrates nutrient and growth factor input, and is in turn responsible for cell growth regulation, mainly through protein synthesis regulators such as 4EBP1 or RPS6 Activation of mTORC1 requires input from active PI3K and Akt kinases meamng that mTORC1 is a downstream effector of the PI3K pathway.
  • mTOR when associated in the mTOR complex 2 has been shown to be responsible for the activation of Akt by phosphorylation of S473 (Akt 1 n ⁇ mbe ⁇ ng) (Sarbassov et al., Science 307 7098 (2005)) mTORC2 is hence here considered as an upstream activator of Akt.
  • mTOR can therefore be considered as being important both upstream and downstream of Akt.
  • mTOR can be regarded as a downstream effector and an upstream activator of Akt depending on its association with the mTOCRI and mT0RC2 complex, respectively mTOR catalytic inhibition might therefore represent a unique way of introducing a very strong block in the PI3K-Akt pathway, by addressing both upstream and downstream effectors Syndromes with an established or potential molecular link to deregulation of mTOR kinase activity are, for instance, described in "K. lnoki et al.
  • Organ or tissue transplant rejection e g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants, graft-versus- host disease, such as following bone marrow transplantation;
  • Fibrotic diseases including scleroderma, pulmonary fibrosis, renal fibrosis, cystic fibrosis
  • Wolf-Parkinson-White syndrome • Neurodegenerative disorders such as Parkinson's, Huntingtin's, Alzheimer's and dementias caused by ta ⁇ mutations, spinocerebellar ataxia type 3, motor neuron disease caused by SOD1 mutations, neuronal ceroid lipofucinoses/Batten disease (pediatric neurodegeneration)
  • muscle wasting atrophy, cachexia
  • myopathies such as Danon's disease.
  • Neurofibromatosis including Neurofibromatosis type 1 ,
  • the catalytic inhibition of mTOR Ser/Thr kinase activity or class I PI3 kinases activity and in particular dual class I PI3-kinase(s) and mTOR kinase inhibition is considered to be useful for the treatment of PI3K/Akt/mTOR pathway dependent diseases.
  • inhibitors of class I and/or IV PI3Ks are considered to be of value in the treatment of proliferative disease and other disorders.
  • WO2003/097641 WO2005/054237, WO2005/054238 and WO2006/ 122806 describe imidazoquinolines for use in the treatment of protein kinase dependent diseases.
  • WO 2008/103636 describes imidazoquinolines as dual lipid kinase and mTor inhibitors.
  • imidazoqutnolinones derivatives of the formula (I) given below have advantageous pharmacological properties and inhibit, for example, lipid or protein kinases such as PI4K (phosphatidylinositol 4-kinase) and/or PI3 kinases (phosphatidylinositol 3-kinases).
  • lipid or protein kinases such as PI4K (phosphatidylinositol 4-kinase) and/or PI3 kinases (phosphatidylinositol 3-kinases).
  • inhibition of the PI3K superfamily which comprises PI3Kalpha, PI3Kbeta, PI3Kdelta, PI3Kgamma and mTOR, or one or more of the individual kinase members thereof.
  • the class IV PI3K also called PI3-kinase ⁇ related protein kinase (PIKK) includes DNA-PK, ATM, ATR, hSMG-1 and mTOR.
  • PIKK PI3-kinase ⁇ related protein kinase
  • tmidazoqutnolinones of the formula (I) given below show a high degree of selectivity in favour of one or more of the class I-IV PI3K against other protein kinases, such as the receptor tyrosine kinases and/or the Ser/Thr kinases outside of the PIKK family in the biochemical and/or in the cellular assay.
  • the imidazoquinofinones of the formula (I) preferably display a favourable solubility and/or membrane permeability at physiological pH.
  • the compounds of formula (I) are suitable, for example, to be used in the treatment of diseases dependent on PI3 kinase, especially proliferative diseases such as tumor diseases, leukaemias, and myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia, and proliferative skin diseases including basal cell carcinoma, squamous cell carcinoma and actinic keratosis and other benign hyperproliferative skin disorders caused by inflammation such as psoriasis or as a result of dysregulation of fibroblasts such as skin fibrosis, scleroderma or keloids
  • the present invention provides compounds of the formula (I)
  • X is O or S
  • Y is CH or N
  • R 1 is a substituted or ⁇ nsubstituted 5-membered heteroaryl
  • R 2 is hydrogen, lower alkyl or lower alkenyl
  • R 3 is a substituted or unsubstituted aryl or heterocyclyl
  • R 4 , R 5 and R 6 are hydrogen; or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
  • the present invention is also directed to use of compounds of formula (I) in the treatment of protein and/or lipid kinase dependent diseases; use of compounds of formula (I) for the manufacture of pharmaceutical preparations for the treatment of protein and/or lipid kinase dependent diseases and in particular PI3K superfamiiy (especially class I PI3K and/or mTOR) dependent diseases, methods of treating protein and/or lipid kinase dependant diseases and in particular PI3K superfamiiy (especially class I PI3K and/or mTOR) dependent diseases comprising administering imidazoquinolinone compounds of the formula (I) to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinolinone compound of the formula (I), especially for the treatment of a protein and/or lipid kinase dependant disease and in particular a PI3K superfamilly (especially class I Pl 3K and/or mTOR) dependent disease, a process for the manufacture of the novel
  • any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
  • compounds of any formula given herein may have asymmetric centers and therefore exist in different stereoisomer ⁇ forms such as different enantiomeric forms.
  • at least one asymmetrical carbon atom is present in a compound of the formula I, such a compound may exist in optically active form or in the form of a mixture of optical isomers, e. g. in the form of a racemic mixture.
  • an asymmetric carbon atom may be present in the (R) ⁇ , (S)- or (R, S)- configuration, preferably in the (R)- or (S)-configuration.
  • any given formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisome ⁇ c forms, and mixtures thereof
  • certain structures may exist as geometric isomers (e g. cis and trans isomers), as tautomers, or as atropisomers.
  • the compounds of the invention may thus be present as mixtures of isomers or preferably as pure isomers, preferably as enantiomer-pure diastereomers or pure enantiomers.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 31 P, 32 P. 18 F 35 S, 36 CI, 125 I respectively.
  • isotopically labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H, 13 C, and 14 C are incorporated.
  • Such isotopically labelled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or labeled compound may be particularly preferred for PET or SPECT studies.
  • isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent,
  • the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the moiety for the variable appearing elsewhere.
  • the choice of the species from a specified fist is independent of the choice of the species for the same variable elsewhere in the formula (where one or more up to all more general expressions in embodiments characterized as preferred above or below can be replaced with a more specific definition, thus leading to a more preferred embodiment of the invention, respectively).
  • Salts are preferably the pharmaceutically acceptable salts of compounds of formula (I) if they are carrying salt-forming groups.
  • salts of compounds of formula (I) are preferably pharmaceutically acceptable salts; acids/bases required to form the salts are generally known in the field.
  • Salt-forming groups in a compound of formula (I) are groups or radicals having basic or acidic properties
  • Compounds having at least one basic group or at least one basic radical, e.g., amino, a secondary amino group not forming a peptide bond or a py ⁇ dyl radical may form acid addition salts, e g , with inorganic acids, such as hydrochloric acid, sulfuric acid or a phosphoric acid; or with suitable organic carboxylic or sulfonic actds, e.g , aliphatic mono- or di-carboxylic acids, such as trifluoroacetic acid, acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, f ⁇ maric acid, hydroxymaleic acid, malic acid, tartaric actd, citric acid or oxalic acid
  • Compounds of formula (1) having acidic groups, a carboxy group or a phenolic hydroxy group may form metal or ammonium salts, such as alkali metal or alkaline earth metal salts, e.g., sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, e.g , triethylamtne or tn(2-hydroxyethyl)-amine, or heterocyclic bases, e.g., N-ethyl-piperidine or N,N'-dimethylpiperazine. Mixtures of salts are possible
  • any reference hereinbefore and hereinafter to the free compounds shall be understood as including the corresponding salts, where appropriate and expedient.
  • any reference to a compound of formula (I) is therefore to be understood as referring also to the corresponding solvate and/or hydrate of the compound of formula (I), as appropriate and expedient
  • the present invention also relates to pro-drugs of a compound of formula (I) that convert in vivo to the compound of formula (I) as such Any reference to a compound of formula (I) is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula (I), as appropriate and expedient
  • the prefix “lower” denotes a radical having 1 carbon atom up to and including a maximum of 7 carbon atoms, especially 1 carbon atom up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single- or multiple-branching
  • Halo or halogen is preferably fluoro, chloro, bromo or iodo, most preferably fluoro, chk>ro or bromo
  • Alkyl preferably has 1 up 12 carbon atoms (C 1-12 alkyl) and is linear or branched one or more times, in particular alkyl is lower alkyl, especially C 1 -C 4 alkyl.
  • alkyl includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyi, with particular preference given to methyl, ethyl, n-propyl, iso-propyl, n-butyl and iso-butyl.
  • Lower alkyl for example, is represented as C 1 -C 7 a(kyl, e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl or n-heptyl, lower alkyl is especially represented as C 1 -C 4 alkyl, e.g.
  • Alkyl in particular lower alkyl, is unsubstituted or substituted, preferably by one or more substrtuents independently selected from those mentioned beiow under "substituted"
  • substituents include, but are not limited to hydroxy, alkoxy, aryl, heterocyclyl, cycloalkyl, halogen, amino and nitro
  • An example of a substituted alkyl is halo-alkyl, such as halomethyl. for example fluoromethyl, e g tnfluoromethyl
  • Another example of a substituted alkyl is hydroxymethyl or hydroxyethyl.
  • a further example of a substituted alkyl is alkoxyalkyl, such as methoxyethyl or methoxypropyl.
  • the alkoxyalkyl may be further substituted, for example to give benzyloxyethyl or benzyfoxy propyl
  • Alkyl may also be cyclic as defined below under "cycloalkyl" Cycloalkyl may also be a s ⁇ bstituent to alkyl Cycloalkyl- lower alkyl is preferably lower alkyl that is substituted (preferably terminally) by unsubstituted or substituted cycloalkyl as defined below
  • An example of cycloalkyl as a substituent to alkyl is alkandiyl-cycloalkyl, such as alkandiyl- cyctoloweralkyl, e.g alkandiyi-cyclopropyl e g -CH 2 -cyclopropyl
  • Aryl-lower alkyl is preferably lower alkyl that is substituted (preferably terminally or in 1 -position) by ⁇ ns ⁇ bstituted or substituted aryl as defined below
  • Aryl-lower alkyl is especially phenyl-lower alkyl, such as benzyl (
  • Heterocyclyl-lower alkyl is preferably lower alkyl that is substituted (preferably terminally) by ⁇ ns ⁇ bstituted or substituted heterocyclyl as defined below.
  • alkyl part of other groups like "alkoxy”, “alkoxyalkyl”, “alkoxyalkoxy”, “alkoxycarbonyl”, “alkoxy-carbonylalkyl”, “"alkylsulfonyl", “alkylsulfonamide' , "alkylsulfmyl”, “alkylamino”, “halogenalkyl” shall have the same meaning as described in the above-mentioned definition of "alkyl", including the prefix 'lower', including substitutions thereof.
  • aryMower alkoxy is preferably lower alkoxy that is substituted (preferably terminally on the alkyl part) by unsubstituted or substituted aryl as defined below.
  • Aryl-lower alkoxy is especially phenyl-lower alkoxy. such as phenyl methoxy (i e. benzoxy) or phenyl ethoxy.
  • Alkoxyalkoxy is. for example, methoxyethoxy, or methoxypropoxy, and may include further substitutions e.g. by aryl such as phenyl, for example to give phenylmethoxyethoxy (alternatively stated benzoxy-ethoxy) or phenylmethoxypropoxy (alternatively stated benzoxy-propoxy).
  • Alkandiyl is a straight-chain or branched-chain divalent alky) group It preferably represents a straight-chain or branched-chain Ci.izalkandiyl, particularly preferably represents a straight- chain or branched-chain Ci ⁇ alkandiyl, for example, methandiyl (-CHr), 1 ,2-ethanediyl (-CH 2 - CH 2 -), 1,1-ethanediyl ((-CH(CH 3 )-), 1 ,1-, 1 ,2-, 1 ,3-propanediyl and 1,1-, 1 ,2-, 1 ,3-, 1 ,4- butanediyl, with particular preference given to methandiyl, 1 ,1-ethanediyl, 1 ,2-ethanediyl, 1 ,3- propanediyl, 1 ,4-butanedryl.
  • Ci.izalkandiyl particularly preferably represents
  • Alkenyl is preferably a moiety with one or more double bonds and preferably has 2-12 carbon atoms; it is linear or branched one or more times (as far as possible in view of the number of carbon atoms), Preferred is C 2 -C 7 alkenyl, especially C 3 -C 4 alkenyl, such as allyl or crotyl.
  • -CH CH-
  • -CH C(CH 3 )-
  • -CH CH-CH 2 -
  • -C(CH 3 ) CH-CH 2 -.
  • Alkynyl is preferably a moiety with one or more triple bonds and preferably has 2-12 carbon atoms; it is linear of branched one or more times (as far as possible in view of the number of carbon atoms) Preferred is C 2 -C 7 alkynyl, especially C 3 -C4alkynyl, such as ethynyl or propyn-2-yl Alkynyl can be unsubstituted or substituted, especially by one or more, more especially up to three of the substituents mentioned below under "substituted”.
  • Substituents such as amino or hydroxy (with free dissociable hydrogen) preferably are not bound to carbon atoms that participate at a triple bond, and also other substituents that are not sufficiently stable are preferably excluded.
  • Unsubstituted alkynyl, in particular, C 2 -C 7 alkynyl is preferred.
  • Cycloalkyl is a saturated, monocyclic, fused polycyclic, or spiro polycyclic, carbocycle having from 3 to 12 ring atoms per carbocycle
  • Cycloalkyl is preferably C 3 -C 10 cycloalkyl, and includes cyclo lower alky I, especially cyclopropyt, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; cycloalkyl being unsubstituted or substituted by one or more substituents, especially 1-3 substrt ⁇ ents independently selected from the group consisting of the substituents defined below under "substituted"
  • Cycloalkenyl is preferably C 5 -C 10 cycloalkenyl, especially cyclopentenyl, cyclohexenyl or cycloheptenyl, cycloalkenyl being unsubstituted or substituted by one or more substituents, especially 1-3 substituents, independently selected from the group consisting of the substituents defined below under "substituted”.
  • Aryi refers to an unsaturated carbocyclic aromatic ring system, preferably, having a ring system of not more than 16 carbon atoms, especially not more than 10 carbon atoms, e g having 6 to 16, preferably 6 to 10 ring carbon atoms, is preferably mono- or bi-cyclic, and is unsubstituted or substituted preferably as defined below under "substituted".
  • aryl is selected from phenyl or naphthyl preferably phenyl, and is preferably in each case unsubstituted or substituted with substituents descnbed under "substituted", in particular from the group consisting of halo, especially fluoro, chloro, bromo or iodo.
  • fluoro in particular fluoro, halo-lower alkyl, especially fluoroalkyl, in particular trifl ⁇ oromethyl: hydroxyl, amino, mono or disubstituted amino, especially alkyl-substituted amino, hydroxyalkyl-substituted amino or alkoxyalkyl-substituted amino, e g. dimethyl ammo.
  • cyclopropylaminomethyl cyclopropylaminoethyl, cyclobutylaminomethyl, cyclobutylaminoethyl, cyclopentylaminomethyl or cyclopentylaminoethyl, dicycloalkylaminoalkyl, e g. dicyctopropylaminomethyl, dicyclopropylaminoethyl, cyclopropylcyclobutylaminomethyl or cyclopropylcyclobutylaminoethyl; alkylcycloalkylaminoalkyl, e.g.
  • alkyl-substituted sulfonyl such as methanesulfonyl; sulfonamide, e.g. N-methylsulfonamide (or lower alkylaminosulfonyi or N,N-di-loweralkyl aminos ⁇ lfonyl, e.g methylaminosufonyl or dimethylaminosulfonyl) or pyrrolJdine-1 -sulfonyl; lower alkyl sulfonyl amino, e g methylsulfonytamino; lower alkyl sulfonylalkandiylamino, e g.
  • sulfonamide e.g. N-methylsulfonamide (or lower alkylaminosulfonyi or N,N-di-loweralkyl aminos ⁇ lfonyl, e.g methylaminosufonyl or dimethylaminosulf
  • acylamino e.g. acetylamino
  • acyl lower alkyl amino e.g acetyl methyl amino, (1 ,3]dioxolo, substituted (1 ,3Jdioxolo, e.g.
  • alkoxy carbonyl such as lower alkoxy carbonyl, e.g, methoxycarbonyl
  • carbamoyl substituted carbamoyl, such as alkyl-substituted carbamoyl, e.g. methylcarbamoyl and dimethylcarbamoyl
  • the aryl group may also be substituted with a substituted or unsubstituted heterocycle, preferabely a 4-7 membered ring, e.g.
  • 1 H-tetrazolyl (in particular 1H-tetrazol-5-yl), pyrazol, imidazole, t ⁇ azoie, azetidtnyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, ethylpiperazinyl , triazolonyl or methylimidazoiy!
  • the aryl group may also be substituted with heterocyclyl lower alkyl, heteroaryl or heteroaryi lower alkyl as defined hereinbelow
  • Preferred unsubstituted or substituted aryl is selected from phenyl; hydroxyphenyl, e.g., 2-, 3- or 4-hydroxyphenyl; methoxyphenyl, e.g., 2-, 3- or 4-methoxyphenyl or 3,4-dimethoxyphenyl; ethoxyphenyl, e.g., 2-, 3- or 4-ethoxyphenyl or 3,4-diethoxyphenyl, propoxyphenyl (e.g iso-propoxyphenyl) such as 3-propoxyphenyl (e g 3-iso-propoxyphenyl); methoxy ethoxy-phenyl, e.g.
  • fl ⁇ oro-hydroxy-phenyi such as 3-fluoro- 5-hydroxy-phenyl; hydroxy-haloalkyl-phenyl, e g. hydroxy-fluoroalkyl-phenyl such as 3- hydroxy-5-trifluoromethyl-phenyl; 2,2-difluoro-benzo[1 ,3]dioxo)o, benzene sulfonamide, e g. 3-N-methylbenzenesulfonamide.
  • the nng which is bonded to the rest of the molecule of formula (I) may or may not contain a heteroatom
  • bicyclic heterocyclyl the nng
  • heterocyclyl refers to a heterocyclic radical that is unsaturated ( ⁇ carrying the highest possible number of conjugated double bonds in the ring(s) e.g heteroaryl, for example pyrazolyl, pyridyl, pyrimidinyl), saturated or partially saturated in the bonding ring and is preferably a monocyclic or in a broader aspect of the invention
  • bicyclic ring 1 has 3-16 nng atoms, more preferably 4-10 ring atoms, wherein at least in the nng bonding to the radical of the molecule of formula (I) one or more, preferably 1-4 ring atoms, especially one or two ring atoms are a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, the bonding ring preferably having 4-12 nng atoms, especially 4-7 ring atoms, for example 6-10 ring atoms, especially for heteroaryl, such as 6, 9 or 10 ring atoms
  • the heterocyclyl may be unsubstituted, or substituted by one or more, especially 1-4 substit ⁇ ents independently selected from the group consisting of the substituents defined below under "substituted”; especially being a heterocyclyl radical selected from the group consisting of oxiranyl, azirinyl, 1 ,2-oxathiolanyl, imldazolyl, thienyl, furyl, tetrahydrofuryl, tetrahydrothiophene, indolyl, 1-methyl-2,3-dihydro-1H-mdolyl, 2,3- dihydro-1H-indolyl, 2-oxo-2 3-dihydro-1H-indoly!, azetidinyl, pyranyl, thiopyranyl, isobenzofuranyl, benzofuranyl, chromenyl, 2H-pyrrolyl, pyrrolyl, pyrrolinyl,
  • ammo, cyclic amino such as aziridinyl, azettdinyl or pyrrolidinyl; substituted cyclic amino, e.g hydroxy cyclic amino, ammo-lower alkyl, e.g., aminomethyl, 2-aminoethyl or 3-aminopropyl; alkylamino-lower alkyl, e.g methylaminomethyl, ethylaminomethyl, methylaminoethyl or ethylaminoethyl, dialkylamino-loweraJkyl, e.g.
  • cycloalkylaminoalkyl e.g. cyclopropylaminomethyl, cyclopropylaminoethyl, cyclobutylaminomethyl, cyctobutylaminoethyl, cyclopentylaminomethyl or cycfopentylaminoethyl, dicycloalkylaminoalkyl, e g.
  • alkyl-substituted sulfonyl such as methanesulfonyi, sulfonamide, e.g. N-methylsulfonamide or pyrrolidine- 1 -sulfonyl, alkyisulf any (amino, e g. methylsulfonylamino, alkylsulfonylalkylamino, e g. methylsulfonylmethylamino; acylamino (also termed alkyl carbonyl amino), e g.
  • acetylamino acyl alkyl amino, e g acetyl methyl amino; alkylcarbonylaminoalkyl, e.g. methylcarbonylaminomethyl; alkyt ⁇ minocarbonylaJkyl e g methylaminocarbonylmethyl; alkylcarbonyl-N-alkylamino, e.g.methylcarbonyl-N-methylamino; [1 ,3]dioxolo, substituted [1 ,3]dioxolo, e g. 2,2-difluoro-(1 ,3]dioxolo, alkoxy carbonyl, such as lower alkoxy carbonyl, e.g.
  • carbamoyl also termed aminocarb ⁇ nyl
  • substituted carbamoyl such as alkyl-substituted carbamoyl, e g methylcarbamoyl, ethyl carbamoyl, iso-propyl carbamoyl or alkoxyalkyl-substituted carbamoyl (also termed alkoxyalkylaminocarbonyl), e.g 2- methoxyethylcarbamoyl.
  • the heterocycJe group may also be substttuted with another substituted or ⁇ nsubstituted heterocycle, preferabely a 4-7 membered ring, e g 1 H-tetrazolyl (in particular 1 H-tetrazol-5-yl), pyrazol, imidazole, triazole, azetkjinyl, pyrrolidine, piperazmyl, methylpiperazinyl, ethylpiperazinyl , triazolonyl, methylimidazolyl or morpholino.
  • the heterocycle group may also be substituted with heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein
  • the heterocyclyl may be unsubstituted, or substituted by one or more, especially 1-4 substrtuerrts independently selected from the group consisting of the substituents defined below under "substituted", especially being a heterocyclyl radical selected from the group consisting of oxiranyl, azirmyl. 1 ,2-oxathiolanyl.
  • fluoro or chloro in particular fluoro, halo-lower alkyl, especially fluoroalkyl, in particular trifluoromethyl, hydroxyl, ammo, mono or disubstituted amino, especially alkyl-substituted amino, hydroxyalkyl-substituted amino or alkoxyalkyl-substituted amino, e g.
  • dimethylaminomethyl dimethylaminoethyl, methylethylaminomethyl, methylethylaminoethyl, diethylaminomethyl or diethylaminoethyl, cycloalkylaminoalkyl, e.g cyctopropylamlnomethyl, cyclopropylaminoethyl, cyclobutylaminomethyl, cyclobutylaminoethyl, cyclopentylaminomethyl or cyclopentylaminoethyl, dicycloalkylaminoalkyl, e.g.
  • dicyclopropylaminomethyl dicyclopropylaminoethyl, cyclopropylcyclobutylaminomethyl or cyclopropylcyclobutylaminoethyl, alkylcycloalkylaminoalkyl.
  • 2-amidino-ethyt, or N-hydroxyamid»no-lower alkyl e g., 2-(N ⁇ hydroxyamidino)-ethyl, nhro- carboxylic acid, substituted sulfonyl, e g alkyl-substituted sulfonyl, such as methanesulfonyl, sulfonamide e g N-methylsulfonamide or pyrrolidine- 1- sulfonyl, alkylsulfonylamino, e.g methylsulfonylamino, alkylsulfonyJalkylamino, e.g methylsulfonylmethylamino, acylamtno, e g.
  • acetylamino acyl alkyl amino, e g. acetyl methyl amino, [1,3]dioxolo, substituted [1 ,3)dioxok>, e g 2,2-difluoro-[1,3]dioxolo, alkoxy carbonyl, such as lower alkoxy carbonyl, e.g methoxycarbonyl, carbamoyl, substituted carbamoyl, such as alkyl-substituted carbamoyl, e g.
  • the heterocycle group may also be substituted with another substituted or unsubstituted heterocycle, preferabely a 4-7 membered ring, e g. 1 H-tetrazolyl (in particular 1H-tetrazol-5-yl), pyrazol, imidazole, t ⁇ azole, azetidinyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, ethylp ⁇ erazinyl triazolonyl or methylimidazolyl
  • the heterocycle group may also be substituted with heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein.
  • heterocyclic groups which may be substituted or unsubstituted, include indolyl, 1-methyl-2,3-dihydro-1H-indolyl, 2-oxo-2,3-dihydro-1H-indolyl, pyridyl pyrimidinyl, 1 H-pyrrolo[2,3-blpyridinyl, 1-methyl-1H-pyrrolo(2,3-b]pyridinyl, pyrazolyl, pyrazinyl, quinolyl, quinoxalyl, 1,3-Dimethyl-2-oxo-2,3-dihydro-1 H-imidazo[4,5-b]pyrid)nyl, 2- oxo-2,3-dihydro-1H-tmidazo[4,5-bJpyridSny ⁇ ( 1-ethyl-3-methyl-2-oxo-2,3-dihydro-1H- imidazo ⁇ 4,5-b ⁇ pyridinyl, 1-(
  • heterocyclic groups each of which may be substituted or unsubstituted, include 1-methyl-2,3 ⁇ dihydro-1H-indolyl, 2-oxo-2,3-dihydro-1 H- indolyl, pyridyl, pyrimidinyl, 1H-pyrro)o ⁇ 2,3-b]pyridinyl, 1-methyl-1 H-pyrrolo[2,3-b]pyridinyl, pyrazolyl, pyrazinyl, q ⁇ inolyl, 1 ,3-Dimethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyndinyl, 2- oxo-2,3-dihydro-1 H-imidazo[4,5-b]pyridinyl, i-ethyl-S-methyl ⁇ -oxo ⁇ .S-dihydro-1H- imidazo(4,5-b]pyridinyl, 1-(
  • heterocyclic groups which may be substituted or unsubstituted, include indolyl 1-methyl-2,3-dihydro-1H-indolyl, 2-oxo-2,3-dihydro-1H-indolyl, pyridyl, pyrimidinyl.
  • 1 H-pyrrolo[2,3-b]pyridinyl 1 -methyl- 1H-pyrrolo[2,3-b]pyridiny I
  • pyrazolyl pyrazinyl
  • quinolyl quinoxalyl
  • unsubstituted or substituted heterocyclyl is selected from pyndyl, alkylpyridyl, in particular lower-alkylpyridyl, e g methylpyridyl, e g , 2-, 3- or 4-methylpyrkJyl especially 2-methylpyridyl or 3-methylpyridyl; alkoxypyridyl, in particular lower-alkoxypyridyl, e.g.
  • methoxypyridyl e g , 2-, 3- or 4-methoxypyridyl, especially 2-methoxypy ⁇ dyl or 3- methoxypyridyl or di-methoxypyridyl, e g, 2,3-dimethoxypyi ⁇ dyi, or ethoxypyridyl, e g., 2-, 3- or 4-ethoxypyridyl especially 2-ethoxypyridyl or 3-ethoxypyridyl or di-ethoxypyridyl e.g.
  • 2,3- diethoxypyridyl, or propyloxypyridyl e.g., 2- or 3-propyloxypyridyl or isopropyloxypyridyt, e.g., 2- or 3-isopropyloxypyridyl; cycloalkyloxypyridyl, e.g. 2- or 3-cyclob ⁇ tyloxypyridyl; (haloalkoxy)pyridyl e.g.
  • alkoxyalkoxypyridyl in particular methoxyethoxypyridyl, e.g. 2 or 3- methoxyethoxypyridyl; (alkyl)(alkoxyalkoxy)pyridyl, e.g. (methyl)(methoxyethoxy)pyridyl; benzyloxyalkoxypyridyl, in particular benzyloxyethoxypyridyl or benzyloxypropoxypyridyl, e.g.
  • hydroxymethylpyridyl especially 2-(hydroxymethyl)-pyridyl
  • alkoxycarbonylpyridyl e.g. methoxycarbonylpyridyl, especially 2-methoxycarbonyl-pyridyl
  • aminopyridyl e.g. 2- or 3- aminopyridyt
  • alkylaminopyridyl in particular loweralkylaminopyridyl, e.g. 2-, 3- or 4- methylaminopyridyl, especially 2- or 3-methylaminopyridyl.
  • 2-, 3- or 4-ethylaminopyridy especially 2- or 3-ethylaminopy ⁇ dyl, e.g.
  • dialkylaminopyridyl in particular di- loweralkylaminopyridyi, e.g. 2-, 3- or 4-dimethylaminopyridyl, especially 2- dimethylaminopyridyl or 2-, 3- or 4-diethylaminopyridyl. especially 2-or 3-diethylaminopyridyl or e.g. 2-, 3- or 4-ethylmethylaminopyridyl especially 2-ethylmethylaminopyridyl or 3- ethylmethylaminopyridyl or e.g.
  • 2-, 3- or 4-isopropylmethylaminopyridyl especially 2- isopropylmethylaminopyridyl or 3-isopropylmethylaminopyridyl; cycloafkylaminopyridyi, e.g. cyclobutylaminopyridyl; (N-alkyl-N-cycloafkylamino)pyridyl, e.g. (N-methyl-N- cyciob ⁇ tylamino)pyrk.yl; (alkyl)(amino)pyridyl, e.g.
  • (loweralkyl) ⁇ amino)pyridyl in particular (methyl)(amino)pyridyl such as 2-methyl-3-amino-pyridyl or (ethyl)(amino)pyridyl such as 2- ethyl-3-amino-pyrJdyi; (halo)(amino)py ⁇ dyl, e.g. (fluoro)(amino)pyridyl or (chloro)(amino)pyridyl; (halo)(alkylamino)pyridyi, e g.
  • (methyl)(ethylamino)pyridyl such as 2-methyl-3-ethylamino-pyridyl or (methy!)(methylamino)pyridyl such as 3-methyl-2-methy)amir ⁇ )-pyridyl or (ethyl)(ethylamino)pyrtdyl such as 2-ethyl-3-ethylamino-py ⁇ dyl or (ethyl)(isopropylamino)pyridyl such as 2-ethyl-3-isopropylamino-pyridyl; (alkyl)(di- alky)amino)pyridyl, e.g (methyl)(N-methyl-N-ethylamino)pyridyl such as 2-methyt-3-(N- methyl-N-ethylamino)-pyridyl or (methylKN.N-dimethylaminoJpyndy
  • azetidinylpyridyl especially 2-azetdin-1- yt-pyridyl or pyrrolidinylpyridyl, especially 2-py ⁇ olidin-2-yipyridyl; cyclic ether-substituted amino-pyridyl, e.g. tetrahydro-pyranytamino-pyridyl, hydroxy-cycloaminopy ⁇ dyl, e.g.
  • hydroxy- pyrrolidinylpyridyl loweralkoxy-cycloaminopyridyl, e g methoxy-pyrrolidinylpyridyl; hydroxyalkylaminopyridyl, e g. 2-(2-hydroxyethylamino)-pyridyl; (afkyl)(hydroxy)pyridyl, e.g. 2-(methyl)-3-(hydroxy)-pyridyl or 2- ⁇ ethyl)-3-(hydroxy)-py ⁇ dyl; (hydroxyalkyl)(alkylamino)pyridyl, e.g.
  • cyanopropylpyridyf cyanocycloalkylpyridinyt, e.g. cyanocyclob ⁇ tylpyridy!
  • halopyridyl in particular fluoropyridyl, especially 2-ftuoropyridyl, halo-alkoxy-pyridyl, e g.
  • fluoro-methoxy- pyridyl such as 3-fluoro-2-methoxy-py ⁇ dyl
  • carbamoylpyridyl especially 2-(carbamoyl)pyridyl
  • alkyl-substituted carbamoyl e.g methylcarbamoyl, especially 2-(methylcarbamoyl)pyridyl
  • piperazinylpy ⁇ dyl e.g. 1-piperazinylpyndyl, N-alkylpiperazinylpyridyl, e.g N- methylpiperazinylpyridyl
  • alkyls ⁇ lfonamidopyridyl e.g.
  • pyrimidinyl loweralkylaminopyrimidinyl, e.g 2- or 4-methylaminopyrimidinyl or 2- or 4- ethylaminopy ⁇ midinyl; di-loweralkylarrunopyrimidinyl, e g 2- or 4- methyfethylaminopyrimtdinyl, 2- or 4-dimethylaminopyrimidinyl, especially 2- dimethylaminopyrimidinyl, alkoxypyrim ⁇ Jinyl, in particular methoxypy ⁇ midinyl or ethoxypyrimidinyl, e.g. 2-methoxypyrimidinyl or 2-ethoxypyrimidinyl.
  • di-alkoxypyrimidinyl e g 2,4-dimethoxypyrimidiny
  • (alkylamino)(alkoxy)pyrimidinyl e.g. (methylamino)(methoxy)pyrimidinyl or (ethylamino)(methoxy)pyrimidinyl
  • cycloaminopyrimtdinyl e g pyrrolidinylpy ⁇ midinyl
  • aminopyrimfdinyl in particular 2- aminopyrimidinyl
  • alkylaminopyrimidinyl e g.
  • unsubstituted or substituted heterocyclyl is selected from pyndyl; alkylpyridyl, >n particular tower-alkylpyridyl, e.g. methylpyndyl, e g., 2-, 3- or 4-methylpyridyl, especially 2- methylpyndyl or 3-methylpyridyl, alkoxypyridyl, in particular lower-alkoxypyndyl, e g methoxypyridyl, e.g , 2-, 3- or 4-methoxypyridyl, especially 2-methoxypyridyi or 3- methoxypyndyl or di-methoxypyridyl, e.g.
  • 2,3-dimethoxypyrfdyl or ethoxypyridyl, e.g., 2-, 3- or 4-ethoxypyridyl especially 2-ethoxypyridyl or 3-ethoxypyridyl or di-ethoxypy ⁇ dyl e.g.
  • 2,3- diethoxypyridyl, or propyloxypyridyl e g., 2- or 3-propyloxypyridyl or isopropyloxypyridyl, e.g., 2- or 3-isopropyloxypyridyl; cycloalkyloxypyridyl, e g 2- or 3-cycJobutyloxypyridyl; cycloalkylalkoxypyridyl, e g. cyclopropylmethoxy-pyridyl, e.g.
  • benzyloxypropoxypyridyl e.g 2-benzyloxyethoxypyridyl or 3-benzyfoxypropoxypyridyl
  • hydroxyalkylpyridyl e.g 2 or 3-(2-hydroxyethyl)-pyridyl
  • alkyl- sulfonyl pyrtdyl e.g, methanesulfonylpyridyl, especially 3-methanesulfonylpyrtdyl, hydroxyalkoxypyridyl, e g.
  • 2-, 3- or 4-methylaminopyridyl especially 2- or 3- methylaminopyridyl, 2-, 3- or 4-ethylaminopyridyl, especially 2- or 3-ethyfaminopyridyl, e.g 2- or 3- (1- or 2 ⁇ propyl)aminopyndyl, dtalkylaminopy ⁇ dyl, in particular di- loweralkylaminopy ⁇ dyl, e g 2- 3- or 4-dimethylaminopyridyl, especially 2- dimethylaminopyrtdyl, cycloamfnopy ⁇ dyl, e g azetidinylpy ⁇ dyl especially 2-azetidin-1-yl- py ⁇ dyl or pyrrolidinylpyridyl, especially 2-pyrrof idin-2-ylpyrrdyl , hydroxyalkylaminopyridyl, e g 2-
  • 5-membered heteroaryl refers to aromatic 5-membered heterocyctyl °5-membered ' meaning that there are 5 nng atoms, one or more being a heteroatom, such as nitrogen, oxygen or sulfur, and, for example includes monocyclic rings, such as thienyl, furyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl isoxazolyl, oxadsazoiyl, t ⁇ azolyl imidazolyl tetrazolyl or thiadiazolyl, preferably pyrazolyl, each being unsubstituted or substituted with 1 to 3 substituents
  • 5-membered heteroaryl refers to pyrazolyl or isoxazolyl, each being unsubstituted or substituted with 1 to 3 substituents
  • 5-membered heteroaryl as defined above refers to pyrazolyl, which is unsubstituted or substituted with 1 to 3 substituents
  • Substituted wherever used for a moiety, means that one or more hydrogen atoms in the respective moiety, especially up to 5 hydrogen atoms, more especially up to three of the hydrogen atoms are replaced independently of each other by a corresponding number of substituents, which preferably are independently selected from the group consisting of lower alkyl e g , methyl, ethyl, isopropyl or propyl, halo, e g F, Cl, Br or I 1 halo-lower alkyl, e g , fl ⁇ oroalkyl, such as trifluoromethyl; hydroxy; carboxy; fower alkoxy, e g., methoxy, ethoxy, propyloxy or isopropyloxy; aryl-lower alkyl, e.g phenyl-lower alkyl; aryl-lower alkoxy, e g.
  • alkylamino-lower alkyl e.g , aminomethyl, 2-aminoethyl or 3- aminopropyl, alkylamino-lower alkandiyl; dialkylammo-lower alkandiyl; ⁇ Mower alkylamino, N,N-di-lower alkylamino, amino lower alkoxy, iower alkanoylamino, lower alkanoyl- lower alkyl-amino; benzoylamino; carbamoyl-lower alkoxy; A/-lower alkylcarbamoyl-lower alkoxy or N,N-di-lower alkylcarbamoyl-lower alkoxy; amidino; N-hydroxy-amidino; hydroxylamine; alkoxyamino; nitro; g ⁇ anidino, amidino-lower alkyl, e.g , aminomethyl, 2-aminoethyl or 3- amino
  • R 8 and Rg can be the same or different and are independently H; lower alkyl, e g , methyl, ethyl or propyl, lower cycloalkyl, e g , cyclopropyt. or
  • R 8 and R 9 together with the N atom, form a 3- to 8-membered heterocyclic nng containing 1-4 nitrogen, oxygen or sulfur atoms, e g , azetidinyl, pyrrolidinyl, piperidino, morpholinyl, imidazolinyl, piperazinyl or lower alkyl-piperazinyl.
  • Substituted also includes amino-carbonyl-lower alkyl, e g , R 8 R 9 N-C(O)-CH 2 -, wherein R 8 and R 9 are as defined above "Substituted” also includes heterocyclyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkoxy or heterocyclyl-lower alkanesulfanyl, wherein the heterocyclyl in each case is a substituted or unsubstituted 3- to 8-membered heterocyclic nng containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazolyl, imidazolinyl, pyrrolidinyl, morphoJinyl, azetidinyl, pyndyt, pyrazolyl piperidino, piperidyl, piperazinyl or lower alkyl-piperazinyl.
  • Substituted also includes C 3 -Ci 0 cycloall ⁇ yl, e g , cyclopropyl or cyclohexyl, hydroxyC 3 - C ⁇ cycloalkyl, e.g., hydroxy-cyclohexyl; heteroaryl with 4 or 6 ring atoms and 1-4 ring heteroatoms selected from O 1 N and S, especially furyl, 1 ,4 oxazinyl, or pyridyl.
  • Substituted also includes -NR 9 R 9 , wherein R 8 and R 9 can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or the R 6 and R 9 can, with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., azetidinyl, pyrrolidinyl, piperidino, morpholinyl, imidazolinyl, piperazinyl or lower alkyl-piperazinyl.
  • R 8 and R 9 can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or the R 6 and R 9 can, with the
  • the present invention provides compounds of the formula (I)
  • X is O or S
  • Y is CH or N 1
  • R 1 is a substituted or ⁇ nsubstituted 5-membered heteroaryl
  • R 2 is hydrogen or lower alkyl
  • R 3 is a substituted or unsubstituted aryl or heterocyclyl.
  • R 4 , R 5 and R° are hydrogen
  • substituents are only bound at positions where chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without inappropriate effort, which substitutions are possible and which are not
  • amino or hydroxy groups with free hydrogen may be unstable if bound to carbon atoms with unsaturated, e.g., olefinic, bonds.
  • treatment refers to the prophylactic or preferably therapeutic including, but not limited to, palliative, curing, symptom-alleviating, symptom-reducing, kinase-regulating and/or kinase-inhibiting, treatment of said diseases, especially of the diseases mentioned below
  • use is mentioned (as verb or noun) (relating to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof)
  • this includes any one or more of the following embodiments of the invention, respectively, the use in the treatment of a protein or lipid kinase dependant disease and in particular PI3K dependent disease, the use for the manufacture of pharmaceutical compositions for use in the treatment of a protein or lipid kinase dependant disease and in particular PI3K dependent disease, methods of use of one or more compounds of the formula (I) in the treatment of a protein or lipid kinase dependant disease and in particular PI3K dependent disease, the use of pharmaceutical preparations
  • the compounds of formula (I) have valuable pharmacological properties and are useful in the treatment of lipid and/or protein kinase dependent diseases, e.g , as drugs to treat proliferative diseases
  • the invention relates to a compound of the formula (I), in e.g free base form or in acid addition salt form, wherein the substituents are as defined herein Detailed Description of the Invention
  • R 1 is a 5-membered heteroaryl having the appropriate corresponding meaning as for heteroaryl given above, with "5-membered” meaning that there are 5 ring atoms, one or more being a heteroatom, such as nitrogen, oxygen or sulfur
  • Such 5-membered heteroaryl groups include monocyclic rings, such as pyrazolyl, thienyl, furyl, pyrrolyl, thiazolyl, «othiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, tnazolyl, imidazolyl, tetrazolyl or thiadiazolyl, preferably pyrazolyl, each being unsubstituted or substituted, e.g. by the groups listed herein under "substituted * '
  • R 1 is pyrazolyl or isoxazolyl, each being unsubstituted or substituted, e g by the groups listed herein under "substituted".
  • R 1 is unsubstituted or substituted pyrazolyl or unsubstituted or substituted isoxazolyJ
  • the pyrazolyl is substituted, preferably by one, two or three substituents and the isoxazolyl is substituted, preferably by one or two substituents, wherein in each case, said substituents may for example be independently selected from halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamino, unsubstituted or substituted alkoxy lower alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl.
  • R' is unsubstituted isoxazolyl.
  • R 1 is isoxazolyl substituted by one or two substituents selected from halo, lower alkyl, unsubstituted or substituted lower alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted lower alkoxy, substituted or unsubstituted lower alkyl amino, hydroxy or amino
  • R 1 is isoxazolyl substituted by one or two substituents selected from halo, unsubstituted or substituted lower alkyl, unsubstituted or substituted lower atkenyl, unsubstituted or substituted lower alky ⁇ yl, u ⁇ substituted or substituted cycloalkyl, hydroxy or ammo
  • R 1 is isoxazolyl substituted by one or two substituents selected from unsubstituted lower alkyl, unsubstituted lower alkenyl, unsubstituted alkynyl, unsubstituted cycloloweralkyl, hydroxy or amino
  • R 1 is isoxazolyl substituted by one or two, same or different, unsubstituted lower alkyl substituents (in particular C 1 -C 4 alkyl) such as methyl or ethyl, preferably methyl.
  • R 1 when R 1 is unsubstituted or substituted isoxazolyl, said isoxazolyl is tsoxa2ol-3-yl, isoxazol-4-yl or isoxazol-5-yl.
  • a substituent of said substituted isoxazolyl is bonded to the isoxazolyl ring at the alpha position to the ring atom which bonds the isoxazolyl ring to the rest of the molecule (that is, the alpha position is at a position on the isoxazolyl ring which is next to the isoxazolyl ring atom which is bonded to the imidazoquinolinone part of the molecule).
  • the isoxazolyl ring atom which is bonded to the rest of the molecule is a carbon atom
  • prefered isoxazolyl groups are alpha-substituted isoxazolyl
  • the ring atom at the alpha position may be a carbon, nitrogen or oxygen ring atom, with at least one atom in the alpha position being a carbon atom, but, for chemical valency reasons, only an alpha carbon atom may be substituted
  • An embodiment of the invention includes compounds of formula (I) wherein R 1 is unsubstituted or substituted isoxazol-4-yl, thus R 1 in this embodiment is represented by a group of formula (AB).
  • the curved line indicates the bonding position to the rest of the molecule and the alpha position is shown by the atoms labeled with a * symbol and
  • R 18 and R 17 are independently selected from hydrogen, halo, unsubstituted or substituted lower alkyl (especially C 1 -C 4 alkyl), unsubstituted or substituted lower alkenyl, unsubstituted or substituted lower alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or s ⁇ bstituted lower aikylamino, unsubstituted or substituted cycioalkyl or unsubstituted or substituted cycloalkenyl
  • R 1 ⁇ and R 17 are independently selected from hydrogen, halo or unsubstituted or substituted lower alkyl (especially C 1 -C 4 alkyl) such as methyl or ethyl
  • R 16 and R 17 are independently selected from hydrogen, methyl or ethyl.
  • At least one of R 16 and R 17 Is not hydrogen.
  • R 1 is of formula (AB) shown above, and
  • R 16 is C 1 -C 4 alkyl (especially methyl or ethyl).
  • R 17 is C 1 -C 4 alkyi (especially methyl or ethyl);
  • R 1 is of formula (AB) shown above, and
  • R 16 and R 17 are each methyl.
  • R 1 is unsubstrtuted or substituted pyrazolyl.
  • the pyrazolyl is substituted, preferably by one, two or three substituents, wherein said substituents may for example be independently selected from halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower aikylamino, urtsubstttuted or substituted alkoxy lower alkyl.
  • unsubstituted or substituted cycloalkyl unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycioalkenyl, unsubstituted or substituted carbamoyl lower alkyl, lower mono- and di-alkyl carbamoyl lower alkyl, unsubstituted or substituted cycloaminocarbonyl lower alkyl, unsubstituted or substituted heterocyclylcarbonyl lower alkyl, unsubstituted or substituted hydroxy! lower alkyl, unsubstituted or substituted carboxy lower alkyl, halo-loweralkyl, hydroxycarbonyl- loweralkyl, morpbolinecarbonylalkyl, hydroxy or amino
  • Preferred substituents are selected from the group consisting of halo, lower alkyl, lower alkenyl, lower alkynyl, cycloloweralkyl, hydroxy, amino, halo lower alkyl, 2-hydroxyethyl, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CHr), dialkylaminocarbonylmethyl e.g. dimethylaminocarbonyimethyl (Me 2 NC(O)CH?-) or ethylmethylaminocarbonylmethyl
  • the substituent if mono-substituted or at least one of the substituents (if two or three substituents are present) is bonded to the pyrazole ring at the alpha position to the ring atom which bonds the pyrazole ring to the rest of the molecule (that is, the alpha position is at a position on the pyrazole ring which is next to the pyrazole ring atom which is bonded to the imidazoquinolinone part of the molecule)
  • the pyrazole ring atom which is bonded to the rest of the molecule i.e the imidazoquinolinone part
  • pyrazolyl groups are alpha-substituted pyrazolyl
  • the ring atom at the alpha position may be a carbon or nitrogen ring atom
  • an embodiment of the invention includes compounds of formula (I) wherein R 1 is a group selected from'
  • the curved line indicates the bonding position to the rest of the molecule and the alpha position is shown by the atoms labeled with a * symbol, and
  • R 10 is independently selected from hydrogen, uns ⁇ bstituted or substituted lower alky I, unsubstituted or substituted lower alkenyl, unsubstituted or substituted alkyny), unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyi, unsubstituted or substituted lower alkoxy, substituted or unsubstituted lower alkyt amino, hydroxy or amino.
  • R 10 is independently selected from hydrogen, unsubstituted or substituted lower alkyl, unsubstituted or substituted lower alkenyl, unsubstituted or substituted lower alkynyl, unsubstituted or substituted cycloalkyl, hydroxy or amino
  • R 10 is independently selected from hydrogen, unsubstituted lower alkyl, unsubstituted lower alkenyl, unsubstituted alkynyl, uns ⁇ bstituted cycloloweralkyl, hydroxy or amino
  • R 10 is independently selected from hydrogen or lower alkyl such as methyl or ethyl
  • R 1 ' is independently selected from hydrogen, halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl.
  • unsubstituted or substituted alkynyl unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamino, unsubstttuted or substituted afkoxy lower alkyl, unsubstituted or substituted cycloalkyl or unsubstituted or substituted cycloalkenyl; unsubstituted or substituted carbamoyl lower alkyl, lower mono- and di-alkyl carbamoyl lower alkyl; unsubstituted or substituted cycloaminocarbonyl lower alkyl; unsubstituted or substituted heterocyclylcarbonyl lower alkyl.
  • R 11 is independently selected from hydrogen, unsubstituted or substituted lower alkyl such as methyl, ethyl, propyl, isopropyl, halo lower alkyl such as trifluoromethyl, hydroxyl lower alkyl such as hydroxyl ethyl, alkoxy lower alkyl such as methoxyethyl, carbamoyl lower alkyl such as carbamoylmethyl, lower mono- or di-alkyl carbamoyl lower alkyl such as methylcarbamoylmethyl, ethylcarbamoylmethyl, dimethylcarbamoylmethyl, ethylmethylcarbamoylmethyl or diethylcarbamoylmethyl; cycloaminocarbonyl lower alkyl such as azetidinylcarbonylmethyl; or carboxy lower alkyl such as carboxy methyl.
  • halo lower alkyl such as trifluoromethyl
  • R 11 is independently selected from hydrogen, lower alkyl such as methy), ethyl, propyl, isopropyl or halo tower alkyl such as trifluoromethyl.
  • R 11 is independently selected from hydrogen, methyl, ethyl or trifluoromethyl.
  • R 14 is independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted hydroxyl lower alkyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamino, unsubstituted or substituted alkoxy lower alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl; unsubstituted or substituted carbamoyl lower alkyl; lower mono- or di-alkyl carbamoyl lower alkyl; unsubstituted or substituted cycloaminocarbonyl lower alkyl, unsubstituted or substituted heterocyclylcarbonyl lower alkyl, unsubstituted or substituted carboxy lower alkyl,
  • R 14 is independently selected from hydrogen or unsubstituted or substituted lower afkyl such as unsubstituted or substituted hydroxyl lower alkyl; unsubstituted or substituted alkoxy lower alkyl; unsubstituted or substituted carbamoyl lower alkyl, lower mono- or di-alkyl carbamoyl lower aikyi; unsubstituted or substituted cycloaminocarbonyl lower alkyl, unsubstituted or substituted heterocyclylcarbonyl lower alkyl, unsubstituted or substituted carboxy lower alkyl
  • R 14 is independently selected from hydrogen, unsubstituted lower alkyl such as methyl, ethyl, propyl or isopropyl, hydroxyl lower alkyl such as hydroxyl ethyl; alkoxy lower alkyl such as methoxyethyl 1 carbamoyl lower alkyl such as carbamoylmethyl; lower mono- or di-alkyl carbamoyl lower alkyl such as methylcarbamoylmethyl, ethylcarbamoylmethyl, dimethylcarbamoylmethyl, ethylmethylcarbamoylmethyl; diethylcarbamoylmethyl or (methoxyethyl)(methyl)carbamoylmethyl, cycloaminocarbonyl lower alkyl such as azetidinylcarbonylmethyl, unsubstituted or substituted heterocyclyicarbonyl lower alkyl such as morpholinecarbonyl lower alkyi
  • R 14 is independently selected from hydrogen, unsubstituted or substituted C r C 4 alkyl, unsubstituted or substituted haloC 1 -C 4 alkyl, 2-hydroxyethyl, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CH 2 -).
  • dialkylaminocarbonylmethyl e.g dimethylaminocarbonylmethyl (Me 2 NC(O)CH 2 -) or ethylmethylaminocarbonylmethyl (EtMeNC(O)CH 2 -), (methoxyethyl)(methyl) aminocarbonylmeihylmethyl ((MeOEt)(Me)NC(O)CH?-), azetidinylcarbonylmethyl e g. 2-azetidin-1-yl-2-oxo-ethyl, morpholinecarbonylmethyl e g 4-morpholinecarbonylmethyl, (4-methylpiperazin- 1yl)carbonylmethyl
  • R 14 is independently selected from hydrogen, methyl, ethyl, isopropyl, tnfluoromethyl, 2-hydroxyethyt, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CH r ), dimethylaminocarbonylmethyl (Me 2 NC(O)CH 2 -), ethylmethylaminocarbonylmethyl (EtMeNC(O)CH 2 -), (methoxyethyl)(methyl) aminocarbonylmethylmethy!
  • R 13 and R 1S are independently selected from hydrogen, halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamino, unsubstituted or substituted cycloalkyl or unsubstttuted or substituted cycloalkenyl
  • R 12 , R 13 and R 15 are independently selected from hydrogen, halo such as fluoro, chloro, bromo, or unsubstituted or substituted lower alkyl such as methyl or ethyl
  • R 12 , R 13 and R 15 are independently selected from hydrogen, chloro, methyl or ethyl
  • one of R 10 and R 12 is not hydrogen
  • At least one of R 13 and R 15 is not hydrogen
  • R is of formula (A) or (8) shown above; and R 10 is d-dalkyl (especially methyl or ethyl);
  • R 11 is hydrogen or d-dalkyl (especially methyl) or fluoroCt -Chalky I (especially trifluoromethyl), and
  • R 1? is hydrogen or d-dalkyl (especially methyl);
  • R 13 is hydrogen or d-dalkyl (especially methyl);
  • R 14 is d-dalkyl (especially methyl, ethyl or isopropyl), 2-hydroxyethyf, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CH 2 -), dimethylaminocarbonylmethyl (Me 2 NC(O)CH 2 -), diethylaminocarbonylmethyl (Et 2 NC(O)CH 2 -).
  • R 15 is methyl or chloro
  • R 1 is of formula (A) shown above, and
  • R 10 is d-dalkyl (especially methyl or ethyl);
  • R 1 t is hydrogen or d-dalkyl (especially methyl) or fluoroCrdalkyl (especially trifluoromethyl), and
  • R 12 is hydrogen or d-dalky! (especially methyl)
  • R 1 is of formula (B) shown above;
  • R 13 is hydrogen or d-dalkyl (especially methyl);
  • R 14 is d-dalkyl (especially methyl, ethyl or isopropyl), 2-hydroxyethyl, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CH 2 -), dimethylaminocarbonylmethyl (Me 2 NC(O)CH 2 -), ethylmethylaminocarbonylmethyl (EtMeNC(O)CH 2 -), (methoxyethyl)(methyl) aminocarbonylmethylmethyl ((MeOEt)(Me)NC(O)CH*-), 2 ⁇ azetidin-1-yl-2-oxo-ethyl, 4- morpholinecarbonylmethyl and (4-methylpiperazin-1yl)carbonylmethyl, and
  • R 15 is methyl or chloro.
  • R 1 is selected from 1 ,5-dimethyl-1H-pyrazol-4-yl, 2-ethyl-2H-pyrazol-3-yl, 2-methyl ⁇ 2M-pyrazol-3-yl, 2,5-dimethyl-2H-pyrazol-3-yl ) 1-isopropyl-3-methyl-1H-pyrazol-4-yl, 1-ethyl-3-methyl-1H-pyrazol-4-y1, 2,4-dimethyl-2H-pyrazol-3-yl, 1 ,3-dimethyl-1H-pyrazol-4-yl, 1,3,5-trimethyf-1 H-pyrazol-4-yl, 2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl 1-hydroxycarbonyl methyl-3-methyl-pyrazol-4-yl, 1 -dimethylaminocarbonylmethyl-S-methyl-pyrazoM-yl, 1 - dimethylaminocarbonylmethyl-3,5-dimethyl-pyra
  • R 1 is selected from 1,5-dimethyl-1 H-pyrazol-4-yl, 2-ethyl-2H-pyrazol- 3-yl, 2-methyl-2H-pyrazol-3-yl, 2,5-dimethyl-2H-pyrazol-3-yl, 1-isopropyl-3-methyl-1H- pyrazol-4-yl, 1-ethyl-3-methyl-1 H-pyrazol-4-yl, 2,4-dimethyl-2H-pyrazol-3-yl, 1 ,3-dimethyl-1H- pyrazol-4-yl, 1 ,3,5-trimethyl-1 H-pyrazol-4-yl, 2-methyl-5-trifluoromethyt-2H-pyrazol-3-yl,1- hydroxycarbonylmethy)-3-methyl-pyrazol-4-yl, i-dimethylaminocarbonylmethyl-3-methyl- pyrazol-4-yl, 1-dimethylaminocarbonylmethyl-3,5-dimethyl
  • R 2 is preferably selected from hydrogen, Ct-C 4 alkyl or d-C ⁇ alkenyl.
  • R 2 is selected from hydrogen, methyl, ethyl and propeny! (especially propen-3-yl)
  • R 2 is preferably selected from hydrogen or Ci-C 4 alkyl Most preferably R 2 is selected from hydrogen, methyl and ethyl.
  • R 3 is unsubstit ⁇ ted or substituted aryi or ⁇ ns ⁇ bstituted or substituted heterocycyl as defined herein above, each of which, when substituted, is substituted by one or more, especially 1 -3, substituents independently selected from the group consisting of the substituents defined under "substituted".
  • R 3 When R 3 is unsubstituted or substituted aryl, it is preferably C 6 -C, 0 aryl which is unsubstituted, or substituted by one or more, especially 1-3, substituents independently selected from the group consisting of the substituents defined under "substituted" When R 3 is an aryt group, (especially Ce-Cioaryl, more especially phenyl) it is unsubstituted, or substituted by one or more, especially 1-3, substituents independently selected from the group consisting of the substituents defined under "substituted”.
  • the substituents may be selected from the group consisting of halo, especially fluoro, chloro, bromo or iodo, in particular fluoro; halo-lower alkyl, especially fluoroalkyl, in particular trifluoromethyl, hydroxyl; amino; mono or disubstituted amino, especially alkyl- substituted amino or hydroxyalkyl-substituted amino, e g.
  • hydroxyethoxy lower alkyl, e g., methyl, ethyl or iso-propyl; cyano; cyano-lower alkyl, e g., 2-cyanoethyl or 3-cyanopropyl; amidino; N-hydroxyamidino; hydroxyamino; alkoxyamino, nitro; amidino-lower alkyl, e g., 2-amidino-ethyl; or N-hydroxyamidino-lower alkyl, e.g , 2- ⁇ N-hydroxyamidino)-ethyl; substituted phenyl or (especially 1- or 2-)naphthyl; sulfonyl, substituted sulfonyl, e.g.
  • alkyl-substituted s ⁇ lfonyl such as methanesulfonyi, sulfonamide, e.g. N-methylsulfonamide (or lower alkylaminosulfonyl or N,N-di-loweralkyl aminosulfonyl, e.g. methylaminosufonyl or dimethylaminosutfonyl) or pyrrolidine- 1 -sulfonyl; lower alkyl sulfonyl amino, e.g. methylsulfonylamino; lower alkyl sulfonylalkandiylamino, e.g.
  • methylsulfonylmethylamino lower alkyls ⁇ lfonyl-N-lower alkylamino, e.g. methylsulfonyl-N- methylamino 1 [1 ,3]dioxolo, substituted [1 ,3Jdioxolo, e.g. 2,2-difluoro-(1 ,3]dioxolo, alkoxy carbonyl, such as lower alkoxy carbonyl, e g, methoxycarbonyl; carbamoyl, substituted carbamoyl, such as alkyl-substituted carbamoyl, e g. methy (carbamoyl; heterocycle, e g. pyrazol; heterocyclyl lower alkyl; heteroaryl or heteroaryl lower alkyl.
  • the substituents may be selected from the group consisting of halo, especially fluoro, chloro, bromo or iodo, in particular fluoro; halo-lower alkyl, especially fluoroalkyl, in particular trifluoromethyl, hydroxyl; amino, mono or disubstituted amino, especially alkyl-substituted amino or hydroxyalkyl-substituted amino, e.g dimethyl amino or 2-hydroxyethyl amino; cyclic amino, such as azindinyl or azetidinyl, amino-lower alkyl, e g., aminomethyl, 2-aminoethyl or 3-aminopropyl; lower alkoxy e.g., methoxy or ethoxy; hydroxy-lower alkyl, e.g , hydroxymethyl
  • sulfonyl substituted sulfonyt, e.g. alkyl-substituted sulfonyl, such as methanesulfonyl: sulfonamide, e g. N-methyls ⁇ lfonamide or pyrrolidine-1 -sulfonyl, [1 ,3]d»oxolo, substituted [1 ,3]dioxolo, e g.
  • substituted sulfonyt e.g. alkyl-substituted sulfonyl, such as methanesulfonyl: sulfonamide, e g. N-methyls ⁇ lfonamide or pyrrolidine-1 -sulfonyl, [1 ,3]d»oxolo, substituted [1 ,3]dioxolo, e g.
  • alkoxy carbonyl such as lower alkoxy carbonyl, e.g methoxycarbonyl, carbamoyl
  • substituted carbamoyl such as alkyl-substituted carbamoyl, e g. methylcarbamoyl, heterocycle, e.g. pyrazol
  • heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl
  • unsubstituted or substituted aryl for R 3 is selected from phenyl; hydroxyphenyl, e.g , 2-, 3- or 4-hydroxyphenyl; methoxyphenyl, e.g , 2-, 3- or 4-methoxyphenyl or 3,4-dimethoxyphenyl; ethoxyphenyl, e.g , 2-, 3- or 4-ethoxyphenyl or 3,4-diethoxyphenyl; propoxyphenyl (e.g iso-propoxyphenyl) such as 3-propoxyphenyl (e g 3-iso-propoxyphenyl), methoxy ethoxy-phenyl, e.g.
  • fluoro- hydroxy-phenyl such as 3-fluoro-5-hydroxy-pheny
  • hydroxy-haloalkyl-phenyl e.g hydroxy- fluoroalkyl-phenyl such as 3-hydroxy-5-t ⁇ fluoromethy1-phenyl
  • 2,2-difluoro-benzo[1 ,3]dioxoIo, benzene sulfonamide e.g.
  • uns ⁇ bstttuted or substituted aryl for R 3 is selected from phenyl; hydroxyphenyl, e.g., 2-, 3- or 4-hydroxyphenyl; methoxyphenyl, e.g., 2-, 3- or 4-methoxyphenyl or 3,4-dimethoxyphenyl; ethoxyphenyl, e g , 2-, 3- or 4-ethoxyphenyl or 3,4-diethoxyphenyl, methoxy ethoxy-phenyl. e.g. 3-methoxy-4-ethoxy phenyl or 4-methoxy-3- ethoxy phenyl, other lower-alkoxy phenyl, e g.
  • 3-methoxy-4-(2-methoxy ethoxy)-phenyl hydroxy alkoxy phenyl, e.g. 3-methoxy ⁇ 4-hydroxy phenyl, halo-hydroxy-phenyl, e g. fl ⁇ oro- hydroxy-phenyl such as 3-fluoro-5-hydroxy-phenyl, hydroxy-haloalkyl-phenyl, e.g.
  • hydroxy- fluoroalkyl-phenyl such as 3-hydroxy-5-trifluoromethyl-phenyl; 2,2-difluoro-benzo[1 ,3]dioxolo, benzene sulfonamide, e.g N-methylbenzenesulfonamide, 3-(pyrrolidine-1-sulfonyl)-phenyl, N-(phen-3-yl)-methanesulfonamide or N-methyl-N-phen-3-yl-methanesu)fonamide, alkyl- sulfonyl phenyl, e g. 3-methanesulfonylphenyl, benzamide e g.
  • said heterocyclyl or heteroaryl may be selected from the group consisting of indotyl, 2,3-dihydro-1H-indol-5-yl, 1-methyl-2,3- dihydro-1H ⁇ ndol-5 ⁇ yl, 2-oxo-2,3-dihydro-1H-indol-5-yl, pyridyl, pyrimidinyl (especially pyrimidin-5-yl), 1H-pyrrolo[2,3-b]pyridin-5-yl, 1 -methyl- 1H-pyrrolo[2,3-b]pyridin-5-yl, pyrazolyl, pyrazol-4-yl, pyrazinyl, quinolyl, quinol-3-yl, 1H-imidazo ⁇ 4 I 5-b]pyridin-2(3H)-one-6-yl, 3H- imidazo[4,5-b]pyridin-6-y
  • hydroxyethoxy lower alkyl, e.g., methyl, ethyl or iso-propyl; cyano; cyano-lower alkyl, e.g., 2-cyanoethyl and 3-cyanopropy), amidino; N-hydroxyamidino; amidino-lower alkyl, e.g , 2-amidino-ethyl, or N-hydroxyamidino- lower alkyl, e.g., 2-(N-hydroxyamidino)-ethyl; substituted phenyl or (especially 1- or 2-) naphthyl; sulfonyl; substituted sulfonyl, e.g.
  • alkyl-substituted sulfonyl such as methanesulfonyl, sulfonamide, e.g N-methylsulfonamide or pyrrolidine- 1 -sulfonyl, [1 ,3]dioxolo, substituted [1 ,3)dioxolo, e.g. 2,2-difluoro-[1 ,3]dioxolo; alkoxy carbonyl, such as lower alkoxy carbonyl, e.g. methoxycarbonyl; carbamoyl; substituted carbamoyl, such as alkyl-substituted carbamoyl, e g.
  • aminocarbonylalkyl such as aminocarbonyl loweralkyl, e g aminocarbonylmethyl
  • N-mono-substituted aminocarbonylalkyl such as N-loweralkyl aminocarbonyl loweralkyl, e g. methylaminocarbonylmethyl
  • N-di-substituted aminocarbonylalkyl such as N-di-loweralkyl aminocarbonyl loweralkyl, e g. dimethylaminocarbonylmethyl, or other N-di-substituted aminocarbonylalkyl, such as 4-morpholinecarbonylmethy! .
  • the heterocycle group may also be substituted with another heterocycle, e.g 3H-tetrazoiyl (in particular 3H-tetrazol-5-yl), pyrazol, heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein.
  • another heterocycle e.g 3H-tetrazoiyl (in particular 3H-tetrazol-5-yl), pyrazol, heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein.
  • Very preferred heterocyclic groups which may be substituted or unsubstituted , include indolyl, 1-methyl-2,3-dihydro-1 H-indolyl, 2-oxo-2,3-dihydro-1H-indolyl, pyridyl, pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-methyl-1H-pyrrolo(2,3-b]pyridinyl, pyrazolyl, pyrazinyl, quinolyl, 1 ,3-Dimethyl-2-oxo-2,3-dihydro-1 H-im!dazo(4,5-b]pyndinyl, 1-erhyl-3-methyl-2-oxo-2,3- dihydro-1 H-imtdazo[4,5-b]pyridinyl, 1-(2-methoxy-ethyl)-3-methyl ⁇ 2 ⁇ oxo-2,3-dihydro-1 H- imidazo(4,5-b
  • cyclic amino such as aziridinyl, azetidinyl or pyrroiidiny!; substituted cyclic amino, e.g. hydroxy cyclic amino; amtno-lower alky!, e.g., aminomethyl, 2-aminoethyl or 3-aminopropyl, alkylamino-lower alkyl, e.g. methylaminomethyl, ethylaminomethyl, methylaminoethyl or ethylaminoethyl, dialkylamino-loweralkyl, e.g.
  • dimethylaminomethyl dimethylaminoethyl, methylethylaminomethyl, methylethylaminoethyl, diethylaminomethyl or diethylaminoethyl, cycloalkylaminoalkyl, e.g.
  • cyclobutoxy lower-alkoxyalkyl, e g. methoxy methyl, methoxypropyl, ethoxypropyl; hydroxy-lower alkyl, e.g., hydroxymethyl or 2-hydroxyethyl; hydroxy lower cycloalkyl, e.g. hydroxy cyclopentyl; hydroxy lower alkoxy, e g.
  • sulfonyl e.g., 2-(N-hydroxyamidmo)- ethyl, nitro
  • carboxylic acid substituted sulfonyl, e.g. alkyl-substituted sulfonyi, such as methanesulfonyl, sulfonamide, e g. N-methylsulfonamide or pyrrolidine-1 -sulfonyl
  • alkylsulfonylamino e.g methylsulfonylamino
  • alkylsulfonylalkylamino e.g.
  • acylamino also termed alkyl carbonyl amino
  • alkyl carbonyl amino e.g acetylamino
  • acyl alkyl amino e.g acetyl methyl amino
  • alkylcarbonylaminoalkyl e.g. methylcarbonylaminomethy
  • alkylaminocarbonylalkyl e g. methylaminocarbonylmethyl
  • alkylcarbonyl-N-alkylamino e g.methylcarbonyl-N-methylainino
  • (1 ,3]dioxolo substituted (1 ,3)dioxolo, e.g.
  • carbamoyl also termed aminocarbonyl
  • substituted carbamoyl such as alkyl-substituted carbamoyl, e.g. methylcarbamoyl, ethyl carbamoyl, iso-propyl carbamoyl or alkoxyalkyl-substituted carb
  • the heterocycle group may also be substituted with another substituted or unsubstituted heterocycle, preferabely a 4-7 membered ring, e.g. 1 H-tetrazolyl (in particular 1H ⁇ tetrazol-5-yl), pyra ⁇ ol, imidazole, tnazole, azetidinyl, pyrrolidinyl, piperazinyl, methylpiperazmyl, ethylpiperazinyl , triazolonyl methylimidazolyl or morpholino
  • the heterocycle group may also be substituted with heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein,
  • R 3 is heterocycyl. In another embodiment, R 3 is heterocycyl which is heteroaryl, In an embodiment, said heterocycyl or heteroaryl is a monocyclic 6 membered ring wherein one or two ring heteroatoms are nitrogen atoms. In a preferred embodiment, R 3 is a monocyclic 6 membered heteroaryl wherein one or two ring heteroatoms are nitrogen atoms. In an embodiment, R 3 is py ⁇ dyl, pyrimidinyl or pyrazinyl, each independently being unsubstituted or substituted. In an embodiment, R 3 is pyridyl or pyrimidinyl, each independently being unsubstituted or substituted.
  • R 3 is unsubstituted or substituted pyridyl (especially pyrid-3-yl or pyndyl-5-yl). In another embodiment R 3 is unsubstituted or substituted pyrimidinyl (especially pyrimidin-5-yl).
  • said pyrimidinyl (especially pyrimidin-5-y!) is unsubstituted or substituted, preferably substituted.
  • said pyrimidinyl is preferably substituted in the 2- 4- or 2- and 4- positions on the pyrimidine ring.
  • the pyrimidine ring is substituted in the 2-position, and when di-substituted, in the 2- and A- posttions
  • said pyrimidinyl is substituted by one or two substituents independently selected from.
  • heterocyclyl or heteroaryl for R 3 is pyndyl, especially pyrid-3-yl or pyrkJ-5- yl - both of these terms mean that the pyridine ring is bonded to the rest of the imidazoquinolinone part of the molecule of formula (I) at a pyridine carbon atom which is arrived at by counting 3 atoms or 5 atoms round the pyridine ring, starting at the nitrogen atom of the pyridine nng, which counts as 1.
  • said pyridyl preferably py ⁇ d- 3-yl or pyrid-5-yl
  • said pyridinyl is preferably substituted in the 5-, 6-, or 5- and 6-posttion positions of the pyridine ring (with reference to pyridin-3-yl)
  • said pyridyl is substituted by one or two substituents independently selected from.
  • specifically preferred unsubstituted or substituted heterocyclyl or heteroaryl for R 3 is selected from.
  • pyridyl e.g. pynd-2-yl, pyrid-3-yl or py ⁇ d-4-yi; especially py ⁇ d-3-yl,
  • alkylpyridyl in particular loweralkylpy ⁇ dyl, e.g. methylpyridyl, e g , 2-, 3- or 4-methylpyridyl, especially 2-methylpyridyl or 3-methylpyridyl, in particular 2-methylpyrid-5-yl or 3-methytpyrid-5-yl;
  • alkoxypy ⁇ dyl in particular lower-alkoxypy ⁇ dyl, e.g. methoxypyridyl, e.g., 2-, 3- or 4-methoxypyridyl, especially 2-methoxypyridy! or 3-methoxypyndyl (in particular 2- methoxypyrkJin-5-yl, 3-methoxypyridin-5-yl); ethoxypyridyl, e.g., 2-, 3- or 4-ethoxypy ⁇ dyl especially 2-ethoxypy ⁇ dyl or 3-ethoxypyridyi (in particular 3-ethoxypyr ⁇ _-5-yl.
  • methoxypyridyl e.g., 2-, 3- or 4-methoxypyridyl
  • 2-methoxypyridy! or 3-methoxypyndyl in particular 2- methoxypyrkJin-5-yl, 3-methoxypyridin-5-yl
  • cycloalkoxypy ⁇ dyl e.g cyclobutoxy-pyridyl, especially 3-cyclobutoxy-pyridyi (in particular 3-cyclobutoxy-pyrid-5-yl);
  • haloalkoxy pyridyl e g. (halo-isopropoxy)pyridyl, such as 3-(1,3-difluoropropan-2- yloxy)-pyridyl (in particular 3-(1,3 ⁇ difl ⁇ oropropan-2-yloxy)-pyrid-5-yl) or 3-(2-fluoroethan-1- yloxy)-pyridyl (tn particular 3-(2-fluoroethan-1-yloxy)-pynd-5-yl) or 3-(difluoromethyloxy)- pyridyl (in particular 3-(difluoromethyloxy)-py ⁇ d-5-yl);
  • cycloalkylalkoxypyridyl e.g cyclopropylmethoxy-py ⁇ dyl, espe ⁇ alty 2- cyclopropylmethoxy-pyridyl (in particular 2-cyclopropylmethoxy-pyrid-5-yl);
  • alkoxyalkylpyridyl e,g ⁇ thoxymethylpyridyl, 2-methoxymethylpyridyl (in particular 2- m ⁇ thoxymethylpyrid-5-yl) or 3-methoxymethylpyridyl (in particular 3-methoxymethylpyrid-5-yl) or 3-(2-methoxy ⁇ prop-2-yl)pyridyl (in particular 3-(2-methoxy-prop-2-yl)pyrid-5-yl or 3-(2- ethoxy-prop-2-yl)pyridyl (in particular 3-(2-ethoxy-prop-2-yl)pyrid-5-yl,
  • alkoxyalkoxypyridyl in particular methoxyethoxypy ⁇ dyl, e g 3- ⁇ 2- methoxyethoxy)py ⁇ dyl or 2-(2-methoxyethoxy)py ⁇ dyl (in particular 3-(2-methoxyethoxy)pyrid- 5-yl or 2-(2-methoxyethoxy)pyrid-5-yl);
  • alkyi ⁇ alkoxyalkoxy)pyr ⁇ tyl in particular (loweralkyl)(loweraJkoxyalkoxy)pyridyl, such as (methyl)(methoxyethoxy)pyridyl, e.g. (2-methyl)-(3-(2-methoxyethoxy))pyridyl (in particular (2-methyl)-(3-(2-methoxyethoxy))pynd-5-yl,
  • benzyloxyalkoxypyridyl in particular benzyloxyethoxypyridyl or benzyloxypropoxypyridyl, e g 2-benzyloxyethoxypyridyl or 3-benzyloxypropoxypyridyl (in particular 2-benzyloxyethoxypy ⁇ d-5-yl or 3-benzyloxypropoxypy ⁇ d-5-yl),
  • hydroxyalkylpyridyl e g hydroxymethylpy ⁇ dyl, especially 2-(hydroxymethyl)-pyridyl (in particular 2-hydroxymethylpyrid-5-yl) or hydroxyethylpy ⁇ dyl, espe ⁇ ally 3-(1-hydroxyethyl)- pyridyl (in particular 3-(i-hydroxyethyl)pyrid-5-yl) or hydroxypentylpy ⁇ dyl (alternatively termed 1 -hydroxy- 1-ethyl-propyi), such as 3-(3-hydroxy ⁇ entyl)-pyridy!
  • 3-(3- hydroxypent-3-yl)py ⁇ dyl in particular 3-(3-hydroxypent-3-yl)pynd-5-yl) or hydroxypropylpyridyl, especially 3-(2 ⁇ ydroxyprop-2-yl)-py ⁇ dyl (in particular 3-(2- hydroxyprop-2-yl)pyrtd-5-yl) or hydroxy* 1 ,1-dimethyl-ethylpyridyl, especially 3-(2-hydroxy-1 ,1- dimethyl-ethyl)-pyridyl (in particular 3-(2-hydroxy-1 ,1-dimethyl-ethyl)pyrid-5-yl),
  • hydroxycycloalkylpyridyl e g hydroxylowercycloalkylpyridyl, especially 3-(1- hydroxycyclopenty1H>yridyl (in particular 3-(1-hydroxycyclopenty ⁇ )-pyrid-5-yl),
  • hydroxyfluoroalkylpyridyl e g. hydroxyfluoropropylpyridyl, especially 3-(1 ,3-difluoro-2- hydroxyprop-2-yl)-pyridyl (in particular 3-(1 ,3-difluoro-2-hydroxyprop-2-yl)py ⁇ d-5-yl)
  • aminoalkylpyridyl e g aminomethylpyndyl, especially 3-(aminomethyl)-pyridyl (in particular S-aminomethylpyrid- ⁇ -yl), alkyl-sulfonyl pyridyl, e g methanesulfonylpyridyl, especially 3-methanesutfonylpyridyl (in particular 3-methanesulfonylpyrld-5-yi),
  • hydroxyalkoxypyridyl e g. 2-(2-hydroxyethoxy)-pyridyl or 2-(3-hydroxypropoxy)- pyridyl (in particular 2-(2-hydroxyethoxy)-pyrrd-5-yl or 2-(3-hydroxypropoxy)-pyrid-5-yl),
  • alkoxycarbonylpyndyl e g. methoxycarbonylpy ⁇ dyl. especially 2-methoxycarbonyl- py ⁇ dyl (in particular 2-methoxycarbonyl-pyrid-5-yl ⁇ ,
  • aminopyridyl e g. 2- or 3-aminopyridyl (in particular 2 ⁇ aminopyrid-5-yl or 3- amtnopyrid-5-yl),
  • alkylaminopyridyl e.g loweralkylaminopyrtdyl, in particular methylaminopyridyl such as 2-methylaminopyridyl, 3-methylaminopyridyl or ethylaminopyridyl such as 2- ethylaminopyridyl (especially 2-methylaminopyrid-5-yl, 3-methylaminopyrid ⁇ 5-yl or 3- ethylaminopyrid-5-yl) or isopropylaminopyridyl such as 3-rsopropyiamtnopyridyl (especially 3- isopropylaminopyrid-5-yl;
  • dialkylaminopyridyl in particular dHoweralkylaminopyridyl, e g. 2-, 3- or 4- dimethylaminopyridyl, especially 2-dimethylaminopyridyl or 3-dimethylaminopyridyl (in particular 2-dimethylaminopyrid-5-yl or 3-dimethylaminopy ⁇ d-5-yl) or e g.
  • 2-, 3- or 4- diethylaminopyridyl especially 2-diethylaminopyridyl or 3-diethylaminopy ⁇ idyl (in particular 2- diethylaminopyrid-5-yl or 3-dtethylamtnopyrtd-5-yl) or e g 2-, 3- or 4-ethylmethylaminopyridyl especially 2-ethylmethylaminopyridyl (in particular 2-ethylmethylaminopynd-5-yl or 3- ethylmethylaminopyndyl (in particular 3-ethylmethylaminopyrid-5-yl) or e g 2-, 3- or 4- isopropylmethylaminopyndyl, especially 2-isopropylmethylaminopy ⁇ dyl or 3- isopropylmethylaminopyridyl (in particular 2-isopropylmethylaminopyrid-5-yl or 3-
  • cycloalkylaminopyridyl e.g cycloloweralkylaminopyridyl, in particular cyclobutylaminopyridyl such as 3-cyclobutylaminopy ⁇ dyl or (especially 3-methylaminopyrid- 5-yl);
  • N-alkyl-N-cyck>alkylamino)py ⁇ dyl e g (N-loweralkyl-N-cycloloweralkylamino)py ⁇ dyl, in particular (N-methyl-N-cyclobutylamino)pyridyl such as 3-(N-methyl-N- cyclobutylamino)pyridy! or (especially 3-(N-methyl-N-cyclobutylamino)py ⁇ d-5-yl)'
  • alkyl)(amtno)py ⁇ dyl e g (loweralkyl)(amino)py ⁇ dyl, in particular (methyl)(amino)pyridyl such as 2-methyl-3-amtno-pyridyl (especially 2-methyt-3-amino-py ⁇ d- 5-yt) or (ethyl)(amino)pyridyl such as 2-ethyl-3-amino-pyridyl (especially 2-ethyl-3-amino- pyrid-5-yl),
  • halo (amino)pyridyl, e g. (fluoro)(amino)pyridyl ) in particular 3-fluoro-2-amino-pyridyl (especially 3-fluoro-2-amino-py ⁇ k.-5-yl), 2-fluoro-3-amino ⁇ pyndyl (especially 2-fluoro-3-amino- pyrid-5-yl), 3-chloro-2-amino-pyridyl (especially 3-chloro-2-amino-pyrid-5-yl) or 2-chloro-3- amino-py ⁇ dyl (especially 2-cnloro-3-amino-py ⁇ d-5-yl);
  • halo (alkylamino)pyridyl, e.g. (halo)(loweralkylamino)pyridyl, in particular (ftuoro)(methylamino)py ⁇ dyl such as 3-fluoro ⁇ 2-methylamino-pyridyl (especially 3-fiuoro-2- methylamino-pyrid-5-yl), 2-fluoro-3-methylamino-py ⁇ dyl (especially 2-fluoro-3-methylamino- py ⁇ d-5-yl), 2-fluoro-3-ethytamino-pyrfdyl (especially 2-fluoro-3-ethylamino-py ⁇ d-5-yl), 3- chlor ⁇ -2-methylamino-pyridyl (especially S-chloro ⁇ -methylamino-pyrid- ⁇ -yl), 3-chloro-2- ethylamino-pyndyl (especially 3-chloro-2-ethy
  • halo dialkylamino)pyridyl, e.g. (hak))(di-loweralkylamino)pyridyl, in particular (fluoro)(dimethylamino)pyndyl such as 2-fluoro-3-dimethylamino-py ⁇ dyl (especially 2-fluoro- 3-dimethylamino-pynd-5-yl),
  • alkoxy(alkyl)pyridyl e.g (methoxy)(methyl)pyridyl, such as 3-methoxy-2-methyl- pyridyl (in particular 3-methoxy-2-methyl-py ⁇ d-5-yi) ) (ethoxy)(methyl)py ⁇ dyl, such as 3- ethoxy-2-methyl-pyridyl (in particular 3-ethoxy-2-methyl-py ⁇ d-5-yl) or e g.
  • (propoxy)(methyl)py ⁇ dyl such as 3-propoxy-2-methyl-pyndyl (in particular 3-propoxy-2- methyl-pyrid-5-yl) or e g (propoxy)(ethyl)pyndyl, such as 3-propoxy-2-ethyl-pyridyl (in particular 3-propoxy-2-ethyl-pyrid-5-yl) or e g (ethoxy)(ethyl)pyridyl, such as 3-ethoxy-2- ethyl-pyndyl (in particular 3-ethoxy-2-ethyl-pyrid-5-yl);
  • 3-methoxy-2-methoxy-pyridyl in particular 3-methoxy-2 « methoxy-py ⁇ d-5-yl
  • ethoxy ethoxy(methoxy)py ⁇ dyl
  • 3-ethoxy-2-methoxy-pyridyl in particular 3-ethoxy-2-methoxy-py ⁇ d-5-yi
  • (alkoxy)(alkoxyalkyl)pyridyl e.g.
  • (isopropoxy) ⁇ methoxymethyl)pyridyl such as 3- isopropoxy-2-methoxymethyl-pyridyl (in particular 3-tsopropoxy-2-methoxymethyl-pynd-5-yl) or (methoxy)(methoxymethyl)pyridyl, such as 3-methoxy-2-methoxymethyl-pyridyl or 2- methoxy-3-methoxymethyl-pyridyl (in particular 3-methoxy-2-methoxymethyl-pyrid-5-yl or 2- methoxy-3-methoxymethyl-py ⁇ d-5-yl) or (methoxy)(ethoxymethyl)pyridyl, such as 3-methoxy- 2-ethoxymethyl-pyridyl (in particular 3-methoxy-2-ethoxymethyl-pyrid ⁇ 5-yl) or (ethoxy)(methoxymethyl)pyridyl 1 such as 3-ethoxy-2-methoxymethyl-py ⁇ dyl (in particular
  • (alkoxy)(hydroxyalkyl)pyridyl e.g. (isopropoxy)(hydroxymethyl)pyridyt, such as 3- isopropoxy-2-hydroxymethy!-pyridyl (in particular 3-isopropoxy-2-hydroxymethyl-pyrid-5-y! or (methoxy)(hydroxymethyl)py ⁇ dy), such as 3-methoxy-2-hydroxymethyl-pyridyl (in particular 3- methoxy-2-hydroxymethyl-pyrid-5-yl) or 2-methoxy-3-hydroxymethyl-pyridyl (in particular 2- methoxy-3-hydroxymethyl-pyrid-5-yl) or (ethoxy)(hydroxymethyl)py ⁇ dyl, such as 3-ethoxy-2- hydroxymethyl-pyridyl (in particular 3-ethoxy-2-hydroxymethyl-pyrid-5-yl),
  • haloalkoxy (alkyl)pyridyl e.g (halo-isopropoxy)(methyl)pyridyl, such as 3-(1 ,3- difluoropropan-2-yloxy)'2-(methyl)-pyndyl (in particular 3-(1,3-difluoropropan-2-yloxy)-2- (methyl)-pyrid-5-yl);
  • haloalkoxy (hydroxyalkyl)pyridyl e.g. (halo>isopropoxy)(hydroxymethyl)pyridyi, such as 3-(1 ,3-difluoropropan-2-yloxy)-2-(hydroxymethyl)-pyridyl (in particular 3-(1.3- difluoropropan-2-yloxy)-2-(hydroxymethyl)-pyrid-5'yl);
  • alkoxyalkoxy)(hydroxyalkyl)pyridyl in particular (loweralkoxy loweralkoxy)(hydroxyloweralkyl)pyridyl, e.g. (methoxyethoxy)(hydroxymethyl)pyridyl, such as 3-methoxyethoxy-2-hydroxymethyl-py ⁇ dyl (in particular 3-methoxyethoxy-2-hydroxymethyl- pyrid-5-yi);
  • alkyl)(alkylamino)pyridyl e g. (loweralkyl)(loweralkylamino)pyridyl, in particular (methyl)(ethylamino)pyridyl such as 2-methyl-3-ethylamino-pyndyl (especially 2-methyl-3- ethylamino-pyrid-5-yl) or (methyl)(methylamino)py ⁇ dyl such as 3-methyl-2-methy)amino- py ⁇ dyl (especially 3 ⁇ methyl-2-methylamino ⁇ pyrid-5-yl) or (ethyl)(ethylamino)pyridyl such as 2- ethyl-3-ethylamino-pyridyl (especially 2-methyl-3-ethy!amino-pyrid-5-yl) or (ethyl)(isopropylamino)pyridy1 such as 2-ethyl*3HS
  • (loweralkyl)(dMoweraiky!amino)pyri ⁇ jyl in particular (methyt)(N-methyt-N-ethylamino)py ⁇ dyl such as 2-methyl-3-(N-methyl-N-ethylamino)-pynclyl ⁇ especially 2-methyt-3-(N-methyl-N ⁇ ethylamino)-pyrid-5-yl) or (methyl)(N,N- dimethylamino)pyridyl such as 2-methy(-3-(N,N-dimethylamino)-pyridyl (especially 2-methyl- 3-(N,N-dimethylamino)-pyrid-S-yl),
  • cycloaminopyridyl e.g azetidinylpyndyl, especially 2 ⁇ azetidin-1-yl-py ⁇ diny I (in particular 2-azetidirv1-yl-pyridirv5-yl) or 3-azetidtn-1-yl-pyridinyl (in particular 3 ⁇ azetidin-1-yl- pyrtdin-5-yl) or pyrrolidinylpy ⁇ dyl, especially 2-pyrrolidinyM-yl ⁇ py ⁇ dinyl (in particular 2- pyrrolidinyl-1-yl-pyridin-5-yl),
  • cyclic ether-substituted amino-py ⁇ dyl e.g tetrahydro-pyranylamino-pyridyl, especially 2-(tetrahydro- ⁇ yran-4-ylamino)-pyridyl (in particular 2-(tetrahydro- ⁇ yran-4-y1amino)pyridyl-5- yi.
  • hydroxy-cycloaminopyridyl such as hydroxy-pyrrolidinylpy ⁇ dyl, e g 3-hydroxy- pyrrolidin-1-yl-py ⁇ dinyl (in particular 6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl, more particularly, 6-((R)-3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl or 6-((S)3-hydroxy-pyrr ⁇ lidin-1-yt)- pyndin-3-yl;
  • loweralkoxy-cycloaminopyridyl such as methoxy-pyrrolidinylpyridyl, e g 3-methoxy- pyrroHdm- 1 -yl-pyridiny I (in particular ⁇ - ⁇ -methoxy-pyrrolidin-1-yO-pyridin-S-yl, more particularly, 6-((R)-3-methoxy-pyrrolidm-1-yl)-pyridin-3-yl or 6-((S)3-methoxy-pyrrolid)n-1-yl)- pyridin-3-yl,
  • hydroxyalkylaminopyridyl e g. 2-(2-hydroxyethylamino)-pyridyl (in particular 2-(2- hydroxyethylamino)-pyrid-5-yi);
  • alkyl)(hydroxy)pyridyl in particular (loweralkyl)(hydroxy)pyridyl e.g 2-(methyl)-3- (hydroxy)-pyridyl (in particular 2-(methyl)-3-(hydroxy)-pyrid-5-yl) or 2- ⁇ ethyl)-3-(hydroxy)- py ⁇ dyl (in particular 2-(ethyl)-3-(hydroxy)-pyrid-5-yl),
  • (hydroxyloweralkyl)(loweralkylamino)pyndyl such as (hydroxymethyl)(ethylamino)-pyridyl, e.g. 2-(hydroxymethyl)-3-(ethylamino)-pyricryl (in particular 2-(hydroxymethyl)-3- (ethylamino)-pyrid-5-yl) or such as (hydroxymethyl)(methylamino)-pyridyl, e g 2- (hydroxymethyl)-3-(methylamino)-pyridyl (in particular 2-(hydroxymethyl)-3-(methylamino)- pyr ⁇ J-5-yl) 3-(hydroxymethyl)-2-(methylamino)-pyridyl (in particular 3-(hydroxymethyl)-2- (methylamino)-py ⁇ d-5-yl), (hydroxyalkyl)(amino)pyridyl, in particular (hydroxy!owera)kyl)(amino)pyridyl, such as (hydroxymethyl)(
  • (loweralkoxyloweralkyl)(loweralkylamino)pyridyl such as (methoxymethyl)(ethylamino)- pyridyl, e.g. 2-(methoxymethyl)-3-(ethylamino)-pyridyl (in particular 2-(methoxymethyl)-3- (ethylamino)-pyrid-5-yl) or such as (methoxymethyl)(methylamino)-pyridyl, e.g.
  • alkoxyalkyl)(amino)pyridyl in particular (alkoxyloweralkyl)(amino)pyridyl ) such as (ethoxymethyl)(amino)-pyridyl 1 e.g. 3-(ethoxymethy!)-2-(amino)-py ⁇ dyl (in particular 3- (ethoxymethyl)-2-(amino)-pyrtd-5-yl) or (methoxymethyl)(amino)-pyridyl, e.g. 3- (methoxymethyl)-2-(amino)-pyridyl (in particular 3-(methoxyrr>ethyl)-2-(amino)-pyrid-5-yl);
  • amino-haloloweralkyl-pyridyl e.g amino-trifluoromethyl-pyr ⁇ dyl, especially 2-amino-3- t ⁇ fluoromethyl-pyridyl (in particular 2-amino-34rifluoromethyl-pyrid-5-yl);
  • alkylamino-haloalkyl-pyridyl such as loweralkylamino-haloloweralkyl-pyridyl, e.g. methylamino-trifl ⁇ oromethyl-pyridyl, especially 2-methylamino-3-trifluoromethyl-pyridyl (in particular 2-methylamino-3-trifluoromethyl-pyrid-5-yl) or e.g. ⁇ thylamino-trrfluoromethyl- pyridyl, especially 2-ethy!amino-3-trifluoromethyl-pyridyl (in particular 2-ethylamino-3- trifl ⁇ oromethyl-pyrid-5-yl);
  • haloalkyl-deuteroloweralkylamino-pyridyl e.g. trifl ⁇ oromethyl-trideuteromethylamino- pyridyl. especially 3-trifluoromethyl-2-trideuteromethylamino-pyridyl (in particular 3- trifluoromethy(-2 ⁇ trideuteromethylamino-pyrid-5-yl);
  • haloalkylpyridinyl in particular haloloweralkylpyridyl, especially, 2 ⁇ , 3- or 4-trifluoromethylpyridyl. most especially 2-trifluoromethylpyridyl (in particular 2- trifluoromethylpyrid-5-yl);
  • cyanoalkylpyridinyl in particular cyanoloweralkylpyridyl, especially, cyanopropylpyridyl, most especially 2-cyanoprop-2-ylpyridyl (in particular 3-(2-cyanoprop-2- yl)- ⁇ yrid-5-yl); cyanocycloalkylpyndinyl, in particular cyanolowercycloalkyipyridyl, especially, cyanocyclobutylpyridyl, most especially 1-cyanocyck>buty)pyridyt (in particular 3-(1 ⁇ cyanocyclob ⁇ tyl)-pyrid-5-yt);
  • halopyridyl in particular fluoropyridy
  • 2-fluoropyridyl in particular 2- fluoropyrid-3-yl or 2-fluoropyrid-4-yl
  • halo-alkoxy-pyridyl e.g. fluor ⁇ -methoxy-pyndyl such as 3-fiuoro-2-methoxy-py ⁇ dyl (in particular 3-fluoro-2-methoxy-pyrid-5-y I);
  • carbamoylpy ⁇ dyl especially 2-(carbamoyl)pyridyl (in particular 2-(carbamoy))pyrid-5- y[); alkyl-substit ⁇ ted carbamoyl, e.g. methy (carbamoyl, especially 2-(methytcarbamoyl)py ⁇ dyl (in particular 2-(methylcarbamoyl)pyrid-5-yi);
  • piperazinylpyridyl e g. 1-piperazinylpyridyl, especially 2-(1-piperazinyl)pyridyi (in particular 2-(1-piperazinyl)pyrid-5-y1); N-alkylpiperazinylpy ⁇ dyl, such as N- loweralkylpiperazinylpyridyl, e.g. N-methylpiperazinylpyridyl, especially 2-(4-methylpiperazin- 1-yl)-pyrtdyl (in parttcular 2'(4-methylptperazin-1-yl)>pyrid-5-yl),
  • alkylsulfonamidopyridyl such as loweralkylsulfonamidopyridyl, especially methylsulfonamidopyridyl, e g. 3-(methy!sulfonamido) pyridyl (in particular 3- (methylsulfonamido)-pyridin-5-yl),
  • dialkylsulfonamidopyndyl such as diloweralkyisulfonamidopyridyl, especially dimethyfsulfortamidopyridyl, e g 3-(dimethylsulfonamido) py ⁇ dyl (in particular 3- (dimethylsulfonamido)-pyridin-5-yl);
  • alkylsulfonamidoKalkyl)pyridyl such as (loweralkylsulfonamido)(loweralkyl)pyridyl, especially (methylsulfonarntdo)(methy!)pyridyl, e g 3-(methy)sulfonamidoKmethyl)pyridy1 (in particular 3-(methylsutfonamido)-2-methyl pyridin-5-yl),
  • alkylsulfonamido)(halo)pyridyl such as (loweralkyls ⁇ tfonamido)(chloro)pyridyl, especially (methylsulfonamido)(chloro)pyridyl, e g. 3-(methylsulfonamido)(chloro)pyridyl (in particular 3-(methytsulfonamido)-2-chloro-pyridin-5-yl);
  • alkylsulfonamidoalkyl)pyridyl such as (loweralkylsulfonamido-loweralkyl)pyridyl, especially (methyls ⁇ lfonamidomethyl)pyridyl, e.g.
  • dialkyls ⁇ lfonamido(alkyl)py ⁇ dyl such as diloweralkylsulfonamido(loweralkyl)pyridyl, especially dimethylsulfonamido(methyl)pyndyl, e g 3-(dimethylsulfonamido)(2-methyl) pyridyl (in particular 3-(dimethylsulfonamido)-(2-methyl)-pyridin-5-yl),
  • alkylcarbonylaminoalkylpyndyl such as loweralkylcarbonylaminoloweralkyl)pyridyl, e g methylcarbonylaminomethylpyndyi, especially 3-methylcarbonylaminomethylpy ⁇ dyl (in particular 3 ⁇ methylcarbonylaminomethylpyrfd-5-yl),
  • halo (alkylcarbonylamino)py ⁇ dyl, such as (halo)(lowera!kylcarbonylamino)pyndy!, e g (chloro)(methylcarbonylamino)pyridyl, especially 2-(chloro)-3- (methylcarbonyfamino)pyridyl (in particular 2-(chloro)-3-(methylcarbonylamino)pynd-5-yl),
  • alkoxy (a ( kylcarbonylamino)py ⁇ dyl, such as (loweralkoxy)(loweralkylcarbonylamino) pyridyl, e g (methoxy)(methylcarbonylamino)pyridyl or (ethoxy)(methylcarbonylammo)pyridyl, especially 2-(methoxy)-3-(methylcarbonylamino)pyridyl or 2-(ethoxy)-3* (methylcarbonylamino)pyridyl (in particular 2-(methoxy)-3-(methylcarbonylamino)py ⁇ d-5 ⁇ yl or 2-(ethoxy)-3-(methylcarbonylamino)pyrid'5-yl) )
  • alkoxy(alkylcarbonyl-N-alkylamino)py ⁇ dyl such as (k>weralkoxy)(loweralky!carbonyl- N-loweralkylamino)pyndyi, e g (methoxy)(methylcarbonyl-N-methylamino)pyndyl or (ethoxy)(methylcarbonyl-N-methylamino)pyridyl, especially 2-(methoxy)-3-(methy)carbonyl-N- methylamino)pyridyl or 2-(ethoxy)-3-(methylcarbonyl-N " methylamino)pyridyl (in particular 2- (methoxy)-3-(methyk:arbonyl-N-methylamino)py ⁇ d-5-yl or 2-(ethoxy)-3-(methylcarbonyl-N- methylaminoJpynd-S-yl),
  • alkoxy)(nitro)py ⁇ dyl such as (lowera ⁇ koxy)(nitro)py ⁇ dyl, e g (methoxy)(nitro)pyridyl, especially 2-(methoxy)-3-(nitro)-py ⁇ dyl (in particular 2 ⁇ (methoxy)-3-(nitro)-pyrid-5-yl),
  • (methoxy)(amino)pyridyl especially 2-(methoxy)-3-(amino)-pyridy( (in particular 2-(methoxy)- 3-(amino)-py ⁇ d-5-yl), (alkoxy)(alkylamino)py ⁇ dyl, such as (loweralkoxy)(alkylamino)pyi ⁇ dyl, e g (methoxy)(elhylamino)pyridyl, especially 2-(methoxy)-3-(ethytamino)pyridyl (in particular 2- (methoxy)-3-(ethylamino)pyrid-5-yl,
  • alkoxyalkyl)(alkylamino)pyridyl such as (loweraikoxyioweralkyl)(alkytamino)pyridyl, e,g (methoxymethyl)(methylamino)pyridyl.
  • 3-(methoxymethyl)-2- (methylamino)pyridyl in particular 3-(methoxymethyl)-2-(methylamino)pyrid-5-yl) or (methoxymethyl)(ethylamino)py ⁇ idyl, especially 3-(methoxymethyl)-2-(ethylamino)pyridyl (in particular 3-(meth ⁇ xymethyl)-2-(ethylamino)pyrid-5-yl) ;
  • (loweralkoxy)(loweralkylaminocarbonyl)pyridyl e.g. (methoxy)(methylaminocarbony))pyridyl, especially 2-(methoxy)-3-(methylaminocarbonyl)pyndyl (in particular 2-(methoxy)-3- (methylaminocarbonyl)pyrid-5-yl,
  • alkylaminocarbonylalkylpy ⁇ dyl such as loweralkylaminocarbonylloweralkylpyridyl, e.g methylaminocarbonylmethylpy ⁇ dyl, especially 3-methylaminocarbonylmethylpyridyl (in particular S-methylaminocarbonylmethylpyrid- ⁇ -yl,
  • (amino)(alkylaminocarbonyl)pyridyl such as (amino)(loweralkylaminocarbonyl)pyridyl, e.g. (amino)(methylaminocarbonyl)py ⁇ dyl, especially 2-(amino)-3- (methylaminocarbonyl)pyridyl (in particular 2-(amino)-3-(methylaminocarbonyl)pyrid-5-yl) or (amino)(ethylaminocarbonyl)pyridyl, especially 2-(amino)-3-(ethylaminocarbonyl)pyridyl (in particular 2-(amino)-3-(ethylaminocarbonyl)pyrid-5-yl) or (amino)(isopropylaminocarbonyl)pyridyl, especially 2-(amino)-3- (isopropylaminocarbonyl)pyridyl (in particular 2-
  • amino (alkoxyalkylaminocarbonyl)py ⁇ idyl, such as amino)(loweralkoxyloweralkylaminocarbonyl)pyridyl, e.g. (amino)(methoxyethylaminocarbonyl)pyndyl. especially 2-(amino)-3-(2- methoxyethylaminocarbonyl)pyridyl (tn particular 2-(amino)-3-(2- methoxyethylaminocarbonyl)pyrid-5-yl)
  • alkylamino)(alkylaminocarbonyl)pyridyl such as (loweralkylamino)(loweralkylaminocarbonyl)pyridy), e.g (methylamino)(ethylaminocarbonyl)py ⁇ dyl, especially 2-(methylamino)-3- (ethylamtnocarbonyl)py ⁇ dyl (in particular 2-(methylamino)-3-(ethylaminocarbonyl)pyrid-5-yl); (alkoxy)(aminocarbonyl)pyridyl, such as (loweralkoxy)(aminocarbonyl)pyridyl, e.g.
  • alkoxy(hydroxycarbonyl)pyridyl such as (loweralkoxy)(hydroxycarbonyl)pyridyl, e.g (methoxy)( hydroxycarbonyl)pyridyl, especially 2-(methoxy)-3-(hydroxycarbonyl)py ⁇ dyl (in particular 2-(methoxy)-3-(hydroxycarbonyl)pyrid-5-yl,
  • morpholi ⁇ ylpy ⁇ dinyl such as morpholin-4-ylpyridinyl, e.g. 3-morpholin-4-ylpyridinyl, especially 3-morpholin-4-ylpyndin-5-yl ,
  • (1H-pyrazolyl)-pyridinyl such as (1H-pyrazoMyl)-pyridinyl, especially 2-(1 H-pyrazol- lyO-pyridinyl, in particular (1H-pyrazo)-1yl)-pyridin-5-yl.
  • k) weralkylsubstituted(1H-imidazol-1-yl)-py ⁇ dinyl, such as methyl-substituted(1 H- imidazol-1-yl)-pyridinyl, e g (2-methyMH-imrclaE ⁇ l-1 ⁇ yl)-pyridinyl especially (2-methyl-1 H- imidazol-1-yl)-py ⁇ din-5-yl,
  • di-lcweralkylaminopy ⁇ midinyl e.g 2- or 4-djmethylaminopynmidinyl, especially 2- dimethylaminopyrimidmyl (in particular 2-dimethylaminopy ⁇ m»din-5-yl),
  • alkoxypyrimidinyl in particular methoxypyrimidinyl or ethoxypyrimidinyl, e g 2- methoxypynmidinyl or 2-ethoxypyrimidinyl (in particular 2-methoxypy ⁇ imidin-5-yl or 2- ethoxypyrimidin-5-yl);
  • di-alkoxypy ⁇ midinyl in particular di-methoxypyrimidinyl, e.g 2,4-dimethoxypy ⁇ midinyl or (in particular 2 4-dimethoxypyf!midin-5-yl),
  • (loweralkylamino)(loweralkoxy)pyrimidinyl e.g (methylamino)(methoxy)py ⁇ midinyl or (ethylamino)(methoxy)py ⁇ midinyl e.g. 2-(methylamino)-4-(methoxy)pyrimtdinyl or 2- (ethytamino)-4-(methoxy)py ⁇ mtdinyl (in particular 2-(methylamino)-4-(methoxy)pyrimidin- ⁇ -yl or 2-(ethylamino)-4-(methoxy)pyrimidin-5-yl),
  • cycloammopyrimidinyl e.g pyrrolidinylpy ⁇ midinyl, especially 2-(pyrrolidinyl) pyrimidiny! (in particular 2-(pyrrolidinyl)py ⁇ midin-5-yl),
  • aminopyrimidinyl in particular 2-aminopy ⁇ midinyl (especially 2-aminopyrimidin-5-yl, alkylaminopy ⁇ midinyl, in particular loweralkyiaminopyrimidinyl, e g. 2- methylaminopynmidinyl (especially 2-methylaminopynmidin-5-yl);
  • dialkylaminopy ⁇ midinyl in particular di-loweraJkylaminopynmtdinyl.
  • dialkylaminopy ⁇ midinyl in particular di-loweraJkylaminopynmtdinyl.
  • 2- dimethylaminopyrimidinyl especially 2-dimethylaminopyrimidin-5-yl
  • substituted pyrazolyl e.g. hydroxyalkylpyrazolyl, especiaHy 1-(2-hydroxy-ethyl)-1H- pyrazolyl (in particular 1-(2-hydroxy-ethyl)-1H-pyrazol-4-yl) or 1-[2-(tetrahydro-pyran-2-yloxy)- ethy)]-1H-pyrazolyl (in particular 1-(2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol-4-yl);
  • quinolinyl in particular quinolin-3-yl
  • 1H-imidazo[4,5-b ⁇ pyridin-2(3H)-one-6-yl (in particular 1 ,3-dimethyl-1H-imidazo(4,5- b)pyridtn-2(3H)-one-6-yl, 1-ethyl-3-methyHH-imidazo[4,5-b]py ⁇ din-2(3H)-one-6-yl or 1-(2- methoxyethyl)-3-methyl-1H-imidazo[4,5-blpyridin-2(3H)-one-6-yl;
  • 3H-imidazo[4,5-b]pyridin-6-yl e.g. (3-methyl)-3H-imidazo(4,5-bJpyridin-6-yl, (2- methyt)-(3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl, (2-methoxy)-(3-methyl)-3H-imidazo[4,5- bJpyridin-6-yl, (2-dimethylamino)-(3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl;
  • specifically preferred unsubstituted or substituted heterocyclyl or heteroaryl for R 3 is selected from
  • pyridyl e.g pyrid-2-yl, py ⁇ d-3-yl or ⁇ yrid-4-yl;
  • alkylpyridyl in particular loweralky lpyridy I , e g methylpyridyl, e.g , 2-, 3- or 4-methylpyridyl, especially 2-methylpy ⁇ dyl or 3-methylpy ⁇ dyl, in particular 2-methylpy ⁇ d-5-yl or 3-methylpyrid-5-yl,
  • alkoxypyridyl in particular lower-alkoxypy ⁇ dyl, e g methoxy pyridyl, e g , 2-, 3- or 4-methoxypyridyl, especially 2 ⁇ methoxypyridyl or 3-methoxypyrtdyl (in particular 2- methoxypyridin-5-yl, 3-methoxypyridin-5-yl), ethoxypyridyl, e g., 2-, 3- or 4-ethoxypy ⁇ dyl especially 2-ethoxypyridyl or 3-ethoxypyridyl (in particular 3-ethoxypyrid-5-yl, 2-ethoxypynd- 5-yl, 2-ethoxypyrid-4-yl), propoxypyridyl, e g. n-propoxypyridyl or iso-propoxypy ⁇ dyl (in particular 6-(n-pro ⁇ oxy)pynd-3-yl or 3-(iso-propoxy
  • cydoalkylalkoxypy ⁇ dyl e.g cyclopropylmethoxy-py ⁇ dyl, especially 2- cyclopropylmethoxy-pyndyl (in particular 2-cyclopropyfmethoxy-pyrid-5-yl)'
  • alkoxyalkylpyridyl e g ethoxymethylpyridyl, 2-methoxymethylpyridyl (in particular 2- methoxymethylpy ⁇ d-5-yl);
  • alkoxyalkoxypyridyl in particular methoxyethoxypyndyl, e g 3-(2- methoxyethoxy)pyridyl or 2-(2-methoxyethoxy)pyridyl (in particular 3-(2-methoxyethoxy)pyrid- 5-yl or 2-(2-methoxyethoxy)pyrld-5-yl), benzyloxyalkoxypyridyl, in particular benzyloxyethoxypyridyl or benzyloxypropoxypyridyl, e.g. 2-benzyloxyethoxypyridyl or 3-benzyloxypropoxypyndyl (in particular 2-benzyloxyethoxypyrid-5-yl or 3-be ⁇ zyloxypropoxypyrid-5-yl);
  • hydroxy alky ipyridyl e g. hydroxy methylpy ⁇ dyl, especially 2-(hydroxymethy!)-py ⁇ dyl (in particular 2-hydroxymethylpy ⁇ d-5-yl);
  • alkyl-s ⁇ lfonyl py ⁇ dyl e.g. methanesulfonylpyndyl, especially 3-methanesulfonylpyridyl (in particular 3-methanesulfonylpyrid-5-yl);
  • hydroxyalkoxypyridyl e.g 2-(2-hydroxyethoxy)-pyridyl or 2-(3-hydroxypropoxy)- pyrtdyl (in particular 2-(2-hydroxyethoxy)-pyrid-5-yl or 2-(3-hydroxypropoxy)-pynd-5-yl),
  • afkoxycarbonylpyridyl e.g methoxycarbonylpyndyl, especially 2-methoxycarbonyl- pyndyl (in particular 2 ⁇ methoxycarbonyl-pyrid-5-yl),
  • aminopyridyl e.g 2- or 3-aminopyridyl (in particular 2-aminopyrtd-5-yl or 3- aminopyrid-5-yl).
  • alkylaminopyrtdyl e.g. loweralkylaminopyridyl, in particular methylaminopyridyl such as 2-methylaminopyndyl or ethylaminopyridyl such as 2-ethylaminopy ⁇ dyl (especially 2- methylaminopyrid-5-yl or 3 ⁇ ethylaminopyrid-5-yl);
  • dialkylaminopyridyl in particular di-loweralkylaminopy ⁇ dyl, e.g 2-, 3- or 4- dimethylaminopyndyl, especially 2-dimethylaminopyridyl (in particular 2-dimethylaminopyrid- 5-yl) or e g 2-, 3- or 4-diethylaminopyridyl, especially 2-diethylaminopyridyl (in particular 3- diethylaminopyrid-5-yl) or e g 2-, 3- or 4-ethylmethylaminopy ⁇ dyl especially 2- ethylmethylaminopy ⁇ dyl (in particular 2-ethylmethylaminopyrid-5-yl);
  • alkoxy)(amino)pyridyl e g (loweralkoxy)(amino)pyridyl, in particular (methoxy)(amino)py ⁇ dyl such as 2-methoxy-3-amino-pyridyl (especialry 2-methoxy-3-amino- pyrid-5-yl),
  • alkyl)(alkyiamino)py ⁇ dy1 e.g. (loweralkyl)(lowefalkylamino)pyridyl > in particular (methyl)(ethylamino)pyridyl such as 2-methyl-3-ethylamino-pyndyl (especially 2 ⁇ methyl-3- ethylamino-pynd-5-yl);
  • alkyl)(di-alkylamino)pyrklyl e g. (loweralkyl)(di-loweralkylamino)pyridyl, in particular (methyl)(N-methyl-N-ethylamino)pyrtdyl such as 2-methyl-3-(N-methyl-N-ethylamino)-pyridyl (especially 2-methyl-3-(N-methyl-N-ethylamino)-py ⁇ d-5-yl)
  • cycloaminopyridyl e g. azetidinylpyridyl, especially 2-azetidin-1-yl-pyridinyl (in particular 2-azetidin- 1 -yl-pyridin-5-yl),
  • hydroxyalkylaminopyridyl e g 2 ⁇ (2-hydroxyethylamino)-py ⁇ dyl (in particular 2-(2- hydroxyethylamino)-pyrid-5-yl), amino-haloloweralkyl-pyridyl, e.g. amino-t ⁇ fluoromethyl- pyridyl, especially 2-amino-3-trtfluoromethyl-py ⁇ dyl (in particular 2-am)no-3-trifluoromethyl- pyrid-5-yl);
  • halopyridyl in particular fluoropyridyl, especialiy 2-fluoropy ⁇ dyl (in particular 2- fluoropyrid-3-yl or 2-fluoropyrid-4-yl),
  • halo-alkoxy-pyridyl e g, fluoro-methoxy-pyridyl such as 3-fluoro-2-methoxy-pyridyl (in particular 3-fluoro-2-methoxy ⁇ py ⁇ d-5-yl);
  • carbamoylpyridyl especially 2-(carbamoy1)pyridyl (in particular 2- ⁇ carbamoyl)pynd-5- yl), alkyl-stibstituted carbamoyl, e.g methylcarbamoyl, especially 2-(methylcarbamoyl)pyridyl (in particular 2-(methylcarbamoyl)pyrid-5-yl);
  • piperazinylpyridyl e g 1 -piperazinylpyridyl. especially 2-(1-piperazinyl)pyridyl (in particular 2-(1-piperazinyl)pyrid-5-yl), N-alkylpiperazinylpyndyl, such as N- toweralkylpiperazmylpyridyl, e g N-methylpiperazinytpyridyl, especially 2- ⁇ 4-methylp ⁇ erazin- 1-y
  • dialkylsulfonamidopyridyl such as diloweralkylsulfonamidopy ⁇ dyl, especially dimethylsulfonamidopyridyl, e.g. 3-(dimethylsulfonamido) py ⁇ dyl (in particular 3- (dimelhylsulfonamido)-pyridin-5-yl);
  • alkylsulfonamido)(alkyl)pyridyl such as (loweralkylsulfonamido)(loweralkyl)py ⁇ dyl, especially (methylsulfonamido)(methyl)pyridyl, e.g. 3-(methylsulfonamido)(methyl)py ⁇ dyl (in particular 3-(methylsulfonamido) ⁇ 2-methyl pyridin-5-yl);
  • dialkylsulfonamido(afkyl)pyridyl such as diloweralkytsulfonamido(loweralkyl)pyridyl, especially dimethylsulfonamido(methyl)py ⁇ dyl ( e.g. 3-(dimethylsulfonamido)(2-methyl) pyridyl (in particular 3-(dimethylsulfonamido)-(2-methyl)-pyridin-5-yl); 3H-tetrazol-5-yl pyridyl, e g. 2- (3H-tetrazol-5-yl)pyridyl (in particular 2-(3H-tetrazol-5-yl)pyrid-5-yl);
  • alkoxy(alkylcarbonylamino)pyridyl such as (loweralkoxy)(loweralkylcarbonylamino) pyridyl, e.g. (methoxy)(methylcarb ⁇ nylamino)pyridyl or (ethoxy)(methylcarbonylamino)pyridyl, especially 2-(methoxy)-3-(methylcarbonylamino)pyridyl or 2-(ethoxy)-3- (methyjcarbonylamino)pyridyl (in particular 2>(methoxy)-3-(methylcarbonylamino)pyrid-5-yl or 2-(ethoxy)-3-(methylcarbonylamino)pynd-5-yl);
  • alkoxy (alkyicarbonyl ⁇ N-alkylamino)pyridyl, such as (loweralkoxy)(loweralkylcarbonyl- N-loweralkylamino)pyrtdyl, e.g.
  • alkoxy)(nitro)pyridyl such as (loweralkoxy)(nitro)pyridyl, e.g, (methoxy)(nitro)pyridyl, especially 2-(methoxy)-3-(nitro)-pyridyl (in particular 2-(methoxy)-3-(nitro)-pyrid-5-yl);
  • (methoxy)(amino)pyridyl especiaHy 2-(methoxy)-3-(amino)-pyridyl (in particular 2-(methoxy)- 3-(amino)-pyrid-5-yl), (alkoxy)(alkylamino)pyridyl, such as (loweralkoxy)(alkylamino)pyridyl, e.g. (methoxy) ⁇ ethylamino)pyridyl, especially 2 ⁇ (methoxy)-3-(ethylamino)pyridyl (in particular 2- (methoxy)-3-(ethylamino)pyrid-5-yl;
  • (loweralkoxy)(loweralkylaminocarbonyl)pyridyl e.g (methoxy)(methylaminocarbonyl)pyridyl, especially 2-(methoxy)-3-(methylaminocarbonyl)pyridyl (in particular 2-(methoxy)-3- (methylaminocarbonyl)pyrid-5-yl,
  • alkoxy(hydroxycarbonyl)pyridyl such as (loweralkoxy)(hydroxycarbonyl)pyridyl, e.g (methoxy)( hydroxycarbonyl)pyridyl, especially 2-(methoxy)-3-(hydr ⁇ xycarbonyl)pyridyl (in particular 2- ⁇ methoxy)-3-(hydroxycarbonyl)pyrid-5-yl;
  • pyrimidinyl in particular pyrimidin-5-yl
  • di-loweralkyfaminopyrimidinyl e g 2- or 4-dimethylaminopyrimidi ⁇ yl, especially 2- dimethylammopyrimidinyl (in particular 2-dimethylaminopyrimidin-5-yl),
  • alkoxypyrimidinyl in particular methoxypyrimidinyl or ethoxypyrimidinyl, e.g 2- methoxypy ⁇ midinyl or 2-ethoxypy ⁇ midinyl (in particular 2-methoxypy ⁇ midin-5-yl or 2- ethoxypyrimidin-5-yl);
  • pyrazolyl e.g. pyrazol-4yl
  • substituted pyrazolyl e g. hydroxyalkylpyrazolyl, especially H2-hydroxy-ethyl)-1H- pyrazolyl (in particular 1-(2-hydroxy-ethyl)-1 H-pyrazol-4-y1 ) or 1-[2-(tetrahydro-pyran-2- yloxy)-ethyl]-1 H-pyrazolyl (in particular 1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol ⁇ 4- yl):
  • quinolinyl in particular quinolin-3-yl.
  • 3H-im(dazo[4,5-b]pyridin-6-yl e.g. (3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl, (2- methyl)-(3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl, (2-methoxy)-(3-methyl)-3H-imidazo[4,5- bJpyridin-6-yl, (2-dfmethylamino)-(3-methyl)-3H-imidazol4,5-b]pyridin-6-yl;
  • R 3 is selected from
  • pyridyl 2-methylpyridyl, 3-methylpyridy), 2-methoxypyridinyl, 3-methoxypyridinyl, 3- ethoxypyrtdyl, 2-ethoxypyndyl, 2-ethoxypy ⁇ dyl, 6-(n-propoxy)pyridyl or 3-(iso- propoxy)py ⁇ dinyl or 2-(iso-propoxy)pyridinyl, 3-cyclob ⁇ toxy-pyridyi, 3-(1 ,3-difl ⁇ oropropan-2- yloxy)-pyridyl, 3-(2-fl ⁇ oroethan-1-yloxy)-pyridyl, S-CdifluoromethyloxyJ-py ⁇ dyl, 2- cyclopropyh ⁇ »ethoxy-pyridyt, 2-methoxymethylpyndyl, 3-methoxymethylpyridyl, 3-(2-methoxy- prop-2-yi)
  • R 3 is selected from
  • a preferred group of compounds of the present invention of formula (i) are those wherein X is O
  • Another preferred group of compounds of the present invention of formula (I) are those wherein Y is CH
  • Another preferred group of compounds of the present invention of formula (I) are those wherein X is O or S and Y is CH.
  • Another preferred group of compounds of the present invention of formula (I) are those wherein X is O and Y is CH.
  • An alternative group of compounds of the present invention of formula (I) are those wherein X is O or S and Y ts N
  • An preferred group of compounds of the present invention of formula (I) are those wherein X is O and Y is N
  • An embodiment of the present invention includes compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein'
  • X is O or S
  • Y is CH or N
  • R 1 is unsubstituted pyrazolyl or pyrazolyl substituted with one, two or three substrtuents at least one of which is in the alpha-position, said substituents being independently selected from lower alkyl, halo, halo lower alkyl, hydroxy lower alkyl, alkoxy lower alky!, carbamoyl lower alkyl, hydroxycarbonyl lower alkyl, dialkylaminocarbonyl lower alkyl, cycloaminocarbonyl lower alkyl, morphoJinecarbonylalkyl, piperazinecarbonyl lower alkyl or alkyl-substituted piperazinecarbony! lower alkyl; or
  • R 1 is unsubstituted isoxazolyl or isoxazolyl substituted with one or two lower alkyl substituents,
  • R 2 is hydrogen, lower alkyl or lower aJkenyl
  • R* is unsubstituted phenyl, or phenyl substituted with one or two groups independently selected from the group consisting of halo, halo-lower alkyl; hydroxy!, amino, mono or disubstituted ammo, cyclic amino, amino-lower alkyl, lower alkoxy, hydroxy-lower alkyl, hydroxy lower alkoxy, lower alkyl, cyano; cyano-lower alkyl, amidino, N- hydroxyamidino, amtdino-lower alkyl, or N-hydroxyamidino-lower alkyl, sulfonyl, alkyl-substituted sulfonyl, sulfonamide; pyrrolidinesulfonyl, lower alkyl sulfonyl amino, lower alkyl sulfonylalkandiylamino, lower alkylsulfonyl-N-lower alkylamino, [
  • R 3 is indolyl, 1-methyl-2,3-dihydro ⁇ 1H-indolyl 2oxo-2,3-dihydro-1H-mdolyl, py ⁇ dyl, pyrimidinyl, 1H-pyrrolo ⁇ 2,3-b]pyridinyl, 1-methyl-1 H-pyrrolo[2,3-bJpyridinyl, pyrazolyl, pyrazinyl, quinolyl, 1 3-Dimethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyndinyl, 1- ethyf-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo(4,5-b]pyridinyl, 1-(2 «methoxy-ethyl) ⁇ 3- methyl-2-oxo-2,3-dihydro-1H-imidazo ⁇ 4,5-b
  • a further embodiment of the present invention includes compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein-
  • R 1 is unsubstituted pyrazolyl or pyrazolyl substituted with one, two or three substituents, at least one of which is in the alpha-position, said substituents being independently selected from lower alkyl; halo, halo lower alkyl, hydroxy lower alkyl, alkoxy lower alkyl, carbamoyl lower alkyl, hydroxycarbonyl lower alkyl, dialkylaminocarbonyl lower alkyl, cycloaminocarbonyl lower alkyl, morpholinecarbonylalkyl, piperazinecarbonyl lower alkyl or alkyl-substituted piperazinecarbonyl lower alkyl; or
  • R 1 is unsubstituted isoxazofyl or isoxazolyl substituted with one or two unsubstituted lower alkyl substituents
  • R 2 is hydrogen, lower alkyi or lower alkenyl
  • R 3 is selected from phenyl, hydroxyphenyl, methoxy phenyl. 3,4-dimethoxypheny), ethoxyphenyl, 3 4-diethoxyphenyl; iso-propoxyphenyl; methoxy ethoxy-phenyl; 3-methoxy-4- (2-methoxy ethoxy)-phenyl, fluoro-(iso-propoxy)-phenyl, 3-methoxy-4 ⁇ hydroxy phenyl, fluoro- hydroxy-phenyl; hydroxy-fluoroalkyl-phenyl, 2,2-difluoro-benzo(1 3]dioxolo benzene sulfonamide; N.N-dimethylbenzenesulfonamide, 3-(pyrrolidine-1-sulfonyl)-phenyl; N- ⁇ phen-3- yl)-methanesulfonamide; N-methyl-N-phen-3-yl-methanes ⁇ lfonamide
  • An embodiment of the present invention includes compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
  • R 1 is ⁇ nsubstituted pyrazolyl or pyrazolyl substituted with one, two or three substituents, at least one of which is in the alpha-position , said substituents being independently selected from lower alkyl; halo; halo lower alkyl, hydroxy lower alkyl, alkoxy lower alky!, carbamoyl lower alkyl, hydroxycarbonyl lower alkyl, dialkylaminocarbonyl lower alkyt, cycloaminocarbonyt lower alkyl, morpholinecarbonylalkyl or piperazinecarbonyl lower alkyl,
  • R 2 is hydrogen or lower alkyl
  • R 3 is uns ⁇ bstituted phenyl, or phenyl substituted with one or two groups independently selected from the group consisting of halo, halo-lower alkyl, hydroxyl; amino, mono or disubstituted amino, cyclic amino; ammo-lower alkyl, lower alkoxy; hydroxy-lower alkyl; hydroxy lower alkoxy, lower alkyl, cyano, cyano-lower alkyl; amidino, N- hydroxyamidino; amkJmo-lower aikyl; or N-hydroxyamidino-Jower alkyl, sulfonyl, alkyl-substituted sulfonyl; sulfonamide; pyrrolidinesulfonyl, [1 ,3]dioxolo, halo- substituted [1 ,3]dioxolo, alkoxy carbonyl; carbamoyl; substituted carb
  • R 3 is indolyl, 2,3-dihydro-1H-indol-5-yl, 1-methy!-2,3-dihydro-1 H-indol-5-yl 2-oxo-2,3- dihydro-1 H-indol-5-yl, py ⁇ dyl, pyrimidinyl, 1H-pyrrolo[2,3-b]pyndin-5-yl, 1-methyl-1H- pyrrolo[2,3-b]pyridin-5-yl, pyrazolyl, pyrazol-4-yl, pyrazinyl, quinolyl quinoi-3-yl, 1 H- imidazo[4,5-b)py ⁇ din-2(3H)-one-6-yl, 3H-imidazo(4,5-b]pyridin-6-y!, 3H- [1 ,2,3]tnazolo[4,5-b]pyridin-6-yl each independently being unsubstituted or substituted by one
  • a further embodiment of the present invention includes compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein' X is O or S;
  • Y is CH or N
  • R 1 is unsubstituted pyrazolyl or pyrazolyl substituted with one, two or three substituents, at least one of which is in the alpha-position, said substituents being independently selected from lower alkyl, halo; halo lower alkyl, hydroxy lower alkyl, alkoxy lower alkyl, carbamoyl lower alkyl, hydroxycarbonyl lower alkyl, dialkylaminocarbonyl lower alkyl, cycloaminocarbonyl lower alkyl, morpholinecarbonylalkyl or piperazinecarbonyl lower alkyl;
  • R 2 is hydrogen or lower alkyl
  • R 3 is selected from phenyl; hydroxyphenyi, methoxyphenyl; 3,4-dimethoxyphenyl; ethoxyphenyl, 3,4-diethoxyphenyl, methoxy ethoxy-phenyl, 3-methoxy-4-(2-methoxy ethoxy) ⁇ phenyl; 3-methoxy-4-hydroxy phenyl, ftuoro-hydroxy-phenyl, hydroxy- fluoroalkyl-phenyl; 2,2-difluoro-benzo[1 ,3]dioxolo; benzene sulfonamide; 3- (pyrrolidine-1-sulfonyl)-phenyl; N «(phen-3-yl)-methanesuffonamide; N-methyl-N- phen-3-yl-methanes ⁇ lfonamide; 3-methanesulfonylphenyi; 3- or 4-benzamide; 3- or 4-NI-methyl-benzamide; 3- or 4-N,
  • the present invention is further directed to a method of treating a protein kinase dependent disease comprising administering a compound of formula (I), where the disease to be treated is a proliferative disease, preferably a benign or especially malignant tumor, more preferably carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina or thyroid, sarcoma, glioblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma or a tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, lymphomas, a mammary carcinoma or a leukemia, and including proliferative diseases such as tumor diseases, leukaemias and myeloproliferative disorders such as polyc
  • Cowden syndrome Lhermitte-Dudos disease and Bannayan-Zonana syndrome or diseases in which the PI3K/PKB pathway is aberrantly activated
  • a compound of the formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof as exemplified hereinbelow under "Examples”
  • the compounds of formula (I) that inhibit the protein or lipid kinase activities mentioned, especially mTOR Ser/Thr kinase activity and/or class I PI3 kinases activrty may therefore be useful in the treatment of protein or lipid kinase dependant diseases, especially diseases depending on class I and/or class IV PI3 kinases, for example, PISKalpha, POKbeta, POKdelta, PI3Kgamma andfor mTOR, or one or more of the individual kinase members thereof, including other PI3-kinases such as DNA-PK ATM, ATR, hSMG-1 and Vps34 or any combination of two or more of the mentioned kinases
  • Protein or lipid kinase dependent diseases are especially proliferative diseases, a benign or especially malignant tumor, a carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach (especially gastric tumors), ovaries, colon, rectum, prostate, pancreas, lung, vagina, thyroid, sarcoma, glioblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma, or a tumor of the neck and head, other diseases such as Cowden syndrome, Lhermitte-Dudos disease and Bannayan-Zonana syndrome, or diseases in which the P13K/PKB pathway is aberrantly activated, an epidermal hyperproliferation, especially psoriasis, prostate hyperplasia, a neoplasia, especially of epithelial character, preferably mammary carcinoma or squamous cell carcinoma or a leukemia.
  • proliferative diseases a benign or especially malignant
  • the compounds desirably are able to bring about the regression of tumors and to prevent the formation of tumor metastases and the growth of (also micro) metastases
  • they may be used in epidermal hyperproliferation , e g , psoriasis, in prostate hyperplasia; in the treatment of neoplasias, especially of epithelial character, e g., mammary carcinoma, in leukemias: and in basal cell carcinoma, squamous cell carcinoma and actinic keratosis
  • epithelial character e g., mammary carcinoma, in leukemias: and in basal cell carcinoma, squamous cell carcinoma and actinic keratosis
  • the compounds of the formula (I) can be prepared according to the following methods
  • a compound of formula (I) is converted into a compound of formula (I) by known in the art chemical reactions such as protecting group deprotection, e g tert-birtyloxycarbonyl (boc) group deprotection with TFA, neat or in presence of a solvent such as a polyhalogeneated alkane, e g. dichloromethane at a temperature between O°C to 40°C ; functional group substitution e g alkylation of a hydroxy! group to form an alkoxy group by treatment with a strong based such as metal hydride, e.g sodium hydride, in an aprotic solvent, e.g.
  • Hal refers to halogen preferably bromine
  • X 1 R 1 , R 2 , R 4 , R 5 and R ⁇ are as defined herein above;
  • R 3 is as defined for a compound of the formula (I), in the presence of a base and a catalyst in a suitable solvent; to provide a compound of formula (I)
  • any protecting groups in a protected derivative of a compound of the formula I are optionally removed, and if desired, transforming an obtainable compound of formula (I) into a different compound of formula (I), or a N-oxide thereof, transforming a salt of an obtainable compound of formula (! into the free compound or a different salt, or an obtainable free compound of formula (I) into a salt; and/or separating an obtainable mixture of isomers of compounds of formula (I) into the individual isomers.
  • R 2 Conversion of R 2 from H to a substituent different from H as defined above for R 2 can be achieved by treating compound of formula (I) or (II) in presence of a strong base in a suitable solvent and subsequent adjunction of a halogenated reagent HaI-R 2 wherein Hal refers to halogen preferably iodine or bromine, e g. methyliodide
  • a compound of formula (Ii) is prepared by reacting a compound of formula (IV)
  • R 1 , R 4 , R* and R 6 are as mentioned for a compound of the formula (I)
  • a compound of the formula (IV) is prepared by reduction of a compound of the formula (V)
  • substituents and symbols are defined as for compounds of the formula (I) in the presence of an appropnate catalyst, e g., a skeleton based catalyst, such as Raney-Ni with hydrogen in an appropriate solvent, e g., an alcohol and or a cycloalkylether, such as methanol and/or tetrahydrofurane, at preferred temperatures e g between O°C and 50 ⁇ C, e.g., at RT
  • an appropnate catalyst e g., a skeleton based catalyst, such as Raney-Ni with hydrogen in an appropriate solvent, e g., an alcohol and or a cycloalkylether, such as methanol and/or tetrahydrofurane
  • a compound of formula (V) is preferably prepared by reacting a compound of the formula (Vl)
  • a base such as a tertiaryamine, e g 1 ,2,2,6,6-pentamethylpiperidine
  • an appropriate solvent preferably a polar aprotic solvent such as dimethylacetamide at preferred temperatures between 2O°C and 12O°C temperature of the reaction mixture, e g , between 2O°C and 7O°C
  • a compound of the formula (Vl) can be prepared by reacting a compound of the formula (VIII) wherein the moieties and symbols have the meanings indicated for a compound of the formula (I) 1 with an inorganic acid halogenide, especially POCI 3 (preferably without solvent) at elevated temperatures, e.g., between 10O°C and 15O°C or under reflux.
  • an inorganic acid halogenide especially POCI 3 (preferably without solvent)
  • a compound of the formula (VIII) is known in the art, can be synthesized according to methods known in the art and/or is commercially-available. For example, it can be synthesized by reacting a compound of the formula (IX)
  • a compound of the formula (VIII) 1 can alternatively be synthesized by reacting a compound of the formula (X)
  • a compound of formula (I) wherein Y - N is prepared in two steps by saponification of the ester group by treatment with a base such as an alkali metal hydroxide, e.g lithium hydroxide in a solvent such as wet cycloaklylether, e g dioxane/water, at a temperature between 20"C and 100°C, preferabely between 3O°C and 6O°C, a compound of the formula (XII)
  • R 1 , R 3 , R 4 R 5 and R ⁇ are as defined herein above and R is uns ⁇ bstituted or substituted lower alky!, e.g. ethyl,
  • the freed intermediate obtained after neutralization of the reaction mixture with an acid, such as a mineral actd e g hydrochloric acid, and evaporation to dryness is converted by a Cursius rearrangement to compound of formula (I) via in situ formation of the acylazide intermediate by treatment with diphenylphosporylazide in an aprotic solvent, such as pot ⁇ r aprotic and/or polar protic, e g toluene/N-methylpyro)idinone, in presence of a base, such as a tertiaryamine, e g triethylamine, at temperature between 6O°C and 12O°C, e g. between 8O°C and 11O°C; the isocyanato intermediate spontaneously cyclized to form compound of formula (I) in the reaction conditions.
  • an acid such as a mineral actd e g hydrochloric acid
  • evaporation to dryness is converted by a Cursius rearrangement
  • a compound of formula (XII) is preferably prepared by reacting a compound of the formula (XIII)
  • Q is halo, especially chloro; and the other moieties have the meanings indicated for compounds of the formula (I) 1 and R is unsubstituted or substituted lower alky), e.g ethyl, with a compound of the formula (VII)
  • R 1 -NH 2 (VII) 1 wherein R 1 is as defined for a compound of the formula (I), in the presence of a base such as a tertiaryamine, e.g. 1 ,2,2,6,6-pentamethylpiperidine, in an appropriate solvent; preferably a polar aprotic solvent such as dimethylacetamide, at preferred temperatures between 20 9 C and 12O°C temperature of the reaction mixture, e.g., between 2O°C and 70 ⁇ C.
  • a base such as a tertiaryamine, e.g. 1 ,2,2,6,6-pentamethylpiperidine
  • an appropriate solvent preferably a polar aprotic solvent such as dimethylacetamide
  • a compound of formula (XIII) is preferably prepared by reacting a compound of the formula (XIV)
  • a compound of formula (XIV) is preferably prepared by reacting a compound of the formula (XV)
  • R and R' being selected independently from unsubstituted or substituted alkyl, e g. being both ethyl; in a solvent and pressure condition, e.g. xylene in a seal tube, allowing reaction at a temperature between 15O°C and 300°C, e.g. between 22O°C and 25O°C.
  • a compound of formula (XV) is known in the art and can be prepared by reduction of a compound of the formula (XVII)
  • moieties have the meanings indicated for a compound of the formula (I) with a compound of formula (XVI) in the presence of an appropriate catalyst, e.g., a skeleton based catalyst, such as Raney-Ni with hydrogen in an appropriate solvent, e.g., an alcohol and or a cycloalkylether, such as methanol and/or tetrahydrofurane; at preferred temperatures e.g. between 0°C and 5O°C, e.g., at RT.
  • a catalyst e.g., a skeleton based catalyst, such as Raney-Ni with hydrogen in an appropriate solvent, e.g., an alcohol and or a cycloalkylether, such as methanol and/or tetrahydrofurane
  • solvent e.g., an alcohol and or a cycloalkylether, such as methanol and/or tetrahydrofurane
  • a compound of formula (XVII) is known in the art and can be prepared by reacting a compound of formula (XVIII)
  • R 3 is as defined for a compound of the formula (I), in the presence of a base and a catalyst in a suitable solvent
  • the present invention relates also to novel starting matenals and/or intermediates and to processes for their preparation
  • the starting materials used and the reaction conditions selected are preferably those that result in the compounds described as being preferred
  • the present invention relates also to novel starting materials and/or intermediates and to processes for their preparation
  • the starting materials used and the reaction conditions selected are preferably those that result in the compounds described as being preferred
  • Salts of compounds of formula (I) having at least one salt-forming group may be prepared in a manner known per se
  • salts of compounds of formula (I) having acid groups may be formed, e g , by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e g , the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used.
  • metal compounds such as alkali metal salts of suitable organic carboxylic acids, e g , the sodium salt of 2-ethylhexanoic acid
  • organic alkali metal or alkaline earth metal compounds such as the corresponding hydroxides, carbonates or hydrogen carbon
  • Actd addition salts of compounds of formula (I) are obtained in customary manner, e.g , by treating the compounds with an a ⁇ d or a suitable anion exchange reagent
  • Internal salts of compounds of formula (I) containing acid and basic salt- forming groups, e g., a free carboxy group and a free amino group may be formed, e g,, by the neutralization of salts, such as acid addition salts, to the isoelectric point, e g , with weak bases, or by treatment with ion exchangers
  • Salts can be converted m customary manner into the free compounds, metal and ammonium salts can be converted, e.g , by treatment with suitable acids, and acid addition salts, e g , by treatment with a suitable basic agent
  • isomers obtainable according to the invention can be separated in a manner known per se into the individual isomers; diastereoisomers can be separated, e.g , by partitioning between polyphasic solvent mixtures, recrystajlization and/or chromatographic separation, e g., over silica gel or by, e.g , medium pressure liquid chromatography over a reversed phase column; and racemates can be separated, e g., by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, e g., by means of fractional crystallization, or by chromatography over optically active column materials
  • functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected, e g , by one or more protecting groups
  • the protecting groups are then wholly or partly removed according to one of the known methods.
  • protecting groups are those that they can be removed readily, i e , without the occurrence of undesired secondary reactions, e g., by solvolysis, reduction, photolysis or alternatively under physiological conditions
  • the end products of formula (I) may however also contain substit ⁇ ents that can also be used as protecting groups in starting materials for the preparation of other end products of formula (I)
  • a readily removable group that is not a constituent of the particular desired end product of formula (I) is designated a "protecting group", unless the context indicates otherwise.
  • All the above-mentioned process steps can be carried out under reaction conditions that are known perse, preferably those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, preferably solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, e.g., ion exchangers, such as cation exchangers, e g , in the H * form, depending on the nature of the reaction and/or of the reactants at reduced, normal or elevated temperature, e g in a temperature range of from about -10O°C to about 19O°C; preferably from approximately -80X to approximately 15O°C, e g , at from -80°C to -6O°C at RT, at from -2O°C to 4O°C or at reflux temperature; under atmospheric pressure or in a closed vessel, where appropnate under pressure and/or in an in
  • mixtures of isomers that are formed can be separated into the individual isomers, e g., diastereoisomers or enantiomers, or into any desired mixtures of isomers, e.g , racemates or mixtures of diastereoisomers, e g , analogously to the methods described under "additional process steps"
  • solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, e g , water, esters, such as lower alkyl- lower alkanoates, e.g. ethyl acetate, ethers, such as aliphatic ethers, e g , diethyl ether, or cyclic ethers, e g , tetrahydrofuran or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitnles, such as acetonit ⁇ le, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases such as heterocyclic nitrogen bases, e g pyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic
  • the compounds, including their salts, may also be obtained in the form of hydrates, or their crystals may e g , include the solvent used for crystallization Different crystalline forms may be present.
  • the invention relates also to those forms of the process in which a compound obtainable as intermediate at any stage of the process is used as starting material and the remaining process steps are earned out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, e g., in protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in sttu
  • those starting materials are preferably used which result in new compounds of formula (I) described at the beginning as being especially valuable
  • reaction conditions that are analogous to those mentioned in the examples
  • the invention relates also to pharmaceutical compositions comprising a compound of formula (I) to their use in the therapeutic (in a broader aspect of the invention also prophylactic) treatment or a method of treatment of a lipid or protein kinase dependent disease, especially the preferred diseases mentioned above, to the compounds for said use and to the preparation of pharmaceutical preparations, especially for said uses
  • the present invention also relates to pro-drugs of a compound of formula (I) that convert in vivo to the compound of formula (I) as such Any reference to a compound of formula (I) is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula (I), as appropriate and expedient
  • the pharmacologically acceptable compounds of the present invention may be used e g , for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as active ingredient together or in admixture with a significant amount of one or more inorganic or organic solid or liquid, pharmaceutically acceptable carriers
  • the invention relates also to a pharmaceutical composition that is suitable for administration to a warm-blooded animal, especially a human (or to ceils or cell lines derived from a warmblooded animal, especially a human, e g. lymphocytes), for the treatment or, in a broader aspect of the invention, prevention of ( ⁇ prophylaxis against) a disease that responds to inhibition of protein kinase activity, composing an amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is effective for said inhibition, especially the in, together with at least one pharmaceutically acceptable carrier.
  • compositions according to the invention are those for enteral, such as nasal, rectal or oral; parenteral, such as intramuscular or intravenous; or topical, such as dermal administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier.
  • the dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
  • the invention relates also to a method of treatment for a disease that responds to inhibition of a lipid or protein kinase which comprises administering an (against the mentioned disease) prophylactically or especially therapeutically effective amount of a compound of formula (I) according to the invention, especially to a warm-blooded animal, e.g , a human, that, on account of one of the mentioned diseases, requires such treatment
  • the dose of a compound of the formula (!) or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals, e.g , humans of approximately 70 kg body weight, is preferably from approximately 3 mg to approximately 10 g, more preferably from approximately 10 mg to approximately 1 5 g, most preferably from about 100 mg to about 1000 mg/person/day, divided preferably into 1-3 single doses which may, e g., be of the same size.
  • children receive half of the adult dose
  • compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
  • Pharmaceutical compositions according to the invention may be, e.g , in unit dose form, such as in the form of ampoules, vials, suppositories, dragees. tablets or capsules
  • compositions of the present invention are prepared in a manner known per se, e g , by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes
  • Solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions are preferably used, it being possible, e.g., in the case of lyophilized compositions that compose the active ingredient alone or together with a carrier, e g., mannitol, for such solutions or suspensions to be produced prior to use.
  • a carrier e g., mannitol
  • compositions may be sterilized and/or may comprise ex ⁇ pients, e g., preservatives, stabilizers, wetting and/or emulsifying agents, sol ⁇ bilizers, salts for regulating the osmotic pressure and/or buffers, and are prepared in a manner known per se, e g., by means of conventional dissolving or tyophilizing processes
  • ex ⁇ pients e g., preservatives, stabilizers, wetting and/or emulsifying agents, sol ⁇ bilizers, salts for regulating the osmotic pressure and/or buffers
  • the said solutions or suspensions may compnse viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylceliulose, dextran, polyvinylpyrrolidone or gelatin
  • Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes.
  • liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8-22 carbon atoms, especially from 12-22 carbon atoms, e g , lauric acid, t ⁇ decylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, e.g , oleic acid, elaidic acid, erucic acid, brasidic acid or linoletc acid, if desired with the addition of antioxidants, e g , vitamin E, ⁇ -carotene or 3,5-di-tert-butyl-4-hydroxytoluene.
  • the alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a mono- or poly-hydroxy, e g., a mono-, di- or tri-hydroxy; alcohol, e.g., methanol, ethanol, propanol, butanol or pentanol, or the isomers thereof, but especially glycol and glycerol.
  • fatty acid esters are therefore to be mentioned' ethyl oleate, isopropyl myristate, reopropyl palmitate, "Labrafil M 2375” (polyoxyethylene glycerol trioleate, Gattefosse, Paris), "Miglyol 812” (triglyceride of saturated fatty acids with a chain length of Ce-Ci ? , H ⁇ ls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil
  • the injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.
  • compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropnate excipients, into tablets, dragee cores or capsules It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts
  • Suitable carriers are especially fillers, such as sugars, e g , lactose, saccharose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates, e g., t ⁇ calcium phosphate or calcium hydrogen phosphate; and binders, such as starch pastes using, e g , corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; and/or, if desired, disintegrators, such as the above-mentioned starches; and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate
  • Excipients are especially flow conditioners and lubricants, e.g., silicic acid, talc, stearic acid or salts thereof, such as magnesium or
  • Dragee cores are provided with suitable, optionally entertc, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide; or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate
  • Capsules are dry- filled capsules made of gelatin and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the dry-filled capsules may comprise the active ingredient in the form of granules, e.g , with fillers, such as lactose; binders, such as starches, and/or gltdants, such as talc or magnesium stearate; and if desired with stabilizers
  • the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added Dyes or pigments may be added to the tablets or dragee coatings or the capsule casings, e g., for identification purposes or to indicate different doses of active ingredient
  • compositions for topical administration can be obtained by combining the active ingredient with a liquid carrier (e.g. an aqueous Itquid carrier) to dissolve or disperse the active, together with further optional formulating ingredients such as solvents/sol ⁇ bilisers, gelling agents, oils, stabilisers, buffers and preservatives to provide for example a solution, lotion, cream, gel or ointment.
  • a liquid carrier e.g. an aqueous Itquid carrier
  • further optional formulating ingredients such as solvents/sol ⁇ bilisers, gelling agents, oils, stabilisers, buffers and preservatives to provide for example a solution, lotion, cream, gel or ointment.
  • the pharmaceutical compositions for topical administration may be provided, for example, for derma) application
  • the pharmaceutical compositions for topical administration may comprise from approximately 0 1% to approximately 2% of active ingredient, the active ingredient being especially a compound of formula (I), in particular, a compound described in the individual examples herein.
  • Compounds of the invention display particularly high solubilities in organic solvents
  • the compounds of the invention are thus particularly useful for topical administration, e g. to a mammal such as a human, e g to the skin of said mammal.
  • the compounds are thus useful for formulation into compositions suitable for topical administration.
  • Compounds displaying high solubility thus provide an advantage for topical administration over compounds having a lower solubility.
  • a compound of the formula (I) may also be used to advantage in combination with each other or in combination with other therapeutic agents, especially other antiproliferative agents
  • antiproliferative agents include, but are not limited to, aromatase inhibitors, arrtiestrogens; topoisomerase I inhibitors, topoisomerase M inhibitors, microtubule active agents, alkylating agents; histone deacetylase inhibitors, compounds, which induce cell differentiation processes; cyclooxygenase inhibitors; MJvIP inhibitors, mTOR inhibitors, antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds, compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorehn agonists; anti- androgens, methionine aminopeptidase inhibitors, bisphosphonates, biological response modifiers, antiproliferative antibodies, heparanase inhibitor
  • aromatase inhibitor relates to a compound which inhibits the estrogen production, i e , the conversion of the substrates androstenedione and testosterone to estrone and estradiol respectively
  • the term includes, but is not limited to, steroids, especially atamestane, exemestane and formestane, and, in particular, non-steroids, especially aminoglutethimide, roglethimtde, py ⁇ doglutethimide, t ⁇ lostane, testolactone, ketokonazole.
  • Vorozole, fadrozole, anastrozole and letrozoie Exemestane can be administered, e g , in the form as it is marketed, e.g., under the trademark AROMASIN Formestane can be administered, e g., in the form as it is marketed, e g., under the trademark LENTARON Fadrozole can be administered, e g , in the form as it is marketed, e.g., under the trademark AFEMA Anastrozole can be administered, e.g., in the form as it is marketed, e g., under the trademark ARIMIDEX
  • Letrozole can be administered, e.g., in the form as it is marketed, e.g , under the trademark FEMARA or FEMAR Aminoglutethimide can be administered, e.g , in the form as it is marketed, e.g., under the trademark ORIMETEN.
  • anti-estrogen relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level
  • Tamoxifen can be administered, e.g , in the form as it is marketed, e.g., under the trademark NOLVADEX.
  • Raloxifene hydrochloride can be administered, e g , in the form as it is marketed, e.g., under the trademark EVISTA.
  • Fulvestrant can be formulated as disclosed in U.S. Patent No.
  • 4,659,516 or it can be administered, e g., in the form as it is marketed, e g , under the trademark FASLODEX.
  • a combination of the invention comprising a chemotherapeutic agent which is an ant ⁇ estrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g , breast tumors
  • anti-androgen relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g., as disclosed in U. S Patent No 4,636,505.
  • CASODEX bicalutamide
  • gonadorehn agonist includes, but is not limited to, abarelix, goserelin and goserelin acetate.
  • Goserelin is disclosed in U S. Patent No. 4,100,274 and can be administered, e g., in the form as it is marketed, e.g , under the trademark ZOLADEX Abarelix can be formulated, e.g., as disclosed in U.S Patent No. 5,843,901
  • topoisomerase I inhibitor includes, but is not limited to, topotecan, gimatecan, i ⁇ notecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in WO 99/17804), lrinotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark CAMPTOSAR Topotecan can be administered, e.g., in the form as it is marketed, e g , under the trademark HYCAMTIN
  • topoisomerase Il inhibitor includes, but is not limited to, the anthracyclmes, such as doxorubicin, including liposomal formulation, e.g., CAELYX, daunorubicin, epirubicin, idarubicin, nemorubicin; the anthraqumones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide Etoposide can be administered, e g , in the form as it is marketed, e g , under the trademark ETOPOPHOS.
  • the anthracyclmes such as doxorubicin, including liposomal formulation, e.g., CAELYX, daunorubicin, epirubicin, idarubicin, nemorubicin
  • the anthraqumones mitoxantrone and losoxantrone e.g , in the form as it is marketed
  • Teniposide can be administered, e g., in the form as it is marketed, e.g., under the trademark VM 26-BRISTOL
  • Doxorubicin can be administered, e g , in the form as it is marketed, e g , under the trademark ADRIBLASTIN or ADRlAMYCiN.
  • Epir ⁇ bicin can be administered, e.g.. in the form as it is marketed, e g , under the trademark FARMORUBICIN Idar ⁇ bicin can be administered, e g , in the form as it is marketed, e g., under the trademark ZAVEDOS.
  • Mitoxantrone can be administered, e g , in the form as it is marketed, e g., under the trademark NOVANTRON.
  • microtubule active agent relates to microtubule stabilizing, microtubule destabilizing agents and microtublin polymerization inhibitors including, but not limited to, taxanes, e.g., paclitaxel and docetaxel; vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate; vincristine, especially vincristine sulfate and vinorelbine; discodermolides; cochicine; and epothilones and derivatives thereof, e g , epothilone B or D or derivatives thereof.
  • taxanes e.g., paclitaxel and docetaxel
  • vinca alkaloids e.g., vinblastine, especially vinblastine sulfate
  • vincristine especially vincristine sulfate and vinorelbine
  • discodermolides e.g., cochicine
  • epothilones and derivatives thereof e g
  • Paclitaxel may be administered, e g , in the form as it is marketed, e g., TAXOL Docetaxel can be administered, e g., in the form as it is marketed, e.g., under the trademark TAXOTERE Vinblastine sulfate can be administered, e,g , in the form as it is marketed, e g., under the trademark VINBLASTIN R.P. Vincristine sulfate can be administered, e g., in the form as it is marketed, e g , under the trademark FARMISTiN Discodermolide can be obtained, e g. ( as disclosed in U S Patent No.
  • epothilone derivatives which are disclosed in WO 98/10121 , U S. Patent No 6,194,181 , WO 98/25929, WO 98/08849. WO 99/43653, WO 98/22461 and WO 00/31247, Especially preferred are epothilone A and/or B
  • alkylating agent includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel).
  • Cyclophosphamide can be administered, e g , in the form as it is marketed, e.g , under the trademark CYCLOSTIN.
  • Ifosfamide can be administered, e.g., in the form as it is marketed, e g , under the tractemark HOLOXAN.
  • histone deacetytase inhibitors or "HDAC inhibitors” relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity This includes compounds disclosed in WO 02/22577, especially N-hydroxy-3-f4-[ «2-hydroxyethyl)[2-(1W-indo! ⁇ 3-yl)ethyl]-aminoJmethyl]phenyl]-2£-2-propenamide, N-hydroxy-3-[4- ⁇ [ ⁇ 2-(2-methyM W-indol-3- yl)-ethyl]-amino]methyl]phenylJ-2£-2-propenamide and pharmaceutically acceptable salts thereof It further especially includes suberoylanilide hydroxamic acid (SAHA)
  • anti-plastic antimetabolite includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine; DNA demethylating agents, such as 5-azacytidtne and decitabine; methotrexate and edatrexate, and folic acid antagonists, such as pemetrexed Capecitabine can be administered, e g , in the form as it is marketed, e g , under the trademark XELODA Gemcitabine can be administered, e g , in the form as it is marketed, e g., under the trademark GEMZAR Also included is the monoclonal antibody trastuzumab which can be administered, e.g., in the form as it is marketed, e g., under the trademark HERCEPTIN
  • platinum compound includes, but is not limited to, carboplatin, c/s-platin, cisplatinum and oxaliplatin
  • Carboplattn can be administered, e.g , in the form as it is marketed, e g., under the trademark CARBOPLAT Oxalipiatin can be administered, e g , in the form as it is marketed, e.g , under the trademark ELOXATIN.
  • compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e g , EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related hgands, and are in particular those compounds, proteins or monoclonal antibodies genencally and specifically disclosed in WO 97/02266, e g , the compound of Example 39, or in EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, U.S.
  • EGFR epidermal growth factor family of receptor tyrosine kinases
  • anti-angiogenic compounds include compounds having another mechanism for their activity, e.g., unrelated to protein or lipid kinase inhibition, e.g., thalidomide (THALOMID) and TNP-470.
  • TAALOMID thalidomide
  • TNP-470 thalidomide
  • Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are, e.g , inhibitors of phosphatase 1 , phosphatase 2A 1 PTEN or CDC25, e g., okadaic acid or a derivative thereof
  • Compounds which induce cell differentiation processes are e.g. retinoic acid, ⁇ - ⁇ - or ⁇ -tocopherol or ⁇ - ⁇ - or ⁇ -tocotrienol.
  • cyclooxygenase inhibitor includes, but is not limited to, e.g., Cox-2 inhibitors, 5-afkyl substituted 2-arylaminophenyiacetic a ⁇ d and derivatives, such as celecoxib (CELEBREX), rofecoxib (VfOXX), etoncoxib, valdecoxib or a 5-alkyf-2-arylamtnophenylacetic acid, e.g., 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid or lumiracoxib.
  • Cox-2 inhibitors 5-afkyl substituted 2-arylaminophenyiacetic a ⁇ d and derivatives, such as celecoxib (CELEBREX), rofecoxib (VfOXX), etoncoxib, valdecoxib or a 5-alkyf-2-arylamtnophenylacetic acid, e.g.
  • bisphosphonates includes, but is not limited to, etndonic, clodronic, tiludronic, pamidronic, alendromc, ibandronic, ⁇ sedronic and zoledronic acid.
  • "Etndonic acid” can be administered, e g., in the form as it is marketed, e g , under the trademark DIDRONEL
  • "Clodronic acid” can be administered, e.g.. in the form as it is marketed, e.g , under the trademark BONEFOS 'Tiludronic acid” can be administered, e.g , in the form as it is marketed, e g , under the trademark SKELID.
  • “Pamidronic acid” can be administered, e.g in the form as it is marketed, e g , under the trademark AREDIATM.
  • “Alendronic acid” can be administered, e g , in the form as it is marketed, e.g., under the trademark FOSAMAX
  • “Ibandronic acid” can be administered, e g , in the form as it is marketed, e.g , under the trademark BONDRANAT.
  • миное кактивное ир ⁇ ество can be administered, e g , in the form as it is marketed, e g., under the trademark ACTONEL
  • Zoledronic acid can be administered, e.g., in the form as it is marketed, e g , under the trademark ZOMETA
  • mTOR inhibitors relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity, such as sirolim ⁇ s (Rapamune* 5 ), everolimus (CerticanTM), CCI-779 and ABT578.
  • heparanase inhibitor refers to compounds which target, decrease or inhibit heparin sulphate degradation
  • the term includes, but is not hmited to, PI-88
  • biological response modifier refers to a lymphokine or interferons, e.g., interferon ⁇ .
  • inhibitor of Ras oncogenic isoforms refers to compounds which target, decrease or inhibit the oncogenic activity of Ras, e g , a "farnesyl transferase inhibitor”, e.g , L-744832, DK8G557 or R115777 (Zarnestra).
  • telomerase inhibitor refers to compounds which target, decrease or inhibit the activity of telomerase.
  • Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e g , telomestatin.
  • methionine aminopeptidase inhibitor refers to compounds whtch target, decrease or inhibit the activity of methionine aminopeptidase Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are, e g , bengamide or a derivative thereof
  • proteasome inhibitor refers to compounds which target, decrease or inhibit the activity of the proteasome.
  • Compounds which target, decrease or inhibit the activity of the proteasome include, e g., PS-341 and MLN 341
  • matrix metalioproteinase inhibitor or "MMP inhibitor” as used herein, includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e g , hydroxamate peptidomimetic inhibitor batimastat and its oralfy bioavailable analogue marimastat (BB-2516), pnnomastat (AG3340). metastat (NSC 683551) BMS-279251 , BAY 12-9566 TAA211 , MMI270B or AAJ996.
  • agents used in the treatment of hematologic malignancies includes, but is not limited to, FMS-like tyrosine kinase inhibitors, e g., compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R), interferon 1-b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, e g., compounds which target, decrease or inhibit anaplastic lymphoma kinase Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the Rt-3R receptor kinase family, e g., PKC412, midostauiin, a sta ⁇ rosporine derivative, SU11248 and MLN518
  • HSP90 inhibitors includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90, degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteasome pathway.
  • Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, e.g , 17-allylamino, 17-demethoxygeldanamycin (17AAG), a geldanamycin derivative, other geldanamycin related compounds radi ⁇ col and HDAC inhibitors
  • antiproliferative antibodies includes, but is not limited to, trastuzumab (HerceptinTM), Trastuzumab-DM1, ertotinib (TarcevaTM), bevacizumab (AvastinTM), rituximab (Rituxan ® ), PRO64553 (anti-CD40) and 2C4 antibody.
  • trastuzumab HerceptinTM
  • Trastuzumab-DM1 ertotinib
  • AvastinTM bevacizumab
  • rituximab Renuxan ®
  • PRO64553 anti-CD40
  • compounds of formula (I) can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML.
  • compounds of formula (I) can be administered in combination with, e g , farnesy! transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adnamycin, Ara-C, VP-16, Tentposide, Mitoxantrone, Idarubicin, Carboplatmum and PKC412
  • a compound of the formula (I) may also be used to advantage in combination with known therapeutic processes, e.g., the administration of hormones or especially radiabon.
  • a compound of formula (t) may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
  • “combination” there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g , synergistic, effect or any combination thereof
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e g a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time
  • pharmaceutical combination as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients
  • the term “fixed combination” means that the active ingredients,
  • non-fixed combination means that the active ingredients, e g a compound of formula (I) and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time Nmits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient
  • cocktail therapy e.g. the administration of three or more active ingredients
  • Stage A.1 8-Bromo-1-(1.3-dimethyM H-pyrazol-4-yl)-1 ,3-dihydro-imidazo[4,5-c]quinolin-2- one
  • the title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1 -(1 ,3-dimethyl-1 H-py ⁇ azoi-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c ⁇ quino!in-2-one (Intermediate A, 60 mg, 0 161 mmol) and 6-ethoxypy ⁇ dine-3-boronic acid (ABCR 1 Düsseldorf, Germany, 36 mg, 0.211 mmol) to give the title compound as a white solid.
  • Example 1.1 The following examples were synthesized in a similar manner as described for Example 1.1 using 6-ethoxypy ⁇ dine-3-boronic acid and the specified intermediate.
  • Example 1.1 The following example was synthesized in a similar manner as described for Example 1.1 using 2-methylpyridine-5-boronic acid and the specified intermediate
  • Example 1.1 The following example was synthesized in a similar manner as described for Example 1.1 using 2-trif)uoromethylpyridine-5-boronic acid and the specified intermediate.
  • the title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyM-(1 ,3,5-trimethyM H-pyrazol-4-yl)-1 ,3 ⁇ dihydro-imidazo[4,5-c]quinolin-2- one (Intermediate H, 39 mg, 0.100 mmol) and 3-pyridineboronic acid (Aldrich, Buchs, Switzerland, 15 mg, 0.122 mmol) to give the title compound as an off-white foam.
  • Example 1.1 The following example was synthesized in a similar manner as described for Example 1.1 using 3-pyrkiineboronic acid and the specified intermediate,
  • Example 12 1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-methoxy-pyridin-3-yl)-3-methyl-1 , 3- dihydro-imidazo[4,5-c]quinolin-2-one
  • Example 13 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-y))-8-(5-fluoro-6-methoxy-pyridin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo ⁇ 4,5-c]quinolin-2-one
  • the title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c)quinolin-2-one (intermediate A, 40 mg, 0.105 mmol) and 3-fluoro-2-methoxypyridine-5-boronic acid (Apollo Scientific Cheshire, United Kingdom, 21 rng, O 123 mmol) to give the title compound as a pink solid.
  • Example 1.1 The following examples were synthesized in a similar manner as described for Example 1.1 using 6-(hydroxymethyl)pyridine-3-boronic acid and the specified intermediate.
  • Example 1.1 The following example was synthesized in a similar manner as described for Example 1.1 using 2-[5-(4 4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridin-2-ylamino]-ethanol and the specified intermediate
  • Example 22 1 -(1 3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-methanesulfonyl-py ⁇ din-3-y1)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one
  • Example 1.1 The following example was synthesized in a similar manner as described for Example 1.1 using 2-aminopyndine-5-boronic acid pinacol ester and the specified intermediate
  • Example 1.1 The following example was synthesized in a similar manner as described for Example 1.1 using 5-(4,4,5,5-tetramethyl ⁇ [1 ,3,2]dioxaborolan-2-yl)-3-t ⁇ fluoromethyl-pyridin-2-ylamine and the specified intermediate
  • Example 29.1 8-(4-Ethoxy-3-methoxy-phenyl)- 1 -( 1 -ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
  • Example 1.1 The following example was synthesized in a similar manner as described for Example 1.1 using 2-[3-methoxy-4-(2'methoxy-ethoxy)-phenyl]-4,4,5,5-tetramethyl-[1 3,2]dioxaborolane and the specified intermediate
  • the title compound was synthesized in a similar manner as described for Example 1.1 using ⁇ -bromo-S-methyl-I ⁇ I .S.S-trimethyl-1H-pyrazol ⁇ -yO-I .S-dihydro-imidazo ⁇ .S-cjquinolin ⁇ - one (Intermediate H, 39 mg, 0 100 mmol) and 4-hydroxy-3-methoxyphenylboronic acid pinacol ester (Aldrich, Buchs, Switzerland, 30 mg, 0 120 mmol) to give the title compound as a lightly yellow foam.
  • Example 1.1 The following example was synthesized in a similar manner as described for Example 1.1 using 3-hydroxyphenylboronic acid and the specified intermediate.
  • Example 36 1 -(1 ,3-Dimethyl-i H-pyrazol-4-yl)-3-methyl-8-(1 H-pyrrolo ⁇ 2,3-b]pyridm-5-yl)-1 ,3- dihydro-imidazo(4,5-c)quinolin-2-one
  • the title compound was synthesized in a simitar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinolin-2-one (Intermediate A 39 mg, 0 105 mmol) and 7-azaindole-5-boronic acid pinacol ester (ABCR, Düsseldorf, Germany, 31 mg. 0 127 mmol) to give the title compound as a white solid.
  • the title compound was synthesized in a similar manner as described for Example 1.1 using S-bromo-I ⁇ I .S-dimethyl-1H-pyrazoM-yO-S-methyl-I .S-dihydro-imidazo l4,5-cJquinolin-2-one (Intermediate A 1 40 mg, 0 107 mmol) and phenylboronic acfd (Aldrich, Buchs, Switzerland, 16 5 mg. 0.135 mmol) to give the title compound as a white solid (HPLC.

Abstract

The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c] quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H- imidazo[4,5-c] quinofinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c] quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H- imidazo[4,5-c] quinolinone derivatives; and a process for the preparation of the novel 1H- imidazo[4,5-c] quinolinone derivatives.

Description

1 H-lMIDAZO [4,5-c]QUINOLINONE DERIVATIVES
Background of the Invention
The invention relates to imidazoquinolinones, salts and prodrugs thereof, processes for their preparation, their use in the treatment of protein or liprd kinase dependent diseases and in particular phosphatidylinositol-3-kinase (PI3K) dependent diseases, their use, either alone or in combination with at least one additional therapeutic agent and optionally in combination with a pharmaceutically acceptable carrier, for the manufacture of pharmaceutical preparations, use of the pharmaceutical preparations for the treatment of protein or lipid kinase dependant diseases and in particular PI3K dependent diseases, and a method of treatment of said diseases, comprising administering the imidazoquinolinones to a warmblooded animal, especially a human The invention also relates to pharmaceutical preparations comprising an imidazoquinolinone of the invention, either atone or in combination with at least one additional therapeutic agent, and optionally in combination with a pharmaceutically acceptable carrier
Summary of the Invention
The phosphatidylinositol-3-kinases superfamily comprises 4 different PI3K related lipid or protein kinases Class 1, 11 and III are lipid kinases that differ from their substrate specificities whereas class IV PI3K also called P!3-kinase-related protein kinase (PIKK) are protein kinases Class I phosphatidylinositol-3-kinases comprise a family of lipid kinases that catalyze the transfer of phosphate to the D-3' position of inositol lipids to produce phosphoinositol-3-phosphate (PIP), phosphomositol-3,4-djphosphate (PIP2) and phosphoinositol-3,4,5-triphosphate (PIP3) that, in turn, act as second messengers in signaling cascades by docking proteins containing pleckstrin-homology, FYVE, Phox and other phospholipid-binding domains into a variety of signaling complexes often at the plasma membrane ((Vanhaesebroeck et al , Annu. Rev Biochem 70.535 (2001), Katso et al., Annu Rev. Cell Dev Biol. 17.615 (2001)). Of the two Class I PI3Ks, Class IA PI3Ks are heterodimers composed of a catalytic p110 subunit (α, β, δ isoforms) constitutively associated with a regulatory subunit that can be ρ85α, p55α, p50α, p85β or p55γ. The Class IB sub-class has one family member, a heterodimer composed of a catalytic p110γ subunit associated with one of two regulatory subunits. p101 or p84 (Fruman et al , Annu Rev. Biochem 67,481 (1998); Sυire et al , Cυrr. Biol. 15.566 (2005)). The modular domains of the p85/55/50 subunits include Src Homology (SH2) domains that bind phosphotyrosine residues in a specific sequence context on activated receptor and cytoplasmic tyrosine kinases, resulting in activation and localization of Class IA P!3Ks. Class IB PI3K is activated directly by G protein-coupled receptors that bind a diverse repertoire of peptide and non-peptide ligands (Stephens et at., Cell 89 105 (1997)); Katso et al , Annu Rev. Cell Dev Biol. 17.615- 675 (2001)) Consequently, the resultant phospholipid products of class I PI3K link upstream receptors with downstream cellular activities including proliferation, survival, chemotaxis, cellular trafficking, motility, metabolism, inflammatory and allergic responses, transcription and translation (Cantley et al , Cell 64:281 (1991); Escobedo and Williams, Nature 335:85 (1988); Fantl et al., Cell 69.413 (1992)).
In many cases, PIP2 and PIP3 recruit Akt, the product of the human homologυe of the viral oncogene v-Akt, to the plasma membrane where it acts as a nodal point for many intracellular signaling pathways important for growth and survival (Fantl et al., Cell 69413- 423(1992); Bader et a) , Nature Rev Cancer 5.921 (2005); Vivanco and Sawyer, Nature Rev. Cancer 2.489 (2002)) Aberrant regulation of PI3K, which often increases survival through AW activation, is one of the most prevalent events in human cancer and has been shown to occur at multiple levels. The tumor suppressor gene PTBN, which dephosphorylates phosphoinositides at the 31 position of the inositol ring and in so doing antagonizes PI3K activity, is functionally deleted in a variety of tumors in other tumors, the genes for the p110α isoform, PIK3CA, and for Akt are amplified and increased protein expression of their gene products has been demonstrated in several human cancers. Furthermore, mutations and translocation of p85α that serve to up-regulate the p85-p110 complex have been described in human cancers, Also, somatic missense mutations in PIK3CA that activate downstream signaling pathways have been described at significant frequencies in a wide diversity of human cancers (Kang at al., Proc. Natt. Acad. Sci. USA 102:802 (2005), Samuels et al., Science 304:554 (2004); Samuels et al , Cancer Cell 7:561 -573 (2005)) These observations show that deregulation of phosphoinosttol-3 kinase and the upstream and downstream components of this signaling pathway is one of the most common deregulations associated with human cancers and proliferative diseases (Parsons et al., Nature 436 792 (2005); Hennessey at el , Nature Rev Drug Disc 4.988-1004 (2005)).
The mammalian target of rapamycin (mTOR) is a member of the class IV PI3K. mTOR assembles a signaling network that transduces nutrient signals and various other stimuli to regulate a wide range of cellular functions including cell growth, proliferation, survival, autophagy, vanous types of differentiation and metabolism. In mammalian cells, the mTOR protein is found complexed in two distinct entities called mTORC1 and mTORC2. The mTORC1 complex, that is to say mTOR associated with raptor, has been the matter of numerous studies. It is mTORC1 that integrates nutrient and growth factor input, and is in turn responsible for cell growth regulation, mainly through protein synthesis regulators such as 4EBP1 or RPS6 Activation of mTORC1 requires input from active PI3K and Akt kinases meamng that mTORC1 is a downstream effector of the PI3K pathway. mTOR when associated in the mTOR complex 2 (mTORC2) has been shown to be responsible for the activation of Akt by phosphorylation of S473 (Akt 1 nυmbeπng) (Sarbassov et al., Science 307 7098 (2005)) mTORC2 is hence here considered as an upstream activator of Akt. Interestingly mTOR can therefore be considered as being important both upstream and downstream of Akt. Taken together, mTOR can be regarded as a downstream effector and an upstream activator of Akt depending on its association with the mTOCRI and mT0RC2 complex, respectively mTOR catalytic inhibition might therefore represent a unique way of introducing a very strong block in the PI3K-Akt pathway, by addressing both upstream and downstream effectors Syndromes with an established or potential molecular link to deregulation of mTOR kinase activity are, for instance, described in "K. lnoki et al. , Disregulation of the TSC-mTOR pathway in human disease, Nature Genetics, vol 37, 19-24", °DM, Sabatini, mTOR and cancer insights into a complex relationship, Nature Reviews, vol. 6, 729-734"; and in "B.T Hennessy et al. , Exploiting the Pi3K/Akt pathway for cancer drug discovery, Nature Reviews, vol. 4, 988-1004", and are as follows'
• Organ or tissue transplant rejection, e g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants, graft-versus- host disease, such as following bone marrow transplantation;
• Restenosis
• Tuberous sclerosis
• Lymphangioleiomyomatosis
• Retinitis pigmentosis
• Autoimmune diseases including encephalomyelitis, insulin-dependent diabetes mellitus, lupus, dermatomyositis, arthritis and rheumatic diseases
• Steroid-resistant acute Lymphoblastic Leukaemia
• Fibrotic diseases including scleroderma, pulmonary fibrosis, renal fibrosis, cystic fibrosis
• Pulmonary hypertension
• lmmunomodulation
• Multiple sclerosis
• VHL syndrome
• Carney complex
• Familial adenonamtous polyposis
• Juvenile polyposis syndrome
• Birt-Hogg-Duke syndrome
• Familial hypertrophic cardiomyopathy
• Wolf-Parkinson-White syndrome • Neurodegenerative disorders such as Parkinson's, Huntingtin's, Alzheimer's and dementias caused by taυ mutations, spinocerebellar ataxia type 3, motor neuron disease caused by SOD1 mutations, neuronal ceroid lipofucinoses/Batten disease (pediatric neurodegeneration)
• wet and dry macular degeneration
• muscle wasting (atrophy, cachexia) and myopathies such as Danon's disease.
• bacterial and viral infections including M tuberculosis, group A streptococcus, HSV type I, HIV infection
• Neurofibromatosis including Neurofibromatosis type 1 ,
• Peutz-Jeghers syndrome or further any combinations thereof.
Compounds with an inhibitory activity on mT0RC1 have shown benefit in immunomoduiation and in treating proliferative diseases such as advance renal cell carcinoma or Tubero- Sclerosis (TSC) germ line mutation associated disorders
The catalytic inhibition of mTOR Ser/Thr kinase activity or class I PI3 kinases activity and in particular dual class I PI3-kinase(s) and mTOR kinase inhibition is considered to be useful for the treatment of PI3K/Akt/mTOR pathway dependent diseases.
The efficacy of a dual PI3 kinase / mTOR inhibitor in malignant glioma has been recently described (Cancer Cell 9, 341 - 349).
In view of the above, inhibitors of class I and/or IV PI3Ks are considered to be of value in the treatment of proliferative disease and other disorders.
WO2003/097641 , WO2005/054237, WO2005/054238 and WO2006/ 122806 describe imidazoquinolines for use in the treatment of protein kinase dependent diseases.
WO 2008/103636 describes imidazoquinolines as dual lipid kinase and mTor inhibitors.
It has now been found that the imidazoqutnolinones derivatives of the formula (I) given below have advantageous pharmacological properties and inhibit, for example, lipid or protein kinases such as PI4K (phosphatidylinositol 4-kinase) and/or PI3 kinases (phosphatidylinositol 3-kinases). for example, inhibition of the PI3K superfamily which comprises PI3Kalpha, PI3Kbeta, PI3Kdelta, PI3Kgamma and mTOR, or one or more of the individual kinase members thereof. The class IV PI3K also called PI3-kinase~related protein kinase (PIKK) includes DNA-PK, ATM, ATR, hSMG-1 and mTOR. In particular, preferably tmidazoqutnolinones of the formula (I) given below show a high degree of selectivity in favour of one or more of the class I-IV PI3K against other protein kinases, such as the receptor tyrosine kinases and/or the Ser/Thr kinases outside of the PIKK family in the biochemical and/or in the cellular assay. In addition, the imidazoquinofinones of the formula (I) preferably display a favourable solubility and/or membrane permeability at physiological pH. Hence, the compounds of formula (I) are suitable, for example, to be used in the treatment of diseases dependent on PI3 kinase, especially proliferative diseases such as tumor diseases, leukaemias, and myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia, and proliferative skin diseases including basal cell carcinoma, squamous cell carcinoma and actinic keratosis and other benign hyperproliferative skin disorders caused by inflammation such as psoriasis or as a result of dysregulation of fibroblasts such as skin fibrosis, scleroderma or keloids
Description of the invention
tn a first aspect, the present invention provides compounds of the formula (I)
Figure imgf000006_0001
wherein
X is O or S,
Y is CH or N;
R1 is a substituted or υnsubstituted 5-membered heteroaryl,
R2 is hydrogen, lower alkyl or lower alkenyl;
R3 is a substituted or unsubstituted aryl or heterocyclyl, and
R4, R5 and R6 are hydrogen; or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
The present invention is also directed to use of compounds of formula (I) in the treatment of protein and/or lipid kinase dependent diseases; use of compounds of formula (I) for the manufacture of pharmaceutical preparations for the treatment of protein and/or lipid kinase dependent diseases and in particular PI3K superfamiiy (especially class I PI3K and/or mTOR) dependent diseases, methods of treating protein and/or lipid kinase dependant diseases and in particular PI3K superfamiiy (especially class I PI3K and/or mTOR) dependent diseases comprising administering imidazoquinolinone compounds of the formula (I) to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinolinone compound of the formula (I), especially for the treatment of a protein and/or lipid kinase dependant disease and in particular a PI3K superfamilly (especially class I Pl 3K and/or mTOR) dependent disease, a process for the manufacture of the novel imidazoquinolinone compounds of the formula (I); the manufacture of a pharmaceutical preparation for the treatment of protein and/or lipid kinase dependant diseases and in particular PI3K superfamily (especially class I PI3K and/or mTOR) dependent diseases, and novel intermediates for their manufacture. Preferably, the PI3K superfamily dependent diseases are class I PI3K and/or mTOR dependent diseases
The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. As used herein, the terms "including", "containing" and "comprising" are used herein in their open, non-limiting sense
Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different stereoisomer^ forms such as different enantiomeric forms. If at least one asymmetrical carbon atom is present in a compound of the formula I, such a compound may exist in optically active form or in the form of a mixture of optical isomers, e. g. in the form of a racemic mixture. Thus an asymmetric carbon atom may be present in the (R)~, (S)- or (R, S)- configuration, preferably in the (R)- or (S)-configuration. All optical isomers and their mixtures, including the racemic mixtures, are part of the present invention. Thus, any given formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeπc forms, and mixtures thereof Furthermore, certain structures may exist as geometric isomers (e g. cis and trans isomers), as tautomers, or as atropisomers. For example, substituents at a double bond or a ring may be present in c/s- (=Z-) or trans (=E-) form. The compounds of the invention may thus be present as mixtures of isomers or preferably as pure isomers, preferably as enantiomer-pure diastereomers or pure enantiomers.
Any formula given herein is intended to represent hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 31P, 32P. 18F 35S, 36CI, 125I respectively. Various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, 13C, and 14C are incorporated. Such isotopically labelled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent,
When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the moiety for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified fist is independent of the choice of the species for the same variable elsewhere in the formula (where one or more up to all more general expressions in embodiments characterized as preferred above or below can be replaced with a more specific definition, thus leading to a more preferred embodiment of the invention, respectively).
Where the plural form (e g. compounds, salts, pharmaceutical preparations, diseases and the like) is used, this includes the singular (e.g. a single compound, a single salt, a single pharmaceutical preparation, a single disease, and the like). "A compound" does not exclude that (e.g. in a pharmaceutical formulation) more than one compound of the formula (I) (or a salt thereof) is present.
Salts are preferably the pharmaceutically acceptable salts of compounds of formula (I) if they are carrying salt-forming groups.
The salts of compounds of formula (I) are preferably pharmaceutically acceptable salts; acids/bases required to form the salts are generally known in the field. Salt-forming groups in a compound of formula (I) are groups or radicals having basic or acidic properties Compounds having at least one basic group or at least one basic radical, e.g., amino, a secondary amino group not forming a peptide bond or a pyπdyl radical, may form acid addition salts, e g , with inorganic acids, such as hydrochloric acid, sulfuric acid or a phosphoric acid; or with suitable organic carboxylic or sulfonic actds, e.g , aliphatic mono- or di-carboxylic acids, such as trifluoroacetic acid, acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, fυmaric acid, hydroxymaleic acid, malic acid, tartaric actd, citric acid or oxalic acid; or amino acids, such as arginine or lysine; aromatic carboxylic acids, such as benzoic acid, 2-phenoxy-benzoic acid; 2-acetoxy-benzoic acid; salicylic acid; 4-aminosalicylic acid; aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid, heteroaromatic carboxylic acids, such as nicotinic acid or isonicotinic acid; aliphatic sulfonic acids, such as methane-, ethane- or 2-hydroxyethanesulfonic acid, or aromatic sulfonic acids, e.g , benzene-, p-toluene- or naphthalene-2-suifonic acid. When several basic groups are present mono- or poly-acid addition salts may be formed
Compounds of formula (1) having acidic groups, a carboxy group or a phenolic hydroxy group, may form metal or ammonium salts, such as alkali metal or alkaline earth metal salts, e.g., sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, e.g , triethylamtne or tn(2-hydroxyethyl)-amine, or heterocyclic bases, e.g., N-ethyl-piperidine or N,N'-dimethylpiperazine. Mixtures of salts are possible
Compounds of formula (I) having both acidic and basic groups can form internal salts
For the purposes of isolation or purification, as well as in the case of compounds that are used further as intermediates, it is also possible to use pharmaceutically-unacceptable salts, e.g , the picrates. Only pharmaceυtically-acceptable, non-toxic salts may be used for therapeutic purposes, however, and those salts are therefore preferred.
Owing to the close relationship between the novel compounds in free form and in the form of their salts, including those salts that can be used as intermediates, e.g., in the purification of the novel compounds or for the identification thereof, any reference hereinbefore and hereinafter to the free compounds shall be understood as including the corresponding salts, where appropriate and expedient.
Compounds of the present invention may also form solvates and hydrates, and as such any reference to a compound of formula (I) is therefore to be understood as referring also to the corresponding solvate and/or hydrate of the compound of formula (I), as appropriate and expedient The present invention also relates to pro-drugs of a compound of formula (I) that convert in vivo to the compound of formula (I) as such Any reference to a compound of formula (I) is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula (I), as appropriate and expedient
The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated
The prefix "lower" denotes a radical having 1 carbon atom up to and including a maximum of 7 carbon atoms, especially 1 carbon atom up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single- or multiple-branching
Halo or halogen is preferably fluoro, chloro, bromo or iodo, most preferably fluoro, chk>ro or bromo
Alkyl preferably has 1 up 12 carbon atoms (C1-12alkyl) and is linear or branched one or more times, in particular alkyl is lower alkyl, especially C1-C4alkyl. For example, alkyl includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyi, with particular preference given to methyl, ethyl, n-propyl, iso-propyl, n-butyl and iso-butyl. Lower alkyl, for example, is represented as C1-C7a(kyl, e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl or n-heptyl, lower alkyl is especially represented as C1-C4alkyl, e.g. methyl, ethyl, n-propyl, iso-propyl, n-bυtyl, isobutyl, sec-butyl, tert-butyl, with preference given to methyl, ethyl or propyl
Alkyl, in particular lower alkyl, is unsubstituted or substituted, preferably by one or more substrtuents independently selected from those mentioned beiow under "substituted" Exemplary substituents include, but are not limited to hydroxy, alkoxy, aryl, heterocyclyl, cycloalkyl, halogen, amino and nitro An example of a substituted alkyl is halo-alkyl, such as halomethyl. for example fluoromethyl, e g tnfluoromethyl Another example of a substituted alkyl is hydroxymethyl or hydroxyethyl. A further example of a substituted alkyl is alkoxyalkyl, such as methoxyethyl or methoxypropyl. The alkoxyalkyl may be further substituted, for example to give benzyloxyethyl or benzyfoxy propyl
Alkyl may also be cyclic as defined below under "cycloalkyl" Cycloalkyl may also be a sυbstituent to alkyl Cycloalkyl- lower alkyl is preferably lower alkyl that is substituted (preferably terminally) by unsubstituted or substituted cycloalkyl as defined below An example of cycloalkyl as a substituent to alkyl is alkandiyl-cycloalkyl, such as alkandiyl- cyctoloweralkyl, e.g alkandiyi-cyclopropyl e g -CH2-cyclopropyl Aryl-lower alkyl is preferably lower alkyl that is substituted (preferably terminally or in 1 -position) by υnsυbstituted or substituted aryl as defined below Aryl-lower alkyl is especially phenyl-lower alkyl, such as benzyl (i.e phenylmethyl) or phenylethyl, especially 1- phenylethyl.
Heterocyclyl-lower alkyl is preferably lower alkyl that is substituted (preferably terminally) by υnsυbstituted or substituted heterocyclyl as defined below.
Each alkyl part of other groups like "alkoxy", "alkoxyalkyl", "alkoxyalkoxy", "alkoxycarbonyl", "alkoxy-carbonylalkyl", ""alkylsulfonyl", "alkylsulfonamide' , "alkylsulfmyl", "alkylamino", "halogenalkyl" shall have the same meaning as described in the above-mentioned definition of "alkyl", including the prefix 'lower', including substitutions thereof.
For example, aryMower alkoxy is preferably lower alkoxy that is substituted (preferably terminally on the alkyl part) by unsubstituted or substituted aryl as defined below. Aryl-lower alkoxy is especially phenyl-lower alkoxy. such as phenyl methoxy (i e. benzoxy) or phenyl ethoxy.
Alkoxyalkoxy is. for example, methoxyethoxy, or methoxypropoxy, and may include further substitutions e.g. by aryl such as phenyl, for example to give phenylmethoxyethoxy (alternatively stated benzoxy-ethoxy) or phenylmethoxypropoxy (alternatively stated benzoxy-propoxy).
Alkandiyl is a straight-chain or branched-chain divalent alky) group It preferably represents a straight-chain or branched-chain Ci.izalkandiyl, particularly preferably represents a straight- chain or branched-chain Ci^ alkandiyl, for example, methandiyl (-CHr), 1 ,2-ethanediyl (-CH2- CH2-), 1,1-ethanediyl ((-CH(CH3)-), 1 ,1-, 1 ,2-, 1 ,3-propanediyl and 1,1-, 1 ,2-, 1 ,3-, 1 ,4- butanediyl, with particular preference given to methandiyl, 1 ,1-ethanediyl, 1 ,2-ethanediyl, 1 ,3- propanediyl, 1 ,4-butanedryl.
Alkenyl is preferably a moiety with one or more double bonds and preferably has 2-12 carbon atoms; it is linear or branched one or more times (as far as possible in view of the number of carbon atoms), Preferred is C2-C7alkenyl, especially C3-C4alkenyl, such as allyl or crotyl. For example, -CH=CH-, -CH=C(CH3)-, -CH=CH-CH2-, -C(CH3)=CH-CH2-. -CH~C(CH3)-CH2-, -CH=CH-C(CH3)H-, -CH=CH-CH-CH-, -C(CH3)=CH-CH=CH-, -CH=C(CH3)-CH=CH- Alkeny! can be unsubstituted or substituted especially by one or more, more especially up to three of the substituents mentioned below under "substituted*. Substituents, such as amino or hydroxy (with free dissociable hydrogen) preferably are not bound to carbon atoms that participate at a double bond, and also other substituents that are not sufficiently stable are preferably excluded. Unsubstituted alkenyl, in particular, C2-C7alkenyl is preferred. Alkynyl is preferably a moiety with one or more triple bonds and preferably has 2-12 carbon atoms; it is linear of branched one or more times (as far as possible in view of the number of carbon atoms) Preferred is C2-C7alkynyl, especially C3-C4alkynyl, such as ethynyl or propyn-2-yl Alkynyl can be unsubstituted or substituted, especially by one or more, more especially up to three of the substituents mentioned below under "substituted". Substituents, such as amino or hydroxy (with free dissociable hydrogen) preferably are not bound to carbon atoms that participate at a triple bond, and also other substituents that are not sufficiently stable are preferably excluded. Unsubstituted alkynyl, in particular, C2-C7alkynyl is preferred.
Cycloalkyl is a saturated, monocyclic, fused polycyclic, or spiro polycyclic, carbocycle having from 3 to 12 ring atoms per carbocycle Cycloalkyl is preferably C3-C10cycloalkyl, and includes cyclo lower alky I, especially cyclopropyt, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; cycloalkyl being unsubstituted or substituted by one or more substituents, especially 1-3 substrtυents independently selected from the group consisting of the substituents defined below under "substituted"
Cycloalkenyl is preferably C5-C10cycloalkenyl, especially cyclopentenyl, cyclohexenyl or cycloheptenyl, cycloalkenyl being unsubstituted or substituted by one or more substituents, especially 1-3 substituents, independently selected from the group consisting of the substituents defined below under "substituted".
Aryi refers to an unsaturated carbocyclic aromatic ring system, preferably, having a ring system of not more than 16 carbon atoms, especially not more than 10 carbon atoms, e g having 6 to 16, preferably 6 to 10 ring carbon atoms, is preferably mono- or bi-cyclic, and is unsubstituted or substituted preferably as defined below under "substituted". For example, aryl is selected from phenyl or naphthyl preferably phenyl, and is preferably in each case unsubstituted or substituted with substituents descnbed under "substituted", in particular from the group consisting of halo, especially fluoro, chloro, bromo or iodo. in particular fluoro, halo-lower alkyl, especially fluoroalkyl, in particular triflυoromethyl: hydroxyl, amino, mono or disubstituted amino, especially alkyl-substituted amino, hydroxyalkyl-substituted amino or alkoxyalkyl-substituted amino, e g. dimethyl ammo. 2-hydroxyethyl amino or 2- methoxyethylamino, cyclic amino, such as azindinyl, azetidinyl or pyrrolidinyl, amino-lower alkyl, e.g , aminomethyl 2-aminoethyl or 3-aminopropyl; alkylamino-lower alkyl, e.g methylaminomethyl, ethylaminomethyl, methylaminoethyl or ethylaminoerhyl, dialkylamino- loweralkyl, e g dimethylaminomethyl, dimethylaminoethyl, methylethylaminomethyl, methylethylaminoethyl, diethylaminomethyl or diethylaminoethyl, cycloalkylaminoalkyl, e.g. cyclopropylaminomethyl, cyclopropylaminoethyl, cyclobutylaminomethyl, cyclobutylaminoethyl, cyclopentylaminomethyl or cyclopentylaminoethyl, dicycloalkylaminoalkyl, e g. dicyctopropylaminomethyl, dicyclopropylaminoethyl, cyclopropylcyclobutylaminomethyl or cyclopropylcyclobutylaminoethyl; alkylcycloalkylaminoalkyl, e.g. cyclopropylmethylaminomethyl, cyclopropylmethylamtnoethyl, cyctopropylethylaminomethyl or cyclopropylethylaminoethyl; lower alkoxy, e g , methoxy, ethoxy or propyloxy (e g iso-propyloxy); hydroxy-lower alkyl, e.g., hydroxymethyl or 2- hydroxyethyl; hydroxy lower alkoxy, e.g. hydroxyethoxy; afkoxy lower alkoxy, e.g. methoxyethoxy or ethoxyethoxy; lower alkyl, e.g., methyl, ethyl or iso-propyl, cyano; cyano- lower alkyl, e.g., 2-cyanoethyl, 2-cyanopropyl, 2-cyano-2-methylpropyl or 3-cyanopropyl; amidino, N-hydroxyamidino, amidino-lower alkyl, e.g., 2-amidino-ethyl; or N-hydroxyamidino- lower alkyl, e.g., 2-(N-hydroxyamidino)-ethyl; nitro; carboxylic acid, substituted sulfonyl, e.g. alkyl-substituted sulfonyl, such as methanesulfonyl; sulfonamide, e.g. N-methylsulfonamide (or lower alkylaminosulfonyi or N,N-di-loweralkyl aminosυlfonyl, e.g methylaminosufonyl or dimethylaminosulfonyl) or pyrrolJdine-1 -sulfonyl; lower alkyl sulfonyl amino, e g methylsulfonytamino; lower alkyl sulfonylalkandiylamino, e g. methylsulfonyimethylamino, lower alkylsulfonyl-N-lower alkylamlno, e g methylsulfonyl-N-methy)amino, acylamino, e.g. acetylamino, acyl lower alkyl amino, e g acetyl methyl amino, (1 ,3]dioxolo, substituted (1 ,3Jdioxolo, e.g. 2,2-difluoro-[1 ,3]dioxok>; alkoxy carbonyl, such as lower alkoxy carbonyl, e.g, methoxycarbonyl; carbamoyl; substituted carbamoyl, such as alkyl-substituted carbamoyl, e.g. methylcarbamoyl and dimethylcarbamoyl The aryl group may also be substituted with a substituted or unsubstituted heterocycle, preferabely a 4-7 membered ring, e.g. 1 H-tetrazolyl (in particular 1H-tetrazol-5-yl), pyrazol, imidazole, tπazoie, azetidtnyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, ethylpiperazinyl , triazolonyl or methylimidazoiy! The aryl group may also be substituted with heterocyclyl lower alkyl, heteroaryl or heteroaryi lower alkyl as defined hereinbelow Preferred unsubstituted or substituted aryl is selected from phenyl; hydroxyphenyl, e.g., 2-, 3- or 4-hydroxyphenyl; methoxyphenyl, e.g., 2-, 3- or 4-methoxyphenyl or 3,4-dimethoxyphenyl; ethoxyphenyl, e.g., 2-, 3- or 4-ethoxyphenyl or 3,4-diethoxyphenyl, propoxyphenyl (e.g iso-propoxyphenyl) such as 3-propoxyphenyl (e g 3-iso-propoxyphenyl); methoxy ethoxy-phenyl, e.g. 3-methoxy-4-ethoxy phenyl or 4-methoxy- 3-ethoxy phenyl, or other lower-alkoxy phenyl, e g. 3-methoxy-4-(2-methoxy ethoxy)-phenyl; halo-alkoxy-phenyl, e.g. fluoro-(iso-propoxy)-phenyl, e g 2-fluoro-3~(iso-propoxy)- phenyl,hydroxyalkoxy phenyl, e g 2-hydroxyethoxy-phenyl, hydroxy alkoxy phenyl, e g. 3- methoxy-4-hydroxy phenyl; halo-hydroxy-phenyl, e.g. flυoro-hydroxy-phenyi such as 3-fluoro- 5-hydroxy-phenyl; hydroxy-haloalkyl-phenyl, e g. hydroxy-fluoroalkyl-phenyl such as 3- hydroxy-5-trifluoromethyl-phenyl; 2,2-difluoro-benzo[1 ,3]dioxo)o, benzene sulfonamide, e g. 3-N-methylbenzenesulfonamide. 3-N,N-dimethylbenzenesulfonamide, 3-(pyrrolidine-1 - sulfonyl)-phenyl, N-phen-3-yl-methanesulfonamide or N-methyl-N-phen-3-yl- methanesulfonamide, alkyl-sυlfonyl phenyl, e.g 3-methanesulfonylphenyl, benzamide e.g 3- or 4-benzamide, 3- or 4-N-methyl-benzamide or 2-, 3- or 4-N,N-dimethyl~benzamide, pyrazol- phenyl, e g. 4-pyrazol-phenyl; imidazol-phenyl, e g. (1H-tmidazol-2-yl)phenyl
Heterocyclyl refers to a heterocyclic radical that is unsaturated (= carrying the highest possible number of conjugated double bonds in the πng(s) e.g. heteroaryl, for example pyrazolyl, pyridyl, pyrimidinyl), saturated or partially saturated in the bonding nng and is preferably a monocyclic or in a broader aspect of the invention bicyclic ring, has 3-16 ring atoms, more preferably 4-10 ring atoms, such as 6, 9 or 10 ring atoms, wherein 1-4 ring atoms, especially one or two ring atoms are a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, the bonding ring preferably having 4-12 ring atoms, especially 4-7 ring atoms, for example 6 ring atoms, For bicyclic heterocyclyl, the nng which is bonded to the rest of the molecule of formula (I) may or may not contain a heteroatom Also, for bicyclic heterocyclyl, both rings (i.e both the bonding nng and non-bonding ring) may contain a heteroatom
In an embodiment, heterocyclyl refers to a heterocyclic radical that is unsaturated (~ carrying the highest possible number of conjugated double bonds in the ring(s) e.g heteroaryl, for example pyrazolyl, pyridyl, pyrimidinyl), saturated or partially saturated in the bonding ring and is preferably a monocyclic or in a broader aspect of the invention bicyclic ring1 has 3-16 nng atoms, more preferably 4-10 ring atoms, wherein at least in the nng bonding to the radical of the molecule of formula (I) one or more, preferably 1-4 ring atoms, especially one or two ring atoms are a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, the bonding ring preferably having 4-12 nng atoms, especially 4-7 ring atoms, for example 6-10 ring atoms, especially for heteroaryl, such as 6, 9 or 10 ring atoms
In an embodiment, the heterocyclyl may be unsubstituted, or substituted by one or more, especially 1-4 substitυents independently selected from the group consisting of the substituents defined below under "substituted"; especially being a heterocyclyl radical selected from the group consisting of oxiranyl, azirinyl, 1 ,2-oxathiolanyl, imldazolyl, thienyl, furyl, tetrahydrofuryl, tetrahydrothiophene, indolyl, 1-methyl-2,3-dihydro-1H-mdolyl, 2,3- dihydro-1H-indolyl, 2-oxo-2 3-dihydro-1H-indoly!, azetidinyl, pyranyl, thiopyranyl, isobenzofuranyl, benzofuranyl, chromenyl, 2H-pyrrolyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imida2θlyl, imidazolidinyl, benzimidazolyl, pyrazolyl, pyrazolidinyl, thiazolyl, isothiazolyl, dithiazolyl, oxazoiyl, isoxazolyl, pyridyl, pyrazinyl, pyπmidinyl, pφeridyl, piperazinyl, pyrtdazinyl, morpholinyl. thiomorpholinyl, indolizinyl, isoindolyl, 3H-indolyl, cumaryl, indazoly), tnazolyl, tetrazolyl puπnyl. 4H-quinolizinyl, isoquinolyl, qumolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, octahydroisoquinolyl, benzofuranyl, dibenzofuranyl, benzothiophenyl, phthalazinyl, naphthyridinyl, 1 H-pyrrolo(2,3-b]pyridinyll quinoxalyl, qυinazolinyl, quinazolinyl, cinnolinyl, pteridinyl, fυrazanyl, chromenyl, isochromanyl, chromanyl, 2-oxo-2,3-dihydro-1H-imidazo[4,5'b)pyridinyl (also termed 1H-imidazo[4,5- b]pyridin-2(3H)-one-6-yl), LS-Dimethyl^-oxo^.S-dihydro-1H-imidazo^.S-blpyridinyl (also termed 1 ,3-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-oneyl), 1-ethyl-3-methyl-2-oxo-2,3- dihydro-1H-imidazo{4,5-b]pyπdiny) (also termed 1-ethyt-3-methyl-1 H-imidazo[4,5-b]pyridin- 2(3H)-one-6-yl), 1 -(2-methoxy-ethyl)-3-methyl-2-oxo-2,3-dihydrθ'1 H-imidazo[4,5-b]pyridinyl (also termed 1-(2-methoxyethyl)-3-methyHH-imidazo[4,5-b]pyπdin-2(3H)-one-6-yl), 3H- imidazo[4,5-b)pyridinyl, 3-methyl-3H-imfdazo[4,5-b]pyridinyl, 2,3-Dimethyl-3H-imidazo[4,5- bjpyπdinyl, 2-methoxy-3-methyl-3H-imidazo[4(5~b)pyridinyl, 2-Dimethylamino-3-methyl-3H- imidazo[4,5-b]pyπdinyl, 3H-[1 ,2,3]triazolQl4,5-blpyridinyl, 3-methyl-3H-[1 ,2ι3]triazob(4 5- b]pyridinyl, 1H-pyrrolo[3,2-bJpyridinyl, 1-methyl-1H-pyrroloJ3,2-b]pyndinyi 1-methyl'1H- pyrrolo[2,3-b]pyndinyl, 2-oxo-1 ,4-dihydro-2H-pyπdo[2,3-d]{1 t3]oxazinyl, 1 -methyl*2-oxo-1 ,4- dihydro-2H-pyrido(2,3-d][1 ,3]oxazinyl, 3,4-dihydro-2H-pyndo[3,2-b]{1 ,4]oxazinyl, 4-methyl- 3,4-dihydro-2H-pyrido[3,2-b][1 ,4]oxazinyl, 2-oxo-2,3-dJhydro-1H-pyrrolo(2,3-b)pyridinyl, 1 ,3,3- trimethyl-2-oxo-2,3-dihydro-1 H~pyrrolo[2,3-b]pyridiny), 2-oxo-1 ,4-dihydro-2H-pyridoi3,2- d][1 ,3Joxazinyl and i-ethyl^-oxo-i ^-dihydro^H-pyridotS^-dKI .SJoxaztnyl, each of these heterocycle radicals being unsubstitυted or substituted by one to two radicals selected from the substituents described under "substituted", in particular from the group consisting of halo, especially fluoro, chloro, bromo or iodo, more especially fluoro or chloro, in particular fluoro; halo-tower alkyi, especially fluoroalkyl, in particular trifluoromethyl; hydroxy!, amino, mono or disυbstituted amino, especially alkyl-sυbstituted amino, hydroxyalkyl-substituted amino or alkoxyaikyl-substituted amino, e.g dimethyl amino, 2-hydroxyethyl amino or 2-methoxyethy! ammo, cyclic amino, such as aziridinyl, azettdinyl or pyrrolidinyl; substituted cyclic amino, e.g hydroxy cyclic amino, ammo-lower alkyl, e.g., aminomethyl, 2-aminoethyl or 3-aminopropyl; alkylamino-lower alkyl, e.g methylaminomethyl, ethylaminomethyl, methylaminoethyl or ethylaminoethyl, dialkylamino-loweraJkyl, e.g. dimethylaminomethyl, dimethylaminoethyl, methylethylaminomethyl, methytethylaminoethyl, diethylaminomethyl or diethylaminoethyt; cycloalkylaminoalkyl, e.g. cyclopropylaminomethyl, cyclopropylaminoethyl, cyclobutylaminomethyl, cyctobutylaminoethyl, cyclopentylaminomethyl or cycfopentylaminoethyl, dicycloalkylaminoalkyl, e g. dicyclopropylaminomethyl, dicyclopropylaminoethyl, cyclopropylcyclobutylaminomethyl or cyclopropylcyclobutylaminoethyl, alkylcycloalkylaminoalkyl e g cyclopropylmethylaminomethyl, cyclopropylmethylaminoethyl, cyclopropylethylaminomethyl or cyclopropylethylaminoethyl' lower alkoxy, e.g.. methoxy, ethoxy or propyloxy, cycloalkoxy, e g. cyclobutoxy, lower-alkoxyalkyl, e g. methoxymethyl, methoxypropyl, ethoxypropyl, hydroxy-lower alkyl, e.g , hydroxymethyl or 2-hydroxyethyl, hydroxy lower cycloalkyl, e g hydroxy cycfopentyl, hydroxy lower alkoxy, e g. hydroxyethoxy; alkoxy lower alkoxy. e.g. methoxyethoxy or ethoxyethoxy; lower alkyl, e g , methyl, ethyl or iso-propyl; cyano, cyano- lower alkyl, e g , 2-cyanoethyl, 2-cyanopropyl, 2-cyano-2-methylpropyl or 3-cyanopropyl; cyano lower cycloalkyl, e g cyano cyclobυtyl; amidino, N-hydroxyamidino, amidino-lower alkyl, e.g., 2-amidmo-ethyl; or N-hydroxyamidino-lower alkyl, e g., 2-(N-hydroxyamidino)- ethyl; nitro, carboxylic acid; substituted sulfonyl, e.g. alkyl-substituted sulfonyl, such as methanesulfonyi, sulfonamide, e.g. N-methylsulfonamide or pyrrolidine- 1 -sulfonyl, alkyisulf any (amino, e g. methylsulfonylamino, alkylsulfonylalkylamino, e g. methylsulfonylmethylamino; acylamino (also termed alkyl carbonyl amino), e g. acetylamino; acyl alkyl amino, e g acetyl methyl amino; alkylcarbonylaminoalkyl, e.g. methylcarbonylaminomethyl; alkytøminocarbonylaJkyl e g methylaminocarbonylmethyl; alkylcarbonyl-N-alkylamino, e.g.methylcarbonyl-N-methylamino; [1 ,3]dioxolo, substituted [1 ,3]dioxolo, e g. 2,2-difluoro-(1 ,3]dioxolo, alkoxy carbonyl, such as lower alkoxy carbonyl, e.g. methoxycarbonyl, carbamoyl (also termed aminocarbσnyl), substituted carbamoyl, such as alkyl-substituted carbamoyl, e g methylcarbamoyl, ethyl carbamoyl, iso-propyl carbamoyl or alkoxyalkyl-substituted carbamoyl (also termed alkoxyalkylaminocarbonyl), e.g 2- methoxyethylcarbamoyl. The heterocycJe group may also be substttuted with another substituted or υnsubstituted heterocycle, preferabely a 4-7 membered ring, e g 1 H-tetrazolyl (in particular 1 H-tetrazol-5-yl), pyrazol, imidazole, triazole, azetkjinyl, pyrrolidine, piperazmyl, methylpiperazinyl, ethylpiperazinyl , triazolonyl, methylimidazolyl or morpholino. The heterocycle group may also be substituted with heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein
In another embodiment, the heterocyclyl may be unsubstituted, or substituted by one or more, especially 1-4 substrtuerrts independently selected from the group consisting of the substituents defined below under "substituted", especially being a heterocyclyl radical selected from the group consisting of oxiranyl, azirmyl. 1 ,2-oxathiolanyl. imtdazolyl, thienyl, furyl, tetrahydrofuryl, tetrahydrothiophene, indolyl, 1-methyl-2,3-dihydro-1H-indolyl, 2-oxo- 2,3-dihydro-1 H-indolyl, azetidinyl, pyranyl, thiopyranyl, isobenzofuranyl, benzofuranyl, chromenyl, 2H-pyrrolyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolidinyl, benzimidazolyl, pyrazolyl, pyrazolidinyl, thiazolyl. isothiazolyl, dithiazolyl, oxazolyl, isoxazolyl, pyndyl. pyrazinyl, pyrimidinyl, pipeπdyl, piperazinyl, pyndazinyl, morpholinyl, thjomorpholinyl, indolizinyl, isoindolyl, 3H-indolyl, cumaryl, indazolyl, tnazolyl, tetrazolyl, purinyl, 4W- quinohzinyl, isoquinolyl, quinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, octahydroisoquinolyl, benzofuranyl, dibenzofuranyl, benzothiophenyl, phthalazinyl, naphthyridinyl, 1H-pyrrolo[2,3-b)pyπdinyl, quinoxalyl, quinazolinyl, quinazolinyl cinnolinyl, pteridinyl, furazanyl, chromenyl, isochromanyl and chromanyl and , each of these heterocycle radicals being unsubstituted or substituted by one to two radicals selected from the substituents described under "substituted", in particular from the group consisting of halo, especially fluoro, chloro, bromo or iodo. more especially fluoro or chloro, in particular fluoro, halo-lower alkyl, especially fluoroalkyl, in particular trifluoromethyl, hydroxyl, ammo, mono or disubstituted amino, especially alkyl-substituted amino, hydroxyalkyl-substituted amino or alkoxyalkyl-substituted amino, e g. dimethyl amino, 2-hydroxyethyl amino or 2-methoxyethyl ammo; cyclic ammo, such as aziridinyl, azetidinyl or pyrroJidinyl, ammo-lower alkyl, e g., aminomethyl, 2-aminoethyl or 3-aminopropyl, alkylamino-lower alkyl, e.g. methylaminomethyl, ethylaminomethyl, methylaminoethyl or ethylammoethyl; dialkylammo- loweralkyl, e.g. dimethylaminomethyl, dimethylaminoethyl, methylethylaminomethyl, methylethylaminoethyl, diethylaminomethyl or diethylaminoethyl, cycloalkylaminoalkyl, e.g cyctopropylamlnomethyl, cyclopropylaminoethyl, cyclobutylaminomethyl, cyclobutylaminoethyl, cyclopentylaminomethyl or cyclopentylaminoethyl, dicycloalkylaminoalkyl, e.g. dicyclopropylaminomethyl, dicyclopropylaminoethyl, cyclopropylcyclobutylaminomethyl or cyclopropylcyclobutylaminoethyl, alkylcycloalkylaminoalkyl. e g cyclopropylmethylaminomethyl, cyclopropylmethylaminoethyl, cyclopropylethylaminomethyl or cyclopropylethylaminoethyl; lower alkoxy, e g , methoxy, ethoxy or propyloxy; hydroxy-lower alkyl, e.g., hydroxymethyl or 2-hydroxyethyl- hydroxy lower alkoxy, e.g hydroxyethoxy; alkoxy lower alkoxy, e.g methoxyethoxy or ethoxyethoxy; lower alkyl, e.g., methyl, ethyl or iso-propyl, cyano, cyano-lower alkyl, e.g , 2-cyanoethyl, 2- cyanopropyl, 2-cyano-2-methylpropyl or 3-cyanopropyl; amidino; N-hydroxyamidino; amidino- lower alkyl, e g . 2-amidino-ethyt, or N-hydroxyamid»no-lower alkyl, e g., 2-(N~hydroxyamidino)-ethyl, nhro- carboxylic acid, substituted sulfonyl, e g alkyl-substituted sulfonyl, such as methanesulfonyl, sulfonamide e g N-methylsulfonamide or pyrrolidine- 1- sulfonyl, alkylsulfonylamino, e.g methylsulfonylamino, alkylsulfonyJalkylamino, e.g methylsulfonylmethylamino, acylamtno, e g. acetylamino, acyl alkyl amino, e g. acetyl methyl amino, [1,3]dioxolo, substituted [1 ,3)dioxok>, e g 2,2-difluoro-[1,3]dioxolo, alkoxy carbonyl, such as lower alkoxy carbonyl, e.g methoxycarbonyl, carbamoyl, substituted carbamoyl, such as alkyl-substituted carbamoyl, e g. methylcarbamoyl The heterocycle group may also be substituted with another substituted or unsubstituted heterocycle, preferabely a 4-7 membered ring, e g. 1 H-tetrazolyl (in particular 1H-tetrazol-5-yl), pyrazol, imidazole, tπazole, azetidinyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, ethylpφerazinyl triazolonyl or methylimidazolyl The heterocycle group may also be substituted with heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein.
In an embodiment very preferred heterocyclic groups, which may be substituted or unsubstituted, include indolyl, 1-methyl-2,3-dihydro-1H-indolyl, 2-oxo-2,3-dihydro-1H-indolyl, pyridyl pyrimidinyl, 1 H-pyrrolo[2,3-blpyridinyl, 1-methyl-1H-pyrrolo(2,3-b]pyridinyl, pyrazolyl, pyrazinyl, quinolyl, quinoxalyl, 1,3-Dimethyl-2-oxo-2,3-dihydro-1 H-imidazo[4,5-b]pyrid)nyl, 2- oxo-2,3-dihydro-1H-tmidazo[4,5-bJpyridSny{( 1-ethyl-3-methyl-2-oxo-2,3-dihydro-1H- imidazo{4,5-b}pyridinyl, 1-(2-methoxy-ethyl)-3-methyl-2-oxo-2,3-dihydro-1 H-imiclazo[4,5- b]pyridinyl, 2-Dimethylamino-3-methyl-3H-imidazo[4,5-b]pyridinyl, 2-methoxy-3-methyl-3H- imidazo[4(5-b]pyridinyl, 3H-imidazo(4,5-b]pyndinyl, 3-methyl-3H-[1 ,2,3]triazolo[4,5-b]pyridinyl, 3H-[1 ,2,3]triazolo(4,5-b)pyridinyl, 2,3-Dirτ>ethyl-3H-imidazo(4,5-bJpyridinyl, 3-methyl-3H- imidazo[4,5-b]pyridinyt, 1H-pyrfolo{3,2-b]pyridinyl, 1-methyl-1H-pyrrolo[3,2-b]pyridinyl, 1- methyl-2-oxo-1 ,4-dihydro-2H-pyrido[2,3-d][1 ,3]oxazinylf 2-oxo-1.4-dihydro-2H-pyrido(213- d][1 ,3]oxazinyl, 4-methyl-3,4-dinydro-2H-pyπdo[3,2-b][1 ,4]oxazinyl, 3,4-dihydro-2H- pyndot3,2-bl[1 ,4]oxazinyl, 1 ,3l3-tπmethyl-2"θxo-2,3-dihydro-1H-pyrrolof2,3-bjpyridinyl, 2-oxo- 2.3-dihydro-1 H-pyrrolo[2,3-bJpyπdinyl, 1-ethyl-2-oxo-1 ,4-d<hydro-2H-pyridoI3,2- d](1 ,3]oxaz)nyl, and 2-oxo-1 ,4-dihydro-2H-pyrido(3,2-d][1 >3]oxazinyleach of which may be unsubstitυted or substituted.
In an further embodiment, very preferred heterocyclic groups, each of which may be substituted or unsubstituted, include 1-methyl-2,3~dihydro-1H-indolyl, 2-oxo-2,3-dihydro-1 H- indolyl, pyridyl, pyrimidinyl, 1H-pyrro)o{2,3-b]pyridinyl, 1-methyl-1 H-pyrrolo[2,3-b]pyridinyl, pyrazolyl, pyrazinyl, qυinolyl, 1 ,3-Dimethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyndinyl, 2- oxo-2,3-dihydro-1 H-imidazo[4,5-b]pyridinyl, i-ethyl-S-methyl^-oxo^.S-dihydro-1H- imidazo(4,5-b]pyridinyl, 1-(2-methoxy-ethyl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazot4,5- bjpyridinyl, 2-Dtmethylamino-3-methyl-3H-imidazo[4,5-b]pyridinyl, 2-methoxy-3-methyl-3H- imtdazot4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, 3-methyl-3H-[1 ,2,3]triazolo(4,5-b)pyridinyll 3H-{1 ^.Sltriazolo^.δ-blpyridinyl, 2,3-Dimethyl-3H-imidazo[4,5-b]pyridinyl, 3-methyl-3H- imidazoi4,5-b}pyπdinyl, 1H-pyrrolo{3,2-b]pyπdinyl, 1-methyl-1H-pyfrolo{3,2-b3pyridinyl, 1- methyl-2-oxo-1 4-dihydro-2H-pyrido{2,3-d][1 ,3]oxazinyl, 2-oxo-1 ,4-d)hydro-2H-pyndoi;2t3- d][1 ,3)oxazinyi, 4-methyl-3,4-dihydro-2H-pyrido[3,2-b][1 ,4]oxazinyl, 3,4-dihydro-2H- pyrido[3,2-b][1 ,4]oxazinyl, 1,3,3-trimethyl-2-oxo-2,3-dihydro-1H-pyrrolo{2l3-b]pyridinyi, 2-oxo- 2,3-dihydro-1 H-pyrrolo[2,3-b]pyr!dinyl, 1-ethyl-2-oxo-1 ,4-dihydro-2H-pyπdo[3,2- d)[1 ,3Joxazinyl, and 2-oxo-1 ,4-dihydro-2H-pyrido[3,2-d][1 ,3]oxazinyl
In another embodiment, heterocyclic groups, which may be substituted or unsubstituted, include indolyl 1-methyl-2,3-dihydro-1H-indolyl, 2-oxo-2,3-dihydro-1H-indolyl, pyridyl, pyrimidinyl. 1 H-pyrrolo[2,3-b]pyridinyl, 1 -methyl- 1H-pyrrolo[2,3-b]pyridiny I, pyrazolyl, pyrazinyl, quinolyl, quinoxalyl, each of which may be unsubstituted or substituted
In an embodiment, unsubstituted or substituted heterocyclyl is selected from pyndyl, alkylpyridyl, in particular lower-alkylpyridyl, e g methylpyridyl, e g , 2-, 3- or 4-methylpyrkJyl especially 2-methylpyridyl or 3-methylpyridyl; alkoxypyridyl, in particular lower-alkoxypyridyl, e.g. methoxypyridyl, e g , 2-, 3- or 4-methoxypyridyl, especially 2-methoxypyπdyl or 3- methoxypyridyl or di-methoxypyridyl, e g, 2,3-dimethoxypyiϊdyi, or ethoxypyridyl, e g., 2-, 3- or 4-ethoxypyridyl especially 2-ethoxypyridyl or 3-ethoxypyridyl or di-ethoxypyridyl e.g. 2,3- diethoxypyridyl, or propyloxypyridyl, e.g., 2- or 3-propyloxypyridyl or isopropyloxypyridyt, e.g., 2- or 3-isopropyloxypyridyl; cycloalkyloxypyridyl, e.g. 2- or 3-cyclobυtyloxypyridyl; (haloalkoxy)pyridyl e.g. 3-(1 ,3-difluoropropan-2-yloxy)-pyridyl or 3-(2-fluoroethan-1-yloxy)- pyridyl or 3-{difluoromethyloxy)-pyridyl; cycIoaJkylalkoxypyridyl, e.g. cydopropylmethoxy- pyrktyl, e.g. 2 or 3-cyclopropylmethoxy-pyridyl; alkoxyalkylpyridyl, e.g. methoxymethylpyridyl, e.g. 2 or 3-methoxymethylpyridyl or ethoxymethylpyridyl or 2-methoxy-prop-2-yl or 2-ethoxy- prop-2-yl; alkoxyalkoxypyridyl, in particular methoxyethoxypyridyl, e.g. 2 or 3- methoxyethoxypyridyl; (alkyl)(alkoxyalkoxy)pyridyl, e.g. (methyl)(methoxyethoxy)pyridyl; benzyloxyalkoxypyridyl, in particular benzyloxyethoxypyridyl or benzyloxypropoxypyridyl, e.g. 2-benzyloxyethoxypyridyl or 3-benzykJxypropoxypyridyl; hydroxyalkylpyridyl, e.g. 2 or 3-(2- hydroxyethyl)-pyridyl or hydroxypentylpyridyl e.g. 3-(3-hydroxypentyl}-pyridyl or hydroxypropylpyridyl, e.g. 3-(2-hydroxyprop-2-yl)-pyridyl or hydroxy- 1 ,1 -dimethyl-ethylpyridyl; hydroxycycloalkylpyridyl, e.g. 3-(1-hydroxycyclopentyl)-pyridyl; hydroxyfluoroalkylpyridyl, e.g. hydroxyffuoropropylpyridyl; aminoalkylpyridyl, e.g. aminomethylpyridyl; alkyl-sulfonyl pyridyl, e.g. methanesulfonylpyridyl, especially 3-methanesulfonytpyridyl; hydroxyalkoxypyridyl, e.g. 2-(2-hydroxyethoxy)-pyridyl or 2-(3-hydroxypropoxy)-pyridyl; hydroxyalkylpyridyl, e.g. hydroxymethylpyridyl, especially 2-(hydroxymethyl)-pyridyl; alkoxycarbonylpyridyl, e.g. methoxycarbonylpyridyl, especially 2-methoxycarbonyl-pyridyl; aminopyridyl, e.g. 2- or 3- aminopyridyt; alkylaminopyridyl, in particular loweralkylaminopyridyl, e.g. 2-, 3- or 4- methylaminopyridyl, especially 2- or 3-methylaminopyridyl. 2-, 3- or 4-ethylaminopyridy), especially 2- or 3-ethylaminopyπdyl, e.g.
2- or 3- (1- or 2-propyl)aminopyridyl; dialkylaminopyridyl, in particular di- loweralkylaminopyridyi, e.g. 2-, 3- or 4-dimethylaminopyridyl, especially 2- dimethylaminopyridyl or 2-, 3- or 4-diethylaminopyridyl. especially 2-or 3-diethylaminopyridyl or e.g. 2-, 3- or 4-ethylmethylaminopyridyl especially 2-ethylmethylaminopyridyl or 3- ethylmethylaminopyridyl or e.g. 2-, 3- or 4-isopropylmethylaminopyridyl, especially 2- isopropylmethylaminopyridyl or 3-isopropylmethylaminopyridyl; cycloafkylaminopyridyi, e.g. cyclobutylaminopyridyl; (N-alkyl-N-cycloafkylamino)pyridyl, e.g. (N-methyl-N- cyciobυtylamino)pyrk.yl; (alkyl)(amino)pyridyl, e.g. (loweralkyl){amino)pyridyl, in particular (methyl)(amino)pyridyl such as 2-methyl-3-amino-pyridyl or (ethyl)(amino)pyridyl such as 2- ethyl-3-amino-pyrJdyi; (halo)(amino)pyπdyl, e.g. (fluoro)(amino)pyridyl or (chloro)(amino)pyridyl; (halo)(alkylamino)pyridyi, e g. (fluoro)(methylamino)ρyridyl, (fluoro)(ethylamino)pyridyl; (hak))(dialkylamino)pyridyl, e.g. (fluoro)(dimethylamino)pyridyl; (halo)(hydroxyaikyl)pyridyl, e.g. (chloro)(hydroxymethyl)pyridyl; (alkoxy)(alkyl)pyridyl e.g. (methoxy)(methyl)pyridyl or (ethoxy)(methyl)pyridyl, or (propoxy)(methyl)pyridyl or (propoxy ) (eth y I ) py ridy I or (ethoxy)(ethyl)pyridyl; (alkoxy)(alkoxy)pyridyl e.g. (propoxy)(methoxy)pyridyl or (propoxy)(ethoxy)pyπdyl or (methoxy)(methoxy)pyridyl or (ethoxy)(methoxy)pyridyl; (alkoxy)(alkoxyalkyl)pyπdyl e.g. (!sopropoxy)(methoxymethy!)pyridyl or (methoxy)(methoxymethyl)pyridyl or (methoxy)(ethoxymethyl)pyridyl or (ethoxy)(methoxymethyl)pyridyl, (alkoxy)(deuteroaJkoxy- alkyl)pyridyl e g. (ethoxy)(trideuteromethoxymethyl)pyridyl: (alkoxy)(hydroxyalkyl)pyridyl e g. (isopropoxy)(hydroxymethyl)pyridyl or (methoxy)(hydroxymethyl)pyridyl, such as 3-methoxy- 2-hydroxymethyl-pyrfdyl or 2-methoxy-3-hydroxymethyl~pyridyl or (ethoxy)(hydroxymethyl)pyridyl, such as 3-ethoxy-2-hydroxymethyl-pyridyl; (haloalkoxy)(alkyl)pyridyl e.g (halo-isopropoxyXmethyl)pyπdyl, such as 3-(1 ,3- difluoropropan-2-yloxy)-2-(methyl)-pyiidyl,(haloalkoxy)(hydroxyalkyl)pyridyl e g. 3-(1 ,3- difluoropropan-2-ytoxy)-2-(hydroxymethyl)-pyridyl, (alkoxyalkoxy)(hydroxyalkyl)pyridyl, e g. (methoxyethoxy)(hydroxymethyl)pyridyl, such as 3-methoxyethoxy-2-hydroxymethyl-pyridyl (in particular 3-methoxyethoxy-2-hydroxymethyl-pyrid-5-yl);(alkyl)(alkytamino)pyridyi, e.g. (methyl)(ethylamino)pyridyl such as 2-methyl-3-ethylamino-pyridyl or (methy!)(methylamino)pyridyl such as 3-methyl-2-methy)amirκ)-pyridyl or (ethyl)(ethylamino)pyrtdyl such as 2-ethyl-3-ethylamino-pyπdyl or (ethyl)(isopropylamino)pyridyl such as 2-ethyl-3-isopropylamino-pyridyl; (alkyl)(di- alky)amino)pyridyl, e.g (methyl)(N-methyl-N-ethylamino)pyridyl such as 2-methyt-3-(N- methyl-N-ethylamino)-pyridyl or (methylKN.N-dimethylaminoJpyndyl such as 2-methyl-3- (N,N-dimethylamino)-pyridyl; cycloaminopyridyl, e g. azetidinylpyridyl, especially 2-azetdin-1- yt-pyridyl or pyrrolidinylpyridyl, especially 2-pyσolidin-2-yipyridyl; cyclic ether-substituted amino-pyridyl, e.g. tetrahydro-pyranytamino-pyridyl, hydroxy-cycloaminopyπdyl, e.g. hydroxy- pyrrolidinylpyridyl; loweralkoxy-cycloaminopyridyl, e g methoxy-pyrrolidinylpyridyl; hydroxyalkylaminopyridyl, e g. 2-(2-hydroxyethylamino)-pyridyl; (afkyl)(hydroxy)pyridyl, e.g. 2-(methyl)-3-(hydroxy)-pyridyl or 2-{ethyl)-3-(hydroxy)-pyπdyl; (hydroxyalkyl)(alkylamino)pyridyl, e.g. (hydroxymethyl)(ethylamino)-pyπdyl, e.g or (hydroxymethyl)(methylamino)-pyridyl, (hydroxyalkyl)(amino)pyridyl, e.g. (hydroxymethyl)(amino)-pyridyl, (alkoxyalkyl)(alkylamino)pyridyl, e g (methoxymethyl)(ethy!amino)-pyπdyl, or (methoxymethyl)(methylamino)-ρyndy), or (ethoxymethyl)(ethy)amino)-pyridyl; (alkoxyalkyl)(amino)pyridyl, e.g (ethoxymethyl)(amino)- pyπdyl, or (methoxymethyl)(amino)-pyridyl; amino-haloloweralkyl-pyridyi, e g amino- trifluoromethyl-pyndyl, especially 2-amino-3-trif}uoromethyl-pyridy!, alkylamino-haloalkyl- pyridyl. e.g. methylamino-tπfluoromethyl-pyπdyl or e.g ethylamino-trifluoromethyl-pyridyl, haloalkyl-deuteroloweralkylamino-pyridyl. e.g. trifluoromethyl-trideuteromethylammo-pyndyl; haloalkylpyridinyl, in particular haloloweralkylpyridyl, especially, 2-. 3- or 4-tπflυoromethylpyndyl, most especially 2-tπfluoromethylpyridyi; cyanoalkylpyridinyl. e.g cyanopropylpyridyf; cyanocycloalkylpyridinyt, e.g. cyanocyclobυtylpyridy!; halopyridyl, in particular fluoropyridyl, especially 2-ftuoropyridyl, halo-alkoxy-pyridyl, e g. fluoro-methoxy- pyridyl such as 3-fluoro-2-methoxy-pyπdyl; carbamoylpyridyl, especially 2-(carbamoyl)pyridyl; alkyl-substituted carbamoyl, e.g methylcarbamoyl, especially 2-(methylcarbamoyl)pyridyl; piperazinylpyπdyl, e.g. 1-piperazinylpyndyl, N-alkylpiperazinylpyridyl, e.g N- methylpiperazinylpyridyl; alkylsυlfonamidopyridyl, e.g. methylsulfonamidopyridyl, dialkylsulfonamidopyridyl, e g. dimethylsulfonamidopyridyl; (alkylsulfcmamido)(alkyl)pyridyl e.g (methylsulfonamido)(methyl)pyridyl; (alkylsυtfonamido)(halo)pyndyl e.g (methylsulfonamido)(chloro)pyridyl; (alkylsulfonamidoalkyl)pyridyl e.g (methylsυlfonamidomethyl)pyridyl, dialkylsυlfonamido(alkyl)pyridyl, e.g. dimethylsulfonamido(methyl)pyridyl, 3H-tetrazol-5-yl pyridyl, e.g. 2-(3H-tetrazol-5-yl)pyridyl (in particular 2~(3H-tetrazol-5-yl)pyrid-5~yl); alkylcarbonylaminoalkylpyridyl, e.g. methylcarbonylaminomethylpyπdyl, (halo)(alkylcarbonylamino)pyridyl, e.g. (chloro)(methylcarbonylamirκ))pyridyl; (alkoxy)(alkylcarbonylamino)pyridyl, e g (methoxy)(methylcarbonylamino)pyridyl or {ethoxy)(methylcarbonylamino)pyr»dyl; (alkoxy)(alkylcarbonyl-N-alkylamino)pyridyl, e.g (methoxy)(methylcarbonyl-N- methylamino)pyridyl or (ethoxy)(methylcarbonyl-N-methylamino)pyπdyl; (alkoxy)(njtro)pyridyl, e g. (methoxy)(nitro)pyridyl; (alkoxy)(cyano)pyridyl, e.g. (methoxy)(cyano)pyridyl; (alkoxy)(amino)pyridyl, e.g. (methoxy)(amino)pyridyl; (alkoxy)(alkylamino)pyridylt e g (methoxy)(ethylamino)pyπdyl; (alkoxyalkyl)(alkylamino)pyridyl, e.g. (methoxymethyl)(methylamino)pyridyl, or (methoxymethyl)(ethylamino)pyπdyl; (alkoxyJialkylaminocarbonyOpyridyl, e.g (methoxy)(methylaminocarbonyl)pyπdyl; alkylaminocarbonylalkylpyridyl, e.g. methylaminocarbonylmethylpyridyl; (amino)(alkylaminocarbonyl)pyπdyl, e g (amino)(methylaminocarbonyl)pyridyl, or (amino)(ethylaminocarbonyl)pyridyl or {amino)(isopropylaminocarbonyH)pyridyl, (amino)(alkoxyalkylaminocarbonyl)pyridyl, e.g (amino)(methoxyethylaminocarbonyl)pyrkjyl; (alkylamino)(alkylaminocarbonyl)pyridyt, e g {methylamino)(ethylaminocarbonyl)pyridyl; (alkoxy)(aminocarbonyl)pyridyl, e.g. (methoxy)(aminocarbonyl)pyridy1; (alkoxy)(hydroxycarbonyl)pyridyl, e g (methoxy)( hydroxycarbonyl)pyridyl; morpholmylpyridinyl, e.g morpholin-4-ylpyridinyl; (I H-pyrazolyl)-pyridinyl, e.g. (1H-pyrazol- 1yl)-pyridinyl; loweralkylsubstitυted{1H-imidazol-1-yl)-pyndinyl, e.g. methyl-sυbstituted(1 H- imidazol-1-yl)-pyridinyl
pyrimidinyl; loweralkylaminopyrimidinyl, e.g 2- or 4-methylaminopyrimidinyl or 2- or 4- ethylaminopyπmidinyl; di-loweralkylarrunopyrimidinyl, e g 2- or 4- methyfethylaminopyrimtdinyl, 2- or 4-dimethylaminopyrimidinyl, especially 2- dimethylaminopyrimidinyl, alkoxypyrimκJinyl, in particular methoxypyπmidinyl or ethoxypyrimidinyl, e.g. 2-methoxypyrimidinyl or 2-ethoxypyrimidinyl. di-alkoxypyrimidinyl, e g 2,4-dimethoxypyrimidiny); (alkylamino)(alkoxy)pyrimidinyl, e.g. (methylamino)(methoxy)pyrimidinyl or (ethylamino)(methoxy)pyrimidinyl; cycloaminopyrimtdinyl, e g pyrrolidinylpyπmidinyl; aminopyrimfdinyl, in particular 2- aminopyrimidinyl; alkylaminopyrimidinyl, e g. 2-methylaminopyrimκJinyl, dialkylammopyrimidinyl, e.g 2-dimethylaminopyrimidinyl; 1H-pyrro)o[2,3-b]pyridinyl( 1-methyl- 1H-pyrrolo[2,3-b]pyridinyl; pyrazinyl; pyrazolyl; substituted pyrazolyl, e g hydroxyalkylpyrazolyl, especially 1~(2-hydroxy-ethyl)-1H-pyrazolyl or 1 -[2-(tetrahydro-pyran- 2-yloxy)-ethyl]-1 H~pyrazolyl; quinolinyl; 2-oxo-2,3-dihydro-1H-indol-5-yl; 1-methyl-2,3- dihydro-1H-indol-5-yl; I .S-Dimethyl^-oxo^^dihydro-1H-imidazol^.S-blpyridinyl, 1-ethyl-3- methyl-2-oxo-2,3-dihydro-1 H-imidazo[4,5-b]pyridinyl, 1-(2-methoxy-ethyl)-3-methyl-2-oxo- 2.3-dihydro-1 H-imidazo|4,5-b]pyridinyl, 2-Dimethylamino-3-methy!-3H-imidazo[4,5- bjpyridinyl, 2-methoxy-3-methyl~3H-imidazo[4,5-b)pyridinyl, 3-methyl-3H-[1 ,2.3]triazolo[4,5- bjpyπdinyl, 2,3-Dimethyl-3H-imidazo[4,5-blpyridinyl, 3-methyl-3H-imidazof4,5-b3pyridinyl, 1 H- pyrrolo(3,2-b]pyridinyl, 1 -methyl-1 H-pyrro<o{3,2-bJpyπdinyl, 1 -methyl-2-oxo-1 ,4-dihydro-2H- pyrido[2,3-d][1 ,3]oxazinyl, 4-methyl-3,4-dihydro-2H-pyrido(3(2-b]l1 ,4]oxazinyl, 1 ,3,3-tnmethyl- 2-0X0-2, 3-dihydro-1H-pyrrolo{2,3-b]pyridinyl, and 1-ethyl-2-oxo-1 ,4-dihydro-2H-pyrido[3,2- dj[1 ,3]oxazinyl.
In another embodiment, unsubstituted or substituted heterocyclyl is selected from pyndyl; alkylpyridyl, >n particular tower-alkylpyridyl, e.g. methylpyndyl, e g., 2-, 3- or 4-methylpyridyl, especially 2- methylpyndyl or 3-methylpyridyl, alkoxypyridyl, in particular lower-alkoxypyndyl, e g methoxypyridyl, e.g , 2-, 3- or 4-methoxypyridyl, especially 2-methoxypyridyi or 3- methoxypyndyl or di-methoxypyridyl, e.g. 2,3-dimethoxypyrfdyl, or ethoxypyridyl, e.g., 2-, 3- or 4-ethoxypyridyl especially 2-ethoxypyridyl or 3-ethoxypyridyl or di-ethoxypyπdyl e.g. 2,3- diethoxypyridyl, or propyloxypyridyl, e g., 2- or 3-propyloxypyridyl or isopropyloxypyridyl, e.g., 2- or 3-isopropyloxypyridyl; cycloalkyloxypyridyl, e g 2- or 3-cycJobutyloxypyridyl; cycloalkylalkoxypyridyl, e g. cyclopropylmethoxy-pyridyl, e.g. 2 or 3-cyclopropylmethoxy- pyπdyl, methoxymethylpyridyl, e.g 2 or 3-methoxymethylpyridyl; alkoxyalkoxypyridyl, in particular methoxyethoxypyridyl, e.g. 2 or 3-methoxyethoxypyπdyl; benzyloxyalkoxypyridyl, in particular benzyloxyethoxypyndy! or benzyloxypropoxypyridyl, e.g 2-benzyloxyethoxypyridyl or 3-benzyfoxypropoxypyridyl; hydroxyalkylpyridyl, e.g 2 or 3-(2-hydroxyethyl)-pyridyl; alkyl- sulfonyl pyrtdyl, e.g, methanesulfonylpyridyl, especially 3-methanesulfonylpyrtdyl, hydroxyalkoxypyridyl, e g. 2-(2-hydroxyethoxy)-pyridyl or 2-(3«hydroxypropoxy)-pyridyl; hydroxyalkylpyridyl, e g. hydroxymethylpyπdyl, especially 2-(hydroxymethyl)-pyridyl, alkoxycarbonylpyridyl, e.g. methoxycarbonylpyrtdyl. especially 2-methoxycarbonyl-pyπdyl, aminopyπdyl, e g 2- or 3-aminopyridyl; alkylaminopyrkiyl, in particular loweralkylaminopyridyl, e.g. 2-, 3- or 4-methylaminopyridyl, especially 2- or 3- methylaminopyridyl, 2-, 3- or 4-ethylaminopyridyl, especially 2- or 3-ethyfaminopyridyl, e.g 2- or 3- (1- or 2~propyl)aminopyndyl, dtalkylaminopyπdyl, in particular di- loweralkylaminopyπdyl, e g 2- 3- or 4-dimethylaminopyridyl, especially 2- dimethylaminopyrtdyl, cycloamfnopyπdyl, e g azetidinylpyπdyl especially 2-azetidin-1-yl- pyπdyl or pyrrolidinylpyridyl, especially 2-pyrrof idin-2-ylpyrrdyl , hydroxyalkylaminopyridyl, e g 2-(2-hydroxyethylamino)-pyndyl, amino-haloloweralkyl-pyndyl, e g amino-tπfluoromethyl- pyπdyl, especially 2~amino-3-trifluoromethyl-pyridyl, haloalkyipyπdinyl, in particular hatoloweralkylpyπdyl, especially, 2-, 3- or 4-tπfluoromethylpyπdyl most especially 2- tnfluoromethylpyndyl, halopyridyl, in particular fluoropyridyl, especially 2-fluoropyndyl, halo- alkoxy-pyπdyl e g fluoro-methoxy-pyπdyl such as 3-fluoro-2-methoxy-pyridyl, carbamoylpyridyl, especially 2-(carbamoyl)pyridyl, alkyl-substituted carbamoyl, e g methylcarbamoyl, especially 2-(methylcarbamoy))pyridyl, pyπmidinyl, loweralkylaminopynmidinyl, e g 2- or 4-methylaminopyrimidinyi or 2- or 4- ethylaminopyπmidinyl, di-loweralkylaminopyrimidinyl, e g 2- or 4- methylethylaminopynmidinyl, 2- or 4-dimethylaminopyrimidinyl, especially 2~ dimethylaminopyπmidinyl, alkoxypynmidmyl, in particular methoxypyrimidinyl or ethoxypyrimidinyl, e g 2-methoxypyπmidmyl or 2-ethoxypynmidinyl, 1H-pyrrolo[2,3- bjpyπdinyl, 1 -methyl- 1H-pyrrolo[2,3-b]pyridiny), pyrazinyl, pyrazolyl, substituted pyrazolyl, e g hydroxyalkylpyrazolyl, espeαaUy 1-(2~hydroxy-ethyl)-1H-pyrazolyl or 1 -[2-(tetrahydro~ pyran-2-yloxy)-ethyl]-1 H-pyrazolyl, quinoiiny), 2-oxo-2,3-dihydro-1H-indol-5-yl i-methyl-2,3- dihydro-1H-indoi-5-yl
The term 5-membered heteroaryl refers to aromatic 5-membered heterocyctyl °5-membered ' meaning that there are 5 nng atoms, one or more being a heteroatom, such as nitrogen, oxygen or sulfur, and, for example includes monocyclic rings, such as thienyl, furyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl isoxazolyl, oxadsazoiyl, tπazolyl imidazolyl tetrazolyl or thiadiazolyl, preferably pyrazolyl, each being unsubstituted or substituted with 1 to 3 substituents
In an embodiment, the term 5-membered heteroaryl as defined above refers to pyrazolyl or isoxazolyl, each being unsubstituted or substituted with 1 to 3 substituents Most preferably the 5-membered heteroaryl as defined above refers to pyrazolyl, which is unsubstituted or substituted with 1 to 3 substituents,
"Substituted", wherever used for a moiety, means that one or more hydrogen atoms in the respective moiety, especially up to 5 hydrogen atoms, more especially up to three of the hydrogen atoms are replaced independently of each other by a corresponding number of substituents, which preferably are independently selected from the group consisting of lower alkyl e g , methyl, ethyl, isopropyl or propyl, halo, e g F, Cl, Br or I1 halo-lower alkyl, e g , flυoroalkyl, such as trifluoromethyl; hydroxy; carboxy; fower alkoxy, e g., methoxy, ethoxy, propyloxy or isopropyloxy; aryl-lower alkyl, e.g phenyl-lower alkyl; aryl-lower alkoxy, e g. phenyl-lower alkoxy lower alkanoyloxy, lower alkanoyl; hydroxy-lower alkyi, e g., hydroxymethyl or 2-hydroxyethyl; alkoxy lower alkyl, e g. 2-methoxyethyl, hydroxy lower alkoxy, e.g. hydroxyethoxy; amino; mono- or di-substituted amino, cyclic amino, e g. aziridinyl, azetidinyl or pyrrrolidiπyl, amino-lower alkyl, e.g , aminomethyl, 2-aminoethyl or 3- aminopropyl, alkylamino-lower alkandiyl; dialkylammo-lower alkandiyl; ΛMower alkylamino, N,N-di-lower alkylamino, amino lower alkoxy, iower alkanoylamino, lower alkanoyl- lower alkyl-amino; benzoylamino; carbamoyl-lower alkoxy; A/-lower alkylcarbamoyl-lower alkoxy or N,N-di-lower alkylcarbamoyl-lower alkoxy; amidino; N-hydroxy-amidino; hydroxylamine; alkoxyamino; nitro; gυanidino, amidino-lower alkyl, e g , 2-amidinoethyl; N-hydroxyamidino- lower alkyl, e.g , N-hydroxy-arrudino-methyl or -2~ethyl; carboxy, lower alkoxycarbonyl; phenyl-lower alkoxycarbonyl, e g , benzyloxycarbonyl; lower alkanoyl; sulfo, lower alkanesulfonyl, e.g., methanesulfonyl (CH3-S(O)2-), sulfonamide (NHrS(O)2-); dioxolo; phosphono (-P(=O)(OH)2); hydroxy-lower alkoxy phosphoryl or di-lower alkoxy phosphoryl; carbamoyl, mono- or di-lower alkylcarbamoyl, carbamoyl lower alkyl, sulfamoyl, sulfamide, mono- or di-lower alkylaminosulfony), lower alkanesυlfonylamino, lower alkanesulfonyl- lower alkyl-amino; cyano, cyano-lower alkyl, e.g , cyanomethyl, 2-cyanoethyl or 3-cyanopropyl, aryl (e.g , phenyl), where aryl is unsubstitυted or substituted with any of the substituerrts defined above, and especially is phenyl which is unsubstituted or substituted with up to 4 sυbstituents, preferably up to 2 substituents, wherein the substituents are the same or different and are independently selected from halo, (e.g., Cl or F)cyano, cyano lower alkyl, (e g., cyanomethyl, cyanoethyl and cyanopropyl)iower alkyl, lower aikoxy, amino-lower alkyl sulfanyl, thiol-lower alkyl, amino-lower alkyl or amino-lower alkoxy, wherein the amino group in each case can be mono- or di-substituted, e.g , -(Ct-C7)mNR$Rθ, or -0-(C1-COmNR8R9, wherein m is O or 1 ; and
R8 and Rg can be the same or different and are independently H; lower alkyl, e g , methyl, ethyl or propyl, lower cycloalkyl, e g , cyclopropyt. or
R8 and R9, together with the N atom, form a 3- to 8-membered heterocyclic nng containing 1-4 nitrogen, oxygen or sulfur atoms, e g , azetidinyl, pyrrolidinyl, piperidino, morpholinyl, imidazolinyl, piperazinyl or lower alkyl-piperazinyl.
"Substituted" also includes amino-carbonyl-lower alkyl, e g , R8R9N-C(O)-CH2-, wherein R8 and R9 are as defined above "Substituted" also includes heterocyclyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkoxy or heterocyclyl-lower alkanesulfanyl, wherein the heterocyclyl in each case is a substituted or unsubstituted 3- to 8-membered heterocyclic nng containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazolyl, imidazolinyl, pyrrolidinyl, morphoJinyl, azetidinyl, pyndyt, pyrazolyl piperidino, piperidyl, piperazinyl or lower alkyl-piperazinyl. "Substituted" also includes C3-Ci0cycloall<yl, e g , cyclopropyl or cyclohexyl, hydroxyC3- Cøcycloalkyl, e.g., hydroxy-cyclohexyl; heteroaryl with 4 or 6 ring atoms and 1-4 ring heteroatoms selected from O1 N and S, especially furyl, 1 ,4 oxazinyl, or pyridyl. "Substituted" also includes -NR9R9, wherein R8 and R9 can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or the R6 and R9 can, with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., azetidinyl, pyrrolidinyl, piperidino, morpholinyl, imidazolinyl, piperazinyl or lower alkyl-piperazinyl.
In an embodiment, the present invention provides compounds of the formula (I)
Figure imgf000025_0001
wherein
X is O or S;
Y is CH or N1
R1 is a substituted or υnsubstituted 5-membered heteroaryl,
R2 is hydrogen or lower alkyl,
R3 is a substituted or unsubstituted aryl or heterocyclyl. and
R4, R5 and R° are hydrogen;
or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
For the avoidance of doubt, substituents are only bound at positions where chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without inappropriate effort, which substitutions are possible and which are not For example, amino or hydroxy groups with free hydrogen may be unstable if bound to carbon atoms with unsaturated, e.g., olefinic, bonds.
The terms "treatment" or "therapy" refer to the prophylactic or preferably therapeutic including, but not limited to, palliative, curing, symptom-alleviating, symptom-reducing, kinase-regulating and/or kinase-inhibiting, treatment of said diseases, especially of the diseases mentioned below Where subsequently or above the term "use" is mentioned (as verb or noun) (relating to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof), this includes any one or more of the following embodiments of the invention, respectively, the use in the treatment of a protein or lipid kinase dependant disease and in particular PI3K dependent disease, the use for the manufacture of pharmaceutical compositions for use in the treatment of a protein or lipid kinase dependant disease and in particular PI3K dependent disease, methods of use of one or more compounds of the formula (I) in the treatment of a protein or lipid kinase dependant disease and in particular PI3K dependent disease, the use of pharmaceutical preparations comprising one or more compounds of the formula (I) for the treatment of a protein or lipid kinase dependent disease, and one or more compounds of the formula (I) for use in the treatment of a protein or lipid kinase dependent disease, as appropriate and expedient and if not stated otherwise In particular, diseases to be treated and are thus preferred for "use" of a compound of formula (I) are selected from protein or lipid kinase dependent ("dependent" meaning also "supported", not only "solely dependent") diseases mentioned herein, especially proliferative diseases mentioned herein, more especially any one or more of these or other diseases that depend on one or more of protein or lipid kinases such as PI4K (phosphatidylinositol 4-kinase) and/or Pl 3 kinases (phosphatidylinositol 3-kinase), for example, inhibition of the PI3K superfamily which comprises PI3Kalpha, PI3Kbeta, PI3Kdelta, PI3Kgamma and mTOR, or one or more of the individual kinase members thereof, including Vps34 (class III PI3K), P13-kinase-related protein kinase family (PIKK, class IV PI3K) which includes DNA-PK, ATM, ATR, hSMG-1 and mTOR, or any combinations of two or more of these, or a mutant of any one or more of these, and a compound of the formula (I) can therefore be used in the treatment of a lipid or protein kinase dependent disease, especially a disease depending on one or more of the kinases mentioned above and below, where (especially in the case of aberrantly highly- expressed, constitutively activated and/or mutated kinases or defective dephosphorylation of their sυbstrate(s)) said kinase-dependent disease is dependent on the activity of one or more of the said kinases or the pathways in which they are involved
The compounds of formula (I) have valuable pharmacological properties and are useful in the treatment of lipid and/or protein kinase dependent diseases, e.g , as drugs to treat proliferative diseases
In the following detailed descnption and embodiments, which are to be taken independently, collectively or in any combination or sub-combination, the invention relates to a compound of the formula (I), in e.g free base form or in acid addition salt form, wherein the substituents are as defined herein Detailed Description of the Invention
With respect to formula (I), the following detailed description is provided
El
As indicated heremabove, R1 is a 5-membered heteroaryl having the appropriate corresponding meaning as for heteroaryl given above, with "5-membered" meaning that there are 5 ring atoms, one or more being a heteroatom, such as nitrogen, oxygen or sulfur Such 5-membered heteroaryl groups include monocyclic rings, such as pyrazolyl, thienyl, furyl, pyrrolyl, thiazolyl, «othiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, tnazolyl, imidazolyl, tetrazolyl or thiadiazolyl, preferably pyrazolyl, each being unsubstituted or substituted, e.g. by the groups listed herein under "substituted*'
In an embodiment, R1 is pyrazolyl or isoxazolyl, each being unsubstituted or substituted, e g by the groups listed herein under "substituted".
In an embodiment, R1 is unsubstituted or substituted pyrazolyl or unsubstituted or substituted isoxazolyJ Preferably the pyrazolyl is substituted, preferably by one, two or three substituents and the isoxazolyl is substituted, preferably by one or two substituents, wherein in each case, said substituents may for example be independently selected from halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamino, unsubstituted or substituted alkoxy lower alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl. unsubstituted or substituted carbamoyl lower alkyl, lower mono- and di-alkyl carbamoyl lower alkyl, unsubstituted or substituted cycloaminocarbonyl lower alkyl, unsubstituted or substituted heterocyclylcarbonyl lower alkyl, unsubstituted or substituted hydroxyl lower alkyl, unsubstituted or substituted carboxy lower alkyl, halo-loweralkyl, hydroxycarbonyl- loweralkyl, morpholinecarbonylalkyl, hydroxy or amino
In an embodiment, R' is unsubstituted isoxazolyl.
In an embodiment, R1 is isoxazolyl substituted by one or two substituents selected from halo, lower alkyl, unsubstituted or substituted lower alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted lower alkoxy, substituted or unsubstituted lower alkyl amino, hydroxy or amino In an embodiment, R1 is isoxazolyl substituted by one or two substituents selected from halo, unsubstituted or substituted lower alkyl, unsubstituted or substituted lower atkenyl, unsubstituted or substituted lower alkyπyl, uπsubstituted or substituted cycloalkyl, hydroxy or ammo
In an embodiment, R1 is isoxazolyl substituted by one or two substituents selected from unsubstituted lower alkyl, unsubstituted lower alkenyl, unsubstituted alkynyl, unsubstituted cycloloweralkyl, hydroxy or amino
In an embodiment, R1 is isoxazolyl substituted by one or two, same or different, unsubstituted lower alkyl substituents (in particular C1-C4alkyl) such as methyl or ethyl, preferably methyl.
In an embodiment, when R1 is unsubstituted or substituted isoxazolyl, said isoxazolyl is tsoxa2ol-3-yl, isoxazol-4-yl or isoxazol-5-yl.
It is prefered that a substituent of said substituted isoxazolyl is bonded to the isoxazolyl ring at the alpha position to the ring atom which bonds the isoxazolyl ring to the rest of the molecule (that is, the alpha position is at a position on the isoxazolyl ring which is next to the isoxazolyl ring atom which is bonded to the imidazoquinolinone part of the molecule). The isoxazolyl ring atom which is bonded to the rest of the molecule (i e the imidazoquinolinone part) is a carbon atom Thus, prefered isoxazolyl groups are alpha-substituted isoxazolyl For the avoidance of doubt the ring atom at the alpha position may be a carbon, nitrogen or oxygen ring atom, with at least one atom in the alpha position being a carbon atom, but, for chemical valency reasons, only an alpha carbon atom may be substituted
An embodiment of the invention includes compounds of formula (I) wherein R1 is unsubstituted or substituted isoxazol-4-yl, thus R1 in this embodiment is represented by a group of formula (AB).
Figure imgf000028_0001
wherein, the curved line indicates the bonding position to the rest of the molecule and the alpha position is shown by the atoms labeled with a * symbol and
R18 and R17 are independently selected from hydrogen, halo, unsubstituted or substituted lower alkyl (especially C1-C4alkyl), unsubstituted or substituted lower alkenyl, unsubstituted or substituted lower alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or sυbstituted lower aikylamino, unsubstituted or substituted cycioalkyl or unsubstituted or substituted cycloalkenyl
In an embodiment R1Θ and R17 are independently selected from hydrogen, halo or unsubstituted or substituted lower alkyl (especially C1-C4alkyl) such as methyl or ethyl
In an embodiment, R16 and R17 are independently selected from hydrogen, methyl or ethyl.
In an embodiment, at least one of R16 and R17 Is not hydrogen.
In an embodiment of the present invention, R1 is of formula (AB) shown above, and
R16 is C1-C4alkyl (especially methyl or ethyl); and
R17 is C1-C4alkyi (especially methyl or ethyl);
In a specific embodiment of the present invention, R1 is of formula (AB) shown above, and
R16 and R17 are each methyl.
Preferably R1 is unsubstrtuted or substituted pyrazolyl. Preferably the pyrazolyl is substituted, preferably by one, two or three substituents, wherein said substituents may for example be independently selected from halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower aikylamino, urtsubstttuted or substituted alkoxy lower alkyl. unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycioalkenyl, unsubstituted or substituted carbamoyl lower alkyl, lower mono- and di-alkyl carbamoyl lower alkyl, unsubstituted or substituted cycloaminocarbonyl lower alkyl, unsubstituted or substituted heterocyclylcarbonyl lower alkyl, unsubstituted or substituted hydroxy! lower alkyl, unsubstituted or substituted carboxy lower alkyl, halo-loweralkyl, hydroxycarbonyl- loweralkyl, morpbolinecarbonylalkyl, hydroxy or amino
Preferred substituents are selected from the group consisting of halo, lower alkyl, lower alkenyl, lower alkynyl, cycloloweralkyl, hydroxy, amino, halo lower alkyl, 2-hydroxyethyl, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CHr), dialkylaminocarbonylmethyl e.g. dimethylaminocarbonyimethyl (Me2NC(O)CH?-) or ethylmethylaminocarbonylmethyl
(EtMeNC(O)CHr), (methoxyethyl)(methyl)aminocarbonylmethyl ((MeOEt)(Me)NC(O)CHr), azetidinylcarbonylmethyl e g. 2-azetidin-1-yl-2-oxo-ethyl, morpholinecarbonylmethyl, (4- methylpiperazin- 1 yl)carbonylmethyl It is prefered that the substituent (if mono-substituted) or at least one of the substituents (if two or three substituents are present) is bonded to the pyrazole ring at the alpha position to the ring atom which bonds the pyrazole ring to the rest of the molecule (that is, the alpha position is at a position on the pyrazole ring which is next to the pyrazole ring atom which is bonded to the imidazoquinolinone part of the molecule) The pyrazole ring atom which is bonded to the rest of the molecule (i.e the imidazoquinolinone part) is preferably a carbon atom. Thus, prefered pyrazolyl groups are alpha-substituted pyrazolyl For the avoidance of doubt the ring atom at the alpha position may be a carbon or nitrogen ring atom Thus an embodiment of the invention includes compounds of formula (I) wherein R1 is a group selected from'
or
Figure imgf000030_0001
Figure imgf000030_0002
wherein, the curved line indicates the bonding position to the rest of the molecule and the alpha position is shown by the atoms labeled with a * symbol, and
R10 is independently selected from hydrogen, unsυbstituted or substituted lower alky I, unsubstituted or substituted lower alkenyl, unsubstituted or substituted alkyny), unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyi, unsubstituted or substituted lower alkoxy, substituted or unsubstituted lower alkyt amino, hydroxy or amino.
Preferably, R10 is independently selected from hydrogen, unsubstituted or substituted lower alkyl, unsubstituted or substituted lower alkenyl, unsubstituted or substituted lower alkynyl, unsubstituted or substituted cycloalkyl, hydroxy or amino
More preferably, R10 is independently selected from hydrogen, unsubstituted lower alkyl, unsubstituted lower alkenyl, unsubstituted alkynyl, unsυbstituted cycloloweralkyl, hydroxy or amino
More preferably, R10 is independently selected from hydrogen or lower alkyl such as methyl or ethyl R1' is independently selected from hydrogen, halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl. unsubstituted or substituted alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamino, unsubstttuted or substituted afkoxy lower alkyl, unsubstituted or substituted cycloalkyl or unsubstituted or substituted cycloalkenyl; unsubstituted or substituted carbamoyl lower alkyl, lower mono- and di-alkyl carbamoyl lower alkyl; unsubstituted or substituted cycloaminocarbonyl lower alkyl; unsubstituted or substituted heterocyclylcarbonyl lower alkyl.
More preferably R11 is independently selected from hydrogen, unsubstituted or substituted lower alkyl such as methyl, ethyl, propyl, isopropyl, halo lower alkyl such as trifluoromethyl, hydroxyl lower alkyl such as hydroxyl ethyl, alkoxy lower alkyl such as methoxyethyl, carbamoyl lower alkyl such as carbamoylmethyl, lower mono- or di-alkyl carbamoyl lower alkyl such as methylcarbamoylmethyl, ethylcarbamoylmethyl, dimethylcarbamoylmethyl, ethylmethylcarbamoylmethyl or diethylcarbamoylmethyl; cycloaminocarbonyl lower alkyl such as azetidinylcarbonylmethyl; or carboxy lower alkyl such as carboxy methyl.
More preferably R11 is independently selected from hydrogen, lower alkyl such as methy), ethyl, propyl, isopropyl or halo tower alkyl such as trifluoromethyl.
More preferably, R11 is independently selected from hydrogen, methyl, ethyl or trifluoromethyl.
R14 is independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted hydroxyl lower alkyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamino, unsubstituted or substituted alkoxy lower alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl; unsubstituted or substituted carbamoyl lower alkyl; lower mono- or di-alkyl carbamoyl lower alkyl; unsubstituted or substituted cycloaminocarbonyl lower alkyl, unsubstituted or substituted heterocyclylcarbonyl lower alkyl, unsubstituted or substituted carboxy lower alkyl,
More preferably R14 is independently selected from hydrogen or unsubstituted or substituted lower afkyl such as unsubstituted or substituted hydroxyl lower alkyl; unsubstituted or substituted alkoxy lower alkyl; unsubstituted or substituted carbamoyl lower alkyl, lower mono- or di-alkyl carbamoyl lower aikyi; unsubstituted or substituted cycloaminocarbonyl lower alkyl, unsubstituted or substituted heterocyclylcarbonyl lower alkyl, unsubstituted or substituted carboxy lower alkyl
More preferably R14 is independently selected from hydrogen, unsubstituted lower alkyl such as methyl, ethyl, propyl or isopropyl, hydroxyl lower alkyl such as hydroxyl ethyl; alkoxy lower alkyl such as methoxyethyl1 carbamoyl lower alkyl such as carbamoylmethyl; lower mono- or di-alkyl carbamoyl lower alkyl such as methylcarbamoylmethyl, ethylcarbamoylmethyl, dimethylcarbamoylmethyl, ethylmethylcarbamoylmethyl; diethylcarbamoylmethyl or (methoxyethyl)(methyl)carbamoylmethyl, cycloaminocarbonyl lower alkyl such as azetidinylcarbonylmethyl, unsubstituted or substituted heterocyclyicarbonyl lower alkyl such as morpholinecarbonyl lower alkyi or piperazinecarbonyl lower alkyl, or carboxy lower alkyl such as carboxy methyl,
More, preferably R14 is independently selected from hydrogen, unsubstituted or substituted CrC4alkyl, unsubstituted or substituted haloC1-C4alkyl, 2-hydroxyethyl, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CH2-). dialkylaminocarbonylmethyl e.g dimethylaminocarbonylmethyl (Me2NC(O)CH2-) or ethylmethylaminocarbonylmethyl (EtMeNC(O)CH2-), (methoxyethyl)(methyl) aminocarbonylmeihylmethyl ((MeOEt)(Me)NC(O)CH?-), azetidinylcarbonylmethyl e g. 2-azetidin-1-yl-2-oxo-ethyl, morpholinecarbonylmethyl e g 4-morpholinecarbonylmethyl, (4-methylpiperazin- 1yl)carbonylmethyl
Most preferably R14 is independently selected from hydrogen, methyl, ethyl, isopropyl, tnfluoromethyl, 2-hydroxyethyt, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CHr), dimethylaminocarbonylmethyl (Me2NC(O)CH2-), ethylmethylaminocarbonylmethyl (EtMeNC(O)CH2-), (methoxyethyl)(methyl) aminocarbonylmethylmethy! ((MeOEt)(Me)NC(O)CH2-), 2~azetidin-1-yl-2-oxo-ethyl, 4-morpho)inecarbonylmethyl and (4- methylpiperazin-1yl)carbonylmethyl
R12. R13 and R1S are independently selected from hydrogen, halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamino, unsubstituted or substituted cycloalkyl or unsubstttuted or substituted cycloalkenyl
More preferably R12, R13 and R15 are independently selected from hydrogen, halo such as fluoro, chloro, bromo, or unsubstituted or substituted lower alkyl such as methyl or ethyl
More preferably R12, R13 and R15 are independently selected from hydrogen, chloro, methyl or ethyl
Preferably, one of R10 and R12 is not hydrogen
Preferably, at least one of R13 and R15 is not hydrogen
In an embodiment of the present invention, R, is of formula (A) or (8) shown above; and R10 is d-dalkyl (especially methyl or ethyl);
R11 is hydrogen or d-dalkyl (especially methyl) or fluoroCt -Chalky I (especially trifluoromethyl), and
R1? is hydrogen or d-dalkyl (especially methyl);
R13 is hydrogen or d-dalkyl (especially methyl);
R14 is d-dalkyl (especially methyl, ethyl or isopropyl), 2-hydroxyethyf, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CH2-), dimethylaminocarbonylmethyl (Me2NC(O)CH2-), diethylaminocarbonylmethyl (Et2NC(O)CH2-). ethylmethylaminocarbonylmethyl (EtMeNC(O)CH2-), (methoxyethyl)(methyl) aminocarbonyimethylmethyl ((MeOEt)(Me)NC(O)CH2-), 4-morpholinecarbonylmethyl, (4-methylpiperazin- 1yl)carbonylmethyl, 2-azetidin-1-yl-2-oxo-ethyl, and
R15 is methyl or chloro
In another embodiment of the present invention, R1 is of formula (A) shown above, and
R10 is d-dalkyl (especially methyl or ethyl);
R1 t is hydrogen or d-dalkyl (especially methyl) or fluoroCrdalkyl (especially trifluoromethyl), and
R12 is hydrogen or d-dalky! (especially methyl)
In another embodiment of the present invention, R1 is of formula (B) shown above; and
R13 is hydrogen or d-dalkyl (especially methyl);
R14 is d-dalkyl (especially methyl, ethyl or isopropyl), 2-hydroxyethyl, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CH2-), dimethylaminocarbonylmethyl (Me2NC(O)CH2-), ethylmethylaminocarbonylmethyl (EtMeNC(O)CH2-), (methoxyethyl)(methyl) aminocarbonylmethylmethyl ((MeOEt)(Me)NC(O)CH*-), 2~azetidin-1-yl-2-oxo-ethyl, 4- morpholinecarbonylmethyl and (4-methylpiperazin-1yl)carbonylmethyl, and
R15 is methyl or chloro.
In an embodiment, R1 is selected from 1 ,5-dimethyl-1H-pyrazol-4-yl, 2-ethyl-2H-pyrazol-3-yl, 2-methyl~2M-pyrazol-3-yl, 2,5-dimethyl-2H-pyrazol-3-yl) 1-isopropyl-3-methyl-1H-pyrazol-4-yl, 1-ethyl-3-methyl-1H-pyrazol-4-y1, 2,4-dimethyl-2H-pyrazol-3-yl, 1 ,3-dimethyl-1H-pyrazol-4-yl, 1,3,5-trimethyf-1 H-pyrazol-4-yl, 2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl 1-hydroxycarbonyl methyl-3-methyl-pyrazol-4-yl, 1 -dimethylaminocarbonylmethyl-S-methyl-pyrazoM-yl, 1 - dimethylaminocarbonylmethyl-3,5-dimethyl-pyrazd-4-y), 1-diethylaminocarbonylmethyl-3- methyl-pyrazo(-4-yl, 1 -(2-hydroxyethyl)-3-methyl-pyrazol-4-yl, 1 -(2-azetidin-1 -yl-2-oxo-ethyl)- 3-methyl-1 H-pyrazol-4-yl, 1-(4-morpholin)-carbonylmethyl-3-methyl-pyrazol-4-yl, 3-methyl-1- [2-(4~methyl-piperazin-1-yl)-2-oxo-ethylJ-1 H-pyrazol-4-yl, i-methyl-S-chloro-pyrazoM-yl, 1-(2- methoxyethyl)-3,5-dimethyt~pyrazol-4-yl, i-N-ethyl-N-methyIaminocarbonyfmethyl-3-methyl- pyrazol-4-yl or 3,5-dimethyl-isoxazol-4-yl.
In another embodiment R1 is selected from 1,5-dimethyl-1 H-pyrazol-4-yl, 2-ethyl-2H-pyrazol- 3-yl, 2-methyl-2H-pyrazol-3-yl, 2,5-dimethyl-2H-pyrazol-3-yl, 1-isopropyl-3-methyl-1H- pyrazol-4-yl, 1-ethyl-3-methyl-1 H-pyrazol-4-yl, 2,4-dimethyl-2H-pyrazol-3-yl, 1 ,3-dimethyl-1H- pyrazol-4-yl, 1 ,3,5-trimethyl-1 H-pyrazol-4-yl, 2-methyl-5-trifluoromethyt-2H-pyrazol-3-yl,1- hydroxycarbonylmethy)-3-methyl-pyrazol-4-yl, i-dimethylaminocarbonylmethyl-3-methyl- pyrazol-4-yl, 1-dimethylaminocarbonylmethyl-3,5-dimethyl-pyrazoJ-4-yl,
1 -diethyfaminocarbonylmethyl-S-methyl-pyrazoM-yl, 1 -(2-hydroxyethyl)-3-methyl-pyrazol-4- yl, 1-(2-azetidin-1-yl-2-oxo-ethyl)-3-methyl-1 H-pyrazol-4-yl, 1-(4-morpholin)-carbonylmethyl- 3-methyl-pyrazol-4-yl, 1-methyl-3-chloro-pyrazol-4-yl, 1-(2«methoxyethyl)-3,5-dimethyl- pyrazol-4-yl.
In an embodiment, R2 is preferably selected from hydrogen, Ct-C4alkyl or d-C^alkenyl. In particular R2 is selected from hydrogen, methyl, ethyl and propeny! (especially propen-3-yl)
In another embodiment, R2 is preferably selected from hydrogen or Ci-C4alkyl Most preferably R2 is selected from hydrogen, methyl and ethyl.
B!
R3 is unsubstitυted or substituted aryi or υnsυbstituted or substituted heterocycyl as defined herein above, each of which, when substituted, is substituted by one or more, especially 1 -3, substituents independently selected from the group consisting of the substituents defined under "substituted".
When R3 is unsubstituted or substituted aryl, it is preferably C6-C,0aryl which is unsubstituted, or substituted by one or more, especially 1-3, substituents independently selected from the group consisting of the substituents defined under "substituted" When R3 is an aryt group, (especially Ce-Cioaryl, more especially phenyl) it is unsubstituted, or substituted by one or more, especially 1-3, substituents independently selected from the group consisting of the substituents defined under "substituted".
When the R3 group is an aryl group, (especially (VC^ary), more especially phenyl) when substituted, the substituents may be selected from the group consisting of halo, especially fluoro, chloro, bromo or iodo, in particular fluoro; halo-lower alkyl, especially fluoroalkyl, in particular trifluoromethyl, hydroxyl; amino; mono or disubstituted amino, especially alkyl- substituted amino or hydroxyalkyl-substituted amino, e g. dimethyl amino or 2-hydroxyethyl amino, cyclic amino, such as aziridinyl or azetidinyl; amino-lower alkyl, e.g , aminomethyl, 2- aminoethyl or 3-aminopropyl; lower alkoxy, e.g., methoxy, ethoxy or propoxy (e.g iso- propoxy), hydroxy-lower alkyl, e.g , hydroxymethyl or 2-hydroxyethyl, hydroxy lower alkoxy, e g. hydroxyethoxy; lower alkyl, e g., methyl, ethyl or iso-propyl; cyano; cyano-lower alkyl, e g., 2-cyanoethyl or 3-cyanopropyl; amidino; N-hydroxyamidino; hydroxyamino; alkoxyamino, nitro; amidino-lower alkyl, e g., 2-amidino-ethyl; or N-hydroxyamidino-lower alkyl, e.g , 2-{N-hydroxyamidino)-ethyl; substituted phenyl or (especially 1- or 2-)naphthyl; sulfonyl, substituted sulfonyl, e.g. alkyl-substituted sυlfonyl, such as methanesulfonyi, sulfonamide, e.g. N-methylsulfonamide (or lower alkylaminosulfonyl or N,N-di-loweralkyl aminosulfonyl, e.g. methylaminosufonyl or dimethylaminosutfonyl) or pyrrolidine- 1 -sulfonyl; lower alkyl sulfonyl amino, e.g. methylsulfonylamino; lower alkyl sulfonylalkandiylamino, e.g. methylsulfonylmethylamino; lower alkylsυlfonyl-N-lower alkylamino, e.g. methylsulfonyl-N- methylamino1 [1 ,3]dioxolo, substituted [1 ,3Jdioxolo, e.g. 2,2-difluoro-(1 ,3]dioxolo, alkoxy carbonyl, such as lower alkoxy carbonyl, e g, methoxycarbonyl; carbamoyl, substituted carbamoyl, such as alkyl-substituted carbamoyl, e g. methy (carbamoyl; heterocycle, e g. pyrazol; heterocyclyl lower alkyl; heteroaryl or heteroaryl lower alkyl.
In an embodiment, when the R3 group is an aryl group, (especially Ce-Cioaryl, more especially phenyl) when substituted, the substituents may be selected from the group consisting of halo, especially fluoro, chloro, bromo or iodo, in particular fluoro; halo-lower alkyl, especially fluoroalkyl, in particular trifluoromethyl, hydroxyl; amino, mono or disubstituted amino, especially alkyl-substituted amino or hydroxyalkyl-substituted amino, e.g dimethyl amino or 2-hydroxyethyl amino; cyclic amino, such as azindinyl or azetidinyl, amino-lower alkyl, e g., aminomethyl, 2-aminoethyl or 3-aminopropyl; lower alkoxy e.g., methoxy or ethoxy; hydroxy-lower alkyl, e.g , hydroxymethyl or 2-hydroxyethyl, hydroxy lower alkoxy, e g hydroxyethoxy, lower alkyl, e.g., methyl, ethyl or iso-propyl, cyano, cyano-lower alkyl, e.g , 2-cyanoethyl or 3-cyanopropyl; amidino, N-hydroxyamidino, hydroxyamino, alkoxyamino, nitro1 amidino-lower alkyl, e.g., 2-amidino-ethyl; or N-hydroxyamidino-lower alkyl, e g , 2-(N-hydroxyamidino)-ethyl; substituted phenyl or (especially 1- or 2-)naphthyl. sulfonyl; substituted sulfonyt, e.g. alkyl-substituted sulfonyl, such as methanesulfonyl: sulfonamide, e g. N-methylsυlfonamide or pyrrolidine-1 -sulfonyl, [1 ,3]d»oxolo, substituted [1 ,3]dioxolo, e g. 2,2-difluoro-[1 ,3]dioxolo; alkoxy carbonyl, such as lower alkoxy carbonyl, e.g methoxycarbonyl, carbamoyl; substituted carbamoyl, such as alkyl-substituted carbamoyl, e g. methylcarbamoyl, heterocycle, e.g. pyrazol; heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl.
In an embodiment, unsubstituted or substituted aryl for R3 is selected from phenyl; hydroxyphenyl, e.g , 2-, 3- or 4-hydroxyphenyl; methoxyphenyl, e.g , 2-, 3- or 4-methoxyphenyl or 3,4-dimethoxyphenyl; ethoxyphenyl, e.g , 2-, 3- or 4-ethoxyphenyl or 3,4-diethoxyphenyl; propoxyphenyl (e.g iso-propoxyphenyl) such as 3-propoxyphenyl (e g 3-iso-propoxyphenyl), methoxy ethoxy-phenyl, e.g. 3-methoxy-4-ethoxy phenyl or 4-methoxy- 3-ethoxy phenyl, other Iσwer-alkoxy phenyl, e.g. 3-methoxy-4-(2-methoxy ethoxy)-phenyl, halo-alkoxy-phenyl, e.g. fluoro-(iso-propoxy)-phenyl, e.g 2-fluoro-3-(iso-propoxy)-phenyl; hydroxy alkoxy phenyl, e g 3-methoxy-4-hydroxy phenyl; halo-hydroxy-phenyl, e.g. fluoro- hydroxy-phenyl such as 3-fluoro-5-hydroxy-pheny), hydroxy-haloalkyl-phenyl, e.g hydroxy- fluoroalkyl-phenyl such as 3-hydroxy-5-tπfluoromethy1-phenyl; 2,2-difluoro-benzo[1 ,3]dioxoIo, benzene sulfonamide, e.g. N-methylbenzenesulfonamide and N,N- dimethylbenzenesulfonamide; 3-{pyrrolidine-1 -sulfonyl)-phenyl, N-(phen-3-yl)- methanesulfonamide or N-methyl-N-phen-3-yl-methanesυlfonamide, alkyl-sulfonyl phenyl, e.g 3-methanesulfonyiphenyl; benzamide e.g 2-, 3- or 4-benzamide, 2-, 3- or 4-N-methyl- benzamide or 2-, 3- or 4-N,N-dimethyl-benzamide; pyrazol-phenyl, e.g 4-(pyrazσl)-phenyl or alternatively (1H~pyrazol-1yl)-phenyl, in particular 4-(1H-pyrazol-1yl)-phenyl, imidazol-phenyl, especially (1H-imidazol-2-yl)phenyl, in particular 4-(1H-imidazol-2-y1)phenyl.
In an embodiment, unsυbstttuted or substituted aryl for R3 is selected from phenyl; hydroxyphenyl, e.g., 2-, 3- or 4-hydroxyphenyl; methoxyphenyl, e.g., 2-, 3- or 4-methoxyphenyl or 3,4-dimethoxyphenyl; ethoxyphenyl, e g , 2-, 3- or 4-ethoxyphenyl or 3,4-diethoxyphenyl, methoxy ethoxy-phenyl. e.g. 3-methoxy-4-ethoxy phenyl or 4-methoxy-3- ethoxy phenyl, other lower-alkoxy phenyl, e g. 3-methoxy-4-(2-methoxy ethoxy)-phenyl, hydroxy alkoxy phenyl, e.g. 3-methoxy~4-hydroxy phenyl, halo-hydroxy-phenyl, e g. flυoro- hydroxy-phenyl such as 3-fluoro-5-hydroxy-phenyl, hydroxy-haloalkyl-phenyl, e.g. hydroxy- fluoroalkyl-phenyl such as 3-hydroxy-5-trifluoromethyl-phenyl; 2,2-difluoro-benzo[1 ,3]dioxolo, benzene sulfonamide, e.g N-methylbenzenesulfonamide, 3-(pyrrolidine-1-sulfonyl)-phenyl, N-(phen-3-yl)-methanesulfonamide or N-methyl-N-phen-3-yl-methanesu)fonamide, alkyl- sulfonyl phenyl, e g. 3-methanesulfonylphenyl, benzamide e g. 2-, 3- or 4-benzamide, 2-, 3- or 4-N-methyl-benzamide or 2-, 3- or 4-N,N-dimethyl-benzamide, pyrazol-phenyl, e g 4- (pyrazol)-phenyl or alternatively (1H-pyrazol-1yi)-phenyl, in particular 4-(1 H-pyrazol-1yl)- phenyl; imidazol-phenyl, especially (1H-imidazol-2-yl)phenyl, in particular 4-(1H-imidazol-2- yl)phenyl,
When the R3 group is a heterocyclyl or preferably heteroaryl, said heterocyclyl or heteroaryl may be selected from the group consisting of indotyl, 2,3-dihydro-1H-indol-5-yl, 1-methyl-2,3- dihydro-1Hπndol-5~yl, 2-oxo-2,3-dihydro-1H-indol-5-yl, pyridyl, pyrimidinyl (especially pyrimidin-5-yl), 1H-pyrrolo[2,3-b]pyridin-5-yl, 1 -methyl- 1H-pyrrolo[2,3-b]pyridin-5-yl, pyrazolyl, pyrazol-4-yl, pyrazinyl, quinolyl, quinol-3-yl, 1H-imidazo{4I5-b]pyridin-2(3H)-one-6-yl, 3H- imidazo[4,5-b]pyridin-6-yl, 3H-[1 ,2,3]tnazolo[4,5-bJpyridin-6-yl each of these heterocycle radicals being unsubstituted or substituted by one or two radicals selected from the substituents described under "substituted", in particular from the group consisting of halo, especially fluoro chloro, bromo or iodo, more especially fluoro or chloro; halo-lower alkyl, especially fluoroalkyl, in particular trifluoromethyl, hydroxy!; amino, mono or disubstituted amino, especially alkyl-substituted amino or hydroxyalkyl-substituted ammo, e.g. dimethyl amino or 2-hydroxyethyl amino, cyclic amino, such as aziridinyl or azetidinyl, amino-lower alkyl, e.g., aminomethyl, 2-aminoethyl or 3-aminopropyl; lower alkoxy, e.g , methoxy or ethoxy; lower alkoxy lower alkyl, e g 2-methoxyethyl; hydroxy-lower alkyl, e g , hydroxymethyl or 2-hydroxyethyl; hydroxy lower alkoxy, e.g. hydroxyethoxy; lower alkyl, e.g., methyl, ethyl or iso-propyl; cyano; cyano-lower alkyl, e.g., 2-cyanoethyl and 3-cyanopropy), amidino; N-hydroxyamidino; amidino-lower alkyl, e.g , 2-amidino-ethyl, or N-hydroxyamidino- lower alkyl, e.g., 2-(N-hydroxyamidino)-ethyl; substituted phenyl or (especially 1- or 2-) naphthyl; sulfonyl; substituted sulfonyl, e.g. alkyl-substituted sulfonyl, such as methanesulfonyl, sulfonamide, e.g N-methylsulfonamide or pyrrolidine- 1 -sulfonyl, [1 ,3]dioxolo, substituted [1 ,3)dioxolo, e.g. 2,2-difluoro-[1 ,3]dioxolo; alkoxy carbonyl, such as lower alkoxy carbonyl, e.g. methoxycarbonyl; carbamoyl; substituted carbamoyl, such as alkyl-substituted carbamoyl, e g. methylcarbamoyi; aminocarbonylalkyl, such as aminocarbonyl loweralkyl, e g aminocarbonylmethyl; N-mono-substituted aminocarbonylalkyl, such as N-loweralkyl aminocarbonyl loweralkyl, e g. methylaminocarbonylmethyl, N-di-substituted aminocarbonylalkyl, such as N-di-loweralkyl aminocarbonyl loweralkyl, e g. dimethylaminocarbonylmethyl, or other N-di-substituted aminocarbonylalkyl, such as 4-morpholinecarbonylmethy! . The heterocycle group may also be substituted with another heterocycle, e.g 3H-tetrazoiyl (in particular 3H-tetrazol-5-yl), pyrazol, heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein.
Very preferred heterocyclic groups, which may be substituted or unsubstituted , include indolyl, 1-methyl-2,3-dihydro-1 H-indolyl, 2-oxo-2,3-dihydro-1H-indolyl, pyridyl, pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-methyl-1H-pyrrolo(2,3-b]pyridinyl, pyrazolyl, pyrazinyl, quinolyl, 1 ,3-Dimethyl-2-oxo-2,3-dihydro-1 H-im!dazo(4,5-b]pyndinyl, 1-erhyl-3-methyl-2-oxo-2,3- dihydro-1 H-imtdazo[4,5-b]pyridinyl, 1-(2-methoxy-ethyl)-3-methyl~2~oxo-2,3-dihydro-1 H- imidazo(4,5-b)pyridinyl, 2-Dimethylamino~3-methyl-3H~imidazo[4,5-b]pyridinyl, 2-methoxy-3- methyl-3H-imidazo(4,5-b]pyridinyl, 3-methyl-3H-[1 ,2,3)triazolo[4,5-b]pyridmyl, 2,3-Dimethyl- 3H-imidazo[4,5-b]pyridinyl, 3-methyl-3H-imidazo[4,5-b]pyridinyl, 1H-pyrrαlo[3,2-b]pyridinyl, 1- methyl-1 H-pyrroto[3,2-b]pyridiny), 1 -methyl~2-oxo-1 ,4-dihydro-2H-pyrido[2,3-d][1 ,3]oxazinyf , 4-methyl-3,4-dihydro-2H-pyπdo(3,2-b]{1 ,4Joxazinyl, 1 ,3,3-trimethyl-2-oxo-2,3-dihydro-1 H- pyrrolo[2,3-b)pyridinyl and 1-ethyl-2-oxo~1 ,4-dihydro-2H-pyrido{3,2-d][1 ,3]oxazinyl each of these heterocycle radicals being unsubstituted or substituted by one to two radicals selected from the substituents described under "substituted", in particular from the group consisting of halo, especially fluoro, chloro, bromo or iodo, more especially fluoro or chloro, in particular fluoro, halo-lower alkyl, especially fluoroalkyl, in particular trifluoromethyl; hydroxyl; amino, mono or disubstituted amino, especially alkyl-substitυted amino, hydroxyalkyl-substituted ammo or alkoxyalkyl-substituted amino, e.g. dimethyl amino, 2-hydroxyethyl amino or 2- methoxyethyl amino; cyclic amino, such as aziridinyl, azetidinyl or pyrroiidiny!; substituted cyclic amino, e.g. hydroxy cyclic amino; amtno-lower alky!, e.g., aminomethyl, 2-aminoethyl or 3-aminopropyl, alkylamino-lower alkyl, e.g. methylaminomethyl, ethylaminomethyl, methylaminoethyl or ethylaminoethyl, dialkylamino-loweralkyl, e.g. dimethylaminomethyl, dimethylaminoethyl, methylethylaminomethyl, methylethylaminoethyl, diethylaminomethyl or diethylaminoethyl, cycloalkylaminoalkyl, e.g. cyclopropylaminomethyl, cyclopropylaminoethyl, cyclobutylaminomethyl, cyclobutylaminoethyl, cyclopentylaminomethyl or cyclopentylaminoethyl; dicycloalkylaminoalkyl, e g dicyclopropylaminomethyl, dicyclopropylaminoethyl, cyclopropylcyclobutylaminomethyl or cyctopropylcyclobutylaminoethyl, alkylcycloalkylaminoalkyl, e g cyclopropylmethylaminomethyl, cyclopropylmethylaminoethyl, cyclopropylethylaminomethyl or cyclopropylethylaminoethyl: lower aJkoxy, e g , methoxy, ethoxy or propyloxy, cycloalkoxy, e.g. cyclobutoxy; lower-alkoxyalkyl, e g. methoxy methyl, methoxypropyl, ethoxypropyl; hydroxy-lower alkyl, e.g., hydroxymethyl or 2-hydroxyethyl; hydroxy lower cycloalkyl, e.g. hydroxy cyclopentyl; hydroxy lower alkoxy, e g. hydroxyethoxy, alkoxy lower alkoxy, e.g methoxyethoxy or ethoxyethoxy, lower alkyl, e.g., methyl, ethyl or røo-propyl, cyano; cyano- lower alkyl, e.g., 2-cyanoethyl, 2-cyanopropyl, 2-cyano-2-methylpropyl or 3-cyanopropyl; cyano lower cycloalkyl, e g cyano cyclobutyl, amidino; N-hydroxyamidino; amidino-lower alkyl, e.g., 2-amidino-ethyl; or N-hydroxyamidino-lower alkyl. e.g., 2-(N-hydroxyamidmo)- ethyl, nitro; carboxylic acid, substituted sulfonyl, e.g. alkyl-substituted sulfonyi, such as methanesulfonyl, sulfonamide, e g. N-methylsulfonamide or pyrrolidine-1 -sulfonyl; alkylsulfonylamino, e.g methylsulfonylamino; alkylsulfonylalkylamino, e.g. methylsulfonylmethylamino, acylamino (also termed alkyl carbonyl amino), e.g acetylamino; acyl alkyl amino, e g acetyl methyl amino; alkylcarbonylaminoalkyl, e g. methylcarbonylaminomethy); alkylaminocarbonylalkyl e g. methylaminocarbonylmethyl; alkylcarbonyl-N-alkylamino, e g.methylcarbonyl-N-methylainino; (1 ,3]dioxolo; substituted (1 ,3)dioxolo, e.g. 2, 2-diftuoro-{ 1 ,3Id(OXoIo1 alkoxy carbonyl, such as lower alkoxy carbonyl, e g. methoxycarbonyl; carbamoyl (also termed aminocarbonyl); substituted carbamoyl, such as alkyl-substituted carbamoyl, e.g. methylcarbamoyl, ethyl carbamoyl, iso-propyl carbamoyl or alkoxyalkyl-substituted carbamoyl (also termed alkoxyalkylaminocarbonyl), e g. 2- methoxyetfiylcarbamoyl The heterocycle group may also be substituted with another substituted or unsubstituted heterocycle, preferabely a 4-7 membered ring, e.g. 1 H-tetrazolyl (in particular 1H~tetrazol-5-yl), pyra∑ol, imidazole, tnazole, azetidinyl, pyrrolidinyl, piperazinyl, methylpiperazmyl, ethylpiperazinyl , triazolonyl methylimidazolyl or morpholino The heterocycle group may also be substituted with heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl as defined herein,
In an embodiment, R3 is heterocycyl. In another embodiment, R3 is heterocycyl which is heteroaryl, In an embodiment, said heterocycyl or heteroaryl is a monocyclic 6 membered ring wherein one or two ring heteroatoms are nitrogen atoms. In a preferred embodiment, R3 is a monocyclic 6 membered heteroaryl wherein one or two ring heteroatoms are nitrogen atoms In an embodiment, R3 is pyπdyl, pyrimidinyl or pyrazinyl, each independently being unsubstituted or substituted. In an embodiment, R3 is pyridyl or pyrimidinyl, each independently being unsubstituted or substituted. In an embodiment, R3 is unsubstituted or substituted pyridyl (especially pyrid-3-yl or pyndyl-5-yl). In another embodiment R3 is unsubstituted or substituted pyrimidinyl (especially pyrimidin-5-yl).
In an embodiment said pyrimidinyl (especially pyrimidin-5-y!) is unsubstituted or substituted, preferably substituted. When substituted, said pyrimidinyl is preferably substituted in the 2- 4- or 2- and 4- positions on the pyrimidine ring. Typically, when mono-substituted, the pyrimidine ring is substituted in the 2-position, and when di-substituted, in the 2- and A- posttions
When substituted, said pyrimidinyl is substituted by one or two substituents independently selected from.
di-)oweralkylamino, df-alkoxy, aikylamino, alkoxy, cycloamino.
(n an embodiment, heterocyclyl or heteroaryl for R3 is pyndyl, especially pyrid-3-yl or pyrkJ-5- yl - both of these terms mean that the pyridine ring is bonded to the rest of the imidazoquinolinone part of the molecule of formula (I) at a pyridine carbon atom which is arrived at by counting 3 atoms or 5 atoms round the pyridine ring, starting at the nitrogen atom of the pyridine nng, which counts as 1.In an embodiment, said pyridyl (preferably pyπd- 3-yl or pyrid-5-yl) is unsubstituted or substituted, preferably substituted. When substituted, said pyridinyl is preferably substituted in the 5-, 6-, or 5- and 6-posttion positions of the pyridine ring (with reference to pyridin-3-yl),
When substituted, said pyridyl is substituted by one or two substituents independently selected from.
loweralkyl, lower-alkoxy, cycloalkoxy, haloalkyl, cycioalkylalkoxy, alkoxyalkyl, alkoxyalkoxy, benzyloxyalkoxy, hydroxyalkyl, hydroxycycloalkyl, hydroxyfluoroalkyl, aminoalkyl, alkyl- sulfonyl, hydroxyalkoxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, cycloalkylamino, N-alkyl-N-cycloalkylamino, halo, deuteroalkoxy-alkyl, haloalkoxy, cycloamino, cyclic ether- substituted amino, hydroxy-cycloamino, loweralkoxy-cycloamino, hydroxyalkylamino, amino- haloloweralkyl, deuteroloweralkylamino, cyanoaikyl, cyanocycloalkyt, carbamoyl, piperazinyl, alkylsulfonamido, dialkylsulfonamido, alkylsulfonamidoalkyl, dialkylsulfonamwio(alkyt), 3H- tetrazol-5-yl, alkytcarbonylaminoalkyl, alkylcarbonyt-N-alkylamino, nttro, alkylaminocarbonylalkyl, alkoxyalkylaminocarbonyl, morpholinyl, 1H-pyrazolyl, loweralkylsubstituted( 1 H-imidazol- 1 -yθ.
In an embodiment, specifically preferred unsubstituted or substituted heterocyclyl or heteroaryl for R3 is selected from.
pyridyl, e.g. pynd-2-yl, pyrid-3-yl or pyπd-4-yi; especially pyπd-3-yl,
alkylpyridyl, in particular loweralkylpyπdyl, e.g. methylpyridyl, e g , 2-, 3- or 4-methylpyridyl, especially 2-methylpyridyl or 3-methylpyridyl, in particular 2-methylpyrid-5-yl or 3-methytpyrid-5-yl;
alkoxypyπdyl, in particular lower-alkoxypyπdyl, e.g. methoxypyridyl, e.g., 2-, 3- or 4-methoxypyridyl, especially 2-methoxypyridy! or 3-methoxypyndyl (in particular 2- methoxypyrkJin-5-yl, 3-methoxypyridin-5-yl); ethoxypyridyl, e.g., 2-, 3- or 4-ethoxypyπdyl especially 2-ethoxypyπdyl or 3-ethoxypyridyi (in particular 3-ethoxypyrκ_-5-yl. 2-ethoxypyrid- 5-yl, 2-ethoxypyπd-4~yl); propoxypyridyl, e g n-propoxypyndyl or iso-propoxypyridyl (in particular 6-(n-propoxy)pyrid-3-yl or 3-(iso-pfopoxy)pyridin"5-yl or 2~(iso-propoxy)pyridin-4-yl),
cycloalkoxypyπdyl, e.g cyclobutoxy-pyridyl, especially 3-cyclobutoxy-pyridyi (in particular 3-cyclobutoxy-pyrid-5-yl);
(haloalkoxy)pyridyl e g. (halo-isopropoxy)pyridyl, such as 3-(1,3-difluoropropan-2- yloxy)-pyridyl (in particular 3-(1,3~diflυoropropan-2-yloxy)-pyrid-5-yl) or 3-(2-fluoroethan-1- yloxy)-pyridyl (tn particular 3-(2-fluoroethan-1-yloxy)-pynd-5-yl) or 3-(difluoromethyloxy)- pyridyl (in particular 3-(difluoromethyloxy)-pyπd-5-yl);
cycloalkylalkoxypyridyl, e.g cyclopropylmethoxy-pyπdyl, espeαalty 2- cyclopropylmethoxy-pyridyl (in particular 2-cyclopropylmethoxy-pyrid-5-yl);
alkoxyalkylpyridyl e,g βthoxymethylpyridyl, 2-methoxymethylpyridyl (in particular 2- mβthoxymethylpyrid-5-yl) or 3-methoxymethylpyridyl (in particular 3-methoxymethylpyrid-5-yl) or 3-(2-methoxy~prop-2-yl)pyridyl (in particular 3-(2-methoxy-prop-2-yl)pyrid-5-yl or 3-(2- ethoxy-prop-2-yl)pyridyl (in particular 3-(2-ethoxy-prop-2-yl)pyrid-5-yl,
alkoxyalkoxypyridyl, in particular methoxyethoxypyπdyl, e g 3-{2- methoxyethoxy)pyπdyl or 2-(2-methoxyethoxy)pyπdyl (in particular 3-(2-methoxyethoxy)pyrid- 5-yl or 2-(2-methoxyethoxy)pyrid-5-yl);
(alkyiχalkoxyalkoxy)pyrκtyl, in particular (loweralkyl)(loweraJkoxyalkoxy)pyridyl, such as (methyl)(methoxyethoxy)pyridyl, e.g. (2-methyl)-(3-(2-methoxyethoxy))pyridyl (in particular (2-methyl)-(3-(2-methoxyethoxy))pynd-5-yl,
benzyloxyalkoxypyridyl, in particular benzyloxyethoxypyridyl or benzyloxypropoxypyridyl, e g 2-benzyloxyethoxypyridyl or 3-benzyloxypropoxypyridyl (in particular 2-benzyloxyethoxypyπd-5-yl or 3-benzyloxypropoxypyπd-5-yl),
hydroxyalkylpyridyl, e g hydroxymethylpyπdyl, especially 2-(hydroxymethyl)-pyridyl (in particular 2-hydroxymethylpyrid-5-yl) or hydroxyethylpyπdyl, espeαally 3-(1-hydroxyethyl)- pyridyl (in particular 3-(i-hydroxyethyl)pyrid-5-yl) or hydroxypentylpyπdyl (alternatively termed 1 -hydroxy- 1-ethyl-propyi), such as 3-(3-hydroxyρentyl)-pyridy! especially 3-(3- hydroxypent-3-yl)pyπdyl (in particular 3-(3-hydroxypent-3-yl)pynd-5-yl) or hydroxypropylpyridyl, especially 3-(2^\ydroxyprop-2-yl)-pyπdyl (in particular 3-(2- hydroxyprop-2-yl)pyrtd-5-yl) or hydroxy* 1 ,1-dimethyl-ethylpyridyl, especially 3-(2-hydroxy-1 ,1- dimethyl-ethyl)-pyridyl (in particular 3-(2-hydroxy-1 ,1-dimethyl-ethyl)pyrid-5-yl),
hydroxycycloalkylpyridyl, e g hydroxylowercycloalkylpyridyl, especially 3-(1- hydroxycyclopenty1H>yridyl (in particular 3-(1-hydroxycyclopenty})-pyrid-5-yl),
hydroxyfluoroalkylpyridyl, e g. hydroxyfluoropropylpyridyl, especially 3-(1 ,3-difluoro-2- hydroxyprop-2-yl)-pyridyl (in particular 3-(1 ,3-difluoro-2-hydroxyprop-2-yl)pyπd-5-yl)
aminoalkylpyridyl, e g aminomethylpyndyl, especially 3-(aminomethyl)-pyridyl (in particular S-aminomethylpyrid-δ-yl), alkyl-sulfonyl pyridyl, e g methanesulfonylpyridyl, especially 3-methanesutfonylpyridyl (in particular 3-methanesulfonylpyrld-5-yi),
hydroxyalkoxypyridyl, e g. 2-(2-hydroxyethoxy)-pyridyl or 2-(3-hydroxypropoxy)- pyridyl (in particular 2-(2-hydroxyethoxy)-pyrrd-5-yl or 2-(3-hydroxypropoxy)-pyrid-5-yl),
alkoxycarbonylpyndyl, e g. methoxycarbonylpyπdyl. especially 2-methoxycarbonyl- pyπdyl (in particular 2-methoxycarbonyl-pyrid-5-yl},
aminopyridyl, e g. 2- or 3-aminopyridyl (in particular 2~aminopyrid-5-yl or 3- amtnopyrid-5-yl),
alkylaminopyridyl, e.g loweralkylaminopyrtdyl, in particular methylaminopyridyl such as 2-methylaminopyridyl, 3-methylaminopyridyl or ethylaminopyridyl such as 2- ethylaminopyridyl (especially 2-methylaminopyrid-5-yl, 3-methylaminopyrid~5-yl or 3- ethylaminopyrid-5-yl) or isopropylaminopyridyl such as 3-rsopropyiamtnopyridyl (especially 3- isopropylaminopyrid-5-yl;
dialkylaminopyridyl, in particular dHoweralkylaminopyridyl, e g. 2-, 3- or 4- dimethylaminopyridyl, especially 2-dimethylaminopyridyl or 3-dimethylaminopyridyl (in particular 2-dimethylaminopyrid-5-yl or 3-dimethylaminopyπd-5-yl) or e g. 2-, 3- or 4- diethylaminopyridyl, especially 2-diethylaminopyridyl or 3-diethylaminopyτidyl (in particular 2- diethylaminopyrid-5-yl or 3-dtethylamtnopyrtd-5-yl) or e g 2-, 3- or 4-ethylmethylaminopyridyl especially 2-ethylmethylaminopyridyl (in particular 2-ethylmethylaminopynd-5-yl or 3- ethylmethylaminopyndyl (in particular 3-ethylmethylaminopyrid-5-yl) or e g 2-, 3- or 4- isopropylmethylaminopyndyl, especially 2-isopropylmethylaminopyπdyl or 3- isopropylmethylaminopyridyl (in particular 2-isopropylmethylaminopyrid-5-yl or 3- isopropylmethylaminopyrid-5-yl;
cycloalkylaminopyridyl, e.g cycloloweralkylaminopyridyl, in particular cyclobutylaminopyridyl such as 3-cyclobutylaminopyπdyl or (especially 3-methylaminopyrid- 5-yl);
(N-alkyl-N-cyck>alkylamino)pyπdyl, e g (N-loweralkyl-N-cycloloweralkylamino)pyπdyl, in particular (N-methyl-N-cyclobutylamino)pyridyl such as 3-(N-methyl-N- cyclobutylamino)pyridy! or (especially 3-(N-methyl-N-cyclobutylamino)pyπd-5-yl)'
(alkyl)(amtno)pyπdyl, e g (loweralkyl)(amino)pyπdyl, in particular (methyl)(amino)pyridyl such as 2-methyl-3-amtno-pyridyl (especially 2-methyt-3-amino-pyπd- 5-yt) or (ethyl)(amino)pyridyl such as 2-ethyl-3-amino-pyridyl (especially 2-ethyl-3-amino- pyrid-5-yl),
(halo)(amino)pyridyl, e g. (fluoro)(amino)pyridyl) in particular 3-fluoro-2-amino-pyridyl (especially 3-fluoro-2-amino-pyτk.-5-yl), 2-fluoro-3-amino~pyndyl (especially 2-fluoro-3-amino- pyrid-5-yl), 3-chloro-2-amino-pyridyl (especially 3-chloro-2-amino-pyrid-5-yl) or 2-chloro-3- amino-pyπdyl (especially 2-cnloro-3-amino-pyπd-5-yl);
(halo)(alkylamino)pyridyl, e.g. (halo)(loweralkylamino)pyridyl, in particular (ftuoro)(methylamino)pyπdyl such as 3-fluoro~2-methylamino-pyridyl (especially 3-fiuoro-2- methylamino-pyrid-5-yl), 2-fluoro-3-methylamino-pyπdyl (especially 2-fluoro-3-methylamino- pyπd-5-yl), 2-fluoro-3-ethytamino-pyrfdyl (especially 2-fluoro-3-ethylamino-pyπd-5-yl), 3- chlorσ-2-methylamino-pyridyl (especially S-chloro^-methylamino-pyrid-δ-yl), 3-chloro-2- ethylamino-pyndyl (especially 3-chloro-2-ethylamino-pyπd-5-yl) or 2-chloro-3-ethylamino- pyridyl (especially 2~chloro-3-ethylamino-pyrid-5-yl);
(halo)(dialkylamino)pyridyl, e.g. (hak))(di-loweralkylamino)pyridyl, in particular (fluoro)(dimethylamino)pyndyl such as 2-fluoro-3-dimethylamino-pyπdyl (especially 2-fluoro- 3-dimethylamino-pynd-5-yl),
(halo)(hydroxyalkyl)pyridyl, e g (halo)(hydroxyloweralkyl)pyridyl, in particular (chloro)(hydroxymethyl)pyridyl such as 3-chloro-2-hydroxymethyl-pyridyl (especially 3-chloro- 2-hydroxymethyl~pynd-5-yl)
(alkoxy)(alkyl)pyridyl e.g (methoxy)(methyl)pyridyl, such as 3-methoxy-2-methyl- pyridyl (in particular 3-methoxy-2-methyl-pyπd-5-yi)) (ethoxy)(methyl)pyπdyl, such as 3- ethoxy-2-methyl-pyridyl (in particular 3-ethoxy-2-methyl-pyπd-5-yl) or e g. (propoxy)(methyl)pyπdyl, such as 3-propoxy-2-methyl-pyndyl (in particular 3-propoxy-2- methyl-pyrid-5-yl) or e g (propoxy)(ethyl)pyndyl, such as 3-propoxy-2-ethyl-pyridyl (in particular 3-propoxy-2-ethyl-pyrid-5-yl) or e g (ethoxy)(ethyl)pyridyl, such as 3-ethoxy-2- ethyl-pyndyl (in particular 3-ethoxy-2-ethyl-pyrid-5-yl);
(alkoxy)(alkoxy)pyπdyl e g (propoxy)(methoxy)pyridyl, such as 3-propoxy-2-methoxy- pyridyl (in particular 3-propoxy-2-methoxy-pynd-5-yl); or e g (propoxy)(ethoxy)pyridyl, such as 3-propoxy-2-ethoxy-pyπdyl (in particular 3-propoxy-2-ethoxy-pyrid-5-yl) or e g (methoxy)(methoxy)pyridyl. such as 3-methoxy-2-methoxy-pyridyl (in particular 3-methoxy-2« methoxy-pyπd-5-yl) or e g (ethoxy)(methoxy)pyπdyl, such as 3-ethoxy-2-methoxy-pyridyl (in particular 3-ethoxy-2-methoxy-pyπd-5-yi) , (alkoxy)(alkoxyalkyl)pyridyl e.g. (isopropoxy){methoxymethyl)pyridyl, such as 3- isopropoxy-2-methoxymethyl-pyridyl (in particular 3-tsopropoxy-2-methoxymethyl-pynd-5-yl) or (methoxy)(methoxymethyl)pyridyl, such as 3-methoxy-2-methoxymethyl-pyridyl or 2- methoxy-3-methoxymethyl-pyridyl (in particular 3-methoxy-2-methoxymethyl-pyrid-5-yl or 2- methoxy-3-methoxymethyl-pyπd-5-yl) or (methoxy)(ethoxymethyl)pyridyl, such as 3-methoxy- 2-ethoxymethyl-pyridyl (in particular 3-methoxy-2-ethoxymethyl-pyrid~5-yl) or (ethoxy)(methoxymethyl)pyridyl1 such as 3-ethoxy-2-methoxymethyl-pyπdyl (in particular 3- ethoxy-2-methoxymethyl-pyrid-5-yl);
(alkoxy)(deuteroalkoxy~alkyl)pyridyl e g (ethoxy)(trideuteromethoxymethyl)pyridyl, such as 3-ethoxy-2-trideuteromethoxymethyl-pyridyl (in particular 3-ethoxy-2- trideυteromethoxymethyl-pyrid-5-yl),
(alkoxy)(hydroxyalkyl)pyridyl e.g. (isopropoxy)(hydroxymethyl)pyridyt, such as 3- isopropoxy-2-hydroxymethy!-pyridyl (in particular 3-isopropoxy-2-hydroxymethyl-pyrid-5-y!) or (methoxy)(hydroxymethyl)pyπdy), such as 3-methoxy-2-hydroxymethyl-pyridyl (in particular 3- methoxy-2-hydroxymethyl-pyrid-5-yl) or 2-methoxy-3-hydroxymethyl-pyridyl (in particular 2- methoxy-3-hydroxymethyl-pyrid-5-yl) or (ethoxy)(hydroxymethyl)pyπdyl, such as 3-ethoxy-2- hydroxymethyl-pyridyl (in particular 3-ethoxy-2-hydroxymethyl-pyrid-5-yl),
(haloalkoxy)(alkyl)pyridyl e.g (halo-isopropoxy)(methyl)pyridyl, such as 3-(1 ,3- difluoropropan-2-yloxy)'2-(methyl)-pyndyl (in particular 3-(1,3-difluoropropan-2-yloxy)-2- (methyl)-pyrid-5-yl);
(haloalkoxy)(hydroxyalkyl)pyridyl e.g. (halo>isopropoxy)(hydroxymethyl)pyridyi, such as 3-(1 ,3-difluoropropan-2-yloxy)-2-(hydroxymethyl)-pyridyl (in particular 3-(1.3- difluoropropan-2-yloxy)-2-(hydroxymethyl)-pyrid-5'yl);
(alkoxyalkoxy)(hydroxyalkyl)pyridyl, in particular (loweralkoxy loweralkoxy)(hydroxyloweralkyl)pyridyl, e.g. (methoxyethoxy)(hydroxymethyl)pyridyl, such as 3-methoxyethoxy-2-hydroxymethyl-pyπdyl (in particular 3-methoxyethoxy-2-hydroxymethyl- pyrid-5-yi);
(alkyl)(alkylamino)pyridyl, e g. (loweralkyl)(loweralkylamino)pyridyl, in particular (methyl)(ethylamino)pyridyl such as 2-methyl-3-ethylamino-pyndyl (especially 2-methyl-3- ethylamino-pyrid-5-yl) or (methyl)(methylamino)pyπdyl such as 3-methyl-2-methy)amino- pyπdyl (especially 3~methyl-2-methylamino~pyrid-5-yl) or (ethyl)(ethylamino)pyridyl such as 2- ethyl-3-ethylamino-pyridyl (especially 2-methyl-3-ethy!amino-pyrid-5-yl) or (ethyl)(isopropylamino)pyridy1 such as 2-ethyl*3HSopropylamino-pyπdyl (especially 2-ethyl-3- isopropylamino-pynd-5-yl), (alky))(di-alkylamino)pyridyl, e.g. (loweralkyl)(dMoweraiky!amino)pyri<jyl, in particular (methyt)(N-methyt-N-ethylamino)pyπdyl such as 2-methyl-3-(N-methyl-N-ethylamino)-pynclyl {especially 2-methyt-3-(N-methyl-N~ethylamino)-pyrid-5-yl) or (methyl)(N,N- dimethylamino)pyridyl such as 2-methy(-3-(N,N-dimethylamino)-pyridyl (especially 2-methyl- 3-(N,N-dimethylamino)-pyrid-S-yl),
cycloaminopyridyl, e.g azetidinylpyndyl, especially 2~azetidin-1-yl-pyήdiny I (in particular 2-azetidirv1-yl-pyridirv5-yl) or 3-azetidtn-1-yl-pyridinyl (in particular 3~azetidin-1-yl- pyrtdin-5-yl) or pyrrolidinylpyπdyl, especially 2-pyrrolidinyM-yl~pyπdinyl (in particular 2- pyrrolidinyl-1-yl-pyridin-5-yl),
cyclic ether-substituted amino-pyπdyl, e.g tetrahydro-pyranylamino-pyridyl, especially 2-(tetrahydro-ρyran-4-ylamino)-pyridyl (in particular 2-(tetrahydro-ρyran-4-y1amino)pyridyl-5- yi.
hydroxy-cycloaminopyridyl, such as hydroxy-pyrrolidinylpyπdyl, e g 3-hydroxy- pyrrolidin-1-yl-pyπdinyl (in particular 6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl, more particularly, 6-((R)-3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl or 6-((S)3-hydroxy-pyrrσlidin-1-yt)- pyndin-3-yl;
loweralkoxy-cycloaminopyridyl, such as methoxy-pyrrolidinylpyridyl, e g 3-methoxy- pyrroHdm- 1 -yl-pyridiny I (in particular β-^-methoxy-pyrrolidin-1-yO-pyridin-S-yl, more particularly, 6-((R)-3-methoxy-pyrrolidm-1-yl)-pyridin-3-yl or 6-((S)3-methoxy-pyrrolid)n-1-yl)- pyridin-3-yl,
hydroxyalkylaminopyridyl, e g. 2-(2-hydroxyethylamino)-pyridyl (in particular 2-(2- hydroxyethylamino)-pyrid-5-yi);
(alkyl)(hydroxy)pyridyl, in particular (loweralkyl)(hydroxy)pyridyl e.g 2-(methyl)-3- (hydroxy)-pyridyl (in particular 2-(methyl)-3-(hydroxy)-pyrid-5-yl) or 2-<ethyl)-3-(hydroxy)- pyπdyl (in particular 2-(ethyl)-3-(hydroxy)-pyrid-5-yl),
(hydroxyalkyl)(aikylamino)pyridyl, in particular
(hydroxyloweralkyl)(loweralkylamino)pyndyl, such as (hydroxymethyl)(ethylamino)-pyridyl, e.g. 2-(hydroxymethyl)-3-(ethylamino)-pyricryl (in particular 2-(hydroxymethyl)-3- (ethylamino)-pyrid-5-yl) or such as (hydroxymethyl)(methylamino)-pyridyl, e g 2- (hydroxymethyl)-3-(methylamino)-pyridyl (in particular 2-(hydroxymethyl)-3-(methylamino)- pyrκJ-5-yl) 3-(hydroxymethyl)-2-(methylamino)-pyridyl (in particular 3-(hydroxymethyl)-2- (methylamino)-pyπd-5-yl), (hydroxyalkyl)(amino)pyridyl, in particular (hydroxy!owera)kyl)(amino)pyridyl, such as (hydroxymethyl)(amino)-pyridyl, e.g. 3-(hydroxymethyl)-2-(amino)-pyridyl (in particular 3- (hydroxymethyl)-2-(amino)-pyrid-5-yl);
(alkoxyalkyl)(alkylamino)pyridyl, in particular
(loweralkoxyloweralkyl)(loweralkylamino)pyridyl, such as (methoxymethyl)(ethylamino)- pyridyl, e.g. 2-(methoxymethyl)-3-(ethylamino)-pyridyl (in particular 2-(methoxymethyl)-3- (ethylamino)-pyrid-5-yl) or such as (methoxymethyl)(methylamino)-pyridyl, e.g. 2- (methoxymethyl)-3-(methylamtno)-pyridyl (in particular 2-(methoxymethyl)-3-(methylamino)- pyrid-5-yl or or such as (ethoxymethyl)(ethylamino)-ρyridyll e.g. 3-(ethoxymethyl)~2~ (ethylamino)-pyridyl (in particular 3-(ethoxymethy!)-2-(methylamino)-pyrid-5-yl;
(alkoxyalkyl)(amino)pyridyl, in particular (alkoxyloweralkyl)(amino)pyridyl) such as (ethoxymethyl)(amino)-pyridyl1 e.g. 3-(ethoxymethy!)-2-(amino)-pyπdyl (in particular 3- (ethoxymethyl)-2-(amino)-pyrtd-5-yl) or (methoxymethyl)(amino)-pyridyl, e.g. 3- (methoxymethyl)-2-(amino)-pyridyl (in particular 3-(methoxyrr>ethyl)-2-(amino)-pyrid-5-yl);
amino-haloloweralkyl-pyridyl, e.g amino-trifluoromethyl-pyrϊdyl, especially 2-amino-3- tήfluoromethyl-pyridyl (in particular 2-amino-34rifluoromethyl-pyrid-5-yl);
alkylamino-haloalkyl-pyridyl, such as loweralkylamino-haloloweralkyl-pyridyl, e.g. methylamino-triflυoromethyl-pyridyl, especially 2-methylamino-3-trifluoromethyl-pyridyl (in particular 2-methylamino-3-trifluoromethyl-pyrid-5-yl) or e.g. βthylamino-trrfluoromethyl- pyridyl, especially 2-ethy!amino-3-trifluoromethyl-pyridyl (in particular 2-ethylamino-3- triflυoromethyl-pyrid-5-yl);
haloalkyl-deuteroloweralkylamino-pyridyl, e.g. triflυoromethyl-trideuteromethylamino- pyridyl. especially 3-trifluoromethyl-2-trideuteromethylamino-pyridyl (in particular 3- trifluoromethy(-2~trideuteromethylamino-pyrid-5-yl);
haloalkylpyridinyl, in particular haloloweralkylpyridyl, especially, 2~, 3- or 4-trifluoromethylpyridyl. most especially 2-trifluoromethylpyridyl (in particular 2- trifluoromethylpyrid-5-yl);
cyanoalkylpyridinyl, in particular cyanoloweralkylpyridyl, especially, cyanopropylpyridyl, most especially 2-cyanoprop-2-ylpyridyl (in particular 3-(2-cyanoprop-2- yl)-ρyrid-5-yl); cyanocycloalkylpyndinyl, in particular cyanolowercycloalkyipyridyl, especially, cyanocyclobutylpyridyl, most especially 1-cyanocyck>buty)pyridyt (in particular 3-(1~ cyanocyclobυtyl)-pyrid-5-yt);
halopyridyl, in particular fluoropyridy), especially 2-fluoropyridyl (in particular 2- fluoropyrid-3-yl or 2-fluoropyrid-4-yl),
halo-alkoxy-pyridyl, e.g. fluorø-methoxy-pyndyl such as 3-fiuoro-2-methoxy-pyπdyl (in particular 3-fluoro-2-methoxy-pyrid-5-y I);
carbamoylpyπdyl, especially 2-(carbamoyl)pyridyl (in particular 2-(carbamoy))pyrid-5- y[); alkyl-substitυted carbamoyl, e.g. methy (carbamoyl, especially 2-(methytcarbamoyl)pyπdyl (in particular 2-(methylcarbamoyl)pyrid-5-yi);
piperazinylpyridyl, e g. 1-piperazinylpyridyl, especially 2-(1-piperazinyl)pyridyi (in particular 2-(1-piperazinyl)pyrid-5-y1); N-alkylpiperazinylpyπdyl, such as N- loweralkylpiperazinylpyridyl, e.g. N-methylpiperazinylpyridyl, especially 2-(4-methylpiperazin- 1-yl)-pyrtdyl (in parttcular 2'(4-methylptperazin-1-yl)>pyrid-5-yl),
alkylsulfonamidopyridyl, such as loweralkylsulfonamidopyridyl, especially methylsulfonamidopyridyl, e g. 3-(methy!sulfonamido) pyridyl (in particular 3- (methylsulfonamido)-pyridin-5-yl),
dialkylsulfonamidopyndyl, such as diloweralkyisulfonamidopyridyl, especially dimethyfsulfortamidopyridyl, e g 3-(dimethylsulfonamido) pyπdyl (in particular 3- (dimethylsulfonamido)-pyridin-5-yl);
(alkylsulfonamidoKalkyl)pyridyl such as (loweralkylsulfonamido)(loweralkyl)pyridyl, especially (methylsulfonarntdo)(methy!)pyridyl, e g 3-(methy)sulfonamidoKmethyl)pyridy1 (in particular 3-(methylsutfonamido)-2-methyl pyridin-5-yl),
(alkylsulfonamido)(halo)pyridyl such as (loweralkylsυtfonamido)(chloro)pyridyl, especially (methylsulfonamido)(chloro)pyridyl, e g. 3-(methylsulfonamido)(chloro)pyridyl (in particular 3-(methytsulfonamido)-2-chloro-pyridin-5-yl);
(alkylsulfonamidoalkyl)pyridyl such as (loweralkylsulfonamido-loweralkyl)pyridyl, especially (methylsυlfonamidomethyl)pyridyl, e.g. 3~(methylsulfonamtdomethyl)pyridyl (in particular 3-(methylsulf σnamidomethy !)-pyridin-5-y!) , dialkylsυlfonamido(alkyl)pyπdyl, such as diloweralkylsulfonamido(loweralkyl)pyridyl, especially dimethylsulfonamido(methyl)pyndyl, e g 3-(dimethylsulfonamido)(2-methyl) pyridyl (in particular 3-(dimethylsulfonamido)-(2-methyl)-pyridin-5-yl),
3H-tetrazol-5-yJ pyπdyl, e g 2-(3H-tetrazol-5-yl)pyπdyl (in particular 2-(3H-tetrazo)-5- yl)pynd-5-yl),
alkylcarbonylaminoalkylpyndyl such as loweralkylcarbonylaminoloweralkyl)pyridyl, e g methylcarbonylaminomethylpyndyi, especially 3-methylcarbonylaminomethylpyπdyl (in particular 3~methylcarbonylaminomethylpyrfd-5-yl),
(halo)(alkylcarbonylamino)pyπdyl, such as (halo)(lowera!kylcarbonylamino)pyndy!, e g (chloro)(methylcarbonylamino)pyridyl, especially 2-(chloro)-3- (methylcarbonyfamino)pyridyl (in particular 2-(chloro)-3-(methylcarbonylamino)pynd-5-yl),
(alkoxy)(a(kylcarbonylamino)pyπdyl, such as (loweralkoxy)(loweralkylcarbonylamino) pyridyl, e g (methoxy)(methylcarbonylamino)pyridyl or (ethoxy)(methylcarbonylammo)pyridyl, especially 2-(methoxy)-3-(methylcarbonylamino)pyridyl or 2-(ethoxy)-3* (methylcarbonylamino)pyridyl (in particular 2-(methoxy)-3-(methylcarbonylamino)pyπd-5~yl or 2-(ethoxy)-3-(methylcarbonylamino)pyrid'5-yl))
(alkoxy)(alkylcarbonyl-N-alkylamino)pyπdyl such as (k>weralkoxy)(loweralky!carbonyl- N-loweralkylamino)pyndyi, e g (methoxy)(methylcarbonyl-N-methylamino)pyndyl or (ethoxy)(methylcarbonyl-N-methylamino)pyridyl, especially 2-(methoxy)-3-(methy)carbonyl-N- methylamino)pyridyl or 2-(ethoxy)-3-(methylcarbonyl-N"methylamino)pyridyl (in particular 2- (methoxy)-3-(methyk:arbonyl-N-methylamino)pyπd-5-yl or 2-(ethoxy)-3-(methylcarbonyl-N- methylaminoJpynd-S-yl),
(alkoxy)(nitro)pyπdyl, such as (lowera{koxy)(nitro)pyπdyl, e g (methoxy)(nitro)pyridyl, especially 2-(methoxy)-3-(nitro)-pyπdyl (in particular 2~(methoxy)-3-(nitro)-pyrid-5-yl),
(alkoxy)(cyano)ρyndyl, such as (loweralkoxy)(cyano)pyπdyl e g
(methoxy)(cyano)pyridyl, especially 2-(methoxy)-3-(cyano)-pyπdyl (in particular 2-(methoxy)- 3-(cyano)-pyrid-5-yl),
(alkoxv)(amino)pyndyl, such as (loweralkoxy)(amino)pyridyl e g
(methoxy)(amino)pyridyl, especially 2-(methoxy)-3-(amino)-pyridy( (in particular 2-(methoxy)- 3-(amino)-pyπd-5-yl), (alkoxy)(alkylamino)pyπdyl, such as (loweralkoxy)(alkylamino)pyiϊdyl, e g (methoxy)(elhylamino)pyridyl, especially 2-(methoxy)-3-(ethytamino)pyridyl (in particular 2- (methoxy)-3-(ethylamino)pyrid-5-yl,
(alkoxyalkyl)(alkylamino)pyridyl, such as (loweraikoxyioweralkyl)(alkytamino)pyridyl, e,g (methoxymethyl)(methylamino)pyridyl. especially 3-(methoxymethyl)-2- (methylamino)pyridyl (in particular 3-(methoxymethyl)-2-(methylamino)pyrid-5-yl) or (methoxymethyl)(ethylamino)pyτidyl, especially 3-(methoxymethyl)-2-(ethylamino)pyridyl (in particular 3-(methαxymethyl)-2-(ethylamino)pyrid-5-yl) ;
(alkoxy)(alkylaminocarbonyl)pyndyl, such as
(loweralkoxy)(loweralkylaminocarbonyl)pyridyl, e.g. (methoxy)(methylaminocarbony))pyridyl, especially 2-(methoxy)-3-(methylaminocarbonyl)pyndyl (in particular 2-(methoxy)-3- (methylaminocarbonyl)pyrid-5-yl,
alkylaminocarbonylalkylpyπdyl, such as loweralkylaminocarbonylloweralkylpyridyl, e.g methylaminocarbonylmethylpyπdyl, especially 3-methylaminocarbonylmethylpyridyl (in particular S-methylaminocarbonylmethylpyrid-δ-yl,
(amino)(alkylaminocarbonyl)pyridyl, such as (amino)(loweralkylaminocarbonyl)pyridyl, e.g. (amino)(methylaminocarbonyl)pyπdyl, especially 2-(amino)-3- (methylaminocarbonyl)pyridyl (in particular 2-(amino)-3-(methylaminocarbonyl)pyrid-5-yl) or (amino)(ethylaminocarbonyl)pyridyl, especially 2-(amino)-3-(ethylaminocarbonyl)pyridyl (in particular 2-(amino)-3-(ethylaminocarbonyl)pyrid-5-yl) or (amino)(isopropylaminocarbonyl)pyridyl, especially 2-(amino)-3- (isopropylaminocarbonyl)pyridyl (in particular 2-(amino)-3-(isopropylaminocarbonyl)pyrid-5- yi).
(amino)(alkoxyalkylaminocarbonyl)pyτidyl, such as amino)(loweralkoxyloweralkylaminocarbonyl)pyridyl, e.g. (amino)(methoxyethylaminocarbonyl)pyndyl. especially 2-(amino)-3-(2- methoxyethylaminocarbonyl)pyridyl (tn particular 2-(amino)-3-(2- methoxyethylaminocarbonyl)pyrid-5-yl)
(alkylamino)(alkylaminocarbonyl)pyridyl, such as (loweralkylamino)(loweralkylaminocarbonyl)pyridy), e.g (methylamino)(ethylaminocarbonyl)pyπdyl, especially 2-(methylamino)-3- (ethylamtnocarbonyl)pyπdyl (in particular 2-(methylamino)-3-(ethylaminocarbonyl)pyrid-5-yl); (alkoxy)(aminocarbonyl)pyridyl, such as (loweralkoxy)(aminocarbonyl)pyridyl, e.g. (methoxy)(aminocarboπyl)pyridyt, especially 2-(methoxy)-3-(amtnocarbonyl)pyridyt (in particular 2-(rτ\ethoxy)-3-(aminocarbonyl)pyπd-5-yl);
(alkoxy)(hydroxycarbonyl)pyridyl, such as (loweralkoxy)(hydroxycarbonyl)pyridyl, e.g (methoxy)( hydroxycarbonyl)pyridyl, especially 2-(methoxy)-3-(hydroxycarbonyl)pyπdyl (in particular 2-(methoxy)-3-(hydroxycarbonyl)pyrid-5-yl,
morpholiπylpyπdinyl, such as morpholin-4-ylpyridinyl, e.g. 3-morpholin-4-ylpyridinyl, especially 3-morpholin-4-ylpyndin-5-yl ,
(1H-pyrazolyl)-pyridinyl, such as (1H-pyrazoMyl)-pyridinyl, especially 2-(1 H-pyrazol- lyO-pyridinyl, in particular (1H-pyrazo)-1yl)-pyridin-5-yl.
k)weralkylsubstituted(1H-imidazol-1-yl)-pyπdinyl, such as methyl-substituted(1 H- imidazol-1-yl)-pyridinyl, e g (2-methyMH-imrclaEθl-1~yl)-pyridinyl especially (2-methyl-1 H- imidazol-1-yl)-pyπdin-5-yl,
pyrimidinyl. tn particular pynmidin-5-yl,
di-lcweralkylaminopyπmidinyl, e.g 2- or 4-djmethylaminopynmidinyl, especially 2- dimethylaminopyrimidmyl (in particular 2-dimethylaminopyπm»din-5-yl),
alkoxypyrimidinyl, in particular methoxypyrimidinyl or ethoxypyrimidinyl, e g 2- methoxypynmidinyl or 2-ethoxypyrimidinyl (in particular 2-methoxypyτimidin-5-yl or 2- ethoxypyrimidin-5-yl);
di-alkoxypyπmidinyl, in particular di-methoxypyrimidinyl, e.g 2,4-dimethoxypyπmidinyl or (in particular 2 4-dimethoxypyf!midin-5-yl),
(alkylaminoXalkoxyJpynmidinyl, in particular
(loweralkylamino)(loweralkoxy)pyrimidinyl e.g (methylamino)(methoxy)pyπmidinyl or (ethylamino)(methoxy)pyπmidinyl e.g. 2-(methylamino)-4-(methoxy)pyrimtdinyl or 2- (ethytamino)-4-(methoxy)pyπmtdinyl (in particular 2-(methylamino)-4-(methoxy)pyrimidin-δ-yl or 2-(ethylamino)-4-(methoxy)pyrimidin-5-yl),
cycloammopyrimidinyl, e.g pyrrolidinylpyπmidinyl, especially 2-(pyrrolidinyl) pyrimidiny! (in particular 2-(pyrrolidinyl)pyπmidin-5-yl),
aminopyrimidinyl, in particular 2-aminopyπmidinyl (especially 2-aminopyrimidin-5-yl, alkylaminopyπmidinyl, in particular loweralkyiaminopyrimidinyl, e g. 2- methylaminopynmidinyl (especially 2-methylaminopynmidin-5-yl);
dialkylaminopyπmidinyl, in particular di-loweraJkylaminopynmtdinyl. e.g. 2- dimethylaminopyrimidinyl (especially 2-dimethylaminopyrimidin-5-yl),
1H-pyrrolo[2,3-b]pyridinyl (in particular I H-pyrrolo^^-bjpyridin-δ-yl),
1-methyHH-pyrrolo(2,3-b]pyrk.inyl (in particular 1 -methyl- 1H-pyrrolo[2,3-b]pyridin-5- yi).
pyrazinyl;
pyrazolyl e.g. pyrazol-4y1,
substituted pyrazolyl, e.g. hydroxyalkylpyrazolyl, especiaHy 1-(2-hydroxy-ethyl)-1H- pyrazolyl (in particular 1-(2-hydroxy-ethyl)-1H-pyrazol-4-yl) or 1-[2-(tetrahydro-pyran-2-yloxy)- ethy)]-1H-pyrazolyl (in particular 1-(2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol-4-yl);
quinolinyl (in particular quinolin-3-yl);
2-oxo-2,3-dihydro-1H-indol-5-yl;
1-methyl-2,3-dihydro-1H-indol-5-yl,
1H-imidazo[4,5-b}pyridin-2(3H)-one-6-yl (in particular 1 ,3-dimethyl-1H-imidazo(4,5- b)pyridtn-2(3H)-one-6-yl, 1-ethyl-3-methyHH-imidazo[4,5-b]pyπdin-2(3H)-one-6-yl or 1-(2- methoxyethyl)-3-methyl-1H-imidazo[4,5-blpyridin-2(3H)-one-6-yl;
3H-imidazo[4,5-b]pyridin-6-yl, e.g. (3-methyl)-3H-imidazo(4,5-bJpyridin-6-yl, (2- methyt)-(3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl, (2-methoxy)-(3-methyl)-3H-imidazo[4,5- bJpyridin-6-yl, (2-dimethylamino)-(3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl;
3H-[1 ^.SlrnazoloH.S-blpyridin-e-yl, e.g. (3-methyl)-3H-[1 ,2,3)triazolo[4,5-b]pyridin-6- yi.
1 H-pyrrolo{3,2-b]pyridinyl, e.g 1H-pyrrolo[3,2-blpyridin-6-yl;
1-methyl-1H-pyrrolo(3,2-b]pyπdinyl, e g. 1 -methyl- 1H-pyrrolo[3,2-b]pyridin~6-yl;
2-0X0-1 , 4-dihydro~2H-pyrido[2,3-d][1.3)oxazinyl, e g 2-oxo-1 ,4-dihydro-2H-pyπdo[2,3- d][1 ,3]oxazin-6-yl, in particular i-methy^-oxo-i ^-dihydro^H-pyrido^.S-d^tSloxazinyl, especiaHy 1-methyl-2-oxo-1 ,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-6-yl, 3,4-dihydro-2H-pyrido[3,2-b][1 ,4Joxazinyl, e.g 3,4-dihydro-2H-pyrido[3,2- b][1 ,4]oxazin-7-yl, in particular 4-methyl-3,4-dihydro-2H-pyrido[3l2-b][1 4]oxazinyl, especially 4-methyl-3,4-dihydro-2H-pyrido[3,2-b][1 ,4]oxazjn-7-yll
1 ,3>trimethyl-2-oxo-2,3-dihydro-1H-pyrroto[2>b]pyridinyl, in particular 1 ,3.3- trimethyl-2-oxo-2>dihydro-1H-pyrrolo(2,3-b]pyridin-5-yl,
2-oxo- 1 ,4-dihydro-2H-pyrido[3,2-d](1,3]oxaztnyl, e g 2-oxo-1 ,4-dihydro-2H-pyrido{3,2- d][1 ,3)oxazin~7~yl, in particular 1-ethyl-2-oxo-1 ,4-dihydro-2H-pyrido[3,2-dJ[1,3]oxazinyl, especially 1-ethyl-2-oxo-1 ,4-dihydro-2H-pyπdo(3,2-d][1 ,3]oxazin-7-yl
In another embodiment, specifically preferred unsubstituted or substituted heterocyclyl or heteroaryl for R3 is selected from
pyridyl, e.g pyrid-2-yl, pyπd-3-yl or ρyrid-4-yl;
alkylpyridyl, in particular loweralky lpyridy I , e g methylpyridyl, e.g , 2-, 3- or 4-methylpyridyl, especially 2-methylpyπdyl or 3-methylpyπdyl, in particular 2-methylpyπd-5-yl or 3-methylpyrid-5-yl,
alkoxypyridyl, in particular lower-alkoxypyπdyl, e g methoxy pyridyl, e g , 2-, 3- or 4-methoxypyridyl, especially 2~methoxypyridyl or 3-methoxypyrtdyl (in particular 2- methoxypyridin-5-yl, 3-methoxypyridin-5-yl), ethoxypyridyl, e g., 2-, 3- or 4-ethoxypyπdyl especially 2-ethoxypyridyl or 3-ethoxypyridyl (in particular 3-ethoxypyrid-5-yl, 2-ethoxypynd- 5-yl, 2-ethoxypyrid-4-yl), propoxypyridyl, e g. n-propoxypyridyl or iso-propoxypyπdyl (in particular 6-(n-proρoxy)pynd-3-yl or 3-(iso-propoxy)pyridin-5-yl);
cydoalkylalkoxypyπdyl, e.g cyclopropylmethoxy-pyπdyl, especially 2- cyclopropylmethoxy-pyndyl (in particular 2-cyclopropyfmethoxy-pyrid-5-yl)'
alkoxyalkylpyridyl e g ethoxymethylpyridyl, 2-methoxymethylpyridyl (in particular 2- methoxymethylpyπd-5-yl);
alkoxyalkoxypyridyl, in particular methoxyethoxypyndyl, e g 3-(2- methoxyethoxy)pyridyl or 2-(2-methoxyethoxy)pyridyl (in particular 3-(2-methoxyethoxy)pyrid- 5-yl or 2-(2-methoxyethoxy)pyrld-5-yl), benzyloxyalkoxypyridyl, in particular benzyloxyethoxypyridyl or benzyloxypropoxypyridyl, e.g. 2-benzyloxyethoxypyridyl or 3-benzyloxypropoxypyndyl (in particular 2-benzyloxyethoxypyrid-5-yl or 3-beπzyloxypropoxypyrid-5-yl);
hydroxy alky ipyridyl, e g. hydroxy methylpyπdyl, especially 2-(hydroxymethy!)-pyπdyl (in particular 2-hydroxymethylpyπd-5-yl);
alkyl-sυlfonyl pyπdyl, e.g. methanesulfonylpyndyl, especially 3-methanesulfonylpyridyl (in particular 3-methanesulfonylpyrid-5-yl);
hydroxyalkoxypyridyl, e.g 2-(2-hydroxyethoxy)-pyridyl or 2-(3-hydroxypropoxy)- pyrtdyl (in particular 2-(2-hydroxyethoxy)-pyrid-5-yl or 2-(3-hydroxypropoxy)-pynd-5-yl),
afkoxycarbonylpyridyl, e.g methoxycarbonylpyndyl, especially 2-methoxycarbonyl- pyndyl (in particular 2<methoxycarbonyl-pyrid-5-yl),
aminopyridyl, e.g 2- or 3-aminopyridyl (in particular 2-aminopyrtd-5-yl or 3- aminopyrid-5-yl).
alkylaminopyrtdyl, e.g. loweralkylaminopyridyl, in particular methylaminopyridyl such as 2-methylaminopyndyl or ethylaminopyridyl such as 2-ethylaminopyπdyl (especially 2- methylaminopyrid-5-yl or 3~ethylaminopyrid-5-yl);
dialkylaminopyridyl, in particular di-loweralkylaminopyπdyl, e.g 2-, 3- or 4- dimethylaminopyndyl, especially 2-dimethylaminopyridyl (in particular 2-dimethylaminopyrid- 5-yl) or e g 2-, 3- or 4-diethylaminopyridyl, especially 2-diethylaminopyridyl (in particular 3- diethylaminopyrid-5-yl) or e g 2-, 3- or 4-ethylmethylaminopyπdyl especially 2- ethylmethylaminopyπdyl (in particular 2-ethylmethylaminopyrid-5-yl);
(alkyl)(amino)pyridylt e g (loweralkyl)(amino)pyridyl, in particular
(methyl)(amino)pyπdyl such as 2-methyl-3-amino-pyπdyl (especially 2-methyl-3-amino-pyrid- 5-yl),
(alkoxy)(amino)pyridyl, e g (loweralkoxy)(amino)pyridyl, in particular (methoxy)(amino)pyπdyl such as 2-methoxy-3-amino-pyridyl (especialry 2-methoxy-3-amino- pyrid-5-yl),
(a!koxy)(alkyl)pyndyl e g (ethoxy)(methyl)pyridyl, such as 3-ethoxy-2-methy(~pyridyl (in particular 3-ethoxy-2-methyl-pyπd-5-yl) or e g (propoxy)(methyl)pyndyl, such as 3- propoxy-2-methyl-pyπdyl (in particular 3~propoxy-2-methy!-pyrid-5-yl); (alkoxy)(aikoxy)pyridyl e.g (propoxy)(methoxy)pyridyl, such as 3-propoxy-2-methoxy- pyπdyl (in particular 3-propoxy-2-methoxy-pyrid-5-yl); or e.g (propoxy)(ethoxy)pyπdyl, such as 3-propoxy-2-ethoxy-pyndyl (in particular 3-propoxy-2-ethoxy-pyrid-5-yl);
(alkyl)(alkyiamino)pyπdy1, e.g. (loweralkyl)(lowefalkylamino)pyridyl> in particular (methyl)(ethylamino)pyridyl such as 2-methyl-3-ethylamino-pyndyl (especially 2~methyl-3- ethylamino-pynd-5-yl);
(alkyl)(di-alkylamino)pyrklyl, e g. (loweralkyl)(di-loweralkylamino)pyridyl, in particular (methyl)(N-methyl-N-ethylamino)pyrtdyl such as 2-methyl-3-(N-methyl-N-ethylamino)-pyridyl (especially 2-methyl-3-(N-methyl-N-ethylamino)-pyπd-5-yl)
cycloaminopyridyl, e g. azetidinylpyridyl, especially 2-azetidin-1-yl-pyridinyl (in particular 2-azetidin- 1 -yl-pyridin-5-yl),
hydroxyalkylaminopyridyl, e g 2~(2-hydroxyethylamino)-pyπdyl (in particular 2-(2- hydroxyethylamino)-pyrid-5-yl), amino-haloloweralkyl-pyridyl, e.g. amino-tπfluoromethyl- pyridyl, especially 2-amino-3-trtfluoromethyl-pyπdyl (in particular 2-am)no-3-trifluoromethyl- pyrid-5-yl);
haioalkylpyπdinyl, in partfcular haloloweralkylpyπdyl, especially, 2-, 3- or 4-trifluoromethylpyridyl, most especially 2-trifluoromethylpyridyl (in particular 2- tπf I uoromethy Ipyrid- 5-y I ) :
halopyridyl, in particular fluoropyridyl, especialiy 2-fluoropyπdyl (in particular 2- fluoropyrid-3-yl or 2-fluoropyrid-4-yl),
halo-alkoxy-pyridyl, e g, fluoro-methoxy-pyridyl such as 3-fluoro-2-methoxy-pyridyl (in particular 3-fluoro-2-methoxy~pyπd-5-yl);
carbamoylpyridyl especially 2-(carbamoy1)pyridyl (in particular 2-{carbamoyl)pynd-5- yl), alkyl-stibstituted carbamoyl, e.g methylcarbamoyl, especially 2-(methylcarbamoyl)pyridyl (in particular 2-(methylcarbamoyl)pyrid-5-yl);
piperazinylpyridyl, e g 1 -piperazinylpyridyl. especially 2-(1-piperazinyl)pyridyl (in particular 2-(1-piperazinyl)pyrid-5-yl), N-alkylpiperazinylpyndyl, such as N- toweralkylpiperazmylpyridyl, e g N-methylpiperazinytpyridyl, especially 2-{4-methylpφerazin- 1-y|)-pyridyl (in particular 2-(4-methylpiperazin-1-yl)-ρynd-5-yl), alkylsυifonamidopyridyl, such as loweralkyteulfonamidopyridyl, especially methylsulfonamidopyridyl, e.g 3-(methylsulfonamido) pyπdyl (in particular 3- (methylsulfonamido)-pyπdin-5-yl);
dialkylsulfonamidopyridyl, such as diloweralkylsulfonamidopyπdyl, especially dimethylsulfonamidopyridyl, e.g. 3-(dimethylsulfonamido) pyπdyl (in particular 3- (dimelhylsulfonamido)-pyridin-5-yl);
(alkylsulfonamido)(alkyl)pyridyl such as (loweralkylsulfonamido)(loweralkyl)pyπdyl, especially (methylsulfonamido)(methyl)pyridyl, e.g. 3-(methylsulfonamido)(methyl)pyπdyl (in particular 3-(methylsulfonamido)~2-methyl pyridin-5-yl);
dialkylsulfonamido(afkyl)pyridyl. such as diloweralkytsulfonamido(loweralkyl)pyridyl, especially dimethylsulfonamido(methyl)pyπdyl( e.g. 3-(dimethylsulfonamido)(2-methyl) pyridyl (in particular 3-(dimethylsulfonamido)-(2-methyl)-pyridin-5-yl); 3H-tetrazol-5-yl pyridyl, e g. 2- (3H-tetrazol-5-yl)pyridyl (in particular 2-(3H-tetrazol-5-yl)pyrid-5-yl);
(alkoxy)(alkylcarbonylamino)pyridyl, such as (loweralkoxy)(loweralkylcarbonylamino) pyridyl, e.g. (methoxy)(methylcarbαnylamino)pyridyl or (ethoxy)(methylcarbonylamino)pyridyl, especially 2-(methoxy)-3-(methylcarbonylamino)pyridyl or 2-(ethoxy)-3- (methyjcarbonylamino)pyridyl (in particular 2>(methoxy)-3-(methylcarbonylamino)pyrid-5-yl or 2-(ethoxy)-3-(methylcarbonylamino)pynd-5-yl);
(alkoxy)(alkyicarbonyl~N-alkylamino)pyridyl, such as (loweralkoxy)(loweralkylcarbonyl- N-loweralkylamino)pyrtdyl, e.g. (methoxy)(methylcarbonyl-N-methy)amino)pyrtdyl or (ethoxy)(methylcarbonyl-N-methylamino)pyridyll especially 2-(methoxy)-3-(methylcarbonyl-N- methytamino)pyπdy1 or 2-(ethoxy)-3-(methytcarbonyl-N-methylamino)pyridyl (in particular 2- (methoxy)-3-(methylcarbonyl-N-methylamino)pyr!d-5-yl or 2~(ethoxy)-3-(methylcarbonyl-N- methylamino)pyπd-5-yl);
(alkoxy)(nitro)pyridyl, such as (loweralkoxy)(nitro)pyridyl, e.g, (methoxy)(nitro)pyridyl, especially 2-(methoxy)-3-(nitro)-pyridyl (in particular 2-(methoxy)-3-(nitro)-pyrid-5-yl);
(alkoxy)(cyano)pyridyl, such as (loweralkoxy)(cyano)pyrtdyl, e.g,
(methoxy)(cyano)pyridyl, especially 2-(methoxy)-3-(cyano)*pyridyl (in particular 2-(methoxy)- 3-(cyano)-pyrid-5-yl);
(alkoxy)(amino)pyridyl, such as (loweralkoxy)(amino)pyridyl, e.g.
(methoxy)(amino)pyridyl, especiaHy 2-(methoxy)-3-(amino)-pyridyl (in particular 2-(methoxy)- 3-(amino)-pyrid-5-yl), (alkoxy)(alkylamino)pyridyl, such as (loweralkoxy)(alkylamino)pyridyl, e.g. (methoxy){ethylamino)pyridyl, especially 2~(methoxy)-3-(ethylamino)pyridyl (in particular 2- (methoxy)-3-(ethylamino)pyrid-5-yl;
(alkoxy)(alkylaminocarboπyl)pyridyl, such as
(loweralkoxy)(loweralkylaminocarbonyl)pyridyl. e.g (methoxy)(methylaminocarbonyl)pyridyl, especially 2-(methoxy)-3-(methylaminocarbonyl)pyridyl (in particular 2-(methoxy)-3- (methylaminocarbonyl)pyrid-5-yl,
(alkoxy)(hydroxycarbonyl)pyridyl, such as (loweralkoxy)(hydroxycarbonyl)pyridyl, e.g (methoxy)( hydroxycarbonyl)pyridyl, especially 2-(methoxy)-3-(hydrαxycarbonyl)pyridyl (in particular 2-{methoxy)-3-(hydroxycarbonyl)pyrid-5-yl;
pyrimidinyl, in particular pyrimidin-5-yl,
di-loweralkyfaminopyrimidinyl, e g 2- or 4-dimethylaminopyrimidiπyl, especially 2- dimethylammopyrimidinyl (in particular 2-dimethylaminopyrimidin-5-yl),
alkoxypyrimidinyl, in particular methoxypyrimidinyl or ethoxypyrimidinyl, e.g 2- methoxypyπmidinyl or 2-ethoxypyπmidinyl (in particular 2-methoxypyπmidin-5-yl or 2- ethoxypyrimidin-5-yl);
1H-pyrrolo[2,3-b]pyridinyl (in particular 1 H-pyrrolo[2,3-b]pyπdin-5-yl);
1-methyl-1H-pyrrolo[2,3-b]pyridmyl (in particular 1-methyt-1H-pyrrolo{2(3-b]pyπdin-5- yi);
pyrazinyl
pyrazolyl, e.g. pyrazol-4yl,
substituted pyrazolyl, e g. hydroxyalkylpyrazolyl, especially H2-hydroxy-ethyl)-1H- pyrazolyl (in particular 1-(2-hydroxy-ethyl)-1 H-pyrazol-4-y1 ) or 1-[2-(tetrahydro-pyran-2- yloxy)-ethyl]-1 H-pyrazolyl (in particular 1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol~4- yl):
quinolinyl (in particular quinolin-3-yl).
2-0X0-2, 3-dihydro-1H-indol-5-yl,
1-methyl-2,3-dihydro-1H-indol~5-yl, 1H-imidazo[4)5-b)pyridin-2(3H)-one-6-yl (in particular 1,3~dimethyl-1H-imidazo[4,5~ b]pyπdin-2(3H)-one-6~yl, 1-ethyl-3-methyl-1 H-imtdazo[4,5-b]pyridin-2(3H)-one-6-yf or 1-(2- methoxyethyl)-3-methyHH-imidazo[4,5-b]pyrfdin-2(3H)-one-6-yl,
3H-im(dazo[4,5-b]pyridin-6-yl, e.g. (3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl, (2- methyl)-(3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl, (2-methoxy)-(3-methyl)-3H-imidazo[4,5- bJpyridin-6-yl, (2-dfmethylamino)-(3-methyl)-3H-imidazol4,5-b]pyridin-6-yl;
3H-[1 ,2,3)triazolo[4,5-b]pyridin-6-yl, e.g (3-mβthyl)-3H-(1 ,2,3]tnazolo[4,5-b]pyridin-6- yi.
In an embodiment, R3 is selected from
pyridyl, 2-methylpyridyl, 3-methylpyridy), 2-methoxypyridinyl, 3-methoxypyridinyl, 3- ethoxypyrtdyl, 2-ethoxypyndyl, 2-ethoxypyπdyl, 6-(n-propoxy)pyridyl or 3-(iso- propoxy)pyπdinyl or 2-(iso-propoxy)pyridinyl, 3-cyclobυtoxy-pyridyi, 3-(1 ,3-diflυoropropan-2- yloxy)-pyridyl, 3-(2-flυoroethan-1-yloxy)-pyridyl, S-CdifluoromethyloxyJ-pyπdyl, 2- cyclopropyhτ»ethoxy-pyridyt, 2-methoxymethylpyndyl, 3-methoxymethylpyridyl, 3-(2-methoxy- prop-2-yi)pyridyl, 3-(2-ethoxy-prop-2-yl)pyridyl, 3-{2-methoxyethoxy)pyridy), 2-(2- methoxyethoxy)pyridyl, (2-methyl)-(3-(2-methoxyethoxy))pyridyl, 2-benzyloxyethoxypyridyi, 3- benzyloxypropoxypyπdyl, 2-hydroxymethylpyndyl, 3-(1-hydroxyethyl)pyridyl, 3-(3- hydroxypent-3-yf)pyndyl, 3-(2-hydroxyprop-2-yl)pyπdyl, 3-{2-hydroxy-1 ,1 -dimethyl- ethyl)pyridyl, 3'(1-hydroxycyclopentyl)-pyridyl, 3-(1 ,3-dif!υoro-2-hydroxyprop-2-yl)pyπdyl, 3- aminomethylpyridyl, 3-methanesulfonylpyridyl, 2-(2-hydroxyethoxy)-pyπdyl, 2-(3- hydroxypropoxy)-pyridyl, 2-methoxycarbonyl-pyridyl, 2-aminopyridyl or 3-aminopyridyl, 2- methytaminopyridyl, 3-methylaminopyridyl, 3-ethylaminopyπdyl, 3-isopropylaminopyridyl, 2- dimethylammopyridyl or 3-dimethylaminopyridyl, 2-diethylaminopyridyl, 3-dϊethylaminopyridyl, 2-ethylmethylaminopyπdyl, 3-ethylmethylaminopyndyl, 2-tsopropylmethylaminopyridyl, 3- isopropylmethylaminopyrtdyl, 3-methylaminopyridyl, 3-(N-methyl-N-cyclobutylamino)pyrtdyl, 2-methyl-3-amino-pyridyl( 2-ethyl-3-amino-pyridyl, 3-fluoro-2-amino-pyridyl, 2-fluoro-3-amino- pyridyl, 3-chloro-2-amino-pyridyl, 2-chJoro-3-amino-pyridyl, 3-ftuoro-2-methylamino-pyridyl, 2- fluoro-3-methylamino-pyridyl 2~fluoro-3-ethylamino-pyπdyl, 3-chloro-2-methy)amino-pyridyl, 3-chtoro-2-ethylamino-pyridyl, 2-chloro-3-ethylamino-pyridyl, 2-fluoro-3-dimethylamino- pyπdyl, 3-chloro-2-hydroxymethyl-pyridyl, 3-ethoxy-2-methyl-pyndyl, 3-propoxy-2-methyl- pyridyl, 3-propoxy-2-ethyl-pyridyl, 3-ethoxy-2-ethyl-pyridyl, 3-propoxy-2-methoxy-pyridyl, 3- propoxy-2-ethoxy-pyridyl, 3-methoxy-2-methoxy-pyπdyl, 3-ethoxy-2-methoxy-pyridyi, 3- isopropoxy-2-methoxymethyl-pyridyl, 3-methoxy-2-methoxymethyl-pyndyl, 2-methoxy-3- methoxymethyl-pyridyl, 3-methoxy-2-ethoxymethyt-pyridyl, 3-ethoxy-2-methoxymethyl- pyπdyl, 3-ethoxy-2-tπdeuteromethoxymethyl-pyridyl, 3-isopropoxy«2-hydroxymethyl-pyridyl, 3-methoxy-2-hydroxymethyl-pyridyt, 2-methoxy-3-hydroxymethyl-ρyridyl, 3-ethoxy-2- hydroxymethyl-pyπdyl, 3-(1 ,3-difluoropropan-2-yloxy)-2-(methyl)-pyπdyl, 3-(1 ,3- difluoropropan-2-yioxy)-2-(hydroxymethyl)-pyridyl, 3-methoxyethoxy-2-hydroxymethyl-pyridyl, 2-methyl-3-ethylamino-pyndyl , 3-methyl-2-methylamino-pyridy 1 , 2-methy l-3-ethy lamino- pyridyl, 2-ethyf-3-isopropytamino-pyfidyl, 2-methyl-3-(N-methyl-N-ethylamino)-pyridyl, 2- methyl-3-(N,N-dimethylamiπo)-pyrκ.yl, 3-azet)din-1-yl-pyπdinyl, 2- pyrroltdinyl-1-yl-pyridinyl, 2-(tetrahydro-pyran-4-ylamino)pyridy)yl, β-(3-hydroxy-pyrrolidin-1 -yl)-pyridinyl, 6-((R)~3- hydroxy-pyrrolidin-1-yO-pyridinyl, 6-((S)3-hydroxy-pyrrolidin-1-yl)-pyridinyl, 2-(2- hydroxyethylamino)-pyridyt, 2-(methyl)-3-(hydroxy)-pyπdyl, 2-(ethyl)-3-(hydroxy)-pyridyl, 2- (hydroxymethyl)-3-(ethytamino)-pyridyl, 2-(hydroxymethyl)-3-(methylamino)«pyridyl) 3- (hydroxymethyl)-2-(methylamino)-pyridy1, 3-(hydroxymethyl)-2-(amino)-pyridyl, 2- (methoxymethyl)-3-(efthylamino)-pyridyl, 2-(methoxymethyl)-3-(methylamino)-pyπdyl1 3- (ethoxymethyl)-2-(methylamino)-pyridyl, 3'(ethoxymethyl)-2-(amino)-pyridyl, 3- (methoxymethyl)-2-(amtno)-pyricJyl 2-amino-3-trifluoromβthyl-pyridyl, 2-methylamino-3- triflυoromethyl-pyndyl, 2-ethytamino-3-tπflυoromethyl-pyridyl, 3-trifluoromethyl-2- trideuteromethylamino-pyndyl, 2~trif tuoromethy lpy rklyl , 3-(2-cyanoprop-2-yl)-pyridyl, 3-(1- cyanocyclobutyl)-pyridyJ, 2-fluoropyridyl, S-fluoro^-mβthoxy-pyftdyl, 2-(carbamoyl)pyridyl, 2- (methylcarbamoyl)pyridyl, 2-(1-piperazlnyl)pyridyl, 2-(4-methylpipera2in-1-yl)-pyridyl, 3- (methylsulfonamido)-pyndinyl , 3-(dimethylsυlfonamtdo)-pyridiny!, 3-(methy!sulfonamido)-2- methyl pyridinyl. 3-(methylsulfonamido)-2-chloro-pyridinyl, 3-{methylsulfonamidomethyl)- pyπdinyl 3-(dimethylsulfonamido)-(2-methyl)-pyridinyl, 2-(3H-tβtrazo!-5-yl)pyridyl, 3- methylcarbonylaminomethylpyridyl , 2-(chloro)-3-(methylcarbonylammo)pyridyl) 2-(methoxy)- 3-(methylcarbonylamino)pyπdyl, 2-(ethoxy)-3-(methylcarbonylamino)pyrκJyl, 2-(methoxy)-3- (methylcarbonyl-N-methylamino)pyrjdyl, 2-(ethoxy)-3-(methylcarbonyl-N-methylamino)pyridyl, 2-(methoxy)-3-(nitro)-pyπdyt, 2-(methoxy)-3-(cyano)-pyπdyl, 2-(mβthoxy)-3-(amino)-pyridyl, 2- (methoxy)-3-(ethylamino)pyridyl, 3-(methoxymethyl)-2-(methylamino)pyridyl, 3- (methoxymethyl)-2-<ethylamino)pyridyl, 2-(methoxy)-3-(methylaminocarbonyl)pyπdyl, 3- methylaminocarbonylmethylpyridyl, 2-(amino)-3-(methylaminocarbonyl)pyπdyl, 2-(amino)-3- (ethylaminocarbonyl)pyπdyl, 2-(amino)-3-(isopropylaminocarbonyl)pyπdyl, 2-(amino)-3-(2- methoxyethylaminocarbonyOpyndyl, 2-(methylamino)-3-(ethylaminocarbonyl)pyndyl, 2- (methoxy)-3-(aminocarbonyθpyπdyl, 2-(methoxy)-3-{hydroxycarbonyl)pyridyt, 3-morpholin-4- ylpyndinyl, (1H-pyrazol-1yl)-pyridinyl, (2-methyl-1 H-imκJazol-1-yl)-pyπdinyl, pyrimidinyl, 2- dimethylaminopyπmidinyl, 2-methoxypyrimidinyl, 2-ethoxypyπmidinyl, 2,4- dimethoxypynmtdinyl, 2-(methylamino)-4-(methoxy)pyπmidinyl, 2-(ethylamtno)-4- (methoxy)pyrimidinyl, 2-(pyrrolidinyl)pyπmfdinyt, 2-aminopyrimidinyl, 2- methylaminopyrimidiπyl, 2-dimethylaminopyrimidinyl, 1H-pyrrolo{2,3-b)pyridinyl, 1 -methyl- 1 H- pyrrolo^.S-bjpyπdinyl, pyrazinyl, pyrazolyl, 1-(2-hydroxy-ethyl)-1 H-pyrazolyl, H2-(tetrahydro- pyran-2-yfoxy)-ethyl]-1H-pyrazotyl, qumolinyl, 2-oxo-2,3-dthydro~1H-indolyl, 1-methyl-2,3- dihydro-1 H-indolyl, 1 ,3-dimethy!-1 H-imtdazo{4,5-b)pyridin-2(3H)-or>eyl, 1-ethyl-3-methyl-1 H- imidazo[4,5-b]pyridin-2(3H)-oney), 1 -(2-methoxyethyl)-3-methyl-1 H-irnidazo[4,5-b]pyridin- 2(3HH>neyl, (3-methyO-3H-irnidazo[4,5-b]pyπdinyl, (2-methyl)-(3-methyl)-3H-imidazo[4,5- bjpyπdinyl, (2-methoxy)-(3-methyl)-3H-imidazo[4,5-b]pyrKiinyl, (2-dimethyJamino)-(3-methyl)- 3H-imidazo(4,5-b]pyridinyl, (3-methyl)-3H-[1 ,2,3]triazolo[4,5-b]pyridinyl, 1H-pyrroto(3,2- b]pyridinyl, 1-mβthy(-1H-pyrrolo[3,2-b]pyndinyl, 1 ,3,3-tπmethyl-2-oxo-2,3-dihydro-1H- pyrrolo[2,3-b]pyridinyl 4-methyl-3,4-dihydro-2H-pyrido[3,2-b][1 ,4]oxazinyl, 1-methy)-2-oxo- 1 ,4-dihydro-2H-pyπdol2.3-dJ[1.Sloxazinyl, 1-ethyl-2-oxo-1 ,4-dthydro-2H-pyrido(3,2- d][1 ,3)oxazinyl
In another embodiment, R3 is selected from
pyrid-3-yl, 2-methy!pynd-5-yl, 3-methylpyπd-5-yl, 2-methoxypyπdin-5-yl, 3- methoxypyridin-5-yl, 3-ethoxypynd-5-yl 2-ethoxypyπd-5-yl, 2-ethoxypyrid-4-yl, 6-(n- propoxy)pyπd-3-yl or 3-(iso-propoxy)pyridtn-5-yl or 2-(tso-propoxy)pyridin-4-yl, 3-cyclobutoxy- pyπd-5-yl, 3-(1 ,3-difluoroρropan-2-yloxy)-pyrid-5-yl, 3-(2-fluoroethan-1-yloxy)-ρyrid-5-yl, 3- (diflυoromethyloxy)-pyrid-5-yl, 2-cyclopropylmethoxy-pynd-5-y1, 2-methoxymethylpyrid-5-y!, 3-methoxymethylpyrid-5-yl, 3-(2-methoxy-prop-2-yl)pyrid-5-yl, 3-(2-ethoxy-prop-2-yl)pyπd-5- yl, 3-(2-methoxyethoxy)pyπd-5-yl, 2-(2-methoxyethoxy)pyrid-5-yl, (2-methyt)-(3-(2- 0IeIhOXyCIhOXy))PyOd-S-^1 2-benzyloxyethoxypyπd«5-yl, 3-benzyloxypropoxypyrid-5-yl, 2- hydroxymethylpynd-5-yl, 3-(1-hydroxyethyl)pyrid-5-yl, 3-(3-hydroxypent-3-yl)pyrid-5-yl, 3-(2- hydroxyprop-2-yl)pyrid-5-yl, 3-(2-hydroxy-1 ,1-dimethyl-ethyl)pyπd-5-yl, 3-(1- hydroxycyclopentyl)-pyπd-5-yl 3-(1 ,3-difluoro-2-hydroxyprop-2-yl)pyπd-5-yl, 3- aminomethylpynd-5-yl, 3-methanesυlfonylpyrid-5-yt, 2-(2-hydroxyethoxy)-pyrid-5-yl 2-(3- hydroxypropoxy)-pyπd-5-yl, 2-methoxycarbonyl-pyrid-5-yl, 2-aminopyrid-5-y1 or 3-aminopyπd- 5-yl, 2-methylaminopyτtd-5-yl, 3-methy)aminopyπd-5-yl, 3-ethylaminopyπd-5-yl, 3- isopropylaminopyrid-5-yl, 2-dimethylaminopyπd-5-yl or 3-dimethylaminopyπd-5-yl, 2- diethylaminopyπd-5-yt 3-diethylammopyπd-5-yt 2-ethylmethylaminopyπd-5-yl, 3- ethylmethylaminopynd-5-yl, 2-»sopropylmethylaminopyrid-5-yl, 3-isopropylmethylaminopyrid- 5-yl, S-methylaminopyπd-δ-yl, 3-(N-methyl-N-cyclobutylamino)pyrid-5-yl, 2-methyl-3-amino- pyrtd-5-yl, 2-ethy!-3-amino-pynd-5-yl, 3-fluoro~2~amino-pyrid-5-yl, 2-flυoro-3-amtno-pyrid-5-yl, 3-chloro-2-amino-pynd-5-yl, 2-chloro-3-amino-pyπd-5-yl, 3-fluoro-2-methylamino-pyrid-5-yl, 2-f)uoro-3-methylamino-pyπd-5-y) 2-fluoro-3-ethylamino-pyπd-5-y! 3-chloro-2-methy)amino- pyrtd-5-yl, 3-chtoro-2-ethylamino-pynd-5-yl, 2-chloro-3-ethylamino-pyrκi-5-yl 2-fluoro-3- dimethylamino-pyrid-5-yl, 3-chtoro-2-hydroxymethyt-pyπd-5-yl, 3-ethoxy-2-methyl-pyπd-5-yl, 3-propoxy-2-methyl-pyπd-5-yl, 3-propoxy-2-ethyl-pyrid-5-yl, 3-ethoxy-2-ethyl-pyrid-5-yl, 3- propoxy^-methoxy-pyncf-δ-yl, 3-propoxy-2~ethoxy-pyπd-5-y!, 3-methoxy-2-methoxy-pyrid-5- yi, 3-ethoxy-2-methoxy-pyrid-5-yl, 3-isopropoxy-2-methoxymethyl"pynd-5-yl, 3-methoxy-2- methoxymethyl-pyπd-5-yl, 2-methoxy-3-methoxymethyl-pyrid-5-yl, 3-methoxy-2- ethoxymethyl-pyrid-5-yl, 3-ethoxy-2-methoxyfnethyl-pynd-5-yl, 3-ethoxy-2- tπdeυteromethoxymethyl-pyrid-5-yl, 3-isopropoxy-2-hydroxymethyl-pyπd-5-yl, 3-methoxy-2- hydroxymethyl-pyπd-5-yl , 2-methoxy-3-hydroxymethyl-pyrid-5-yl, 3-ethoxy-2-hydroxymethyl- pyrtd-5-yl, 3-(1 ,3-difluoropropan-2-yloxy)-2-(methyl)-pyπd-5-yl, 3-(1 ,3-difluoropropan-2~yloxy)~ 2-(hydroxymethyl)-pyrid-5-yl, 3-methoxyethoxy-2-hydroxymethyl-pyrid-5-yl, 2-methyl-3- ethylamino-pyπd-5-yl, 3-methyl-2-methylamino-pyrtd-5-yl, 2-methyl-3-ethylamino-pyπd-5-yl, 2-ethyt-3-isopropylamino-pyr»d-5-yl, 2-methyl-3-(N-methyl-N-ethylamino)-pyπd-5-yl, 2-methyl- 3-(N,N-dimethylamino)-pyrid-5-yl, 3-azetidin-1-yl-pyπdin'5-y), 2- pyrrolidinyH-y(-pyπdin-5-yl, 2-(tetrahydro-pyran-4-ylamino)pyndyl-5-yl, 6-(3-hydroxy-pyrrolidin-1-yl)-pyπdin-3-yl, 6-((R)-3- hydroxy-pyrrolidin-1-yi)-pyridin-3-yl, 6-((S)3-hydroxy-pyrrolidin-1-yl)-pyπdin-3-yl, 2-(2- hydroxyethylamino)-pyπd-5-yl, 2-(methyl)-3-(hydroxy)-pynd-5-yl, 2-(ethyl)-3-(hydroxy)-pyrid- 5-yl, 2-(hydroxymethyl)-3-(ethylamino)-pyπd-5-yl, 2-(hydroxymethyl)~3-(methylamtno)-pyπd-5- yl, 3-(hydroxytnethyl)-2-(methylamino)-pyrid-5-yl, 3-{hydroxymβthyl)-2-(amino)-pyrid-5-yl, 2- (m€thoxymethyl)-3-(ethy!amino)-pyrid-5-yl, 2~(methoxymethyl)-3-(methylamino)-pyrid-5-y1, 3- (ethoxymethyl)-2-(methylafnino)-pyπd-5-yl, 3-(ethoxymethyl)-2-{amino)-pyrid-5-yl, 3- (methoxymethyl)-2-(amino)-pyπd-5-yl> 2-amino-3-triflυoromettiyl-pyπd-5-yl, 2-methylamino-3- tnflυoromethyl-pyπd-5-yl, 2-ethylamtno-3-tπflLKJromθthyl-pyπd-5-yl, 3-trifluoromethyl-2- trideuteromethylamino-pyrid-5-y), 2-tπfluoromethylpyπd-5-yl, 3-(2-cyanoprop-2-yi)-pyrid-5-yJ, 3-{1-cyanocyclobutyl)-pyπd-5-yl, 2-fluoropynd-3-yl, 2-fluoropyπd-4-yl, 3-flυoro-2-methoxy- pyrid-5-yl, 2-(carbamoyl)pyrid-5-yj, 2-(methylcarbamoyl)pyπd-5-yl 2-{1-piperazinyl)pyrid-5-yi, 2-(4-methylpiperazin-1-yl)-pyπd-5-yl, 3-(methylsulfonamido)-pyπdm-5-yl, 3» (dimethylsυlfonamido)-pyπdin-5-yl, 3-{methylsulfonamido)-2-methyl pyridin-5-yl 3- (methylsulfonamido)-2-chloro-pyridin-5-yl 3-(methylsulfonamidomethyl)-pyridin-5-yl, 3- (drmethylsulfonamido)-(2'methyl)-pyridin-5-y), 2-(3H-tetra2ol-5-yl)pynd-5-yl, 3- methylcarbonyiaminomethylpyrid-5-yl, 2-(chloro)-3-(methylcarbony)amino)pyπd-5-yl 2- (methoxy)-3-(methylcarbonylamino)pyrid-5-yl, 2-(ethoxy)-3-(methylcarbonylamino)pynd-5-yl, 2-(methoxy)-3-(methylcarbonyl-N-methylamino)pyπd-5-yl, 2-(ethoxy)-3-(methytearbonyl-N- methylamino)pyπd-5-yl, 2-(methoxy)-3-(nrtro)-pyπd-5-yl, 2-(methoxy)-3-(cyano)-pynd-5-yl, 2- (methoxy)-3-(amino)-pyπd-5-yl, 2-(methoxy)-3-(ethylamino)pyrid-5-yl, 3-(methoxymethyl)-2- (methylamino)pyπd-5-yl, 3-(methoxymethyl)-2-(ethylamino)pyrid-5-yl, 2-(methoxy)-3- (methylaminocarbonyl)pyfid-5-yl, S-methylaminocarbonylmethylpyπd-δ-yl, 2-(amino)-3- (methylamtnocarbonyl)pynd-5-yl, 2-(amino)-3-(ethylaminocarbony!)pyπd-5-yl 2-(amino)~3- (isopropylaminocarboπyl)pyrid-5-yl, 2-(amino)-3-(2-methoxyethylam(nocarbonyl)pyπd-5-yl, 2- (methylamino)-3-(ethylaminocarbonyl)pyπd-5-yl 2-(methoxy)-3-(amirvocarbonyl)pyrid-5-yl, 2- (methoxy)-3-(hydroxycarbonyl)pyπd-5-yl, 3-morpholin-4-ylpyrκJin-5-yl, (1H-pyrazol-1yl)- pyπdin~5-y1, (2-methyl-1H-imidazoM-yl)-pyridin-5-yl, pyrimidin-5-yl, 2- dimethylaminopyrimidin-5-yl, 2~methoxypynmidin-5-yl, 2-ethoxypyrimidin-5-yl, 2,4- dimethoxypyrimidin-5-yl, 2-(methylamino)-4-(methoxy)pyrimidin-5-yI, 2-(ethylamino)-4- (methoxy)pyrimidin-5-yl, 2-(pyrroltdinyl)pyrimtdin-5-yl, 2-aminopyrimidin-5-yl, 2- methylaminopyrimidin-5-yl, 2-dimethylaminopyrimidm-5-yll 1H-pyrrolo|:2,3-b]pyndin-5~yl, 1 - methyl-1H-pyrrolot2,3~b]pyπdin-5-yl, pyrazinyl, pyrazol-4yl, 1-(2-hydroxy-ethyl)-1H-pyrazol-4- yl, 1-{2-(tetrahydro-pyran-2-yloxy)-ethyl)-1H-pyrazoi-4-yl, quinolin-3-yl, 2-oxo-2,3-dihydro-1H- indol-5-yl, 1-methyl-2,3-dihydro-1H-indol-5-yl, 1 ,3-dimethyl-1 H-imidazo[4,5-bJpyπdin-2(3H)- one-6-yt, 1-ethyl-3-methyt-1H-im\dazof4,5-b]pyridin-2(3H)~one-6-yl> 1-(2-methoxyethyl)-3- methyl-1 H-imidazo[4,5-b]pyridin-2(3H)-one-6-yl, (3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl, (2- methyl)-(3-mβthyl)-3H-im(dazot4,5-b]pyridin-6-yl, (2-methoxy)-(3-methyl)-3H-imidazo(4,5- b]pyridin-6-yl, (2-dimethylamino)-(3-methyl)-3H-imidazo{4,5-b]pyridm-6-y1, (3-methyl)-3H- [1 (2,3]tπazofo(4,5-blpyπdin-6-yl, 1 H-pyrrolo[3,2-b]pyridm'6-yi, 1 -methyl- 1 H-pyrrolo{3,2- b)pyήdin-6-yl, 1 ^.S-trimethyl-a-oxo^.S-dihydro-1H-pyrrolo^.S-blpyπdin-δ-yl, 4-methyl-3,4- dihydro-2H-pyrido[3,2-b][1 ,4]oxazin-7-yl, 1 -mβthyl-2-oxo-1 ,4-dihydro-2H-pyπdo[2,3- d)[1 ,3}oxazin-6-yl, 1-ethyl-2-oxo-1 t4-dihydro-2H-pyrido|;3,2-d)[1 ,3)oxazin-7-yl
With the groups of preferred compounds of formula (!) mentioned herein, definitions of substituents from the general definitions mentioned hereinbefore may reasonably be used, e.g., to replace more general definitions with more specific definitions or especially with definitions characterized as being preferred.
A preferred group of compounds of the present invention of formula (i) are those wherein X is O
Another preferred group of compounds of the present invention of formula (I) are those wherein Y is CH
Another preferred group of compounds of the present invention of formula (I) are those wherein X is O or S and Y is CH.
Another preferred group of compounds of the present invention of formula (I) are those wherein X is O and Y is CH.
An alternative group of compounds of the present invention of formula (I) are those wherein Y is N
An alternative group of compounds of the present invention of formula (I) are those wherein X is O or S and Y ts N An preferred group of compounds of the present invention of formula (I) are those wherein X is O and Y is N
An embodiment of the present invention includes compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein'
X is O or S, Y is CH or N,
R1 is unsubstituted pyrazolyl or pyrazolyl substituted with one, two or three substrtuents at least one of which is in the alpha-position, said substituents being independently selected from lower alkyl, halo, halo lower alkyl, hydroxy lower alkyl, alkoxy lower alky!, carbamoyl lower alkyl, hydroxycarbonyl lower alkyl, dialkylaminocarbonyl lower alkyl, cycloaminocarbonyl lower alkyl, morphoJinecarbonylalkyl, piperazinecarbonyl lower alkyl or alkyl-substituted piperazinecarbony! lower alkyl; or
R1 is unsubstituted isoxazolyl or isoxazolyl substituted with one or two lower alkyl substituents,
R2 is hydrogen, lower alkyl or lower aJkenyl;
R* is unsubstituted phenyl, or phenyl substituted with one or two groups independently selected from the group consisting of halo, halo-lower alkyl; hydroxy!, amino, mono or disubstituted ammo, cyclic amino, amino-lower alkyl, lower alkoxy, hydroxy-lower alkyl, hydroxy lower alkoxy, lower alkyl, cyano; cyano-lower alkyl, amidino, N- hydroxyamidino, amtdino-lower alkyl, or N-hydroxyamidino-lower alkyl, sulfonyl, alkyl-substituted sulfonyl, sulfonamide; pyrrolidinesulfonyl, lower alkyl sulfonyl amino, lower alkyl sulfonylalkandiylamino, lower alkylsulfonyl-N-lower alkylamino, [1 ,3]dioxolo, halo-substituted [1,3)dioxolo, alkoxy carbonyl carbamoyl, substituted carbamoyl, heterocycle; heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl, or
R3 is indolyl, 1-methyl-2,3-dihydro~1H-indolyl 2oxo-2,3-dihydro-1H-mdolyl, pyπdyl, pyrimidinyl, 1H-pyrrolo{2,3-b]pyridinyl, 1-methyl-1 H-pyrrolo[2,3-bJpyridinyl, pyrazolyl, pyrazinyl, quinolyl, 1 3-Dimethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyndinyl, 1- ethyf-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo(4,5-b]pyridinyl, 1-(2«methoxy-ethyl)~3- methyl-2-oxo-2,3-dihydro-1H-imidazo{4,5-b|pyπdinyl 2-Dimethylamino-3-methyl-3H- imidazo[4,5-b]pyridinyl, 2-methoxy-3-methyl-3H-imidazo[4,5-bJpyridinyl, 3-methyl- 3H-[1 ,2,3]triazolo[4,5-b]pyridinyl, 2,3-Dimethyl-3H-imidazo[4 5-bJpyπdinyl, 3-methyl- 3H-imκJazo(4,5-b)pyridinyl, 1 H-pyrrolo[3,2-b]pyπdinyl, 1 -methyl-1 H-pyrrolo[3,2- b]pyπdinyl 1 -methyl-2-oxo-1 ,4-dihydro-2H-pyπdo(2,3-d]|1 ,3]oxaziny), 4-methyl-3,4- dihydro-2H-pyrido(3,2-b}[1,4]oxazinyl, 1 ,3,3-trimethyl-2-oxo-2,3-dihydro-1H- pyrrolo(2,3-b]pyπdinyl and 1-ethyl-2-oxo-1 ,4-dihydro-2H-pyrido(3,2-dH1,3]oxazinyl each of these heterocycle radicals being unsubstituted or substituted by one to two radicals selected from the group consisting of halo; halo-lower alky}; hydroxyl; amino, mono or disυbstituted amino; cyclic amino; substituted cyclic amino; amino- lower alkyl; alkylamino-lower alky!, diafkylamino-loweralkyl; cycloalkylaminoalkyl; dicycloalkylaminoalkyl; alkylcycloalkylaminoalkyl; lower alkoxy; cycloalkoxy, lower- alkoxyalkyl; hydroxy-lower alkyl; hydroxy lower cycloalkyl, hydroxy lower alkoxy; alkoxy lower alkoxy; lower afkyt; cyano; cyano-tower aikyl, cyano lower cyctoalkyl; amidino, N-hydroxyamidino, amidino-lower alkyl; N-hydroxyamidinθ'lower alkyl; nitro; carboxylic acid; substituted sulfonyl; sulfonamide; alkylsulfonylamino; alkylsulfonylalkylamino, acylamino; acyl alkyl amino; alkyJcarbonylaminoalkyl, alkytaminocarbonylalkyl, alkylcarbonyl-N-alkylamino, [1 ,3]dioxok>, substituted [1 ,3)dioxolo; alkoxy carbonyl; carbamoyl; substituted carbamoyl; 1 H-tetrazolyl, pyrazol; imidazole, triazole, azetidinyl; pyrrolidinyl; piperazinyl; methylpiperazinyl; ethylpiperazinyl; triazolonyl; methylimidazolyl or morpholino
A further embodiment of the present invention includes compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein-
X is O or S; Y is CH or N,
R1 is unsubstituted pyrazolyl or pyrazolyl substituted with one, two or three substituents, at least one of which is in the alpha-position, said substituents being independently selected from lower alkyl; halo, halo lower alkyl, hydroxy lower alkyl, alkoxy lower alkyl, carbamoyl lower alkyl, hydroxycarbonyl lower alkyl, dialkylaminocarbonyl lower alkyl, cycloaminocarbonyl lower alkyl, morpholinecarbonylalkyl, piperazinecarbonyl lower alkyl or alkyl-substituted piperazinecarbonyl lower alkyl; or
R1 is unsubstituted isoxazofyl or isoxazolyl substituted with one or two unsubstituted lower alkyl substituents, R2 is hydrogen, lower alkyi or lower alkenyl,
R3 is selected from phenyl, hydroxyphenyl, methoxy phenyl. 3,4-dimethoxypheny), ethoxyphenyl, 3 4-diethoxyphenyl; iso-propoxyphenyl; methoxy ethoxy-phenyl; 3-methoxy-4- (2-methoxy ethoxy)-phenyl, fluoro-(iso-propoxy)-phenyl, 3-methoxy-4~hydroxy phenyl, fluoro- hydroxy-phenyl; hydroxy-fluoroalkyl-phenyl, 2,2-difluoro-benzo(1 3]dioxolo benzene sulfonamide; N.N-dimethylbenzenesulfonamide, 3-(pyrrolidine-1-sulfonyl)-phenyl; N-{phen-3- yl)-methanesulfonamide; N-methyl-N-phen-3-yl-methanesυlfonamide; 3- methanesulfonylphenyl, 3- or 4-benzamide; 3- or 4-N-methyl-benzamide, 3- or 4-N1N- dimethyt-benzamide, pyrazol-phenyl, imidazol-phenyl, pyπdyl, alkylpyridyl; alkoxypyridyl; cycloalkoxypyridyl: (haloalkoxy)pyridyl, cycloalkylalkoxypyπdyl; alkoxyalkylpyndyl, alkoxyalkoxypyridyl, (alkyl)(alkoxyalkoxy)pyridyl, benzyloxyalkoxypyridyl; hydroxyalkylpyπdyl; hydroxycycloalkylpyridyl, hydroxyfluoroalkylpyridyl; aminoalkylpyndyl, alkyl-sulfonyl pyπdyl, hydroxyalkoxypyridyl, alkoxycarbonylpyridyl: aminopyridyl, alkylaminopyridyl; dialkytaminopyrtdyl; cycloalkylaminopyridyl; (N-alkyl-N-cycloalkylamino)pyridyl; (alkyl)(amino)pyndyl; (halo)(amino)pyrtdyl; (halo)(alkylamiπo)pyπdyl; {halo)(dialkylamino)pyridyl, (halo)(hydroxyalkyl)pyridyl; (alkoxy)(alkyl)pyridyl, (alkoxy)(alkoxy)pyridyl; (alkoxy)(alkoxyalkyl)pyridyl; (alkoxy)(deuteroalkoxy-alkyl)pyridyl, (alkoxy)(hydroxyalkyl)pyridyl, (haloalkoxy)(alkyl)pyπdyt; (haloalkoxy)(hydroxyalkyl)pyridyl; (alkoxyalkoxy)(hydroxyalkyl)pyridyl; (alkylKalkylamino)pyridyl; (alkyt)(di-alkylamino)pyridyl; cycloaminopyridyl; cyclic ether-substituted amino-pyridyl, hydroxy-cydoaminopyπdyl; loweralkoxy-cycloaminopyridyl; hydroxyalkylaminopyπdyl; (alkyl)(hydroxy)pyridyj, (hydroxyalkyl)(alkylamino)pyridyl, (hydroxyalkyl)(amino)pyπdyl; (alkoxyalkyl)(alkylamino)pyridyl; (aikoxyalkyl)(amirκ>)pyπdyl; amino-haloloweralkyl-pyridyl, alkylamino-haloalkyl-pyridyl, haloalkyl-deu(eroloweralkylamino-pyridy), haloalkylpyridinyl; cyanoalkylpyridinyl; cyanocycloalkylpyridinyl; halopyridyl; halo-alkoxy-pyrtdyl, carbamoylpyridyl, alkyl-substituted carbamoylpyπdyl' piperazinylpyridyl' N- alkylpiperazmylpyridyl; alkylsulfonamidopyridyl' dialkylsulfonamidopyπdyl, (alkylsυlfonamidoKalkyl)pyridyl; (alkylsulfonamido)(halo)pyndyl, (alkylsυlfonamidoalkyl)pyridyl, dialkylsu)fonamido(alkyl)pyridyl, 3H-tetrazol-5-yl pyπdyl, alkylcarbonylaminoalkylpyridyl, (halo)(alkylcarbonylamino)pyrtdyl1 (alkoxy)(alkylcarbonylamino)pyridyl; (alkoxy)(alkylcarbonyl-N-a)kylamino)pyridyl, (alkoxy)(nitro)pyπdyl, (alkoxy)(cyano)pyridyl; (alkoxy)(amino)pyridyl; (alkoxy)(alkylamino)pyridyl, (alkoxyalkyl)(alkylamino)pyridyl; (alkoxy)(alkylaminocarbonyl)pyπdyl; (alkoxyalkyl)(alkyiamino)pyridyl; (amino)(alkylaminocarbonyl)pyridyl; (amtno)(aikoxyalkylaminocarbonyl)pyπdyt, (alkylamino)(alkylaminocarbonyl)pyridyl; (alkoxy)(aminocarbonyl)pyridyl, (alkoxy)(hydroxycarbonyl)pyridyl, morpholinylpyridmyl; (1 H-pyrazolyl)-pyridinyl, loweralkylsubstituted(1 H-imidazol-1-yl)-pyπdinyl; pyπmidinyl; di-loweralkylaminopyrimidinyi, alkoxypyrimidtnyl; d(-alkoxypyπmidinyl, (alkylamino)(alkoxy)pyrimid!nyl, cycloaminopyπmtdtnyl, aminopyπmidmyl, alkylamtnopynmidtnyi, dialkylaminopyπmidinyl, 1 H- pyrrolo{2,3-b]pyridinyl, 1 -methyl- 1 H-pyrrolo[2,3-b]pyridinyl, pyrazinyl, pyrazoJyl; hydroxyalkylpyrazolyl, 1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazolyl, quinolinyl, 2-oxo- 2,3-dihydro-1 H-indol-5-yt, 1-methyl-2,3-dihydro-1H-indol-5-yl, 1H-imidazo[4,5-b]pyridin- 2(3H)-one-6-yl; 3H-imtdazo[4,5-b}pyridin-6-yl; (3-methy[)-3H-imidazo{4,5-b]pyridin-6-yl; (2- methyl)-(3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl, (2-methoxy)-(3-methyl)-3H-imidazo[4,5- b]pyridin-6-yl, (2-dimethylamino)-(3-methyl)-3H-imidazo(4,5-b]pyrκiin-6-yl: 3H- [1 t2,3)tπazolol4,5-b]pyiidin-6-yi, (3-methyl)-3H-(1 ,2,3)triazoto[4,5-b]pyridin-6-yl, H-pyrrolo[3,2- b]pyπdin-6-yl, 1-methyl-1H~pyrrolo[3,2-b]pyridin-6-yl; 2-oxo-1 ,4-dihydro-2H-pyπdo{2,3- d][1,3)oxazin-6-yl; 1-methyl-2-oxo-1 ,4-dihydro-2H-pyrido[2,3-d]{1 ,3]oxazin-6-yl' 3,4-dihydro- 2H-pyrido[3,2-b](1 ,4)oxazin-7-yl; 4-methy(~3,4-dihydro-2H-pyrido(3.2-b][1 ,4]oxazin-7-yl; 1 ,3,3- trimethyl-2-oxo-2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl, 2-oxo-1 ,4-dihydro-2H-pyrido[3,2- d)[1 ,3]oxazin-7-yl, 1 -ethyl-2-oxo-1 ,4-dihydro-2H-pyrido(3,2-d][1 ,3]oxazin-7-yl.
An embodiment of the present invention includes compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
X is O or S; Y is CH or N;
R1 is υnsubstituted pyrazolyl or pyrazolyl substituted with one, two or three substituents, at least one of which is in the alpha-position , said substituents being independently selected from lower alkyl; halo; halo lower alkyl, hydroxy lower alkyl, alkoxy lower alky!, carbamoyl lower alkyl, hydroxycarbonyl lower alkyl, dialkylaminocarbonyl lower alkyt, cycloaminocarbonyt lower alkyl, morpholinecarbonylalkyl or piperazinecarbonyl lower alkyl,
R2 is hydrogen or lower alkyl,
R3 is unsυbstituted phenyl, or phenyl substituted with one or two groups independently selected from the group consisting of halo, halo-lower alkyl, hydroxyl; amino, mono or disubstituted amino, cyclic amino; ammo-lower alkyl, lower alkoxy; hydroxy-lower alkyl; hydroxy lower alkoxy, lower alkyl, cyano, cyano-lower alkyl; amidino, N- hydroxyamidino; amkJmo-lower aikyl; or N-hydroxyamidino-Jower alkyl, sulfonyl, alkyl-substituted sulfonyl; sulfonamide; pyrrolidinesulfonyl, [1 ,3]dioxolo, halo- substituted [1 ,3]dioxolo, alkoxy carbonyl; carbamoyl; substituted carbamoyl, heterocycle, heterocyclyl lower alkyl; heteroaryl or heteroaryl lower alkyl; or
R3 is indolyl, 2,3-dihydro-1H-indol-5-yl, 1-methy!-2,3-dihydro-1 H-indol-5-yl 2-oxo-2,3- dihydro-1 H-indol-5-yl, pyπdyl, pyrimidinyl, 1H-pyrrolo[2,3-b]pyndin-5-yl, 1-methyl-1H- pyrrolo[2,3-b]pyridin-5-yl, pyrazolyl, pyrazol-4-yl, pyrazinyl, quinolyl quinoi-3-yl, 1 H- imidazo[4,5-b)pyπdin-2(3H)-one-6-yl, 3H-imidazo(4,5-b]pyridin-6-y!, 3H- [1 ,2,3]tnazolo[4,5-b]pyridin-6-yl each independently being unsubstituted or substituted by one or two radicals independently selected from the group consisting of halo, halo-lower alkyl; hydroxy!, amino; mono or disubstituted amino; cyclic amino; amino-lower alkyf: tower alkoxy; lower alkoxy lower alkyl; hydroxy-lowβr alkyl; hydroxy lower alkoxy; lower alkyl, cyaπo; cyano-lower alkyl; amidino; N- hydroxyamidino; amidino-lowef alkyl; or N-hydroxyamidino-lower alkyl; sulfonyl, alkyl-sυbstituted sutfonyl; sulfonamide; pyrrolidine-1 -sulfonyl; I1 ,3]dioxolo; halo substituted [1 ,3]dioxolo; alkoxy carbonyl; carbamoyl; aminocarbonylalkyl, N-mono- substituted aminocarbonylalkyl, N-di-substituted aminocarbonylalkyl; 3H-tetrazolyl, pyrazol. heterocyclyl lower alkyl, heteroaryl or heteroaryl lower alkyl,
A further embodiment of the present invention includes compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein' X is O or S;
Y is CH or N;
R1 is unsubstituted pyrazolyl or pyrazolyl substituted with one, two or three substituents, at least one of which is in the alpha-position, said substituents being independently selected from lower alkyl, halo; halo lower alkyl, hydroxy lower alkyl, alkoxy lower alkyl, carbamoyl lower alkyl, hydroxycarbonyl lower alkyl, dialkylaminocarbonyl lower alkyl, cycloaminocarbonyl lower alkyl, morpholinecarbonylalkyl or piperazinecarbonyl lower alkyl;
R2 is hydrogen or lower alkyl;
R3 is selected from phenyl; hydroxyphenyi, methoxyphenyl; 3,4-dimethoxyphenyl; ethoxyphenyl, 3,4-diethoxyphenyl, methoxy ethoxy-phenyl, 3-methoxy-4-(2-methoxy ethoxy)~phenyl; 3-methoxy-4-hydroxy phenyl, ftuoro-hydroxy-phenyl, hydroxy- fluoroalkyl-phenyl; 2,2-difluoro-benzo[1 ,3]dioxolo; benzene sulfonamide; 3- (pyrrolidine-1-sulfonyl)-phenyl; N«(phen-3-yl)-methanesuffonamide; N-methyl-N- phen-3-yl-methanesυlfonamide; 3-methanesulfonylphenyi; 3- or 4-benzamide; 3- or 4-NI-methyl-benzamide; 3- or 4-N,N-dimethyI-benzamide; pyrazol-phenyl; imidazol- phenyl, pyridyl; alkylpyridyl; alkoxypyπdyl, cycloalkylalkoxypyridyl, alkoxyalkylpyrtdyl; alkoxyalkoxypyπdyl, benzyloxyalkoxypyridyl, hydroxyalkylpyridyl; alkyl-sulfonyl pyridyl, hydroxyalkoxypyrkJyl; alkoxycarbonylpyπdyl; aminopyridyl; alkylaminopyridyl, dialkylaminopyridyl; (alkyl)(amino)pyridyl, (alkoxy){alkyl)pyrtdyl, (alkoxy)(alkoxy)pyridyl; (alkyl)(alkylamino)pyridyl, (alkyl)(di-alkylamino)pyπdyl, cycloaminopyridyl, hydroxyalkylaminopyπdyl; ammo-hatoloweralkyl-pyridyl, haloalkylpyridinyl, halopyπdyl; halo-alkoxy-pyndyl; carbamoyJpyridyl alkyl- substituted carbamoylpyridyl, piperazinylpyridyl; N-alkylpiperazinylpyndyl, alkylsυlfonamidopyπdyl, dialkylsulfonamidopyridyl; (alkylsulfonamido){alkyl)pyridyl, dialkylsulfonamido(alkyl)pyridyl; 3H-tetrazol-5-yl pyridyl; (alkoxy)(alkylcarbonylamino)pyridyl; {alkoxy)(alkylcarbonyl-N-alkylamino)pyπdyl, (alkoxy)(nitro)pyridyl; {alkoxy)(cyano)pyπdyl, (a!koxy)(amino)pyridyl, (alkoxy)(alkylamino)pyπdyl; (alkoxy)(alkylaminocarbonyt)pyridyl, (alkoxy)(hydroxycarbonyl)pyridyl, pyπmidinyl, di-loweralkylaminopyπmidinyl; alkoxypyπmidinyl, 1 H-pyrrolof2,3-b)pyridinyl; 1 -methyM H-pyrrolo[2,3-b]pyridinyl, pyrazinyl, pyrazolyl; hydroxyalkylpyrazolyl; 1-(2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H- pyrazolyl, qυinolinyl; 2-oxo-2,3~dihydro-1H-indol-5-yl, 1-methyl~2,3-dihydro-1H-indol- 5-yl; 1H-im»da2θ[4,5-bJpyridin-2(3H)-one-6-yl, 3H-tmidazo[445-b)pyridin-6-yl, (3- methyl)-3H-imidazo[4,5-b]pyridin~6-yl, (2-methyl)-(3-methyl)-3H-imidazo[4,5- b)pyridin-6-yl, (2-methoxy)«(3-methyl)-3H-imidazo[4,5-bJpyridin-6-yl, (2- dimethylam!no)-(3-methyl)-3H-imidazo[4,5-b]pyridin-6-yl; 3H-[1,2,3)triazolo[4,5- b)pyridin-6~yl; (3-methyl)-3H-[1 ,2,3)tπazolo[4,5-b]ρyπdin-6-y1
Most preferred is a compound of the formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, as exemplified hereinbelow under "Examples".
The present invention is further directed to a method of treating a protein kinase dependent disease comprising administering a compound of formula (I), where the disease to be treated is a proliferative disease, preferably a benign or especially malignant tumor, more preferably carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina or thyroid, sarcoma, glioblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma or a tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, lymphomas, a mammary carcinoma or a leukemia, and including proliferative diseases such as tumor diseases, leukaemias and myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia, basal cell carcinoma, squamous cell carcinoma and actinic keratosis and other benign hyperproliferative skin disorders caused by inflammation such as psoriasis or as a result of dysregulation of fibroblasts such as skin fibrosis, scleroderma or keloids.
Other diseases include Cowden syndrome, Lhermitte-Dudos disease and Bannayan-Zonana syndrome or diseases in which the PI3K/PKB pathway is aberrantly activated
Most preferred is the use in accordance with the present invention of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, as exemplified hereinbelow under "Examples" The compounds of formula (I) that inhibit the protein or lipid kinase activities mentioned, especially mTOR Ser/Thr kinase activity and/or class I PI3 kinases activrty , may therefore be useful in the treatment of protein or lipid kinase dependant diseases, especially diseases depending on class I and/or class IV PI3 kinases, for example, PISKalpha, POKbeta, POKdelta, PI3Kgamma andfor mTOR, or one or more of the individual kinase members thereof, including other PI3-kinases such as DNA-PK ATM, ATR, hSMG-1 and Vps34 or any combination of two or more of the mentioned kinases
Protein or lipid kinase dependent diseases are especially proliferative diseases, a benign or especially malignant tumor, a carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach (especially gastric tumors), ovaries, colon, rectum, prostate, pancreas, lung, vagina, thyroid, sarcoma, glioblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma, or a tumor of the neck and head, other diseases such as Cowden syndrome, Lhermitte-Dudos disease and Bannayan-Zonana syndrome, or diseases in which the P13K/PKB pathway is aberrantly activated, an epidermal hyperproliferation, especially psoriasis, prostate hyperplasia, a neoplasia, especially of epithelial character, preferably mammary carcinoma or squamous cell carcinoma or a leukemia. The compounds desirably are able to bring about the regression of tumors and to prevent the formation of tumor metastases and the growth of (also micro) metastases In addition, they may be used in epidermal hyperproliferation , e g , psoriasis, in prostate hyperplasia; in the treatment of neoplasias, especially of epithelial character, e g., mammary carcinoma, in leukemias: and in basal cell carcinoma, squamous cell carcinoma and actinic keratosis It may also be possible to use the compounds of formula (I) in the treatment of diseases of the immune system insofar as several or, especially, individual lipid kinases and/or (further) serine/threonine protein kinases are involved.
The compounds of the formula (I) can be prepared according to the following methods
A compound of formula (I) is converted into a compound of formula (I) by known in the art chemical reactions such as protecting group deprotection, e g tert-birtyloxycarbonyl (boc) group deprotection with TFA, neat or in presence of a solvent such as a polyhalogeneated alkane, e g. dichloromethane at a temperature between O°C to 40°C ; functional group substitution e g alkylation of a hydroxy! group to form an alkoxy group by treatment with a strong based such as metal hydride, e.g sodium hydride, in an aprotic solvent, e.g. THF or dimethylformamide, followed by addition of an akylhahde, e.g methyliodide, at a temperature between -20°C and 4O°C* or functional group modification e.g conversion of a carbonyl to a thiocarbonyl by treatment with Lawesson's reagent in a cyclyether solvent, e g. dtoxane at a temperature between 6O°C and 120°C or at reflux A compound of formula (I) wherein Y - CH is prepared by reacting a compound of the formula (II)
Figure imgf000069_0001
wherein
Hal refers to halogen preferably bromine; and
X1 R1, R2, R4, R5 and Rβ are as defined herein above;
A. with a boronic acid of the formula III
R3-B(OH)2 (III)
or a boronate ester such as of formula ilia
Figure imgf000069_0003
wherein R3 is as defined for a compound of the formula (I), in the presence of a base and a catalyst in a suitable solvent; to provide a compound of formula (I)
or,
B; with a bis(diborane), such as bis(pinacolato)-diborane, in the presence of a base and a catalyst in a suitable solvent, to provide an intermediate of formula HA:
Figure imgf000069_0002
followed by reaction of the compound according to formula (Ha) with a compound according to formula (HIb)
Figure imgf000070_0002
wherein Hal refers to halogen preferably bromine, in the presence of a base and a catalyst in a suitable solvent; to provide a compound of formula (I);
where the above starting compounds II, Ha, III, IHa and HIb may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt- forming group is present and the reaction in salt form is possible;
any protecting groups in a protected derivative of a compound of the formula I are optionally removed, and if desired, transforming an obtainable compound of formula (I) into a different compound of formula (I), or a N-oxide thereof, transforming a salt of an obtainable compound of formula (!) into the free compound or a different salt, or an obtainable free compound of formula (I) into a salt; and/or separating an obtainable mixture of isomers of compounds of formula (I) into the individual isomers.
In the following, more detailed description of the preferred process conditions, X, R1, R2, R3, R4, R5 and R6 have the meanings given herein for compounds of the formula (I), if not indicated otherwise,
Conversion of R2 from H to a substituent different from H as defined above for R2 can be achieved by treating compound of formula (I) or (II) in presence of a strong base in a suitable solvent and subsequent adjunction of a halogenated reagent HaI-R2 wherein Hal refers to halogen preferably iodine or bromine, e g. methyliodide
A compound of formula (Ii) is prepared by reacting a compound of formula (IV)
Figure imgf000070_0001
with phosgene or trichloromethyl chloroformate in a suitable solvent in presence of a base wherein
R1, R4, R* and R6 are as mentioned for a compound of the formula (I)
A compound of the formula (IV) is prepared by reduction of a compound of the formula (V)
Figure imgf000071_0001
wherein the substituents and symbols are defined as for compounds of the formula (I) in the presence of an appropnate catalyst, e g., a skeleton based catalyst, such as Raney-Ni with hydrogen in an appropriate solvent, e g., an alcohol and or a cycloalkylether, such as methanol and/or tetrahydrofurane, at preferred temperatures e g between O°C and 50βC, e.g., at RT
A compound of formula (V) is preferably prepared by reacting a compound of the formula (Vl)
Figure imgf000071_0002
wherein
Q is halo, especially chloro, and the other moieties and symbols have the meanings indicated for compounds of the formula (I) with a compound of the formula (VII)
R1-NH2 (VII), wherein R1 is as defined for a compound of the formula (I), in the presence of a base such as a tertiaryamine, e g 1 ,2,2,6,6-pentamethylpiperidine, in an appropriate solvent, preferably a polar aprotic solvent such as dimethylacetamide at preferred temperatures between 2O°C and 12O°C temperature of the reaction mixture, e g , between 2O°C and 7O°C
A compound of the formula (Vl) can be prepared by reacting a compound of the formula (VIII)
Figure imgf000072_0001
wherein the moieties and symbols have the meanings indicated for a compound of the formula (I)1 with an inorganic acid halogenide, especially POCI3 (preferably without solvent) at elevated temperatures, e.g., between 10O°C and 15O°C or under reflux.
A compound of the formula (VIII) is known in the art, can be synthesized according to methods known in the art and/or is commercially-available. For example, it can be synthesized by reacting a compound of the formula (IX)
O )
Figure imgf000072_0002
wherein the moieties and symbols have the meanings indicated for a compound of the formula (I) (x is preferably zero), with nitnc acid (aqueous) at a preferred temperature between 5O°C and 10O°C, e g., at 85°C.
A compound of the formula (VIII)1 can alternatively be synthesized by reacting a compound of the formula (X)
Figure imgf000072_0003
wherein the moieties and symbols have the meanings indicated for a compound of the formula (I), with an anhydride of a carbonic acid, especially acetic anhydride, preferably in the presence of an alkali metal salt of a carboxylic acid, e g , potassium acetate, at a preferred temperature between 5O°C and 150°C, e g , at ca 100-140°C A compound of the formula (X) can be obtained, e g , by converting a compound of the formula (Xl)
Figure imgf000073_0001
to the corresponding compound of the formula (X) by reacting nitromethane in the presence of an alkali metal hydroxide, especially sodium hydroxide, at preferred temperatures between approximately O°C and 6O°C, e.g , between O°C and RT, then pounng the product under cooling to approximately O°C into concentrated HCI and adding the compound of the formula (Xl) and further concentrated HCI, subsequently allowing for further reaction at preferred temperatures between O°C and RT to result in the corresponding compound of formula (X)
A compound of formula (I) wherein Y - N is prepared in two steps by saponification of the ester group by treatment with a base such as an alkali metal hydroxide, e.g lithium hydroxide in a solvent such as wet cycloaklylether, e g dioxane/water, at a temperature between 20"C and 100°C, preferabely between 3O°C and 6O°C, a compound of the formula (XII)
Figure imgf000073_0002
wherein
R1, R3, R4 R5 and Rβ are as defined herein above and R is unsυbstituted or substituted lower alky!, e.g. ethyl,
The freed intermediate obtained after neutralization of the reaction mixture with an acid, such as a mineral actd e g hydrochloric acid, and evaporation to dryness is converted by a Cursius rearrangement to compound of formula (I) via in situ formation of the acylazide intermediate by treatment with diphenylphosporylazide in an aprotic solvent, such as potør aprotic and/or polar protic, e g toluene/N-methylpyro)idinone, in presence of a base, such as a tertiaryamine, e g triethylamine, at temperature between 6O°C and 12O°C, e g. between 8O°C and 11O°C; the isocyanato intermediate spontaneously cyclized to form compound of formula (I) in the reaction conditions.
A compound of formula (XII) is preferably prepared by reacting a compound of the formula (XIII)
Figure imgf000074_0001
wherein
Q is halo, especially chloro; and the other moieties have the meanings indicated for compounds of the formula (I)1 and R is unsubstituted or substituted lower alky), e.g ethyl, with a compound of the formula (VII)
R1-NH2 (VII)1 wherein R1 is as defined for a compound of the formula (I), in the presence of a base such as a tertiaryamine, e.g. 1 ,2,2,6,6-pentamethylpiperidine, in an appropriate solvent; preferably a polar aprotic solvent such as dimethylacetamide, at preferred temperatures between 209C and 12O°C temperature of the reaction mixture, e.g., between 2O°C and 70βC.
A compound of formula (XIII) is preferably prepared by reacting a compound of the formula (XIV)
Figure imgf000074_0002
wherein the moieties have the meanings indicated for a compound of the formula (I) and R is unsubstituted or substituted lower aikyl, e.g ethyl, with an inorganic acid halogenide, especially POCI3 (preferably without solvent) at elevated temperatures, e.g , between 100°C and 15O°C or under reflux A compound of formula (XIV) is preferably prepared by reacting a compound of the formula (XV)
Figure imgf000075_0001
wherein the moieties have the meanings indicated for a compound of the formula (I) with a compound of formula (XVI)
Figure imgf000075_0002
R and R' being selected independently from unsubstituted or substituted alkyl, e g. being both ethyl; in a solvent and pressure condition, e.g. xylene in a seal tube, allowing reaction at a temperature between 15O°C and 300°C, e.g. between 22O°C and 25O°C.
A compound of formula (XV) is known in the art and can be prepared by reduction of a compound of the formula (XVII)
Figure imgf000075_0003
wherein the moieties have the meanings indicated for a compound of the formula (I) with a compound of formula (XVI) in the presence of an appropriate catalyst, e.g., a skeleton based catalyst, such as Raney-Ni with hydrogen in an appropriate solvent, e.g., an alcohol and or a cycloalkylether, such as methanol and/or tetrahydrofurane; at preferred temperatures e.g. between 0°C and 5O°C, e.g., at RT.
A compound of formula (XVII) is known in the art and can be prepared by reacting a compound of formula (XVIII)
Figure imgf000076_0001
with a boronic acid of the formula III
R3-B(OH)2 (III)
or a boronate ester such as of formula Ilia
Figure imgf000076_0002
wherein R3 is as defined for a compound of the formula (I), in the presence of a base and a catalyst in a suitable solvent
Other starting materials are either known in the art, can be prepared according to methods that are known in the art, e g , in analogy to the methods described hereinabove or in the examples, and/or are commercially-available
The present invention relates also to novel starting matenals and/or intermediates and to processes for their preparation The starting materials used and the reaction conditions selected are preferably those that result in the compounds described as being preferred
Other starting materials are either known in the art, can be prepared according to methods that are known in the art, e g , in analogy to the methods described hereinabove or tn the examples, and/or are commercially-available
The present invention relates also to novel starting materials and/or intermediates and to processes for their preparation The starting materials used and the reaction conditions selected are preferably those that result in the compounds described as being preferred
Salts of compounds of formula (I) having at least one salt-forming group may be prepared in a manner known per se For example, salts of compounds of formula (I) having acid groups may be formed, e g , by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e g , the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used. Actd addition salts of compounds of formula (I) are obtained in customary manner, e.g , by treating the compounds with an aαd or a suitable anion exchange reagent Internal salts of compounds of formula (I) containing acid and basic salt- forming groups, e g., a free carboxy group and a free amino group, may be formed, e g,, by the neutralization of salts, such as acid addition salts, to the isoelectric point, e g , with weak bases, or by treatment with ion exchangers
Salts can be converted m customary manner into the free compounds, metal and ammonium salts can be converted, e.g , by treatment with suitable acids, and acid addition salts, e g , by treatment with a suitable basic agent
Mixtures of isomers obtainable according to the invention can be separated in a manner known per se into the individual isomers; diastereoisomers can be separated, e.g , by partitioning between polyphasic solvent mixtures, recrystajlization and/or chromatographic separation, e g., over silica gel or by, e.g , medium pressure liquid chromatography over a reversed phase column; and racemates can be separated, e g., by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, e g., by means of fractional crystallization, or by chromatography over optically active column materials
Intermediates and final products can be worked up and/or purified according to standard methods, e.g.. using chromatographic methods distribution methods, re-crystallization and the like
Additional process steps
In the additional process steps, carried out as desired, functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected, e g , by one or more protecting groups The protecting groups are then wholly or partly removed according to one of the known methods.
Protecting groups, and the manner in which they are introduced and removed are described, e.g , Protective Groufis in Organic Chemistry, Plenum Press, London, NY (1973), Methoden der organischen Chemie. Houben-Weyl, 4ιn Edition, Vol. 15/1 , Georg-Thieme-Verlag, Stuttgart (1974), and Theodora W Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, NY (1981) A characteristic of protecting groups is that they can be removed readily, i e , without the occurrence of undesired secondary reactions, e g., by solvolysis, reduction, photolysis or alternatively under physiological conditions The end products of formula (I) may however also contain substitυents that can also be used as protecting groups in starting materials for the preparation of other end products of formula (I) Thus, within the scope of this text, only a readily removable group that is not a constituent of the particular desired end product of formula (I) is designated a "protecting group", unless the context indicates otherwise.
General process conditions
The following applies in general to all processes mentioned hereinbefore and hereinafter, while reaction conditions specifically mentioned above or below are preferred
All the above-mentioned process steps can be carried out under reaction conditions that are known perse, preferably those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, preferably solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, e.g., ion exchangers, such as cation exchangers, e g , in the H* form, depending on the nature of the reaction and/or of the reactants at reduced, normal or elevated temperature, e g in a temperature range of from about -10O°C to about 19O°C; preferably from approximately -80X to approximately 15O°C, e g , at from -80°C to -6O°C at RT, at from -2O°C to 4O°C or at reflux temperature; under atmospheric pressure or in a closed vessel, where appropnate under pressure and/or in an inert atmosphere, e g , under an argon or nitrogen atmosphere.
At all stages of the reactions, mixtures of isomers that are formed can be separated into the individual isomers, e g., diastereoisomers or enantiomers, or into any desired mixtures of isomers, e.g , racemates or mixtures of diastereoisomers, e g , analogously to the methods described under "additional process steps"
The solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, e g , water, esters, such as lower alkyl- lower alkanoates, e.g. ethyl acetate, ethers, such as aliphatic ethers, e g , diethyl ether, or cyclic ethers, e g , tetrahydrofuran or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitnles, such as acetonitπle, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases such as heterocyclic nitrogen bases, e g pyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, e g , acetic anhydride, cyclic, linear or branched hydrocarbons, such as cyclohexane hexane or isopentane; or mixtures of those solvents. e g aqueous solutions, unless otherwise indicated in the description of the processes Such sotvent mixtures may also be used in working up, e g , by chromatography or partitioning
The compounds, including their salts, may also be obtained in the form of hydrates, or their crystals may e g , include the solvent used for crystallization Different crystalline forms may be present.
The invention relates also to those forms of the process in which a compound obtainable as intermediate at any stage of the process is used as starting material and the remaining process steps are earned out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, e g., in protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in sttu In the process of the present invention those starting materials are preferably used which result in new compounds of formula (I) described at the beginning as being especially valuable Special preference is given to reaction conditions that are analogous to those mentioned in the examples
Pharmaceutical Compositions
The invention relates also to pharmaceutical compositions comprising a compound of formula (I) to their use in the therapeutic (in a broader aspect of the invention also prophylactic) treatment or a method of treatment of a lipid or protein kinase dependent disease, especially the preferred diseases mentioned above, to the compounds for said use and to the preparation of pharmaceutical preparations, especially for said uses
The present invention also relates to pro-drugs of a compound of formula (I) that convert in vivo to the compound of formula (I) as such Any reference to a compound of formula (I) is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula (I), as appropriate and expedient The pharmacologically acceptable compounds of the present invention may be used e g , for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as active ingredient together or in admixture with a significant amount of one or more inorganic or organic solid or liquid, pharmaceutically acceptable carriers
The invention relates also to a pharmaceutical composition that is suitable for administration to a warm-blooded animal, especially a human (or to ceils or cell lines derived from a warmblooded animal, especially a human, e g. lymphocytes), for the treatment or, in a broader aspect of the invention, prevention of (~ prophylaxis against) a disease that responds to inhibition of protein kinase activity, composing an amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is effective for said inhibition, especially the in, together with at least one pharmaceutically acceptable carrier.
The pharmaceutical compositions according to the invention are those for enteral, such as nasal, rectal or oral; parenteral, such as intramuscular or intravenous; or topical, such as dermal administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
The invention relates also to a method of treatment for a disease that responds to inhibition of a lipid or protein kinase which comprises administering an (against the mentioned disease) prophylactically or especially therapeutically effective amount of a compound of formula (I) according to the invention, especially to a warm-blooded animal, e.g , a human, that, on account of one of the mentioned diseases, requires such treatment
The dose of a compound of the formula (!) or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals, e.g , humans of approximately 70 kg body weight, is preferably from approximately 3 mg to approximately 10 g, more preferably from approximately 10 mg to approximately 1 5 g, most preferably from about 100 mg to about 1000 mg/person/day, divided preferably into 1-3 single doses which may, e g., be of the same size. Usually, children receive half of the adult dose
The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, e.g , in unit dose form, such as in the form of ampoules, vials, suppositories, dragees. tablets or capsules
The pharmaceutical compositions of the present invention are prepared in a manner known per se, e g , by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes
Solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions, are preferably used, it being possible, e.g., in the case of lyophilized compositions that compose the active ingredient alone or together with a carrier, e g., mannitol, for such solutions or suspensions to be produced prior to use. The pharmaceutical compositions may be sterilized and/or may comprise exαpients, e g., preservatives, stabilizers, wetting and/or emulsifying agents, solυbilizers, salts for regulating the osmotic pressure and/or buffers, and are prepared in a manner known per se, e g., by means of conventional dissolving or tyophilizing processes The said solutions or suspensions may compnse viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylceliulose, dextran, polyvinylpyrrolidone or gelatin
Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes. There may be mentioned as such especially liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8-22 carbon atoms, especially from 12-22 carbon atoms, e g , lauric acid, tπdecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, e.g , oleic acid, elaidic acid, erucic acid, brasidic acid or linoletc acid, if desired with the addition of antioxidants, e g , vitamin E, β-carotene or 3,5-di-tert-butyl-4-hydroxytoluene. The alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a mono- or poly-hydroxy, e g., a mono-, di- or tri-hydroxy; alcohol, e.g., methanol, ethanol, propanol, butanol or pentanol, or the isomers thereof, but especially glycol and glycerol. The following examples of fatty acid esters are therefore to be mentioned' ethyl oleate, isopropyl myristate, reopropyl palmitate, "Labrafil M 2375" (polyoxyethylene glycerol trioleate, Gattefosse, Paris), "Miglyol 812" (triglyceride of saturated fatty acids with a chain length of Ce-Ci?, Hϋls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil
The injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.
Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropnate excipients, into tablets, dragee cores or capsules It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts
Suitable carriers are especially fillers, such as sugars, e g , lactose, saccharose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates, e g., tπcalcium phosphate or calcium hydrogen phosphate; and binders, such as starch pastes using, e g , corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; and/or, if desired, disintegrators, such as the above-mentioned starches; and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate Excipients are especially flow conditioners and lubricants, e.g., silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate; and/or polyethylene glycol. Dragee cores are provided with suitable, optionally entertc, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide; or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate Capsules are dry- filled capsules made of gelatin and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, e.g , with fillers, such as lactose; binders, such as starches, and/or gltdants, such as talc or magnesium stearate; and if desired with stabilizers In soft capsules the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added Dyes or pigments may be added to the tablets or dragee coatings or the capsule casings, e g., for identification purposes or to indicate different doses of active ingredient
Pharmaceutical compositions for topical administration can be obtained by combining the active ingredient with a liquid carrier (e.g. an aqueous Itquid carrier) to dissolve or disperse the active, together with further optional formulating ingredients such as solvents/solυbilisers, gelling agents, oils, stabilisers, buffers and preservatives to provide for example a solution, lotion, cream, gel or ointment. The pharmaceutical compositions for topical administration may be provided, for example, for derma) application The pharmaceutical compositions for topical administration may comprise from approximately 0 1% to approximately 2% of active ingredient, the active ingredient being especially a compound of formula (I), in particular, a compound described in the individual examples herein.
Compounds of the invention display particularly high solubilities in organic solvents The compounds of the invention are thus particularly useful for topical administration, e g. to a mammal such as a human, e g to the skin of said mammal. The compounds are thus useful for formulation into compositions suitable for topical administration. Compounds displaying high solubility thus provide an advantage for topical administration over compounds having a lower solubility.
The solubility of certain compounds was determined in the organic solvents PEG400, propyleneglycol and ethanol The results are provided in the following table, showing high solubilities of the specified compounds demonstrating that those compounds are particularly suitable for formulation into compositions for topical administration, - 82 -
Figure imgf000083_0001
Combinations
A compound of the formula (I) may also be used to advantage in combination with each other or in combination with other therapeutic agents, especially other antiproliferative agents Such antiproliferative agents include, but are not limited to, aromatase inhibitors, arrtiestrogens; topoisomerase I inhibitors, topoisomerase M inhibitors, microtubule active agents, alkylating agents; histone deacetylase inhibitors, compounds, which induce cell differentiation processes; cyclooxygenase inhibitors; MJvIP inhibitors, mTOR inhibitors, antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds, compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorehn agonists; anti- androgens, methionine aminopeptidase inhibitors, bisphosphonates, biological response modifiers, antiproliferative antibodies, heparanase inhibitors, inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors, agents used in the treatment of hematologic malignancies, compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors; temozolomide (TEMODAL61); and leucovorin.
The term "aromatase inhibitor", as used herein, relates to a compound which inhibits the estrogen production, i e , the conversion of the substrates androstenedione and testosterone to estrone and estradiol respectively The term includes, but is not limited to, steroids, especially atamestane, exemestane and formestane, and, in particular, non-steroids, especially aminoglutethimide, roglethimtde, pyπdoglutethimide, tπlostane, testolactone, ketokonazole. vorozole, fadrozole, anastrozole and letrozoie Exemestane can be administered, e g , in the form as it is marketed, e.g., under the trademark AROMASIN Formestane can be administered, e g., in the form as it is marketed, e g., under the trademark LENTARON Fadrozole can be administered, e g , in the form as it is marketed, e.g., under the trademark AFEMA Anastrozole can be administered, e.g., in the form as it is marketed, e g., under the trademark ARIMIDEX Letrozole can be administered, e.g., in the form as it is marketed, e.g , under the trademark FEMARA or FEMAR Aminoglutethimide can be administered, e.g , in the form as it is marketed, e.g., under the trademark ORIMETEN. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g , breast tumors.
The term "anti-estrogen", as used herein, relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level The term includes, but is not limited to, tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen can be administered, e.g , in the form as it is marketed, e.g., under the trademark NOLVADEX. Raloxifene hydrochloride can be administered, e g , in the form as it is marketed, e.g., under the trademark EVISTA. Fulvestrant can be formulated as disclosed in U.S. Patent No. 4,659,516 or it can be administered, e g., in the form as it is marketed, e g , under the trademark FASLODEX. A combination of the invention comprising a chemotherapeutic agent which is an antøestrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g , breast tumors
The term "anti-androgen", as used herein, relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g., as disclosed in U. S Patent No 4,636,505.
The term "gonadorehn agonist", as used herein, includes, but is not limited to, abarelix, goserelin and goserelin acetate. Goserelin is disclosed in U S. Patent No. 4,100,274 and can be administered, e g., in the form as it is marketed, e.g , under the trademark ZOLADEX Abarelix can be formulated, e.g., as disclosed in U.S Patent No. 5,843,901
The term "topoisomerase I inhibitor", as used herein, includes, but is not limited to, topotecan, gimatecan, iπnotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in WO 99/17804), lrinotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark CAMPTOSAR Topotecan can be administered, e.g., in the form as it is marketed, e g , under the trademark HYCAMTIN
The term "topoisomerase Il inhibitor", as used herein, includes, but is not limited to, the anthracyclmes, such as doxorubicin, including liposomal formulation, e.g., CAELYX, daunorubicin, epirubicin, idarubicin, nemorubicin; the anthraqumones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide Etoposide can be administered, e g , in the form as it is marketed, e g , under the trademark ETOPOPHOS. Teniposide can be administered, e g., in the form as it is marketed, e.g., under the trademark VM 26-BRISTOL Doxorubicin can be administered, e g , in the form as it is marketed, e g , under the trademark ADRIBLASTIN or ADRlAMYCiN. Epirυbicin can be administered, e.g.. in the form as it is marketed, e g , under the trademark FARMORUBICIN Idarυbicin can be administered, e g , in the form as it is marketed, e g., under the trademark ZAVEDOS. Mitoxantrone can be administered, e g , in the form as it is marketed, e g., under the trademark NOVANTRON.
The term "microtubule active agent" relates to microtubule stabilizing, microtubule destabilizing agents and microtublin polymerization inhibitors including, but not limited to, taxanes, e.g., paclitaxel and docetaxel; vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate; vincristine, especially vincristine sulfate and vinorelbine; discodermolides; cochicine; and epothilones and derivatives thereof, e g , epothilone B or D or derivatives thereof. Paclitaxel may be administered, e g , in the form as it is marketed, e g., TAXOL Docetaxel can be administered, e g., in the form as it is marketed, e.g., under the trademark TAXOTERE Vinblastine sulfate can be administered, e,g , in the form as it is marketed, e g., under the trademark VINBLASTIN R.P. Vincristine sulfate can be administered, e g., in the form as it is marketed, e g , under the trademark FARMISTiN Discodermolide can be obtained, e g.( as disclosed in U S Patent No. 5,010,099 Also included are epothilone derivatives which are disclosed in WO 98/10121 , U S. Patent No 6,194,181 , WO 98/25929, WO 98/08849. WO 99/43653, WO 98/22461 and WO 00/31247, Especially preferred are epothilone A and/or B
The term "alkylating agent", as used herein, includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide can be administered, e g , in the form as it is marketed, e.g , under the trademark CYCLOSTIN. Ifosfamide can be administered, e.g., in the form as it is marketed, e g , under the tractemark HOLOXAN.
The term "histone deacetytase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity This includes compounds disclosed in WO 02/22577, especially N-hydroxy-3-f4-[«2-hydroxyethyl)[2-(1W-indo!~ 3-yl)ethyl]-aminoJmethyl]phenyl]-2£-2-propenamide, N-hydroxy-3-[4-{[{2-(2-methyM W-indol-3- yl)-ethyl]-amino]methyl]phenylJ-2£-2-propenamide and pharmaceutically acceptable salts thereof It further especially includes suberoylanilide hydroxamic acid (SAHA)
The term "antineoplastic antimetabolite" includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine; DNA demethylating agents, such as 5-azacytidtne and decitabine; methotrexate and edatrexate, and folic acid antagonists, such as pemetrexed Capecitabine can be administered, e g , in the form as it is marketed, e g , under the trademark XELODA Gemcitabine can be administered, e g , in the form as it is marketed, e g., under the trademark GEMZAR Also included is the monoclonal antibody trastuzumab which can be administered, e.g., in the form as it is marketed, e g., under the trademark HERCEPTIN
The term "platin compound", as used herein, includes, but is not limited to, carboplatin, c/s-platin, cisplatinum and oxaliplatin Carboplattn can be administered, e.g , in the form as it is marketed, e g., under the trademark CARBOPLAT Oxalipiatin can be administered, e g , in the form as it is marketed, e.g , under the trademark ELOXATIN.
The term "compounds targeting/decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti-angiogenic compounds", as used herein, includes, but is not limited to, protein tyrosine kinase and/or senne and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g., a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, e.g., a N-phenyl-2-pyrimidine-amine derivative, e g , imatinib, SU101 , SU6668 and GFB-111; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor 1 (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-(R, especially compounds which inhibit the IGF-IR receptor, such as those compounds disclosed in WO 02/092599; d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family; e) compounds targeting, decreasing or inhibiting the activity of the AxI receptor tyrosine kinase family; f) compounds targeting, decreasing or inhibiting the activity of the c-Met receptor, g) compounds targeting, decreasing or inhibiting the activity of the Kit/SCFR receptor tyrosine kinase; h) compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases - (part of the PDGFR family), such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor e.g., imatinib i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family and thetr gene-fusion products e g , BCR-AbI kinase, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, e g , a N-phenyl-2-pynmidine-amtne derivative, e g , imatinib, PD180970, AG957, NSC 680410 or PD173955 from ParkeDavis, j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of seπneΛhreonine kinases, members of the MEK, SRC, JAK, FAK, PDK and Ras/MAPK family members, or Pl(3) kinase family or of the Pf(3)-kinase-related kinase family, and/or members of the cychn-dependent kinase family (CDK) and are especially those staurosponne derivatives disclosed in U S Patent No 5 093 330, e g , midostaurin, examples of further compounds include, e g , UCN-01 , safingol, BAY 43-9006, Bryostatin 1, Peπfosine, llmofosine, RO 318220 and RO 320432 GO 6976, lsis 3521 LY333531/LY379196, isochinohne compounds, such as those disclosed in WO 00/09495, FTIs, PD184352, or QAN697 (a P13K inhibitor), k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC) or tyrphostin A tyrphostin is preferably a low molecular weight {Mr < 1500) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitnle class or the S-arylbenzenemaloniπle or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG-50810, AG 99, Tyrphostin AG 213 Tyrphostin AG 1748, Tyrphostin AG 490, Tyrphostin B44, Tyrphostin B44 (+) enantiomer, Tyrphostin AG 555 AG 494, Tyrphostin AG 556, AG957 and adaphostin (4-{((2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester, NSC 680410, adaphostin, and
I) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR, ErbB2, ErbB3 ErbB4 as homo- or hetero-dimers) such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e g , EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related hgands, and are in particular those compounds, proteins or monoclonal antibodies genencally and specifically disclosed in WO 97/02266, e g , the compound of Example 39, or in EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, U.S. Patent No 5,747,498, WO 98/10767: WO 97/30034; WO 97/49688, WO 97/38983 and, espectatly, WO 96/30347, e.g , compound known as CP 358774, WO 96/33980, e.g., compound ZD 1839; and WO 95/03283, e.g., compound ZM 105180, e.g., trastuzumab (HERCEPTIN), cetuximab, Iressa, Tarceva, OSI-774, CI-1033, EKB-569, GW-2016. EU, E2.4, E2 5, E6.2, E6.4, E2.11. E6.3 or E7 6.3; and 7/-/-pyrrolo-[2,3-cf|pyrimidine derivatives which are disclosed in WO 03/013541
Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g., unrelated to protein or lipid kinase inhibition, e.g., thalidomide (THALOMID) and TNP-470.
Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are, e.g , inhibitors of phosphatase 1 , phosphatase 2A1 PTEN or CDC25, e g., okadaic acid or a derivative thereof
Compounds which induce cell differentiation processes are e.g. retinoic acid, α- γ- or δ-tocopherol or α- γ- or δ-tocotrienol.
The term cyclooxygenase inhibitor, as used herein, includes, but is not limited to, e.g., Cox-2 inhibitors, 5-afkyl substituted 2-arylaminophenyiacetic aαd and derivatives, such as celecoxib (CELEBREX), rofecoxib (VfOXX), etoncoxib, valdecoxib or a 5-alkyf-2-arylamtnophenylacetic acid, e.g., 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid or lumiracoxib.
The term "bisphosphonates", as used herein, includes, but is not limited to, etndonic, clodronic, tiludronic, pamidronic, alendromc, ibandronic, πsedronic and zoledronic acid. "Etndonic acid" can be administered, e g., in the form as it is marketed, e g , under the trademark DIDRONEL "Clodronic acid" can be administered, e.g.. in the form as it is marketed, e.g , under the trademark BONEFOS 'Tiludronic acid" can be administered, e.g , in the form as it is marketed, e g , under the trademark SKELID. "Pamidronic acid" can be administered, e.g in the form as it is marketed, e g , under the trademark AREDIA™. "Alendronic acid" can be administered, e g , in the form as it is marketed, e.g., under the trademark FOSAMAX "Ibandronic acid" can be administered, e g , in the form as it is marketed, e.g , under the trademark BONDRANAT. "Risedronic acid" can be administered, e g , in the form as it is marketed, e g., under the trademark ACTONEL "Zoledronic acid" can be administered, e.g., in the form as it is marketed, e g , under the trademark ZOMETA The term "mTOR inhibitors" relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity, such as sirolimυs (Rapamune*5), everolimus (Certican™), CCI-779 and ABT578.
The teim "heparanase inhibitor", as used herein, refers to compounds which target, decrease or inhibit heparin sulphate degradation The term includes, but is not hmited to, PI-88
The term "biological response modifier", as used herein, refers to a lymphokine or interferons, e.g., interferon γ.
The term "inhibitor of Ras oncogenic isoforms", e g , H-Ras, K-Ras or N-Ras, as used herein, refers to compounds which target, decrease or inhibit the oncogenic activity of Ras, e g , a "farnesyl transferase inhibitor", e.g , L-744832, DK8G557 or R115777 (Zarnestra).
The term "telomerase inhibitor" as used herein, refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e g , telomestatin.
The term "methionine aminopeptidase inhibitor", as used herein, refers to compounds whtch target, decrease or inhibit the activity of methionine aminopeptidase Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are, e g , bengamide or a derivative thereof
The term "proteasome inhibitor", as used herein, refers to compounds which target, decrease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include, e g., PS-341 and MLN 341
The term "matrix metalioproteinase inhibitor" or "MMP inhibitor" as used herein, includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e g , hydroxamate peptidomimetic inhibitor batimastat and its oralfy bioavailable analogue marimastat (BB-2516), pnnomastat (AG3340). metastat (NSC 683551) BMS-279251 , BAY 12-9566 TAA211 , MMI270B or AAJ996.
The term "agents used in the treatment of hematologic malignancies", as used herein, includes, but is not limited to, FMS-like tyrosine kinase inhibitors, e g., compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R), interferon 1-b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, e g., compounds which target, decrease or inhibit anaplastic lymphoma kinase Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the Rt-3R receptor kinase family, e g., PKC412, midostauiin, a staυrosporine derivative, SU11248 and MLN518
The term "HSP90 inhibitors", as used herein, includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90, degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteasome pathway. Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, e.g , 17-allylamino, 17-demethoxygeldanamycin (17AAG), a geldanamycin derivative, other geldanamycin related compounds radiαcol and HDAC inhibitors
The term "antiproliferative antibodies", as used herein, includes, but is not limited to, trastuzumab (Herceptin™), Trastuzumab-DM1, ertotinib (Tarceva™), bevacizumab (Avastin™), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 antibody. By antibodies is meant, e.g , intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.
For the treatment of acute myeloid leukemia (AMI), compounds of formula (I) can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML. In particular, compounds of formula (I) can be administered in combination with, e g , farnesy! transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adnamycin, Ara-C, VP-16, Tentposide, Mitoxantrone, Idarubicin, Carboplatmum and PKC412
The structure of the active agents identified by code nos , generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g , Patents International, e.g , IMS World Publications.
The above-mentioned compounds, which can be used in combination with a compound of the formula (t), can be prepared and administered as described in the art, such as in the documents cited above
A compound of the formula (I) may also be used to advantage in combination with known therapeutic processes, e.g., the administration of hormones or especially radiabon.
A compound of formula (t) may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy. By "combination", there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g , synergistic, effect or any combination thereof The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e g a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients The term "fixed combination" means that the active ingredients, e g. a compound of formula I and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e g a compound of formula (I) and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time Nmits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients
The following examples are merely illustrative and not meant to limit the scope of the present claims in any manner.
EXAMPLES
The following examples serve to illustrate the invention without bmiting the scope thereof:
Temperatures are measured in degrees Celsius Unless otherwise indicated, the reactions take place at it The following HPLC/MS and MS methods are used in the preparation of the Intermediates and Examples'
HPLC Method:
Method A
HPLC linear gradient between A = H2O fTFA 1000 1 and B = acetonttπle/TFA 1000 1 Grad 1 ' 2-100 % Bin 4.5 min and 1 min at 100 % B; column: Chromolith Performance 100 mm x 4.5 mm (Merck, Darmstadt, Germany); flow rate 2 ml/mm Detection at 215 nM,
LC-MS Method:
Method B
System: Agilent 1100 Series with Waters Micromass ZQ
Column' XBridge C18, 3 x 30 mm, 2.5 micron
Flow Rate- 1.4-2.4 mL/min
Eluent A H2O1 containing 5% acetonitrile and 0 8% HCOOH
Eluent B' acetonitrile, containing 0.6% HCOOH
Gradient 0 ~ 2.4 min: 10% to 95% of B
!n the following examples, the abbreviations given below are used:
DCM dichloromethane
DIPEA N,N-diisopropylethylamine
DMA dimethylacetamide
DME 1 ,2-dimethoxyethane
DMF N,N-dimethy!formamide
DMSO dimethyl sulfoxide
EtOAc ethyl acetate h hour(s)
HPLC high performance liquid chromatography
HV high vacuum
Intermed. intermediate iPrMgCI isopropylmagnesium chloride iPrOH isopropanol
LC-MS liquid chromatography coupled with mass spectrometry
MeOH methanol ml milliliter(s) min minute(s)
MS-ES electrospray mass spectrometry
NMP N-methyl-2-pyrrolidone
PdCb(dppf) [1 ,1'-bis(diphenylphosphino)ferrocene]dichloropalladiυm (II) PdCI?(PPh3)2 bis(tπphenylphosphine)pa!ladium (II) dichloride
Pd2(dba)3 tns(dibenzylideneacetone)dipalladium (0) Prep HPLC preparative high performance liquid chromatography qt quintuplet
RM reaction mixture rt room temperature
TEA tπethylamine
TFA trifluoroacetic acid
THF tedrahydrofurane tR retention time
TPTU O-π .2-dihvdro-2-oxo-1-Dvndvl)-N.N.N'-N'-tetramethvluronium tetraflυoroborate
Intermediate A • 8-Bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo(4 , 5-c]quinoKn-2-one
Figure imgf000093_0001
NaOH (0.568 g, 14.19 mmol) and tetrabutylammonium bromide (0.229 g, 0 710 mmol) were added to a mixture of 8-bromo-1-(1 ,3-dimethyI-1H-ρyrazol-4-yi)-1 l3-dihydrcHmidazo[4,5- c]quinolin-2-one (Stage A.1 3.10 g, 7 100 mmol) in DCM (108 ml) and H2O (54 ml) and stirred at rt for 5 mm Then iodomethane (1.52 ml, 24.1 mmol) was added and the mixture was stirred for 14 h at rt Iodomethane (0 4 ml, 6 35 mmol) was added and the RM was stirred at rt for 23 5 h Then the RM was extracted with DCM (2 x), washed with saturated aqueous NaHCO3 and brine, dπed over Na2SO4, filtered and evaporated to dryness The residue was dissolved in DCM and purified by flash chromatography (DCM/MeOH 0% - 4.5%) to give the title compound as a brownish solid (HPLC tR 2 37 min (Method A), M+H ~ 374 MS-ES- 1H-NMR (d6-DMSO, 400 MHz) 9 00 (s, 1H), 8 08 (s, 1 H), 7 91-7 99 (m, 1H), 7 64-7 71 (m, 1 H), 7.41-7.47 (m, 1H), 3 90 (s, 3H), 3 55 (s, 3H), 1 94 (s, 3H))
Stage A.1 : 8-Bromo-1-(1.3-dimethyM H-pyrazol-4-yl)-1 ,3-dihydro-imidazo[4,5-c]quinolin-2- one
Figure imgf000094_0001
To a solution of 6-bromo-NM*-(1 ,3-dimethyMH-pyrazol-4-yl)-quinoline-3,4-diamine (Stage A.2, 3.15 g, 8.15 mmo!) and TEA (1 36 ml, 9.79 mmol) in DCM (65 ml) was added under argon, after cooling with an ice-bath, a solution of trichloromethyl chloroformate (1.08 ml, 8.97 mmol in DCM (65 ml). The mixture was stirred for 25 min at 0 °C. Then the RM was quenched with sat aqueous NaHCO3 (300 ml) and 10 M aquoeus NaOH (4 ml) and well stirred. The phases were separated and extracted with EtOAc (3x). The combined organic layers were washed with brine (2x), dried over Na2SO4, filtered and evaporated to dryness to give the title compound as a brownish solid (HPLC tR 2 29 mm (Method A); M+H - 360; M-H = 358 MS-ES)
Stage A.2 6-Bromo-N*4*-(1 ,3-dimethyl-1H-pyrazol-4-yl)-quinoline-3,4-diamine
Figure imgf000094_0002
(6-8romo-3-nitro-quinoHn-4-yl)-(1,3-dimethyl-1H-pyrazol-4-yl)'amine (Stage A.3, 3 67 g 9.73 mmol) was shacked in MeOH/THF 1 1 (120 ml) under 1.1 bar H2 in presence of Raney nickel (1.50 g) as catalyst for 5 h at rt The RM was filtered over celite, the catalyst was washed with MeOH/DCM and the solution was evaporated to dryness to give the title compound as a red solid (HPLC tR 2.44 min (Method A): M+H = 334, M-H = 332 MS-ES)
Stage A.3 (6-Bromo-3-nitro-quinolin-4-yl)-(1 ,3-dimethyl-1H-pyrazol-4-yl)~amine
Figure imgf000094_0003
To a mixture of 6-bromo-4-chloro*3-nitro-quinoline (Stage A,4, 3 O g, 20.43 mmol) and 4- amino-I .S-dimetylpyrazole'HC! (CbemCollect, Remscheid, Germany, 1 85 g, 12.53 mmol) in DMA (45 ml) was added 1 ,2,2,6,6-pentamethylpiperidine (6 67 ml, 36 δ mmol). The RM was stirred at 50 °C for 4 5 h. Then the RM was cooled down to rt and quenched with H2O The suspension was filtered the solid cake was washed with H2O and dried under vacuum. before being dissolved in EtOAc. The solution was washed with brine (2 x), dried over Na2SO4, filtered and evaporated to dryness to give the title compound as an orange solid (HPLC tR 2 55 min (Method A), M+H = 362; M-H = 360 MS-ES)
Stage A.4 6-Bromo-4-chloro-3-nitro-quinoline
Figure imgf000095_0001
6-Bromo-3-nitro~quinolin-4-ol (Fluorochem Ltd., Derbyshire, UK1 10 g, 37 2 mmol) was added to POCI3 (70 ml) The RM was stirred at 120 °C for 17 h. Then the RM was cooted with an ice -bath, before being slowly dropped onto ice-water. The precipitate was filtered and washed with cold water. The residue was dissolved in DCM, washed with brine, dried over Na2SO4, filtered and evaporated to give the title compound as a beige solid ( HPLC tR 3.64 mm (Method A))
The following intermediates were synthesized in a similar manner as described for intermediate A using as replacement for the 4-amino-1 ,3-dimetylpyrazole»HCI a different aminopyrrazole starting material
5-Amino-1-ethylpyrazo!e (Aldrich, Buchs, Switzerland, B) 5-Amino-1 ,3-dimethylpyrazole (Aldrich, Buchs, Switzerland; C) 5-Amino-1~methyl-3-(tπfluoromethyl)pyrazole (Art-Chem, Akos, Steinen, Germany; D) 5-Amtno-1-methylpyrazo!e (Combi-Blocks, San Diego, USA; E) 4~Amino-1-ethyl-3-methylpyrazole HCI (Art-Chem, Akos, Steinen, Germany, F) 4-Amino-1-isopropyl-3-methylpyrazoie HCI (Art-Chem Akos, Steinen, Germany; G) 4-Amino-1 ,3,5-tnmethylpyrazole (ABCR, Karlsruhe, Germany H) 5-Amino-1,4-dimethy!pyrazole (ChemBridge, San Diego, USA, I) 4-Amino-1 ,5-dimethylpyrazole*2HCI (Art-Chem, Akos, Steinen, Germany, J)
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0002
Stage K.1 3-Chloro-1-methyl-1H-pyrazo!~4~y1amine
Figure imgf000098_0001
3-Chloro-1-methyl-4-nitro-1H-pyrazole (Stage K.2, 1 0 g 6 19 mmol) was shacked in MeOH/THF 1.1 (62 ml) under 1.1 bar H2 in presence of Raney nickel (0.35 g) as catalyst for 24 h at rt. The RM was filtered over Celite, the catalyst was washed several times with MeOH/THF and the filtrate was evaporated to dryness to give the title compound as a blue oil (HPLC tR 0.89 mm (Method A), M+H = 132 MS-ES)
Stage K.2 3-Chloro-1 -methyl-4-nitro- 1 H-pyrazole
Figure imgf000099_0001
To a solution of 3-chloro-1-methylpyrazole (Maybridge, Basel, Switzerland, 953 mg, 8.18 mmol) in concentrated sulfuric acid (1.4 ml), cooled with an ice-bath, was added over 30 min fuming nitric acid (1 19 mL, 28.6 mmol). The reaction mixture was stirred at rt for 2 h before being poured on ice/water and extracted with EtOAc (2 x) The organic layers were washed with saturated aqueous NaHCO3 (2 x) and brine, dried over Na2SO4, filtered, evaporated and dried over vacuum to give the title compound as a white solid (HPLC tR 2 24 mm (Method A), M+H ~ 162 MS-ES)
Stage L.1 2-(4-Amino-3-methyl-pyrazol- 1 -yl)-N , N-dimethyl-acetamide
Figure imgf000099_0002
The title compound was synthesized in a similar manner as described for stage K.1 using N,N-dimethyl-2-(3-methyl-4-nittx>-pyrazol-1-y1)-acetamide (stage L.2) to give the title compound as an oil (HPLC tR 1 03 mm (Method A), M+H = 183 MS-ES)
Stage L.2 N,N-Dimethyl-2-(3-methyl-4-nitro-pyrazol-1-yl)-acetamide
Figure imgf000099_0003
To a solution of 3-methyf-4-nitropyrazole (Apollo, Cheshire, UK, 500 mg, 3 93 mmoi) in DMF (10 mt) was added 55% NaH in oil (198 mg, 4 54 mmol) and the reaction mixture was stirred for 30 mm at rt Then to the reaction mixture was added a solution of 2-bromo-N.N- dimethylacetamide (stage L.3, 720 mg, 4.34 mmol) in DMF (3 ml) The reaction mixture was stirred for 1 h at rt then quenched with saturated aqueous NaHCO3 and extracted with EtOAc (2x) The combined organic layers were washed with water (2x), brine, dried over Na2SO4, filtered and evaporated The crude product was purified by Prep HPLC (H2O (0 1% TFA)/CH3CN 97 2 to 75.25, πverse phase silica gel) The fractions containing product were collected together, basified with NaHCOe and concentrated before being extracted with EtOAc (3x) The combined organic layers were washed with brine, dned over Na?SO«, filtered and evaporated to give the title compound as a white solid (HPLC tR 2 06 mm (Method A), M+H ~ 213 MS-ES)
Stage L3 2-Brorno-N,N-dimethyl-acetarnide
Figure imgf000100_0001
To a solution of bromoacetylbromide (Aldπch, Buchs, Switzerland, 4 56 g, 22 6 mmol) in dichloromethane (90 ml) were added sequentially a 2 M solution of dimethylamine in THF (Aldrich, Buchs, Switzerland, 14 mi, 28 mmol) and triethylamine (3 8 ml, 27 3 mmol) The reaction mixture was stirred for 1 h at rt then diluted with dichloromethane and washed with 2 M aqueous HCI, sat aqueous NaHCO3 and brine, dned over Na2SO4, filtered and evaporated to give the title compound as a brownish oil (HPLC tR 1 64 mm (Method A), M+H - 166, 168 MS-ES)
Stage M.1 2-(4-Amino-3-methyl-pyrazol-1-yl)-1-morpholin-4-yl-ethanone
Figure imgf000100_0002
The title compound was synthesized in a similar manner as described for Stage L.1 -2 using 2-bromo-1-morpholin-4-yl-ethanone (ChemBridge, San Diego, USA) to give the title compound as a pink solid (HPLC t« 1 05 mm (Method A), M+H = 225 MS-ES)
Stage N.1 1-(2-Methoxy-ethyl)-3,5-dimethyl-1H-pyrazol-4-ylamine
Figure imgf000101_0003
The title compound was synthesized in a similar manner as described for Stage K.1 using 1- (2-methoxy-ethyl)-3,5-dimethyl-4-nitro-1H-pyrazole (Stage N.2) to give the title compound as an oil (HPLC tR 1 15 mm (Method A), M+H * 170 MS-ES)
Stage N.2 1-(2-Methoxy-ethyl)-3,5-dimethyl-4-nitro-1H-pyrazole
Figure imgf000101_0001
To a solution of 3 5-dimethyl-4-nitropyrazole (Fluorochem, Derbyshire, UK1 989 mg, 7 01 mmol) in DMF (40 ml) was added in two portions 55% NaH in oil (420 mg, 9 63 mmol) The reaction mixture was stirred for 30 mm at rt then 2-bromoethyl methyl ether (Aldrich, Buchs, Switzerland, 1 17 g, 8 42 mmol) was added and the reaction mixture stirred for 2 h at rt The reaction mixture was quenched wtth water and extracted with EtOAc The organic layer was washed with water (2x) and brine (2x), dπed over Na2SO4, filtered and evaporated The crude product was purified by Prep HPLC (H2O (0 1% TFA)/CH3CN 95 5 to 50 50 πverse phase silica gel) The fractions containing product were collected together, basified with NaHCO3 and concentrated before being extracted with EtOAc (3x) The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to give the title compound as a white solid (HPLC tR 2 57 mm (Method A), M+H = 200 MS-ES)
Stage 0.1 2-(4-Amino-3,5-dimethyl-pyrazol-1-yl)-N N-dimethyt-acetamide
Figure imgf000101_0002
The title compound was synthesized in a similar manner as described for stage L.1-3 using 3 5-dimethyl-4-nitroρyrazole (Fluorochem, Derbyshire UK) to give the title compound as an oil (HPLC tR 1 13 mm (Method A), M+H * 197 MS-ES) Stage P.1 2-(4~Amtno-3-methyl-pyrazol-1 -yty-N-ethyl-N-methyl-acetamide
Figure imgf000102_0001
The title compound was synthesized in a similar manner as described for Stage K1 using 2- bromo-1 -morpholin-4-yl-ethanone (ChemBndge, San Diego, USA) to give the title compound as a pink solid (HPLC tR 1.05 mm (Method A); M+H = 225 MS-ES)
Stage P.2 N-Ethyl-N-methyl«2-(3-methyl-4-nitro-pyrazol- 1 -yl)-acetamide
Figure imgf000102_0002
A mixture of S-MethyM-nitro-pyrazoM-yl-acetic acid methytester (ChemCoJlect, Remscheid, Germany, 1 0 g , 5 02 mmol) in dioxane (40 ml) and 1 M aqueous LiOH (10 ml, 10 mmo!) was stirred for 1 h at 5O°C. Were added 2 M aqueous HCI (5 ml, 10 mmol) and the solution was evaporated to dryness. The dried residue, TPTU (2 98 g, 10.04 mmol) and DIPEA (2.63 ml, 15.06 mmol) in DMA (30 ml) was stirred under argon at rt for 5 min. Then N- ethylmethylamine (Aldrich, Buchs, Switzerland, 1 78 ml, 20 08 mmol) was added and the RM was stirred at rt for 20 h. The RM was diluted with EtOAc and washed with saturated aqueous NaHCO3 (2x) and with brine. The aqueous layers were extracted with dichloromethane (3x) and the combined organic layers were dried over Na2SO4, filtered and evaporated The residue was taken in DMA and purified by Prep. HPLC (H2O (0.1% TFA)/CH?CN 97:3 to 75 25) The fractions containing products were collected together and concentrated. The solution was basified with NaHCO3 and extracted with dichloromethane (2x), The organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to dryness to give the title compound as a light yellow oil (HPLC- tR 2.25 mm (Method A); M+H = 227, M-H * 225 MS-ES)
Intermediate Q : 8-Bromo~1-(3,5-dimethyhsoxazoi-4-yl)-3-methyM ,3~dihydro- imidazo[4,5-c]quinolin-2-one
Figure imgf000103_0001
The intermediate Q was synthesized in a similar manner as described for intermediate A and stage A1 to A3 using as replacement for the (6-bromo-3-nitro-quinolin-4-yl)-(1 ,3- dimethyl-1 H-pyrazol~4-yl)-amine the (6-bromo-3-nitro-quinolin-4-yl)-(3,5-dimethyl-isoxazol-4- yl)-amine (stage Q1) (HPLC. tR 2.58 mm (Method A); M+H = 373, 375 MS-ES)
Stage Q1 : (6-Bromo-3-nitro-quinolin-4-yl)-(3, 5-dimethyl-isoxazol-4-yl)-amine
Figure imgf000103_0002
A mixture of 6-bromo-4-chloro-3-nitro-quinoline (Stage AA 1.1 g, 3.83 mmol) and 3 5- dimethyl-4-aminoisoxazol (Aldrich, Buchs, Switzerland, 472 mg, 4 21 mmol) in acetic acid (10 ml) was stirred at rt for 4. h. Then the RM was quenched with H2O (40 ml) The suspension was filtered, the solid cake was washed with H?O (2x) and dned under vacuum, before being dissolved in EtOAc. The solution was washed with saturated aqueous NaHCO3, dried over Na2SO4, filtered and evaporated to dryness to give the title compound as an orange solid (HPLC tR 2 96 min (Method A)1 M+H * 363, 365, M-H ~ 361 , 363 MS-ES)
Example 1,1 8-(3,4-Dimethoxy-phenyl)-1-(1 ,5-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000103_0003
A mixture of 8-bromo-1-(1 ,5-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5- c]quinolin-2-one (Intermediate J, 50 mg, 0 132 mmol), 3,4-dimethoxyphenylboronic acid (Aldrich, Buchs, Switzerland, 29 mg, 0 156 mmol) and PdCI2(PPh3)2 (6 mg, 0 0085 mmol) in DMF (1 2 ml) and 1 M aqueous K2CO3 (O 329 ml) was stirred under argon at 105X for 1.5 h Then the RM was cooled to rt, diluted with MeOH/DMA + 3 drops TFA and purified directly by Prep HPLC (H2O (O 1% TFA)ZCH1CN 95 5 to 5545) The fractions containing product were collected together and basified with NaHCO3 (O 3 g), before being concentrated The resulting suspension was filtered and the cake was washed with water, before being dned under high vacuum to give the title compound as an off-whrte solid (HPLC tR 2 66 mm (Method A); M+H * 430 MS-ES, 1H-NMR (d6-DMSO 400 MHz) 8 92 (s. 1H), 8 08-8 01 (m, 1H), 7 95-7 88 (m, 1H)1 7 76 (s, 1H), 7 60-7 55 (m, 1H), 7 13-7 08 (m, 1H), 7 05-7 00 (m, 1H), 6 99-6 94 (m, 1H), 3 88-382 (m, 6H), 3 78 (s, 3H), 3 56 (s, 3H) 2 11 (s, 3H))
The following examples were synthesized in a similar manner as described for Example 1.1 using as replacement for intermediate J a different intermediate
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0002
Example 2.1 1-(2,4-Dimethyl-2H-pyrazol-3-yl)-8-(6-methoxy-pyπdin-3-yl)-3-methyl-1 ,3- dihydro-imidazo[4 5-c]quinolin-2-one
Figure imgf000106_0001
The title compound was synthesized in a simitar manner as described for Example 1.1 using 8-bromo-1-(2,4-dimethyl-2H-pyrazof-3-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one (Intermediate I, 40 mg, 0 106 mmol) and 2-methoxy-5-pyπdineboronic acid (Aldrich, Buchs, Switzerland, 20 mg, 0 131 mmol) to give the title compound as a white solid (HPLC t« 2 69 mm (Method A), M+H * 401 MS-ES, 1H-NMR (de~DMSO, 400 MHz) 9 03 (s, 1 H), 8 27-8 21 (m, 1H)1 8 16-8 09 (m, 1H) 7 96-7 89 (m, 1H), 7 84-7 77 (m, 1H) 7 65 (s 1H)1 7 00-6 88 (m, 2H), 3.88 (s, 3H)1 3 61 (s, 6H)1 1 82 (s, 3H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 2-methoxy-5-ρynd)neboronic acid and the specified intermediate
Figure imgf000107_0001
Figure imgf000108_0001
Example 3.1 1-<1.S-Dimethyl-1H-pyrazoU-yO-θ^β-ethoxy-pyr^in-S-yO-S-methyl-i ,3-dihydro- !m!dazo[4,5-c]quinolin-2-one
Figure imgf000109_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1 -(1 ,3-dimethyl-1 H-pyτazoi-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c}quino!in-2-one (Intermediate A, 60 mg, 0 161 mmol) and 6-ethoxypyπdine-3-boronic acid (ABCR1 Karlsruhe, Germany, 36 mg, 0.211 mmol) to give the title compound as a white solid. (HPLC tR 2.69 min (Method A); M+H = 415 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) Θ.96 (s, 1H)1 8 32-8.24 (m, 1H), 8.15-8.05 (m, 2H), 7.92-7.85 (m, 1 H), 7 79-7.72 (m. 1H), 7.47 (s, 1H), 6 94-6 87 (m, 1H), 4 32 (q, 2H), 3.90 (s, 3H), 3 57 (s, 3H), 1.95 (s, 3H), 1 32 (t, 3H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 6-ethoxypyπdine-3-boronic acid and the specified intermediate.
Example Intermed. structure Name of the example MS-ES HPLC tR
(M+H) (min)
3.2 D 8-(6-Ethoxy-pyridin- 469 3 31
— /r 3-yl)-3-methyl- fi t
1-(2-methyl-5- trifluoromethyl-2H- pyrazol-3-yl)-1 ,3- dihydro-imidazo(4.5
-c]quinolin-2-one
3.3 H
-N'N 8-(6-Ethoxy-pyridin- 429 2 73
3-yl)-3-methyl-
CL -4 1-(1 ,3,5-trimethyl-1H~
'H' pyrazol-4-yJ)
-1 ,3-dihydro- imidazo[4,5- c]quinolin-2-one
Figure imgf000109_0002
Figure imgf000110_0001
Figure imgf000111_0001
Example 4.1 8-(6-Dimethylamino-pyridin-3-yl)-1-(1-isopropyl-3-methyl-1H-pyra2θl-4-yt)-3- methyl-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one
Figure imgf000112_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-brorno-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-rnetriyl-1 ,3-dihydro-irnida2o[4,5- c]quinolin-2-one (Intermediate G1 50 mg, 0 125 mmol) and 2-(dimethylamino) pyridine-5- boronic acid hydrate (Flυorochem Ltd., Derbyshire, United Kingdom, 31 mg, 0 163 mmol) to give the title compound as a yellow solid. (HPLC: tR 2.31 min (Method A); M+H ~ 442 MS- ES1 1H-NMR (dβ-DMSO, 400 MHz) 8.90 (s, 1H), 8 27-8.18 (m, 2H), 8.07-7.99 (m, 1H), 7 90- 7.82 (m, 1H), 7.62-7.55 (m, 1H), 7 41 (s, 1H), 6 70-6 61(m, 1H), 4.62-4 49 (m, 1H), 3.56 (s, 3H), 3.04 (s, 6H), 1 96 (s, 3H), 1 49 (s, 6H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 2-(dimethylamino) pyridine-5-boronic acid hydrate and the specified intermediate
Figure imgf000112_0002
wυ zυn )i lay /Ji PCT/EP2010/057719
Figure imgf000113_0001
Figure imgf000114_0001
Example 5.1 8-(6-Azetidin-1-yl-pyπdin-3-yl)-1-(1 3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imtdazo[4,5-c]qυinolin-2-one
Figure imgf000115_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-y1)-3-methyl-1 ,3-dihydro-imidazo l4,5-clquinolin-2-one (Intermediate A, 40 mg, 0.107 mmol) and 2-azetidin-1-yl-5-(4,4,5,5-tetramet
hyt-|;i ,3,2]dioxaborolan-2-yl)-pyridine (Stage 5.1.1 , 39 mg, 0.150 mmol) to give the title compound as a white solid (HPLC tR 2.24 min (Method A); M+H = 426 MS-ES1 1H-NMR (d6- DMSO, 400 MHz) 8.91 (s, 1H), 8.25-8,18 (m, 1 H), 8.14-8.09 (m, 1H), 8.06-8,02 (m, 1 H), 7.89-7.81 (m, 1H), 7.62-7 53 (m, 1H), 7.42 (s, 1H), 6.48-6.42 (m. 1H), 4.01-3.93 (m, 4H), 3.91 (S, 3H), 3 56 (S, 3H), 2 36-2 28 (m, 2H), 1.96 (s, 3H))
Stage 5.1.1 2-Azetidin-1-yl~5-(4,4,5,5-tetramethyl-[1 ,3,2)dioxaborolan-2-yO-pyπdine
Figure imgf000115_0002
A mixture of 2-azetidin-1-yl-5-bromo-pyπdine (Stage 5.1.2, 55 mg, 0.259 mmol), bis(pinacolato)~diborane (74 mg, 0.285 mmol), potassium acetate (76 mg, 0.778 mmol) and PdCI2(dppf) (9 mg, 0.012 mmol) in dioxane (1.2 ml) was stirred in a closed vial flushed with argon at 90 °C for 2 h Then the RM was diluted with EtOAc and washed with brine (2x) The organic layer was dried over Na2SO4, filtered and evaporated to dryness to give the title compound as a crude brownish sticky solid. (HPLC: tR 1.79 min (Method A), M+H = 261 MS- ES)
Stage 5.1.2 2-Azetidin-1-yl-5-bromc~pyridine
Figure imgf000115_0003
A mixture of 5-bromo-2-chloropyndine (Sigma-Aldrich, Bυchs, Switzerland 196 mg, 1 018 mmol), azetidine (Sigma-Aldrich, Buchs, Switzerland 0 213 ml, 3 06 mmol) and pyridine (0 124 ml 1 528 mmol) in DMA (2 5 ml) was heated under microwave irradiation at 150 °C for 10 mm and 170 °C for 10 mm The reaction was not completed Again azetidine (0 106 ml) was added and the RM was heated under microwave irradiation at 170 °C for 1 h Then the RM was quenched with saturated aqueous NaHCCh (50 ml) and extracted with EtOAc (2x) The combined organic layers were washed with brine (2x), dried over Na2SO4, filtered and evaporated to dryness to give the title compound as an off-white solid (HPLC tR 1 97 mm (Method A), M+H ~ 213, 215 (Br-pattern) MS-ES 1H-NMR (de-DMSO, 400 MHz) 8 12 (s 1H), 7 70-7 60 (m 1H), 6 37-6 29 (m, 1H), 3 96-3 86 (m 4H), 2 34-2 24 (m, 2H))
The following example was synthesized in a similar manner as described for Example 1.1 using 2-azetidin-1-yl-5-(4,4,5 5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridine (Stage 5.1.1)
and the specified intermediate
Figure imgf000116_0002
Example 6.1 8-(2-Dimethylamino-pynmidin-5-yl)-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3- methyl-1 3-dihydro-imidazol4,5-c]qu<nolin"2-one
Figure imgf000116_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4, 5- cJquinolin-2-one (Intermediate G, 50 mg, 0 125 mmol) and 2-dimethylamino-pyrimidine-5- boronic acid pinacol ester (Frontier Scientific, Logan, USA, 38 mg, 0 153 mmol) to give the title compound as a white solid. (HPLC t* 2.68 min (Method A). M+H - 443 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.93 (s, 1H), 8.46 (s, 2H), 8.20 (s. 1 H), 8.09-8.02 (m, 1 H). 7.91-7 84 (m, 1H)1 7 38 (s, 1H)1 460-4.51 (m, 1 H), 3.56 (s. 3H), 3.13 (s, 6H), 1 97 (s, 3H), 1.49-1.44 (m, 6H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 2-dimethylamino-pynmidine-5-boronic acid pinacol ester and the specified intermediate
Figure imgf000117_0001
Figure imgf000118_0002
Example 7.1 1-(2,5-Dimethyl-2H-pyrazol-3-yl)-3-methyl-8-(6-methyl-pyr!din-3-yl)-1 (3-dihydro- imidazo[4,5-c)quinolin-2-one
Figure imgf000118_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(2l5-dimethyl-2H-pyrazol-3-yl)-3-methyl-1,3-dihydro-imidazo[
4,5-c]quinolin-2-one (Intermediate C, 50 mg, 0.135 mmol) and 2-methylpyridine-5-boronic acid (Frontier Scientific, Logan, USA, 28 mg, 0 181 mmol) to give the titte compound as a red solid (HPLC. t« 2 20 mm (Method A); M+H = 385 MS-ES; 1H-NMR (dε-DMSO, 400 MHz) 9.02 (s, 1H), 8 62-8.52 (m, 1 H), 8.17-8.08 (m 1 H)1 8.00-7 91 (m. 1 H) 7 81-7 73 (m, 1H), 7.39-7 32 (m, 1H), 7 13 (s, 1H), 6 52 (s, 1H), 3 62 (s, 3H), 3.51 (s, 3H), 2 55-2 45 (3H), 2.29 (s, 3H))
The following example was synthesized in a similar manner as described for Example 1.1 using 2-methylpyridine-5-boronic acid and the specified intermediate
Figure imgf000118_0003
Figure imgf000119_0003
Example 8.1 3-Methyl- 1 -(2-methyJ-2H-pyrazol»3-yl)-8-(6-trif luoromethyl-pyridin-3-yl)- 1 ,3- dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000119_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyl-1-(2-methyl-2H-pyrazol-3-y1)-1 ,3-dihydro-imidazo[4,5-cJquinolin-2-one (Intermediate E, 58 mg, 0 163 mmol) and 2-trifluoromethylpyridine-5-boronic acid (Frontier Scientific, Logan, USA, 40.5 mg. 0.212 mmol) to give the title compound as a red solid (HPLC- fe 2 87 mm (Method A)1 M+H = 425 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 9 08 (s, 1 H), 8.82 (d, 1H)1 8.27-8.16 (m, 2H), 8.10-7.98 (m, 2H), 7 82 (d, 1H) 7.18-7.16 (m, 1 H), 6 72 (s, 1H). 3.72 (8, 3H), 3 63 (s, 3H))
The following example was synthesized in a similar manner as described for Example 1.1 using 2-trif)uoromethylpyridine-5-boronic acid and the specified intermediate.
Figure imgf000119_0002
Figure imgf000120_0002
Example 9 1-(2,5-Dimethy(-2H-pyrazol-3-yl)-8'(2-fluoro-pyrκJin-3-yl)-3-methyl-1 ,3-d!hydro- imidazo[4 ,5-c]quinolin-2-one
Figure imgf000120_0001
The trtle compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(2,5-dimethyl-2H-pyrazol-3-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5-c)quinolin-2-one (Intermediate C, 50 mg, 0.135 mmol) and 2-fluoropyridine-3-boronic acid (Aldπch, Buchs, Switzerland, 25 mg, 0 179 mmol) to give the title compound as a red solid. (HPLC tR 2 57 min (Method A), M+H = 389 MS-ES. 1H-NMR (dβ-DMSO, 400 MHz) 9 07 (s, 1H), 8 27-8.22 (m, 1H), 8.18-8.13 (m, 1H), 8.06-7.99 (m, 1H), 7.89-7 83 (m, 1 H), 7.51-7.45 (m, 1 H), 7.24- 7 20 (m, 1 H), 6.45 (s, 1H). 3 60 (s, 3H), 3.55 (s, 3H), 2 24 (s, 3H))
Example 10,1 S-Methyl-δ-pyridin-S-yi-I^I .S.S-trimethyl-I H-pyrazol^-yO-I .S-dihydro- irnidazo[4,5-c)quinolin-2-one
Figure imgf000121_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyM-(1 ,3,5-trimethyM H-pyrazol-4-yl)-1 ,3~dihydro-imidazo[4,5-c]quinolin-2- one (Intermediate H, 39 mg, 0.100 mmol) and 3-pyridineboronic acid (Aldrich, Buchs, Switzerland, 15 mg, 0.122 mmol) to give the title compound as an off-white foam. (HPLC: tR 2.08 min (Method A); M+H = 385 MS-ES; 'H-NMR (de-DMSO, 400 MHz) 9,00 (s, 1 H), 8,70- 8.64 (m, 1H)1 8,60-8 55 (m, 1H), 8.16-8,10 (m, 1H), 7.99-7.92 (m, 1H), 7.90-7.84 (m, 1H), 7,54-7.47 (m, 2H), 3.82 (s, 3H), 3.60 (s, 3H), 2.09 (s, 3H), 1.92 (s, 3H))
The following example was synthesized in a similar manner as described for Example 1.1 using 3-pyrkiineboronic acid and the specified intermediate,
Figure imgf000121_0003
Example 11 8-(2-Fluoro-pyridin-4-yl)-3-methyl-1-(2-methyl-2H-pyrazol-3-yl)-1 ,3-dihydro- imidazo{4,5-c]quinolifv2-one
Figure imgf000121_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyl-1-(2-methyl-2H-pyra2θl-3-yl)-1 ,3-dihydro-imidazo{4,5-c]quinolin-2-one (Intermediate E, 65 mg. 0.181 mmol) and 2-fluoropyridine-4-boronlc acid (Frontier Scienttfic, Logan USA1 33 mg, 0.236 mmol) to give the title compound as a pink solid. (HPLC tR 2 55 min (Method A); M+H = 375 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 9 08 (s, 1H), 8 35-8.26 (m, 1H), 8 22-8 13 (m, 1H)1 8 10-8.01 (m, 1H)1 7.84-7.76 (m, 1H), 7.43-7 35 (m, 1 H), 7.29- 7.23 (m, 1 H), 7 23-7.16 (m. 1H), 6.73 (S1 1 H), 3.68 (S1 3H), 3.60 (S1 3H))
Example 12 1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-methoxy-pyridin-3-yl)-3-methyl-1 , 3- dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000122_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinoiin-2-one (Intermediate A, 40 mg, 0.105 mmol) and 3-methoxypyridine-5-boronic acid pinacol ester (Aldrich, Buchs, Switzerland, 30 mg, 0.125 mmol) to give the title compound as an off-white solid. (HPLC: tR 2.17 mm (Method A), M+H = 401 MS-ES. 1H-NMR (de-DMSO, 400 MHz) 8.98 (s, 1H), 8 39-8 26 (m, 2H), 8 21-8 07 (m, 2H), 8.04-7.96 (m, 1H) 7.66-7.56 (m, 1H)1 7.45-7.36 (m, 1H)1 3.91 (s, 6H), 3 60 (s, 3H), 1.97 (s, 3H))
Example 13 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-y))-8-(5-fluoro-6-methoxy-pyridin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo{4,5-c]quinolin-2-one
Figure imgf000122_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c)quinolin-2-one (intermediate A, 40 mg, 0.105 mmol) and 3-fluoro-2-methoxypyridine-5-boronic acid (Apollo Scientific Cheshire, United Kingdom, 21 rng, O 123 mmol) to give the title compound as a pink solid. (HPLC: tR 2 70 min (Method A); M+H « 419 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8.97 (S1 1H), 8 18-Θ.05 (m, 3H), 7 96-7 89 (m, 1 H), 7 81-7 74 (m, 1H), 7 49 (s, 1H), 3.99 (s, 3H), 3 92 (s, 3H), 3.59 (s, 3H), 1.98 (s 3H))
Example 14 5-[1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo{4,5- c]quinαlin-8-yl]-pyridine-2-carboxylic actd amide
Figure imgf000123_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 ,3-dimethyl* 1 H-pyrazol-4-y!)-3-methyl- 1 , 3-dihydro-imidazo (4,5-c]quincrtin-2-one (Intermediate A, 40 mg, 0.105 mmol) and 5-(4,4 5,5-tetramethyl-[1 ,3,2]dioxa
borolan-2-yl)-pyridine-2-carboxylic acid amide (Stage 14.1.1 , 106 mg, 0.427 mmol) to give the title compound as a lightly yellow solid (HPLC tR 2 28 min (Method A), M+H = 414 MS- ES, 1H-NMR (Cl6-DMSO, 400 MHz) 9.01 (s, 1 H)1 8.73-8.67 (m, 1H), 8.22-8.04 (m, 5H), 8.03- 7.98 (m, 1 H), 7 71-7.61 (m, 2H), 3 92 (s, 3H)1 3 59 (s, 3H), 1 97 (s, 3H))
Stage 14.1.1 5-(4,4,5,5-Tetramethy)-|;i ,3,2]dioxaborolan-2-yl)-pyridine-2-carboxylic acid amide
Figure imgf000123_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-pyπdine-2-carboxylic acid amide (Combi-Blocks, San Dtego, USA, 360 mg, 1.791 mmol) to give the title compound as a brownish sticky solid (HPLC: tR 2.27 mm (Method A), M+H * 249 MS-ES Example 15,1 5-[1-(1,3-Dimethy)-1H-pyraz^-4-yl)'3-methyl-2-oxo-2,3-dihydro-1H- imidazo(4,5-c]quinolin-8-yt]-pyridine-2-carboxylic ac!d methylamide
Figure imgf000124_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1.3-dihydro-imidazo [4,5-c]quinolin-2-one (Intermediate A, 40 mg, 0 105 mmo!) and 5-(4A5,5-tetramethyH1 ,3,2]dioxaborolan-2-yl)- pyridine-2-carboxylic acid methylamide (Stage 15.1.1, 42 mg, 0.160 mmol) to give the title compound as a lightly yellow solid (HPLC tR 2.39 min (Method A), M+H = 428 MS-ES, 1H- NMR (dβ-DMSO, 400 MHz) 9.01 (s, 1H). 8 87-8.80 (m, 1H), 8 71-8.67 (m, 1H), 8.18-8 07 (m 4H), 8 04-7 98 (m, 1 H), 7 65 (s, 1H)1 3.92 (s, 3H), 3 58 (s, 3H), 2 83 (s, 3H), 1.97 (s, 3H))
Stage 15.1.1 5-(4l4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine-2-carboxylic acid methylamide
Figure imgf000124_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-pyridine-2-carboxylic acid methylamide (Combi-Blocks, San Diego, USA, 240 mg, 1.116 mmol) to give the title compound as a brownish sticky solid (HPLC: IR 2.46 min (Method A). M+H - 263 MS-ES.
The following examples were synthesized in a similar manner as described for Example 1.1 using 5-(4,4,5v5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-pyndine-2-carboxylic acid methylamide and the speσfied intermediate
Figure imgf000124_0003
Figure imgf000125_0002
Example 16.1 1 -( 1 -Ethyl-3-methyl-1 H-pyrazol-4-yl)-8~(6~hydroxymethyl-pyr idin-3-yl)-3- methyl- 1 ,3-dihydro-imidazo(4 5-c]quinolin-2-one
Figure imgf000125_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-i^i-ethyl-S-methyl-1H-pyrazoM-yO-S-methyl-I .S-dihydro-imidazo^ δ-clquinolin^- one (Intermediate F, 80 mg, 0.207 mmol) and 6-(hydroxymethyl)pyridine-3-boronJc acid (Combi-Blocks, San Diego, USA, 39 mg, 0 254 mmol) to give the title compound as a white solid. (HPLC: tR 2.04 min (Method A); M+H ~ 415 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.98 (S1 1H), 8.61-8.56 (m, 1H), 8.21-8.17 (m, 1 H)1 8.15-8.09 (m, 1H)1 7.97-7.93 (m, 1H), 7.90-7.85 (m, 1H), 7.57-7.49 (m, 2H), 5.47 (t, 1H), 4.61-4.55 (m, 2H), 4.23-4.14 (m, 2H)1 3.57 (S1 3H)1 1.95 (s, 3H). 1.43 (t, 3H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 6-(hydroxymethyl)pyridine-3-boronic acid and the specified intermediate.
Figure imgf000126_0001
Figure imgf000127_0002
Example 17,1 1 -(1 -Ethyl-3-methyl- 1 H-pyrazol-4-yl)-8-(2-methoxy-pyrimidin-5-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinohn-2-one
Figure imgf000127_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-ethyl-3-methyl-1H-pyra2θt-4-yl)-3-methyl-1 ,3-d!hydro-imidazo[4,5-c]quinolin-2- one (Intermediate F, 49 mg, 0 126 mmol) and 2-methoxy-5-pynmidineboronic acid (A8CR, Karlsruhe, Germany, 25 mg, 0.162 mmol) to give the title compound as a white solid (HPLC t* 2 47 min (Method A), M+H ~ 416 MS-ES, 1H-NMR (d6~DMSO, 400 MHz) 8 98 (s, 1H), 8 76-8 68 (m, 2H), 8 23-8 16 (m, 1H), 8 16-8 09 (m, 1H), 7 99-7.93 (m, 1 H), 7 52-7.45 (m, 1 H), 4 19 (q, 2H), 3 96 (s, 3H), 3 59 (s, 3H), 1 97 (s, 3H), 1 42 (t, 3H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 2~methoxy-5-pyrimidineboronic acid and the specified intermediate
Figure imgf000127_0003
Figure imgf000128_0002
Example 18 1-(1 ,3-Dimethyl-1 H-pyrazo!-4-yl)-8-t6-(2-methoxy-ethoxy)-pyπdin-3-yl]-3-methyl- 1,3-dihydro-imidazo[4,5-c]qutnolin-2-one
Figure imgf000128_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dtmethyl-i H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c}quinolin-2-one (Intermediate A1 40 mg, 0 105 mmol) and 2-(2-methoxy-ethoxy)-5-(4A5,5-tet
ramerthy!-[1 )3,2]dioxaborolan-2-yl)-pyridine (Stage 18.1.1 38 mg, 0 137 mmol) to give the title compound as an off-white foam (HPLC' tR 2.58 mm (Method A)1 M+H - 445 MS-ES; 1H- NMR (dβ-DMSQ, 400 MHz) 8 96 (s, 1H), 8.32-8 25 (m, 1H)1 8 16-8 04 (m, 2H), 7 93-7 86 (m, 1H), 7.81-7 74 (m, 1H), 7 51-7 45 (m, 1H), 6 99-6.92 (m, 1H), 4 45-4 38 (m, 2H), 3.92 (s, 3H), 3 70-3 64 (m, 2H), 3 57 (s, 3H), 3 31 (s, 3H) 1 96 (s 3H))
Stage 18,1.1 2-(2-Methoxy-ethoxy)-5-(4 ,4, 5, 5-tetramethyl-[ 1 , 3, 2]dioxaborolan-2-yl)-pyridine
Figure imgf000129_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-2~(2-methoxy-ethoxy)-pyr»dine (Stage 18.1.2, 251 mg, 1.082 mmol) to give the title compound as a brownish oil (HPLC tR 1.88 min (Method A), M+H = 280 MS-ES)
Stage 18.1.2 5-Bromo-2-(2-methoxy-ethoxy)-ρyridine
Figure imgf000129_0002
A mixture of NaH 55% (133 mg, 3 06 mmol) in DME (3 ml) was cooled to 0 °C, then 2- methoxyethanol (Aldrich, Buchs, Switzerland, 0 362 ml, 4.58 mmol) was added. The solution was stirred at rt for 15 mm After that 5-bromo-2-chtoropyridine (Aldnch, Buchs, Switzerland, 294 mg, 1.528 mmol) was added and the RM was heated by microwaves at 150 °C for 10 mm Then the RM was quenched with saturated aqueous NaHCOj (50 ml) and extracted with EtOAc (2x) The combined organic layers were washed with brine (2x), dned over Na2SO4, filtered and evaporated. The residue was absorbed on silica gel and purified by MPLC (hexane/EtOAc 0 to 30%). The fractions containing product were evaporated together to give the title compound as a colorless oil (LC-MS tR 1 20 mm (Method B); M+H = 232, 234 (Br- pattern) MS-ES. 1H-NMR (de-DMSO, 400 MHz) 8.28.8 21 (m, 1H), 7 91-7 84 (m, 1H), 6 86- 6 79 (m, 1H), 4 31 (t, 2H), 3.62 (t, 2H) 3 26 (s, 3H))
Example 19 8-{6-(2-Benzy!oxy-ethoxy)-pyridin-3-yl]-1 -{1 ,3-dimethyl-1 H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imtdazo[4 5-c]quinolin-2-one
Figure imgf000130_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3'methyl-1 ,3-dihydro-imidazo{4,5-c]quinolin-2-one (Intermediate A1 50 mg, 0 132 mmol) and 2-(2-benzyloxy-ethoxy)-5-(4,4,5,5-tetramethyl- (1 ,3,2}dioxaborolan-2-y!)-pyridine (Stage 19.1.1, 65 mg, 0 184 mmol) to give the title compound as a white solid (HPLC. tR 3 12 mm (Method A), M+H = 521 MS-ES, 1H-NMR (d0- DMSO, 400 MHz) 8 95 (s, 1H), 8.33-8 24 (m, 1H), 8 16-8 05 (m, 2H), 7 93-7 86 (m, 1H), 7 81-7 75 (m, 1H), 7 51-7.45 <m, 1 H), 7 40-7 22 (m, 5H). 7 01-6 93 (m, 1 H), 4.55 (s, 2H), 4 47 (t, 2H), 3 92 (s, 3H)1 3 78 (t, 2H), 3.57 (s, 3H), 1 97 (s, 3H))
Stage 19.1.1 2-(2-Benzyloxy-ethoxy)-5-(4,4,5,5-tetramethyl-(1,3,2]dioxaborolan-2-yl)-pyridine
Figure imgf000130_0002
The title compound was synthesized in a similar manner as described for Stages 18.1.1 and 18.1.2 using 2-benzyloxyethanol (Aldπch, Buchs, Switzerland) to give the title compound as a brownish oil (HPLC tR 2 59 mm (Method A); M+H = 356 MS-ES)
Example 20 8-[6-(3-Benzyloxy-propoxy)-pyπdin-3-yl]~1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one
Figure imgf000131_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl-1 , 3-dihydro-imidazo {4,5-c]quinolin-2-one (Intermediate A, 50 mg, 0 132 mmol) and 2-(3-benzyloxy-propoxy)-5-(414,5,5-
tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-pyndine (Stage 20.1.1, 68 mg, 0.184 mmol) to give the title compound as an off-white solid (HPLC: tR 322 min (Method A); M+H = 535 MS-ES; 1H- NMR (dδ-DMSO, 400 MHz) 8.95 (s. 1H), 8.31-8.26 (m, 1H), 8.15-8.05 (m, 2H), 7 93-7 86 (m, 1H), 7.79-7.73 (m, 1H), 7.50-7.45 (m, 1 H), 7.35-7.22 (m, 5H), 6 93-6.87 (m, 1 H)1 4 55 (s, 2H), 4 36 (t, 2H)1 3.91 (s, 3H). 3 60-3 55 (m, 5H), 2.05-1.97 (m, 2H), 1 95 (s, 3H))
Stage 20.1.1 2-(3-Benzyloxy-propoxy)-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2~yl)- pyπdine
Figure imgf000131_0002
The title compound was synthesized in a simitar manner as described for Stages 18.1.1 and 18.1.2 using 3-benzyloxypropanol (Aldπch, Buchs, Swttzerland) to give the title compound as a brownish oil (HPLC: tR 2 66 min (Method A), M+H - 370 MS-ES) Exampie 21,1 8-[6"-(2--Hyclroxy-ethylamino)-pyridin-3-yl]-3-methyl-1-(2-methy!-2H-pyrazol-3- yl)-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000132_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyl-1-(2-methyl-2H-pyrazot-3-yl)-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one (Intermediate E1 65 mg, 0.181 mmol) and 2-(5-(4,4,5,5~tetramethyl-[1 ,3,2]di
oxaborotan-2-yl)-pyridin-2-y!amino]-ethanol (stage 21.1.1 82 mg, 0.218 mmol) to give the title compound as an off-white foam. (HPLC: t« 2.08 min (Method A): M+H = 416 MS-ES; 1H- NMR (de-DMSO, 400 MHz) 8.96 (β, 1H), 8.12-8.02 (m, 2H), 7.80-7.75 (m, 2H), 7.51-7.44 (m, 1H), 6.95-6.89 (m, 1H), 6.85-6.73 (br, 1H), 6.69 (s, 1 H), 6.60-6.53 (m, 1H), 3 66 (s, 3H), 3.58 (S, 3H), 3.54-3.49 (m, 2H), 3.37-3.31 (m, 2H))
Stage 21.1.1 2-[5-(4,4,5,5-Tetramethyl-[1 ,3,2Jdioxaborolan-2-yl)-pyridin-2-ylamino]-ethanol
Figure imgf000132_0002
The title compound was synthesized in a similar manner as described for Stages 5.1.1 using 2-(5-Bromo-pyridin-2-ylamino)-ethanol (stage 21.1.2) to give the title compound as a white solid trifiuoroacetate salt. (M+H « 379 MS-ES)
Stage 21.1.2 2-(5-Bromo-pyridin-2-ylamino)-ethanol
Figure imgf000133_0001
A mixture of 5-bromo-2-chloropyπdine (Aldnch, Buchs, Switzerland, 1 g, 5 2 mmol) and 2- hydroxyethylamme (1 59 g, 26 mrnol) in 3 ml DMA was heated by microwaves at 170 °C for 1 h Then the RM was quenched with saturated aqueous NaHCO3 (50 ml) and extracted with EtOAc The organic layers were washed with saturated aqueous NaHCO3 (4x), dried over Na?SO4, filtered and evaporated The residue was purified by flash chromatography (DCM/MeOH O to 5%) The fractions containing product were evaporated together to give the title compound as an off-white solid (HPLC tR 1 66 mm (Method A), M+H - 217, 219 (Br- pattern) MS-ES)
The following example was synthesized in a similar manner as described for Example 1.1 using 2-[5-(4 4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridin-2-ylamino]-ethanol and the specified intermediate
Figure imgf000133_0002
Example 22 1 -(1 3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-methanesulfonyl-pyπdin-3-y1)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one
Figure imgf000134_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyM H-pyrazol-4-y!)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinolin-2-one (Intermediate A, 40 mg, 0 105 mmol) and 5-(methylsulfonyi)pyridine-3-boronic acid (Combi- Blocks, San Diego, USA, 25 mg, 0.125 mmol) to give the title compound as a white solid. (HPLC .R 2.30 mm (Method A); M+H = 449 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 9 09- 9 01 (m, 3H)1 8.32-8.27 (m, 1H), 8.21-8.14 (m, 2H)1 8 11-8.06 (m, 1 H)1 7.67-7 62 (m, 1H)1 3 92 (S, 3H). 3 59 (s, 3H)1 3.40 (s, 3H). 1 94 (s, 3H))
Example 23.1 8-(6-Amino-pyπdin-3-yl)-1-(1 ,3-dimethyl-i H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imidazol4,5-c]quinolin-2-one
Figure imgf000134_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3~dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c}quinolin-2~one (Intermediate A1 40 mg, 0 105 mmol) and 2-aminopyπdine-5-boronic acid pinacol ester (Aldrich, Buchs, Switzerland, 26 mg, 0.125 mmol) to give the title compound as a white solid (HPLC' tR 2 02 mm (Method A), M+H - 386 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.90 (s. 1 H), 8 16-8 10 (m, 1 H)1 8 07-7 98 (m, 2H), 7.86-7.78 (m, 1H)1 7 54-7 46 (m, 1H). 7.42-7.36 (m, 1 H). 6.54-6.46 (tn, 1H), 6 20 (s, br, 2H), 3 91 (s, 3H), 3 56 (s. 3H)1 1.95 (s, 3H))
The following example was synthesized in a similar manner as described for Example 1.1 using 2-aminopyndine-5-boronic acid pinacol ester and the specified intermediate
Figure imgf000134_0003
Figure imgf000135_0003
Example 24 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(5-methyl-pyridin.3-yl)-1,3-dihydro- tmidazo(4,5-cJquinolin-2-one
Figure imgf000135_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1 -{1 ,3-dimethyl-i H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinolin-2~one (Intermediate A, 40 mg. 0.105 mmol) and 5-methylpyridine-3-boronic acid (Combi-Blocks, San Diego, USA, 17 mg, 0 123 mmol) to give the title compound as an off-white solid. (HPLC: tR 2 07 min (Method A); M+H = 385 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 98 (S1 1H), 8.54-8.48 (m. 1H), 8.45-8 39 (m, 1H), 8.19-8 08 (m, 2H), 7.99-7 92 (m, 1H), 7.71-7.66 (m, 1H), 7 58-7 53 (m, 1H), 3.92 (s, 3H), 3 59 (s, 3H), 2.37 (s, 3H), 1.95 ($, 3H))
Example 2S.1 8-(β-Amino-5-trifluoromethyl-pyπdin-3~yl)-1-{1 ,3-dimethyl-1 H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo{4,5-c]quinol!n-2-one
Figure imgf000135_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c)quinolm-2-one (Intermediate A, 40 mg, 0 105 mmol) and 2-amino-3-(tnfluoromethyl)pyndine-5-boronfc acid pinacol ester (stage 26.1.1, 37 mg, O 128 mmol) to give the title compound as a pinkish solid (HPLC. tR 2 40 mm (Method A), M+H = 454 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 93 (s 1H), 8 43-8 36 (m, 1H), 8 16-8 11 (m, 1 H), 8 09-8 02 (m. 1H), 7 97-7 90 (m, 1 H)1 7 76-7 70 (m, 1H), 7 45-7.39 (m, 1H), 6 76 (s, br, 2H), 3 88 (s. 3H), 3 56 (s, 3H), 1 95 (s, 3H))
Stage 25.1.1 5-(4,4,5 5-Tetramethyl-(1,3,2]dioxaborolan-2-yl)-3-tnfkioromethyl-pyndin-2- ylamine
Figure imgf000136_0001
The title compound was synthesized in a similar manner as descnbed for stage 5.1.1 using 5-bromo-3-trifluoromethyl-pyridln-2-ylamine (Stage 25.1.2 8 04 g, 31 7 mmol) to give the title compound as an off-white solid (HPLC tR 1 62 mm (Method A), M+H = 289 MS-ES)
Stage 25.1.2 5-Bromo-3-trifluoromethyl-pyridin-2-ytamine
Figure imgf000136_0002
To a solution of 3-trifluoromethy)-pyπdin-2-ylamine (Flυorochem Ltd , Derbyshire, United Kingdom 5 37 g, 32 8 mmol) in 100 ml of dry CH3CN under argon were added N- bromosuccinimide (645 g, 36 2 mmol) in 4 equal portions over a period of 1 h at 0-5°C The cooling bath was removed and stirring was continued for 3 h The solvent was evaporated under vacuum, then the residue was dissolved in EtOAc and washed with water and brine The organic layer was dned over Na∑SOή and evaporated to give the title compound as a orange oil. (M+H = 239, 241)
The following example was synthesized in a similar manner as described for Example 1.1 using 5-(4,4,5,5-tetramethyl~[1 ,3,2]dioxaborolan-2-yl)-3-tπfluoromethyl-pyridin-2-ylamine and the specified intermediate
Figure imgf000136_0003
Figure imgf000137_0001
Figure imgf000138_0003
Example 26 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-pyrimidin-5-yl-1 ,3-dihydro
-imidazo{4,5-c]qυinolin-2-one
Figure imgf000138_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo (4, 5-c)quinolin-2-one (Intermediate A, 40 mg, 0.105 mmol) and pyπmidine-5-boronic acid (Frontier Scientific, Logan, USA , 16 mg, 0 129 mmoi) to give the title compound as a white solid. (HPLC' tR
2 24 min (Method A); M+H = 372 MS-ES1 1H-NMR (dβ-DMSO, 400 MHz) 9.20 (s, 1 H), 9.02 (s, 1H), 8.93 (s, 2H), 8.20-8.12 (m, 2H), 8 06-7 99 (m, 1H), 7 62-7.56 (m, 1 H), 3 90 (s, 3H),
3 58 (s. 3H), 1 97 (s, 3H))
Example 27.1 8-(3 ,4-Diethoxy-phenyl)- 1 -( 1 -ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl-
1,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000138_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-i^i-ethyl-S-methyl-1H-pyrazoM-yO-S-methyl.i.S-dihydro-imidazo^^-clqutnolin^- one (Intermediate F, 49 mg, 0,126 mmol) and 2-(3,4-diethoxy-phenyl)-4,4,5,5-tetramethyl- (1 ,3,2]dioxaborolane (stage 27.1.1, 47 mg, 0.161 mmol) to give the title compound as an off- white solid (HPLC- tκ 3.02 min (Method A), M+H * 472 MS-ES; 1H-NMR (de~DMSO, 400 MHz) 8.97 (s, 1H), 8.18 (s, 1H), 8.08-8.02 (m, 1H), 7.95-7 84 (m, 1H)1 7.52-7.48 (m, 1H), 7.06-6.97 (m, 3H), 4.22-3.98 (m, 6H), 3.58 (s, 3H), 1.97 (s, 3H) 1.45-1 25 (m, 9H))
Stage 27.1.1 2-(3,4-Diethoxy-phenyl)-4,4,5l5-tetramethyl-i;i ,3,2]dioxaborolane
Figure imgf000139_0001
The title compound was synthesized in a simitar manner as described for Stage 5.1.1 using 4-Bromo-1 ,2-diethoxy-benzene (Stage 27.1.2, 500 mg, 2 04 mmol) to give the title compound as a colourless oil. (HPLC' tR 3.94 min (Method A)1 M+H = 293 MS-ES)
Stage 27.1.24-Bromo-1,2-diethoxy~benzene
Figure imgf000139_0002
A mixture of 4-bromocatechol (Aldrich, Buchs, Switzerland, 500 mg, 2 65 mmol), potassium carbonate (1.1 g, 7.94 mmol) and iodoethane (1.03 g, 6.61 mmol) in 10 ml DMF was stirred protected from the light for 17 h at it The reaction mixture was quenched with 50 ml saturated aqueous NaHCO3 and extracted with EtOAc (2x). The organic layers were washed with saturated aqueous NaHCO3 (4x) and bnne, dried over Na2SO4, filtered and evaporated The residue was purified by flash chromatography (petrol ether/diethyl ether 0% to 10%) to give the title compound as a colorless oil. (HPLC' tR 3 79 min (Method A)) The following example was synthesized in a similar manner as described for Example 1.1 using 2-(3,4-diethoxy-phenyl)-4A5,5-tetramethyl-(1 ,3,2]dioxaborolane and the specified intermediate
Figure imgf000140_0002
Exampte 28.1 8-(3-Ethoxy-4-methoxy-phenyl)-1 -{ 1 -ethyl-3-methyl- 1 H~pyrazo!-4-yl)-3-methyl- 1 ,3-dihydro-imidazo(4,5-c)quinolin-2-one
Figure imgf000140_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo»1-(1-ethyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c}quinolin-2- one (Intermediate F, 39 mg. 0 100 mmol) and 3-ethoxy-4-methoxyphenylboronic acid (Combi-Blocks, San Diego, USA, 25 5 mg, 0 130 mmol) to give the title compound as an off- white foam (HPLC: tR 2 86 mm (Method A), M+H = 458 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8.92 (S1 1 H), 8 16 (s, 1 H), 8.08-8.01 (m, 1H), 7 93-7 87 (m, 1H), 7 52-7 46 (m, 1 H), 7 06-6 96 (m, 3H), 4.20-4 03 (m. 4H)1 3 77 (s, 3H), 3 57 (s, 3H). 1 97 (s, 3H), 1 45-1.33 <m, 6H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 3-ethoxy-4-methoxyphenylborontc acid and the specified intermediate
Figure imgf000141_0002
Example 29.1 8-(4-Ethoxy-3-methoxy-phenyl)- 1 -( 1 -ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
v
Figure imgf000141_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-i^i-ethyl-S-methyl-1H-pyrazoM-yO-S-methyl-I .S-dihydro-imidazo^.S^cJquinolin^- one (Intermediate F, 39 mg, 0 100 mmol) and 2-(4~ethoxy-3-methoxy-phenyl)-4,4.5,5- tetramethyl-[1,3,2)dioxaborolane (Stage 29.1.1 , 34 mg, 0.123 mmol) to give the title compound as a white solid (HPLC t« 2 88 min (Method A), M+H = 458 MS-ES, 1H-NMR (d8- DMSO, 400 MHz) 8.92 (S1 1H), 8 16 (s, 1H)1 8 07-8 02 (m, 1H), 7.94-7 88 (m. 1 H), 7.51-7 47 (m, 1 H), 7 06-6 96 (m, 3H)1 4.20-4 12 (m, 2H). 4 06-3 98 (m, 2H), 3.85 (s, 3H), 3 57 (s, 3H), 1 97 (s, 3H), 1.42-1 29 (m, 6H))
Stage 29.1.1 2-(4-Ethoxy-3-methoxy-phenyl)-4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolane
Figure imgf000142_0001
To a mixture of 4-hydroxy-3-methoxyphenylboronic actd pinacol ester (Aldrich, Buchs, Switzerland, 200 mg, 0.800 mmol), triphenylphosphine (315 mg, 1.200 mmol) and ethanol (0 056 ml, 0 960 mmol) in THF (4ml) under Argon was added dropwise dnsopropyl azodicarboxylate (0.253 ml, 1.20 mmol). The RM was stirred at rt for 17.5 h Then the RM was diluted with EtOAc and the organic layer was washed with brine (2x), before being dried over Na2$O,i, filtered and evaporated The residue was absorbed on silica gel and purified by MPLC (hexane/EtOAc 0 to 30%) The fractions containing product were together evaporated to give the title compound as a white solid (HPLC. tR 3 58 min (Method A); M+H = 279 MS- ES)
The following examples were synthesized in a similar manner as described for Example 1,1 using 2-(4-ethoxy-3-methoxy-phenyt)-4,4,5l5-tetramethyl-[1,3,2]dioxaborolane and the specified intermediate.
Figure imgf000142_0002
Figure imgf000143_0002
Example 30.1 1 -(1 ,3-DimethyM H-pyrazol-4-yl)-8-[3-methoxy-4«(2«methoxy'ethoxy)-phenyl]- 3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin~2-one
^v
Figure imgf000143_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using θ-bromo-1-(1 ,3-dimethyl-1 H~pyrazol-4-y))-3-methyl-1 ,3-dihydro-imidazo t4,5-c]quinol)n-2-one (Intermediate A, 39 mg, 0.105 mmol) and 2-[3-methoxy~4-(2-methoxy-ethoxy)-phenylj- 4,4,5l5-tetramethy!-[1 ,3,2)dioxaboroiane (Stage 30.1.1, 39 mg, 0.126 mmol) to give the title compound as a white solid. (HPLC: t* 2 71 min (Method A); M+H = 474 MS-ES: 'H-NMR (dβ- DMSO, 400 MHz) 8.93 (s, 1 H), 8.15-8.02 (m, 2H), 7.97-7.89 (m, 1 H), 7.59-7.51 (m, 1H), 7.11-7.02 (m, 2H), 7.00-6.94 (m, 1H), 4.16-4.07 (m, 2H), 3.94-3.84 (m, 6H). 3.70-3.64 (m, 2H), 3.58 (S1 3H), 3.31 (s, 3H), 1.97 (S, 3H))
Stage 30.1.1 2-[3-Methoxy-4-(2-methoxy-ethoxy)~phenyl]-4,4,5,5-tetramethyl-
[1 ,3.2]dioxaborolane
Figure imgf000144_0001
The title compound was synthesized in a similar manner as described for stage 29.1.1 using 2-methoxyethancH (AkJrich, Buchs, Switzerland) to give the title compound as a colorless oil (HPLC t* 3 42 mm (Method A), M+H = 309 MS-ES)
The following example was synthesized in a similar manner as described for Example 1.1 using 2-[3-methoxy-4-(2'methoxy-ethoxy)-phenyl]-4,4,5,5-tetramethyl-[1 3,2]dioxaborolane and the specified intermediate
Figure imgf000144_0003
Example 31 8-(4-Hydroxy-3-methoxy-phenyl)-3-methyl-1-(1 ,3,5-rnmethyl-i H-pyrazol-4-yl)- 1 ,3-dihydrc~imidazo[4,5-c]quinolin-2-one
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-S-methyl-I ^I .S.S-trimethyl-1H-pyrazol^-yO-I .S-dihydro-imidazo^.S-cjquinolin^- one (Intermediate H, 39 mg, 0 100 mmol) and 4-hydroxy-3-methoxyphenylboronic acid pinacol ester (Aldrich, Buchs, Switzerland, 30 mg, 0 120 mmol) to give the title compound as a lightly yellow foam. (HPLC: tR 2.50 rnin (Method A); M+H ~ 430 MS-ES; 1H-NMR (dβ- DMSO, 400 MHz) 9.23 (s, 1 H), 8 93 (s, 1 H), 8 06-7.99 (m, 1H), 7 92-7 85 (m, 1H)1 7.51-7,46 (m, 1H), 7.03-6.96 (m. 1H), 6 94-6 89 (m, 1 H), 6 87-6 81 (m, 1 H), 3 85 (s, 3H), 3.79 (s, 3H), 3.58 (s, 3H), 2.08 (s, 3H), 1.94 (s, 3H))
Example 32,1 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(3-hydroxy-phenyl)-3-methyl-1 ,3-dihydro- imidazo(4 , 5-c}quinolin-2-one
Figure imgf000145_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinolin-2-one (Intermediate A, 39 mg, 0.105 mmol) and 3-hydroxyphenylboronic acid (Aldrich Buchs, Switzerland. 17 mg, 0.123 mmol) to give the title compound as a white solid. (HPLC tR 2 46 mm (Method A). M+H = 386 MS-ES, 1H-NMR (d8-DMSO, 400 MHz) 9.58 <s, 1H), 8 95 (S1 1H), 8 20-8 11 (m, 1 H), 8 10-8.01 (m, 1H), 7 88-7 77 (m 1H), 7.57-7 47 (m, 1H)1 7 31-7.20 (m, 1H), 6.93-6.83 (m, 2H), 6 82-6.73 (m, 1H), 3 95 (s, 3H), 3 58 (s, 3H), 1 95 (s, 3H))
The following example was synthesized in a similar manner as described for Example 1.1 using 3-hydroxyphenylboronic acid and the specified intermediate.
Figure imgf000145_0002
Figure imgf000146_0003
Example 33 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(3-fluoro-5-hydroxy-phenyl)-3-methyl-1,3- dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000146_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol~4-yl)-3-methyl-1 ,3-dihydro-imidazo {4,5-c]qumolin-2-one (Intermediate A, 40 mg, 0 107 mmol) and 3-fluoro-5-hydroxyphenylboronic acid (Combi- Blocks, San Diego, USA, 21 mg, 0.132 mmol) to give the title compound as a white solid (HPLC, tR 2.58 min (Method A); M+H = 404 MS-ES; 1H-NMR (dθ-DMSO, 400 MHz) 10 09 (s, 1 H)1 8 96 (S1 1H), 8 17 (s, 1H), 8 10-8.03 (m, 1H), 7 87-7 80 (m, 1H), 7.52-7.46 (m, 1H), 6 75- 6.64 (m, 2H). 6.63-6.52 (m, 1 H), 3.92 (s, 3H), 3.57 (s, 3H)1 1 94 (s, 3H))
Example 34 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(3-hydroxy-5-trifluoromethyl-phenyl)-3- methyl-1.3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000146_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinolin-2-one (Intermediate A, 40 mg, 0 107 mmol) and 3-hydroxy-5-{trifluoromethyl)phenylboronic acid (Combi-Blocks, San Diego, USA1 27 mg, 0.132 mmol) to give the title compound as a white solid. (HPLC. tR 2 83 min (Method A)1 M+H ~ 454 MS-ES, 1H-NMR <d6-DMSO, 400 MHz) 10.38 (S1 br, 1H), 8 98 (s, 1 H)1 8.18 (s, 1 H), 8 12-8.07 (m, 1 H)1 7 93-7 87 (m, 1H)1 7 58-7 53 (m, 1H), 7 21-7 16 (m, 1H), 7.13-7.09 (m, 1H). 7 07-7,03 (m, 1 H)1 3.89 (S1 3H). 3 58 (s, 3H). 1.93 (s, 3H))
Exam tale 35 8-(2,2-Diflυoro-benzo(1 ,3]dioxol-4-yl)-1-<1 ,3-dimethyl-1H-pyrazo)-4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000147_0001
The title compound was synthesized in a similar manner as described for Example 1,1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinolin-2-one (Intermediate A, 40 mg, 0 107 mmol) and 2,2-difluorobenzo[1 ,3]dioxole-4-boronic acid (Apollo. Cheshire, United Kingdom, 26 mg, 0.130 mmol) to give the title compound as a white soiid. (HPLC tR 2.95 mm (Method A); M+H * 450 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 9.01 (s, 1H), 8.18-8.13 (m, 1H)1 8.08 (s, 1 H)1 7 97-7 91 (m, 1 H)1 7 88-7 84 (m, 1H), 7 441-7 38 (m, 2H), 7 36-7 29 (m. 1H), 3.85 (s. 3H). 3 58 (s, 3H), 1 94 (s. 3H))
Example 36 1 -(1 ,3-Dimethyl-i H-pyrazol-4-yl)-3-methyl-8-(1 H-pyrrolo{2,3-b]pyridm-5-yl)-1 ,3- dihydro-imidazo(4,5-c)quinolin-2-one
Figure imgf000147_0002
The title compound was synthesized in a simitar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinolin-2-one (Intermediate A 39 mg, 0 105 mmol) and 7-azaindole-5-boronic acid pinacol ester (ABCR, Karlsruhe, Germany, 31 mg. 0 127 mmol) to give the title compound as a white solid. (HPLC1 tR 2.35 mm (Method A); M+H = 410 MS-ES; 1H-MMR (d6-DMSO, 400 MHz) 11 75 (s, br, 1H)1 8 95 (S, 1 H)1 8 38-8 28 (m, 1H), 8 22-8.15 (m, 1H), 8 13-8 03 (m, 2H), 8.01-7 95 (m, 1H), 7 59-7.51 (m, 2H), 6 55-6 47(m, 1H), 3 93 (s, 3H), 3.58 (s, 3H), 1 97 (s, 3H))
Example 37.1 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-phenyl-1 ,3-dihydro-imidazo[4,5- c]quinolin-2-one
Figure imgf000148_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using S-bromo-I^I .S-dimethyl-1H-pyrazoM-yO-S-methyl-I .S-dihydro-imidazo l4,5-cJquinolin-2-one (Intermediate A1 40 mg, 0 107 mmol) and phenylboronic acfd (Aldrich, Buchs, Switzerland, 16 5 mg. 0.135 mmol) to give the title compound as a white solid (HPLC. t* 2.70 mm (Method A), M+H = 370 MS-ES1 1H-NMR (d6-DMSO, 400 MHz) 8.95 (s, 1H), 8.16 (s, 1 H)1 8 11-8 06 (m, 1H). 7.93-7.88 (m, 1H), 7.56-7.53 (m, 1 H), 7 50-7 44 (m, 4H), 7.42-7.34 (m, 1 H)1 3 92 (s, 3H), 3 57 (s, 3H), 1.95 (s, 3H))
The following examples were synthesized in a similar manner as described for Example 1.1 using phenylboronic acid and the specified intermediate
Figure imgf000148_0002
Figure imgf000149_0002
Example 38 1-(1,3-Dimethy(-1 H-pyrazol-4-yl)-3-methyl-8-quinolin-3-yl-1 ,3-dihydfθ-
imidazo[4,5-c}quinolin-2-one
Figure imgf000149_0001
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyH ,3-dihydro-imidazo [4,5-c]quinolin-2-one (intermediate A, 39 mg, 0 105 mmol) and 3-qumoltneboronic acid (AIdrich, Buchs, Switzerland 22 mg, 0 127 mmol) to give the title compound as an off-white solfd (HPLC t«
2 40 mm (Method A), M+H « 421 MS-ES, 1H-NMR (dc-DMSO, 400 MHz) 9 03-8.96 (m 2H), 8 52 (S, 1 H), 8 21-7 99 (m, 5H), 7 83-7 76 (m, 1 H)1 7 75-7 71 (m, 1H), 7 71-7 65 (m, 1 H)
3 95 (s. 3H) 3 59 (s, 3H), 1 98 (s 3H)) Example 39 3-[1 -( 1 3-DimethyM H-pyrazol-4-yl)-3-methyl-2-oxo-2 , 3-dihydro- 1 H-imidazo{4 , 5- c]quinolin~8-yl]-N-methyl-benzenesulfonamide
Figure imgf000150_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazo!-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c]quinolin~2~one (Intermediate A, 40 mg, 0 107 mmol) and methyl-3-boronobenzenesulfonamide (Ccwnbi- Blocks, San Diego, USA, 28 mg, 0 128 mmol) to give the title compound as a white solid. (HPLC- IR 2 47 mm (Method A)1 M+H ~ 463 MS-ES1 1H-NMR (dβ~DMSO, 400 MHz) 9 00 (s, 1H), 8 18-8 11 (m 2H), 7 97-7 91 (m, 1H), 7 83-7 70 (m, 4H), 7.66-7 60 (m, 1H), 7 53-7.47 (m, 1H), 3.93 (s, 3H), 3.58 (s, 3H), 2.44 (s, 3H)1 1 95 (s, 3H))
Example 40 1-(1 3-DimethyM H-pyrazol-4-yl)-8-(3-methanesulfonyl~phenyl)'3-methyl
-1 ,3-dihydro-irnidazo[4,5-c]quinolin-2-one
Figure imgf000150_0002
The title compound was synthesized in a similar manner as descπbed for Example 1.1 using 8-bromo-1-(1 ,3-dimethy!-1 H-pyrazol~4~yl)-3-methyl-1 ,3-dihydro-imidazo [4,5-c)quinolin-2-one (Intermediate A, 40 mg, 0 107 mmol) and (3-methylsulfonylphenyl) boronic aαd (Combi- Blocks, San Diego, USA, 26 mg, 0 127 mmof) to give the title compound as a white solid (HPLC tR 2 45 mm (Method A), M+H = 448 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 9.00 (s, 1H), 8 19-8.1 1 (m, 2H), 8 02-7 97 (m, 1H). 7.95-7 86 (m, 3H), 7 80-7 74 (m, 1H), 7 64-7 60 (m, 1 H), 3 93 (s, 3H)1 3 59 (s, 3H), 3 33-3 30 (3H). 1 94 (s 3H)) Examote 41 4-(1 -( 1 , 3- Dimethyl- 1 H-pyrazol-4-y l)-3-methyl-2-oxo-2 , 3-dihydro-1 H-imidazo[4, 5- c]quinolin-8-yl]-benzamide
Figure imgf000151_0001
The title compound was synthesized in a similar manner as described for Example 1,1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5-c3quinolin-2-one (Intermediate A, 40 mg, 0.107 mmol) and (3-methylsulfonylpheflyl) boronic acid (Aldrich, Buchs, Switzerland, 21 mg, 0 130 mmol) to give the title compound as a white solid. (HPLC. tR 2.31 mm (Method A); M+H ~ 413 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8.98 (s, 1 H)1 8.19-8.15 (m, 1 H), 8 14-8.08 (m, 1 H), 8.07-8.01 (m, 1H)1 7.99-7.93 (m, 3H), 7 61-7 52 (m, 3H), 7.47-7.39 (m, 1H), 3.94 (s, 3H), 3 58 (s, 3H), 1.95 (s, 3H))
Example 42 8-(6-Cyclopropytmethoxy-pyridin-3-yl)'1 -(1 ,3-dimethyM H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinoNn-2-one
Figure imgf000151_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro^midazo(4,5-c]quinolin-2-one (Intermediate A, 40 mg, 0.107 mmol) and 6-(cyclopropy1methoxy)pyridine-3-boronic acid pinacol ester (ABCR, Karlsruhe, Germany, 36 mg, 0 131 mmol) to give the title compound as a white solid (HPLC. IR 2.88 mm (Method A), M+H - 441 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 95 (s, 1H), 8 29-8.23 (m, 1 H), 8 16-8 04 <m, 2H), 7.92-7 85 (m, 1H). 7 80-7 72 (m, 1 H), 7.49-7 43 (m, 1 H), 6 98-6 90 (m, 1 H), 4 15-4 09 (m. 2H)1 3 90 (s, 3H) 3 57 (s, 3H), 1.94 (S, 3H), 1.31-1 17 (m, 1 H), 0 62-0 48 (m. 2H)1 040-0.30 (m. 2H)) Example 43.1 4-[1-(1 ,3-DimethyMHφyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo[4,5-c)quinolin-8-yl]-N-methyl-benzam»de
Figure imgf000152_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2~one (Intermediate A, 48 mg, 0.129 mmoi) and 4-(N-methylaminocarbonyl) phenylboronic acid (ABCR1 Karlsruhe, Germany, 27 mg, 0 153 mmot) to give the title compound as a white solid. (HPLC tR 2 40 min (Method A); M+H = 427 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 97 (s, 1H), 8 54-8.48 (m. 1H), 8 19-8.15 (m, 1H)1 8 13-8.07 (m, 1H)1 7 98-7.89 (m, 3H)1 7 61-7 53 (m, 3H), 3.94 (s, 3H), 3,57 (s, 3H), 2 79 (d, 3H)1 1 95 (S1 3H))
The following example was synthesized in a similar manner as described for Example 1.1 using 4-(N-methylaminocarbortyl) phenylboronic acid and the specified intermediate.
Figure imgf000152_0002
Example 44 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-[3-(pyrrolidine-1-sulfonyl)-phenyl]- 1 ,3-dihydro-imidazo[4,5-cJquinolin-2-one
Figure imgf000153_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using SΦromo-I^I .S-dfmethyl-1H-pyrazoM-yO-S-methyl-I .S-dihydro-imidaz^.δ-cJquinoiin^-one (Intermediate A, 40 mg, 0.106 mmol) and 3-(pyrrolidinylsulfonyl) phenylborαnic acid (Combi- Blocks, San Diego, USA, 33 mg, 0.129 mmol) to give the title compound as a white solid (HPLC. tn 2.78 mm (Method A); M+H ~ 503 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 9 00 (s, 1 H), 8.16-8.11 (m, 2H)1 8.02-7 96 (m, 1 H), 7 94-7 89 (m, 1H), 7 83-7.78 (m, 1 H)1 7 77-7.71 (m. 2H), 7 69-7,65 (m, 1H), 3.92 (s, 3H), 3 58 (s, 3H), 3.21-3.14 (m, 4H), 1 95 (s, 3H), 1 70- 1 63 (m, 4H))
Example 45.1 8-(5-Amino-pyndin-3-yl)-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 3- dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000153_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A, 40 mg, 0 106 mmol) and 3-aminopyridine-5-boronic acid pinacol ester (Apollo Scientific, Cheshire, United Kingdom, 29 mg, 0.132 mmol) to give the title compound as a white solid (HPLC: tR 1.99 min (Method A); M+H ~ 386 MS-ES1 'H-NMR (CJ6-DMSO, 400 MHz) 8 97 (s, 1 H), 8 16-8 05 (m, 2H). 7 94-7 89 (m, 1 H), 7 81-7 74 (m, 2H), 7 54-7 48 (m 1 H), 7 04-6 98 (m, 1 H), 545 (s, br, 2H), 3 91 (s, 3H), 3 57 (s, 3H), 1 95 (s, 3H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 3-aminopyrid)ne-5-boronic acid pinacol ester and the specified intermediate
Figure imgf000153_0003
Figure imgf000154_0002
Example 46 3-{1-{1 ,3-CHmethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo{4,5- c]quinolin-8-yl]-benzamide
NH
Figure imgf000154_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 3-cfihydro-imidazo(4,5-c)quinolin-2-one (Intermediate A, 40 mg 0 106 mmol) and benzamide-3-boronic acid (ABCR, Karlsruhe, Germany, 21 mg, 0 129 mmol) to give the title compound as a white solid (HPLC tR 2 34 mm (Method A), M+H = 413 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8 98 (s, 1H), 8 19-8 16 (m, 1H) 8 14-8 10 (m, 1H), 8 09-8 04 (m, 1H), 8 02-7 95 (m, 2H), 7 89-7 83 (m 1H) 7 65- 7 59 (m 2H), 7 58-7 47 (m 2H), 3 94 (s, 3H), 3 58 (S1 3H), 1 93 (s, 3H))
Example 47 N-{3-[1-(1 ,3>Dimethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imic(azo [4,5-c]quinolin-8-yl)-phenyl}-methanesu!fonamκie
Figure imgf000155_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using θ-bromo-1-CI .S-dimethyl-1H-pyrazoM-yO-S-methyl-I .S-dihydro-imidazo^.δ-clquinolin^-one (Intermediate A, 40 mg, 0 106 mmo)) and 3~(Methanesulfonylamirto)phenylboronic acid (ABCR, Karlsruhe, Germany, 28 mg, 0.126 mmol) to give the title compound as a white solid. (HPLC. fe 2.46 min (Method A), M+H = 463 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 9.88 (β. 1 H), 8.97 (s. 1 H)1 8.12-8.10 (m, 2H), 7.82-7.79 (m, 1H). 7.56-7.54 (m, 1H), 7.45-7.41 (m, 1H), 7.36-7.34 (m, 1H), 7.21-7 16 (m, 2H), 3.90 (s, 3H), 3 58 (s 3H)1 3.03 (s, 3H), 1.96 (s, 3H))
Example 48 4-(1-(1 ,3-Dtmethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-knidazo[4,5- c]quinolin-8~yl]-N,N-dimethyl-benzamide
Figure imgf000155_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl-1.3-dihydro-imidazo(4, 5-c]quinolin-2-one (Intermediate A, 40 mg, 0.106 mmol) and 4-(N,N-dimethylaminocarbonyl)phenylboronic acid (Combi-Blocks, San Diego, USA, 25 mg, 0.126 mmol) to give the title compound as a white solid (HPLC: tR 2.51 min (Method A)1 M+H = 441 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8 97 (s, 1H), 8.17 (s, 1H), 8 12-8.10 (m, 1 H), 7 96-7 93 (m, 1 H), 7 59-7 58 (m, 1H)1 7 55-7.50 (m, 4H), 3.93 (s, 3H), 3,58 (s, 3H), 2 99 (s, 3H), 2.94 (s, 3H), 1 95 (s, 3H))
Example 49 1 -(1.3-Dimethyl-1 H-pyrazol-4-yl)-3~methyl-8-{2~oxo-2,3-dihydro-1 H-indol-5-yl)- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000156_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one (Intermediate A, 40 mg 0.106 mmol) and 5~(4,4,5,5-tetramethy)-[1 (3,2]dioxaborolan-2-yl)- 1 ,3-dihydro-indol-2-one (Combi-Blocks, San Oiego, USA, 35 mg, 0 128 mmol) to give the title compound as an off-white solid (HPLC: fe 2.40 mm (Method A); M+H = 425 MS-ES, 1H-NMR (ds-DMSO, 400 MHz) 10.52 (s, 1H), 8.92 (s, 1 H), 8.17 (s, 1H)1 8.05-8.03 (m, 1H), 7.86-7 83 (m. 1H), 7 46 (s, 1 H), 7.33-7.29 (m, 2H), 6 90-6.88 (m, 1 H), 3.94 (s, 3H), 3 57 (s. 3H), 3 54 (S, 2H), 1.93 (s, 3H))
Example 50 I^I .S-Dimethyl-1H-pyrazoM-yO-S-methyl-δ^i-methyl^^-dihydro-1H-indol-δ- yl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000156_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A, 40 mg, 0 106 mmol) and i-methylindoline-5-boronic acid pinacol ester (Maybridge, Basel, Switzerland, 34 mg, 0.127 mmol) to give the title compound as a yellow solid. (HPLC tR 2.52 mm (Method A), M+H = 425 MS-ES; 1H-NMR (dθ-OMSO, 400 MHz) 8 87 (S1 1H), 8.16 (s, 1 H), 8 00-7.97 (m, 1H), 7 83-7.81 (m, 1 H), 7.41-7 40 (m. 1H), 7.20- 7 17 (m, 1 H), 7 14-7.13 (m 1H), 6.57-6.55 (m, 1 H), 3 94 (β. 3H), 3 56 (s. 3H), 3 33-3.29 (m, 2H), 2 92 (t, 2H), 2.73 (S1 3H), 1.94 (s, 3H))
Example 51,1 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-3-methyl-8-(4-pyrazol-1-yl-phenyl)-1 ,3- dihydro-imidazo|4,5-c]quinolin-2-one
Figure imgf000157_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methy)-1 ,3-dihydro-imidazo[4,5-c]qυinolin-2-one (Intermediate A, 40 mg, 0.106 mmol) and 4-(1H-pyrazol-1-yl)phenylboronic acid (Combi- Blocks, San Diego, USA. 24 mg, 0.126 mmol) to give the title compound as a white solid. (HPLC. tR 2 79 min (Method A); M+H « 436 MS-£S, 1H-NMR (d6-DMSO, 400 MHz) 8 96 (s, 1H), 8 60-8.56 (m, 1 H)1 8.19-8.15 (m, 1H)1 8 13-8 07 (m, 1H), 7.99-7.93 (m, 3H), 7.80-7.75 (m, 1H), 7 63-7 56 (m, 3H), 6 59-6 53 (m, 1 H), 3 95 (s. 3H), 3 57 (s, 3H), 1.97 (s, 3H))
The following examples were synthesized in a similar manner as described for Example 1.1 using 4-(1 H-pyrazoM-yl)phenylboronic acid and the specified intermediate.
Figure imgf000157_0002
Figure imgf000158_0002
Examote 52 1 -(1 ,3-Dimethyl-1 Hi3yrazol-4-yl)-8-{2-ethoxy-pyrimidin-5-yl)-3-methyl- 1 ,3- dihydro-tmidazo(4,5-c]quiπolin-2-one
Figure imgf000158_0001
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo-1-(1 (3-dimethyl-1 H-pyrazol-4-yt)-3-methyl-1 ,3-dihydro-imtdazo[4,5-c]quinolin-2-one (intermediate A 40 mg, 0 106 mmol) and 2-ethoxypyrimidine-5-boronic acid (Synthonix, Wake Forest, USA, 22 mg, 0 130 mmol) to give the title compound as a white solid (HPLC tR 2 51 mm (Method A), M+H ~ 416 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 98 (s, 1 H)1 8 73-8 67 (m, 2H), 8 16-8 09 (m, 2H), 7 98-7 91 (m, 1H), 7 51-7 46 (m, 1H), 4 39 (q, 2H)1 3 89 (s, 3H) 3.57 (s, 3H)1 1 96 (s, 3H), 1 35 (t, 3H))
Example S3.1 3-(1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo{4,5-c]quinolin-8-yl]-N,N-dimethyl-benzenesulfonamide
Figure imgf000159_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-I^I .S-dimethyl-1H-pyrazoM-yl^S-methyl-I .S-dihydro-imidazoμ.S-cJquinolin^-one (Intermediate A1 40 mg, 0 106 mmol) and 3-(N,N-dimethyfsulfonamide)phenylboronic acid (Combi'Blocks, San Diego, USA1 20 mg, 0 128 mmol) to give the title compound as a white solid (HPLC U 2 66 mm (Method A)1 M+H = 477 MS-ES1 1H-NMR (dδ-DMSO, 400 MHz) 8 97 (s 1H), 8 17-8 09 (m, 2H), 8 01-7 90 (m, 2H), 7 80-7 72 (m, 2H), 7 71 -7 64 (m, 2H), 3 91 (S, 3H), 3 58 (s, 3H)1 2 66 (s, 6H)1 1 96 (s 3H))
The following example was synthesized in a similar manner as described for Example 1.1 using 3-(N,N-dimethylsulfonamide)phenylboronic acid and the specified intermediate
Figure imgf000159_0002
Example 54.1 1-(1,3'Dimethyl-1H-pyrazol-4-yl)-β-(5-methoxymethyl-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000160_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yJ)-3-methyl-1,3-dihydro-imidazo[4,5-c]quino)in-2-one (Intermediate A, 40 mg, 0 107 mmol) and 5-(methoxymethyl)pyridine-3-boronic acid pinacol ester (PepTeck, Burlington, USA, 32 mg, 0 128 mmol) to give the title compound as a white solid (HPLC tR 2 08 mm (Method A) M+H - 415 MS-ES, 1H-NMR (d«-DMSO, 400 MHz) 9 01 (s, 1H), 8 70-8 67 (m, 1H), 8 56-8 54 (m, 1 H), 8 19-8 13 (m, 2H)1 8 02-7 98 (m, 1H), 7 82-7 80 (m, 1H), 7 62-7 59 (m, 1 H), 4 53 (s. 2H), 3 94 (s, 3H)1 3 60 (β, 3H), 3 37 (s, 3H), 1 97 (S, 3H))
The following example was synthesized in a similar manner as described for Example 1.1 using 5-(methoxymethyl)pyridine-3-boronic acid pinaco) ester and the specified intermediate
Figure imgf000160_0002
Ejκ,armtt)lem5g 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-propoxy-pyπdin-3-yl)-1 ,3- dihydro-imidazo(4 5-c]quinolin-2-one
Figure imgf000161_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using β-bromo-I^I .S-dimethyl-1H-pyrazαl^-yO-S-methyl-I .S-dihydro-imidazoH.S-clquinolin^-one (Intermediate A) and 2-propoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridine (stage 55.1.1) to give the title compound as a white solid. (HPLC: fo 2.87 min (Method A); M+H = 429 MS-ES; 1H-NMR (U6-DMSO, 400 MHz) 8.95 (s, 1H), 8.28 (s, 1H), 8.15-8.11 (m, 1H)1 8.11-8.05 (m, 1H), 7.92-7.86 (m, 1 H), 7.79-7.73 (m. 1H), 7.50-7.45 (m, 1H), 6.95-6.89 (m, 1H), 4,24 (t, 2H), 3.91 (s, 3H), 3 57 (s, 3H), 1.95 (s. 3H), 1.78-1.68 (m, 2H), 0.98 (t, 3H))
Stage 55.1.1 2-Propoxy-5-(4 ,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridine
Figure imgf000161_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-2-propoxypyridine (Combi-Btocks, San Diego, USA) to give the title compound as a brown oil. (HPLC: tR 2,00 min (Method A); M+H = 264 MS-ES).
Exajmjie^gsl 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(5-ethoxy-pyridin-3-yl)-3-methyl-1 ,3- dihydro-imidazo[4,5-c]c|uino!in-2-one
Figure imgf000161_0003
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-i H-pyrazol-4-yl)-3-methy!-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one (Intermediate A) and 3-ethoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxabordan-2-yl)-pyridine (stage 56.1.1) to give the title compound as a white solid. (HPLC. tj* 2 28 mm (Method A); M+H = 415 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8 98 (s, 1H), 8 34-8 24 (m, 2H) 8 16- 8 08 (m, 2H), 8.02-7.96 (m, 1H), 7 61-7.57 (m, 1H), 7 40-7 34 (m, 1H), 4 17 (q, 2H), 3.89 (s, 3H)1 3 57 (s, 3H), 1 96 (s, 3H), 1.40 (t. 3H))
Stage 56.1.1 3-Ethoxy-5-(4,4l5,5-tetramethyl-(1,3,2]d)Oxaborolan-2-yl)-pyridine
Figure imgf000162_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 3-bromo-5-ethoxypyridine (SynChem, Des Plaines, USA) to give the title compound as a brown oil (HPLC. tR 2.45 min (Method A), M+H * 250 MS-ES).
The following examples were synthesized in a similar manner as described for Example 1.1 using 3-ethoxy~5-(4,4,5,5-tetramethyl-(1 ,3,2)dioxaborolan-2-yl)-pyπdine and the specified intermediate
Figure imgf000162_0002
Figure imgf000163_0002
Example 57 i-CI.S-Dimethyl-1H-pyrazof^-yl^S^S-ethoxy-phenyO-S-methyl-I .S-dihydro- imidazo[4 5-c]quinolin-2-one
Figure imgf000163_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A 40 mg, 0 107 mmol) and 3-ethoxyphenylboronic acid (Aldrich, Buchs, Switzerland. 21 4 mg, 0 129 mmol) to give the title compound as a white solid (HPLC tR 2 84 mm (Method A) M+H = 414 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8 96 (s, 1H), 8 16 (s, 1H), 8.09-8 06 (m, 1H), 7 94-7 91 (m, 1H), 7 57-7 59 (m, 1H), 7 39-7 35 (m, 1H), 7.12- 6.92 (m, 3H), 4 09 (q, 2H), 3 92 (S1 3H)1 3 58 (s, 3H), 1 96 (S1 3H), 1 37 (t, 3H))
Example 58.1 1 -M .3-Dimethvl- 1 H-Dvrazol-4-vh-8-(5-isoproDθxγ-Dvridin-3- vh-3-methvl- 1 3- dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000164_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-I^I .S-dimethyl-1H-pyrazol^-yO-S-rriethyl-I .S-dihydro-imidazoH.δ-cJquinolin^-one (Intermediate A) and 3-isopropoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-pyncl<ne (Stage 58.1.1) to give the title compound as a white solid (HPLC tR 2 30 min (Method A), M+H = 429 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8.99 (s, 1H) 8 33-8 28 (m, 1H), 8.28- 8 23 (m, 1H), 8.16-8 08 (m 2H), 8 02-7.96 (m. 1H), 7 61-7.55 (m, 1 H), 7.38-7.33 (m, 1H)1 4 84-4 73 (m, 1H), 3 89 (s, 3H)1 3 58 (s, 3H)1 1 96 (s, 3H), 1 33 (d, 6H))
Stage 58.1,1 3-lsopropoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridine
Figure imgf000164_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 3-bromo-5-isopropoxypyridine (Stage 58.1.2) to give the title compound as a brown sticky solid (HPLC tR 2 12 mm (Method A), M+H - 264 MS-ES)
Stage 58.1.2 3-Bromo-5-isopropoxypyπdine
Figure imgf000164_0003
The title compound was synthesized in a similar manner as described for Stage 29.1.1 using 3-bromo-5-hydroxypyridine (Aldrich, Buchs, Switzerland) and isopropanol (Merck Dietikon. Switzerland) to give the title compound as a colorless oil (HPLC: tR 2 92 min (Method A); M+H = 216, 218 MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using 3-isopropoxy-5-(4,4t5,5-tetramethy)-[1 ,3,2|dioxaboro!an-2-yl)-pyridine (Stage 58,1.1) and the specified intermediate.
Figure imgf000165_0001
Example 59.1 1 -( 1 , 3-Dimethyl- 1 H~pyrazol-4-yl)-8-[5-(2-methoxy-ethoxy)-pyrtdin~3-y)]-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinoiin-2-one
Figure imgf000166_0001
The title compound was synthesized tn a similar manner as described for Example 1.1 using 8-bromo-1 -(1 ,3-dimethyM H-pyrazol«4-yl)-3~methyl-1 ,3-dihydro-imidazo[4,5-c3quinolin-2-one (Intermediate A) and 3-(2-methoxy-ethoxy)-5-(4,4,5,5-tetramethyl-[1 ,3,2]d)θxaborolan-2-yl)- pyπdine (Stage 59.1.1) to give the title compound as a white solid (HPLC fo 2 17 mm (Method A); M+H - 445 MS-ES, 1H-NMR (ds-DMSO, 400 MHz) 8.99 (s, 1H), 8.35-8.27 (m, 2H), 8.18-8.08 (m, 2H), 8.04-7.97 (m, 1H), 7.61-7.56 (m, 1H), 7 44-7.38 (m, 1H)1 4 25 (t, 2H), 3.89 (s, 3H)1 3 71 (t, 2H), 3.57 (s, 3H), 3.31 (S1 3H)1 1.96 (s, 3H))
Stage 59.1.1 3-(2-Methoxy-ethoxy)-5-(4,4,5,5-tetramethyl-[1 ,3,2)dioxaborolan-2-yl)-pyridine
Figure imgf000166_0003
The title compound was synthesized in a similar manner as descnbed for Stage 5.1.1 using 3-bromo-5-(2-methoxy-ethoxy)-pyπdine (Stage 59.1.2) to give the title compound as a brown oil. (HPLC- tR 2 10 min (Method A)).
Stage 59.1.2 3-Bromo-5-(2-methoxy-ethoxy)-pyridine
Figure imgf000166_0002
A mixture of 3-bromo-5-hydroxypyridine (Atørich, Buchs, Switzerland, 611 mg, 3.51 mmol), potassium carbonate (971 mg, 7.02 mmol) and 2-bromoethyl methyl ether (537 mg, 3.86 mmol) in 30 ml DMF was stirred for 14 h at rt and for 2 h at 80°C The reaction mixture was quenched with water and extracted with EtOAc (2x). The organic layers were washed with brine (3x), dried over Na2SO4, filtered and evaporated. The residue was purified by flash chromatography (dichloromethane/MeOH 0% to 3%) to give the title compound as an oil (HPLC- tκ 2.38 min (Method A), M+H = 232, 234 MS-ES) The following example was synthesized in a similar manner as described for Example 1.1 using 3-(2-methoxy-ethoxy)-S-{4 ,4,5,5-tetramethyHI ,3,2Jdioxaborolan-2-yl)-pyridine (Stage 59.1.1) and the specified intermediate
Figure imgf000167_0002
Example 60.1 8-(5-Cyclobutoxy-pyndin-3-yl)-1 -(1 ,3-dimeihyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imida2θ[4,5-c]quinolin-2-one
Figure imgf000167_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using θ-bromo-1-ii .S-dimethyl-1H-pyrazoM-yO-S-methyl-I .S-dihydro-imidazoH.δ-clqutnolin^-one (Intermediate A) and 3-cyclobutoxy-5-(4,4)5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)-pyridine (Stage 60.1.1) to give the title compound as a white solid (HPLC: tR 2.43 min (Method A); M+H - 441 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 9 00 (S1 1H)1 8.32-8.30 (m, 1H)1 8.24- 8 20 (m, 1 H), 8 15 (s, 1H). 8 14-8.10 (m. 1 H). 8 00-7.95 (m, 1H), 7.58-7 56 (m, 1H)1 7.26- 7 24 (ID1 1 H), 4.84 (qt, 1H), 3.91 (s, 3H)1 3.58 (s, 3H), 2 53-2 45 (m, 2H), 2.15-2.00 (m, 2H), 1 96 (S1 3H), 1.88-1 66 (m, 2H))
Stage 60.1.1 3-Cyclobutoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2)dioxaborolan-2-yi)-pyπdine o
Figure imgf000168_0001
The title compound was synthesized in a similar manner as described for Stage 58.1.1-2 using cyclobυtanol (Aldπch, Buchs, Swttzerland) to give the title compound as a brown oil (HPLC- 1« 2 25 mm (Method A). M+H = 276 MS-ES),
The following example was synthesized in a similar manner as described for Example 1.1 using 3-cyclobutoxy-5-(4,4,5,5-tetramethyl-[1,3l2]dioxaborolan-2-yl)-pyπdine (Stage 60.1.1) and the specified intermediate
Figure imgf000168_0003
Example 61 8-(5-Cyclopropylmethoxy-py ridin-3-yl)-1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-y l)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinohn-2-one
Figure imgf000168_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 l3-dihydro-imidazo(4 5-c]qumolin«2-one (Intermediate A) and 3-cydobutoxy-5-(4A5,5-tetramethyl-[1,3l2]dioxaborolan-2~yl)i>yrk.ine (Stage $0.1.1) to give the title compound as a white solid. (HPLC: t« 2.39 min (Method A), M+H ~ 441 MS-ES; 1H-NMR (αVDMSO, 400 MHz) 8.99-8 98 (m, 1 H), 8.32-8.27 (m, 2H), 8 15 (st 1H), 8.13-8 09 (m, 1H), 8.02-7 97 (m, 1H), 7.59-7 57 (m, 1H), 7 37-7 35 (m, 1H), 4.02-3.92 (m, 2H), 3.90 (s, 3H), 3 58 (s, 3H), 1.96 (s, 3H), 1 32-1 23 (m, 1H). 0 65-0 59 (m, 2H), 0 41-0 36 (m, 2H))
Stage 61.1.1 3-Cyclopropylmethoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- pyπdine
Figure imgf000169_0001
The title compound was synthesized in a similar manner as described for Stage 58.1.1-2 using cyclopropylmethanol (Aldrich, Bυchs, Switzerland) to give the title compound as a brown oil. (HPLC: tR 2 25 min (Method A) M+H = 276 MS-ES)
Example 62 N-{5-[ 1 -( 1 , 3-Dimethyl- 1 H-pyra20(-4-yi)-3-methyl-2-oxo-2, 3-dihydro- 1 H- imidazo[4,5-c]qυinolin-8-yl]-2-methoxy-pyridin-3-yl}-N-methyl-acetamide
Figure imgf000169_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 3-dimethyl-1H-pyrazo)-4-yl)-3-methy}-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and N-[2~methoxy-5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)-pyridin- 3~yl]-N-methyf-acetamide (Stage 62.1.1) to give the title compound as a white solid (HPLC' tR 2 52 mm (Method A), M+H * 472 MS-ES; 1H-NMR (Cl6-DMSO, 400 MHz) 8.97 (s, 1 H). 8 40-8 31 (m, 1H). 8 18-8 06 (m, 2H), 8.03-7 90 (m, 1H)1 7.86-7 71 (m, 1H). 7 55-7 43 (m, 1 H), 3 97 (S1 3H), 3 88 (s, 3H), 3 57 (s, 3H), 3.07 (s, 3H), 1 94 (s, 3H)1 1 74 (s. 3H)) Stage 62.1.1 N-[2-Methoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yf)-pyridin-3-yt}~N- methyl-acetamide
.0
Figure imgf000170_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using N-(5-bromo-2-methoxy-pyridin-3-y))-N-methyl-acetamide (Stage 62.1.2) to give the title compound as a brown solid. (HPLC. tR 1.99 min (Method A), M+H = 307 MS-ES).
Stage 62,1.2 N-(5-βfomo-2-methoxy-pyπdJn-3"yl)-N-^τ)ethyl-acetamide
Figure imgf000170_0002
To N-(5-bromo-2-methoxy-pyridin-3-yl)-acetamide (Stage 62.1.3, 100 mg ,0.408 mmol) DMF (1 ml) was added NaH 55% in oil (19 6 mg, 0.45 mmol) The reaction mixture was stirred for 10 min at rt then was added Me! (0.031 ml, 049 mmol) The reaction mixture was stirred for 1 h at rt then quenched with brine and extracted with EtOAc (2x). The organic layers are washed with brine (3x), dried over NajSO4, filtered and evaporated The crude product was purified by Prep. HPLC The fractions containing the product were collected together and basified with NaHCO3, before being concentrated and extracted with EtOAc (3x) The organic layers were dried over Is^SO4, filtered and evaporated to dryness to give the title compound as an off-white solid (HPLC' tR 2.75 min (Method A), M+H - 259, 261 MS-ES).
Stage 62.1.3 N-(5-Bromo-2-methoxy-pyridtn-3-y!)-acetamide
Figure imgf000170_0003
A suspension of 5-bromo-2-methoxy-3-nrtro-pyridine (Stage 63.1.4, 450 mg, 1 93 mmol) and tin dichloπde (1 465 mg, 7 72 mmol) in EtOAc (30 ml) was refluxed for 3 h. The reaction mixture was evaporated to dryness and then quenched with cold 3 M aqueous NaOH (50 mf) and CH2CIi; (50 ml) and stirred for 3 h at rt The organic layer was separated and the aqueous layer was extracted with CH2CIa The combined organic layers were washed with 30 ml sat. aqueous NaHCO3, dried over Na?SO< filtered and evaporated The crude product was dry loaded on silica gel and purified by MPLC (CH?CI2/MeOH 0% to 4%) to give after evaporation the title compound as an off-white solid (HPLC: tR 2.72 min (Method A); M+H - 245, 247 MS-ES).
Stage 62,1.4 5-Bromo-2-methoxy-3-nitro-pyridine
Figure imgf000171_0002
In a vial are introduced 1 ml of MeOH and 50 8 rng (2.21 mmol) of Na. After dissolution of the metal, the solution was added to a suspension of 5-bromo-2-chloro-3-nrtropyridine (Matrix, Columbia, USA, 500 mg, 2.11 mmol) in MeOH (2 ml) The reaction mixture is stirred for 1 h at O6C and for 15 h at rt, then concentrated and quenched with water. The precipitate was filtered, washed with water (2x) and dried under vacuum to give the title compound as a pale yellow solid (HPLC. tR 3.06 mm (Method A)
Example 63 N-{5-[1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl~2-oxo-2,3-dihydro-1H- imida2o[4,5-c]quinolin-8-yl]-2-ethoxy-pyridin-3-yl}-N-methyl-acetamide
Figure imgf000171_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 3-dihydro-imidazo{4,5-c]quinolin-2-one (Intermediate A) and N-{2-ethoxy-5-(4A5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)-pyridin-3- yl)-N-methyl-acetamide (Stage 63.1.1) to give the title compound as a white solid (HPLC: tR 2.64 min (Method A). M+H « 486 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8 97 (s, 1H), 8.40- 8 28 (m, 1H), 8.18-8 06 (m, 2H), 8 04-7.91 (m, 1 H), 7 85-7 69 (m, 1H), 7 54-7.41 (m, 1 H), 4.52-4 33 (m, 2H), 3.88 (s, 3H), 3 58 (s, 3H), 3.08 (s, 3H)1 1.93 (s, 3H), 1.75 (s, 3H), 1.32 (t, 3H))
Stage 63.1.1 N-[2-Ethoxy-5-(4,4,5,5-tetramethyH1 ,3,2}dioxaborolan-2-yl)-ρyridin-3-yl]-N- methyl-acetamide
Figure imgf000172_0001
The title compound was synthesized in a similar manner as described for Stage 62.1.1 «4 using ethano! as solvent and a sodium ethanoiate solution to give the title compound as an off-white solid. (HPLC: tR 2.21 min (Method A); M+H * 3217 MS-ES)
Example 64 N-{5-[1-(1 ,3-Dimethyl-1H-pyra2θl-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinoltn-8-yl]-2-methoxy-pyridin~3-yl}-acetamide
Figure imgf000172_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using β-bromo-I^I .S-dimethyH H-pyrazol^-yO-S-methyl-I .S-dihydro-imidazo^.δ-cJqυinolin^-one (Intermediate A) and N-[2-methoxy-5-(4,4,515-tetramethyl-(1 ,3,2Jdioxaborolan-2-yl)-pyridin- 3-y!]-acetamide (Stage 64.1.1) to give the title compound as a white solid. (HPLC. tR 2.51 mm (Method A). M+H = 458 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 9.52 (s, br, 1H), 8 96 (s, 1H), 8.50-8 41 (m, 1H), 8.15-809 (m, 2H)1 8.06-8.02 (m. 1H), 7.88-7 83 (m, 1 H), 7.55-7 49 (m, 1H), 3 97 (s, 3H), 3.91 (s, 3H), 3 57 (S, 3H), 2.14 (s, 3H), 1 93 (s, 3H))
Stage 64.1.1 N-[2-Methoxy-5-(4,4,5,5-tetramethyl-[1 ,3.2)dioxaborolan-2-yl)-pyridin~3-yl)- acetamide
Figure imgf000173_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using N-(5~bromo-2-methoxy-pyndin-3-yl)-acetamide (Stage 62.1.3) to give the title compound as a beige solid. (HPLC- tR 1 84 mm (Method A); M+H = 293 MS-ES)
Exam pie 65 N-{5-[1-(1 ,3-DimethyM H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H- fmidazo(4 , 5-c}quinolin~8-yl]-2-ethoxy-pyπdin-3-y !}-acetamκie
Figure imgf000173_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and N-^-ethoxy-S^^.S.δ-tetramethyHI .S^Jdioxaborolan^-yO-pyridin-S- y!]-acetamide (synthesized in a similar manner as Stage 64.1.1, (HPLC tR 1 84 min (Method A), M+H - 293 MS-ES)) to give the title compound as a white solid (HPLC: tR 2 Θ4 min (Method A); M+H = 472 MS-ES, 1H-NMR (dβ«DMSO. 400 MHz) 9 37 (s, 1H). 8.96 (s, 1H), 8 45-8.43 (m, 1H)1 8 12-8 08 (m, 2H), 8 01-8 00 (m, 1H), 7 85-7 82 (m, 1H), 7.52-7 50 (m, 1H), 4 44 (q, 2H), 3 91 (s, 3H), 3 57 (s, 3H)1 2.15 (S1 3H), 1 92 (s, 3H)1 1 37 (t, 3H))
Example 66 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(6-methoxy-5-nitro-pyridin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000174_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -(1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4 , 5-c]quinolin-2-one (Intermediate A) and 2-methoxy-3-nitro-5-(4,4,5,5-tetramethyl-[1 ,3,2JdioxaboroJan-2-yl)~ pyridine (Stage 66.1.1) to give the title compound as a white solid (HPLC tR 2 62 min (Method A), M+H = 446 MS-ES; 'H-NMR (de-DMSO, 400 MHz) 9 00 (s, 1H), 8 72-8 66 (m, 1H), 846-8 39 (m, 1 H). 8 18-8 10 (m, 2H), 8 05-7 96 (m, 1H), 7 58-7 53 (m, 1H), 4 07 (s, 3H), 3 91 (S1 3H), 3 59 (s, 3H)1 1.94 (s 3H))
Stage 66.1.1 2-Methoxy-3-nitro-5-(4,4,5,5-tetramethyl-(1 ,3,2)dioxaborolan-2-yl)-pyridine
Figure imgf000174_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-2-methoxy-3-nitro-pyridine (Stage 62.1.4) to give the title compound as a brown solid (HPLC. tR 2 22 mm (Method A) M+H « 281 MS-ES)
Example 67 8-(1 ,3-Dimethyl-2~oxo~2,3-dihydro-1H~imκiazo[4,5-b]pyridin-6-yl)-1-(1 ,3- dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000174_0003
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and I .S-dimethyl-δ^^.δ.S-tetramethyl-ti.S.∑lclioxaborolan^-yl^i .S- dihydro~imidazo(4,5-b}pyridin-2-one (Stage 67.1.1) to give the title compound as a white solid (HPLC: t« 2.39 mm (Method A); M+H = 455 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8.97 (S, 1H)1 8.16-8.07 (m, 3H), 7 99-7.94 (m, 1H), 7.58-7.53 (m, 2H), 3.91 (s, 3H), 3.57 (s. 3H), 3.41 (S, 3H), 3.35 (s, 3H), 1.97 (s, 3H))
Stage 67.1.1 1 ,3-Dimethyl-6-(4.4,5,5-tetramethyl-(1 ,3,2)dioxaborolan-2-yl)-1 ,3-dihydro- imidazo[4,5-b]pyridin-2-one
Figure imgf000175_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-2-methoxy-3-nitro-pyπdine (Stage 67.1.2) to give the title compound as an off-white solid. (HPLC. tR 1.93 mm (Method A), M+H = 290 MS-ES).
Stage 67.1.2 6-Bromo-1 ,3-dimethyl-1 ,3-dihydro-irmdazo{4,5-b]pyπdin-2-one
Figure imgf000175_0002
The title compound was synthesized in a similar manner as described for Intermediate A using 5-bromo-2-methoxy-3-nitro-pyπdine (Stage 67.1.3) to give the title compound as a violet solid (HPLC: tR 2.63 mm (Method A), M+H = 242, 244 MS-ES).
Stage 67.1.3 6-Bromo-3-methyl-1 ,3-dihydro-imidazo[4,5-b]pyridin-2-one
Figure imgf000175_0003
The title compound was synthesized in a similar manner as described for Stage A.1 using 5- bromo-N*2*-methyl-pyridine-2,3-diamine (Stage 67.1.4) to give the title compound as a gray solid (HPLC. tR 2.37 min (Method A); M+H ~ 228, 230 MS-ES)
Stage 67.1.4 5-Bromo-N*2*-methyl-pyπdine-2,3-diamine
Figure imgf000176_0002
A suspension of (5-brorno~3~nitro-pyπdin-2-yl)-methyl-amine (Stage 67.1.5, 4.58 g, 19.75 mmol) and tin dichloride dihydrate (Acros, Basel, Switzerland, 13.38 g, 59 3 mmol) in 200 ml of THF was heated at 7O°C for 220 miα The solvent was removed by evaporation and the residue taken in CH2CI2 (100 ml) and 5 M aqueous NaOH (50 ml) and stirred until all the solid was dissolved. The organic layer was separted and the aqueous layer was extracted with CH2CI2 The combined organic layers were washed with brine, dried over Na?SO4l ftltered and evaporated to give the tiϋe compound as a brown solid. (HPLC tR 1 69 min (Method A), M+H = 202, 204 MS-ES)
Stage 67.1.5 (5-Bromo-3-nitro-pyridin-2-yl)-methyl-amine
Figure imgf000176_0003
To a solution of δ-bromo^-chlofo-S-nitropyridine (Matrix, Columbia, USA, 9 8 g, 41 3 mmol) in 250 ml THF was added 8 M methylamine in EtOH (Aldπch, Buchs, Switzerland, 12 9 ml, 103 mmol) The reaction mixture was stirred 1 h at it then was quenched with 300 ml water The precipite was filtered and the filtrate concentrated before being filtered again. The yellow solids were combined and dried to give the title compound as a yellow solid (HPLC tR 3 13 mm (Method A))
Example 68 1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-8-( 1 -ethyl-3-methyl~2-oxo-2 ,3-dihydro- 1 H- imidazo[4,5-b)pyπdin-6-yl)-3-methyl-1 ,3-dihydro-<midazo[4,5-c]quino!in-2-one
Figure imgf000176_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1.3-dimetriyl-1H-pyrazol-4-yl)-3-methy!-1,3-dihydro-tmida2θ[4,5-c]quinolin-2-one (Intermediate A) and i-ethyl-S-methyl-β-^AS.δ-tetramethyl-π Λ∑jdioxaborolan^-yO-I .S- dihydro-imidazo(4,5-b]pyπdin-2-one (Stage 68.1.1) to give the title compound as a white solid (HPLC. tR 2.47 min (Method A), M+H - 469 MS-ES, 'H-NMR (dβ-DMSO, 400 MHz) 8.97 (S, 1H), 8 14-8 08 (m, 3H), 8 01-7 94 (m, 1H). 7.62-7 58 (m, 1H), 7.58-7.54 (m, 1 H), 3 94 (q, 2H), 3.89 (s. 3H), 3 57 (s, 3H), 3 37 (s, 3H), 1.97 (s, 3H), 1 28 (t, 3H))
Stage 68.1.1 1 -Ethyl-3-methyl-6-(4,4,5 5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-1 ,3-dihydro- imidazo[4,5-b]pyndin-2-one
Figure imgf000177_0002
The title compound was synthesized in a similar manner as described for Stage 67.1.1-2 using ethyliodide (Aldrich, Buchs, Switzerland) to give the title compound as a white solid (HPLC U 1 98 mm (Method A), M+H » 304 MS-ES).
Example 69 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-[1-(2-methoxy-ethyl)-3-methyl-2-oxo-2,3- dihydro-1H-im(dazo[4,5-b]pyridin-6-yl3-3-methyl-1 ,3-dihydro-imidazof4,5-c]quinolin-2one
Figure imgf000177_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8~bromo-1-(1 ,3-dimethyM H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro~imidazo[4,5-c]quinolin-2-one (Intermediate A) and 1-(2-methoxy-ethyl)-3-methyl-6«(4,4,5,5-tetramethyl-
[1 ,3,2]dioxaboro!an-2-y1)-1 ,3-dihydro-imidazo[4,5-b]pyridtn-2~one (Stage 69.1.1) to give the title compound as a white solid (HPLC t« 2.46 min (Method A), M+H = 499 MS-ES, 1H-NMR (Cl6-DMSO, 400 MHz) 8.97 (s, 1H)4 8 15-8.05 (m, 3H)1 7.97-7.91 (m, 1H), 7 64-7.60 (m, 1 H), 7,57-7.53 (m, 1H), 4.11-4.03 (m, 2H), 3 90 (s, 3H) 3.67-3 62 (m, 2H), 3 57 (s, 3H), 3.36 (s, 3H), 3 23(s, 3H), 1 98 (s, 3H))
Stage 69.1.1 1-(2-Methoxy-ethyl)-3-methyl-6-(4,4,5,5-tetramethyK1 ,3,2]dioxaborolan-2-yl)- 1 ,3-dthydro-imidazo(4,5-b]pyridin-2-one
Figure imgf000178_0001
The title compound was synthesized in a similar manner as described for Stage 67.1.1-2 using 2-bromoethyl methyl ether (Aldrich, Buchs, Switzerland) to give the title compound as a brown solid. (HPLC tR 2.03 min (Method A), M+H = 334 MS-ES)
Example 70 8-(2-Dtmethylamino-3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-1-(1 ,3-dimethyl- 1H-pyrazoi-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinotin-2-one
Figure imgf000178_0002
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo-1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro-knidazo[4, 5-cJquinolin-2-one (Intermediate A) and dimethyl-[3-methyl-6-(4,4l5,5-tetramethyl-t1 ,3,2)dioxaborolan-2-yl)-3H- imidazo[4,5-b]pyridtn-2-y!]-amine (Stage 70.1.1) to give the title compound as a white solid (HPLC: tR 2.21 min (Method A); M+H * 468 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8.95 (s, 1H), 8.17-8 06 (m, 3H), 7 96-7 90 (m, 1H), 7 72-7.67 (rn. 1H), 7 56-7.52 (m, IH), 3 91 (s, 3H), 3 71 (s, 3H)1 3 57 (s, 3H), 3.06 (s, 6H)1 1 97 (s, 3H))
Stage 70.1.1 Dimethyl-[3-methyl-6-(4,4,5,5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-3H- imidazo[4,5-b]pyridin-2-yl]-amine
Figure imgf000179_0001
The title compound was synthesized in a similar manner as described for Stage 5.1,1 using (6-bromo-3-methyl-3H-imidazo{4,5-b]pyridin-2-yl)-dimethyl-amine (Stage 70.12) to give the title compound as a brown oil (HPLC tR 1 76 mm (Method A), M+H ~ 303 MS-ES)
Stage 70.1.2 (6-Bromo-3-methyl-3HHmidazo[4,5-b)pyridin-2-yi)-dimethyl-amine
A solution of 5-bromo-N*2*-methyl-pyridine-2,3-diamine (Stage 67,1.4, 2 09 g 10 34 mrnol) and dichloromethylene-dimethyliminium chloride (Aldrich, Buchs, Switzerland 5 04 g, 31 0 mmol) in NMP (60 ml) was stirred for 17 h at rt The reaction mixture was quenched with saturated aqueous NaHCO3 and EtOAc The aqueous layer was extracted with EtOAc and the combined organic layers washed with saturated aqueous NaHCO3 and with brine, then dned over Na2SO4, filtered and evaporated The crude product was dry loaded on silica gel and puπfied by MPLC (DCM/MeOH 0% • 5%) to give the title compound as a red solid (HPLC t« 2 13 mm (Method A). M+H - 255, 257 MS-ES)
Example 71 1-(1 3-D!methyl-1H-pyrazol-4-yl)-8-(2-methoxy-3-methyl-3H-imidazo[4,5- b]pyridm-6-yl)-3-methyl- 1 , 3-dihydro-imidazo{4 , 5-c]quinolin-2-one
Figure imgf000179_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 l3-dimethyl-1 H-pyrazol~4-yl)-3-methyl-1 ,3-d)hydro-imidazo{4,5-c3quinolin-2-one (intermediate A) and 2-methoxy-3-methyl~6-(4 4,5,54etramethyt-[1 ,3,2]dioxaborolan-2-yl)- 3H-imidazo[4,5-b]pyridine (Stage 71.1.1) to give the title compound as a white solid (HPLC' t* 2 62 min (Method A), M+H - 455 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.97 (s, 1 H), 8.24-8.20 (m, 1H), 8.17-8 13 (m, 1H), 8 13-8 08 (m, 1 H), 7.97-7.92 (m, 1 H), 7 87-7.83 (m. 1 H), 7.55-7.53 (m, 1 H)1 4 16 (s, 3H), 3 91 (s, 3H)1 3.57 (s, 6H), 1 97 (s, 3H))
Stage 71.1.1 2-Methoxy-3-methyl-6-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-3H- imidazo|4,5-b]pyridine
Figure imgf000180_0001
The title compound was synthesized in a similar manner as described for Stage 6.1.1 using 6-bromo-2-methoxy-3«methyl-3H-imidazo{4,5-bJpyridine (Stage 71,1.2) to give the title compound as a yellow solid. (HPLC1 tR 1 94 mm (Method A)1 M+H ~ 290 MS-ES).
Stage 71.1.2 6-Bromo-2-methoxy-3-methyl-3H-imidazo(4,5-b]pyridine
Figure imgf000180_0002
A solution of 5-bromo-N*2*-merny!-pyπdine~2,3-diamine (Stage 67.1.4, 960 mg, 4 75 mmo!) and tetramethylorthocarbonate (Akiπch, Buchs, Switzerland, 2 ml, 14 7 mmol) and acetic acid (0 273 ml, 4 75 mmol) was stirred for 90 mm at 100°C The reaction mixture was diluted with EtOAc and washed with saturated aqueous NaHCO3 and brine The aqueous layer was extracted with EtOAc and the combined organic layers washed with saturated aqueous NaHCO3 and with brine, then dried over Na2SO4, filtered and evaprated The crude product was dry loaded on silica gel and purifted by MPLC (DCM/MeOH 0% - 4%) to g>ve the title compound as a green solid. (HPLC tR 2.83 mm (Method A), M+H - 242, 244 MS-ES)
Example 72 1 -( 1 ,3-Drmethyl~1 H-pyrazo!-4-yl)-3-methyl-8~(3-methyl-3H-[ 1 , 2, 3]triazolo[4 , 5- b]pyridin-6-y!)-1 ,3-dihydro-imidazo(4,5~c)quinolin-2-one
Figure imgf000181_0001
The title compound was synthesized in a similar manner as described for Example 1.1 usrng 8-bromo-1-(1(3-dimethyl-1 H-pyra2ol-4-yl)-3-methyl-1 ,3-dihydro-imida2o[4,5-cJquinolin-2-one (Intermediate A) and 2-methoxy-3-methyl-6-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- 3H-imidazo(4,5-b]pyndine (Stage 72.1.1) to give the title compound as a white solid. (HPLC- tR 2,43 mm (Method A); M+H = 426 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 9.01 (s, 1H), 8.86-8,81 (m, 1 H), 8 65-8 61 (m, 1H), 8 21-β 13 (m, 2H), 8.10-8.04 (m, 1 H) 7 63-7 59 (m, 1H), 4 33 (s, 3H), 3.92 (s, 3H)1 3 58 (S, 3H), 1.96 (s, 3H))
Stage 72.11 3-Methy!-6-(4,4,5,5-tetramethyl-{1 ,3,2Jdioxaborolan-2-yl)-3H- [1 ,2,3]tπazolo[4,5-b]pyridine
Figure imgf000181_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 6-bromo-3-methyl-3H-[1 ,2,3]triazolo[4(5-b]pyridtne (Stage 72.1.2) to give the title compound as a yellow solid. (HPLC. tR 1 85 min (Method A)1 M+H - 261 MS-ES).
Stage 72,1.2 6-Bromo-3-methyl-3H-(1 ,2,3]triazolo[4,5~b]pyridme
Figure imgf000181_0003
To a solution of 5-bromσ-N*2*-methyl-pyridine-2,3-diamine (Stage 67.1.4, 1 2 g, 5.94 mmol) in 2 M aqueous HCI (70 ml) cooled with an ice-bath was added a solution of sodium nitrite (Fluka, Buchs, Switzerland, 492 mg, 7 13 mmol) in water (10 ml) The reaction mixture was stirred at 0°C for 1 h and at rt for 75 mm then basifϊed with 2 M aqueous NaOH (75 ml) and extracted with EtOAc The organic layer was washed with brine, dried over NaaSO,., filtered and evaprated The crude product was dry loaded on silica gel and purified by MPLC (heptane/EtOAc 0% - 30%) to give the title compound as a blue solid (HPLC tR 2 46 min (Method A), M+H * 213, 215 MS-ES),
Example 73 8-(2,3-Dimethyl-3H-imidazo[4,5-b]pyridin-6-yl)-1-(1 ,3-dimethyl-1H-pyrazol-4- yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000182_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1.3-dimeihyl-1 H-pyrazol~4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-cJquinolin-2-one (Intermediate A) and 3-methyl-6-(4>4,5.5-tetramethyl-[1 ,3)2]dioxaborolan-2-yl)-3H- imidazo[4,5-b]pyridine (stage 73.1.1) to give the title compound as an off-white solid. (HPLC: tR 2 20 min (Method A); M+H * 439 MS-ES; 'H-NMR (Ci8-DMSO, 400 MHz) 8 98 (s, 1 H), 8.41-8.38 (m. 1H), 8.18-8.15 (m, 1H), 8,13-8.09 (m, 1H), 8 02-7.96 (m, 2H), 7 58-7 54 (m, 1H)1 3.92 (s. 3H), 3.77 (s, 3H), 3.58 (s, 3H), 2.59 (S, 3H), 1 97 (s, 3H))
Stage 73.1.1 2,3-Dimethyl-6-(4,4l5,5-tetramethyl-{1 ,3,2]dtoxaborolan-2-yl)-3H-imidazo(4,5- b]pyridine
Figure imgf000182_0002
The title compound was synthesized in a similar manner as described for stage 5.1.1 using 6~bromo-2«3~dimethyl-3H-imidazo[4,5-b]pyridine (stage 73.1.2) to give the title compound as a green solid (HPLC Xn 1 51 mm (Method A), M+H = 274 MS-ES)
Stage 73.1.2 6-Bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine
Figure imgf000182_0003
A solution of 5-bromo-N*2*-methyl-pyridine-2 3-diamine (Stage 67.1.4, 960 mg, 4 75 mmol) in triethylorthoacetate (Aldrich, Buchs, Switzerland, 25 ml) was stirred for 38 5 h at 140°C. The reaction mixture was evaporated to dryness. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3. The aqueous layer was extracted with EtOAc and the combined organic layers washed with brine, dried over NajSO^, filtered and evaprated. The crude product was dry loaded on silica gel and purified by MPLC (DCM/MeOH 0% - 4%) to give the title compound as a brown solid (HPLC. tR 1 95 mm (Method A); M+H = 226, 228 MS-ES).
Example 74 1 -(1 ,3-DimethyM H-pyrazoM-yl)-3-methyl-8-(3-methyl-3H-imidazo[4,5- b]pyridin-6-yl)-1 ,3-dihydro-imidazo{4,5-c]quinolin-2-one
Figure imgf000183_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro-imidazo[4, 5-c]quinolin-2-one (Intermediate A) and 3-methyl-6-(4.4Λ5-tetramethyl-(1 ,3,2j[dioxaborolan-2-yl)-3H- imidazo[4,5-b]pyridine (Stage 74.1.1) to give the title compound as a white solid. (HPLC- tR 2.26 min (Method A); M+H = 425 MS-ES; 1H-NMR (de-DMS0, 400 MHz) 8.97 (s, 1H), 8 52- 8.46 (m, 2H), 8 20-8 08 (m. 3H)1 8.05-7.98 (m, 1H), 7.60-7.55 (m, 1H), 3 93 (s, 3H), 3.86 (s, 3H), 3.58 (s, 3H), 1 97 (s, 3H))
Stag© 74.1.1 3-Methyl-6-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)-3H-imidazo{4,5- b]pyridine
Figure imgf000183_0002
The title compound was synthesized in a similar manner as described for Stage 73.1.1-2 using triethylorthoformate (Aldrich, Buchs, Switzerland) to give the title compound as a brown solid (HPLC' tR 1 39 mm (Method A), M+H = 260 MS-ES). Exartiole 75 N^δ-li^i .S-Dimethyl-1H-pyrazoM-yO-a-methyl^-oxo^.S-clihyclro-1H- imidazo[4,5-c]quinolin-8-yl]-2-methyl-pyridin-3-yl}-N-methyl-methanesulfonamide
Figure imgf000184_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyM , 3-dihydro-imidazo[4 ,5-c]quinolin-2-one (Intermediate A) and N-methyl-N-ia-methyl-δK^^.δ.δ-tetramethyl-fi.a.aidioxaborolan^-yl)- pyridin-3-ylJ-methanesulfonamide (Stage 75.1.1) to give the title compound as a white solid. (HPLC: tR 2 19 min (Method A), M+H ~ 492 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.99 (s, 1H), 8 55-8 51 (m, 1H), 8.16-8 10 (m. 2H), 8.03-7.97 (m, 1H), 7 95-7.91 (m, 1H), 7 60-7 56 (m, 1H)1 3 89 (S, 3H), 3.58 (s, 3H), 3 23 (s, 3H), 3.16 (s, 3H)1 2.53 (s, 3H), 1 96 (s, 3H))
Stage 75.1.1 N-Methyl-N-[2-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin- 3-ylJ-methanesulfonamide
Figure imgf000184_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 6-bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine (Stage 75.1.2) to give the title compound as a brown oil. (HPLC: tR 2 15 min (Method A); M+H - 327 MS-ES)
Stage 75.1.2 N-(5-Bromo-2-methyl-pyridin-3-yl)-N-methyl-methanesulfonamide
Figure imgf000184_0003
The title compound was synthesized in a similar manner as described for Stage 62.1.2 using N-(5-bromo-2-methyl~pyridin-3-yl)-methanesulfonamide (Stage 75.1.2) to give the title compound as a brownish solid. (HPLC. tR 2 28 min (Method A); M+H = 279, 281 MS-ES)
Stage 75.1.3 N-(5-Bromo-2-methyl-pyridin-3-yl)-methanesurfonamide
Br
Figure imgf000185_0001
To a solution of 5-bromo-2-methyl-pyridin-3-ylamine (Stage 75.1.4, 573 mg, 3.06 mmol) in pyridine (6 ml) was added dropwise methansulfonyl chloride (Aldrich, Buchs, Switzerland, 0 286 ml, 3.68 mmol). The reaction mixture was stirred for 18 h at rt then are added methansulfonyl chloride (0 03 ml, 0.39 mmol) The reaction mixture was stirred 4 h at rt before being evaporated to dryness The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered and evaporated. The crude product was dry loaded on silica gel and purified by MPLC (DCM/MeOH 0% - 5%) to give the title compound as a pinkish solid (HPLC. tR 2.05 min (Method A)1 M+H ~ 265, 267 MS-ES)
Stage 75.1.4 5-Bromo-2-methyl-pyridin-3-ylamine
Figure imgf000185_0003
To a solution of 5-bromo-2-methyl-3-nitro-pyridine (stage 75,1.5, 765 mg, 3.53 mmol) in acetic acid (7 ml) and water (1 75 ml) was added in three portions iron powder (591 mg, 10.6 mmol). The reaction mixture was stirred for 2 5 h at rt then quenched with 20 ml of 10 M aqueous NaOH, 20 g ice and 20 ml EtOAc before being filtered over Celite The solid was washed with EtOAc and the filtrate was extracted with EtOAc The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to give the title compound as a gray solid (HPLC' tR 1 52 min (Method A), M+H = 187, 189 MS-ES)
Stage 75.1.5 5-Bromo-2-methyl-3-nitro-pyridine
0
Figure imgf000185_0002
To a suspension of NaH 55% in oil (300 mg, 6 87 mmol) in 6 ml DMF was added dropwise diethyl malonate (Aldrich, Buchs, Switzerland, 1.0 g, 6.24 mmol), The reaction mixture was stirred for 20 min at rt before adding δ-bromo^-chloro-S-nitropyridme (Matrix, Columbia, USA, 1 19 g, 5 0 mmol). The reaction mixture was stirred for 30 min at rt and for 1 h at 4O°C. The reaction mixture was quenched with 10% aqueous NH4CI and extracted with EtOAc (2x) The combined organic layers were washed with brine (4x), dried over Na2SO4, filtered and evaporated. The residue was stirred in concentrated HCI (20 ml) for 13 h at 10O°C. After cooling, the reaction mixture was basified with 10 M aqueous NaOH and extracted with EtOAc (2x) The organic layers were washed with brine, dried over Na2SO,,, filtered and evaporated. The residue was dry loaded on silica gel and purified by MPLC (heptane/EtOAc 0% to 15%) to give the title compound as a yellow solid. (HPLC' tR 2 84 (Method A).
Example 76 N-{5-{ 1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-2*oxo-2,3-dihydro- 1 H- imidazo[4,5-c]qυinolin-8-yl)-2-methyl-pyridin-3-yl}-methanesulfonamide
Figure imgf000186_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and N-[2-methyl-5-(4,4,5,54etramethyl-[1 ,3,2Jdioxaborolan-2-yl)-pyridin-3- yl]-methanesulfonamide (Stage 76.1.1) to give the title compound as a white solid, (HPLC- 1« 2.06 min (Method A), M+H = 478 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 9.51-9.47 (m, 1 H), 8 98 (S, 1H), 8.46-842 (m. 1H), 8 15-8 09 (m, 2H), 7.94-7.88 (m, 1H), 7.72-7 68 (m, 1H), 7 60-7 56 (m 1H), 3 90 (s, 3H), 3.57 (s, 3H), 3 09 (S1 3H), 3.54 (s, 3H), 1.95 (s, 3H))
Stage 76.1.1 N-[2-Methyl-5-(4,4,5,5-tetramethyl-(1 ,3,2}dioxaborolan-2-yl)-pyridin-3-yl]- methanesulfonamide
Figure imgf000186_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using N-(5-bromo-2-methyl-pyridin-3-yl)-methanesulfonamide (Stage 75.1.2) to give the title compound as a bown oil. (HPLC: tR 1.96 min (Method A); M+H = 313 MS-ES).
Example 77 I^I .S-Dimethyl-1H-pyrazoM-y^-β-^-fiH-tmidazol^-yO-phenylhS-methyl-tS- dihydro~imidazo[4,5-c]quinolin-2-one
Figure imgf000187_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol~4-yl)-3-methyl-1 , 3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and N-[2-methyl-5-(4,4l5,5-tetramethyl-[1,3,2}dioxaborolan-2-yl)-pyridin-3- yH-methanesulfonamide (Stage 77.1.1) to give the title compound as a white solid. (HPLC: tR 2.15 min (Method A); M+H = 436 MS-ES, 1H-NMR (Ci0-DMSO, 400 MHz) 12.58 (s br, 1H), 8.96 (s, 1H). 8 20-8.15 (m, 1 H), 8 14-8.07 (m, 1 H)1 8 05-7.94 (m, 3H)1 7.63-7.53 (m, 3H), 7.31-7.07 (m, br, 2H), 3.95 (s. 3H), 3 57 (s, 3H), 1 97 (s, 3H))
Stage 77.1,1 2-[4-(4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pnenyl]-1H-imidazole
Figure imgf000187_0002
The title compound was synthesized in a similar manner as described for Stage 5.1,1 using 2-(4-bromo-phenyl)-1H-imidazole (Chem-lmpex. Cogliate, Italy) to give the title compound as a bown oil (HPLC tR 1 67 mm (Method A), M+H = 271 MS-ES)
Example 78 1-(1 ,3-DimethyM H-pyrazol-4-yl)-3-methyl-8-[6-(2-methyMmidazol-1-yl)~ pyridin-3-ylJ- 1 , 3-dihydro-imidazo(4 , 5-c]quinolin-2-one
Figure imgf000188_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl~1 ,3~dihydro-imidazo[4,5-cJquinolin-2-one (Intermediate A) and 2-(2-methyl-imidazol-1-yl)-5-(4,4,5,5-tetramethyl-[1 l3,2]dioxaborolan-2- y!)-pyridine (Stage 78.1.1) to give the title compound as a white solid. (HPLC tR 2 10 min (Method A), M+H = 451 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 9 01 (s, 1 H), 8.68-8.66 (m, 1H), 8.18-8 13 (m, 2H). 8 09-8.00 (m, 2H), 7.78-7.74 (m, 1H), 7 63-7.59 (m, 2H)1 6 94-6.93 (m, 1 H), 3 93 (S, 3H), 3 59 (s, 3H), 2.54 (s, 3H), 1 96 (s, 3H))
Stage 78.1.1. 2-(2-Methyl-imidazol-1-yl)-5-(4,4,5 5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- pyπdine
Figure imgf000188_0002
The title compound was synthesized in a similar manner as described for Stage 5,1.1 using 5-bromo-2~(2-methyl-imidazol-1-yl)-pyridine (Stage 78.1.2) to give the title compound as a brown solid (HPLC fo 1.57 mm (Method A); M+H = 286 MS-ES).
Stage 78.1.2. 5-Bromo-2-(2-methyl-imidazol-1-yl)-pyridine
Figure imgf000188_0003
A mixture of 5-bromo-2-chloro-pyridine (Aldπch, Buchs Switzerland, 392 mg, 2 04 mmol), 2- methyl-1 H-imidazole (Aldπch. Buchs, Switzerland. 251 mg, 3 06 mmol) and ceasium carbonate (1 33 g, 4 08 mmol) in DMA (10 ml) was heated by microwave irradiation for 20 mm at 100°C and 2 5 h at 15O°C. The reaction mixture was quenched with diluted brine (200 ml) and cooled The precipitate was filtered, washed with water and dried to give the tilte compound as off-white solid (HPLC. tR 2 03 min (Method A); M+H ~ 238, 240 MS-ES)
Example 79 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-pyrazol-1-yl-pyfidin-3-yl)-1 ,3- dihydro-imidazo[4,5-c]qυinolin-2-one
Figure imgf000189_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyM H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quino)in-2-one (Intermediate A) and 2-pyrazol-1-yl-5-(4l4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (Stage 79.1.1) to give the title compound as a white solid (HPLC' tR 2 64 mm (Method A); M+H = 437 MS-ES, 1H-NMR (d6-DMSO. 400 MHz) 9 00 (s, 1 H), 8 68-8 66 (m, 1H), 8 59- 8 57 (m, 1H)1 8.16-8 12 (m, 2H)1 8.10-7 98 (m, 3H), 7 87-7.85 (m, 1H), 7 60-7.58 (m, 1H), 6 62-6 59 (m, 1H), 3.93 (s. 3H), 3 58 (S1 3H), 1.97 (s, 3H))
Stage 79.1.1. 2-PyrazGl-1-yl-5-(4,4,5 5-tetramethyH1 ,3,2ldioxaboro1an-2-yl)-pyπdϊne
Figure imgf000189_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-2-pyrazol-1-yl-pyridine (Combi-Blocks, San Diego, USA) to give the title compound as a brown solid (HPLC. tR 2 19 min (Method A); M+H = 272 MS-ES)
Example 80.1 1-(1.3-Dimethvl-1 H-Dvrazol-4-vl)-3-methvl-8^2-methvlamino-Dvrimidin-5-vl)- 1 ,3-dihydro-imidazo[4,5-c]quinoltn-2-one
Figure imgf000190_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazo!-4-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5-c)quinolin-2-one (Intermediate A) and methyl-[5-(4,4,5,5-tetramethyl-|;i ,3,2]dioxaborolan-2-yl)-pyrimidin-2-yl]- amine (Stage 80.1.1) to give the title compound as a white solid (HPLC tR 2 18 min (Method A); M+H * 401 MS-ES1 1H-NMR (dβ-DMSO, 400 MHz) 8.93 (S1 1 H)1 8.49-8 34 (s, br, 2H), 8.13-8.11 (m, 1H), 8.07-8 04 (m, 1H), 7.89-7 85 (m, 1 H), 7 42-7.37 (m, 2H), 3 90 (s, 3H), 3.57 (S, 3H)1 2,84 (d, 3H), 1 96 (S1 3H))
Stage 60.1.1. Methyl-|5-(4,4,5,5-tetramethyl-(1 ,3,2)dioxaborolan-2-yl)-pyrimidin-2-yl]-amine
Figure imgf000190_0002
The title compound was synthesized in a similar manner as descnbed for Stage 5.1.1 using (5-bromo-pynmidin-2-yl)-methyl-amine (Combi-Blocks, San Diego, USA) to give the title compound as a beige solid (HPLC. tR 1 20 mm (Method A), M+H « 236 MS-ES)
The following example was synthesized in a similar manner as described for Example 1.1 using methyH5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyrimid)n-2-yl]-amine (Stage 80.1.1) and the specified intermediate
Figure imgf000190_0003
Figure imgf000191_0003
Example 81.1 8-(2-Amino-pyrimidin-5-yl)- 1 -( 1 ,3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3- dihydro-imidazo{4,5-c]quinolin-2-one
Figure imgf000191_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-I^I .S-dimethyl-1H-pyrazoM-yO-S-methyl-I .S-dthydro-imidazo^.S-cJquinolin^-one (Intermediate A) and 5-(4 4,5 5-tetramethyl-(1 ,3,2]dioxaborolan-2~yl)-pynmidin-2-ylamine (Combi-Blocks, San Diego, USA) to give the title compound as a white sc4id (HPLC tR 2 04 mm (Method A) M+H = 387 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 93 (s, 1 H), 8 37 (s, 2H)1 8 14-8 12 (m, 1H), 8 07-8 03 (m 1H), 7 90-7 86 (m, 1H), 7 41-7 38 (m, 1H), 6 93 (s, br, 2H) 3 91 (s, 3H)1 3 57 (s, 3H) 1 95 (S1 3H))
The following example was synthesized tn a similar manner as described for Example 1.1 using 5-(4l4,5,5-tetramethyl-[1 ,3,2)dioxaboroian-2-yl)-pyπmid)n-2-ylamine and the specified intermediate
Figure imgf000191_0002
Exampte 82 1 -(1 ,3-Dimethyl-1 H-pyrazol-4-y))-8-(3-isopropoxy-pheny!)-3-methyl-1 ,3- dihydro-imidazo[4,5-c]qυinolin-2-one
Figure imgf000192_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using β-bromo-I^I .S-dimethyl-1H-pyrazol^-yO-S-methyl-I .S-dihydro-imidazo^.S-cJquinolin^-one (Intermediate A) and 3-isopropoxyphenylboronic acid (Aldrich, Bυchs, Switzerland) to give the title compound as a white solid (HPLC fo 2 95 mm (Method A); M+H = 428 MS-ES1 1H- NMR (dδ-DMSO, 400 MHz) 8.96 (s 1 H), 8 19-8 16 (m, 1 H), 8 09-8 05 (m, 1H)T 7.94-7.89 (m, 1 H)1 7.57-7.54 (m, 1H), 7 39-7 33 (m, 1H)1 7 10-7 06 (m, 1 H), 6 94-9-6 90 (m, 2H)1 4 68 (hp, 1H)1 3 92 (s. 3H) 3 57 (s. 3H), 1 95 (s, 3H), 1 30 (t, 6H))
Example 83 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(2-f)uoro-3-isopropoxy-phenyl)-3-methyl- 1 , 3-dihydro-imidazo{415-c]quinolin-2-one
Figure imgf000192_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-drmethyl- 1 H~pyrazol-4-yl)-3-methyl- 1 , 3-dihydro-imidazo[4, 5-c]quinolin-2-one (Intermediate A) and 2-fluoro-3-isopropoxyphenylboronic acid (Combi-Blocks, San Diego, USA) to give the title compound as a white solid (HPLC tR 2 91 mm (Method A), M+H = 446 MS-ES. 1H-NMR (d6-DMSO 400 MHz) 8 99 (s, 1H)1 8 11-8 07 (m, 2H), 7 77-7 73 (m, 1H) 7 56-7 54 (m, 1 H), 7 22-7 15 (m, 2H)1 6 99-6 92 (m 1H), 4 64 (hp 1H), 3 87 (s, 3H)1 3 58 (s, 3H)1 1 94 (S. 3H) 1 33-1 28 (m, 6H)) Example 84.1 1-(1,3-Dimethvl-1H-Dvrazol-4-vn-8'f5-isooropoxv-6-methv)-DvrκJin-3-vn-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000193_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3~dimethyl-1 H-pyrazol-4-yl)-3-methy!-1 ,3-dihydro-imidazo[4,5-c]quino)in-2-one (Intermediate A) and 3-isopropoxy-2-methyl-5-(4,4,5,5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)- pyndine (Stage 84.1.1) to give the title compound as a white solid (HPLC- tR 2.31 min (Method A); M+H « 443 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 8 98 (s, 1H), 8 17-8 16 (m, 1H), 8.13-8.09 (m, 2H), 8.00-7.96 (m, 1H), 7.59-7.57 (m, 1 H). 7 31-7 29 (m, 1 H), 4.74 (hp, 1H), 3.89 (s, 3H), 3 58 (s, 3H), 2 36 (S, 3H), 1 97 (s, 3H), 1.35 (t, 6H))
Stage 84.1.1. 3-lsopropoxy-2-methyl-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaboro)an-2-yl)- pyridine
Figure imgf000193_0002
I
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-3-isopropoxy-2-methyl-pyridine (Stage 84.1.2) to give the title compound as a brown oil (HPLC. tR 2.21 min (Method A); M+H * 278 MS-ES)
Stage 84.1.2. 5~Bromo-3-isopropoxy-2-methyl-pyridine
To a solution of 5-bromo-2-methyl-pyridin-3-ylamine (Stage 75.1.4, 400 mg, 2 13 mmol) in isopropanol (33 ml) were added 4 M HCI in dioxane (0 535 ml, 2 13 mmol) and isoamyl nitrite (1 25 g, 10 7 mmol) The reaction mixture was heated at 80°C for 2 5 h, before being evaporated to dryness The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO3 The aqueous layer was extracted with EtOAc and the combined organic layers were dned over NaaS04 filtered and evaporated The residue was dry loaded on silica gel and purified by MPLC (heptane/EtOAc 0% to 30%) to give the title compound as an orange oil (HPLC tR 2 47 mm (Method A), M+H « 230, 232 MS-ES)
The following example was synthesized in a similar manner as described for Example 1.1 using 3-isopropoxy-2-methyl-5-(4,4l5,5-tetramethyl-[1 ,3 2Jdioxaborolan-2-yl)-pyridine (Stage 84.1.1) and the specified intermediate
Figure imgf000194_0002
Example 8S.1 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-ethoxy-6-methyl-pyridin-3-yl)-3- methyl-1 ,3-dihydro-irmdazo{4,5-c]quinotin-2-one
Figure imgf000194_0001
The titte compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyt-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and 3-ethoxy-2-methyl-5-(4,4,5,5-tetramethyl-(1 3.2]dioxaborolan-2-yl)~ pyndine (Stage 88.1.1) to give the title compound as a white solid (HPLC tR 2 22 mm (Method A), M+H « 429 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8 98 (s, 1H), 8.19-8 17 (m, 1H), 8 13-8 09 (m, 2H) 8 02-7 98 (m, 1H)1 7 61-7 59 (m, 1H), 7 30-7 28 (m, 1H), 4 20-4 12 (m, 2H)1 3 89 (s, 3H), 3 58 (s, 3H), 2 39 (s, 3H) 1 97 (S1 3H), 1 43 (t, 3H))
Stage 85.1.1, 3-Ethoxy-2-methyl-5-(4,4,5,5-tetramethyl-[1 ,3 2]dioxaborolan-2-yl)-pyridine
Figure imgf000195_0001
The title compound was synthesized in a similar manner are descnbed for Stage 84.1.1-2 using ethanol instead of isopropanol (HPLC t« 2 03 mm (Method A), M+H = 264 MS-ES)
The following examples were synthesized in a similar manner as descnbed for Example 1.1 using 3-ethoxy-2-methyl-5-(4 4,5(5-tetramethyl-(1 ,3,2)dκ>xaborolan-2-yl)-pyridine (Stage 85.1.1) and the specified intermediate
Figure imgf000195_0002
Example 86,1 1-(3-Chloro-1 -methyl- 1 H-Dvrazol-4-vn-8-f5-(2-methoxv-ethoxv)~6-methvl- pyridin-3-yl]-3-methyl-1 ,3-dihydroHmida2θ|4,5-c)quinolin-2-one
Figure imgf000196_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro-imidazo{4 ,5-c]quinolin-2-one (Intermediate A) and 3-(2-methoxy-ethoxy)»2-methyl-5-(4,4 5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-pyridtne (Stage 86.1.1 ) to give the title compound as a white solid (HPLC tR 2 33 mtn (Method A); M+H ~ 479 MS-ES, 1H-NMR (U6-DMSO, 400 MHz) 9.01 (s 1H), 8 38 (s, 1H), 8 22-8.20 (m, 1 H), 8.15-8 12 (m, 1H)1 8 03-8.00 (m, 1H), 7 58-7 57 (m, 1 H) 7 39-7 37 (m, 1H), 4 30-4 19 (m, 2H), 3 97 (s, 3H)1 3 76 (t, 2H)1 3.60 (a, 3H), 3 36 (s, 3H), 2 40 (S, 3H))
Stage 86.1.1. 3-(2-Methoxy-ethoxy)-2-methy)-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2- yl)-pyridine
Figure imgf000196_0002
The title compound was synthesized in a similar manner are described for Stage 84,1.1 «2 using 2-methoxyethanoi instead of isopropano). (HPLC- tR 2 05 mm (Method A)1 M+H - 294 MS-ES)
The following example was synthesized in a similar manner as described for Example 1.1 using 3-(2-methoxy-ethoxy)-2-methyl-5-(4,4)5(5-tetramethy(-[1 (3,2]dioxaborolan-2-yl)-pyridine (Stage 86,1.1) and the specified intermediate
Figure imgf000197_0002
Example 87.1 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-ethylamino-6-methyl-pyπdin-3- yl)-3-methyl-1 ,3-dihydro-imidazo{4,5-c]quinolin-2-one
Figure imgf000197_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethy!-1 H-pyrazo!-4-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one (Intermediate A) and ethyl-[2-methyl-5-(4,4,5,5-tetramett>y1-[1 ,3,2]dioxaborolan-2-yi)-pyπdin- 3-y!)-arnine (Stage 87.1.1) to give the title compound as a white solid (HPLC: tR 2 18 mtn (Method A)1 M+H - 428 MS-ES; 1H-NMR (dθ-DMSO, 400 MHz) 8.96 (s, 1H), 8 11-8 07 (m, 2H), 7 95-7.91 (m, 1H), 7 88-7 86 (in, 1H), 7 61-7.59 (m, 1H), 6 78-6.76 (m, 1H)1 5 23 (t, 1H), 3 88 (s, 3H), 3 58 (s, 3H), 3.21-3 14 (m 2H), 2 33 (s, 3H), 1 97 (s, 3H). 1.25 (t, 3H))
Stage 87.1.1. Ethy42-methyl-5-(4,4,5,5-terramethyl-[1 ,3,2Jdioxaborolan-2-y!)-pyridin-3-yf]- amme
Figure imgf000198_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (5-bromo-2~methyl-pyridin-3-yl)-ethyl-amine (Stage 87.1.2) to give the title compound as a brown oil (HPLC. tR 1.85 min (Method A); M+H = 263 MS-ES).
Stage 87.1.2. (5-8romo-2-methyl-pyridin~3-yl)-ethyl-amine
Figure imgf000198_0002
A solution of 5-bromo-2-methy)-pyπdin-3-ytamine (Stage 75.1.4, 300 mg, 1 604 mmol), acetaldehyde (Fluka, Buchs, Switzerland, 71 mg, 1.6 mmol) in dicWoromethane (30 ml) was stirred for 1 5 h at rt in presence of acetic aαd (0 3 ml. 5 24 mmol) Was added sodium triacetoxyborohydride (850 mg. 4 01 mmol) and the reaction mixture was stirred 4 h at rt, then was added acetaldehyde (45 mg, 1 02 mmol) twice at 1 5 h interval and the reaction was stirred at rt for 15 h before being quenched with aqueous saturated NaHCOa and extracted with dicWoromethane (2x). The combined organic layers were dried over Na2SO4, filtered and evaporated to dryness (HPLC tR 2 08 mm (Method A), M+H ~ 215, 217 MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using ethyl-[2-methyl-5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-amine (Stage 87.1.1) and the specified intermediate
Figure imgf000198_0003
87 2 K ~N- - 1-(3-Chloro-1-methyl- 448 2 35
1H-pyrazol-4-yl)-8-{5- ethylamiπo-6-methyl- ππβ iCc 7 pyridin-3-y!)-3-methyl-
1 ,3-dihydro- imidazo[4,5- c]quinolin-2-one
87 3 F 8-(5-Ethylamino-6- 442 2 22 methy t-pyridm-3-yl)- 1 -
(1-ethyl-3-methyl-1H-
J pyrazol-4-yl)-3- methyl-1 ,3-dihydro- imida2θ[4,5- c]quinolin-2-one
87.4 N 8-(5-Ethylamino-6- 486 2 26
1O methyl-pyridin-3-yl)- 1 - p-(2-methoxy~ethyl)-
3,5-dimethyl-1 H- pyrazol-4-yl]-3> methyl-1 ,3-dihydro- imidazo[4,5- c]quinolin-2-one
87.5 O 2-{4-(8-{5-Ethylamino- 513 2.25
6-methyl-pyrid»n-3-y1)-
3-mβthy 1-2-0X0-2, 3-
N
1 1 dihydrowmidazo[4,5-
J c]quinolin-1-yl]-345- dimethyl-pyrazol- 1 -y I}-
N.N-dimethyl- acetamide
Figure imgf000199_0001
Example 88,1 8-(5-Amino-6-methyl-pyrid!n-3-yl)-1-(3-chloro-1 -methyl-1 H-pyrazol-4- yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000200_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(3-chloro-1-methyl-1H-pyrazot-4-yl)-3-methyl-1 ,3-dihydro-imida2θ{4,5-cJquinolin-2- one (Intermediate K) and 2-rπethyl-5-(4,4,5,5-tetramethyl-(1,3,2]dioxaborolan-2-yl)-pyndin-3- ylamine (Stage 88.1.1) to give the title compound as a white solid (HPLC' tR 2 14 mm (Method A), M+H = 420 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.99 (s, 1H)1 8.38 (s, 1H), 8 13-8 10 (m, 1H), 7 80-7 77 (m, 1H), 7 75-7 73 (m, 1H), 7 48-7.47 (m, 1H), 7 08-7.06 (m, 1H), 5 21-5 16 (m, br, 2H), 3.99 (s 3H), 3 59 (s, 3H)1 2.30 (s, 3H))
Stage 88.1.1. 2-Methyl-5-(4 ,4, 5, 5-tetramethyl-[ 1 , 3,2]dioxaborolan-2-yl)-pyπdin-3-ylamine
Figure imgf000200_0002
The title compound was synthesized in a similar manner as described for stage 5.1.1 using 5-bromo-2-methyl-pyridin-3-ylamine (Stage 75.1.4) to give the title compound as a brown oil. (HPLC: tR 1 30 min (Method A), M+H = 235 MS-ES)
The following example was synthesized in a similar manner as descnbed for Example 1.1 using 3-(2-methoxy-ethoxy)-2-methyl-5-(4,4,5,5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-pyridine (stage 86.1.1) and the specified intermediate.
Figure imgf000200_0003
Figure imgf000201_0004
Example 89 8-(5-Amino-6-methoxy-pyrκ.in-3-yl)-1-(3-chloro-1 -methyl- 1 H-pyrazol-4- yl)-3-methyl-1 ,3-dihydro-imidazo{4,5~c]quinolin-2-one
Figure imgf000201_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-I^S-chloro-1-methyl-1H-pyrazol^-yO-S-methyl-I.S-dihydro-imidazoH.δ-cJquinolm-Σ- one (Intermediate K) and 2-methoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaboroJan-2-yl)-pyπdin- 3-ylamine (Stage 89.1.1) to give the title compound as an off-white solid (HPLC. tR 2 45 min (Method A); M+H - 436 MS-ES; 1H-NMR (drDMSO, 400 MHz) 8 97 (s, 1H) 8.38 (s, 1 H)1 8.11-8.07 (m, 1 H)1 7.80-7 75 (m, 1H), 7 48-7.42 (m, 2H), 7 03-7.00 (m. 1H), 5.15-5.07 (s, br, 2H), 4.00 (s, 3H), 3.90 (s, 3H), 3.59 (s, 3H))
Stage 89.1.1. 2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-3-ylamine
Figure imgf000201_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-2-methoxy-pyridin-3-ylamine (Stage 89.1.2) to give the title compound as a brown oil. (HPLC. tR 1 10 min (Method A), M+H = 251 MS-ES)
Stage 89.1.2. 5-Bromo-2-methoxy-pyridin-3-ylamine
Figure imgf000201_0003
The title compound was synthesized in a similar manner as described for Stage 67.1.4 using 5~Bromo-2-methoxy~3-nitro-pyridine (Stage 62.1.4) to give the title compound as an off-white solid. (HPLC: tR 2.51 min (Method A); M+H = 203, 205 MS-ES).
Example 90.1 1-(3-Chloro-1-methvl-1H-pvrazol-4-vl)-8-(5-ethvlamino-6-methoxv-pvridin-3- yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c}qυinolin-2-one
Figure imgf000202_0001
The title compound was synthesized in a similar manner as described for Example 11 using δ-bromo-I^S-chloro-1-methyl-1H-pyrazoM-yO-S-methyl-i ^-dihydro-imidazo^^-clquinolin-Z- one (Intermediate K) and ethyl-(2-memoxy-5-(4,4,5,5-tetramethy!-[1 ,3)2]dioxaborolan-2-yl)- pyridin-3-y!]-amine (stage 90.1,1 , 0.138 mmol) to give the title compound as a white solid. (HPLC. tR 2.45 min (Method A); M+H = 415 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.99 (s, 1H), 8 24-8.16 (m. 2H), 8.14-8.07 (m, 1 H), 8.02-7.94 (m, 1H), 7.66-7.59 (m, 1 H), 7.09-7.02 (m, 1H), 6.87-6.80 (m, 1H)1 4.32 (q, 2H), 3.94 (s, 3H), 3.57 (s, 3H), 1.96 (s, 3H), 1.34 (t, 3H))
Stage 90.1.1. Ethyl-[2-methoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxabαrolan-2-yl)-pyridin-3-yl]- amine
Figure imgf000202_0002
The title compound was synthesized in a similar manner as described for Stage 87.1.1-2 using 5-bromo-2-methoxy-pyrJdin-3-ylamine (Stage 89.1.2) to give the title compound as a brown oil. (HPLC: tR 1.75 min (Method A); M+H = 279 MS-ES) The following example was synthesized m a similar manner as described for Example 1.1 using ethyl-[2-methoxy-5-(4 ,4 ,5,5-tetramethyH 1 , 3, 2]dioxaborolan-2-yl)-pyridin-3-yl)-amine (Stage 90.1.1) and the specified intermediate.
Figure imgf000203_0002
Example 91 1 -(1 ,3-DimethyM H-pyrazoi-4-yl)-8-(2-ethoxy-pyndin-4-yl)-3-methyl-1 ,3- dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000203_0001
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro>imidazo(4 , 5-c]quinolin-2-one (Intermediate A1 40 mg, 0.107 mmol) and 2-ethoxy-4-pyridinylboronic acid (Combi-Blocks, San Diego, USA, 22.4 mg, 0.134 mmol) to give the title compound as a white solid (HPLC tR 2 45 mm (Method A); M+H = 415 MS-ES, 1H^NMR (d6-DMSO, 400 MHz) 8 99 (s, 1 H), 8.24- 8 16 (m, 2H), 8.14-8 07 (m, 1 H), 8.02-7 94 (m. 1H), 7 66-7.59 (m, 1H), 7 09-7 02 (m, 1H), 6.87-6 80 (m. 1H), 4 32 (q, 2H), 3 94 (s. 3H), 3 57 (S, 3H)1 1.96 (s, 3H), 1 34 (t, 3H))
Example 92 ^(I.S-Dimethyl-1H-pyrazol^-yO-S^-isopropoxy-pyridin^yO-S-methyl-I .S- dihydro-imidazo(4 5-c]quinolin-2-one
Figure imgf000204_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bronio-I^I .S-dimethyt-1H-pyrazoM-yO-S-methyl-I .SHJihydro-imidazo^.S-cJquinolin^-oπe (Intermediate A) and 2-lsopropoxy-4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridtne (Stage 92.1.1) to give the title compound as a white solid (HPLC: tR 2.56 mm (Method A); M+H = 429 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 9 00 (s, 1H), 8.23-8.19 (m, 2H), 8.14- 8 09 (m, 1H)1 8 00-7 96 (m, 1H)1 7 64-7 62 (m, 1H), 7.05-7,02 (m, 1H), 6 80-6 78 (m, 1 H), 5 28 (hp, 2H), 3 96 (S1 3H), 3 59 (s, 3H), 1 94 (s, 3H), 1.34-1.29 (m, 6H))
Stage 92.1.1. 2-lsopropoxy-4-(4,4,5,5-tetramethyl-{1,3,2jdioxaborolan-2-yl)-pyridine
Figure imgf000204_0002
The titte compound was synthesized in a similar manner as described for Stage 5.1.1 using 4-bromo-2-isopropoxy-pyridine (Stage 92.1.2) to give the title compound as a brown oil (HPLC tR 2.36 mm (Method A), M+H = 264 MS-ES)
Stage 92.1.2. 4-Bromo-2-isopropoxy-pyridine
Figure imgf000204_0003
To isopropanol (12 ml) under Ar was added 55% sodium hydride in oil (343 mg, 7 86 mmol) «i two portions After 30 mm stirπng at rt was added 4-bromo-2-chloropyridine (Aldπch, Buchs Switzerland, 1.01 g, 5.24 mmol) and the reaction mixture was heated with microwave irradiation to 15O°C for 30 mm The reaction mixture was concentrated, quenched with saturated aqueous NaHCO3 and extracted with EtOAc The organic layer was washed with brine, dried over Na2SO*. filtered and evaporated The crude product was purified by MPLC (heptane/EtOAc 0% to 20%) to give the title compound as an oil (HPLC tR 3 58 min (Method A), M+H - 216, 218 MS-ES)
Example 93 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropo>fy-6-methoxy-pyπdin-3-yl)-3- methyl-1 ,3-dihydro-imidazol4,5-c]quino)in-2-one
Figure imgf000205_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-i H-pyrazot-4-yl)-3-methyl-1 3-dihydro-imidazo[4,5-c)quinolin-2-one (Intermediate A) and 3-isopropoxy-2-methoxy-5-(4,4,5,5-tetramethyl-{1 ,3,2Jdioxaborolan-2- yl)-pyπdine (Stage 93.1,1) to give the title compound as a white solid (HPLC- tR 2 73 mm (Method A), M+H = 459 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8 96 (s, 1H), 8 11-8.07 (m, 2H), 7 97-7 93 (m, 1H)1 7 92-7 90 (m, 1H), 7 53-7 51 (m, 1H)1 7 23-7 21 (m, 1 H), 4.70 (hp, 2H)1 3 89 (s, 3H), 3 89 (S, 3H), 3.58 (s, 3H), 1 98 (s, 3H), 1 36-1 30 (m, 6H))
Stage 93.1.1. 3-lsopropoxy-2-methoxy-5-(4,4,5,5-tetramethyl-[1 3,2]dioxaborolan-2-yl)- pyridme
Figure imgf000205_0002
The titte compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-or 6-bromo-3-isopropoxy-2-methoxy-pyridine mixture (Stage 93.1.2) to give the title compound as an orange oil after silica gel flash chromatography purification (CH2C!2/iPr0H 0% to 3 5%) (HPLC tR 2 24 mm (Method A)1 M+H - 294 MS-ES)
Stage 93.1.2. 5- or 6-Bromo-3-isopropoxy-2-methoxy-pyridine
Figure imgf000206_0001
To a solution at 1O°C of 3-lsopropoxy-2-methoxy-pyπdine (Stage 93.1.3, 865 mg 5 17 mmol) and potassium acetate (635 mg, 6 47 mmol) in acetic acid (4 ml) was added over 1 5 h a solution of bromine (1 1 g, 6 88 mmol) in acetic acid (2 ml) The reaction was stirred for 1 h at rt an then basified with 20% aqueous NaOH and extracted with EtOAc (2x) The organic layers were washed with saturated aqueous NaHCO3, dried over Na2SO4, filtered and evaporated The crude product is punfied by flash chromatography (hexane/EtOAc 40 1 to 15 1) to give the title compounds as an oil (1 2) (HPLC tR 3 55 mm (Method A), M+H - 246, 248 MS-ES)
Stage 93.1.3. 3-lsopropoxy-2-methoxy-pyπdine
Figure imgf000206_0002
To a solution of methanolate obtained by dissolving sodium (534 mg 23 25 mmol) in MeOH (8 ml) was added a solution of 2-chloro-3-isopropoxy-pyπdine (Stage 93.1.4, 1 14 g, 664 mmol) in MeOH (2 ml) The reaction mixture was heated at 15O°C by microwave irradiation for 25 mm then concentrated and quenched with EtOAc and bnne The organic layer was dried over Na2SO4 filtered and evaporated to give the title compound as an oil (HPLC tR 2 66 mm (Method A), M+H = 264 MS-ES)
Stage 93.1.4. 2-Chloro-3-isopropoxy-pyπdine
Figure imgf000206_0003
The title compound was synthesized in a similar manner as described for Stage 29.1.1 using 2-chloro-3-hydroxypyridine (Aldnch, Buchs, Switzerland) The crude product obtained was bulb-to-bulb distilled (160°C, ~0 1 mmbar) and then purified by MPLC (heptane/EtOAc 0% to 35%) to give the title compound as an oil (HPLC: tR 2.97 min (Method A); M+H ~ 172 MS- ES)
Example 94 1-(1,3-Dfmethyl-1H-pyrazol-4-yl)-8-(5-ethoxy-6-methoxy-pyridifv3-yl)-3- methyl-1 ,3-dihydro-imidazo[4 5-c]quiπolin-2-one
Figure imgf000207_0001
The title compound was synthesized in a stmilar manner as described for Example 1.1 using 8-bromo-1~(1 ,3-dimethyM H-pyrazol~4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and 3-ethoxy-2-methoxy-5-(4,4.5,5-tetramethyl-(1.3,2]dκ>xaborolan-2-yi)- pyridine (Stage 92,1.1) to give the title compound as a white solid (HPLC: tR 2 63 min (Method A); M+H - 445 MS-ES; 1H-NMR (dθ-DMSO, 400 MHz) 8.96 (s, 1H), 8 11-8.07 (m, 2H), 7 98-7 94 (m, 1H), 7 92-7.90 (m, 1H)1 7.54-7.53 (m, 1H), 7.22-7 21 (m, 1H), 4.16-4.09 (m, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.58 <s, 3H), 1 97 (s, 3H)1 1 41 (t, 3H))
Stage 94.1.1. 3-Ethoxy-2-methoxy-5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-y))-pyridine
Figure imgf000207_0002
The title compound was synthesized in a similar manner as described for Stage 93.1.1-4 using isopropanoi as replacement for ethanol to give the title compound as a brown oil (HPLC. tR 2 09 min (Method A))
Example 95 8-(5-Diethylamtno-pyridin-3-yl)-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-irntdazo[4,5-c]quinolin-2«one
Figure imgf000208_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bfomo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyM , 3-dihydro-imidazo{4, 5-c]quinolin-2-one (Intermediate A) and diethyl-[5-(4,4,5,5-tetramethyl-{1 ,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- amine (Stage 95,1,1) to give the title compound as a white solid. (HPLC: tR 2 31 min (Method A); M+H - 442 MS-ES; 1H-NMR (dδ-DMSO, 400 MHz) 8 98 (s, 1H)1 8.13-8.09 (m, 2H), 8 07 - 8 05 (m, 1H), 7.96-7 91 (m, 2H), 7.60-7.58 (m, 1H), 6 95-6 92 (m, 1H), 3 87 (s, 3H), 3 58 (s, 3H), 3 46-3.39 (m, 4H). 1.97 (s, 3H), 1.13 (t, 6H))
Stage 95.1.1. Diethyl-(5-(4,4,5,5-tetramethyH1 ,3,2]dioxaborolan-2~yl)-pyridin-3-yl)-amine
Figure imgf000208_0002
The title compound was synthesized in a similar manner as described for Stage S.11 using (5-bromo-pyridin-3-yl)-diethyl-amine (Stage 95.1.2) to give the title compound as a brown oil. (HPLC. tR 2 14 mm (Method A); M+H ~ 277 MS-ES)
Stage 91.1.2. (5-Bromo-pyπdin-3-yl)-diethy!-arnine
Figure imgf000208_0003
A solution of 3-amino-5-bromopyridine (Aldπcn, Buchs, Switzerland, 400 mg, 2.31 mmol), acetic acid (0.4 ml, 6 99 mmol) and acetaldehyde (Fluka, Buchs, Switzerland 153 mg, 3 47 mmol) in dichloromethane was stirred for 1 5 h at rt then was added sodium triacetoxyborohydride (980 mg, 4 62 mmol) The reaction mixture was stirred 17 5 h at rt then were added at 1 5 h interval acetaldehyde (153 mg, 3 47 mmol) and sodium tracetoxyborohydride (490 mg, 2 31 mmol). The RM was stirred 7 h at rt then were added at
1 5 h interval acetaldehyde (77 mg, 1 75 mmot) and sodium tracetoxyborohydride (490 mg,
2 31 mmol). After 15 h sttrring at rt, the reaction mixture was diluted with dichtoromethane and quenched with saturated aqueous NaHCθ3 The aqueous layer was extracted with dichloromethane and the combined organic layers were dried over Na7SO4, filtered and evaporated The crude product was purified by flash chromatography (DCM/iPrOH 1% to
3 5%) to give the title compound as a yellowish oil (HPLC: tR 2.31 min (Method A); M+H = 229, 231 MS-ES)
Example 96 1 -(1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-8-[6-(4-methyl-piperazin-1 -yl)- pyndin-3-ylJ-1 ,3-dihydro-imidazo[4,5-c)qu)nolin-2-one
Figure imgf000209_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dtmethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo{4l5-c]quinolin-2-one (Intermediate A, 40 mg, 0.107 mmol) and 2-(4-methylpiperazine-1-yl)pyridine-5-boronic acid pinacol ester (Combi-Blocks, San Diego, USA, 40 mg, 0.132 mmol) to give the title compound as a white solid. (HPLC' tR 2 04 min (Method A); M+H = 469 MS-ES; 1H-NMR (dc- DMSO, 400 MHz) 8.91 (s, 1H)1 8 30-8.24 (m, 1H), 8 14-8.10 (m, 1H), 8.07-8.01 (m, 1H), 7 90-7 83 (m, 1H), 7.62-7.56 (m, 1H), 7.45-7.41 (m, 1 H), 6 97-6.90 (m, 1H), 3.92 (s, 3H), 3 55 (S, 7H). 2.41-2.35 (m, 4H), 2 21 (s, 3H), 1 95 (s, 3H))
Example 97 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-pyrrolidin-1-yl-pyridin-3-y!)-1 ,3- dihydro-imidazo[4,5-c]quinohn-2-one
Figure imgf000209_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 >3-dimethyl-1H-pyrazoM-yl)-3-methyl-1 )3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and 2-pyrrolidin-1-ylpyridine-5-boronic acid pinacol ester (Boron Molecular, Reaserch Triangle Park, USA) to give the title compound as a white solid. (HPLC: tR 2.23 min (Method A), M+H = 440 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.90 (s, 1 H)1 8 25-8 23 (m, 1H), 8.13-8.11 (m, 1H), 8 05-8.01 (m, 1H)1 7.87-7.83 (m, 1H), 7.58-7.53 (m, 1H). 7 42-7-40 (m, 1H), 6 56-6 52 (m, 1H), 3 92 (s, 3H), 3.56 (s, 3H), 3.44-3 38 (m, 4H), 1 97-1 92 (m, 7H))
Example 98.1 1 -( 1 , 3-Dimethyf- 1 H-pyrazol-4-yl)-8-(6-(ethyl-methyl-amino)-pyridin-3- yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000210_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro«im!dazo[4,5-c]qυindin-2-one (Intermediate A) and ethyl-methyl-[5-(4,4,5,5-tetramethyl-|:1 ,3,2]dioxaborolan-2-yl)-pyridin-2- yl]-amine (stage 98 1.1 ) to give the title compound as a white soltd (HPLC. tR 2 18 mm (Method A); M+H = 428 MS-ES, 1H-NMR (dβ-DMSO 400 MHz) 8 90 (s, 1H)1 8 26-8.24 (m, 1 H), 8 14-8.12 (m 1H)1 8.04-8.01 (m, 1 H), 7 88-7 84 (m, 1H), 7 57-7 52 (m. 1 H). 7 43-7-40 (m, 1 H)1 6 73-6.69 (m, 1H), 3.93 (s, 3H), 3.62-3.53 (m, 5H), 3 01 (s, 3H). 1.96 (s 3H), 1.07 (t, 3H))
Stage 98.1.1. Ethyt-methyl-[5-(4,4,5,5-tetramethyl-t1 ,3,2]dioxaborolan-2-yl)-pyridin-2-yl]- amine
Figure imgf000210_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1-2 using methylethylamine (Aldrich, Buchs, Switzerland) to give the title compound as a brown solid (HPLC. tR 1 77 mm (Method A), M+H = 263 MS-ES) The following examples were synthesized in a similar manner as described for Example 1.1 using ethyl-methyl-[5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyπdin-2-yl]-arnine
(Stage 98.1.1) and the specified intermediate.
Example lntermed structure Name of the example MS-ES HPLC t*
(M+H) (min)
98.2 G \ 8-t6-(Ethyl-methyl- 456 2.31
/~N amino)-pyπdin-3-yl]-1- i r I (1-isopropy!-3-methyl-
X Ύ 'T 1H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro- imidazo[4f5- c]qutnolin-2-one
98 3 F 8-[6-(Ethyμmethyl- 442 2 25
I amino)-pyndin-3-yl]-1 -
(1~ethyl-3-methyl-1H-
1 N--
Y Ύ -T pyrazol-4-yl)-3- methyl-1,3-dihydro- imidazo(4,5- c]quinolin-2-one
Figure imgf000211_0002
Example 99 i-CI .S-Dimethyt-I H-pyrazol^-yO-S-methyl-θ-CI H-pyrrolofS^-blpyπdin-δ-yl)- 1,3-dihydro-imidazo[4,5-c]quino)in-2-one
Figure imgf000211_0001
The titte compound was synthesized tn a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and 6-(4,4,5,5'tetramethyl-|;i ,3,2)dioxaborolan-2-yl)-1 H-pyrrolol3,2- b]pyridine (PepTech, Burlington, USA) to give the title compound as a white solid (HPLC ΪR 2 03 mm (Method A); M+H = 410 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 11.52 (s. 1 H)1 8 96 (s, 1H), 8,43-841 (m, 1H), 8.18-8 16 (m, 1H), 8.13-8.10 (m, 1H)1 8 00-7.95 (m, 1H), 7,83- 7 81 (m 1H), 7 72-7.69 (m, 1H), 7 60-7 58 (m, 1H), 6 60-6 58 (m 1 H), 3.94 (s, 3H), 3.58 (s, 3H), 1 97 (s, 3H))
Example 100 5-[1-(1 ,3-Dimethyl-1H-pyra2θl-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo ^δ-ctøuinolin-β-yil-pyπdine^-carboxylic acid methyl ester
Figure imgf000212_0001
A mixture of 8-bromo-1-(1 )3-d)methyl-1 H-pyrazol-4-yf)-3-methyl-1 <3-dihydro-imida2θt4,5- c]quinolin-2-one (Intermediate A, 39 mg, 0 105 mmol), 2-methylcarboxypyndine-5-boronic acid pmacol ester (Aalen Chemical, Nanjing, China, 49 mg, 0 186 mmol), potassium fluoride (22 mg, 0 379 mmol), Pd2(dba)3 (7.7 mg, 0 0085 mmol) and tri-t-butylphosphonium tetrafluoroborate (4.9 mg, 0 017 mmol) in dioxane (0.6 m!) was stirred under argon in a sealed microwave tube at rt for 20 h. The reaction was not completed Therefore, again Pd2(dba)3 (7.7 mg 0 0085 mmoi) and tri-t-butylpho$phonium tetrafluoroborate (4.9 mg, 0 017 mmol) and 2-methylcarboxypyrid)ne-5-boronic acid pinacol ester (Combi-Blocks San Diego, USA, 15 mg, 0 186 mmol) were added, the mixture was flushed with argon and stirred at rt for further 23 h. The RM was diluted with EtOAc The organic layer was washed with brine, dried over Na2SO4 filtered and evaporated The residue was dissolved in MeOH and purified directly by Prep HPLC (H2O (0 1% TFA)/CH3CN 95 5 to 60 30) The fractions containing products were collected together and basified with NaHCO3 (0.3 g), before being concentrated The resulting suspension was filtered and the cake was washed with water, before being dried under high vacuum to give the title compound as a white solid (HPUC tπ
2 45 min (Method A), M+H = 429 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 99 (s, 1H) 8.83- 8 78 (m, 1 H)1 8 20-8 12 (m, 3H), 8.11-8 06 (m 1H), 8 05-7 98 (m, 1H)1 7.69-7.62 (m, 1H),
3 92 (s, 3H), 3.90 (s, 3H), 3 58 (s, 3H), 1 96 (s, 3H))
Example 101 {4-[8-(6-Methoxy-pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-imidazot4,5- c]quinolin-1 -yl)-3-methyt~pyrazoM -yi}-acetic acid
Figure imgf000213_0001
A mixture of [4-(8-bromo-3-methyl-2-oxo-2,3-d)hydro-imida2θ{4,5-c]quinoltn«1-yl)-3-methyl- pyrazol-1-yl]-acetic acid (Stage 101.1.1b, 161 mg, 0 387 mmol), 2-methoxypyπdine-5- boronic acid (AWπch Buchs, Switzerland, 77 mg, 0 503 mmol), and PdCI2(PPh3)S (17 mg, 0 024 mmol) in DMF (4 0 ml) and 1 M aqueous K2CO3 (1 16 ml) was stirred under argon at 105 °C for 1 25 h The RM was cooled to rt The mixture was diluted with MeOH + 3 drops TFA and purified directly by Prep HPLC (H2O (0 1% TFA)ZCH3CN 95 5 to 65 35) The fractions containing products were collected together concentrated, before being lyophilized to give the title compound as a TFA-salt and wh»te powder (HPLC tR 2 38 mm (Method A), M+H ~ 446 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 9 22 (β, 1H)1 8 46 (s, 1H), 8 23-8 14 (m, 3H), 7 87-7 79 (m, 1H), 7 74-7 68 (m, 1H), 6 94-6 88 (m, 1H), 5 15-4 98 (m, 2H), 3 89 (s, 3H), 3 60 (s, 3H)1 1 97 (s, 3H))
Stage 101.1.1b [4-(8-Bromo-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-c)quinolin-1-yl)-3- methy!-pyrazol-1-yl]-acettc acid
Figure imgf000213_0002
To a mixture of [4-(8-biOmo-2-oxo-2)3-dihydro-imidazo{4 5-c]quinolin-1-y))-3-methyl-pyrazol- 1-yl]-acet)c acid (Stage 101.1.2, 422 mg, 1 050 mmol) tn DMF (6 ml) cooled to 0 "C was added NaH 55% (92 mg, 2 mmol) The cooling bath was removed and the RM was stirred for 45 mm at rt Then iodomethane (0 132 ml, 2 mmol) was added and the RM was stirred for 1h The reaction was not completed Therefore again NaH 55% (50 mg, 1 2 mmol) was added and stirred for 15 mm and after that iodomethane (0 070 ml, 1 2 mmol) was added and stirred at rt for one further hour Then the RM was quenched with saturated aqueous NaHCO3 and extracted with EtOAc (2x) in the organic layer was found the ester side product [4-(8-Bromo-3-methy)-2-oxo-2,3-dihydro-irnidazo[4,5-c]quinolin-1-yl)-3-methyl-pyrazol-1-yl]- acetic acid methyl ester (Stage 101.1.1a)
The aqueous layer was adjusted with 4 M aqueous HCI to pH 5 The mixture was then extracted with rvbutanol (2x) The combined organic layer was evaporated. The residue was diluted with DCM/MeOH. The mixture was filtered over celite, and the filtrate was evaporated to give the title compound as a orange sticky solid. (HPLC- tR 2 21 mm (Method A): M+H = 416, 418 Br-Pattern MS-ES)
Stage 101,1.2 [4-(8-Bromo-2-oxo-2,3-dihydro-imidazo(4,5-c]quinoJin-1-yl)-3-methyl-pyrazol- 1-y1]-acetic acid
HO^0
\ — (,
Figure imgf000214_0001
1LA
To a mixture of (4-(8-bromo-2-oxo-2,3-dihydro-imida2o(4,5-c]quinolin-1-yl)-3-methyl-pyrazo)- 1-yl]-acetic acid methyl ester (Stage 101.1.3, 3 22 g, 7 73mmol) and tetrabutylammonium (250mg, 0.773 mmol) in CH2CI2 (150ml) was added 1 M aqueous NaOH (80 ml). The reaction mixture was energetically stirred for 4h30 at rt The organic layer was separted and the aqueous layer washed with CHjCI? (2x), adjusted to pH 4 with concentrated aqueous HCI and extracted with n-butanol (5x) The combined organic layers were washed with bnne adjusted to pH 4 with HCI and evaporated to dryness. The residue was dry loaded on Isolute, washed with water/1 -propanol 3% and eluted with acetonitnle/1-propanol 3% on reverse phase silica gel plug To acetonitπle filtrate was added water and solution was concentrated. The formed precipitate was filtered, washed with water and dried to give the title compound as a yellow solid (HPLC. tR 2 08 min (Method A); M+H = 402, 404 Br-Pattem MS-ES)
Stage 101.1.3 [4-(8-Bromo-2-σxo-2, 3-dihydro-imidazo[4, 5-c)quinoltn- 1 -yl)-3-methyl-pyrazol- 1-y1]-acetic acid methyl ester
Figure imgf000215_0003
The title compound was synthesized in a similar manner as described in Stage A.1-3 using (4-amino-3-methyl-pyrazol-1-yl)-acetic acid methyl ester (Stage 101.1.4) to give the title compound as green solid. (HPLC: tR 2.35 min (Method A))
Stage 101.1-4 (4-Amino-3-methyl-pyrazol-1-yl)-acetic acid methyl ester
Figure imgf000215_0001
The title compound was synthesized in a similar manner as described in Stage A.2 starting from S-MethyM-nitro-pyrazoi-1-yl-acetJC acid methylester (ChemCollect, Remscheid, Germany) to give the title compound as a pinkish oil. (HPLC: tR 0.96 mfn (Method A): M+H = 170 MS-ES)
ExamDte 102 2-(4-f8-(6-Methoxv-pvr)din-3-vl)-3-methvl-2-oxo-2,3-dihvdro-imidazof4,
δ-clquinolm-1-yll-S-methyt-pyrazol-1-yO-N.N-dimethyl-acetamide
Figure imgf000215_0002
A mixture of {4-[8-(6-Methoxy-pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-imtdazo[4r5-c)quinolin- 1-yl]-3-methyl-pyrazol-1-yl}-acetic acid TFA salt (Example 101, 60 mg, 0.107 mmol), TPTU (128 mg, 0.430 mmol) and DlPEA (0.094 ml, 0.537 mmol) in DMA (1.5 ml) was stirred under argon at rt for 20 mm Then dimethtylamine in THF 2 M (Aldrich, Buchs Switzerland, 0,242 ml, 0 483 mmol) was added and the RM was stirred at rt for 3 h. The RM was directly purified by Prep.HPLC (H2O (0 1% TFA)/CH3CN 95:5 to 50:50). The fractions containing products were collected together and basified with NaHCO3 (0.3 g), before being concentrated. The resulting layer was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and evaporated to dryness to give the title compound as a white solid. (HPLC. tR 2.57 min (Method A), M+H = 472 MS-ES, 1H-NMR (dδ-DMSO, 400 MHz) 8.95 (s, 1H), 8.50-8 43 (m, 1H)1 8 14-8.04 (m. 2H)1 8.01-7 96 (m, 1H)1 7.95-7 90 (m, 1H), 7-77-7.71 (m. 1 H), 6.87-6 81 (m. 1H), 5.25-5.09 (m, 2H), 3 86 (s, 3H), 3.56 (s, 3H), 3.05 (s, 3H)1 2.88 (s, 3H). 1.93 (s, 3H))
Example 103,1 1 -[1 -(2-Hydroxy-ethyl)-3-methyl-1 H-pyrazol-4-yl]-8-(6-methoxy-pyridin-
3-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000216_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -{ 1 -(2-hydroxy-ethyt)-3-methyl- 1 H-pyrazol-4-yl]-3-methy>- 1 ,3-dihydro-imidazo(4, 5- c)quinolin-2-one (Stage 103.1.1, 37.4 mg, 0.093 mmol) and 2-methoxypyridϊne-5-boronic actd (Aldrich, Buchs, Switzerland, 20 mg, 0 131 mmol) to give the title compound as a white solid. (HPLC: tR 2 42 min (Method A); M+H = 431 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.95 (S1 1H)1 8 35 (s, 1 H), 8.13 (s, 1 H), 8 10-8 05 (m, 1H)1 7 95-7 88 (m, 1H), 7.81-7.75 (m, 1H), 7.51 -7.46 (m, 1 H). 6 93-6 86 (m, 1 H), 5 00-4,94 (m, 1 H), 4 24-4.17 (m. 2H), 3.88 (s 3H), 3.86-3.74 (m, 2H), 3.57 (s. 3H), 1 94 (s, 3H))
Stage 103.1.1 8-Bromo-1-f1-(2-hydroxy-ethyl)-3-methyl-1 H-pyrazol-4-yl]-3-methyl-1 ,3-
dihydro-imidazol4,5-c]quinolin-2-one
Figure imgf000217_0001
A mixture of [4-(8-lxornθ'3-methyl-2-oxo-2,3-dihyclro-imidazo[4,5-c)qυinolin-1-yl)-3-methyj- pyrazol-1-yl]-acetic aαd methyl ester (Stage 101.1.1a, 60 mg, 0 139 mmol) and MeOH (0 021 ml, 0 519 mmol) in THF (1 5 ml) was cooled to 0 °C Then NaBH4 (14 mg. 0 370 mmol) was added and the RM was heated to 50 "C for 30 mm After that, the RM was quenched with saturated aqueous NaHCO3 (20 ml) and extracted with EtOAc (2x) The combined organic layers were washed with brine, dned over Na2SO4, filtered and evaporated to dryness to give the title compound as a lightly yellow solid (HPLC tR 2 23 mm (Method A), M+H = 402, 404 Br-Pattern MS-ES)
Alternatively, the titte compound was synthesized in a similar manner as described for intermediate A starting from 2-(4-amino-3-methyl-pyrazol-1-yl)-ethanol (Stage 103.1.2)
The following example was synthesized in a similar manner as descπbed for Example 1.1 using 6-ethoxypyridine-3-boronic acid (ABCR, Karlsruhe, Germany) and 8-bromo-1-[1-(2- hydroxy-ethyl)-3-methyl-1H-pyra2θ)-4-ylj-3-methyl-1 ,3-d)hydfθ-tmidazo[4,5-cjquinolin-2-one (Stage 103.1.1)
Figure imgf000217_0002
Figure imgf000218_0002
To solution of S-methyl-Φ-nitropyrazol-1-yl-acetic acid methylester (ChemCollect, Remscheid, Germany, 297 mg, 1 491 mmol) in THF (12 ml) cooled with an ice-bath was added a 1 M solution of lithium aluminium hydride in THF(1 ,5 ml, 1.5 mmol) The reaction mixture was stirred 1 h at rt then was added more of the reducing reagent (0.75 ml, O 75 mmol), stirring 2 h at rt, (1 5 ml, 1 5 mmol), stirring 45 min, (2 ml, 2 mmol) and the reaction mixture was stirred 17 h at rt before being quenched with water and taken in EtOAc The suspension was filtered and the solid washed with EtOAc. The filtrate was dried over Na2SO4, filtered and evaporated to give crude brown solid. (HPLC: tR 0.85 mm (Method A), M+H - 142 MS-ES)
Example 104 1-(1-Ethyl-3-methyl-1H-pyrazol-4-yl)-8-(6-methoxymethyl-pyridin-3-yl)-3- methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000218_0001
To a mixture of 1-(1 -ethyls-methyl- 1 H-pyrazol-4-yl)-8-(6~hydroxymethyl-pyridin-3-yl)-3- methyl-1,3-dihydro-imidazo(4,5-c]quinolin-2-one (Example 16.1, 28 mg 0.068 mmol) in DMF (1ml) was added NaH 55% (4 mg, O 092 mmol) and the mixture was stirred for 20 mm Then iodomethane (0 006ml, 0 096 mmol) was added and the RM was stirred again at rt for 30 mm. After that, the RM was quenched with saturated aqueous NaHCO3 (20 ml) and extracted with EtOAc (2x) The combined organic layers were washed with brine, dried over Na?SO4, filtered and evaporated The residue was dissolved in DMA and punfied directly by Prep.HPLC (H2O (0 1% TFA)ZCH3CN 95:5 to 65 35) The fractions containing products were collected together and basified with NaHCθ3 (0 3 g), before being concentrated The resulting suspension was filtered and the cake was washed with water, before being dried under high vacuum to give the title compound as a white solid (HPLC tR 2 30 min (Method A); M+H = 429 MS-ES, 1H-NMR (ds-DMSO, 400 MHz) 8.98 (s, 1H) 8 63 (s, 1 H). 8 20 (s, 1 H), 8 15-8 10 (m, 1 H), 7 98-7 93 (m, 1 H), 7.92-7.87 (m, 1 H), 7.58-7 53 (m, 1H) 7 49-7 44 (m, 1H), 4 54-4 50 (m, 2H)1 4 23-4.15 (m, 2H), 3.58 (s, 3H), 3 37 (s, 3H), 1.95 (s, 3H), 1 32 (t, 3H))
Example 105 1-(1-lsopropyl-3-methyl-1H-pyrazol-4-yl)-8-(6-methoxymethyl-pyπdin-3-yl)-3- methyl- 1 ,3-dihydro-imidazo[4 , 5-c]quinolin-2-one
Figure imgf000219_0001
The title compound was synthesized in a similar manner as described for Example 104 using 8-(6-hydroxymethyl-pyridin-3-yl)-1-(1-isopropyl-3-methyl-1H-pyra2θl-4-yl)-3-methyl-1 ,3- dihydro-imidazo|4,5-c]quinolin-2-one (Example 16.3, 26 mg, 0.061 mmd) to give the title compound as an off-white solid (HPLC tR 2 39 min (Method A): M+H - 443 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8 98 (s, 1H), 8 68-8.59 (m 1H), 8 27-8 20 (m, 1H), 8.17-8 09 (m, 1 H), 7 99-7 85 (m, 2H), 7 59-7 51 (m, 1H), 7 49-7 41 (m, 1 H), 4.60-4.49 (m, 3H), 3.59 (s, 3H)1 3 38 (S, 3H) 1.98 (s, 3H), 1 47 (s, 6H))
Example 106 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-8 -[1 -(2-hydroxy-ethyl)- 1 H-pyrazol-4-ylJ-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000219_0002
To a mixture of 1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-{1-(2-(tetrahydro-pyran-2-yloxy)- ethyl]-1 H-pyrazol-4-yl}-1 ,3-dihydro-imida2θ[4l5-c)quinolin-2-one (Stage 106.1.1 95 mg, 0 195 mmol) in MeOH (2ml) was added dloxane 4 M (0 248 ml 0 993 mrnol) and the RM was stirred at rt for 45 min Then the RM was evaporated, before being quenched with saturated aqueous NaHCO3 (20 ml) and extracted with DCM (2x). The combined organic layers were washed with brine, dried over Na2SO4, fiitered and evaporated The residue was diluted with MeOH + 2 drops TFA and purified directly by Prep.HPLC (H?0 (0.1% TFA)/CH3CN 95:5 to 65.35). The fractions containing product were collected together and basified with NaHCO3 (0.3 g), before being concentrated. The resulting layer was extracted with DCM, washed with brine, dried over Na2SO4, filtered and evaporated to dryness to give the title compound as a white solid. (HPLC: tR 2.24 min (Method A); M+H = 404 MS-ES; 1H- NMR (de-DMSO, 400 MHz) 8.87 (s, 1H), 8.14-8.08 (m, 1H), 8.01-7.92 (m, 2H), 7.82-7.75 (m, 1H), 7.52-7.47 (m, 1 H), 7.39-7.35 (m, 1H), 4.96-4.89 (m, 1H). 4.17-4.11 (m, 2H), 3.96 (s, 3H), 3.77-3.69 (m, 2H), 3.55 (s, 3H), 1.94 (s, 3H))
Stage 106.1.1 1-(1 ,3-Dimethyl-1H-pyrazol-4-yi)-3-methyl-8-{1-[2-(tetrahydro-pyran-2-yloxy)- ethy!]-1 H-pyrazol-4-yl}-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000220_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyt-1,3-dihydro-imidazo (4,5-c]quinoiin-2-one (Intermediate A. 80 mg, 0.215 mmol) and 1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-4-(4,4,5,5- tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-1 H-pyrazote (Stage 106.1.2, 91 mg, 0.279 mmol) to give the title compound as red sticky oil. Used for next step without further purification. (HPLC: fe 2.66 min (Method A); M+H = 488 MS-ES)
Stage 106.12 1-[2-(Tβtrahydro-pyran-2-y!oxy)-βthyl]-4-(4(4,5,δ-tβtramethyl-[1,3.2]clioxa borolan-2-yl)-1 H-pyrazote
Figure imgf000220_0002
To a solution of 4-iodo-1-(2~(tetrahydrσ-pyran-2-yloxy)-ethyl]-1H-pyrazole (Stage 106.1.3, 8.50 g, 26.4 mmol) in THF at 0 °C under argon was added dropwise iPrMgCI 2 M in THF (26.4 ml, 52.8 mmol) The RM was stirred at 0 °C for 1h Then 2-methoxy-4,4,5,5- tetramethyl-1 ,3,2-dioxaborolane (Aldrich, Buchs, Switzerland, 6 25 g, 52 8 mmol) was added at 0 °C and the solution was stirred again and allowed to warm to rt for 1 h After that, the RM was quenched with saturated aqueous NH4CI (140 ml) and extracted with EtOAc (3x) The combined organic layers were washed with saturated aqueous NH4CI, dried over Na2SO4, filtered and evaporated The residue was puriffed by flash chromatography (hexane/EtOAc 5 % to 45 %). The fractions containing product were combined and evaporated to dryness to give the title compound as a colorless oil. (HPLC tR 3.23 mm (Method A); M+H = 323 MS- ES)
Stage 106.1.3 4-lodo-1 -[2-(tetrahydro-pyran-2-yloxy)-ethylj-1 H-pyrazole
Figure imgf000221_0001
To a mixture of 4»iodopyrazole (Aldrich, Buchs. Switzerland, 10 g, 51 6 mmol) and Cs2CO3 (20.16 g 61 9 mmol) was added 2-(2-bromoethoxy)tetrahydro-2H-pyran (Aldrich, Buchs, Switzerland, 9 IA ml, 61.9 mmol) The RM was stirred at 70 °C for 17h. Then the RM was quenched with water (100 ml) and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated. The residue was absorbed on silica gel and purified by flash chromatography (hexane/EtOAc 0 % to 30 %) The fractions containing product were combined and evaporated to dryness to give the title compound as a colorless oil (HPLC tR 3 12 mm (Method A), M+H = 323 MS-ES)
Example 107 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-t6-(2-hydroxy-ethoxy)-pyridin-3-yl]-3- methyM ,3-dihydro-imidazo(4,5-c}quinol!n-2-Qne
Figure imgf000222_0002
To a mixture of 1-(1 >Dimethyl-1H-pyrazol-4-yl)-8-(6-(2-hydroxy-ethylamino)-pyridin-3-yl]-3- methyl-1 ,3-dihydro--imidazo[4,5-c]quinolin-2-one (Example 19, 40 mg, 0.077 mmol) in MeOH/THF=1 :1 (4ml) was added under nitrogen Pd/C 10% (20 mg, 0.026 mmol). The RM was shacked under H2 at rt for 22 h. The reaction was not completed, again Pd/C catalyst (20mg) was added and the mixture was stirred under H2 at rt for 22 h. This procedure was repeated for a third time. Then the suspension was filtered over celitβ and washed with MeOH. The filtrate was evaporated. The residue was dissolved in MeOH and purified directly by Prep.HPLC (H2O (0.1% TFA)/CH3CN 95:5 to 65:35). The fractions containing product were collected together and basified with NaHCO3 (0.3 g), before being concentrated. The resulting suspension was filtered and the cake was washed with water, before being dried under high vacuum to give the title compound as a white solid. (HPLC: tR 2.32 min (Method A); M+H = 431 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.97 (s, 1H), 8.30-8.26 (m. 1 H), 8.17- 8.06 (m, 2H), 7,93-7.86 (rn, 1H), 7.81-7.75 (m, 1H), 7.50-7.46 (m, 1H), 6.97-6.91 (m, 1 H), 4.80-4.86 (m, 1H), 4.34-4.28 (m, 2H), 3.92 (s, 3H), 3.75-3.69 (m, 2H), 3.58 (s, 3H), 1 ,95 (s, 3H))
Example 108 1-(1,3-Dimethyl~1H-pyra2ol-4-y!)-8-[6-(3-hydroxy-propoxy)-pyridin-3-yl]-3- methyl- 1 , 3-dihydro-jmtdazo(4 , 5-c]quinolin-2-one
Figure imgf000222_0001
The title compound was synthesized in a similar manner as described for Example 107 using 1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-8-[6-(2-hydroxy-ethylamino)-pyridin-3-yl]-3-methyl-1 ,3- dihydro-imidazo[4,5-c)quinolin-2-one (Example 20, 42 mg, 0.078 mmol) to give the title compound as a white solid. (HPLC: tR 2.42 min (Method A); M+H - 445 MS-ES; 1H-NMR (d6- DMSO1 400 MHz) 8 95 (s, 1H), 8 33-8.25 (m, 1H)1 8.18-8 05 (m, 2H), 7.93-7.86 (m, 1H), 7 80-7.73 (m, 1H), 7 51-7.45 (m. 1H)1 6.97-6 89 (m, 1 H), 4.57-4.50 (m, 1 H), 4.41-4.31 (m. 2H), 3 93 (S, 3H), 3.61-3.52 (m, 5H), 1.97 (s, 3H), 1 91-1.82 (m, 2H))
Example 10S 1-(1 ,3-Dimethyl-i H-pyrazot-4-yl)-8-(6-methoxy-pyridin-3-yl)-1 ,3-dihydro- imidazo[4,5-c]qυinolin-2-one
Figure imgf000223_0001
A mixture of 8-bromo-1-(1 ,3-dimethyl-1H-pyrazo!-4-yl)-3-methyl-1 ,3-dihydro-imidazo [4,5- c]quinolin-2-one (Stage A.1 , 49 mg, 0.137 mmol), 2-methoxypyridine-5-boronic acid (Sigma- Aldπch. Bυchs, Switzerland, 26 mg, 0 170 mmol), and PdCI2(PPh3)2 (6 mg, 0.0085 mmol) in DMF (1.2 ml) and 1 M aqueous K2CO3 (0.343 ml) was stirred under argon at 105 °C for 1.5 h. The RM was cooled to rt. The mixture was diluted with MeOH + 3 drops TFA and purified directly by Prep.HPLC (H2O (0 1% TFA)/CH3CN 95 5 to 60.40). The fractions containing products were collected together and basifted with NaHCO3 (0 3 g), before being concentrated. The resulting suspension was filtered and the cake was washed with water, before being dried under high vacuum to give the title compound as a white solid. (HPtC- IR 2 46 min (Method A); M+H = 387 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 11.66 (s, br, 1 H), 8.72 (s, 1H) 8.33-8 26 (m, 1H), 8.16-8.10 (m, 1H), 8.09-8.01 (m, 1H), 7.91-7.84 (m, 1 H), 7 81-7.74 (m, 1H), 7 51-7 43 (m, 1H), 6.98-6.91 (m, 1H)1 3 90 (s, 3H), 3,87 (s, 3H), 1.95 (s, 3H))
Example 110 1-(1 ,3-Dimethyl-1H-pyrazol-4-yt)-8-(6-ethoxy-pyπdin-3-yf)-1 ,3-dihydro
-imidazo[4,5-c]quinolin-2-one
Figure imgf000223_0002
The title compound was synthesized in a similar manner as described for Example 109 using 2-ethoxypyridine-5-boronic acid (ABCR, Karlsruhe, Germany, 29 mg, 0 170 mmol) to give the title compound as a white solid. (HPLC: t« 2 59 min (Method A), M+H = 401 MS-ES; 1H-NMR (oVDMSO, 400 MHz) 11.67 (s, br, 1 H), 8.71 (s, 1H), 8.30-8.25 (m, 1H), 8.15-8 11 (m, 1H), 8.07-8.02 (m, 1H), 7 90-7 84 (m, 1H), 7 79-7.73 (m. 1H), 7.49-7.44 (m, 1 H), 6 95- 6.88 (m, 1H), 4.33 (q, 2H), 3.89 (s, 3H), 1.95 (s, 3H), 1 33 (t, 3H))
Example 111 8-(3,4Oimethoxv-phenv1H-(l3-dimethvl-1H-Dvrazol-4-v1H ,3-dihvdro-
imidazo(4, 5-c]quinolin-2-one
Figure imgf000224_0001
The title compound was synthesized in a similar manner as described for Example 109 using (3,4-dimethoxyphenyl)boronic acid (Aldπch, Buchs, Switzerland, 31 mg, 0.167 mmol) to give the title compound as a white solid (HPLC: tR 2 57 mm (Method A); M+H - 416 MS- ES; 1H-NMR (dδ-DMSO, 400 MHz) 11.67 (s, br, 1 H), 8,68 (s, 1 H), 8.14-8.09 (m, 1 H)1 8.05- 7.98 (m, 1 H), 7.94-7.87 (m, 1 H)1 7 56-7.51 (m, 1H), 7.12-7 07 (m, 1H), 7 07-7 00 (m, 1H), 6.97-6 92 (m, 1H) 3 88 (s, 3H) 3.83 (s, 3H), 3 78 (s, 3H), 1.97 (s, 3H))
Example 112 5-[1-(1-lsopropyl-3-methyl-1H-pyrazol-4-yt)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo[4,5-c}qufnolin-8-ylJ-pyπdine-2-carboxylic acid amide
Figure imgf000224_0002
A mixture of 1-(iHsopropyl~3-methyl~1H-pyrazol-4-yf)-3-methyl-8-(4,4 5,5-tetramethyl- (1 ,3,2]dioxaborolan-2-yl)-1,3-d!hydro-imidazo[4,5-c]quinolin-2-one (Stage 112.1.1 , 34 mg, 0.075 mmol), δ-bromo-pyπdine^-carboxylic acid amide (Combi-Blocks, San Diego, USA, 20 mg, 0 099 mmol), and PdCI2(PPh3)2 (3.5 mg, O 005 mmol) in DMF (O 9 ml) and 1 M aqueous K2CO3 (0.187 ml) was stirred under argon at 105 °C for 2.5 h The RM was cooled to rt. The mixture was diluted with MeOH + 3 drops TFA and purified directly by Prep.HPLC (H2O (0.1% TFA)/CH3CN 97:3 to 55:45). The fractions containing product were collected together and basifted with NaHCO3 (0.3 g), before being concentrated The resulting layer was extracted with DCM, washed with brine, dned over Na2SO4, filtered and evaporated to dryness to give the title compound as a white solid (HPLC: tR 2.44 mm (Method A): M+H ~ 442 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 9.00 (s, 1H). 8 75-8 69 (m, 1H), 8.24-8.19 (m, 1H), 8.18-8.07 (m, 2H) 8.07-7.98 (m, 3H), 7.75-7.67 (m, 1 H), 7 61-7.56 (m, 1H)1 4.61-4 48 (m, 1H). 3.58 (s, 3H), 1 97 (s, 3H), 1.45 (s, 3H), 1.43 (s, 3H))
Stage 112.1.1 1-(1-lsopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-8-(4,4,5,5-tetramethyl- [1.3,2]dioxaborolan-2-yl)-1.3-dihydro-imidazo(4,5-c]quinolin-2-one
Figure imgf000225_0001
A mixture of 8-bromo-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1,3-dihydro- imidazo[4,5-c]quinolin-2-one (Intermediate G1 100 mg, 0 250 mmol) bis(pinacolato)- diborane (Aldrich, Buchs, Switzerland, 78 mg, 0.3 mmol), potassium acetate (74 mg, 0.754 mmoi) and PdCI2(dppf) (8 mg, 0.011 mmol) in dioxane (1 1 ml) and DMSO (0 02 ml) was stirred in a closed microwave vial flushed with argon at 90 °C for 7 5 h Then the RM was diluted with EtOAc and washed with brine (2x). The organic layer was dried over Na2SO4, filtered and evaporated to dryness. The residue was dissolved in DCM and purified by flash chromatography (DCM/MeOH 0 % to 4 %), The fractions containing product were evaporated together to give the title compound as an off-white solid (HPLC tR 2 16 mm (Method A), M+H = 448 MS-ES)
Example 113 1-(1-lsopropyi-3-methyl-1 H-pyrazol-4-yl)-3-methyl-8-pyπdin-2-yl-1 ,3-dihydro- imidazo(4,5-c]quinolin-2-one
Figure imgf000226_0001
The title compound was synthesized tn a similar manner as described in Example 112 using 2-bromopyridine (Aldπch, Buchs, Switzerland, 0 009 ml, 0 093 mmol) to give the title compound as a white solid (HPLC: tR 2 49 mm (Method A); M+H « 399 MS-ES; 1H-NMR (dθ- DMSO, 400 MHz) 8 98 (s, 1H)1 8 61-8 56 (m, 1H), 8 28-8 23 (m, 1H), 8 23-8 19 (m, 1H)1 8 13-8 06 (m, 2H), 7.88-7.81 (m, 1H). 7.69-7.63 (m 1H). 7 38-7.31 (m, 1H), 4 63-4.52 (m, 1H), 3.58 (s, 3H), 1.95 (s, 3H), 1.51 (d, 6H))
Example 114 1 -(1 ,3-Dimethyl-i H-pyrazol-4-yl)-3-methyl-8-pyndin-2-y!-1 ,3-dihydro- imidazo(4, 5-c]qυinolin-2-one
Figure imgf000226_0002
The title compound was synthesized in a similar manner as described in Example 112 using 1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-8-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Stage 114.1.1 , 34.5 mg, 0 082 mmol) and 2- bromopyridine (Aldrich, Buchs, Switzerland, 0 011 ml, 0 114 mmol) to give the title compound as a white solid (HPLC. tR 2 25 mm (Method A); M+H » 371 MS-ES; 1H-NMR (d6- DMSO, 400 MHz) 8 98 (s, 1 H), 8.67-8.61 (m, 1H), 8.30-8 24 (m, 1 H), 8 17-8 06 (m, 3H), 7 94-7 86 (m, 1 H), 7 67-7 61 (m, 1 H), 7 39-7 32 (m, 1 H), 3 95 (s. 3H), 3 57 (s, 3H)1 1.95 (s, 3H))
Stage 114.1.1 1 -(1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-8-(4,4,5.5-tetramethyl-
{I Λ∑JdioxaborolarhΣ-ylJ-I .S-dihydro-imkJazo^δ-clquinolin-Σ-one
Figure imgf000227_0001
The title compound was synthesized in a similar manner as described in stage 112.1.1 using 8-bromo-1-(1 3-dtmethyl-1 H-pyrazol-4-yl)-3-methy!-1 ,3-dihydro-imidazo {4,5-c]quinolin-2-one (Intermediate A, 200 mg, O 532 mmol) to give the title compound as an off-white solid (HPLC tft 2 00 mm (Method A); M+H = 420 MS-ES)
Example 115 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-pyrazin-2-yl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one
Figure imgf000227_0002
The title compound was synthesized in a similar manner as described in Example 112 using 1-(1 ,3-dimethyl-1 H-pyrazo!-4-yl)-3-methyl-8-(4 4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-y1)- 1,3-dihydro-imidazo(4,5-c]quinolin-2-one (Stage 114.1.1, 33 5 mg, 0080 mmoi) and 2- bromopyrazine (Synchem, Huddersfield, UK, 17 2 mg, 0 108 mmol) to give the title compound as a white solid (HPLC. tR 2.34 mm (Method A); M-t-H = 372 MS-ES, 'H-NMR (σV DMSO, 400 MHz) 9 01 (8, 1 H), 8 98 (s, 1 H), 8.72-8 70 (m. 1 H)1 8 62-860 (m. 1 H)1 8.32-8.28 (m, 1H), 8.16-8 13 (m, 3H), 3 94 (s, 3H)1 3.59 (s 3H), 1 95 (s, 3H))
Example 116 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(1-methyl-1H-pyrrolot2,3- b)pyridin-5-yl>- 1 , 3-dihydro-(midazo[4 , 5-cJquinolin-2-or>e
Figure imgf000228_0001
A mixture of a new batch of 1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(1H-pyrrolo[2,3- b]pyπdin-5-yi)-1 ,3-dihydro-tmJdaEθ(4,5-c]quinolin-2-one (Example 36, 45.4 mg, 0.111 mmol) in 1.5 ml anhydrous DMF was treated with 55% NaH in oil (6.0 mg, 0.138 mmol) The reaction mixture was stirred for 20 mm at rt, then was added iodomethane (0.009 ml, 138 mmol). The reaction mixture was stirred for 1 5 h at rt. The RM was diluted with MeOH + 3 drops TFA and purified directly by Prep.HPLC (H2O (0.1% TFA)/CH3CN 95.5 to 60:40). The fractions containing products were coltected together and ossified with NaHCO3 (0 3 g), before being concentrated. The resulting suspension was filtered and the cake was washed with water, before being dried under high vacuum to give the title compound as a white solid (HPLC- tR 2 62 mm (Method A); M+H = 424 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.96 (s, 1H), 8 38-8 36 (m, 1H)1 8,18-8.16 (m, 1H)1 8.13-8 09 (m. 1H), 8 06-8.04 (rn, 1H)1 7 99-7 95 (m, 1 H), 7 60-7 58 (m, 1H), 7 57-7.55 (m, 1H), 6 54-6.51 (m, 1 H), 3.93 (s, 3H)1 3 85 (S, 3H), 3 58 (S1 3H)1 1.97 (s 3H))
Example ii? N-{3-[1-(1,3-Dimethyl-1H-pyrazo)-4-yl)-3-methyl-2>oxo-2,3-dihydro-1 H- imidazo[4,5-c}quinolin-8-yl]-phenyl}-N-methyl-rnethanesulfonamide
Figure imgf000228_0002
The title compound was synthesized in a similar manner as described for Stage 62.1.2 using N~{3-[1-(1 ,3-dimethyl-i H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo [4,5- c]quinolin-8-yl]-phenyl}-methanesulfonamide (Example 47) to give the title compound as a white solid (HPLC tR 2 59 mm (Method A)1 M+H = 477 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 97 (s, 1H), 8 16-8.07 (m. 2H), 7 95-7 90 (m 1H), 7 60-7 56 (m, 1H), 7 54-7.48 (m, 1H), 7 47-7 40 (m, 3H), 3 90 (s, 3H), 3.57 (s, 3H)1 3 29 (S1 3H). 2 99 (s, 3H) 1 95 (s, 3H)) Examole 118,1 1 -{ 1 -lsopropyl-3-methyl-1 H-pyrazol-4-yl)-3-methyl-8-(6-methylamino- pyridin-3-yl)-1 ,3-dihydro-tmidazo[4,5-c]quinolin«2-one
'
Figure imgf000229_0001
The title compound was synthesized in a similar manner as described (or Example 1.1 using 8-bromo-1-(1-tsopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imida2θ[4,5- cJquinoHn-2-one (Intermediate G, 58 8 mg, 0 147 mmol) and 6-(N-boc- methylarrnno)pyrtdine-3-borontc acid pinacol ester (Alfa Aesar, Heysham, UK, 58 8 mg,
0 176 mmol) to give crude boc-protected title compound that is treated for 25 mm at rt with triflυoroacetic acid (1 5 ml) and then purified by prep HPLC to give the title compound as a light yellow solid (HPLC tR 2 21 mm (Method A), M+H = 428 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 90 (s, 1H), 8 23-8 14 (m, 2H), 8 05-7 98 (m, 1 H), 7 87-7 79 (tn, 1H), 7 48-7 37 (m, 2H)1 6 78-6 70 (m, 1 H), 649-6 42 (m, 1 H), 4 61 -4 50 (m, 1 H), 3 56 (s 3H), 2 77 (d, 3H),
1 95 (d, 3H), 1 51-1 45 (m 6H))
The following examples were synthesized in a similar manner as described for Example 118 using the specified intermediate
Figure imgf000229_0002
Figure imgf000230_0002
Example 119 1 »(3-Chloro-1 -methyl-1 H-pyrazol-4-yI)-3-methyl-8-(5-mβthyl-6-methylamtno- pyπdm-S-yl^i .S-dihydro-imidazo^.δ-cjquinoli^-one
Figure imgf000230_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(3-chloro-1-methyl-1H-pyra2o)-4-yl)-3-rn€thyl-1,3-dthydro-imidazo{4,5-c]quinoJin-2- one (Intermediate K) and 6-(N-boc-methylamino)-5-methylpyπdine-3-boronic acid pinacol ester (Combi-Btocks, San Diego, USA, 58.8 mg, 0.176 mmol) to give crude boc-protected title compound that was treated for 30 min at rt with tnfluoroacetic acid (0.5 ml) and then purified by prep. HPLC to give the title compound as an off-white foam. (HPLC' tR 2.24 min (Method A), M+H = 434 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.92 (s, 1H), 8.40 (s, 1H), 8.14-8 12 (m, 1H), 8.05-8.03 (m, 1H)1 7 90-7.85 (m, 1H), 7.38-7 37 (m, 2H), 6.28-6 20 (br, 1 H), 4.01 (S, 3H), 3.58 (s, 3H)1 2.88 (m, 3H)1 2 11 (s, 3H))
Example 120 N-{5-[1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methyt-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]qu(noliry8-yl]-pyridin-3-yl}-methanesulfonamide
Figure imgf000231_0001
The title compound was synthesized in a similar manner as described for Stage 75.1.3 using 8-(5-amino-pyπdin-3-yl)-1 -( 1 , 3-dimethyl- 1 H~pyrazol-4-yJ)-3-methyl- 1 ,3-dihydro-imida2θ[4, 5- c)quinolin-2-one (Example 45, 72 mg, 0.187 mmol) to give the title compound as a white solid (HPLC tR 2.19 mm (Method A); M+H = 464 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 10 20-10.15 (m. 1H), 9 00 (s, 1H), 8.43-8 37 (m, 2H), 8 19-8 09 (m, 2H), 7.92-7.84 (m. 1H), 7 72-7 66 (m, 1H)1 7 61-7 56 (m, 1H), 3.88 (s 3H), 3.58 (s, 3H), 3 11 (s, 3H), 1 96 (s, 3H))
Example 121 N~{5-[1-(1 ,3-Dimethyl-1H~pyrazoM-yl)-3-methyl-2-oxo-2,3-dihydro-1 H- imidazo^.δ-clquinolin-δ-yll-pyridin-S-yli-N-methyl-methanesulfonamicie
Figure imgf000231_0002
The title compound was synthesized in a similar manner as described for stage 62.1.2 using N-{5-[1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3wOethyl-2-oxo-2,3-dihydro-1 H-irnidazo[4,5-c]quinolin- 8-yl]-pyridin-3-yl}-methanesulfonamide (Example 120) to give the title compound as an off- white solid. (HPLC- tR 2 28 min (Method A); M+H = 478 MS-ES; 1H-NMR (CJ6-DMSO. 400 MHz) 9 00 (s, 1H)1 8 64-8 58 (m, 2H), 8.17-8,12 (m. 2H)1 8 03-7.97 (m, 1H), 7 92-7.88 (m, 1H), 7 63-7 59 (m, 1H), 3 88 (s, 3H), 3 58 (s, 3H)1 3.35 (S1 3H), 3.07 (s, 3H)1 1 96 (s, 3H))
Example 122 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-{5-ethylamino-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4.5-c]quinolin-2-one
Figure imgf000232_0001
A solution of 8-(5-amino-pyridin-3-yl)-1~(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imida2θ[4,5-c]quinolin-2-one (Example 45, 38 mg, 0 099 mmol), acelaldehyde (Fluka, Buchs, Switzerland, 4.8 mg, 0.108 mmol) in DCM (2 ml) was stirred for 1 5 h at rt in presence of acetic acid (0 02 ml 3.54 mmol). Was added sodium triacetoxyborohydride (52 2 mg, 0 246 mmol) and the RM was stirred 1 5 h at rt, before being quenched with aqueous saturated NaHCO3 and extracted with DCM (2x). The combined organic layers were dried over Na2SO4, filtered and evaporated to dryness The residue was purified by Prep.HPLC (H2O (0.1% TFA)/CH3CN 95:5 to 60:40) The fractions containing products were collected together and basified with NaHCO3 (0.3 g), before being concentrated, saturated with NaCI and extracted with EtOAc (3x). The combined organic layers were dried over Na2SO4, filtered and evaporated to give the title compound as an off-white solid (HPLC- tR 2 13 mm (Method A), M+H ~ 414 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 97 (s, 1 H)4 8.13-8 08 (m, 2H), 7 97- 7.95 (m, 1 H). 7.92-7.88 (m, 2H), 7 60-7 58 (m, 1H), 6.88-6.85 (m, 1H), 6 01 (t, 1H), 3.89 (s, 3H), 3 58 (s, 3H), 3 15-3.06 (m, 2 H), 1.95 (s, 3H), 1.21 (t, 3H))
Example 123 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-3-methyl-8-[6-(2H-tetrazol-5-yl)- pyπdin-3-yl]-1 ,3-dihydro-imidazo[4,5-c]qυinolin-2-one
Figure imgf000233_0001
A mixture of 5-(1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo[4,5- c]quinolin-8-yl]-pyπdine-2-carbonitrile (stage 123.1.1 , 41.1 mg, 0 104 mmol), sodium azide (10 mg, 0,154 mmcH) and ammonium chloride (18 mg, 0.337 mmol) in DMF (0 3 ml) was sealed and heated at 120"C for 80 mm. The reaction mixture was quenched with aqueous NaHCO3 and washed with EtOAc (2x) The aqueous layer was adjusted to pH 5 with 1 M aqueous HCI and extracted with dichloromethane (3x) The combined organic layers were dried over Na2SO4 filtered and evaporated. The crude product was purified by Prep.HPLC (H2O (0 1% TFA)/CH3CN 95.5 to 65 35). The fractions containing products were collected together and lyophilized to give the title compound as a white lyophilizate TFA salt (HPLC tR 2 34 min (Method A); M+H = 439 MS-ES, 1H-NMR (ds-DMSO, 400 MHz) 9,18 (s, 1H), 8 90- 8.85 (m, 1H), 8 37-8 32 (m, 1H), 8 26-8 15 (m, 4H), 7 75-7 70 (m, 1H), 3.94 (s, 3H), 3.61 (s, 3H), 2 00 (s, 3H))
Staαe 123,1,1 5-[ 1 -( 1 , 3-Dimethyl- 1 H-pyrazol~4-yl)-3-methyl-2-oxo-2 ,3-dihydro-1 H- imidazo(4,5-c]quinolin-8-yl]-pyridine-2-carbonitrile
Figure imgf000233_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and 2-cyanopyήdine-5-boronic acid pinacol ester (Frontier Scientific, Logan, USA) to give the title compound as a brown solid (HPLC: tR 2 42 mm (Method A), M+H * 396 MS-ES) Example 124 5-[1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo(4,5~c]quinolin-8-yl]-2-methoxy-nicotinic acid
Figure imgf000234_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using β-bromo-IKI .S-dimethyl-1H-pyrazoM-yO-S-methyl-i ^-dihydro-imtdaz^^-clquinolin^-one (Intermediate A) and 2-methoxy-3-(carbomethoxy)pyridine-5-boronic acid pinacol ester (Combi-Blocks, San Diego, USA) to give the title compound as a white lyophilizate TFA salt (HPLC: tR 2.31 mm (Method A), M+H = 445 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 9 21 (s, br, 1H), 8.62-8.56 (m, 1H), 8 23-8 16 (m, 3H), 8 11-8 07 (m. 1 H), 7.62-7.57 (m, 1 H), 3 96 (s, 3H), 3.93 (S1 3H), 3.59 (S1 3H), 1 94 (s, 3H))
Example 125.1 5-(1-(1 ,3-Dtmethyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-8-yl]-2-methoxy-N-methyl-nicotinamide
Figure imgf000234_0002
To a cooled with an ice-bath suspension of 5-[1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-2- oxo-2,3-dihydro-1H-imidazo[4,5H;]quinolm-8-yl}-2-methoxy-nicotinic acid TFA salt (Example 124, 60 mg, 0089 mmol) in dichtoromethane (1 5 ml) containing DMF (0 005 ml) was added oxallyl chloride (0 038 ml, 0.449 mmol). The reaction mixture was stirred for 1 h at rt then cooled with an tee-bath and quenched with 8 M methylamine in ethanol (2 5 ml, 20 mmol). After 5 mm stirring, the reaction mixture was evaporated to dryness and the residue punfied by Prep HPLC (H2O (0.1% TFA)/CH3CN 95 5 to 65- 35) The fractions containing products were collected together, basified with NaHCO3 concentrated and the formed precipitate was filtered, washed with water and dned to give the title compound as white solid (HPLC' t« 2 45 mm (Method A); M+H = 458 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 8 97 (s, 1 H)1 8.52- 8 46 (m, 1H), 8 35-8 27 (m 1H), 8.19-8 07 (m, 3H), 7 99-7.93 (m, 1H), 7 56-7 51 (m, 1H)1 4.00 (s, 3H), 3.95 (s, 3H), 3.57 (s, 3H), 2 83 (d, 3H), 1 94 (s, 3H))
The following example was synthesized in a similar manner as descnbed for Example 125.1 using ammonia.
Figure imgf000235_0002
Example 126 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methy}"8-(6-piperazin-1-yl-pyrkJin~3- yl)-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one
Figure imgf000235_0001
The title compound was synthesized in a similar manner as described for Example 118.1 using 8-bromo-1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin- 2-one (Intermediate A) and 2-(4-boc-piperazine)pyndine-5-boronic acid pinacol ester (Combi-Blocks, San Diego, USA) to give the title compound as a white solid. (HPLC. tR 1 97 mm (Method A), M+H * 455 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8.91 (s, 1H), 8 30-8.25 (m 1H), 8 14-8 11 (m, 1H), 8 07-8 01 (m, 1 H), 7 90-7 84 (m, 1 H)1 7.62-7 56 (m, 1H), 7 46- 7 41 (m. 1H), 6.95-6.89 (m. 1H)1 3 92 (s, 3H), 3 57 (s, 3H), 3 53-3.46 (m, 4H), 2.86-2 76 (m, 4H) 1 95 (S, 3H)) Example 127 8-(5-Amino-6-methoxy-pyndin-3-yl)- 1 -( 1 , 3-dimethyl-1 H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imida2ol4,5-c]quinolin-2-one
Figure imgf000236_0001
A solution of I^I.S-dimethyl-1H-pyrazoM-yO-δ-Cβ-methoxy-δ-nttro-pyridtn-S-yl^S-methyl-I .S- dihydro-imidazo(4,5-c]quinolin-2-one (Example 66, 50 mg, 0 112 mmol) in 5 ml THF and 5 ml MeOH was stirred in presence of palladium 10% on charcoal under 1 1 bar of hydrogen for 5 h at rt. The reaction mixture was filtered over Celite and the catalyst was washed with MeOH/THF. The filtrate was evaporated and the crude product was purified by Prep HPLC (H2O (0.1% TFA)/CH3CN 95 5 to 50.50). The fractions containing products were collected together, basified with NaHCO3, concentrated and extracted with EtOAc (3x) The combined organic layers were dried over Na2SO4, filtered and evaporated to give the title compound as a light yellow solid (HPLC tR 2 29 mm (Method A)1 M+H = 416 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.94 (s, 1H), 8.12-8.10 (m, 1H), 8.08-8 05 (m, 1H). 7 76-7 72 (m, 1H), 7 47-7 45 (m, 1 H)1 7.43-7.41 (m, 1H), 7.00-6 97 (m, 1H), 5 11 (s, br, 2H), 3.92 (s, 3H), 3 89 (s, 3H), 3.57 (s, 3H), 1 94 (s, 3H))
Example 128.1 1 -( 1 , 3-DimethyJ- 1 H-pyrazol-4-yl)-3-methyl-8-pyridin-3-yl- 1 , 3-dihydro- imidazo[4,5-c)quinoline-2-thione
Figure imgf000236_0002
A mixture of a new batch of 1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-pyridin-3-yl-1,3- dihydro-imtdazo[4,5-c]qυinolin-2-one (Example 10.2, 8 mg, 0 219 mmol) and Lawesson's reagent (98 mg, 0 242 mmol) in dioxane (1 ml) was stirred in a seal vial for 28 h at 100°C The reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with DCM (2x) The combined organic layers were washed with bnne, dned over Na7SO4, filtered and evaporated to dryness. The residue was taken in NMP and purified by Prep. HPLC (H2O (0 1% TFA)/CH3CN 95 5 to 65 35) The fractions containing products were collected together and basified with NaHCθ3 (0 3 g), before being concentrated The resulting suspension was filtered and the cake was washed with water, before being dried under high vacuum to give the title compound as a white solid (HPLC Xn 2 32 rmn (Method A), M+H * 387 MS-ES, 1H- NMR (d6-DMSO, 400 MHz) 9 21 (s, 1H), 8 72-8 68 (m, 1 H) 8 62-8 58 (m, 1 H), 8 23-8 16 (m, 2H), 8 08-8 04 (m, 1H), 7 93-7 88 (m, 1H)1 7 56-7 48 (m 2H), 3 97-3 93 (m, 6H)1 1 92 (s, 3H))
The following example was synthesized in a similar manner as described for Example 128.1 using Example 1.8 as starting material
Example structure Name of the example MS-ES HPLC
(M+H)
(mtn)
128 2 8-(3,4-Dimethoxy- 446 2 85 phenyl)-1-(1 ,3- r ii JL N-- dimethyl- 1 H-pyrazol-
T 4-yl)-3-methyl-1 ,3-
I if ^r dthy dro-imκlazot4 , 5- c]quinoline-2-thione
Figure imgf000237_0002
Example 129 I^I .S-Dimethyl-1H-pyrazol^-yO-S-methyl-δ^i-methyl-1H-pyrrololS^- b]pyridin-6-yl)'1 ,3-dihydro-imidazo(4,5-clquinolin-2-one
Figure imgf000237_0001
The title compound was synthesized in a similar manner as described for Example 116 using 1-(1 ,3-dimethyl-1H-pyra2θl-4-yl)-3-methyl-8-(1 H-pyrrolo[3,2-b]pyridin-6-yl)-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one (Example 99) to give the title compound as an off-white solid (HPLC tR 2 1 1 mm (Method A), M+H ~ 424 MS-ES, 1H-NMR (dfa-DMSO 400 MHz) 8 97 (s, 1H) 8 47-8 45 (m, 1 H)1 8 18-8 16 (m, 1H), 8 15-8 11 (m 1H) 8 08-8 04 (m, 1H), 8 00-7 98 (m, 1H), 7 71-7.69 (m. 1H), 7 65-7 63 (m, 1H), 6 59-6 57 (m, 1H)1 3 92 (s, 3H), 3 89 (s, 3H), 3 59 (s, 3H), 1.97 (s, 3H))
Example 130 1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-[2-(isopropyl-methyl-amino)-pyπdin-
4-yl]-3-methyl-1,3-dihydro-imidazo(4,5-c)quinolin-2-one
Figure imgf000238_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl-1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro-imidazoJ4,5-c]quinolin-2-one (Intermediate A) and isopfopyl-methy44-(4,4 5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- pyπdin-2-yl]-amine (Stage 130.1.1) to give the title compound as a white solid (HPLC tR 2 24 mm (Method A), M+H « 442 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8 98 {s, 1H)1 8 14- 8 08 (m. 3H), 7 97-7 93 (m. 1H)1 7 69-7 66 (m, 1 H), 6 69-6 66 (m 1H)1 6 56-6 53 (m, 1H), 4 90 (hp, 1H), 3 89 (s 3H), 3 58 (s, 3H)1 2 85 (s, 3H), 1 96 (s, 3H) 1 17-1 11 (m, 6H))
Stage 130.1,1 isopropyl-methyl-[4-(4 4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- pyridin-2-yl]-amine
Figure imgf000238_0002
The title compound was synthesized in a similar manner as described for stage 5.1,1-2 using 4-bromo-2-chloropyridine (Aldrich, Buchs Switzerland) and N-methylisopropylamine (Aldπch, Buchs, Switzerland) to give the title compound as a brown oil (HPLC tR 2 06 mm (Method A) M+H = 277 MS-ES) Example 13t 8-(6-Ethoxy~pyridin-3-yl)-1 -(1 -(2-methoxy-ethyl)-3-methyl-1 H-pyrazol-4-yl]-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000239_0001
The title compound was synthesized in a similar manner as described for Example 104 using 8-(6-ethoxy-pyridin-3-yl)-1-(1 -(2-hydroxy-ethyl)-3-methyl-1 H-pyrazol-4-yl]-3-methyl-1 ,3- dihydro-imidazo[4,5-c]quinolin-2~one (Example 103.2) to give the title compound as an off- white solid. (HPLC. tπ 2 70 min (Method A); M+H * 459 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 96 (s, 1H), 8 28-8.26 (m, 1 H), 8 12-8 06 (m, 2H), 7 91-7 87 (m, 1 H), 7.81-7 78 (m, 1H), 7 49-7.47 (m, 1H)1 6.90-6 87 (m, 1H), 4.37-4.29 (m, 4H)1 3.71 (q, 2H)1 3 58 (s, 3H) 3.12 (s, 3H), 1.97 (s, 3H), 1.33 (t, 3H))
Example 13? 5-[1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H- imida2θ[4,5-cJquinolin-8-yl)-2-methoxy-nicotinonitri)e
Figure imgf000239_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4~y!)-3-methyl-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one (Intermediate A) and 2-Methoxy-5-(4,4,5,5-tetramethyH1 ,3,2]dioxaborotan-2-yl)- nicotinonitπle (Combi-Blocks, San Diego, USA) to give the title compound as a white sold (HPLC tR 2 60 mm (Method A). M+H = 426 MS-ES)
Example 133 8-(6-Ethoxy-pyridin-3-yl)-1-{3-methyl-1-[2-(4-methyl-piperazin-1-yl)-2-oxo- ethyl]- 1 H-pyrazol-4-yl)- 1 , 3-dihydro-imidazo[4 , 5-c]quinolin-2-one
Figure imgf000240_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-brorτκ)-1-{3-methyl-1-(2-(4-methyl-pipera2in-1-yl)-2~oxo-ethy)]-1H-pyrazol-4-yf}-1 (3-dihydro- imidazo[4,5-c}quinolio2-one (Stage 133.1.1) and 6-ethoxypyndine-3-boronic acid (ABCR, Karlsruhe, Germany) to give the title compound as a white solid. (HPLC: tR 2 27 mm (Method A), M+H a 527 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 11.69 (s, br, 1H), 8 71 (s, 1H), 8 45- 8 42 (m, 1H)1 8 08-8 03 (m, 2H), 7 96-7.88 (m, 2H), 7.74-7.71 (m, 1H)1 6 81-6 67 (m, 1 H), 5 27-5.11 (m, 2H), 4.32 (q, 2H), 3 58-3.38 (m, 4H), 2 38-2 26 (m, 4H), 2 19 (s, 3H), 1 92 (s, 3H), 1.31 (t, 2H))
Stage 133.1. 8-Bromo-1-{3-methyl-1-f2-(4-methyl-piperazin-1 -yl)-2-oxo-ethyl3-1H-pyrazol-4- yl}-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one
Figure imgf000240_0002
A solution of [4-(8-bromo-2-oxo-2,3-dihydro-imidazo{4,5-c]quinolin-1-yl)-3-methyl>pyrazoi-1- yl]~acetic acid (Stage 101.1.2, 178 mg, 0 443 mmol). DIPE (0.232 ml, 1.33 mmol), TPTU (223 mg, 0 752 mmol) in DMA (5 ml) was stirred at rt for 5 mm, then was added N- methylpiperazine (0 1 ml, 0.90 mmol). The reaction mixture was stirred 19 h at rt and then was added N-methylpiperazine (0 1 ml, 0.90 mmol) and the reaction mixture was stirred 25 h at rt The reaction mixture was purified by prep HPLC to give the title compound as an off- white soJid (HPLC: tH 1.98 min (Method A)1 M+H = 484, 486 MS-ES)
Example 134 3-Methyl-1-{3-methyl-1-l2-(4-methyl-p)perazin-1-yl)-2-oxo-ethyl]-1H-pyrazoi-4- yl}-8-phenyl-1 ,3-d)hydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000241_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyl- 1 -{3-methyl-1 -[2-(4-methyl-piperazJn- 1 -yl)-2-oxo-ethyl}~ 1 H-pyrazol-4-yl}- 1 ,3-dihydro-imidazo[4,5-c3quinolin-2-one (Stage 134.1.1) and phenylboronic add (Aldrich, Buchs, Switzerland) to give the title compound as a white solid. (HPLC: t« 2,32 min {Method A); M+H - 496 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 8.96 (s, 1H), 8, 11-8.07 (m, 2H)1 7.96- 7.92 (m, 1H), 7.81-7.79 (m, 1H), 7.69-7.65 (m, 2H), 7.45-7.39 (m. 2H), 7.37-7.32 (m, 1H), 5.28-5.16 (m, 2H), 3.59-3.43 (m, 7H), 2.40-2.29 (m, 4H), 2.20 (s, 3H), 1.92 (s, 3H))
Staαe 134.1 8-Bromo-3-methyl-1-{3-methy)-1-f2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-1 H- pyrazol-4-yl}- 1 , 3-dihydro-imϊdazo[4 , 5-c)quinolin-2-one
Figure imgf000241_0002
The title compound was synthesized in a similar manner as described for Intermediate A using 8-bromo- 1 -{3-methyM -[2-(4-methyl-piperazin- 1 -yl)-2-oxo-ethyl]-1 H-pyrazol-4-yl}- 1 , 3- dihydro-imidazo[4,5-c]quinolin-2-one (Stage 133.1.1) to give the title compound as an off- white solid. (HPLC; tR 2.06 min (Method A); M+H ~ 498, 500 MS-ES)
Example 13S N-Ethyl-N-methyl-2-[3-methyl-4-(3-methyl-2-oxo-8-phenyl-2,3-dihydro- imidazo[4,5-c]qυinolin-1-yl)-pyrazol-1-yl]-acetamide
Figure imgf000242_0001
The title compound was synthesized in a similar manner as described for Example 134 using N-ethyl-N-methylamine (Aldπch, Buchs, Switzerland) to give the title compound as a white solid (HPLC tR 2 76 mm (Method A). M+H = 455 MS-ES, 1H-NMR (d6-DMSO, 500 MHz) 8 98 (S, 1H), 8 14-8 09 (m, 2H), 7 98-7 94 (m, 1H), 7 83-7 81 (m, 1H), 7 72-7 68 (m, 2H), 7 47-7 42 (m, 2H), 7 38-7 34 (m, 1H), 5 25-5 15 (m, 2H), 3.60 (s, 3H), 3 48-3 36 (m, 2H), 3 05 and 2 90 (2 x s, 3H), 1 93 and 1 93 (2 x s, 3H), 1 20 and 1 08 (2 x t, 3H))
Example 136 2-{4-l8-(6-Ethoxy-pyridin-3-yi)-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5- cjquinolin- 1 -yl j-3-methyl-pyrazol-1 -y1}-N-ethyl-N-methyl-acetamide
Figure imgf000242_0002
The title compound was synthesized in a similar manner as described for Example 135 using 6-ethoxypyridine-3-boronic acid (ABCR, Karlsruhe, Germany) to give the title compound as a white solid. (HPLC. tR 2 70 mm (Method A), M+H * 500 MS-ES, 1H-NMR (dβ- DMSO, 400 MHz) 8 95 (s 1H), 8 46-8 43 (m 1 H), 8 1 1-8 05 (m, 2H), 8 00-7 91 (m, 2H), 7 74-7.71 (m, 1H) 6 77-6 82 (m, 1H), 5 24-5 10 (m, 2H), 4 36-4 28 (m, 2H), 3.57 (s, 3H), 3 46-3 30 (m, 2H), 3 02 and 2 86 (2 x s 3H), 1 92 and 1 91 (2 x s, 3H), 1 31 (t, 3H), 1 18 and 1 03 (2 x t, 3H))
Example 137 N-(2-Methoxy-ethyl)-N-methyl-2-[3-methyl-4-(3-methyl-2-oxo-8-phenyl-2,3- dihydro-imidazo[4,5-c]quinolin-1-yl)-pyrazol-1-yl]-acetamide
Figure imgf000243_0001
The title compound was synthesized in a similar manner as described for Example 134 using N-(2-methoxyethyl)-N-methylamine (ABCR, Karlsruhe, Germany) to give the title compound as a white foam (HPLC tR 2.73 min (Method A); M+H * 485 MS-ES, 1H-NMR (dθ- DMSO1 500 MHz) 8.96 (s, 1H)1 8 12-8 07 (m, 2H), 7 97-7 93 (m, 1H), 7.82-7.79 (m, 1H)1 7 70-7.65 (m, 2H)1 7.45-7 40 (m, 2H), 7 38-7.32 (m, 1H), 5 28-5.15 (m, 2H), 3 62-3 44 (m, 7H)1 3.33 and 3.26 (2 x s, 3H), 3.09 and 2.93 (2 x s, 3H), 1.92 and 1.91 (2 x s, 3H))
Example 138 1 -[1 -(2-Azetidin-1 -yl-2-oxo-ethy!)-3-methyl-1 H-pyrazol-4-yl]-8-(δ-ethoxy- pyridin-3-yl)-3-methyl~1,3-dihydro-imidazo[4,5-cJquinolin-2-one
Figure imgf000243_0002
The title compound was synthesized in a similar manner as descnbed for Example 134 using azetidine (Fluka, Buchs, Switzerland) and 6-ethoxypyndine-3-boronic acid (ABCR1 Karlsruhe, Germany) to give the title compound as a white solid. (HPLC: tR 2 62 min (Method A); M+H ~ 498 MS-ES, 'H-NMR (d6-DMSO, 500 MHz) 8.95 (s, 1H), 8 41-8 39 (m, 1H), 8.13- 8 07 (rn, 2H), 7.95-7.88 (m, 2H), 7 61-7 63 (m. 1 H), 6.86-6.82 (m. 1H)1 4.94-4.84 (m, 2H), 4.34 (q, 2H), 4 27-4 15 (m. 2H), 3.99-3.88 (m, 2H), 3.58 (s, 3H), 2 28-2 14 (m, 2H), 1 94 (s, 3H), 1 33 ( t, 3H))
Example 139 N N-Diethyl-2-{3-methyl-4-(3-methyl-8-(6-methyl-pyridin-3-yl)-2-oxo-2,3- dihydro-imidazo(4, 5-c]quinolin- 1 -yl]-pyrazol- 1 -yl}-acetamide
Figure imgf000244_0001
The title compound was synthesized in a similar manner as described for Example 134 using dimethylamine (Fluka, Buchs, Switzerland) and 2-methylpyridine-5-boronic acid (Frontier Scientific, Logan, USA) to give the title compound as a white foam (HPLC tR 2 21 mm (Method A)1 M+H - 484 MS-ES, 1H-NMR (CL5-DMSO, 500 MHz) 8 97 (s, 1 H), 8 71-8.69 (m, 1 H), 8 13-8.08 (m, 2H), 7 97-7.92 (m, 2H), 7 80-7 78 (m, 1H), 7.28-7 25 (m, 1 H), 5 21- 5 09 (m, 2H), 3 59 (s, 3H), 3 44-3 28 (m, 7H), 1 93 (s, 3H), 1.20 ( t, 3H), 1 05 (t, 3H))
Example 140.1 N-Ethyl-N-methyl-2-{3-methyl-4-[3-methyl-2-oxo-8-(2-pyrrolidin- 1 -yl- pyπmidin-5-yl)-2,3-dihydro-imidazot4,5-c]quinolin-1-yπ-pyrazol-1-yl}-acetamide
Figure imgf000244_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 2-[4-(8-bromo~3-methyl-2-oxo-2 3-dihydro-imidazo(4,5-c)quinolin-1-yl)-3-methyl-pyrazoM-yl]- N-ethyl-N-methyl-acetamide (Intermediate P) and 2-(pyrrolidin-1-yl)pynmidine-5-boronic acid pinacol ester (Frontier Scientific, Logan, USA, 37 mg, 0 132 mmol) to give the title compound as an off-white solid. (HPLC tft 2 53 mm (Method A), M+H = 526 MS-ES, 1H-NMR (d6- DMSO, 400 MHz) cis&trans amide 8.92 (s, 1H), 8 59-8 55 (m. 2H), 8 08-8 01 (m, 2H), 7 88- 7.84 (m, 1H)1 7.68-7.63 (m, 1 H)1 5 23-5 15 (m, 1H), 5 11-5 04 (m. 1H), 3 57 (s, 3H) 3 53- 3 21 (m, 6H), 3 01 , 2 83 (2x s, 3H), 1 97-1 89 (m, 4H), 1 94, 1.93 (2xs, 3H), 1 17, 0.99 (2x t, 3H)) The following example was synthesized in a similar manner as described for Example 1.1 using 2-(pyrrolidin-1-yl)pyrimidine-5-boronic acid pinacol ester and the specified intermediate.
Figure imgf000245_0002
Example 141.1 δ-CS-Fluoro-β-methylamino-pyridin-a-yO-S-methyl-i^i .a.S-trimethyl-1H- pyrazol-4-yl)-1 ,3-dihydro-imidazo|4,5-c]quino)in-2-one
Figure imgf000245_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyl-1-(1 ,3l5-trimethyl-1H-pyrazol-4-yl)-1 ,3-dihydro-imidazo{4,5-c]quinolin-2- one (Intermediate H) and (S-flυoro-δ^^.S.S-tetramethyl-II .S^Jdioxaborolan^-yO-pyridin^- yl}-methyl~amine (stage 141.1.1) to give the title compound as a yellow foam. (HPLC. tR 2.15 min (Method A); M+H = 432 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 8.92 (s, 1H), 8.05-7.99 (m, 2H), 7.89-7.84 (m, 1H), 7.41-7.36 (m, 1 H), 7.35-7.33 (m, 1 H), 6,92-6.86 (m, 1 H), 3.83 (s, 3H), 3,58 (s, 3H), 2.88 (d, 3H). 2.07 (s, 3H)1 1.91 (s, 3H))
Stage 141.1.1 [3-Fluoro-5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)-pyndin-2-yl]-methyl- amine
Figure imgf000246_0001
A mixture of (5-bromo-3-fluoro-pyridin-2-yl)-methyl-amine (Stage 141.1.2, 1.255 mmol), bis(pinacolato)-diborane (1 381 mmol), potassium acetate (3 77 mmol) and PdCI2(dppf) (O 063 mmol) in dioxane (7 ml) was stirred in a closed vtal flushed with argon at 90 °C for 15 h Then the RM was diluted with toluene (7 ml), sonicated and filtered The solid residue is washed with hot toluene and the filtrated is evaporated to dryness to give the crude title product as a brown oil (HPLC tκ 3 68 mm (Method A), M+H = 253 MS-ES)
Stage 141.1.2 (5-Bromo-3-fluoro-pyπdin-2-yl)-methyl-amine
Figure imgf000246_0002
A mixture of 5-bromo-2,3-d)fluoropyridine (Matrix, Columbia, USA, 2 53 mmol) and 8 M methylamine in EtOH (Atdrich, Buchs, Switzerland 2 ml, 16 mmol) was sealed in a vial and heated with microwave irradiation at 100°C for 30 mm The cooled RM was diluted with EtOAc, washed with brine, dried over Na2SO4, filtered and evaporated to dryness to give the title product as an off-white solid (HPLC tR 1 94 mm (Method A) M+H = 205, 207, M-H = 203, 205 MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using [3-fluoro-5-(4,4,5,5-tetramethyl-[1 3,2]dioxaborolan-2-yl)-pyridin-2-yl]-methyl-amine (stage 141.1.1) and the specified intermediate
Figure imgf000246_0003
-246-
Figure imgf000247_0003
Example 142.1 8-(6-Amino-5-fluoro-pyridin-3-yl)-3-methyl-1 -(1 ,3,5-trimethyM H- pyrazoI-4-yl)-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one
Figure imgf000247_0001
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using β-bromo-S-rηethyl-I^I .S.S-trimethyl-1H-pyrazoM-yO-I .S-dthydro-imidazoH.δ-clquinolin^- one (Intermediate H) and 3-fluoro-5-(4,4,5,5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-pyridin-2- ylamine (stage 142.1.1) to give the title compound as a yellow foam (HPLC' fo 2 07 mm (Method A); M+H = 418 MS-ES, 1H-NMR (dθ-DMSO, 400 MHz) 8.92 (s, 1H), 8 05-8 01 (m, 1 H), 7 91-7.84 (m, 2H), 7.47-7.42 (m, 1 H)1 7 35-7 32 (m, 1 H)1 649 (β, 2H), 3.83 (S1 3H), 3.58 (s, 3H)1 2 07 (S, 3H), 1 90 (s, 3H))
Stage 142.1.1 3-Fluoro-5-(4,4,5,5-tetramethyl-l1 ,3,2Jdioxaborolan-2-yl)-pyridin-2-ylamine
Figure imgf000247_0002
The title compound was synthesized in a similar manner as described for stage 141.1.1-2 using 2 M ammonia in isopropanol (Aldπch, Buchs, Switzerland) and heating up to 195°C (unstable in the HPLC condition (Method A), M+H = 239 MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using 3-fluoro-5-(4,4,5,5-tetramethy)-[1 ,3 2)dioxaborolan-2-yl)-pyridin-2-ylamine (stage 142.1.1) and the specified intermediate
Figure imgf000248_0002
Example 143 3-Methyl-8-(6-trideuteromethylamino-5-tπflυoromethyl-pyπdin-3-yl)-1 -(1 ,3,5- tπmethyl-1 H-pyrazol-4-yl)-1 ,3-dihydro-imidazo[4 5-c]quinolin-2-one
Figure imgf000248_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyl-1-(1 3,5-trimethyl-1H-pyrazol-4-yl)-1 3-dihydro-imidazo[4,5-c]quinolin-2- one (Intermediate H, 0 104 mmo!) and trideuteromethyl-[5-(4,4,5,5-tetramethyl~ [1 ,3,2Jdioxaborolan-2-yl)-3-tπfluoromethyl-pyridin-2-yl)-amine (stage 143.1.1) to give the title compound as a yellow foam (HPLC tR 2 53 mm (Method A); M+H * 485 MS-€S; 1H-NMR (dβ-DMSO, 400 MHz) 8 94 (s, 1H), 8.51-8.49 (m, 1H), 8 08-8.04 (m. 1 H), 7 96-7.92 (m, 1H), 7 72-7 69 (m, 1H), 7 39-7 36 (m, 1 H), 6 74 (s, br, 1H), 3 80 (s, 3H), 3 58 (s, 3H), 2.08 (s, 3H), 1 89 (S, 3H))
Stage 143.1.1 Tπdeuteromethyl-[5-(4,4,5,5-tetramethyl-(1,3,2]dioxaborolan-2-yl)-3- trifluoromethyl-pyπdin-2-y!]-amine
Figure imgf000249_0001
The title compound was synthesized in a similar manner as described for stage 5.1.1 using (5-bromo-3-trifluoromethyl-pyrtdin-2-yl)-trideuteromethyl-amine (Stage 143.1.2, 0 833 mmol) to give the title compound as a crude brown oiL (degrading under the HPLC condition (Method A), M+H - 306 MS-ES)
Stage 143.1.2 (5-Bromo-3-trifluoromethyl-pyπdin-2-yl)-trideuteromethyl-amine
Figure imgf000249_0002
To a solution of 5-bromo-3-trifluoromethyl-pyridin-2-ylamine (Stage 25.1.2. 1 66 mmol) in DMF cooled with an ice-bath was added 55% sodium hydride in oil (1 66 mmol) The RM was stirred for 30 mm at 0βC then was added d3-iodomethane (Aldπch, Buchs. Switzerland, 1.66 mmol) and the RM was stirred for 30 mm at rt and the formed slurry was sonicated for 30 min at rt The RM was quenched with saturated aqueous NaHCO3 and extracted with EtOAc (2x). The combined organic layers were washed with saturated aqueous NaHCθ3 (3x), with brine, dried over Na2Sθ4 filtered and evaporated The residue was purified by flash chromatography (hexane/CH2Cl2 1.1 to 1 :8) to give the title compound as an oil (HPLC tR 3.30 mm (Method A); M+H = 258, 260 MS-ES) Example 144.1 3-Methyl-8-(6-methylamino-5-tnfluoron>ethyl-pyrlciin-3-yl)-1-( 1 ,3,5- trimethyl-I H-pyrazol^-yO-i .a-dihydro-imfciazo^.S-clquinolin-a-one
Figure imgf000250_0001
The title compound was synthesized in a similar manner as described for Example 143 using iodomethane as replacement for d3-iodomethane to give the title compound as a yellow film (HPLC tR 2 53 mm (Method A), M+H = 482 MS-ES, 1H-NMR (Cl6-DMSO, 400 MHz) 8.94 (s, 1 H)1 8.51-8.49 (m, 1 H), 8.08-8.04 (m, 1 H)1 7 96-7 92 (m, 1H), 7 72-7.69 (m, 1H), 7 38- 7 36 (m, 1 H)1 6.77 (q, 1H), 3 79 (s, 3H)1 3 58 (s, 3H)1 2.92 (d, 3H)1 2 07 (s, 3H)1 1.89 (s, 3H))
The following examples were synthesized in a similar manner as described for Example 144.1 usin the s ecified intermediate
Figure imgf000250_0002
Figure imgf000251_0003
Example 14S.1 8-(6-Ethylamino-5-triflυoromethyl-pyridin-3-yl)-3-methyl-1 -(1 ,3,5- trimethyl-1 H-pyrazol-4-yl)-1 ,3<JihydroHmidazo[4,5-c]qumolin-2-one
Figure imgf000251_0001
The title compound was synthesized in a similar manner as described for Example 143 using iodoethane as replacement for d3-iodomethane to give the title compound as a yellow foam. (HPLC: tR 2.74 min (Method A); M+H = 496 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8 94 (S1 1H)1 8 50-6.47 (m, 1H), 8.08-8.03 (m, 1H), 7 96-7 91 (m, 1H), 7 71-7.67 (m, 1H), 7,37-7 34 (m, 1H), 6.74 (t, 1H), 3.79 (s, 3H), 3 58 (s, 3H)1 3.49 (qt, 2H). 2.08 (s, 3H)1 1.89 (s, 3H), 1 14 (t. 3H))
The following example was synthesized in a similar manner as described for Example 145.1 using the specified intermediate
Figure imgf000251_0002
Example 146.1 8-(5-Chloro-6-methylamino-pyridin-3-yl)- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4- yl)-3-methyl-1 ,3-dihydro-imtdazo[4,5-c]quinolin-2-one
Figure imgf000252_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 ,3-dimethyl- 1 H-pyrazol-4-yl)~3-methyl- 1 , 3-dihydro-imidazo[4 ,5-c]quinolin-2-one (Intermediate A, 0 107 mmol) and (3-chloro-5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolaiv2-yl)- pyridin-2-yl]-methyl-amine (stage 146.1.1) to give the title compound as a yellow foam. (HPLC: tR 2 53 mm (Method A); M+H - 485 MS-ES: 1H-NMR (dβ-DMSO, 400 MHz) 8.91 (s, 1H), 8,24-8 21 (m, 1H), 8.15 (s, 1 H), 8.06-8.01 (m. 1H), 7 92-7 87 (m, 1H), 7 62-7,57 (m, 1 H). 7.40-7.37 (m, 1H), 6 81-6 76 (m, 1H)1 3 95 (s, 3H)1 3.57 (s, 3H), 2 89 (d, 3H)1 1 95 (s, 3H))
Stage 146.1.1 [3-Chloro-5-(4,4,5,5-tetramethyl-{1 ,3,2]dioxaborolan-2-yO-pyridin-2-yl]-methyl- amine
Figure imgf000252_0001
The title compound was synthesized in a similar manner as described for Stage 141.1-2 using 5-bromo-2,3-dtch!oropyndine (Asymchem Laboratories, Morπsville, NC, USA) and heating to 150cC as replacement for 5-bromo-2,3-dif!uoropyridine to give the title compound as a crude brown oil. (HPLC tR 1.62 mm (Method A), M+H « 269 MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using [3-chloro-5-(4,4,5,5-tetramethyl-(1 ,3.2Jdioxaborolan-2-yl)-pyridin-2-yl]-methyl-amine and the specified intermediate
Figure imgf000252_0003
Figure imgf000253_0001
Figure imgf000254_0003
Example 147 S^δ-Chloro-δ-ethylamino-pyπdin-S-ylJ-1-dS-dimethyl-1H-pyrazol^-ylVS- methyl-1 , 3-dihydro-imidazo(4 , 5-c)quinolin-2-one
Figure imgf000254_0001
The title compound was synthesized in a similar manner as described for Example 146.1 using 2 M ethylamine in MeOH (Aldnch, Buchs, Switzerland) as replacement for the methylamine to give the titie compound as a beige foam. (HPLC: tR 2 35 mm (Method A); M+H = 448 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.92 (s, 1 H), 8 22-8 20 (m, 1 H), 8.16 (s, 1 H), 8 05-8 01 (m, 1 H), 7 91-7.87 (m, 1 H), 7.61-7 58 (m, 1H). 7.39-7 36 (m, 1 H), 6.74 (t, 1 H)1 3.94 (s 3H), 3.57 (s, 3H), 3.43 (qt, 2H), 1 94 (s, 3H), 1 15 (t, 3H))
Example 148 8-(6-Amino-5-chloro-pyndin-3-yl)-3-methyl-1 -(1 ,3,5-trimethyM H-pyrazol-4-yl)- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000254_0002
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo-3-methyl-1-(1 ,3,5-trimethyl-1H-pyrazol-4-yl)-1 ,3-dihydro-imidazo(4 5-cJquinolin-2- one (Intermediate H, 0 075 mmol) and 3-chloro-5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaboro)an-2- yl)-pyridin-2-ylamine (stage 148.1.1) to give the title compound as a yellow foam. (HPLC. tR 2 53 mm (Method A); M+H ~ 485 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 94 (s, 1 H), 8 51- 8 49 (m, 1H), 8.08-8 04 (m, 1H), 7 96-7 92 (m, 1H), 7 72-7.69 (m, 1H), 7 39-7.36 (m, 1 H), 6 74 (s, br, 2H), 3 80 (s 3H), 3 58 (s, 3H), 2 08 (s, 3H), 1 89 (s, 3H))
Stage 148.1.1 3-Chloro-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyndin-2-ylamine N
Figure imgf000255_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 2-amino-5-bromo-3-chloropyndine (Beta Pharma, New Haven, CT, USA) to give the title compound as a crude sticky black solid (degrading under the HPLC condition t* 1 44 mm (Method A) M+H = 255 MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using 3-chloro-5-(4,4 5,5-tetramethyl-[1,3,23dtoxaborolan-2-yl)-pyridin-2-ylamine and the specified intermediate
Figure imgf000255_0002
Exarnple 149 8-(5-Amino-6-fluoro-pyridin-3-yl)-1 -( 1 -isopropyl-3-methyl-1 H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo(4,5-c]qυinolin-2-one
Figure imgf000256_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5- cJquinolrn-2-one (Intermediate G, 0 098 mmcrt) and 2-fluoro-5-(4,4,5,5-tetramethyl- (1 ,3,2Jdioxaborolan-2-yl)-pyridin-3-y)amine (stage 149.1.1) to give the title compound as a yellow foam (HPLC t* 2 53 mm (Method A)1 M+H = 485 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8 97 (s, 1 H), 8 20 (s, 1 H)1 8 12-8 08 (m, 1H), 7.76-7 72 (m, 1H), 7 47-7 44 (m, 1 H), 7.29-7 23 (m, 2H), 5.57 (s, br, 2H), 4 54 (hp 1 H), 3.58 (s, 3H), 1 95 (S1 3H)1 1 44 (d, 6H))
Stage 149,1.1 2-Fluoro-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yi)-pyridin-3-ylamine
Figure imgf000256_0002
The title compound was synthesized tn a similar manner as described for Stage 5.1.1 using 3-amino-5-bromo-2-fluoropyπdine (Matrix Scientific, Columbia, SC. USA) to give the title compound as a crude sticky black solid (degrading under the HPLC condition (Method A), M+H = 239 MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using 2-fluoro-5-(4,4,5,5-tetramethyl-|1 ,3,2}dioxaborolan-2-yl)-pyridin-3-y)amine and the specified intermediate
Figure imgf000256_0003
- 256 -
Figure imgf000257_0002
Example 150.1 1-(1-Ethyl-3-methy)-1H-pyfa2θl-4-yl)-8-(6-fluoro-5-methylamino-pyridin-
3-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000257_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-i^i-ethyl-S-methyl-1H-pyrazol^-yO-S-methyl-I .S-dihydro-imidazo^^-clquinolin-Σ- one (Intermediate F1 0 078 mmol) and [2-fluoro-5-(4,4,5,5-tetramethyl-[1 ,3 2]dioxaborolan-2- yl)-pyridin-3-yl)-methyl-amine (stage 150.1.1) to give the title compound as a yellow foam. (HPLC. in 2 53 mm (Method A); M+H = 485 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8 97 (s, 1H), 8.16 (S, 1 H), 8.11-8.07 (m, 1H), 7 95-7.90 (m, 1 H), 7 53-7 51 (m, 1 H), 7 42-7.39 (m, 1 H), 7 01 -6.97 (m, 1H), 6 08 (q, br, 1 H), 4.15 (q, 2H), 3 58 (s, 3H). 2 80 (d, 3H), 1 97 (s, 3H), 1.37 (t, 3H))
Stage 150.1.1 (2-F!uoro-5-(4,4,5,5~tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-pyridinh3-yl]-methyl- amine
Figure imgf000258_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-2-fluoro-3-methylaminopyfκJine (Stage 150.1.2) to give the title compound as a crude black oil (degrading under the HPLC condition tR 1 70 mm (Method A), M+H = 239 MS-ES)
Stage 150.1.2 (5-Bromo-2-fluoro-pyridin-3-y1)-methyl-amine
Figure imgf000258_0002
A mixture of 3-am!no-5-bromo-2-fluoropyπdme (Matrix Scientific, Columbia, SC, USA, 1 571 mmol) in DMF (3 ml) and 55% NaH in oil (1 571 mmol) was stirred for 15 mm at rt Was added iodomethane (Aldrich, Buchs, Switzerland, 1 571 mmoJ) and the RM was stirred for 13 h at rt The RM was diluted with EtOAc washed with brine (4x), dried over Na2SO4, filtered and evaporated The residue was absorbed on silica gel and purified by flash chromatography (heptane/EtOAc 0 % to 40 %) The fraction containing the first eluting product were evaporated to give (5-bromo-2-fluoro-pyndin-3-yl)-dimethyl-amine as an orange oil (HPLC tR 3 15 mm (Method A), M+H = 219, 221 MS-ES) and the fraction containg the second eluting product were evaporated to give the title compound as a red solid (HPLC tR 2 90 mm (Method A) M+H = 205 207 MS-ES)
The following example was synthesized in a similar manner as described for Example 1.1 using [2-fluoro-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyndin-3-yl]-methyl-amine and the specified intermediate
Figure imgf000258_0003
Figure imgf000259_0003
Example 151 8-{5-Dim€thylamino-6-fluoro-pyridin-3-yl)-1-(1.3-dimethyl-1H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quino!in-2-one
Figure imgf000259_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5- c]qυinolin-2-one (Intermediate G, 0 098 mmol) and [2-fluoro-5-(4,4,5,5-tetramethyl- [1.3,2]dioxaboroJan-2-yl)-pyridin-3-yl]-dimethyl-amine (stage 151.1.1) to give the title compound as a yellow foam (HPLC tR 2 59 min (Method A), M+H * 432 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 8 98 (s, 1 H)1 8.13-8 08 (m, 2H), 7.99-7.94 (m. 1 H), 7 80-7 77 (m, 1 H), 7.57-7 54 (m, 1H)1 7 28-7 23 (m, 1H), 3 88 (s, 3H), 3 58 (s, 3H), 2.89 (s, 6H), 1 96 (s, 3H))
Stage 151.1.1 (2-Fluoro-5-(4.4 , 5, 5-tetramethyl-[ 1 , 3,2]dtoxaborolan-2~yl)-pyrϊdin-3-yl]- dimethyl-amine
Figure imgf000259_0002
The title compound was synthesized in a similar manner as described for Stage 6.1.1 using 5-bromo-2-f)uoro-3-dimethylaminopyπdine (Stage 150.1.2, side product) to give the title compound as a crude black oil. {degrading under the HPLC condition tR 1,77 min (Method A)1 M+H = 267 MS-ES).
Example 152.1 8-(5-Amino-6-chk)ro-pyridin-3-yl)-1-(1-isopropyl-3-methyl-1H-pyrazol-
4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c)quinoNn-2-one
Figure imgf000260_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-isopropyl-3-methyl-1H-pyrazol-4-y1)-3-methyl-1 ,3-dihydro-imidazo[4,5- c]quinσ!in-2-one {Intermediate G, 0098 mmol) and 2-chloro-5-(4,4,5,5-tetramethyl- [1,3,2)dioxaborolan-2-yl)-pyπdin-3-ylamine (stage 152.1.1) to give the title compound as a yellow foam (HPLC tR 2 55 mm (Method A), M+H = 448 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 99 (s, 1H), 8 19 (s, 1 H)1 8 14-8 09 (m, 1H) 7 78-7 73 (m, 1H)1 7 57-7 53 (m, 1 H), 7 50-7 47 (m, 1H), 7 28-7 24 (m, 1H)1 5 68 (s, br 2H)1 4 55 (hp, 1H), 3.58 (s, 3H), 1 95 (s, 3H). 1 44 (d, 6H))
Stage 152.1.1 2-Chloro-5-(4,4,5,5-tetramethyl-{1 ,3,2)dioxaborolan-2-yl)-pyπdin-3-ylamine
H,N
Figure imgf000260_0002
The title compound was synthesized in a similar manner as descnbed for Stage 5.1.1 using 5-bromo-2-chloro-pyridin-3-ylamine (stage 152.1.2, 2.6 mmoi) to give the title compound as a crude black solid (degrading under the HPLC condition tH 1 57 mm (Method A), M+H ~ 255 MS-ES)
Stage 152.1.2 5-Bromo-2-chloro-pyndin-3-ylamine
H2N^^Br A suspension of δ-bromo^-chloro-S-nitropyndine (Combi-Blocks, San Diego, USA, 41.3 mmol) in concentrated HCI (45 mf) was cooled with an ice-bath Was added portionwise over 1.5 h SnCI2 dihydrate (124 mmol) The RM was stirred for 24 h at rt then poured on ice and basified with 6 M aqueous NaOH (125 ml) The resulting slurry was filtered and the solid was taken in aqueous NaHCO3, sonicated and filtered The solid was dissolved in EtOAc and water and the aqueous layer was separted and extracted with EtOAc. The combined organic layers were washed with water, brine, dried over Na2SO4, filtered and evaporated to give the title compound as an off-white solid (HPLC tR 2 52 mm (Method A), M+H = 207 (BrCI pattern) MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using 2-chloro-5-(4,4,5,5-tetramethyl-I1 ,3,2]dioxaborolan-2-yl)-pyridin-3-ylamine and the specified intermediate
Figure imgf000261_0001
Example 153.1 8-(6-Chloro-5-ethylamino-pyπdin-3-yl)-3-methyl-1-(1 ,3,5-trimethyl-1 H- pyrazol-4-yi)- 1 ,3-dihydro-irnidazo[4,5-c]quinolin-2-one
Figure imgf000262_0003
The title compound was synthestzed in a similar manner as described for Example 1.1 using 8-bromo-3-methyl-1 -(1 (3,5-trimethyl-1 H-pyrazol-4-yl)-1 ,3-dihydro-imidazo[4,5-c]quinolin-2- one (Intermediate H, 0 101 mrnol) and [2-chloro-5-(4(4,5,5-tetramethyl-(1 ,3,2]dioxaborolan- 2-yl)-pyridin-3-yl]-ethyl-amine (stage 153.1.1) to give the title compound as a yellow solid. (HPLC: t* 2 74 mm (Method A)1 M+H = 462 MS-ES, 1H-NMR (de-DMSC\ 400 MHz) 8 99 (s, 1 H), 8 13-8 08 (m 1 H)1 7 98-7 93 (m, 1H), 7 76-7.73 (m, 1 H)1 7.58-7.54 (m. 1H), 6 97-6.93 (m, 1 H), 5 72 (t. 1 H), 3 79 (S1 3H), 3 59 (s, 3H), 3.26 (qt, 2H), 2 07 (s, 3H)1 1.91 (s, 3H), 1.22 (t. 3H))
Stage 153.1.1 [2-Chloro-5-(4,4,5,5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-pyridin-3-yl]-ethyl- amine
Figure imgf000262_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (5-bromo-2-chloro-pyridin-3-yl)-ethyl-amine (stage 153,1.2, 3 71 mmol) to give the tttle compound as a crude black oil. (degrading under the HPLC condition, fo 2.17 mm (Method A), M+H * 283 MS-ES)
Stage 153.1.2 (5-Bromo-2-chloro-pyridin-3-yl)-ethyl-amine
Figure imgf000262_0002
The title compound was synthesized in a similar manner as described for (Stage 87.1.2.) using 3-amino-5-bromo-2-chloropyridine (stage 152.1.2, 4 34 mmol) to give the title compound as an oil (HPLC. tR 3 38 mm (Method A); M+H = 235 (BrCI pattern) MS-ES) The following examples were synthesized in a similar manner as described for Example 1.1 using 2-chloro-5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-ethyl-amine and the specified intermediate
Figure imgf000263_0002
Example 154,1 8-(5-Ethylamino-6-fluoro-pyridin-3-yl)-3-methyl-H1 ,3^-tπmethyl-i H- pyrazol-4-yl)-1 ,3-dihydro-imidazo(4,5-cJquinolin-2-one
Figure imgf000263_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-3-methyl-1-{1,3,5-trimethyl-1H-pyrazol-4-yl)-1 ,3-dihydro-im(dazo(4,5-c]quinolin-2- one (Intermediate H1 0.104 mmol) and ethyK2-fluoro-5-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-pyπdin-3-y!}-amine (stage 154.1.1) to give the title compound as a whitβ solid. (HPLC: tR 2.63 min (Method A), M+H = 446 MS-ES; 1H-NMR (O6-DMSO1 400 MHz) 8 97 (s, 1H), 8 11-8.07 (m, 1H), 7 96-7 91 (m, 1 H)1 7 55-7.52 (m, 1H), 7 48-7.45 (m, 1 H), 7 00-6 95 (m, 1H), 5 96 (t, 1H)1 3.78 (s, 3H), 3.59 (s, 3H), 3.20 (qt, 2H), 2.07 (s, 3H), 1 91 (S, 3H)1 1.23 (t, 3H))
Stage 154.1.1 Ethyl-f2-fluoro-5-(4,4,5,5-tetramethyl-|;1,312]dioxabθfθlan-2-yl)-pyridin-3-yl]- amine
Figure imgf000264_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (5-bromo-2-fluoro-pyridin-3-yl)-ethyl-amine (stage 154.1.2, 2.283 mmol) to give the title compound as a crude black oil. (degrading under the HPLC condition. tR 1.92 mm (Method A); M+H = 267 MS-ES)
Stage 154.1.2 (5-Bromo-2-fluoro-pyπdin-3-y!)-ethyl-amine
HN XA..
The title compound was synthesized in a similar manner as described for (Stage 87.1.2.) using 3-amino-5-bromo-2-fluropyπdine (Matrix Scientific, Columbia, SC, USA, 3 14 mmol) to give the title compound as greenish solid (HPLC t« 3.20 mm (Method A), M+H = 219, 221 MS-ES).
The following example was synthesized in a similar manner as described for Example 1.1 using ethyl-[2-fluoro-5-(4,4 5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-amine and the specified intermediate.
Figure imgf000264_0002
Figure imgf000265_0002
Example 155,1 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(5-ethylamino-6-hydroxymethyl- pyridin-S-yO-S-methyl-I.S-dihydro-imidazoH.S-cjquinolin^-one
Figure imgf000265_0001
A solution of acetic acid 3-(tert-butoxycarbony)-ethyl-amino)-δ-[1-(1 ,3-dimethyl-1H-pyrazol-4- yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo(4 5-c)quinolin-8-ylj-pyridin-2-ylmethyl ester (stage 155.1.1, O 041 mmol) in dioxane (0 33 ml) was treated with 1 M aqueous LiOH (0 082 ml) for 1 5 h at rt then was added 1 M aqueous LiOH (O 082 ml) and the RM was stirred for 2 h at rt The RM was diluted with EtOAc and washed with sat aqueous NaHCO3, dned over Na2SO4, filtered and evaporated. The residue was taken in DMA and purified by preparative HPLC. The pure fraction was basified with NaHCO3, concentrated and extracted with EtOAc (3x) The combined organic layers were dned over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as a film. (HPLC tR 2 10 mm (Method A), M+H = 444 MS- ES 1H-NMR (dβ-DMSO, 400 MHz) 8 97 (s, 1H), 8.12-8 08 (m, 2H), 7 97-7.90 (m, 2H), 7 63- 7 60 (m, 1H), 6 87 (s, 1H), 5 49 (t, 1 H), 5 31 (t, 1 H), 4.57 (d, 2H) 3 88 (s, 3H), 3 58 (β. 3H), 3 19 (qt, 2H), 1 96 (S1 3H), 1.25 (t, 3H))
Stage 155.1,1 Acetic acid 3-(tert-butoxycarbonyl-ethyl'amino)-5-[1-(1 ,3-dimethyl-1H- pyrazoi-4-yl)-3-methyl-2-oxo-2f3-dihydro-1H-imidazo[4,5-c]quinolin-8-yl]-pyndtn-2-ylmethyl ester
Figure imgf000266_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromα-1-(1 ,3-dimethyl-i H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A, 0 109 mmol) and acetic acid S-O÷ert-butoxycarbonyl-ethyl-aminoJ-S-^AS.S- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridin-2-ylmethyl ester (stage 155.1.2) to give the title compound as an off-white solid (HPLC tR 2 88 min (Method A), M+H = 586 MS-ES)
Stage 155.1.2 Acetic acid 3-(tert-butoxycarbonyt-ethyl-amino)-5-(4,4,5,5-tetramethyl- (1 ,3,2]dioxaborolan-2-yl)-pyπdin-2-ylmethyl ester
Figure imgf000266_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using acetic acid 5-bromo-3-(tert-butoxycarbonyl-ethyl-amino)-pyridin-2-ylmethyl ester (stage 155.1.3 0 968 mmol) to give the title compound as a crude black oil (degrading under the HPLC condition tR 3 09 mm (Method A); M+H * 421 MS-ES)
Stage 155.1.3 Acetic acid 5-bromo-3-(tert-butoxycarbonyl-ethyl-amino)-pyridin-2-ylmethyl ester
Figure imgf000266_0003
(5-Bromo-2-methyl-1-oxy-pyridin-3~yl)-ethyl-carbamic acid tert-butyl ester (Stage 155.1.4, 1 467 mmol) in acetic anhydride (1 5 ml) was stirred under Ar for 35 mm at 12O°C The RM was quenched with EtOH and stirred then diluted with water, neutralized with saturated aqueous NaHCO3 and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, filtered and evaporated The residue was purified by flash chromatography (heptane/EtOAc 0% to 30%) to give after evaporation of the fractions containing the title compound an oil (HPLC: tR 3 51 min (Method A); M+H - 373, 375 MS-ES).
Stage 165.1.4 (S-Bromo-Σ-methyl-1-oxy-pyridin-S-yO-ethyl-carbamic acid tert-butyl ester
Figure imgf000267_0001
A mixture of (5-bromo-2-methyl-pyridin-3-yl)-ethyl-carbamic acid tert-butyl ester (stage 155.1.5, 1 508 mmol) in dichloromethane (13 ml) and 65% m-chloroperbenzoic acid (3 02 mmol) was stirred for 4 h at rt The RM was diluted with dichloromethane, washed with saturated aqueous Na2CO3, saturated aqueous NaHCO3 (4x) and brine, dried over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as an oil (HPLC- tR 3 02 mm (Method A); M+H * 331 , 333 MS-ES)
Stage 155.1.5 (5-Bromo-2-methy)-pyridin-3-yl)-ethyl-carbamic acid tert-butyl ester
Figure imgf000267_0002
A mixture of (5-bromo-2-methyl-pyndin-3-y!)-ethy}-amine (Stage 87.1.2, 1 634 mmol) and di- tertbutyl dicarbonate (Fluka, Buchs, Switzerland, 1.961 mmol) in THF (1 6 ml) was stirred for 1 h at rt and 3 h at 65βC Was added di-tertbutyl dicarbonate (Fluka, Buchs, Switzerland, 1 961 mmol) and an extra stirring for 22 h at 65°C to bring reaction to completion. The RM was diluted with EtOAc, washed with saturated aqueous NaHCO3, with brine, dried over Na2SO4, filtered and evaporated, The residue was absorbed on silica gel and purified by flash chromatography (heptaneVEtOAc O % to 30 %) to give after evaporation of the fractions containing the title compound an oil (HPLC: tR 341 mm (Method A), M+H = 315, 317 MS- ES)
The following examples were synthesized in a similar manner as described for Example 155.1 using the specified intermediate.
Figure imgf000267_0003
Figure imgf000268_0002
Examplfr 156 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-{5-ethylamino-6-methoxymethyl-pyridin-3- yl)-3-methyl-1 ,3-dthydro-imidazo(4 5-c]quinolin-2-one
Figure imgf000268_0001
A solution of 1-(1 ,3-dimethyl-1H-pyra2ol-4-yl)-8-(5-ethylamino-6-hydroxymelhy{-pyndtn-3-yl)- 3-methyl-1 ,3-dihydro-imidazo|4,5-c;|quinolin-2-one (Example 15S.1 , 0 086 mmol) in DMF (0 5 ml) was treated with 55% NaH in oil (0 086 mmol) and the RM was stirred for 10 mm at rt, then was added iodomethane (0 086 mmol) and the RM was stirred for 2 h at rt The RM was quenched with water, diluted with DMF, filtered and purified by preparative HPLC The pure fractions were basified with NaHCθ3, concentrated and extracted with CH?CI? (3x) and with EtOAc The combined organic layers were dried over Na2SO4, filtered, evaporated and dned under vacuum to give the title compound as a film (HPLC tR 2 24 min (Method A), M+H = 458 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 97 (s, 1 H), 8.13-8 08 (m 2H) 7.98- 7 91 (m, 2H), 7 64-7 61 (m, 1H), 6 90 (s, 1 H), 5 32 (t 1 H) 4 53 (s, 2H) 3 88 (s, 3H), 3 58 (s, 3H), 3 28 (s 3H), 3 20 (qt, 2H), 1 97 (s, 3H) 1 23 (t, 3H))
Example 1S7 8-(5-Ethylamino-6-methoxymethyl-pyridin-3-yl)-1-(1-ethyl-3-methyl-1H- pyrazol-4-yl)-3-methyl-1 t3-dihydro-imidazo{4,5-c]quinolin-2-one
Figure imgf000269_0001
The title compound was synthesized in a similar manner as descnbed for Example 156.1 using 8-(5-ethylamino-6-hydroxymethyl-pyridin-3-y))-1-(1-ethyl-3-methyl-1 H-pyrazol-4-yl)-3- methyM 3-dihydro-imidazo[4,5-c]quinolin-2-one (Example 155.2) to give the title compound as an off-white solid (HPLC tR 2 29 mm (Method A), M+H = 472 MS-ES, 1H-NMR (dθ- DMSO, 400 MHz) 8 97 (s, 1H), 8 16 (s, 1 H) 8 12-8 08 (m, 1 H), 7 96-7 92 (m, 1H), 7 87-7 85 (m, 1 H) 7 58-7 56 (m, 1 H) 6 95-6 92 (m 1 H), 5 31 (t. 1 H), 4 52 (s, 2H) 4 15 (q, 2H)1 3 58 (s, 3H), 3 26 (s 3H), 3 25-3 17 (m, 2H), 1 97 (s 3H). 1 37 (t, 3H), 1 22 (t 3H))
Example 158.1 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(6-hydroxymethyl-5-methylamino- pyridin-3-yl)-3-methyl-1 ,3-dihydroHmidazo[4,5-c}quino}in-2-one
Figure imgf000270_0001
The title compound was synthesized in a similar manner as described for Example 156.1 using {5-bromo-2-methyl-pyridin-3-yl)-methyl-<-arbamic acid tert-butyl ester (stage 158.1.1) to give the title compound as an off-white solid (HPLC' tR 2.02 mm (Method A), M+H = 430 MS- ES; 1H-NMR (de-DMSO, 400 MHz) 8.97 (β, 1H), 8.13-8,07 (m, 2H), 7.99-7.90 (rn, 2H), 7.65- 7 61 (m, 1H), 6.85-6.80 (m, 1 H), 5.67 (q, br, 1H), 5.22 (br, 1H)1 4 55 (d, 2H), 3 88 (S1 3H) 3 58 (S1 3H), 2.83 (d, 3H), 1 97 (S1 3H))
Stage 158.1.1 (5-Bromo-2-methyl-pyridin-3-yl)-methyl-carbamic acid tert-butyl ester
Figure imgf000270_0002
A solution of (5-bromo-2-methyl-pyridin-3-yl)-carbamic acid tert-butyl ester (Stage 158.1.2, 4.53 mmol) in DMF (20 ml) was cooled with an ice-bath and 55% NaH in oil (5.89 mmol) was added. The RM was stirred for 25 min at O°C then was added ϊodomethane (5.22 mmol) The RM was stirred for 2 h at rt then was quenched with aqueous NaHCO5 and extracted with EtOAc. The organic layer was washed with water (3x)s with brine (3x), dried over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as a brown solid (HPLC: tR 3 20 mm (Method A), M+H = 301 , 303 MS-ES).
Stage 158.1.2 (5-Bromo-2-methyl-pyridin-3-yl)-carbamic acid tert-butyl ester
Figure imgf000270_0003
The title compound was synthesized in a similar manner as described for stage 155.1.5 using 5-bromo-2-methyl-pyridin-3-ylamine (Stage 75.1.4, 7.86 mmol) to give the title compound as an oil (HPLC t* 2 88 min (Method A), M+H = 287, 289 MS-ES).
The following examples were synthesized in a similar manner as described for Example 158.1 using the specified intermediate.
Figure imgf000271_0001
Example 159 1-(1 , 3-Di methyl- 1 H-pyrazoM-yl)-8-(6-methoxymethyl-5-methylamino-pyridin- 3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000272_0001
The titte compound was synthesized in a similar manner as described for Example 166.1 using 1 -(1 ,3-dimethyl-i H-pyrazol-4-yl)-8-(6-hydroxymethyl-5-methylamino-pyridin-3-yl)-3- methyl-I .S-dihydro-imidazoKδ-ctøυinolin^-one (Example 158.1) to give the title compound as an off-white foam. (HPLC tR 2.15 mm (Method A); M+H = 444 MS-ES; 1H-NMR (d6- DMSO1 400 MHz) 8 97 (S1 1H), 8.12-8.08 (m, 2H)1 7.99-7 91 (m, 2H)1 7 65-7.62 (m, 1 H), 6 85-6.82 (m, 1H), 5 57 (q, 1H), 4 49 (s, 2H). 3.88 (β. 3H), 3.58 (s, 3H), 3 27 (s, 3H), 2.82 (d, 3H), 1.97 (s, 3H))
Example 160.1 1 -(3-Chloro-1 -methyl-1 H-pyrazol-4-yl)-8-(6-methoxymethyl-5- methylamino-pyridin-3-yl)-3-methyl- 1 3-dihydro-imidazo[4, 5-c]qυinolin-2-one
Figure imgf000272_0002
The title compound was synthesized in a similar manner as descnbed for Example 166.1 using 1-(3-chloro-1 -methyl- 1H-pyrazol-4-yl)-8-(6-hydroκymethyl-5-methylamino-pyridin-3-yl)- 3-methyl-1 l3-dihydro~imidazot4,5-cJquinolin-2-one (Example 158.3) to give the title compound as an off-white solid (HPLC. tR 2.32 min (Method A), M+H ~ 464 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 9.00 (S1 1 H)1 8.37 (s, 1H), 8.14-8.09 (m, 1 H), 8.02-7 94 (m, 2H)1 7 63- 7 60 (m, 1H), 6.90-6.86 (m, 1 H), 5.60 (q, br, 1H), 4.50 (s. 2H), 3 95 (s, 3H), 3 59 (s, 3H)1 3 28 (s, 3H), 2 83 (d, 3H))
The following example was synthesized in a similar manner as descnbed for Example 156.1 using the specified example as intermediate
Figure imgf000273_0002
Example 161 i^i .a-Dimethyl-1H-pyrazoM-yO-δ-CΘ-ethyl-S-ethylamino-pyridin-a-yO-S- methyl-1 ,3-dihydro-imidazo[4,5-c]quir>ol)n-2-one
Figure imgf000273_0001
The title compound was synthesized in a similar manner as described for Example 87.1 using diethyl methylmalonate (Fluka, Buchs Switzerland) to give the title compound as a white solid. (HPLC. tR 2.26 min (Method A), M+H * 442 MS-ES, 1H-NMR (Cl6-DMSO, 400 MHz) 8 96 (s, 1H), 8 12-8.07 (m, 2H), 7 96-7 91 (m, 2H), 7.63-7 59 (m, 1H), 6.78-6 75 (m, 1 H)1 5.29 (t, 1H), 3 88 (s, 3H), 3 58 (S, 3H)1 3.18 <qt, 2H)1 2 67 (q, 2H), 1 97 (S1 3H), 1 25 (t, 3H), 1 20 (t, 3H))
Example 162 1 -(1 ,3-Dimethy!-1 H-pyrazol-4-yl)-8-(6-ethyl-5-isopropylamino-pyridin-3-yl)-3- methyl-1 ,3-dihydronmtdazo(4,5-cJquinolin-2-one
Figure imgf000274_0001
The title compound was synthesized in a similar manner as described for Example 161 using (5-bromo-2-ethyl-pyndin-3-yl)-isopropyl-amine (Stage 162.1.1) to give the title compound as an off-white foam (HPLC- tR 2 34 mm (Method A), M+H = 456 MS-ES, 1H- NMR (dβ-DMSO, 400 MHz) 8 96 (S1 1H)1 8 12-8 07 (m, 2H)1 7 95-7 90 (m, 2H), 7 61-7 58 (m, 1 H), 6 81 -6 78 (m 1 H) 4 88 (d, 1 H), 3 88 (S1 3H)1 3 76-3 62 (m, 1 H), 3.58 (s, 3H), 2 67 (q, 2H), 1 97 (S1 3H), 1 25 (d, 3H), 1 21 (d, 3H), 1.19 (t, 3H))
Stage 162.1.1 (5-Bromo-2-ethyl-pyndin-3-yl)-isopropyl-amine
Figure imgf000274_0002
To solution of (5-bromo-2-ethyl-pyridin-3-yl)-isopropylidene-amine (Stage 162.1.2, 1.17 mmol) in dichloromethane (25 ml) was added AcOH (0 25 ml) and sodium tπacetoxyborohydride (3 51 mmol) The reaction mixture was stirred for 4 h at rt. The RM was quenched with aqueous NaHCO3 and extracted wtth dichloromethane (2x). The combined organic layers were washed with saturated aqueous NaHCO3, with brine, dried over Na∑SOo, filtered and evaporated. The residue was absorbed on silica gel and eluted (CH2CI7ZMeOH 0 % to 3 %) The fractions containing the product were purified by preparative HPLC. The fractions containing pure product were basified with NaHCO3, concentrated and extracted with EtOAc (3x). The combined organic layers were dried over Na∑SO^ filtered and evaporated to the title compound as an oil (HPLC. tR 2 40 mm (Method A), M+H ~ 243, 245 MS-ES)
Stage 162.1.2 (5-Bromo-2-ethyl~pyπdin-3-yl)-isopropylidene-amine
Figure imgf000274_0003
To a solution of 5-bromo-2-ethyl-pyridin-3-yiamine (1.492 mmol), synthesized in a similar manner as described for 5-bromo-2~methyl-pyridin-3-ylamine (Stage 75.1,4) using diethyl methylmalonate (HPLC tR 1.71 mm (Method A), M+H - 201 , 203 MS-ES), in chloroform (0 75 ml) and 2-methoxypropene (Aldrich Bυchs, Switzerland, 7.46 mmol) were added triethylamine (1.492 mmol) and pyπdinium para-toluensulfonate (0 149 mmol). The RM was stirred for 17 h at 100°C, then was quenched with aqueous Na2CO3 and extracted with EtOAc (2x) The combined organic layers were washed with brine, dned over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as a brown oil (M+H = 241 , 243 MS-ES).
Example 163 1 -( 1 , 3-Dimethyt- 1 H-pyrazol-4-yi)-3-methyl-8-(6-methyl-5-methylamino-pyridin- 3-yl)-1 ,3-dihydro-imidazo[4,5-cjquinolin-2-one
Figure imgf000275_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methy)-1 ,3-dihydro-imidazo(4t5-c]quinolin-2-one (Intermediate A) and methyl-(2-methyl-5-(4,4,5,5-tetramethyl-[1.3,2]dioxaborolan-2-yl)- pyridin-3-ylj-amine (Stage 163.1.1) to give the title compound as a white solid. (HPLC' t« 2 10 mm (Method A), M+H * 414 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 95 (s, 1H), 8.12- 8.06 (m, 2H), 7.96-7 92 (m, 1 H) 7 89-7 87 (m, 1 H), 7 62-7 60 (m, 1H)1 6 73-6.70 (m, 1 H), 5.51 (q, br, 1H), 3 88 (s, 3H), 3.57 (s, 3H) 2.80 (d, 3H), 2.31 (s, 3H), 1.97 (s, 3H))
Stage 163,1.1 Methyl-[2-methyl-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- amine
Figure imgf000275_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (5-bromo-2-methyl-pyridin-3-yl)-methyl-amine (stage 163.1.2, 1 194 mmol) to give the title compound as a crude black otl (degrading under the HPLC condition tR 1 64 min (Method A) M+H = 249 MS-ES)
Stage 163.1.2 (5-Bromo-2-methyl-pyridin-3-yl)-methyl-amine
Figure imgf000276_0002
To a solution of 5-bromo-2-methyl~pyndin-3-ylamine (Stage 78,1,4, 3 81 mmol) in THF (25 ml) cooled with an ice-bath was added 1 M bis(tπmethylsilyl)amide in THF (4 38 mmol) The RM was stirred for 1 h at rt then was added iodomethane (4 38 mmol) The RM was stirred for 1 h at rt The RM was cooled with an ice-bath and was added 1 M bis(trimethylsilyt)arnide in THF (1 9 mmol) The RM was stirred for 30 mm at rt then was added iodomethane (1 9 mmol) The RM was stirred for 1 h at rt then was diluted with EtOAc and washed with aqueous Na2CO3 with brine, dried over Na2SO4, filtered and evaporated The residue was taken in MeOH and separated by preparative HPLC The first eluting pure fractions containing product were basjfied with NaHCO3, concentrated and extracted with dichloromethane (2x) The combined fractions were washed with bπne dried over Na2SO4, filtered and evaporated to give the title compound as a brown od (HPLC tH 1 86 mm (Method A) M+H = 201 203 MS-ES) The second eluting pure fractions, that contained (5-bromo-2- methyl-pyridin-3-yl)-dimetbyl-amine side product, were basified with NaHCO3, concentrated and extracted with dichloromethane (2x) The combined fractions were washed with brine dned over Na2SO4, filtered and evaporated to give the title compound as a brown oil (HPLC t* 2 01 mm (Method A), M+H = 215, 217 MS-ES)
Example 164 8-(5-Dimethylamino-6-methyl-pyridin-3-yl)-1-(1 (3-dimethyHH-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000276_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and dimethyl-[2-methyl-5-(4,4 5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)- pyridin-3-ylJ-amine (Stage 164.1.1) to give the title compound as an off-white foam. (HPLC" t* 2 15 min (Method A); M+H - 428 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8.97 (s, 1H), 8.30-8.27 (m, 1H), 8.13-8.08 (m, 2H), 7.99-7 94 (m, 1H), 7 59-7 56 (m, 1H), 7.33-7.30 (m, 1 H), 3 88 (s, 3H), 3.58 (S1 3H) , 2.72 (s, 6H), 2.50 (s, 3H), 1 97 (s, 3H))
Stage 164.1.1 DJmethyl-[2-methyl-5-(4,4(5,5-tetramethyl-(1 l3,2Jdioxaborolan-2-yl)-pyndin-3- yl}-amine
Figure imgf000277_0001
The title compound was synthesized in a similar manner as described for Stage 5,1.1 using (5-bromo-2-methyl-pyridin-3-yl)-dimethyl-amine (stage 163.1.2, 1.255 mmol) to give the title compound as a crude black oil (degrading under the HPLC condition- t« 1.93 min (Method A), M+H = 263 MS-ES).
Example 16S 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-[5-(ethyl-methyl-amino)-6-methyl-pyr»din-3- yl]-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000277_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro-imidazo[4, 5-c]quinolin-2-one (Intermediate A) and ethyt-methyl-[2-methyl-5-(4,4.5,5-tetramethyl-[1 ,3,2Jdioxaborolan-2-yl)- pyridin-3-yl]-amine (Stage 166.1.1) to give the title compound as a white foam (HPLC; tR
2 26 min (Method A), M+H - 442 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 95 (s, 1H), 8 32- 8 29 (m, 1H), 8.13-8.09 (m, 2H), 7 99-7 94 (m, 1 H), 7 61-7 58 (m, 1H), 7.35-7.32 (m, 1 H),
3 89 (s, 3H). 3 58 (s, 3H)1 2 97 (q, 2H), 2 71 (s, 3H), 2 45 (s, 3H), 1 97 (s, 3H), 1 09 (t 3H))
Stage 165.1.1 Ethyl-methyl-[2-methyl-5-(4l4,5,5-tetramethyl-[1 τ3,2]dioxaborolan-2-yl)-pyridin- 3-yl)-amine
Figure imgf000278_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (5-bromo-2-methyl-pyridin-3-yl)-ethyl-methyl-amine (stage 165.1.2, 0 646 mmol) to give the title compound as a crude black oil (degrading under the HPLC condition- tR 2 12 min (Method A); M+H - 277 MS-ES)
Stage 165.1.2 (5-Bromo-2~methyl-pyridin-3-yl)-ethyl-methyl-amine
Figure imgf000278_0002
The title compound was synthesized in a similar manner as described for Stage 163.1.2 using (5-bromo-2-methyl-pyridin-3-yl)-ethyl-amine (Stage 87.1.2, 0.677 mmol) to give the title compound as a brown oil (HPLC' tR 2 22 min (Method A); M+H - 229, 231 MS-ES).
Example 166.1 8-(6-Amino-5-ethoxymethyl-pyridin-3-yl)-1-(1 ,3-dimethyl-1 H-pyrazol-4- yl)-3-methyl-1 ,3-dihydro-imidazo(4,5-cJquinotin-2-one
Figure imgf000278_0003
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo{4,5-c]quinolin-2-one (Intermediate A) and 3-ethoxymethyl-δ-(4,4,5,5-tetramethyl-[1.3,2]dioxaborolan-2-yl)- pyrκ.in-2-ylamine (Stage 166.1.1) to give the title compound as a white solid (HPLC: fo 2 17 mm (Method A); M+H = 444 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.90 (s, 1H), 8 13 (s, 1H), 8 08-8.06 (m, 1H), 8 05-8.01 (m, 1H), 7.86-7 82 (m, 1H), 7.49-7.47 (m, 1H), 744-7.42 (m, 1H), 6 02 (s, br, 2H), 4.37 (s, 2H), 3 92 (s. 3H), 3.57 (s 3H). 3 51 (q. 2H), 1 95 (s, 3H), 1 18 (t, 3H)) Stage 166.1.1 3-Ethoxymethyl-5-(4A5,5-tetramethyH1 ,3,2}dioxaboroian-2-yl)-pyridin-2- ylamine
Figure imgf000279_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-3-ethoxymethyl-pyridin-2-ylamine (stage 166.1.2, 1 082 mmol) to give the title compound as a crude black oil (degrading under the HPLC condition: tR 1.72 mm (Method A); M+H a 279 MS-ES)
Stage 166.1.2 5-Bromo-3-ethoxymethyl-pyτidin-2-ylamine
Figure imgf000279_0002
A solution of (2-amino-5-bromo-pyridin-3-yl)-methanol hydrobromide (Apollo, Cheshire, UK, 3.52 mmol) in DMF (15 ml) cooled with an ice-bath was treated with 55% NaH in oil (7 4 mmol) and the RM was stirred for 5 min at O°C and 30 min at rt, then was added iodoethane (3.87 mmol) and the RM was stirred for 1 h 15 min at rt The RM was quenched with water and extracted with EtOAc. The organic layer was washed with saturated aqueous NaHCO3, with brine (2x), dried over Na2SO4, filtered and evaporated The residue was taken in DMF and purified by preparative HPLC. The fractions containing product were basified with NaHCOs, concentrated and extracted with CHgCt2 (2x) The combined organic layers were washed with brine, drted over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as a light yellow oil. (HPLC' t« 2 07 min (Method A), M+H = 231 , 233 MS- ES)
The following examples were synthesized in a similar manner as described for Example 1,1 using 3-ethoxymethyl-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyπdin-2-ylamine
(Stage 166.1.1) and the specified intermediate
Figure imgf000279_0003
Figure imgf000280_0001
Example 167 1 -( 1 , 3-Dimethyl>1 H-pyrazol-4-yl)-8-(5-ethoxymethyl-6-ethylamino-pyridin-3-yl)- 3-methyl-1 ,3-dihydro-imidazo[4 5-c]quinolin-2~one
Figure imgf000281_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using S-bromo-I^I.S-dimethyl-I H-pyrazol^-yO-S-methyl-I .S-dihydro-imidazo^.S-cJquinolin-Σ-one (Intermediate A) and [3-ethoxymethyl-5-(4,4,5,5-tetramethyl-(1,3l2]dioxaborolan-2-yl)- pyridin-2-yl)~ethyt-amine (Stage 167.1.1) to give the title compound as a white solid. (HPLC. tR 2.30 mm (Method A); M+H = 472 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 90 (S1 1 H)1 8 19-8 16 (m, 1 H), 8 12 (β, 1H), 8 05-8 01 (m, 1H)1 7.87-7 83 (m, 1H), 7 44-7 41 (m, 2H), 6.07 (t, 1H), 4 39 (s. 2H), 3.92 (s, 3H), 356 (s, 3H), 3.51 (q, 2H), 3.46-3.37 (m. 2H), 1.95 (s. 3H)1 1 19 (t, 3H), 1.15 (t, 3H))
Stage 167.1.1 {a-Ethoxymethyl-S^^.δ.δ-tetramethyHI .S^Jdioxaborolan^-yO-pyridin^-yl]- ethyl-amine
Figure imgf000281_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (5-bromo-3-ethoxymethyl-pyridin-2-yl)-ethyl-amine (stage 167.1.2, 0 99 mmo!) to give the title compound as a crude black oil (degrading under the HPLC condition. tR 1 98 min (Method A); M+H * 307 MS-ES).
Stage 167.1.2 (5-Bromo-3-βthoxymethyl-pyndin-2-yl)-ethyl-amine
Figure imgf000281_0003
The title compound was synthesized m a similar manner as described for Stage 87.1.2 using 5-bromo-3~ethoxymethyt-pyπdin-2-yiamine (stage 166.1.2, 1.082 mmol) to give the title compound as a yellow oil. (HPLC tR 2.30 min (Method A); M+H = 259. 261 MS-ES) Example 168.1 8-(6-Amino-5-methoxymethyl-pyridin-3-yl)-1-(1-isopropyl-3-methyl~1H- pyrazoM-yl)-3-methyl-1 ,3-dihydro-irmdazo(4,5-c]qυinol}n-2-one
Figure imgf000282_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imida2θ(4,5- cJquinolin-2-one (Intermediate G) and 3-methoxymethyl-5-(4,4,5,5-tetramethyl- [1,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine (Stage 168.1.1) to give the title compound as a white solid (HPLC' tR 2.19 min (Method A), M+H * 468 MS-ES, 1H-NMR (dθ-DMSO, 400 MHz) 8.91 (S, 1H)1 8.20 (S1 1 H)1 8 06-8 01 (m, 2H), 7.85-7 80 (m, 1H), 7 53-7 50 (m, 1H), 7 44-7.41 (m. 1H), 5.99 ($, br, 2H), 4.54 (hp, 1 H), 4.30 (s, 2H), 3.57 (s, 3H), 3 31 (s, 3H), 1.95 (S1 3H), 1.47 (d, 6H))
Stage 168.1.1 3-Methoxymethyl-5-(4,4,5,5-tetramethyl-[1 ,3,2)dioxaborolan-2-yl)-pyridin-2- ylamine
Figure imgf000282_0002
The title compound was synthesized in a similar manner as descnbed for Stage 166.1.1-2 using iodomethane as replacement for iodoethane to give the title compound as a crude black soft solid, (degrading under the HPLC condition, tft 1 47 min (Method A), M+H « 265 MS-ES).
The following examples were synthesized in a similar manner as described for Example 1.1 using 3-methoxymethyl-5-(4,4,5,5-tetramethyH1 ,3,2)dioxaborolan-2-yl)-pyridin-2-ylamine (Stage 168.1.1) and the specified intermediate.
Figure imgf000282_0003
Figure imgf000283_0002
Example 169.1 8-(δ-Amino-5-hydroxymethyl-pyridin-3-yl)-1-(1-isopropy1-3-methyl-1H- pyrazoM-yO-S-methyl-I .S-dihydro-imidazo^.S-cJquinolin^-one
Figure imgf000283_0001
A mixture of 8-bromo-1-(1-tsopropyl-3-methyl-1H-pyrazol-4-yl)-3-methy!>1 ,3-dihydro- imidazo(4,5-c]quinolin-2-one (Intermediate G, 0 098 mmoi), crude acetic acid 2- diacetylamino-5-(4,4)5,5-tetramethyl-(1 3,2)dioxaborolan-2-yl)-pyridin-3-ylmethyl ester (stage 169.1.1, 0 92 mg) and PdCI2(PPh3)2 (0.0057 mmo!) in DMF (1.2 ml) and 1 M aqueous K2CO3 (0 245 ml) was stirred under argon at 105°C for 1 h Then the RM was cooled to rt and 2 M aqueous LiOH (0 245 ml) was added The RM was stwred for 1 h 15 mm at rt then quenched with 2 M aqueous HCI (0 245 ml), diluted with MeOH and purified directly by Prep HPLC The fractions containing product were collected together, basified with NaHCO^, concentrated and extracted with dϊchloromethane (2x) The combined organic layers were washed with brine dried over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as a white solid (HPLC. tR 2 04 min (Method A); M+H = 444 MS-ES, 1H-NMR (d6- DMSO, 400 MHz) 8 91 (s, 1H)1 8 20 (s, 1H)1 8 06-8 02 (m, 1H), 7.97-7 94 (m, 1H)1 7 83-7 78 (m, 1H)1 7.57-7.54 (m 1H), 7.45-7 42 (m, 1H), 5 95 (s, br, 2H), 5 20 (t, 1H), 4 55 (hp, 1H), 4.37 (d, 2H), 3.57 (s, 3H), 1 95 (s, 3H). 1 47 (d, 6H))
Stage 169,1.1 Acetic acid 2-diacetylamino-5-(4.4l5,5-tetramethyl-[1 3,2)dioxaborolan-2-yl)- pyridin-3~ylmethyl ester
Figure imgf000284_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using acetic acid 2-diacetylamino-5-(4,4,5 5-tetramethyl-[1 ,3)2)dioxaborolan-2-y1)-pyridin-3-ylmethyl ester (stage 169.1.2, 1 762 mmol) to give the title compound as a crude black oil. (degrading under the HPLC condition- tR 2 05 mm (Method A), M+H - 377 MS-ES)
Stage 169.1.2 AceUc acid 2-diacetylamino-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- pyπdin-3-ylmethyl ester
Figure imgf000284_0002
To a suspension of 2-amino-5-brorno-3-hydroxymethyfpyridtne hydrobromide (Apollo, Cheshire, UK, 1 761 mmol) in dichloromethane (9 ml) were added triethylamine (7.92 mmol) and then acetyl chloride (5 81 mmol) The RM was stirred for 1 5 h at rt then was diluted with dichloromethane, washed with brine (2x), dried over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as an oil (HPLC' tR 1 69 min (Method A)1 M+H = 329, 331 MS-ES)
The following examples were synthesized in a similar manner as described for Example 169.1 using the specified intermediate
Figure imgf000285_0002
Example 170 1 -( 1 -lsopropyl-3-methyl-1 H-pyrazol-4-yl)-3-methyl-8-( 1 -methyl-2-oxo- 1 ,4- dihydro-2H-pyrido[2,3-dJ[1 ,3]oxazin-6-yl)-1 ,3-dihydro-imida2θ{4,5-c]qutnolin-2-one
Figure imgf000285_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4 , 5- cJquinolin-2-one (Intermediate G1 0.125 mrnol) and 1-methyi-6-(4,4,5,5-tetramethyl- [1 (3,2]dioxaborolan-2-yl)-1 ,4-d!hydro-pyndo(2,3-d]{1 ,3]oxaz!n-2-one (Stage 170.1.1) to give the title compound as a beige solid. (HPLC: tR 2 59 mm (Method A), M+H ~ 484 MS-ES, 1H- NMR (d6-DMSO( 400 MHz) 8 98 (s, 1H), 8.35-8 33 (m, 1H), 8.21 (s, 1H), 8 15-8 11 (m, 1 H), 7.91-7 83 (m, 2H), 7 52-7 49 (m, 1H), 5 36-5.29 (m, 2H), 4.56 (qt, 1H). 3 58 (β, 3H), 3.35 (s, 3H). 1.95 (s, 3H), 1 46 (d, 6H))
Stage 170.1.1 1-Methyl-6-(4,4,5,5-tetramethy!-(1 ,3,2]dioxaboro!an-2-yl)-1 ,4-dihyciro- pyrido(2,3-dj[1 ,3}oxaztn-2-one
Figure imgf000286_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 6-bromo-1-methyl-1 ,4-dihydro-pyπdo[2,3-d][1,3]oxazin-2-one (stage 170.1.2, 0 30 mmol) to give the title compound as a crude brown soft solid (degrading partially under the HPLC condition, t* 1.87 and 3.68 min (Method A), M+H « 291 MS-ES)
Stage 170.1.2 6-Bromo-1-methyl-1 ,4-dihydro-pyrido[2,3-d][1 ,3]oxazin-2-one
Figure imgf000286_0002
To a solution of e-bromo-M-dihydro-pyπdo^.S-dHI .SJoxazin^-one (Stage 170.1.3, 0 707 mmol) in DMF (1 4 ml) was added 55% sodium hydride tn oil (0 778 mmol). The RM was stirred for 5 mtn at rt then was added iodomethane (0.778 mmol) and the RM was stirred for 30 min at rt The RM was diluted with EtOAc, washed with saturated NaHCO3, with brine (3x), dried over Na2SO4 filtered and evaporated The residue was absorbed on siltca gel and separated by flash chromatography (heptane/EtOAc 0% to 70%) The fractions containing product were evaporated together to give the title compound as a yellow solid (HPLC- tR 2.64 mm (Method A)
Stage 170.1.3 6-Bromo-1 ,4-dihydro-pyπdo[2,3-d][1 3]oxazin-2-one
Figure imgf000286_0003
A mixture of 2-am<no-5~bromo-3~hydroxymethylρyπdine hydrobromide (Apollo, Cheshire UK, 0 528 mmol) in dichloromethane (1 25 ml) and tπethylamine (1 162 mmol) was cooled with an ice-bath Was added to the RM tπchloromethyl chloroformate (0 317 mmol) in dichloromethane and the RM was stirred for 30 min at O°C and 1 h at rt. The RM was diluted with dichloromethane, washed with saturated aqueous NaHCO3, dried over Na2SO4, filtered and evaporated The residue was absorbed on silica gel and separated by flash chromatography (heptane/EtOAc 0% to 80%) The fractions containing product were evaporated together to give the title compound as a yellow solid (HPLC t* 2, 16 min (Method A), M+H = 229, 231 MS-ES)
Example 171 8-(5-Hydroxymethyl-6-methylamino-pyridin-3-yl)-1-(1-isopropyl-3-methyl-1H' pyrazol-4-yl)-3-methyH ,3-dihydro-imida2θ[4,5-c]quinolin-2-one
Figure imgf000287_0001
A solution of 1-(1-isopropyl-3-methyl-1H-pyrazoM-yl)-3-methyl-8-(1-methyl-2-oxo-1 ,4- dihydro-2H-pyrido[2,3-d][1 ,3]oxazin-6-yl)-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one (Example 170. 0.04 mmoi) in dioxane (0 32 ml) and 1 M aqueous LiOH (0 08 ml) was stirred for 1.5 h at rt The reaction mixture was diluted with EtOAc and quenched with 2 M aqueous HCI (0.12 ml) and water Then was added saturated aqueous NaHCO3 and the aqueous layer was extracted with EtOAc (2x). The combined organic layers were dried over Na?SO^(, tittered, evaporated and dried under vacuum to give the title compound as an off-white solid (HPLC tR 2 09 min (Method A), M+H = 458 MS-ES; 1H-NMR (dδ-OMSO, 400 MHz) 8.90 (s, 1H), 8.20 (s, 1H)1 8.09-8.01 (m, 2H), 7.83-7.79 (m, 1H), 7.52-7.49 (m, 1H), 7.45-7 42 (m, 1H)1 6.10 (q, br, 1H), 5.21 (t, 1 H), 4 56 (qt, 1H)1 4 38 (d, 2H), 3 57 (s, 3H), 2.86 (d, 3H). 1.95 (s, 3H), 1 49-1.45 (m, 6H))
Example 172 8-(5-Cyclobutylammo-pyridin-3-yl)-1-(1 ,3-dimethyl-1H-pyrazo1-4-y!)-3-methyl- I .S-dthydro-imidazo^.δ-clquinolin^-one
Figure imgf000288_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-1-CI ^-dimethyl-1H-pyrazoM-yl^S-methyl-I.S-dihydro-imidazo^.S-cJqujnolin^-one (Intermediate A) and cyclobutyH5-(4,4,5,5-tetramethyl-π,3,2]dioxaborolan-2-yl)-pyπdm-3- yi)-amine (Stage 172.1.1) to give the title compound as a white solid (HPLC. fo 2 29 mm (Method A), M+H = 440 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 97 (s, 1H), 8 13-8 07 (m, 2H)1 7 93-7 84 (m, 3H)1 7 58-7 55 (m 1H), 6 80-6 76 (m, 1H)1 6 34 (d, 1H), 3 94-3 85 (m, 1H), 3,90 (S1 3H) 3 58 (s, 3H), 2 44-2 34 (m, 2H), 1 96 (S1 3H), 1 93-1 73 (m, 4H))
Stage 172.1.1 Cyclobuty!-[5-(4,4 δ.δ-tetramethyl-ti .S.ajdioxaborolan^'yO-pyπdin-S-yll-amine
Figure imgf000288_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (5-bromo-pyndin-3-yl)-cyclobutyl-amine (stage 172.1.2, 2 349 mmol) to give the title compound as a crude brown foam (degrading under the HPLC condition tR 2.06 min (Method A), M+H * 275 MS-ES)
Stage 172.1.2 (δ-Bromo-pyridin-S-yO-cyclobutyl-amtne
Figure imgf000288_0003
,
A mixture of 3-bromo-5-fluoropyπdine (Frontier Scientific, Logan, USA, 5 63 mmol) and cyclobutylamine (Fluka, Buchs Switzerland, 12 38 mmol) in NMP (8 ml) was heated under microwave irradiation for 1 h at 19O°C and for 5 5 h at 200"C The reaction mixture was diluted with EtOAc and washed with saturated aqueous NaHCO3, with brine (3x), dried over Na2SO4, filtered, evaporated and dned under vacuum to give the title compound as an off- white solid (HPLC- tft 2 31 mm (Method A), M+H = 227, 229 MS-ES) Exampte 173 1 -(1 ,3-DimethyM H-pyrazot-4-yl)-8-[5-(isopropyl-methyl-amino)-pyridin-3-yl]-3- methyl-1 ,3-djhydro-imidazoI4,5-c]qυinolin'2-one
Figure imgf000289_0001
The title compound was synthesized in a similar manner as described for Example 172 using N-isopropylmethylamine (Fluka, Buchs, Switzerland, 7.61 mmol) as replacement of the cyclobutylamine to give the title compound as a white solid (HPLC tR 2.29 min (Method A), M+H * 442 MS-ES, 1H-NMR ((J6-DMSO1 400 MHz) 8 98-8.97 (m, 1H)1 8 18-8 15 (m, 1H)1 8 13-8.08 (m, 2H), 8.03-8 00 (m, 1H), 7.98-7.93 (m, 1H), 7 61-7 58 (m, 1H)1 7,05-7.03 (m, 1H), 4 20 (qt, 1 H), 3 87 (s, 3H) 3 58 (s, 3H), 2 77 (s, 3H), 1 97 (β, 3H)1 1 17 (d, 3H)1 1 16 (d, 3H))
Example 174 8-[5-(Cyclobutyl-methyl~amino)-pyridin-3-yl)-1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)- 3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000289_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c}quinolin-2-one (Intermediate A) and Cyclobutyl-methyl-(5-(4,4,5,5-tetramethyl-{1 3,2)dioxaborolan-2-y!)- pyndtτv3-yl]-amine (Stage 174.1.1) to give the title compound as a white solid. (HPLC- tR 2 39 min (Method A), M+H ~ 454 MS-ES1 1H-NMR (Cl6-DMSO, 400 MHz) 8.97 (s, 1H)1 8 15- 8 04 (m, 4H), 7 96-7.92 (m. 1H) 7 60-7 57 (m, 1H), 7 06-7 03 (m, 1H), 4 17 (qt, 1H), 3 88 (S1 3H), 3 58 (s, 3H), 2.89 (s, 3H), 2.28-2.02 (m, 4H) 1 97 (s, 3H). 1.81-1.63 (m, 2H))
Stage 174.1.1 Cyclobutyl-methyl-[5-(4,4,5,5-tetramethyl-[1 ,3,2|dioxaborolan-2-yl)-pyridin~3~ yl]-amine
Figure imgf000290_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (δ-bromo-pyπdin-S-yO-cyclobutyl-methyl-amine (stage 174,1.2, 2 349 mmol) to give the title compound as a crude black sticky ot) (degrading under the HPLC condition. tR 2.27 min (Method A); M+H = 289 MS-ES)
Stage 174.1.2 (δ-Bromo-pyridin-S-yO-cyclobutyl-methyl-amine
Figure imgf000290_0003
The title compound was synthesized in a similar manner as described for Stage 163.1.2 using (δ-bromo-pyfidin-S-yO-cyclobutyl-amine (stage 172.1.2, 0 427 mmot) to give the title compound as a crude brown oil (HPLC. tR 2.49 min (Method A), M+H - 241 , 243 MS-ES).
Example 175.1 1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-8-(5-morpholin-4-yl-pyπdin-
3-yl)-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000290_0002
The title compound was synthesized in a similar manner as described for Example 172 using morpholine (Fluka, Buchs, Switzerland, 6 02 mmol) as replacement of the cyclobutylamine to give the title compound as an off-white solid (HPLC. t« 2 10 mm (Method A), M-t-H = 456 MS-ES. 1H-NMR (de-DMSO, 400 MHz) 8 98 (s 1H), 8 34-8.31 (m, 1H), 8.20- 8 17 (m, 1H), 8 14-8.09 (m, 2H), 8 01-7.96 (m, 1H), 7 60-7 58 (m, 1H), 7 29-7 26 (m, 1H), 3 88 (S, 3H), 3.82-3.77 (m, 4H), 3.58 (S, 3H). 3 27-3 21 (m, 4H), 1 95 (s, 3H))
The following examples were synthesized in a simitar manner as described for Example 175.1 using the specified intermediate - 290 -
Figure imgf000291_0002
Examote 176 1-(1 ,3-Dimethyt-1H-pyrazol-4-yl)-8-[5-(ethyl-methy!-amino)-pyridni-3-yl]-3- methyl-1 ,3-clihydro-imidazo(4,5-c]quinolii>2-one
Figure imgf000291_0001
The title compound was synthesized in a similar manner as described for Example 172 using N-ethylmethylamine (Aldrich, Bυchs, Switzerland, 5 75 mmol) as replacement for the cyclobutylarnine to give the title compound as a yellowish solid (HPLC tR 2 21 mm (Method A); M+H = 428 MS-ES, 1H-NMR (ds-DMSO, 400 MHz) 8 97 (s, 1H)1 8 13-8 07 (m, 3H), 8 02- 7 99 (m, 1H) 7 98-7.93 (m, 1H), 7.62-7.58 (m, 1H), 6.99-6 96 (m, 1H), 3 87 (s, 3H). 3.58 (s, 3H)1 3.53-3 43 (m, 2H), 2 95 (s, 3H). 1.96 (s, 3H), 1 07 (t, 3H)) Example 177.1 1-(1,3-Dimethyl-1Hi3yrazoM-yl)-8-(5-isopropylamino-pyndin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-cJquinolin-2-one
Figure imgf000292_0001
The title compound was synthesized in a similar manner as described for Example 172 using isopropylamine (Aldnch, Buchs, Switzerland, 6 27 mmol) as replacement of the cyclobutylamine to give the title compound as an off-white solid. (HPLC t* 2 21 min (Method A); M+H = 428 MS-ES1 1H-NMR (dβ-DMSO, 400 MHz) 8 97 (s, 1 H), 8.13-8.07 (m, 2H), 7 96- 7.92 (m, 1H). 7.90-7 84 (m, 2H), 7.59-7 56 (m. 1H), 6 87-6 84 (m, 1H), 5.87 (d, 1H), 3 88 (s, 3H), 3.63 (oc, 1H), 3 58 (s, 3H), 1 95 (s, 3H)1 1 22-1.13 (m, 6H))
The following example was synthesized in a similar manner as described for Example 177.1 using the specified intermediate.
Figure imgf000292_0002
Example 178 8-(5-Dimethylamino-pyridin-3-yl)-1-(1 ,3-dimethyl-1H-pyrazo!-4-yl)-3-methyl- 1 , 3-dihydro-irnidazo(4 , 5-c]quinolf n-2-one
Figure imgf000293_0001
The title compound was synthesized in a similar manner as described for Example 172 using 2 M dimethylamine in THF (Aldπch, Buchs, Switzerland, 6 11 mmol) as replacement of the cyclobutylamine to give the title compound as a yellowish solid. (HPLC. tR 2 12 min (Method A)1 M+H = 414 MS-ES1 1H-NMR (d6-DMSO, 400 MHz) 8.97 (S1 1H), 8 13-8.04 (m, 4H)1 7 99-7.94 (m 1H), 7.62-7.59 (m, 1H), 7.02-6.99 (m, 1H), 3 88 (s, 3H), 3 58 (s, 3H), 3 00 (S1 6H)1 1.96 (S1 3H))
Example 179 8-(5-Azetidin- 1 -yl-pyridin-3-yl)- 1 -( 1 ,3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3- dihydro-imidazo(4,5-c]quinolin-2~one
Figure imgf000293_0002
The title compound was synthesized in a similar manner as described for Example 172 using azetidine (Fluka, Buchs, Switzerland, 8 79 mmol) as replacement of the cyclobutylamine to give the title compound as a yellowish solid (HPLC. t« 2 18 min (Method A), M+H = 426 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.97 (s 1H), 8.13-8 05 (m, 3H), 7 97- 7.92 (m, 1H)1 7 81-7 77 (m, 1 H)1 7 60-7.57 (m, 1 H), 6 78-6 74 (m, 1 H), 3 98-3.86 (in, 7H), 3 58 (s, 3H), 2 39 (qt, 2H), 1 96 (s 3H))
Example 180.1 1-(1-Ethyl-3-methyl-1 H-pyrazol-4-yl)-3-methyl-8-(5-methylamino- pyridin-3-yl)-1 3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000294_0001
The title compound was synthesized in a similar manner as described for Example 172 using 8-bromo-1 -(1 -ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyM , 3-dJhydro-im!dazo[4, 5- c]quinolin-2-one (Intermediate F. 0.071 mmol) and 8 M methylamine in ethanol (Fiuka, Bυchs, Switzerland, 6.48 mmol) as replacement of the cyclobutylamine to give the title compound as an off-white solid. (HPLC- t* 2 08 mm (Method A); M+H - 414 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8 97 (s, 1H), 8.17 (s, 1 H)1 8.12-8 08 (m, 1H), 7.94-7 92 (m, 1H), 7.91- 7 87 (m, 1 H)1 7 86-7 84 (m, 1H)1 7 57-7.55 (s, 1H), 6.89-6 86 (s, 1H), 6 05 (q, br, 1H), 4 16 (q, 2H), 3 58 (s, 3H), 2 75 (d, 3H). 1 97 (s, 3H)1 1 39 (t, 3H))
The following example was synthesized in a similar manner as described for Example 180.1 using the specified intermediate
Figure imgf000294_0002
Example 181 1-(1,3-Dimethyl>1H-pyrazol-4-yl)-8-(5-(2-fluoro-e1hoxy)-pyridin-3-yl]-3-methyl- 1 ,3~dihydro-imidazo[4,5-c]qutnohn-2-one
Figure imgf000295_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1.3-dihydro-imidazo[4, 5-cJquinolin-2-one (Intermediate A) and 3-(2-fluoro*ethoxy)-5-(4.4,5(5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- pyridine (Stage 181.1.1) to give the title compound as a white solid. (HPLC: t« 2.20 mm (Method A); M-t-H = 433 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 99 (s, 1H)1 8 36-8.32 (m, 2H)1 8.17-8.10 (m, 2H)1 8 03-7.98 (m, 1H)1 7 61-7.57 (m, 1 H), 7.47-7 44 (m, 1H)1 4 89-4.73 (m, 2H)1 4.48-4.36 (m, 2H), 3.90 (S, 3H), 3 58 (s, 3H)1 1.96 (s, 3H))
Stage 181.1.1 3-(2-Fluoro-ethoxy)-5-(4,4,5,5-tetramethyl-{1l3l2ldioxaborolan-2-yl)-py'rfdine
Figure imgf000295_0002
The title compound was synthesized in a similar manner as described for Stage 58.1.1 using 2-fluoroethancl (Aldrich, Buchs, Switzerland, 1 672 mmol) as replacement for isopropanol to give the title compound as a crude brown sticky oil. (degrading under HPLC condition: tR 2.10 min (Method A); M+H « 268 MS-ES).
Example 182 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-y!)-8-[5-(2-fluoro- 1 -fluoromethyl-ethoxy)-pyπdin- 3-yl]-3-methyl-1 ,3-dihydro-irnidazo(4,5-c]quinolin-2-one
Figure imgf000295_0003
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-I^I .S-dimethyl-1H-pyrazot^-yO-S-methyl-I .S-dihydro-imidazo^.S-cJquinolin^-one (fntermediate A) and 3-(2-fluoro-1-fluoromethyl-ethoxy)-5-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-pyridine (Stage 182.1.1) to give the title compound as a white solid (HPLC- tR 2 31 min (Method A)1 M+H = 465 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 99 (S1 1H), 8 40-8 37 (m, 1 H), 8 36-8 33 (m, 1 H), 8.16-8 10 (m, 2H)1 8 02-7.97 (m, 1H) 7 59-7 54 (m, 2H)1 5.24-5.08 (m, 1H), 4 91-4.65 (m, 4H), 3 90 (s, 3H)1 3.58 (s, 3H), 1.96 (s, 3H))
Stage 182,1.1 3-(2-Fluoro-1-fluoromethyl-ethoxy)-5-(4,4,5,5-tetramethyl-[1 ,3,2]d(oxaborolan- 2-yl)-pyπdine
Figure imgf000296_0001
The title compound was synthesized in a similar manner as described for Stage 58.1.1 using I .S-difluoro^-propanol (Aldπch, Buchs, Switzerland, 1 672 mmol) as replacement for isopropanol to give the title compound as a crude black oil. (degrading under HPLC condition tR 2 00 mm (Method A), M+H = 300 MS-ES)
Example 183 8-{5~Dif luoromethoxy-pyπdin-3-yl)- 1 -( 1 , 3-dimethyl-1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-cJquinoIin-2-one
Figure imgf000296_0002
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1 H-pyrazol-4-yi)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and 3-difluoromethoxy-5-(4,4 5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- pyridine (Stage 183.1.1) to give the title compound as a white foam (HPLC- tR 2 48 mm (Method A), M+H * 437 MS-ES, 1H-NMR (dδ-DMSO, 400 MHz) 9 01 (s, 1 H), 8 61-8 59 (m, 1H)1 8 52-8 50 (m, 1H)1 8 17-8.13 (m, 2H) 8.02-7.98 (m, 1H) 7 74-7.71 (m, 1 H), 7 61-7 59 (m, 1 H), 7.39 (t 1 H)1 3 90 (s, 3H) 3 59 (s, 3H), 1 95 (s, 3H))
Stage 183.1.1 3-Difluoromethoxy-5-(4,4,5,5-tetramethyl-(1 ,3 2]dioxaborolan-2-yl)-pyndine
Figure imgf000297_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 3-bromo-5-diflυoromethoxy-pyridine (stage 183.1.2, 0.192 mmo!) to give the title compound as a crude brown oil. (degrading under the HPLC condition: t* 2 27 rnin (Method A), M+H ~ 227 MS-ES).
Stage 183.1.2 3-Bromo-5-difluoromethoxy-pyridme
Figure imgf000297_0003
A mixture of 3-bromo-5-hydroxypyridine (Aldrich, Buchs, Switzerland, 1.394 mmoi), sodium chlorodifluoroacetate (Aldrich, Buchs, Switzerland, 1.672 mmol) and potassium carbonate (2.79 mmol) in acetonitπte (10 ml) was refiuxed for 4 h 45 mm. The reaction was cooled and diluted with dichloromethane, washed with saturated aqueous NaHCO3 with brine, dned over Na2SO4, filtered and evaporated The residue was taken in DMA and purified by preparative HPLC. The fractions containing product were basified with NaHCO3, concentrated and extracted with dichloromethane (2x) The combined organic layers were washed with brine, dned over Na2SO4, filtered, evaporated to give the title compound as a brown oil. (HPLC- tR 2.91 min (Method A); M+H = 224. 226 MS-ES).
Example 184 1 -(1 ,3-Dimethyl-i H-pyrazol-4-yl)-8-(5-methoxy-6-methyl-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c}quinolin-2-one
Figure imgf000297_0002
The title compound was synthesized in a similar manner as described for Example 84 using methanol (Fluka, Buchs, Switzerland) as replacement for the isopropanol to give the title compound as a white solid. (HPLC. tR 2.10 mm (Method A), M+H = 415 MS-ES, 1H-NMR (d6- DMSO, 400 MHz) 8.98 (s, 1H), 8.20-8.17 (m, 1H), 8 14-8 10 (m, 2H), 8.03-7 98 (m, 1H), 7.62-7 59 (m 1 H), 7.32-7 29 (m, 1 H)1 3 92 (s, 3H). 3.89 (s, 3H)1 3 59 (s, 3H), 2 39 (s, 3H)1 1.98 (s, 3H))
Example 18S.1 1 -( 1 , 3-Dimethyl-1 H-pyrazol~4-yl)-8-(5-hydroxy-6-methyl-pyπdin-3-yl)-3- methyl-I .S-dihydro-irnldazoβ.S-cJquinolin^-one
Figure imgf000298_0001
The title compound was synthesized in a similar manner as described for Example 84 using dioxarve/water 1 • 1 as replacement for the isopropanol to give the title compound as a white solid (HPLC. tR 1 98 min (Method A); M+H ~ 401 MS-ES; MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 9.97 (s, 1 H), 8 97 (s, 1H), 8.14-8 09 (m, 2H), 7 99-7 96 (m, 1H)1 7 82-7.77 (m, 1H), 7.55-7 52 (m, 1H), 7.21-7.18 (m, 1H), 3 92 (s, 3H) 3.58 (s. 3H), 2 36 (s, 3H), 1.96 (s, 3H))
The following example was synthesized in a similar manner as described for Example 18S.1 using the specified intermediate
Figure imgf000298_0002
Figure imgf000298_0003
Exaropte 186 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(6-ethyl-5-isopropoxy-pyridin-3-yl)-3- methyl-1 ,3-dihydro-tmidazo[4,5-c]quinolin-2-one
Figure imgf000299_0001
The title compound was synthesized in a similar manner as described for Example 84 using diethyl methylmalonate (Fluka, Bυchs, Switzerland) as replacement for the diethyl malonate to give the title compound as a white solid (HPLC: tR 2 44 mm (Method A); M+H = 467 MS- ES, 1H-NMR (d6-DMSO, 400 MHz) Θ.98 (s, 1H), 8.23-8.20 (m, 1H), 8.13-8 09 (m, 2H), 8.01- 7 96 (m, 1H), 7 61-7.58 (m, 1H), 7 31-7.28 (m, 1H), 4 75 (hp, 1H), 3.89 (s, 3H), 3 58 (s, 3H), 2.75 (q, 2H) 1 98 (s, 3H), 1 37-1 33 (m, 6H), 1 19 (t, 3H))
Example 187 1-(1,3-Dimethyl-1H-pyrazoi-4-yl)-8-(5-ethoxy-6-ethyl-pyridin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000299_0002
The title compound was synthesized in a similar manner as described for Example 186 using ethanol as replacement for isopropanol to give the title compound as a white solid (HPLC. tR 2 32 mm (Method A)1 M+H « 443 MS-ES. 1H-NMR (d6~DMSO, 400 MHz) 8 98 (s 1H), 8.25-8.22 (m, 1H), 8 14-8.09 (m, 2H), 8 02-7.98 (m, 1H) 7 62-7 59 (m, 1H), 7 30-7.27 (m, 1H). 4.24-4 10 (m, 2H). 3 89 (s, 3H), 3 58 (s, 3H). 2 77 (q, 2H), 1 97 (s, 3H), 1 43 (t, 3H), 1 20 (t, 3H))
Example 188 1 -( 1 3-Dimethyl-1 H-pyrazol-4-yl)-8-(6-ethyl-5-hydroxy-pyndin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c)quino!in-2-one
Figure imgf000300_0001
The title compound was synthesized in a similar manner as described for Example 186 using dioxane/water 1.1 as replacement for isopropanoi to give the title compound as an off- white solid. (HPLC. tR 2.07 min (Method A); M+H = 415 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 9 98 (S, br, 1H)1 8.97 (s. 1H)1 8.14-8.08 (m, 2H), 8.03-7.99 (m, 1H), 7 82-7.76 (m, 1H), 7.55-7.52 (m, 1 H), 7.20-7 17 (m, 1 H), 3.91 (s. 3H), 3.58 (s, 3H), 2.73 (q, 2H)1 1.96 (s, 3H), 1.18 (t, 3H))
Example 189 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-y l)-8-[5-(2-fIuoro- 1 -fluoromethy l-ethoxy)-6- methyl-pyridin-3-yl]-3-methyl-1 ,3-dihydro-imidazo(4,5-c}quinolin-2-one
Figure imgf000300_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quirK)l)n-2-one (Intermediate A) and 3-(2-fluoro-1-flυoromethyl-ethoxy)-2-methyl-5-(4,4l5,5-tetramethyl- [1 ,3,2]dκ>xaborolan-2-yl)-pyridine (Stage 189.1.1) to give the title compound as a white foam. (HPLC' tR 2 26 min (Method A), M+H - 479 MS-ES, 1H-NMR (dδ-DMSO. 400 MHz) 8.98 (s, 1H), 8.19-8 17 (m, 1 H), 8.14-8 10 (m, 2H), 8,00-7.95 (m, 1H), 7.58-7.52 (m, 2H), 5.16-5.01 (m, 1H), 4.92-4.66 (m, 4H), 3 89 (s, 3H), 3.58 (s, 3H), 2 41 (s, 3H), 1.97 (s, 3H))
Stage 189.1.1 3-(2-Ruoro-1-fluoromethyl-ethoxy)-2-methyl-5-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-pyπdine
Figure imgf000300_0003
.0
Figure imgf000300_0004
The title compound was synthesized in a similar manner as described for Stage 182.1.1 using 5-bromo-2-methyl-pyndin-3-ol (stage 189.1.2) as replacement for 3-bromo-5- hydroxypyridme to give the title compound as a crude black oil (degrading under the HPLC condition- tR 2.06 mm (Method A): M+H = 314 MS-ES),
Stage 189.1.2 5-Bromo-2-methyl-pyrκ.in-3-ol
The title compound was synthesized in a similar manner as described for Stage 84.1.2 using dioxane/water 1 1 as replacement for isopropanol to give the title compound as an orange solid. (HPLC. tR 1 41 min (Method A); M+H = 188, 190 MS-ES)
Example 190 I^I.S-Dimethyl-I H-pyrazol^-yO-δ-Cβ-hydroxymethyl-δ-isopropoxy-pyndin-S- yl)-3-methyl- 1 ,3-dihydro-imidazo[4, 5-c]quinolin-2-one
Figure imgf000301_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-y!)-3-methyl-1 3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and [3-isopropoxy-5-(4,4)5l5-tetramethyl-[1.3,2]dioxaboro!an-2-yl)-pyridin- 2-y!)-methanol (Stage 190.1.1) to give the title compound as a white solid (HPLC. tR 2.19 mm (Method A)1 M+H ~ 459 MS-ES; 1H-NMR (drDMSO, 400 MHz) 8 99 (s, 1H), 8 27-8.23 (m. 1H), 8 15-8 10 (m, 2H), 8 03-7.98 (m, 1H), 7 62-7 59 (m, 1H), 7 40-7 37 (m, 1 H), 4.84 (br, 1H), 4 76 (hp, 1H), 4 55 (s 2H), 3.88 (s, 3H)1 3.58 (S4 3H), 1 97 (s, 3H), 1.36-1 31 (m, 6H))
Stage 190.1.1 [3-lsopropoxy-5-(4,4,5l5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)-pyπdin-2-yl]- methano! OH
Figure imgf000302_0001
B .0 O
Figure imgf000302_0002
The title compound was synthestzed in a similar manner as described for Stage 6.1.1 using (5-bromo-3-isopropoxy~pyndtn~2-yl)-methanol (stage 190.1.2, 0 546 mmol) to give the title compound as a crude black oil (degrading under the HPLC condition- fo 2 06 min (Method A)).
Stage 190.1.2 (5-Bromo-3-isopropoxy-pyridin-2-yl)-methanol
Figure imgf000302_0003
To a solution of 5-bromo-3-isopropoxy-2-methyl-pyridine 1-oxide (Stage 190.1.3, 2.054 mmol) in THF (13 ml) was added triflυoroacetic anhydride (10 27 mmol) The RM was stirred for 4 h at rt The RM was evaporated to dryness The residue was treated with saturated aqueous NaHCO3 (20 ml), stirred for 15 h at rt and then extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over Na2SO^ filtered and evaporated The residue was taken in DMA and purified by preparative HPLC. The fractions containing the product are basified with NaHCO3, concentrated and extracted with dichloromethane (2x) The combined organic layers were washed with bnne, dried over Na2SO4, filtered and evaporated to give a yellowish slowly crystallizing solid (HPLC' tR 2 21 min (Method A), M+H « 246, 248 MS-ES)
Stage 190.1.3 5-Bromo-3-isopropoxy-2-methyl-pyπdine 1 -oxide
O Il
Figure imgf000302_0004
Br
The title compound was synthesized in a similar manner as described for Stage 155.1.4 using 5-bromo-3-isopropoxy-2-methyl-pyπdine (Stage 84.1.2, 2 108 mmol) as replacement for (5-bromo-2-methyl-pyridm-3-yl)-ethyl-carbamic acid tert-butyl ester to give the title compound as a slowly crystallizing orange solid (HPLC. t« 2 75 mm (Method A); M+H * 246, 248 MS-ES) Examole 191.1 1-(1,3«Dimethyl~1 H-pyrazoM«yl)-8«(5-isopropoxy-6-methoxymethyl- pyridin-3-yl)-3-methyl-1 ,3-dihydro-imtdazo[4,5-c]quinGlin-2-one
Figure imgf000303_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4~yl)~3-methyl-1 ,3-dihydro-imidazo[4,5-c]quino)in-2-one (Intermediate A) and 3-isopropoxy-2-methoxymethyl-5-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-pyridine (Stage 191.1.1) to give the title compound as a white foam. (HPLC: tR 2.41 min (Method A); M+H ~ 473 MS-ES, 1H-NMR (dθ~DMSO, 400 MHz) 8.99 (s, 1H)1 8 27-8 25 (m, 1 H), 8 15-8.10 (m, 2H), 8.03-7.98 (m, 1H), 7 62-7 60 (m, 1H)1 7 42-7 40 (m, 1 H), 4.77 (hp, 1H). 4.47 (s, 2H), 3.88 (s, 3H), 3.58 (s, 3H), 3 31 (s, 3H), 1 97 (s, 3H), 1.37-1 32 (m, 6H))
Stage 191.1.1 3-lsopropoxy-2-methoxymethyl-5-(4,4,5,5-tetramethyl-(1 ,3,2}dioxaborolan-2- yl)-pyridine
Figure imgf000303_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-3-isopropoxy~2-methoxymethyl-pyridine (stage 191.1.2, 0 142 mmol) to give the title compound as a crude brown oil (degrading under the HPLC condition: tR 2.40 mm (Method A); M+H = 308 MS-ES)
Stage 191.1.2 5-Bromo-3-isopropoxy-2-methoxymethy)-pyridine
Figure imgf000303_0003
To a solution of (5-bromo-3-isopropoxy-pyπdin-2-yI)-methanol (stage 190.1.2, O 61 mmof) in DMF (3 ml) was added 55% NaH in oil (0 688 mmol) was added The RM was stirred for 30 mm at rt then was added iodomethane (0 684mmo!) The RM was stirred for 2 5 h at rt then was quenched with MeOH and purified by preparative HPLC The fractions containing product were combined, basified with NaHCO3, concentrated and extracted with dichloromethane (2x) The combined organic layers were washed with bnne, dried over Na5-SO4, filtered and evaporated to dryness to give the title compound as a yellow oil (HPLC tR 2 83 mm (Method A), M+H = 260, 262 MS-ES)
The following example was synthesized in a similar manner as descnbed for Example 191.1 using the specified intermediate
Figure imgf000304_0002
Example 192 ^(I .S-Dimethyl-1H-pyrazoM-yO-S-lS^a-fluoro-1-fluoromethyl-ethoxyVe- hydroxymethyl-pynd!n-3-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000304_0001
The title compound was synthesized in a similar manner as described for Example 190 using 5-bromo-3-(2-fluoro-1-fluoromethyl-ethoxy)-2-methyl-pyridine (Stage 192.1.1) to give the title compound as a white solid (HPLC fe 2 15 min (Method A), M+H = 495 MS-ES1 1H- NMR (CL5-DMSO1 400 MHz) 8.99 (s, 1H)1 8.29-8.26 (m, 1H), 8.15-8.10 (m, 2H)1 8.02-7.98 (m, 1H), 7 63-7 58 (m, 2H), 5.19-5 04 (m, 1H), 4.93 (t, 1H), 4 91-4 66 (m, 4H), 4.60 (d, 2H), 3.89 (S, 3H), 3 58 (S, 3H), 1.97 (s, 3H))
Stage 192.1.1 5-Bromo-3-(2-fluoro-1-fluoromethyl-ethoxy)-2-methyl-pyridine
Figure imgf000305_0002
The title compound was synthesized in a similar manner as described for stage 58.1.2 using 5-bromo-2-methyl~pyridin-3-ol (stage 109.1.2, 2.234 mmol) and 1 ,3-difluoro-2-propanol (Aldrich, Bυchs, Switzerland, 2 68 mmol) to give the title compound as a yellow oil. (HPLC. tR 2 41 mm (Method A), M+H = 266, 268 MS-ES)
Example 193 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(6-hydroxymethyl-5-methoxy-pyridin-3-y))- 3~methy!-1 ,3-dihydro-imidazo(4,5~c]quinolin-2-one
Figure imgf000305_0001
The title compound was synthesized in a similar manner as described for Example 190 using methanol as replacement for isopropanol to give the title compound as a white foam (HPLC tR 1.99 min (Method A); M+H * 431 MS-ES; 1H-NMR (d6-DMSQ, 400 MHz) 8 99 (s, 1H), 8.28-8.25 (m, 1H), 8.15-8 11 (m, 2H), 8.05-8.01 (m, 1H), 7.64-7 62 (m, 1H) 7 40-7-37 (m, 1H), 4.90 (t, 1 H). 4 56 (d, 2H), 3 92 (s, 3H), 3.89 (s, 3H), 3 58 (s, 3H), 1.98 (s, 3H))
Example 194.1 8-(6-Hydroxymethyl-5-methoxy-pyridin-3-yl)-1 -(1 -isopropyl-3-methyl-
1 H-pyra2θl-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000306_0001
The title compound was synthesized in a similar manner as descnbed for Example 169.1 using acetic acid 3-methoxy-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyndin-2- ylmethyl ester (stage 194.1) to give the title compound as an off-white solid. (HPLC" t« 2 13 mm (Method A); M+H = 459 MS-ES, 1H-NMR (d6~DMSO, 400 MHz) 8 99 (s, 1H), 8 22-8 11 (m, 3H), 8 03-7 98 (rn. 1H), 7.58-7 54 (m, 1H), 7 48-7-45 (m, 1H), 4 96 (t, 1H), 4 54 (d, 2H) 4.52 (hp, 1 H), 3 92 (s, 3H), 3.59 (s, 3H), 1 99 (s, 3H), 1.46-1 40 (m, 6H))
Stage 194.1.1 Acetic acid 3-methoxy-5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolan-2-yl)-pyrid<n- 2-ylmethyl ester
Figure imgf000306_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using acetic aad 5-bromo-3-methoxy-pyridin-2-ylmethyl ester (stage 194.1.2, 0.142 mmol) to give the title compound as a crude brown oil. (degrading under the HPLC condition tR 2 54, 3 69 mm (Method A); M+H « 308 MS-ES)
Stage 194.1.2 Acetic acid 5-bromo-3-methoxy-pyridin-2-ylmethyl ester
Figure imgf000306_0003
To a mixture of (5-bromo-3-methoxy-pyndin-2-yl)-methanol (Stage 194.1.3, 2 79 mmol) and triethylamine (4 18 mmol) in dichloromethane was added slowly acetyl chloride (3.35 mmol) and the RM was stirred for 1 h at rt The RM was diluted with dichloromethane, washed with saturated aqueous NaHCO3, with brine, dried over Na?SO4, filtered and evaporated The residue was absorbed on silica gel and purified by flash chromatography (neptane/EtOAc 0% to 60%) The fractions containing product were evaporated together to give the title compound as a white solid (HPLC tR 2 72 min (Method A), M+H = 260, 262 MS-ES)
Stage 194.1.3 (5-Bromo-3-methoxy-pyπdin-2-yl)-methanol
Figure imgf000307_0001
The title compound was synthesized in a similar manner as described for Stage 190.1.2 using methanol as replacement for isopropanol to give the title compound as an off-white solid (HPLC tR 1 76 mm (Method A), M+H = 218, 220 MS-ES).
The following example was synthesized in a similar manner as descπbed for Example 194.1 using the specified intermediate
Figure imgf000307_0003
Example 195,1 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(5-methoxy-6-methoxymethyl- pyridin-3-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one
Figure imgf000307_0002
The title compound was synthesized in a similar manner as descnbed for Example 191 using (5-bromo-3-methoxy-pyndin-2-yl)-methanol (Stage 194.1.3) to give the title compound as a white foam (HPLC- tR 2 21 mm (Method A) M+H « 445 MS-ES, 1H-NMR (CDCI3, 400 MHz) 8 81 (s, 1H), 8 40-8 38 (m, 1H), 8 31-8 24 (m, 1H), 7 91-7 86 (m, 1H), 7 73-7 70 (m, 1 H), 7 66-7 64 (m, 1H), 7 19-7 17 (m 1H) 4 68 (s, 2H)1 3 97 (s, 3H)1 3 96 (s 3H), 3 70 (s, 3H)1 3 53 (s, 3H)1 2 14 (s, 3H))
The following examples were synthesized in a similar manner as described for Example 195,1 using the specified intermediate
Example lntermed structure Name of the MS-ES HPLC example tR
(M+H)
(mm)
195 2 G 1-(1-lsopropyi-3- 473 2 37 methyl-1 H-pyrazol-4- y-i0 yl)-8-(5-methoxy-6-
? C J methoxymethyl- pyridin-3-yl)-3- methy!-1,3-dihydro- imidazo(4,5- c]quinolin-2-one
195 3 F 1-(1-Ethyl-3-methyl- 459 2 28
1Q 1H-pyrazol-4-yl)-8-
(5-methoxy-6-
J _<
O methoxymethyl- pyrtdin-3-yl)-3- methyl-1 ,3-dihydro- imidazo[4 5- c]quinolin-2-one
195 4 K H3-Chloro-1- 459 2 28
O methyl-1 H-pyrazc4-4- yl)-8-(5-methoxy-6-
? O
7 methoxymethyl- pyridin-3-yl)-3- methyl-1 ,3-dihydro- imidazo[4,5-
Figure imgf000308_0001
Figure imgf000309_0003
Example 196.1 1-(3-Chloro-1 -methyl- 1 H-pyrazol-4-yl)-8-(6-ethoxymethyl-5-methoxy- pyndin-3-yl)-3-methyl-1 3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000309_0001
The title compound was synthesized in a similar manner as described for Example 195.1 using iodoethane as replacement for iodomethane to give the title compound as a white foam (HPLC' tR 2.51 min (Method A), M+H = 479 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 9.02 (s, 1 H), 8.38-8.37 (m, 1H), 8 31-8 29 (m, 1 H), 8 17-8.14 (m, 1H), 8.07-8.03 (m, 1H), 7.63-7.61 (m, 1H), 7 47-7.45 (m, 1 H), 4 53 (s, 2H), 3.96 (s, 3H)1 3 93 (s, 3H), 3.60 (s, 3H), 3.52 (q, 2H), 1 11 (t, 3H))
The following example was synthesized in a similar manner as described for Example 196.1 using the specified intermediate.
Figure imgf000309_0002
§txrarrηp|j&r,19,7.j 1 -(1 ,3-Dimethyl-i H-pyrazol-4-yl)-8-(5-ethoxy-6-methoxymethyl-pyridin-
3-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c}quinolin-2-one
Figure imgf000310_0001
The title compound was synthesized in a similar manner as described for Example 191 using (5-bromo-3-ethoxy-pyridin-2-yl)~methanol (Stage 197.1.2) to give the title compound as a white foam (HPLC: tR 2 33 mm (Method A); M+H = 459 MS-ES; 1H-MMR (do-DMSO, 400 MHz) 8.99 (S1 1H), Θ.28-Θ 26 (m, 1 H), 8 15-8 10 (m, 2H), 8.04-8.00 (m, 1 H), 7.64-7 61 (m, 1 H), 7.41-7 38 (m, 1H), 4 49 (s, 2H), 4 22-4.14 (m, 2H), 3.89 (s, 3H), 3 58 (S1 3H), 3.31 (s, 3H)1 1.97 (st 3H), 1.41 (t, 3H))
Stage 197.1.2 (5-Bromo-3-ethoxy-pyπdin-2-yl)-methanol
Figure imgf000310_0002
The title compound was synthesized in a similar manner as described for Stage 190.1.2 using ethanol as replacement for isopropanol to give the title compound as an orange solid (HPLC tR 2 03 mm (Method A); M+H * 232. 234 MS-ES)
The following example was synthesized in a similar manner as described for Example 197.1 using the specified intermediate
Figure imgf000310_0003
Ex.arnpje .198 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yi)-8-(5-ethoxy-6-trideuteromethoxymethyl- pyridin-3-yl)-3-methyl-1 ,3~dihydro-imidazo(4,5-c]quinolin-2-one
Figure imgf000311_0001
The title compound was synthesized in a similar manner as described for Example 197.1 using da-iodomethane (Aldrich, Buchs, Switzerland) as replacement for iodomethane to give the title compound as an off-white foam (HPLC' tR 2.33 min (Method A); M+H = 462 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8 99 (s, 1H), 8 29-8.26 (m, 1H), 8.15-8,1 1 (m, 2H), 8.04-8 00 (m, 1H), 7 64-7.61 (m, 1H), 7 41-7 38 (m, 1 H), 4 49 (s, 2H), 4 22-4 14 (m, 2H), 3 89 {s, 3H). 3.58 (S, 3H), 1.97 (s, 3H), 1 41 (t, 3H))
Example 199 1-(3-Chtoro-1 -methyl- 1 H-pyrazol-4-yl)-8-{5-methoxy-6- trideuteromethoxymethyl-pyridin-3-yl)-3-methyl-1 ,3-dihydro-imidazot4,5-c]quinolin-2-one
Figure imgf000311_0002
A solution of 1-(3-chloro-1 -methyl- 1H-pyrazol-4-yl)-8-(6-hydroxymethyl-5~methoxy-pyridin-3- yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Example 194.2, 0 033 mmol) in DMF (0 4 ml) was treated with 55% NaH in oil (0.037 mmoO and the RM was stirred for 5 mm at it, then was added d3-iodomethane (Aldπch, Buchs, Switzerland, 0.037 mmol) and the RM was stirred for 30 mm at rt. The RM was quenched with water, diluted with DMF1 filtered and purified by preparative HPLC. The pure fractions were basified with NaHCO3 concentrated and extracted with EtOAc (3x) The combined organic layers were dried over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as a foam (HPLC' tR 2 40 min (Method A), M+H = 468 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 9.02 (s, 1 H), 8 37 (s, 1H), 8 32-8 30 (m, 1H), 8 17-8 13 (m. 1 H), 8 07-8 03 (m 1 H), 7.63-7 61 (s, 1H), 7 48-7 45 (m, 1H), 4 49 (s, 2H), 3 96 (s, 3H), 3.93 (s. 3H), 3 60 (s, 3H)) Example 200 I^S-Chloro-1-methyl-1H-pyrazoM-yO-β^S-hyclroxymethyl-S-methoxy-pyπdin- 3-yl)-3-fnethyl-1 ,3-dihydro-imidazo(4,5-c]qutnolin-2-one
Figure imgf000312_0001
To a solution of δ-II-CS-chloro-1-methyl-1H-pyrazol^-yO-a-methyl^-oxo-a.S-dihydro-1H- imidazo{4,5-c]quinotin-8-yl)-2-methoxy-nicotinic acid methyl ester (stage 200.1, 0 176 mmof) in THF (2 ml) cooled with an ice-bath was added dropwise a 1 M solution of LiAIH4 in THF (0 150 mmol) The reaction mixture was stirred for 1h 15 mm at rt, then quenched with water, diluted with EtOAc and filtered over Celite The filtrate was washed with saturated aqueous NaHCO3 with water, with brine, dried over Na2SO4, filtered and evaporated The residue was dissolved in MeOH/TFA and purified by preparative HPLC The fractions containing pure product were basified with NaHCθ3 and concentrated The precipitate was filtered, washed with water(2x) and dried under vacuum to give the title compound as a white solid (HPLC. tR 2 53 mm (Method A) M+H = 451 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 99 (s, 1H), 8 41 (s 1 H), 8 30-8 27 (m, 1 H), 8 14-8 10 (m, 1 H) 7 98-7 93 (m, 1H), 7 84-7 81 (m, 1 H) 7 53- 7 50 (m 1H) 5 32 (t, 1H) 4 51 (d, 2H) 4 01 (s, 3H), 3.92 (s, 3H), 3 59 (s, 3H))
Stage 200.1.1 5-[1-(3-Chloro-1-methyl-1H-pyra2θl-4-yl)-3-methyl-2~oxo-2 3-dihydro-1 H- imidazo[4 S-cJquinolin-δ-ylJ^-methoxy-nicotinic acid methyl ester
Figure imgf000312_0002
The title compound was synthesized in a similar manner as descπbed for Example 1 using 8-bromo-1-(3-chloro-1-methyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]qυinoHn-2- one (Intermediate K) and 2~methoxy-3-(carbomethoxy)pyridine-5-boronic acid pinacol ester (Combi-Blocks, San Diego, USA) to give the title compound as a white solid (HPLC tR 2 75 mm (Method A), M+H « 479 MS-ES) Example 201 1 -(3-Chloro-1 -methyl-1 H-pyrazo(-4-yl)-8-(6-methoxy-5-methoxymethyl-pyπdin- 3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000313_0001
The title compound was synthesized in a similar manner as described for Example 166 using 1 -(3-chloro- 1 -methyl- 1 H-pyrazol-4-yl)-8-(5-hydroxymethyl-6-methoxy-pyndin-3-yl)-3- methyl-1 ,3-d)hydro-imidazo{4.5-c)quinolin-2-one {Example 200, 0.081 mmol) to give the title compound as a white foam (HPLC tR 2.82 mm (Method A)1 M+H = 465 MS-ES, 1H-NMR (d6- DMSO, 400 MHz) 8.99 (s, 1 H), 8 40 (s, 1H), 8 35-8 32 (m, 1H), 8 14-8 10 (m, 1H)1 7 98-7.93 (m, 1H)1 7 75-7 72 (m, 1 H), 7 50-7.47 (m, 1H), 4 43 (s, 2H), 3 99 (S1 3H), 3 93 (s, 3H), 3 59 (s, 3H), 3.40 (s, 3H))
PttJJPJPJf 2Q? H1 ,3-DimethyM H-pyrazol-4-yl)-8-(6-methoxy-5-methoxymethyl-pyπdin-3-yl)- 3-methyl-1 ,3-dihydro-imidazo[4,5-c]quino)in-2-one
Figure imgf000313_0002
The title compound was synthesized in a similar manner as described for {Example 201 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin- 2-one (Intermediate A) to give the WIe compound as a yellow solid (HPLC tR 2.36 min (Method A), M+H = 431 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 96 (S1 1 H), 8 31-8 28 (m, 1H). 8 13 (s, 1 H) 8 11-8 07 (m, 1H), 7.94-7 90 (m, 1 H), 7.72-7.69 (m, 1H), 7 54-7 51 (m, 1H). 4 42 (S1 2H). 3 92 (S1 3H), 3 92 (s 3H), 3 58 (s, 3H), 3 39 (s, 3H), 1 95 (s. 3H)) Examole 203 1 -{3-Chloro-1 -methyl-1 H-pyrazoi«4~yl)-8-(6-methoxymethyl-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000314_0001
The title compound was synthesized in a similar manner as descπbed for Example 104 using 1 -(3~chloro- 1 -methyl- 1 H-pyrazol-4-yt)-8-(6-hydroxymethyl-pyridin-3-yl)-3-methyl- 1 , 3- dihydro-imidazo(4,5-c)quinolin-2-one (Example 16.6, 0 085 mmol) to give the title compound as a white solid (HPLC. t* 2.31 mm (Method A), M+H = 435 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 9.02 (s. 1H)1 8.67-8 65 (m, 1 H), 8 40 (S1 1H), 8.17-8 13 (m. 1 H), 8.01-7 91 (m, 2H)1 7.56-7.51 (m, 2H), 4.54 (s, 2H), 3 99 (s, 3H), 3 60 (s. 3H)1 3.39 (s, 3H))
Example 204 8-(5,6-Dimethoxy-pyridin-3-yl)-1 -( 1 ,3-dimethyM H-pyrazol-4-yl)-3-methyl- 1 , 3- dihydro-imidazo{415-c)quinolin-2-one
Figure imgf000314_0002
The title compound was synthesized in a similar manner as described for Example 93.1 using 2-chloro-3-methoxy-pyridine (Apollo, Cheshire, UK, 7.1 mmol) to give the title compound as a white solid. (HPLC tR 2.52 mm (Method A)1 M+H = 431 MS-ES; 1H-NMR (dβ- DMSO. 400 MHz) 8 96 (s, 1 H) 8 12-8 07 (m, 2H)1 7 99-7.95 (m, 1H), 7.92-7.90 (m, 1 H), 7 55-7 53 (m, 1H), 7 25-7 23 (m, 1H)1 3.90 (s, 3H), 3.89 (s, 6H), 3 58 (s, 3H)1 1 98 (S, 3H))
Example 205 1 -( 1 -(2-Azettdin- 1 -yl-2-oxo-ethyl)-3-methyl- 1 H-pyrazol-4-yl]-8-(5-isopropoxy- pyridin-3-yl)-3-methyl-1 ,3-dihydro-imidazo[4 5-cJquinolin-2-one
Figure imgf000315_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-{1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imtdazo[4,5-c]quinolin-2-one (stage 205.1.1, 0 067 mmol) and 3-isopropoxy-5-(4,4,5,5-tetramethy)-[1 (3,2)dioxaborolan-2- yl)-pyridine (Stage 58.1.1 , 0 102 mmol) to give the title compound as a white foam. (HPLC. tR 2 35 min (Method A); M+H - 512 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 99 (s, 1 H), 8 34- 8 32 (m, 1 H), 8.24-8.21 (m, 1H), 8 13-8.09 (m, 2H), 8 01-7 96 (m, 1H), 7.67-7.64 (m. 1 H), 7 38-7.35 (m, 1H), 4.91-4.73 (m, 3H), 4.18^ 07 (m, 2H), 3 91-3.78 (m, 2H), 3.58 (s, 3H), 2.22-2.05 (m, 2H). 1.98 (s, 3H)1 1.33 (d, 3H), 1.31 (d, 3H))
Stage 206,1.1 1 -[1 -(2-Azetidin-1 -yl-2-oxo-ethyl)-3-methyl-1 H-pyrazol-4-yl)-8-bromo-3-methyl- 1 ,3-dihydro-(midazo[4 5-c]quinolin-2-one
Figure imgf000315_0002
The title compound was synthesized in a similar manner as described for Stage 134,1 using azetidine (Fluka, Buchs, Switzerland) as replacement for N-methylpiperazine to give the title compound as a white solid. (HPLC. tR 2 28 mm (Method A); M+H - 441 , 443 MS-ES)
Example 206.1 1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(6-ethylamino-5-methoxymethyl- pyridin-3-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000316_0001
The title compound was synthesized in a similar manner as descπbed for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyra2ol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (stage 205.1.1, 0 067 mmol) and ethyl-β-methoxymethyl-δ-^Aδ.S-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-pyπdin~2-yl]-amine (Stage 206.1.1) to give the title compound as a yellow solid (HPLC: tR 2.20 min (Method A), M+H * 458 MS-ES1 1H-NMR (do-DMSO, 400 MHz) Θ.90 (S, 1H), 8.22-8 18 (m, 1 H), 8.13 (s, 1H), 8.05-8.00 (m, 1H), 7 88-7 84 (m, 1 H), 7 45-7.40 (m, 2H), 6.09 (t, 1 H), 4.38-4.30 (m, 2H), 3.92 (s, 3H), 3.56 (s, 3H)1 3.45-3.37 (m. 2H), 3.33 (s. 3H), 1.95 (s, 3H)1 1.14 (t, 3H))
Stage 206.1.1 Ethyl-[3-methoxymethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)- pyπdin-2-yl]-amine
Figure imgf000316_0002
The title compound was synthesized in a similar manner as described for Stage 167.1.1 using fodomethane as replacement for iodoethane to give the title compound as a crude black oil (degrading under the HPLC condition fo 1 81 mm (Method A), M+H = 293 MS-ES).
The following example was synthesized in a similar manner as described for Example 206.1 using the specified intermediate
Figure imgf000316_0003
Figure imgf000317_0003
Example 207 8-(2-Dimethylamino-pyrimidin-5-yl)-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-1 > dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000317_0001
The title compound was synthesized in a similar manner as described for Example 109 using 2-dimethylamino-pyrimidine-5-boronic acid pinacol ester (Frontier Scientific, Logan, USA) to give the title compound as a white solid (HPLC. tR 2 31 min (Method A); M+H = 401 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 11 66 (s, br, 1 H) 8 69 (s, 1H), 8 46 (s. 2H), 8 10 (s. 1 H), 8.05-8 00 (m, 1H)1 7 87-7.82 (m, 1 H)1 7 43-7.40 (m, 1 H), 3 90 (s. 3H), 3 16 (s, 6H) 1.96 (S1 3H))
Example 208 8-(5-Amtno-6-ethyl-pyπdin-3-yl)- 1 -( 1 , 3-dimethyl-1 H-pyrazol-4-yl)-3-methy!-1 , 3- dihydro-imidazo[4,5-c)quinotin-2-one
Figure imgf000317_0002
The title compound was synthesized in a similar manner as described for Stage A2 using 1- (1 ,3-dimethyl-1 H-pyrazol-4-yl)-8-(6-ethyl-5-nitro-pyndin-3-yl)-3-methyl-1 ,3-dihydro- imκiazo[4,5-c)quinolin-2-one (Stage 208.1.1 , 0 06 mmol) to give the title compound after purification as a white foam (HPLC: tR 2 06 min (Method A); M+H = 414 MS-ES; 1H-NMR (d9- DMSO, 400 MHz) 8.96 (s, 1H), 8.13-8 07 (m, 2H), 7.79-7.74 (m, 2H), 7 54-7 51 (m, 1 H)1 7.06-7.03 (m 1H), 5 18 (s, br, 2H), 3.92 (s, 3H), 3 58 (s, 3H), 2.64 (q, 2H), 1 96 (s, 3H), 1 19 (t, 3H))
Stage 208.1.1 1-(1 ,3-Dimethyl-1H-pyra2θl-4-yl)-8-(6-ethyl-5-nitro-pyndin-3-yl)-3-methyl-1 ,3- dihydro-imidazo{4,5-c]quinolin-2-one
Figure imgf000318_0001
The title compound was synthesized in a similar manner as described for for Example 1.1 using 8~bromo-1 -( 1 , 3-dimethy 1-1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro-imidazo[4,5-c]qumolin- 2-one (Intermediate A) and 2-ethyl-3-nitro-5-(4,4,5,5-tetramethyl-[1 ,3,2}dioxaborolan-2-yl)- pyridine (stage 208.1.2) to give the title compound as a yellow foam (HPLC. \a 2.72 min (Method A), M+H ~ 444 MS-ES).
Stage 208.1.2 2-EthyJ-3-nitro-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyndine
Figure imgf000318_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bromo-2-ethy!-3-nitro-pyridine (stage 208.1.3, 0 493 mmol) to give the title compound as a crude brown oil. (degrading under the HPLC condition: tR 2 65 min (Method A); M+H ~ 279 MS-ES).
Stage 208.1.3 5-Bromo-2-ethyl-3-nitro-pyπdine
Figure imgf000319_0001
The title compound was synthesized in a similar manner as described for Stage 75.1.5 using diethyl methylmatonate (Fluka, Buchs, Switzerland) as replacement for diethyl malonate to give the title compound as a brown oil. (HPLC- tR 3.34 min (Method A); M+H - 231 , 233 MS- ES).
Example 209 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(4-methyl-3,4-dihydro-2H- pyπdo{3,2-b){1 ,4]oxazin-7-yl)-1 (3-dihydroπmidazo[4,5<]quinolin-2-one
Figure imgf000319_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using β-bromo-1-CI.S-dimethyl-I H-pyrazoM-yO-S-methyl-I .S-dihydro-imidazo^.δ-cJquinolin^-one (Intermediate A) and 4-methyl-7-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-3,4-dihydro- 2H-pyrido[3,2-b][1,4]oxazine (ABCR, Karlsruhe, Germany) to give the title compound as a yellow foam. (HPLC. tR 2 15 mm (Method A)1 M+H « 442 MS-ES' 1H-NMR (d6-DMSO, 400 MHz) 8 90 (S, 1H), 8 13 (s, 1 H), 8.03-7.99 (m, 1H), 7 89-7 82 (m, 2H), 7 40-7.37 (m, 1 H)1 6.S7-6 94 (m, 1H)1 4.25 (t, 2H), 3 92 (s, 3H)1 3 56 (s, 3H)1 3.47 (t, 2H), 3 06 (s, 3H), 1.95 (S, 3H))
Example 210 8-(5-Ethylamino-6-methyl-pyridin-3-yl)-H1-(2-hydroxy-ethyl)'3,5-dimethyl-1 H- pyrazol-4-yl]-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000320_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-Bromo-1 -{1 -[2-(tert-butyl-dimethyl-silanyloxy)-ethyl}-3,5-dimethy)-1 H-pyrazol-4-yl}-3-methyl- 1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one (stage 210.1.1) and ethyK2-methyl-5-(4,4,5,5- tetramethyl-{1 ,3,2}dioxaborolan-2'yl)-pyridin-3-yl]-amine (Stage 87.1.1) to give the title compound as an off-white solid; deprotection of the silyl group occurred dunng the purification step (HPLC tκ 2.16 mm (Method A), M+H = 472 MS-ES, 1H-NMR (d6~DMSO, 400 MHz) 8.96 (s, 1H). 8 10-8 06 (m, 1H), 7 94-7 90 (m, 1H)1 7.85-7 82 (m, 1H)1 7.55-7.52 (m, 1H), 6 83-6.80 (m, 1H), 5.21 (t, 1 H), 4 92 (t, 1H), 4 21-4 03 (m, 2H), 3.81-3 67 (m, 2H)1 3 59 (s, 3H), 3.24-3.14 (m, 2H)1 2 32 (s, 3H)1 2.09 (s, 3H)1 1.94 (s, 3H) 1.24 (t, 3H))
Stage 210.1.2 8-Bromo-H1-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-3,5-dimethyl-1H- pyra2θl-4-yl)-3-methyl-1 ,3-dihydro-tmidazo[4,5-cJquinolin-2-one
Figure imgf000320_0002
The title compound was synthesized in a similar manner as described for intermediate N using (2-bromoethoxy)-tertbutyldimethylsilane (Frontier Scientific, Logan, USA) as replacement for the 2-bromoethyl methyl ether to give the title compound as a brown foam (HPLC. tR 3.61 mm (Method A), M+H = 530. 532 MS-ES)
Example 211.1 1-[1-(2-Hydroxy-ethyl)-3-methyl-1 H-pyrazol-4-yl]-8-(5-methoxy-6-methyl- pyridin-3-yl)-3-methyl-1 ,3-dihydro-imidazo|4,5-c)quinolin-2-one
Figure imgf000321_0001
The title compound was synthesized in a similar manner as described for Example 103.1 using 3-methoxy-2-methyl-5~(4,4,5,5-tetramethyl-[1 ,3,2]dioxabσrolan-2-yi)-pyridine (stage 211.1.1) to give the title compound as a white solid. (HPLC tR 2 02 min (Method A), M+H ~ 445 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 9.00-8.96 (m, 1 H), 8 19-8.09 (m, 3H), 8.03-7 97 (m, 1H), 7 58 (s, 1 H), 7.33 (s. 1H) 4.94 (t, 1 H), 4 25-4.11 (m, 2H)1 3.92 (s, 3H), 3 84-3.69 (m, 2H), 3 59 (s, 3H), 2.38 (s, 3H), 1 98 (s, 3H))
Stage 211.1.1 3-Methoxy-2-methyl-5-(4,4,5,5-tetramethyl-[1,3,23dioxaboroJan-2-yl)-pyridine
Figure imgf000321_0002
The title compound was synthesized in a similar manner as described for Stage 84.1.1 using methanol as replacement for isopropanol to give the title compound as a crude black oil. (degrading under the HPLC condition tR 1.86 mm (Method A), M+H = 250 MS-ES).
The following example was synthesized tn a similar manner as descnbed for Example 211.1 using 3-ethoxy-2-methyl-5-(4,4,5,5-tetramethyl>[1 ,312]dioxaborolan-2-yl)-pyridine (Stage 85.1.1)
Figure imgf000321_0003
Example 212.1 1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yi)-8-[6-((R)-3-hydroxy-pyrrolidin-1 -y!)- pyridirh3-yl]-3-methyl-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one
Figure imgf000322_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-1-CI .S-dimethyl-1H-pyrazoM-yO-S-methyl-I.S-dihydro-imidazoH.δ-clquinolin^-one (Intermediate A) and {R^I-Iδ^^.δ.δ-tetramethyHI.S.ΣJdioxaborolan-a-yO-pyridin^-yl]- pyrrolidin-3-ol (stage 212.1.1) to give the title compound as a white solid. (HPLC tR 2.03 min (Method A); M+H * 456 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8.90 (s, 1H), 8.25-8 22 (m. 1 H), 8.12 (s, 1H)1 8 05-8 01 (m, 1H), 7 87-7.83 (m, 1H), 7 57-7 53 (m, 1H), 7 43-7 41 (m, 1 H), 6.55-6.51 (m, 1 H), 4.95 (d, 1H) 4.42-4.36 (m, 1H), 3 92 (s, 3H), 3 56 (s, 3H), 3 54-3.43 (m, 3H), 3 37-3.31 (m, 1H), 2.08-1 86 (m, 2H), 1 96 (s, 3H))
Stage 212.1.1 (R)- 1 -(5-(4 ,4, 5.5-TetramethyH 1 , 3,2]dioxaborolan-2-yl)-pyπdin-2-yl]-pyrrolidin- 3-ol
Figure imgf000322_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 -2 using (R)-3-hydroxypyrrolidine (Fluka, Buchs, Switzerland) to give the title compound as a crude black oil (degrading under the HPLC condition tR 1.54 min (Method A), M+H = 291 MS-ES)
The following example was synthesized in a simitar manner as descnbed for Example 212,1 using (S)-3-hydroxypyrrolidine {Fluka, Buchs, Switzerland).
Figure imgf000322_0003
Figure imgf000323_0003
Example 213.1 1-(1 ,3-Dimethyl-1H-pyrazo)-4-yl)-8-|;6-((R)-3-methoxy-pyrrolidin-1-yl)- pyridin-3-yl]-3-me{hyl-1,3-dihydro-imidazo[4,5-c]quinoNn-2-one
Figure imgf000323_0001
The title compound was synthesized in a similar manner as described for Example 104 using 1-(1 ,3-D)methyl-1 H-pyrazo!-4-yl)-8-[6-((R)-3-hydroxy-pyrrolidin-1-yt)-pyridin-3-yl]-3- methyl-1 ,3-dihydrcwmidazo(4,5-c)qumolin-2-one (Example 212.1 , 0 116 mmol) to give the title compound as a white solid (HPLC tR 2.20 mm (Method A), M+H = 470 MS-ES1 1H-NMR (de-DMSO, 400 MHz) 8 90 (s, 1H), 8 26-8.23 (m, 1H)1 8 12 (s, 1H) 8 05-8 02 (m, 1H)1 7 88- 7 84 (m, 1H), 7 59-7.55 (m, 1H), 7 44-7.41 (m, 1H), 6 59-6 54 (m, 1H)1 4.08 (qt, 1H), 3 93 (s, 3H)1 3 57 (S1 3H), 3 56-3 49 (m, 4H)1 3 45-3 34 (m, 1H), 3 27 (s, 3H) 2.11-2.02 (m, 2H)1 1.97 (s. 3H))
The following example was synthesized in a similar manner as descnbed for Example 213.1 using (S)-3-hydroxypyrrolidine (Fluka, Buchs. Switzerland)
Figure imgf000323_0002
Figure imgf000324_0002
Example 214 1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-[6-(tetrahydro-pyran~4-ylamino)- pyπdin-3-yl]-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000324_0001
The tftle compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo-1-(1 ,3-dimethy!-1H-pyrazoM-yl)-3-methyl-1,3-dihydro-imidazo|;4,5-c]quinolin-2-one (Intermediate A) and (tetrahydro-pyran-4-yl)-[5-(4l4,5,5-tetramethyl-l1 )3 2)d!θxaborolan-2- yl)-pyπdin-2-yi]-amine (stage 214.1.1) to give the title compound as a white solid (HPLC- tR 2 13 min (Method A), M+H = 470 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 89 (s, 1H)1 8.15- 8 10 (m. 2H), 8.04-8.00 (m, 1H)1 7 84-7 79 (m, 1H), 7 47-7.42 (m, 1H), 7,41-7 38 (m, 1H)1 6.78-6.73 (m, 1H), 6.57-6 53 (m, 1H), 4 00-3 82 (m, 3H), 3 91 (s 3H), 3 56 (s, 3H), 3 45-3 37 (m, 2H)1 1.96 (s 3H), 1 91-1.83 (m, 2H), 1.49-1.37 (m, 2H))
Stage 214.1.1 (Tetrahydro-pyran-4-yl)-(5-(4,4,5 5-tetramethyl-(1 ,3,2Jdioxaborolan-2-yl)- pyπdin-2-yl]-amine
Figure imgf000325_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1-2 using 4~aminotetrahydropyran (Maybridge, Basel, Switzerland) to give the title compound as a crude brown sticky solid, (degrading under the HPLC condition. t« 1.74 mm (Method A); M+H ~ 305 MS-ES).
Example 21 S.1 8-[5-( 1 -Hydroxy- 1 -methyl-ethyl)-pyridin-3-yl]- 1 -( 1 -isopropy)-3-methyl-
1 H-pyrazol-4-yl)«3-methyl- 1 , 3-dihydro-imidazo[4, 5-c]quinolin-2-one
Figure imgf000325_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-isopropyl-3-methy!-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-im'ida2θ[4,5- c]quinolin-2-one (Intermediate G) and 2-{5~(4,4>5,5-tetramethy!-[1 ,3,2]dioxaborolan-2-yt)- pyπdin~3-yl]-propan-2-ol (Stage 215.1.1) to give the title compound as a white foam (HPLC: tR 2 13 mm (Method A), M+H * 457 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.99 (s, 1 H)1 8.69-8.66 (m, 1H)1 8 46-8.44 (m, 1H), 8.21 (s, 1H)1 8 16-8.12 (m, 1H), 7.98-7 91 (m, 2H)1 7 58-7 56 (m, 1H), 5 26 (s, 1H), 4.53 (hp, 1 H), 3.59 (s, 3H), 1.97 (s, 3H), 1.49 (s, 6H), 1.44 (d. 6H))
Stage 215.1.1 2-[5-(4,4,5,5-Tetramethyl-[1 ,3l2]dioxaborolan-2-yl)-pyndin-3-yl]-propan-2-ol
Figure imgf000325_0003
The title compound was synthesized in a simitar manner as described for Stage 5.1.1 using 2-(5-bromo-pyridin-3-yl)-propan-2-ol (stage 215.1.2, 1 518 mmol) to give the title compound as a crude black sticky oi! (degrading under the HPLC condition tR 1 87, 3 68 mm (Method A), M+H = 264 MS-ES)
Stage 215.1.2 2-(5-Bromo-pyridin-3-yl)-propan-2-ol
Figure imgf000326_0001
To a solution of 3,5-dibromopyπdme (Aldπch Buchs, Switzerland, 4 6 mmol) in dry THF under Ar was added slowly a -2 M solution of isopropylmagnesium chloride in THF (2 76 ml) The RM was stirred for 2 h at rt then was added acetone (6 9 mmol) and the RM was stirred for 2 h at rt The RM was quenched with bnne and extracted with EtOAc (2x) The combined organic layers were washed with brine, dried over Na2SCX1, filtered and evaporated The residue was absorbed on silica gel and purified by flash chromatography (heptane/EtOAc 0% to 70%) The fractions containing product were evaporated together to give the title compound as an oil (HPLC tR 1 82 mm (Method A)1 M+H - 216, 218 MS-ES)
The following examples were synthesized in a similar manner as described for Example 215.1 using the specified intermediate
Figure imgf000326_0002
Figure imgf000327_0002
Example 216 1 -( 1 ,3-DimethyM H-pyrazol-4-yl)-8-[5-( 1 -ethyl- 1 -hydroxy-propyl)-pyridin-3-yl]- 3-methyl-1 ,3-dihydro-imidazo{4,5-clquinolin-2-one
Figure imgf000327_0001
The title compound was synthesized in a similar manner as descnbed for Example 21S.1 using 8-bromo- 1 -( 1 ,3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4 , 5-c)qumolin- 2-one (Intermediate A) and 3-pentanone (Flυka, Buchs, Switzerland) to give the title compound as a white solid (HPLC- tR 2.13 mm (Method A)' M+H * 457 MS-ES, 1H-NMR (dδ- DMSO, 400 MHz) 8 99 (s, 1H), 8 63-8 57 (m, 2H). 8 16-8 11 (m, 2H)1 8 01 -7 96 (m, 1H), 7.76-7 73 (m, 1H), 7 65-7 62 (m, 1H)1 4 82 (s, 1H), 3 90 (s, 3H), 3 58 (s, 3H), 1 96 (s, 3H)1 1 87-1 72 (m, 4H), 0.72-0 65 (m. 6H))
Example 217 (rac)- 1 -(1 , 3-Dimethyl- 1 H-py razol-4-yl)-8-[5-{ 1 -hydroxy-ethy!)-pyridin-3-yl]-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000328_0001
The tide compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-I^I.S-dimethyl-1H-pyrazoM-yiJ-S-methyl-I .S-dihydro-imidazo^.δ-cJquinolin^-one (Intermediate A) and acetaldehyde (Flυka, Buchs, Switzerland) to give the title compound as a white solid. (HPLC: tR 1.95 mm (Method A); M+H = 415 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.99 (S1 1H)1 8.63-8.60 (m, 1H), 8.56-8 53 (m, 1H), 8.16-8.11 (m, 2H)1 8 00-7.95 (m. 1 H), 7.81-7.76 (m, 1H), 7.61-7.58 (m, 1H), 5 42-5 38 (m, 1H), 4,88-4.80 (m, 1H), 3.94- 3 90 (m, 3H)1 3 58 (β, 3H), 1.97-1.92 (m. 3H). 1 43-1 39 (m, 3H))
Example 218 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-8-[5-( 1 -hydroxy-cyclopentyl)-pyridin-3-yl]-3- methyl-1 ,3-dihydro-irnidazo[4,5-c]quinolin-2-one
Figure imgf000328_0002
The title compound was synthesized in a similar manner as described for Example 1,1 using 8-bromo-1-(i (3-dimethyl-1H-pyrazol>4-yl)-3-methyl-1 l3-dihydro-imidazo[4,5-c)quindin-2-one (Intermediate A) and cyclopentanone (Fluka, Buchs, Switzerland) to give the title compound as a white solid (HPLC. to 2.14 mm (Method A); M+H « 455 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.99 (s, 1 H), 8.71-8.68 (m, 1 H), 8 61-8.58 (m, 1 H), 8 16-8 11 (m, 2H), 8.01-7.96 (m. 1H), 7 85-7 81 (m, 1H). 7 63-7.59 (m, 1H). 5 05 {s, 1H), 3 90 (s, 3H), 3 58 (s, 3H), 1.98- 1.77 (m. 8H)1 1 95 (s, 3H))
Example 219 8-(5-(2-Fluoro-1-fluoromethyl-1-hydroxy-ethyl)-pyπdin-3-yl)-1-(1-isopropyl-3- methyt-1H-pyrazol-4-yl)-3-methy)-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000329_0001
The title compound was synthesized in a similar manner as described for Example 215.1 using 1 3-difluoropropanone (Apollo Scientific, Cheshire, United Kingdom) to give the title compound as a yellow solid (HPLC tR 2 24 mm (Method A), M+H = 493 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 9.00 (s, 1H), 8 72-8 70 (m, 1H), 8 55-8 52 (m, 1H) 8 22 (s, 1H)1 8.18- 8 14 (m, 1H), 8 09-8 07 (m, 1H), 7 96-7 92 (m, 1 H) 7 59-7 57 (m, 1H) 6 31 (S1 1 H), 4 78- 4 70 (m, 2H), 4 66-4 58 (m, 2H)1 4 54 <hp 1H), 3 59 (s, 3H), 1 97 (s, 3H), 1 47-1 42 (m, 6H))
Example 220.1 2-{5-[1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-d<hydro-1 H- imidazo[4>5-c]quinolin-8-yl]-pyrk-in-3-yl}-2-methyl-prop!onitrile
Figure imgf000329_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo{4,5-c]quinolin-2-one (Intermediate A) and 2-methyl-2-[5-(4,4,5 5-tetramethyl-(1 >3 2]dioxaboro)an-2-yl)-pyndin-3- yH-propionitrile (Stage 220.1.1) to give the title compound as a white solid (HPLC t« 2 36 mm (Method A), M+H = 438 MS-ES, 1H-NMR (d6-DMSO 400 MHz) 9 01 (s 1H) 8 78-8 76 (m, 1H), 8 73-8 71 (m, 1H), 8 18-8 14 (m 1H) 8 12 (s, 1H) 8 05-8 01 (m, 1H), 7 93-7 90 (m, 1H), 7 62-7 60 (m. 1H). 3 88 (s, 3H)1 3 59 (s, 3H) 1 97 (s, 3H), 1 80 (s 3H)1 1 79 (s, 3H))
Stage 220.1.1 2-Methyl-2-[5-(4 4,5,5-tetramethyl-[1 ,3,2]diO3<aborolan-2-yl)-pyndin-3-yl]- propionitrile
Figure imgf000329_0003
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 2-(5-bromo-pyridin-3-yl)-2-methyl-propionitrile (stage 220.1.2, 1 111 mmol) to give the title compound as a crude brown soft solid (degrading under the HPLC condition (Method A)1 M+H * 273 MS-ES).
Stage 220.1.2 2~(5-Bromo-pyrtdin-3-yl)-2-methyl-propionitnte
Figure imgf000330_0001
To a solution of (5-bromo-pyridin-3-yi)-acetonitπle (Stage 220,1.3, 4 61 mmol) in dry DMF (15 ml) cooled with an ice-bath was added portionwise 55% sodium hydride in oil (9.97 mmol) Was then added iodomethane (13.56 mmol) and DMF (5ml) The RM was stirred for 3 h at OX then was quenched with saturated aqueous NH4CI, diluted with water and extracted with EtOAc(3x) The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated The residue was purified by flash chromatography (heptane/EtOAc 25%). The fractions containing product were evaporated together to give the title compound as an oil. (HPLC tR 2 72 min (Method A), M+H = 225, 227 MS-ES)
Stage 220.1.3 (5-Bromo-pyridin-3-yl)-acetonitπle
Figure imgf000330_0002
βr
To SOCI2 (26.7 ml) cooled with an ice-bath was added portionwise (5-bromo-pyπdin-3-yl)- methanol (ABCR, Karlsruhe, Germany, 26.6 mmol). The RM was refluxed for 1 h then was cooled at 0°C and quenched with diethyl ether The resulting precipitate was filtered, washed with cooled diethyl ether and dried under vacuum at 5O°C The solid was mixed with potassium cyanide (64.5 mmol), MeOH (35 ml) and water (14 ml) and the RM was refluxed for 2 h The RM was cooled, quenched with aqueous K2CO3 and extracted wtth diethyl ether (3x). The combined organic layers dried over NajSO^ filtered and evaporated to give the title compound as a purple solid (HPLC- tR 2 16 min (Method A): M+H = 197. 199 MS-ES)
The following examples were synthesized in a similar manner as described for Example 220.1 using the specified intermediate.
Figure imgf000330_0003
Figure imgf000331_0002
Example 2211 i-lδ-li-CI .S-Dimethyl-1H-pyrazoM-yO-S-methyl-Σ-oxo^.S-dihydro-1H- imidazo[4,5-c]qυino}in-8-yl]-pyridin-3-yl}-cyclobυtanecarbonitrile
Figure imgf000331_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 >3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1l3-dihydro-imidazo[4,5-cJquinolin-2-one (Intermediate A) and 1-[5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- cyclobutanecarbonitnle (Stage 221.1.1) to give the title compound as an off-white foam. (HPLC- tR 2.43 mtn (Method A), M+H = 450 MS-ES1 1H-NMR (dε-DMSO, 400 MHz) 9 01 (s, 1H), 8 74-8.73 (m, 1H), 8 70-8 68 (m, 1H), 8 17-8.12 (m, 2H). 8 06-8 03 (m, 1H), 7 90-7 88 (m, 1 H)1 7 63-7.61 (m, 1H), 3 89 (s, 3H), 3.59 (s, 3H), 2 86-2 71 (m, 4H) 2.13-2 01 (m. 2H), 1 97 (s, 3H)) Stage 221.1.1 1-I5-(4,4,5,5-TetramethyK1,3,2]dioxaborolan-2-yl)-pyficlin-3-yl}- cyclobutanecarbonitπle
Figure imgf000332_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using i-fδ-bromo-pyπdin-S-yO-cyclobutanecarbonitπle (stage 221.1.2, 0.476 mmol) to give the title compound as a crude back oH. (degrading under the HPLC condition' tR 2.69 mm (Method A); M+H = 285 MS-ES)
Stage 221.1.2 Hδ-Bromo-pyπdin-S-yO-cyclobutanecarbσnitrile
Figure imgf000332_0002
To a solution of (5-bromo-pyπdin-3-yl}-acetonitrile (Stage 220.1.3, 1 37 mmol) in dry DMF (10 ml) was added 55% sodium hydride in oil (1.507 mmol). After 30 mm stirring at rt was added 1-bromo~3-chloropropane (1 507 mmol), The RM was stirred for 1 h at rt then was added 55% sodium hydride in oil (1 507 mmol) The RM was stirred for 1 h at rt then quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic layer was washed with brine (2x), dried over Na?SO4, filtered and evaporated The residue was taken in DMA and purified by preparative HPLC. The fractions containing product were basifted with NaHCO3. concentrated and extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over NajSO^, filtered, evaporated and dned under vacuum to give the title compound as a red oil (HPLC' t* 2 86 mm (Method A); M+H = 237, 239 MS-ES)
The following example was synthesized in a similar manner as described for Example 221.1 using the specified intermediate.
Figure imgf000332_0003
- 332 -
Figure imgf000333_0003
Example 222 N-{2-Chloro-5-[1-(1,3-dimethyl-1H-pyrazol-4-y!)-3-methyl-2-oxo-2l3-dihydro- 1 H-imidazot4.δ-cJquinolin-δ-yll-pyπdtn-S-ylJ-acetamide
Figure imgf000333_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1.3-dimethyl'1H-pyra2θl-4-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and N-[2-chloro-5-(4,4,5l5-tetramethy!-[1 ,3,2]dioxaborolan-2-yl)-pyπdin-3- ylj-acetamide (Stage 222.1.1) to give the title compound as an off-white solid (HPLC. t« 2 33 mm (Method A); M+H - 462 MS-ES; 1H-NMR (d0-DMSO 400 MHz) 9.80 (s, 1H), 9 01 (s, 1H)1 8 34-8 28 (m, 2H), 8 17-8 11 (m, 2H), 7.95-7.90 (m, 1H), 7 61-7 58 (m 1H)1 3 92 (s, 3H), 3.59 (S1 3H), 2.18 (s, 3H), 1 ,93 (s, 3H))
Stage 222.1.1 N-[2-Chloro-5-(4 4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrtdin-3-yl]« acetamide
Figure imgf000333_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using N-(5-bromo-2-ch!oro-pyridin-3-yl)-acetamide (stage 222.12, 2,434 mmol) to give the title compound as a crude back oil. (degrading under the HPLC condition' tR 1 71 min (Method A); M+H - 297 MS-ES)
Stage 222.1.2 N-(5-Bromo-2-chloro-pyridin-3-yl)-acetamide
KH
Figure imgf000334_0001
To a solution of 3-amino-5-bromo-2-chloropyridine (stage 152.1.2, 3.59 mmol) and triethylamine (1 mi) in dichloromethane (20 ml) was added acetyl chloride (Aldrfch, Buchs, Switzerland, 0 312 ml) The RM was stirred for 17 h at rt then was added acetyl chloride (0.3 ml), the RM was stirred for 3 h at rt. Acetyl chloride (0.1 ml) was added and the RM was stirred for 1 h at rt. The RM was quenched with aqueous NaHCO3 and extracted with EtOAc The organic layer was washed with brine, dried over Na2SO4, filtered and evaporated The residue was absorbed on silica gel and purified by flash chromatography (heptane/EtOAc 0% to 40%). The fractions containing product were evaporated together to give the title compound as a white solid (HPLC tR 2.46 min (Method A); M+H = 249, 251 MS-ES)
Example 223 N^-Chioro-δ-li-CI .S-dimethyl-1H-pyrazol^-yO-S-methyl^-oxo^.S-dihydro- 1H-imidazol4,5-c]quinolin-8-yt]-pyπdm-3-yl}-methanesu!fonam»de
Figure imgf000334_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethy!-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and N-^-chloro-δ-^Aδ.δ-tetramethyl-p .S^jdioxaborolan-Σ-yO-pyπdin-S- yl]-methanesulfonarntde (Stage 223.1.1) to give the title compound as a white solid. (HPLC: tR 2 31 mm (Method A), M+H = 498 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 9 87 (s, 1H), 9.01 (s 1H), 8.41-8 38 (m, 1 H)1 8 18-8.11 (m, 2H) 7 98-7 93 (m, 1H), 7 91-7 88 (m, 1H), 7 62-7 59 (m, 1H), 3 92 (S1 3H), 3.59 (s, 3H), 3,18 (s, 3H), 1.95 (s, 3H)) Stage 223.1.1 N-[2-Chloro-5-(4,4,5.5-tetramethyK1,3.2]dioxaborolan~2-yl)-pyriclin-3-yt]- methanesulfonamide
Figure imgf000335_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using N-(5-bromo-2-chloro-pyndin-3-yl)-methanesulfonamide (stage 223.1.2, 3 56 mmol) to give the title compound as a crude back oil (degrading under the HPLC condition. tR 2 05 mm (Method A), M+H = 333 MS-ES)
Stage 223.1.2 N-(5-Bromo-2-chloro-pyridin-3-y!)-methanesulfonamide
Figure imgf000335_0002
To a solution of 3-amino-5-bromo-2-chloropyndine (stage 152.1.2, 3.59 mmol) in pyridine (7 ml) was added methanesulfonyl chloride (Fluka, Suchs, Switzerland, 0.365 ml) The RM was stirred for 22 h at rt then was added methanesulfonyl chloride (0 2 ml), the RM was stirred for 5 h at rt. Methanesulfonyl chloride (0.2 ml) was added and the RM was stirred for 17 h at rt The RM was evaporated to dryness and then taken in EtOAc, washed with aqueous NaHCO3, with brine, dried over Na2SO4, filtered and evaporated. The residue was absorbed on silica gel and purified by flash chromatography (heptane/EtOAc 0% to 40%) The fractions containing product were evaporated together to give the title compound as a pink solid. (HPLC t* 2 91 min (Method A), M+H = 285, 287 MS-ES)
Example 224,1 2-Amino-5-[1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yt)-3-methyl-2-oxo-2, 3- dihydro-1H-imidazo[4,5-c]quinotin-8-yl]-N-methyl-nicotinamide
Figure imgf000336_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo(4,5-cJquino)m-2-one (Intermediate A) and 2-amino-N-methyl~5-(4,4,5,5-tetramethy!-[1 ,3,2]dk>xaborolan-2-yi)- nicotinamide (Stage 224.1,1) to give the title compound as an off-white solid. (HPLC. tR 2 01 mm (Method A), M+H ~ 443 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 8 92 (s, 1H), 8.54 (q, 1H), 8 14-8.11 (m, 2H)( 8.10-8.06 (m, 2H), 7.96-7 92 (m, 1H), 7 47-7 44 (m, 1H), 7.27 (s. br, 2H), 3 89 (s, 3H), 3.57 (s, 3H), 2.78 (d, 3H), 1 95 (s, 3H))
Stage 224.1.1 2-Amino-N-methyl-5-(4)4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)- nicotinamide
Figure imgf000336_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 2-amino-5-bromo-N-methyl-nicotinamide (stage 224.1.2, 0 352 mmol) to give the title compound as a crude brown oil (degrading under the HPLC condition t« 1 46 mm (Method A), M+H ~ 278 MS-ES).
Stage 224.1.2 2-Amino-5-bromo-N-methyl-nicotinamide
Figure imgf000336_0003
To a solution of 2-amino-5~bromonicotin)c acid (Combi-Blocks, San Diego, USA, 1 355 mmol) and tπethylamine (0 378 ml) in dichloromethane (10 ml) cooled with an ice-bath was added a solution of trichloromethyl chloroformate (Acros, , Basel, Switzerland, 0.677 mmol) in dichloromethane (10 ml). After 40 mm stirring at 0°C, was added a solution 8 M of methylamine in EtOH (1 7 ml). The RM was stirred for 30 mm at rt then was diluted with dichlromethane, washed with saturated aqueous NaHCO3, with brine, dried over Na2SO4, filtered and evaporated. The residue was taken in DMF and purified by preparative HPLC The fractions containing product were basified with NaHCO3, concentrated and extracted with dichloromethane (2x). The combined organic layers were washed with brine, dried over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as a white solid (HPLC' tH 1 69 min (Method A), M+H ~ 230, 232 MS-ES)
The following example was synthesized in a simitar manner as described for Example 224.1 using the specified intermediate
Figure imgf000337_0002
Example 225 2-Amtno-5-[1-(1 ,3-chmethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H- imidazo(4,5-c]quinolin-8-yl]-N-isopropyl-nicotinamide
Figure imgf000337_0001
The title compound was synthesized in a similar manner as described for Example 224 using isopropylamine (Aldπch, Buchs, Switzerland) as replacement for methylamine to give the title compound as an off-white solid. (HPLC U 2.20 mm (Method A); M+H - 471 MS-ES: 1H-NMR (de-DMSO. 400 MHz) 8 93 (s, 1 H), 8 30 (d, 1H), 8 13-8 04 (s, 4H), 7 97-7 92 (m. 1H), 7.45-7 42 (m, 1 H)1 7.21 (s, br, 2H), 4 08 (oc, 1H)1 3.88 (s, 3H), 3.57 (s, 3H), 1 97 (s. 3H)1 1.22-1 15 (m, 6H)) Example 226 2-Amino-5-{1-(1 ,3^imethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo[415-cJquinolin-8-ylJ-N-(2-methoxy-ethyl)-nicotinamide
Figure imgf000338_0001
The title compound was synthesized in a similar manner as described for Example 224 using 2-methoxyethylamine (Fluka, Buchs, Switzerland) as replacement for methylamine to give the title compound as a white solid (HPLC tR 2.10 mm (Method A), M+H ~ 487 MS-ES; 1H-NMR ((J6-DMSO, 400 MHz) 8.93 (s, 1H), 8 65 (t, 1H), 8.15-8.06 (m, 4H), 7 97-7.93 (m, 1H), 7.47-7.44 (m, 1 H), 7.27 (s, br, 2H), 3 89 (s, 3H)1 3.57 (s, 3H), 3 50-3 34 (m, 4H), 3 26 (s, 3H), 1 96 (s, 3H))
Example 227 2-Amino-N-ethyl-5-[1-(1-isopropyl-3-methyl-1H-pyrazoM-yl)-3-methyl-2~oxo- 2,3-dthydro-1 H-imidazo[4,5-c]quinolin-8-yl]-nicotinamide
Figure imgf000338_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo{4,5- cJquinolin-2-one (Intermediate G, 0.098 mmol) and 2-amino-N-methyl-5-(4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-nicotinamide (stage 227,1.1) to give the title compound as a white solid. (HPLC. tR 2.22 mm (Method A); M+H = 485 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8.93 (s, 1 H), 8.53 (t, 1 H), 8 19 (s, 1 H), 8 11-8 06 (m, 3H), 7 95-7 91 (m, 1H), 7.44- 7 41 (m, 1 H), 7 22 (s, br, 2H), 4.52 (hp, 1 H), 3.57 (s, 3H), 3 35-3 18 (m, 2H), 1.96 (s, 3H), 1 47-1 42 (tn, 6H), 1 14 (t 3H)) Stagβ 227.1.1 2-Aminc~N-methyl-5-(4,4,5,5-tetramethyH1 ,3,2]dioxaborolan-2-yl)- nicotinamide
Figure imgf000339_0001
The title compound was synthesized in a similar manner as described for Stage 224.1.1 using 2 M ethylamine in MeOH (Aldrich, Buchs, Switzerland) as replacement for the methylamine to give the title compound as a crude brown sticky oil (degrading under the HPLC condition- tR 1 69 mm (Method A), M+H = 292 MS-ES)
Example 228 2-{5-(1-(1 ,3-Dimethyl-1H-pyra2Ol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]qutnolin-δ-yl]-pyndin-3'yl}-N-methyl-acetamide
Figure imgf000339_0002
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one (Intermediate A) and N-methyl-2-[5-(4,4,5,5-tetramethyl-[1 ,3,2)dioxaborolan-2-yl)-pyriclin-3- yf]-acetamide (Stage 228,1.1) to give the title compound as an off-white foam. (HPLC: tR 1.97 min (Method A)1 M+H * 442 MS-ES, 1H-NMR (d$-DMSO, 400 MHz) 8 99 (s, 1H), 8.55- 8.53 (m, 1H), 8.45-8 43 (m. 1H), 8 16-8 12 (m, 2H), 8 07-8 01 (m, 1H), 7 95-7 90 (m, 1 H), 7 77-7.74 (m 1H) 7 59-7.57 (m, 1H) 3 92 (s, 3H), 3 58 (s, 3H), 3 51 (s, 2H), 2 60 (d, 3H), 1.95 (s, 3H))
Stage 228.1.1 N-Methyl-2-t5-(4,4,5.5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyπdin-3-yi]- acetamide
Figure imgf000340_0001
The title compound was synthesized in a similar manner as descnbed for Stage 5.1.1 using 2-(5-bromo-pyridirv3-yl)-N-methyl-acetamide (stage 228.1.2, 0 851 mmol) to give the title compound as a crude black oil (degrading under the HPLC condition (Method A), M+H - 277 MS-ES)
Stage 228.1.2 2-(5~Bromo-pyridin-3-yl)~N-methyl-acetamκ.e
Figure imgf000340_0002
The title compound was synthesized in a similar manner as described for Example 103 using (5-bromo-pyπdin-3-yl)-acetic acid (ABCR, Karlsruhe, Germany, 1 815 mmol) and 8 U methylamine in EtOH (Aldrich, Buchs, Switzerland, 7 26 mmol) to give the title compound as an off-white solid (HPLC' fe 1 74 mm (Method A), M+H * 229, 231 MS-ES)
Example 229 1 -(1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-(2-hydroxy- 1 , 1 -dimethyl-ethyl)-pyπdin-3- yl]-3-methyl-1 ,3-dihydro-imidazo[4,5-c]qυino)in-2-one
Figure imgf000340_0003
To a solution of 2-{5-(1-{1 ,3-dimethyl-1H-pyrazol-4-yt)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-8-yl)-pyπdin-3~yl}-2-methyI-propionic acid methyl ester (Stage 229.1.1, 0 134 mmo!) in THF (1 2 ml) were added MeOH (O 009 ml) and NaBH4 (0 185 mmol) four times during the course of the heating at 4O°C for 39 h. After that, the RM was quenched with saturated aqueous NaHCO3 and extracted with EtOAc (2x) The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated. The residue was taken in DMF and purified by preparative HPLC The fractions containing product were basified with NaHCOs, concentrated and extracted with dichloromethane (2x) The combined organic layers were washed with brine, dried over Na2SO4, filtered, evaporated and dried under vacuum to give the title compound as a white foam. (HPLC. t« 2.06 min (Method A), M+H - 442 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8.99 (s, 1H), 8 62-8 58 (m, 2H), 8 15-8 11 (m, 2H), 8.01-7 96 (m, 1 H), 7 74-7.71 (m, 1H)1 7 62-7 59 (m, 1H), 4.79 (t, 1H), 3 88 (s, 3H), 3.58 (s, 3H)1 3.50 (d, 2H), 1.96 (s, 3H), 1 30 (s, 6H))
Stage 229,1.1 2-{5-(1-(1 ,3-Dtmethyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2.3-dihydro-1H- imidazo[4,5-c]quinolin-8-yl]-pyridin-3-yl}-2-methyl-propion*c acid methyl ester
Figure imgf000341_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-d)methyl-1H-pyrazo!-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one (Intermediate A, 0.215 mmol) and 2-methyl-2-[5-(4,4,5,5-tetramethyl-(1 ,3,2]dioxaborolan-2- yl)-pyrfdin-3-yl)-propionic acid methyl ester (Stage 229.1.1 , 0.279 mmol) to give the title compound as a brown solid (HPLC: t« 2.28 mm (Method A); M+H = 471 MS-ES)
Stage 229.1,22-Methyt-2-[5-(4,4,5,5-tetramethyl-[1 ,3 2]dioxaborolan-2-yl)~pyrκ.in-3-yl)- propionic acid methyl ester
Figure imgf000341_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 2-(5-bromo-pyridin-3-yl)-2-methyl-propionic acid methyl ester (stage 229.1.2, 0.872 mmol) to give the titte compound as a crude black sticky solid (degrading under the HPLC condition : tR 2 20 mm (Method A), M+H ~ 306 MS-ES).
Stage 229.1,3 2-(5-Brorno-pyrtdin-3-y!)-2-methyl~propionic acid methyl ester
Figure imgf000342_0001
The title compound was synthesized in a similar manner as described for stage 220.1.2 using (δ-bromo-pyπdm-S-yO-acetic acid methyl ester (stage 229.1.4, 1.815 mmol) to give the title compound as yellowish oil (HPLC- tR 2.74 min (Method A), M+H ~ 258, 260 MS-ES)
Stage 229.1.4 (δ-Bromo-pyπdin-S-yO-acetic acid methyl ester
Figure imgf000342_0002
A mixture of (5-bromo-pyndin-3-yl)-acetic acid (ABCR, Karlsruhe, Germany, 4 54 mmol) and concentrated sulfuric acid (0.02 ml) in MeOH was reluxed for 13 5 h The RM was concentrated, taken in EtOAc and sonicated. The organic layer was washed with saturated aqueous NaHCO3, with brine, dried over Na2SO4, filtered and evaporated to dryness to give the title compound as a brown oil. (HPLC tR 2 21 mm (Method A), M+H = 230, 232 MS-ES)
Example 230 8-(5-Aminomethyl-pyrkJin-3-yl)-1-(1 ,3-dimethyl-1H~pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imidazo(4,5-c)quinolin-2-one
Figure imgf000342_0003
The titfe compound was synthesized in a similar manner as described for Example 1.1 using δ-bromo-I^I .S-dimethyl-1H-pyrazoW-yO-S-methyl-I .S-dihydrcHmidazo^.δ-cJqυinolin^-one (Intermediate A) and 3-(N-boc-aminomethyl)pyridine-5-boronic acid pinacol ester (Frontier Scientific, Logan, USA) to give the title compound as an off-white solid. (HPLC tR 1 87 min (Method A); M+H = 400 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 8 99 (s, 1H)1 8 56-8 51 (m, 2H), 8 17-8 11 (m, 2H), 7 99-7 95 (m, 1H), 7 86-7 83 (m. 1H). 7 61-7 58 (m, 1 H), 3 92 (s, 3H)1 3 79 (s, 2H), 3 58 (s, 3H), 2 06-1 97 (br, 2H), 1.95 (s, 3H)) Examole 231 N-{5^1-(1 >Dimethyl-1H-pyrazoi-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- !mtdazo[4,5-c]quinolin-8-y!]-pyridin-3-ylmethyl}-acetarnide
Figure imgf000343_0001
To a mixture of δ^δ-aminomethyl-pyridin-S-ylJ-I^I .S-dimethyl-I H-pyrazol^-yO-S-methyl-I .S- dihydro-imidazo{4,5-c]quino!tn-2-one (Example 230, 0 053 mmol) and Hυnig's base (0.014 ml) (D dichloromethane (1 ml) was added acetyl chloride (Aldrich, Buchs, Switzerland, 0.058 mmol) The RM was stirred for 45 min at rt then evaporated to dryness. The residue was taken in MeOH and purified by preparative HPLC The fractions containing product were basified with NaHCO3 concentrated and extracted with dichloromethane (2x) The combined organic layers were washed with bnne dried over Na2SO*, filtered, evaporated and dried under vacuum to give the title compound as a white solid. (HPLC. t* 1 95 mm (Method A); M+H = 442 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8 99 (s, 1 H), 8 56-8 53 (m, 1H), 8.48- 8.46 (m, 1H)1 8 40 (t. 1 H), 8 16-8.12 (m, 2H), 7.94-7 90 (m, 1H), 7 78-7 75 (m, 1H), 7.58-7.56 (m, 1H)1 4 38-4.27 (m, 2H), 3.92 (S1 3H), 3.58 (s, 3H), 1.95 (s, 3H)1 1 89 (s, 3H))
Example 232 8-(5-Aminomethyl-pyridin-3-yl)-1 -(1 ,3-dimethyl-1H-pyrazoi-4-yi)-3-methyl-1.3- dihydro-imidazo[4,5-c]quinotin-2-one
Figure imgf000343_0002
The title compound was synthesized in a similar manner as described for Example 231 using methansulfonyl chloride (Aldrich, Buchs, Switzerland) to give the title compound as a white solid (HPLC t* 1 98 mm (Method A); M+H » 478 MS-ES, 1H-NMR (dβ-DMSO, 400 MHz) 9 01-8 99 (m, 1H), 8.58-8 55 (m, 2H), 8.17-8.13 (m, 2H), 7 95-7 91 (m. 2H), 7.65-7 58 (m, 2H), 4.26 (s, 2H), 3 92 (s, 3H), 3.58 (s, 3H), 2 96 (s, 3H), 1 95 (s, 3H)) Example 233 1-{1 (3-Dimethyl-1H-pyrazot-4-yl)-3-methyl-8-(1,3,3-tπmethyl-2Oxo-2l3- dihyctro-I H-pyrrolo^.S-bjpyridin-δ-yO-I .S-dthydro-imiclazo^.S-cJquinolin-Z-one
Figure imgf000344_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-i H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and 1 ,3,3-trimethyl-5^4,4,5>5-tetramethy)-{1 ,3,2}dioxaborolan-2-y))-1,3- dihydro-pyrrok>[2,3-b]pyridin-2-one (Stage 233.1.1) to give the title compound as a white solid. (HPLC tR 2 53 mm (Method A) M+H ~ 468 MS-ES, 1H-NMR (dθ-DMSO, 400 MHz) 8 96 (S1 1 H)1 8 32-8 29 (m. 1H), 8 14-8 09 (m, 2H) 7 96-7 91 (m, 1 H), 7 79-7 76 (m, 1 H)1 7 54-7 51 (m, 1 H), 3 90 (s, 3H), 3 58 (s 3H), 3 18 (s, 3H) 1.96 (s, 3H), 1 37 (s, 3H)1 1 36 (s, 3H))
Stage 233.1.1 1.S.S-Trimethyt-S^^.δ.δ-tetramethyl-fi ,3,2]dioxaborolan-2-yl)-1 ,3-dihydro- pyrrolo(2,3-b]pyπdin-2-one
Figure imgf000344_0002
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using 5-bfomo-1 ,3,3-trimethyl-1 ,3-dihydro-pyπrolo[2l3-b]pyridin-2-one (stage 233.1.2 0 779 mmol) to give the title compound as a crude black solid (degrading under the HPLC condition tR 2 05 mm (Method A), M+H = 303 MS-ES)
Stage 233.1.2 5-Bromo-1 ,3.3-tπmethyl-i ,3-dihydro-pyrrolo[2,3-b]pyridin-2-one
Figure imgf000344_0003
To a mixture of 5-bromo-1 ,3-dihydro-pyrrolo[2,3-b3pyridin-2-one (Aldrich, Buchs, Switzerland, 1 394 min) in DMF (7 ml) cooled with an ice-bath was added 55% NaH in oil (1.6 mmol) and the RM was stirred for 30 mm at rt, then was added iodomethane (0 1 ml) and the RM was stirred for 30 mm at rt. The RM was cooled with an ice-bath and was added 55% NaH in o»l (1.6 mmol) and the RM was stirred for 15 min at rt, then was added iodomethane (0.1 ml) and the RM was stirred for 30 min at rt The RM was cooled with an ice-bath and was added 55% NaH in oil (1.6 mmol) and the RM was stirred for 15 min at rt, then was added iodomethane (0.1 ml) and the RM was stirred for 1 5 h at rt The RM was quenched with saturated aqueous NaHCO3 and extracted with EtOAc The organic layer was washed with brine (3x), dried over Na2SO4, filtered and evaporated The residue was absorbed on silica gel and purified by flash chromatography (heptane/EtOAc 0% to 40%) The fractions containing product were evaporated together to give the title compound as an off-white solid (HPLC tR 2 99 mm (Method A), M+H * 255, 257 MS-ES)
Example 234.1 8-(2,4-Dimethoxy-pynmidin-5-yl)- 1 -( 1 -ethyl-3-methy!-1 H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo{4,5-c]quinoJin-2-one
Figure imgf000345_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-ethyl-3-methyl-1 H-pyrazoi-4-yl)-3-methyl-1 3-dihydro-imidazo[4,5-c]quinohn-2- one (Intermediate F, 0.101 mmol) and 2,4-dimethoxypyrimidine-5-boronic acid pinacol ester (Frontier Scientific Logan, USA, 0 119 mmol) to give the title compound as a white foam. (HPLC tR 2 51 mm (Method A)1 M+H = 446 MS-ES1 1H-NMR (d6-DMSO, 400 MHz) 8.97 (s, 1H)4 8 32 (S. 1H)1 8 11 (s, 1H), 8.07-8 04 (m, 1H), 7 78-7.74 (m, 1H), 7 56-7.54 (m, 1H), 4 14 (q, 2H), 3.92 (s, 1H), 3.92 (s, 3H), 3 57 (s, 3H), 1 95 (s, 3H), 1 33 (t, 3H))
The following examples were synthesized in a similar manner as described for Example
234.1 using the specified intermediate
Figure imgf000345_0002
Figure imgf000346_0002
Example 235 1-(1 l3-Dimethyl-1H-pyrazol-4-yl)-8-(2-«thylamino-4-methoxy-pyrimidin-5-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]qυinolin-2-one
Figure imgf000346_0001
The titie compound was synthesized in a similar manner as descnbed for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and ethyK4-methoxy-5-(4,4(5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- pynmidin-2-yl]-amine (Stage 236.1.1) to give the title compound as a white solid. (HPLC t« 2.24 min (Method A); M+H = 445 MS-€S; 1H-NMR (de-DMSO, 400 MHz) 8 91 (s, 1H), β 16- 6.06 (m, 3H), 8 01 -7 97 (m, 1H), 7.74-7 69 <m, 1H), 7.61-7 58 (m, 1H)1 3.88 (s, 3H), 3.84 (s, br, 3H), 3 56 (s, 3H), 3.36-3.28 (m, 2H), 1.93 (s, 3H), 1 13 (t, 3H))
Stag© 235.1.1 Ethyl-[4-methoxy-5-(4,4,5l5-tetramethyl-[1 ,3,2}dioxaborolan-2-y])-pyrimidin-2- yl]-amine
Figure imgf000347_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using (5-bromo-4-methoxy-pyπmidin-2-yl)-ethyl-amine (stage 235.1.2, 0 366 mmol) to give the title compound as a crude back oil. (degrading under the HPLC condition. tR 1 91 min (Method A), M+H = 280 MS-ES).
Stage 235.1.2 (5-Bromo-4-methoxy-pyrimidin-2-yl)-ethyl-amine
Figure imgf000347_0002
To a solution of 5-bromo~2-chloro-4-methoxypyrimidine (Frontier Scientific, Logan, USA, 0 895 mmol) in THF (2 5 ml) cooled with an ice-bath was added a 2 M solution of ethyiamine in MeOH (Aldrich, Buchs, Switzerland, 0 492 ml) The RM was stirred at O°C for 1 h and at rt for 66 h then the reaction mixture was diluted with EtOAc1 washed with saturated aqueous NaHCθ3, with brine, dried over Na2SO4, filtered and evaporated. The residue was absorbed on silica ge! and purified by flash chromatography (CHjCI2ZiPrOH 0% to 6%) to give after evaporation of the fractions containing the title compound an off-white solid (HPLC' t« 2 16min (Method A), M+H = 232, 234 MS-ES)
Example 236 1-(1-Ethyl-3-methyl-1 H-pyrazol-4-yl)-8-(4-methoxy-2-methylamino-pyπmidin~5- yl)-3-methyM , 3-dthydro-imidazo{4 , 5-c]quinotin-2-one
Figure imgf000348_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1-ethyl-3-methyl-1 H-pyrazol-4-yt)-3-methyl-1 ,3-dihydro-imidazo{4,5-c]quinoHn-2- one (Intermediate F) and (4-methoxy-5-(4A5,54etramethyl-(1 ,3,2Jdioxaborolan-2-yi)- pyrimidin-2-yl]-methy!-amine (stage 236.1.1) to give the title compound as a white solid, (HPLC: t* 2.19 min (Method A); M+H = 445 MS-ES: 1H-NMR (de-DMSO, 400 MHz) 8.91 (s, 1 H), 8.11 (s, 1H), 8.08-8,02 (m, 1H), 8.01-7.97 (m, 1 H), 7.74-7.69 (m, 1H), 7.50-7,48 (m, 1 H), 7.27-7, 16 (m, 1H), 4.15 (q, 2H), 3.85 (s, br. 3H), 3,56 (s, 3H), 2.82 (d, 3H), 1.95 (s, 3H) 1.36 (t 3H))
Stage 236.1.1 {4-Methoxy-5-(4,4l5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyrimidin-2-yl)- methyl-amine
Figure imgf000348_0002
The title compound was synthesized in a similar manner as described for Stage 235.1.1 using 8 M methylamine in EtOH (Fluka, Buchs, Switzerland, 0.366 mmol) to give the title compound as a crude back oil. (degrading under the HPLC condition: tH 1.69 min (Method A); M+H - 266 MS-ES).
Example 237 1 -( 1 ,3-DimethyM H-pyrazol-4-yl)-8-( 1 -ethyl-2-oxo-1 ,4-dihydro-2H-pyrido{3,2- d][1,3]oxazin-7-yl)-3-methyt-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000348_0003
A mixture of acetic acid S-tfert-butoxycarbonyt-ethyl-aminoJ-S-π-CI.S-dimethyMH-pyrazoM- yl)-3-metbyl-2-oxo-2, 3-dihydro-1 H-imidazo[4 , 5-ctøuinolin-8-yl]-pyridin-2-ylmethyl ester (stage 156.1.1, 0 107 mmol) and KCN (0.16 mmoi) in EtOH (0,6 ml) was stirred for 17 h at 80°C. The RM was diluted with EtOAc and washed with water, wrth brine, dried over Na2SO4, filtered and evaporated. The residue The residue was absorbed on silica get and purified by flash chromatography (CH2CI2/Me0H 0% to 8%) The fractions containing product were evaporated together to give the title compound as an off-white solid. (HPLC: tR 2,42 min (Method A), M+H = 470 MS-ES, 1H-NMR (dθ-DMSO, 400 MHz) 9.00 (s. 1H), θ 35-8 32 (m, 1H), 8.17-8 13 (m. 1H), 8.11 (s, 1H)1 8.04-8 00 (m, 1H), 7 62-7 59 (m, 1H), 7 49-7 47 (m, 1H), 5 40-5.31 (m, 2H), 4 04-3.85 (m. 2H), 3 87 (s, 3H), 3 59 (S1 3H)1 1 97 (s, 3H), 1 24 (t, 3H))
Example 238 8-(5-Chloro-6-hydroxymethyt-pyrid(n-3-yl)-1-(1 ,3-dimethyl-1H-pyra2θl-4-yl)-3' methyl-1,3-dihydrθ"imidazo[4,5-cjquino!m-2-one
Figure imgf000349_0001
The title compound was synthesized in a similar manner as described for Example 169.1 using 8-bromo-1-(1 ,3-d(methyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin- 2-one (Intermediate A) and acetic acid 3-chloro-5-(4,4,5,5-tetramethyl-{1 ,3,2]dioxaborolan- 2-yl)-pyridin-2-ylmethyl ester (Stage 238.1.1) to give the title compound as an off-white solid (HPLC: t* 2.27 mm (Method A), M+H * 435 MS-ES; 1H-NMR (dβ-DMSO, 400 MHz) 9 00 (s, 1H)1 8 65-8 62 (m, 1H)1 8 18-8 11 (m, 2H)1 8.05-8 00 (m, 1H)1 7 97-7 94 (m, 1H), 7 58-7 55 (m, 1H), 5 30 (t, 1H), 4.67 (d, 2H). 3.94 (s, 3H), 3 58 (s, 3H)1 1 95 (s, 3H))
Stage 238.1.1 Acetic acid S-chloro-δ^^.δ.S-tetramethyl-li.S^Jdioxaborolan^-yO-pyπdin^- ylmethyl ester
Figure imgf000350_0001
The title compound was synthesized in a similar manner as described for Stage 5.1.1 using acetic acid 5-bromo-3-ch)oro-pyridin-2-ylmethyl ester (stage 238.1.2, 0.306 mmo!) to give the titte compound as a crude back oil, (degrading under the HPLC condition. tR 2 65 min (Method A); M+H = 312 MS-ES).
Stage 238.1.2 Acetic acid S-bromo-S-chloro-pyπdm^-ylmethyl ester
Figure imgf000350_0003
r
The title compound was synthesized in a similar manner as described for Stage 194.1.2 using (5-bromα-3-ch!oro-pyπdin-2-yl)-methanot (stage 238.1.3, 0.351 mmol) to give the title compound as an oil (HPLC tR 3 04 min (Method A)1 M+H = 264 (BrCI pattern) MS-ES)
Stage 238.1.3 (5-Bromo-3-chloro-pyridin-2-yl)-methanol
Figure imgf000350_0002
The title compound was synthesized in a similar manner as descnbed for Stage 190.1.2-3 using 5-bromo-3-chloro-2-methyl-pyridine (stage 238.1.4, 0.801 mmol) to give the title compound as a white solid (HPLC t« 2.40 min (Method A); M+H = 222, 244 MS-ES)
Stage 238.1.4 5-Bromo-3'Ch)oro-2-methyl-pyridine
Figure imgf000350_0004
The title compound was synthesized in a similar manner as described for Stage 75.1.5 using 5-bromo-2,3-dichloropyπdine (Asymchem Laboratories, MorrisviPe, NC, USA, 2.182 mmol) to give the title compound as a crude black solid. (HPLC. tR 3 29 mm (Method A), M+H = 206, 208 MS-ES)
Example 239 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-[5-(iMDethoxy-1-methyl-ethyl)-pyπdin-3-yl]- 3-methyl-1 ,3-dihydro-imidazol4,5-c)quino}in-2~one
Figure imgf000351_0001
The title compound was synthesized in a similar manner as described for Example 104 using 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-8-(5-( 1 -hydroxy-1 -methyl-ethyl )-pyridtn-3-yl]-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (Example 215.2, 0.121 mmol) to give the title compound as a film (HPLC- tR 2 19 min (Method A), M+H = 443 MS-ES, 1H-NMR (dδ-DMSO, 400 MHz) 8.99 (s, 1 H), 8 71-8 68 (m, 1H), 8 62-8 59 (m, 1 H), 8.16-8 11 (m, 2H), 8 04-7.99 (m, 1 H), 7 76-7 73 <m, 1H) 7.63-7 60 (m, 1H), 3 89 (s, 3H), 3 58 (s, 3H)1 3.05 (s, 3H), 1.97 (S, 3H), 1.54 (s, 6H))
Example 240 1-(1 ,3-Dimethyl-1H-pyrazo)-4-yl)-8-[5-(1-etho)cy-1-methyl-ethy()-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo{4,5-c]qυinolin-2-one
Figure imgf000351_0002
The title compound was synthesized in a similar manner as described for Example 104 using 1-(1 <3-dimethyl-1H-pyrazol-4-yl)-8-[5-(1-hydroxy-1-methyl-ethyl)-pyridin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo{4,5-c]qυinolin-2-one (Example 215.2, 0 063 mmol) and iodethane as replacement for the iodomethane to give the title compound as a film (HPLC tR 2,30 mm (Method A)1 M+H ~ 457 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 99 (s, 1H), 8 69-8 67 (m, 1 H), 8 63-8 61 (m, 1H), 8 16-8 12 (m, 2H), 8 03-7 98 (m, 1 H), 7 77-7 74 (m, 1 H) 7 63-7 61 (m 1H), 3 89 (s, 3H). 3 58 (s 3H), 3 21 (q, 2H), 1 97 (s. 3H)1 1 55 (s, 3H), 1 54 (s, 3H)1 1 09 (t, 3H))
Example 241 1-(1-isopropyl-3-methyMH-pyrazd-4*yl)-3-methyl-8-(6-(methylamino)pyπdin- 3-yl)-1HHmidazo[4l5-c]qυinoline-2(3H)-thione
Figure imgf000352_0001
The title compound was synthesized in a similar manner as described for Example 128,1 using 1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl-8-(6~methylamino-pyridin-3-yl)- 1 ,3- dihydro-imidaεo[4,5-c]quinolin-2-one (Example 118.1 , 0 051 mmol) to give the title compound as a white solid (HPLC tR 2 44 mm (Method A), M+H = 444 MS-ES, 1H-NMR (d9- DMSO, 400 MHz) 9 11 (β, 1 H). 8 21-8 17 (m 2H)1 8 12-8 08 (m 1 H)1 7 95-7 90 (m 1H) 7 49-7 44 (m, 1H), 7 39-7 36 (m, 1H), 6 75 (q, 1H), 6 50-6 45 (m 1H), 4 58 (hp, 1H), 3 94 (s, 3H) 2 79 (d, 3H) 1 93 (s, 3H) 1 52-1 46 (m, 6H))
Example 242,1 5-[1-(1 ,3-DimethyM H-pyrazol-4-yl)«3-methyl-2-oxo-2,3-dihydro-1 H- imidazo^.S-cJquinolin-β-yll-N-ethyl^-methylamino-nicottnamide
Figure imgf000352_0002
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro-imidazo(4,5-c]quinolin-2-one (Intermediate A) and N-ethyl-2-methylamino-5-(4 4,5,5-tetramethyK1 3 2]dioxaborolan-2- yl)-nicotinamide (Stage 242.1.1) to give the title compound as a yellowish foam. (HPLC: t* 2 17 min (Method A), M+H = 471 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.92 (s, 1H), 8 58 (t, 1H), 8.25-8.20 (m, 2H)1 8.11-8.06 (m, 2H), 8.05-8.02 (m, 1H), 7 96-7 92 (m, 1H), 7.47-7.44 (m, 1H), 3.89 (s, 3H), 3.57 (s, 3H), 3.40-3 19 (m, 2H), 2 93 (d. 3H) 1.97 (s, 3H), 1.15 (t, 3H))
Stage 242.1.1 N-Ethy!-2-methylamino-5-(4.4,5,5-tetramethyl-{1,3l2]dioxaboroian-2-yl)- nicotinamide
^
Figure imgf000353_0001
The title compound was synthesized in a similar manner as described for Stage 227.1.1 using 5-bromo-2-methylamino-nicotinic acid (Princeton BioMotecular Research, Monmouth Junction, NJ, USA) to give the title compound as a crude brown oil. (degrading under the HPLC condition. tR 1.81 min (Method A), M+H = 306 MS-ES).
The following example was synthesized in a similar manner as described for Example 242.1 using the specified intermediate.
Figure imgf000353_0002
Example 243 1 -(1 ,3-DimethyM H-pyrazo!-4-yl)-8-(5-ethoxy-6-hydroxymethyl-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one
Figure imgf000354_0001
The title compound was synthesized in a similar manner as described for Example 190 using ethanol as replacement for isopropanol to grve the title compound as a white solid. (HPLC- tR 2 11 mm (Method A): M+H = 445 MS-ES, 1H-NMR (U6-DMSO, 400 MHz) 8 99 (s, 1H), 8.28-8 25 (m, 1H), 8.14-8.10 (m. 2H), 8.04-8.00 <m, 1 H), 7.63-7.61 (m, 1 H), 7.38-7 35 (m, 1H)1 4 88 (t, 1H), 4.57 (d, 2H)1 4 22-4 14 (m, 2H), 3.89 (s, 3H), 3.58 (s, 3H), 1 97 (s, 3H), 1.41 (t, 3H))
Example 244 1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yi)-8-[6-hydroxymethyl-5-(2-methoxy-ethoxy)- pyndin-3-yl]-3-methyl-1 ,3-d)hydro-imidazo{4,5-c)quinolin-2-one
Figure imgf000354_0002
The title compound was synthesized in a similar manner as described for Example 190 using 2-methoxyethanol as replacement for isopropanol to give the title compound as a white solid. (HPLC- tR 2 09 min (Method A), M+H = 475 MS-ES: 1H-NMR (Cl6-DMSO, 400 MHz) 8.99 (s, 1H), 8 27-8 25 (m, 1H), 8,15-8 11 (m, 2H), 8 04-8 00 (m, 1 H), 7.63-7 60 (m, 1H), 7 44-7.41 (m, 1 H), 4.87 (t, 1H), 4.57 (d, 2H), 4 31-4 22 (m, 2H), 3.89 (s, 3H), 3 75 (t, 2H), 3.58 (s, 3H), 3.35 (s, 3H), 1 97 (S, 3H))
Example 245 8-(5-Amino-pyridin-3-yl)-1-(1 ,3-dimethy!-1 H-pyrazof-4-yl)-3-ethyl-1 ,3-dihydro- imidazo{4,5-c]quinolin-2-one
Figure imgf000355_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-y1)-3-ethyl-1 ,3-dihydro-imidazo(4 5-c]quinolin-2-one (stage 245.1.1) and 3-aminopyπdme-5-boronic acid pinacol ester (Apollo Scientific, Cheshire, United Kingdom) to give the title compound as a white solid. (HPLC' tR 2.02 mm (Method A), M+H - 400 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 9.02 (s, 1 H)1 8 15 (s, 1 H), 8.12-8.07 (m, 1H) 7 94-7 91 (m, 1 H), 7 81-7 76 (m, 2H), 7 54-7.51 (m, 1H), 7 03-7.00 (m, 1 H), 5 44 (S, 2H), 4.11 (q, 2H), 3 91 (s, 3H), 1.94 (s, 3H), 1.35 (t, 3H))
Stage 245.1.1 8-Bromo-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-ethyl-1 ,3-dihydro-imidazo{4,5- cJquinolin-2-one
Figure imgf000355_0002
To a solution of 8-bromo-1-(1,3-dimethyl-1H-pyrazol~4~yl)-3-methyl-1 ,3-dihydro-imidazo [4,5- cJquinolin-2-one (Stage A.1, 0 698 mmol) in DMF (5 ml) cooled with an ice-bath was added 55% NaH in oil (1 398 mmol). The RM was stirred for 30 mm at rt then was added iodoethane (0 085 ml) and the RM was stirred for 30 min at rt. The RM was diluted with EtOAc and washed with saturated aqueous NaHCO3, with brine (2x), dried over Na?SO4, filtered and evaporated The residue was absorbed on silica gel and purified by flash chromatography (CH2CI2/Me0H 0% to 3.5%). The fractions containing product were evaporated together to give the title compound as a brown solid (HPLC tR 2 41 mm (Method A), M+H = 386, 388 MS-ES)
Example 246 3-Altyl-8-(5-amino-pyπdin-3-yl)-1-(1 ,3-dimerhyl-1 H-pyra2θl-4-yl)-1 ,3-dihydro- imidazo{4,5-c]quinolin-2-one
Figure imgf000356_0001
The title compound was synthesized in a similar manner as described for Example 245 using sllyl bromide (Flυka, Buchs, Switzerland) as replacement for iodoethane to give the title compound as a white solid. (HPLC- tR 2 08 min (Method A), M+H = 412 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8.89 (s, 1H)1 8.17 (s, 1H), 8.1 1-8 08 (m, 1 H), 7.94-7.92 (m, 1H), 7 81- 7 77 (m, 2H), 7.55-7.53 (m, 1H), 7 03-7 01 (m 1H), 6 09-5 98 (m, 1H), 5.44 (β, 2H), 5.26- 5.17 (m, 2H), 4.72 (d, 2H), 3 92 (s, 3H), 1 95 (S, 3H))
Example 247.1 N,N-Diethyl-2-{3-methyl-4-[3-methyl-2-oxo-8-(2-pyrroiidin-1 -yi- pyπmidin-5-yl)-2 , 3-dihydro-imidazo[4,5-c]quinolin- 1 -yl]-pyrazσl- 1 -yl}-acetamide
Figure imgf000356_0002
To a solution of {3-methyl-4-j:3-methyl-2-oxo-8-(2-pyrro)idin-1-yl'pyπmidin-5-yl)-2,3-dihydro- imida2θ(4,5-c]quinolin-1-yl]-pyrazol-1-yl}-acetic acid (Stage 247.1.1, 0.12 mmol) and DMF (0.007 ml) in dichloromethane (2 ml) was added oxaltyl chloride (0 36 mmol) and the RM was stirred for 45 mm at rt The RM was quenched with diethylamine (Riedel-deHaen, Buchs, Switzerland, 2.4 mmol) and stirred for 5 min at rt then diluted with saturated aqueous NaHCO3 and extracted with EtOAc (2x) The combined organic layers were washed with brine (2x), dried over Na2SO4, filtered and evaporated The residue was taken in MeOH/DMF and purified by preparative HPLC The fractions containing pure product were basified with NaHCO3, concentrated, cooled at 4°C and the precipitate was filtered, washed with water and dried under vacuum to give the title compound as white solid (HPLC tR 2 63 mm (Method A)1 M+H = 540 MS-ES, 1H-NMR (de-DMSO, 400 MHz) 8 92 (s, 1H), 8 57 (s, 2H) 8 07-8.04 (m, 2H). 7.87-7 84 (m, 1 H), 7.67-7 65 (m, 1 H) 5.21-5 04 (m, 2H), 3 57 (S1 3H)1 3.52-3.46 (m, 4H), 3.42-3.34 (m, 2H), 3.32-3.34 (m, 2H), 1.96-1,90 (m, 4H), 1 ,94 (s, 3H), 1.18 (t, 3H), 0.99 (t, 3H))
Stage 247.1.1 {3-Methyl-4-[3-methyl-2-oxo-8-{2-pyrrolidin-1-yi-pyrimidin-5-yl)-2,3-dihyclro- imidazo{4, 5-c]quinolin- 1 *yl]-pyrazol- 1 -yl)-acetic acid
Figure imgf000357_0001
The title compound was synthesized in a similar manner as descnbed for Example 1.1 using ^-(θ-bromo-S-methyl^-oxo^.S-dihydro-imidazo^.δ-cJquinolin-1-yO-S-methyl-pyrazol-1-ylj- acetic acid methyl ester (stage 247,1.2) and 2-(pyrrolidin-1-yJ)pyrimidine-5-boronic acid pinacol ester (Frontier Scientific, Logan, USA) to give the title compound as a yellow hydrochloride salt after evaporation of the fractions containing pure product and exchange of the trifluoroacetate to the chlorure. (HPLC: tκ 2.29 mm (Method A); M+H * 485, M-H ~ 483 MS-ES)
Stage 247.1.2 {4-{8-Bromo-3-methyl-2-oxo-2.3-dJhydro-imlcla2o[4,5-cJquinolin-1-yl)-3-methyl- pyrazol-1-yl]-acetic acid methyl ester
Figure imgf000357_0002
The title compound was synthesized in a similar manner as described for Stage 246.1.1 using ^-(β-bromo^-oxo^.S-dihydro-imidazo^.S-clquinolin-1-ylJ-S-methyl-pyrazol-1-yll-acetic acid methyl ester (Stage 101.1.3, 3 43 mmol) and iodomethane to give the title compound as brown solid (HPLC. tR 2.42 min (Method A), M+H = 430, 432 MS-ES)
The following examples were synthesized in a similar manner as described for Example 247.1 using the specified amines (Fluka, Buchs, Switzerland).
Figure imgf000358_0001
Figure imgf000359_0003
Example 248.1 1-(1-!sopropyl-3-methyl-1 H-pyrazol-4-yl)-8-(5-methoxymethyl-6- methylamino-pyπdin-S-ylJ-S-methyl-I.S-dihydro-imidazo^.δ-cJquiπolm^-one
Figure imgf000359_0001
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo- 1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro-imidazo[4,5- c]quinolin-2-one (Intermediate G) and {3-methoxymethyl-5-(4,4,5,5-tetramethyl- [1 ,3,2}dioxaborolan-2-yl)-pyridin-2-yl]-methyl-amine (Stage 248.1.1) to give the title compound as a yellowish foam. (HPLC tR 2.24 mm (Method A); M+H = 472 MS-ES; 1H-NMR (de-DMSO, 400 MHz) 8 90 (s, 1H), 8 20 (s, 1 H), 8.15-8.13 (m, 1H), 8 05-8 02 (m, 1 H), 7 85- 7.81 (m. 1H)1 7 48-7 45 (m, 1 H)1 7.43-7 41 (m, 1H), 6.13 (q, 1 H), 4 55 (hp 1 H), 4 30 (s, 2H), 3.57 (s. 3H), 3.31 (s, 3H),2.86 (d. 3H)1 196 (s, 3H), 1.49-1 45 (m, 6H))
Stage 248.1.1 [3-Methoxymethyl-5-(4,4)5l5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridin-2- yl}-methy!-amine
Figure imgf000359_0002
The title compound was synthesized in a similar manner as described for Stage 168.1.1 using (5-bromo-2-methylamino-pyridin-3-yl)-methanol (stage 248.1.2) to give the title compound as a crude back oil (degrading under the HPLC condition (Method A); M+H - 279 MS-ES)
Stage 248.1.2 (5-Bromo-2-methy!amino-pyπdin-3-y!)-methanol
Figure imgf000360_0001
The title compound was synthesized in a similar manner as descnbed for Example 171 using 6-bromo-1 ,4-dihydro-pyrido[2,3-dK1 ,3)oxazin-2-one (Stage 170.1.3) to give the title compound as a solid (HPLC t* 1 92 mm (Method A)1 M+H * 217, 219 MS-ES)
The following examples were synthesized in a similar manner as described for Example 1.1 using (3-methoxymethyl-5-(4 4,5,5-tetramethyl-[1 ,3,2]dioxaboroJan-2-yl)~pyridin-2-y!]-methyl- amme (Stage 248.1.1) and the specified intermediate
Example lrrtermed structure Name of the example MS-ES HPLC t*
(M+H)
(mm)
248 2 F 1-(1-Ethyl-3-methyl- 458 2 18
I 1H-pyrazol-4-yl)-8-(5-
HhL methoxymethyl-6- methylamino-pyndin- n
3-yl)-3-methyl-1 ,3- dihydro-imidazo[4,5- c]quinolin-2-one
248 3 A 1-(1.3-Dimethyl-1 H- 444 2 12
I pyrazol-4-yl)-8-(5- methoxymethyl-6-
I J U >^° ,0 I 1 ;j methylamino-pyridin-
3-yl)-3-methyl-1 ,3- dihydro-imidazo{4,5- c]qυinolin-2-one
248 4 K 1-(3-Chloro-1-methyl- 464 2 27
I 1 H-pyτazol-4-yl)-8-(5- methoxymethyJ-6-
I J U methylamino-pyndin-
3-yl)-3-methyM .3- dihydro-imidazo[4 , 5-
Figure imgf000360_0002
Figure imgf000361_0002
Example 249 8-(3,4-dimethoxy-phenyl)-1~(1 ,3-d)methyl-1H-pyrazol-4-yl)-1 ,3-dihydro-1 ,3,5,9- tetraaza-cyclopenta[a}naphthalen~2-one
Figure imgf000361_0001
A mixture of 6-(3,4-dimethoxy-phenyl)-4-(1 ,3-dimethyl-1 H-pyrazol-4-ylamir>o)- [1.SJnaphthyridme-S-carboxylic acid ethyl ester (Stage 249.1.1, 160 mg, 0.358 mmol) and LiOH 1 M (0.715 ml, 0 715 mmol) in dioxane (2 6 ml) was stirred at 50 °C for 2 5 h The RM was then quenched with 2 M aqueous HCI (0 36 ml, 0 072 mmol) and evaporated to dryness The residue was diluted with toluene (2.6 ml) and NMP (1 3 ml) and treated under argon wrth TEA (0.164 ml) and diphenylpbosphoryiazide (0 231 ml). The RM was stirred again at 95 °C for 2 5 h. After that, the RM was quenched with saturated aqueous NaHCO3. the suspension was then filtered The cake was dissolved with EtOAc (200 ml) and THF (30 ml). The solution was extracted with brine (2x) The combined organic layers were drrød over Na2SO4, filtered and evaporated to dryness to give the title compound as an off-white solid, (HPLC; tR 2.56 min (Method A), M+H « 417 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 1 1.80 (s, 1H), 8.75 (s, 1H), 8.38 (d, 1H), 8.22 (d, 1H), 7.96 (s, 1 H), 7.60-7 55 (m, 1H), 7.42-7.38 (m, 1 H), 7.02-6 98 (m, 1 H), 3 83 (s, 6H), 3 81 (s, 3H), 1.97 (s, 3H))
Stage 249.1.1 6-(3,4-Dimethoxy-phenyl)-4-(1 ,3-dimethyl-1 H-pyrazol-4-ylamino)-
[1.5]naphthyridine-3-carboxylic acid ethyl ester
Figure imgf000362_0001
A mixture of 4-chloro-6-(3,4-dimethoxy-phenylM1 <5]naphthyπdine-3-carboxylic acid ethyl ester (Stage 249.1.2, 170 mg, 0 456 mmol), 1 ,3-dimethyl-4-aminoρyrazole.HCI (ChemCollect, Remscheid, Germany, 85 mg, 0 576 mmol) and 1 ,2,2,6,6-pentamethylpyridine (0 292 ml. 1.596 mmol) in DMA (2 ml) was stirred at 50 X for 5.5 h. Then the RM was cooled to rt and quenched with water, before being extracted with EtOAc (2x). The combined organic layers were dried over Na∑SO^, filtered and evaporated to dryness to give the title compound as an orange solid. (HPLC. tR 2 93 min (Method A): M+H = 448 MS-ES)
Stage 249.1.2 4-Chloro-6-(3,4-dimethoxy-phenyl)-(1 ,5]naphthyridine-3-carboxylic acid ethyl ester
Figure imgf000362_0002
A mixture of 6-(3,4-dimethoxy-phenyl)-4-hydroxy-[1 ,5)naphthyridine-3-carboxyl!C acid ethyl ester (Stage 249.1.3, 493 mg, 1.391 mmol) in POCI3 was stirred at 125 °C for 1 5 h Then the RM was evaporated to dryness. The residue was quenched with saturated aqueous NaHCO3. The suspension was filtered, the cake was washed with water and dried in the vacuum oven to give the title compound as a brown solid Used for next step without further purification (HPLC: tR 3.80 min (Method A)1 M+H « 373 MS-ES)
Stage 249.1.3 6-(3,4-Dimethoxy-phenyl)-4-hydroxy-[1 ,5)naphthyridine-3-carboxylic acid ethyl ester
Figure imgf000362_0003
A mixture of 6-(3,4-dimetboxy-phenyi)~pyridin-3~y1amine (Stage 249.1.4, 2.0 g, 8.69 mrnol) and diethyl ethoxymethylenemalonate (Aldπch, Buchs, Switzerland, 2 087 ml, 10 42 mmol) in o«xytene (22 ml) was heated by microwaves at 150 °C for 45 mm and at 250 9C for 9 h The RM was cooled to rt and crystallized with diethylether. The suspension was filtered and the cake was triturated again in hot EtOAc and cooled after in the freezer The suspension was filtered again. The cake was washed with EtOAc and dried in the vacuum oven to give the title compound as a brown solid. Used for next step without further purification. (HPLC. IR 2 58 mm (Method A); M+H = 355 MS-ES)
Stage 249.1.4 6-(3,4-dimethoxy-phenyl)-pyridin-3-ylamine
Figure imgf000363_0001
To a mixture of 2-(3,4-dimethoxyphenyl)-5-nitropyridine (Interchim, Montlucon, France, 2 85 g, 10 95 mmol) in MeOH (27 ml) and THF (27 ml), Ra/Ni catalyst (1 10 g, 10.95 mmol) was added and shaked under hydrogen at rt for 15 h After that, the RM was filtered over celite, the catalyst was washed with MeOH and the filtrate was evaporated to dryness to give the title compound as an off-white solid. (HPLC' tR 2.22 min (Method A), M+H = 231 MS-ES)
Example 260 8-(3,4-Dimethoxy-phenyl)-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-l3- dihydro-1 3,5,9-tetraaza-cyclopenta[a]naphthalen-2-one
Figure imgf000363_0002
A mixture of 8-(3,4-dimethoxy-phenyl)-1-(1 ,3-dimethyl-1 H~pyrazol-4-yl)-1 ,3-dihydrθ'1 , 3,5,9- tetraaza-cyclopenta[a]naphthalen-2-one (Example 249. 50 mg, 0 120 mmol) and NaH 55 % (8 mg, 0 183 mmol) in DMF (1 2 ml) was stirred at rt for 20 mm Then iodomethane (0 011 ml, 0 180 mmol) was added and the RM was stirred at rt for 2 25 h After that, the RM was quenched with saturated aqueous NaHCO3, the suspension was then filtered, the cake was washed with water and dried in the vacuum oven to give the title compound as an off-white solid. (HPLC: tR 2.67 min (Method A); M+H ~ 431 MS-ES; 1H-NMR (dc-DMSO, 400 MHz) 8.98 (s, 1H), 8.38 (d. 1H), 8.24 (d, 1H), 7.96 (s, 1H), 7.62-7.64 (m, 1H), 7.42-7,38 (m, 1H), 7.02 (d, 1 H), 3,85 (s. 6H), 3.81 (s. 3H), 3.59 (S1 3H), 1.97 (s, 3H))
Example 251 8-(3,4-Dimethoxy~phenyl)-1 -(1 ,3-dimethy)-1 H-pyrazol-4-yl)-3-ethyl-1 ,3-dihydro- 1,3,5,9-tetraaza-cyclopenta{a]naphtha)en-2-one
Figure imgf000364_0001
A mixture of 8-(3,4-dimethoxy-phenyl)-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-1 ,3-dihydro-1 ,3,5,9- tetraaza-cyclopenta(a]naphthalen-2-one (Example 249, 50 mg, 0.120 mmol) and NaH 55 % (8 mg, 0 183 mmol) in DMF was stirred at rt for 25 min. Then iodoethane (0.015 ml, 0.186 mmol) was added and the RM was stirred at rt for 5,5 h. After that, the RM was quenched with saturated aqueous NaHCO3, the suspension was then filtered, the cake was washed with water and dried in the vacuum oven to grve the title compound as a white solid. (HPLC: t* 2.74 min (Method A); M+H = 445 MS-ES; 1H-NMR (d8-DMSO, 400 MHz) 9,03 (s, 1 H)1 8.40-8.32 (m, 1 H), 8.25-8.19 (m, 1 H), 7.95 (s, 1H), 7.60-7.52 (m, 1 H), 7.41-7.36 (m, 1H), 7.04-6.97 (m, 1H), 4,11 (q, 2H), 3,85 (s, 3H), 3.83 (s, 3H), 3,81 (s, 3H)1 1.94 (s, 3H), 1 ,37 (t, 3H))
Example 252 8-(3,4-Dimethoxy-phenyl)-1 -(2,5-dimethyl-2H-pyrazol-3-yl)-1 ,3-dihydro-
1 ,3,5,9-tetraaza-cyclopenta(a]naphthalen-2-one
Figure imgf000364_0002
The titie compound was synthesized in a similar manner as described for Example 249 using 2,5-dimethyl-2H-pyrazoi-3-ylamine (Aldπch, Buchs, Switzerland, 130 mg, 1.170 mmo!) to give the title compound as an off-white solid (HPLC. tR 2 73 mm (Method A); M+H = 417 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 1 1 96 (s, 1H), 8.79 (s, 1H)1 8 38 (d, 1 H), 8.25 (d. 1H), 7.62-7,56 (m, 1H)1 7 42-7.38 (m, 1H). 7 02-6.97 (m, 1H), 6 26 (s, 1 H)1 3 85 (s, 3H)1 3.81 (s, 3H), 3 58 (s, 3H). 2.23 (s, 3H))
Example 253 8-(3,4-Dimethoxy-phenyl)-1-(2,5-dimethyl-2H-pyrazol-3-y1)-3-methyl-1 ,3- dihydro- 1 ,3,5, 9-tetraaza-cyclopenta(a]naphthalen-2-one
Figure imgf000365_0001
The title compound was synthesized in a similar manner as described for Example 260 using 8-(3,4-dimethoxy-phenyl)-1-(2,5-dimethyl-2H-pyrazol-3-yl>1 ,3-dihydro-i ,3,5,9- tetraaza-cyclopenta[a)naphthalen-2-one (Example 252, 37 mg, 0.088 mmol) to give the title compound as an off-whrte solid. (HPLC: tR 2.90 mm (Method A), M+H * 431 MS-ES1 1H-NMR (d6-DMSO( 400 MHz) 9.03 (s, 1 H), 8 43-8 35 (m, 1 H), 8 29-8 22 (m, 1 H), 7 62-7.54 (m, 1 H), 7,38 (st 1H) 7 03-6.95 (m, 1H), 6.31-6 23 (m, 1H)1 3.86 (s, 3H), 3.81 (s, 3H), 3.60 (s, 3H), 3 52 (s, 3H), 2.23 (s, 3H))
Example 254 8-(3,4-Dimethoxy-phenyl)- 1 -( 1 -ethyl-3-methyl- 1 H-pyrazol«4-yl)-3-methyl- 1 ,3- dihydro-1 ,3,5,9-tetraaza-cyclopenta(a]naphthalen-2-one
Figure imgf000365_0002
The title compound was synthesized in a similar manner as described for Example 250 using 1-ethyl-3-methyl-1 H-pyrazol-4-yiamine HCI (ChemColtect, Remscheid, Germany 95 mg, 0 587 mmol) to give the title compound as a light yellow foam (HPLC tR 2 74 mm (Method A)1 M+H = 445 MS-ES, 1H-NMR (d6-DMSO, 400 MHz) 8 98 (s, 1H), 8 41-8 32 (m, 1H)1 8 25-8 18 (m. 1H), 7 95 (S1 1H), 7 56-7 49 (m, 1H), 7.46-7 39 (m 1H), 7 02-6 94 (m, 1H), 4 18-4 07 (m, 2H), 3 87 (s, 3H), 3 81 (s, 3H). 3 60 (s, 3H), 1 97 (s 3H), 1.46-1 35 (m, 3H))
PhvsicochemJcal properties
The physicochemical properties of relevarκe for the absorption of the compound, such as the solubility and the membrane permeability especially at a pH close to neutral pH can be measured using the procedure as described by L ZHOU et al in JOURNAL OF PHARMACEUTICAL SCIENCES. VOL 96, NO 11 p 3052-3071 (2007) for the solubility at pH 6 8 and the procedure as described by F Wohnsland and B Faller in Journal of Medicinal Chememistry VoI 44 p 923-930 (2001) for the Parallel Artificial Membrane Permeability Assay (PAMPA) at pH 6 8
The following solubility in mg/l was measured at pH 6 8 for compounds of formula (I) as exemplified below
Figure imgf000366_0001
Figure imgf000367_0001
Figure imgf000368_0001
Figure imgf000369_0001
The following permeability tog Pe was measured for compound of formula (I) as exemplified below:
Figure imgf000369_0002
Figure imgf000370_0001
Figure imgf000371_0001
The permeability in 10-6 cm/s of compounds of formula (I) have been confirmed for selected example using a cellular CaCo2 permeability assay from apical to basal (A-B) ■
Figure imgf000371_0002
Figure imgf000372_0001
Skin penetration
The skin penetration/permeation properties of two representative compounds of the present invention were tested as follows.
In vitro test to determine skin penetration and permeation properties
The compounds were applied as 0.5% solutions in propylene glycol to pig skin mounted in static Franz-type diffusion cells At the end of a 48 hours exposure time, drug concentrations were measured in the skin (after removal of stratum corneum) and in the receiver
Skin penetration and permeation in vitro
Example Skin Formulation Concentration Skin Permeation [%] concentration rate
WQ) [ng/cm?/hr]
84 1 Pig+ PG 0 5 6 4 ± 3 5 < 0 4
Figure imgf000372_0002
58 1 Pig* PG 0 5 9.3 ± 6 2 0 5 ± 0 3
Mean ± standard deviation of triplicate determinations are given, -»■ skin from 4 months old farm pigs (Landrace X Deursches Edelschwein) PG propylene glycol
In conclusion, both examples penetrate well into pig skin (pig skin is similar to human skin regarding barrier function and architecture) in vitro, while permeation rate through pig skin is low, indicating a low systemic exposure.
In vivo test to determine penetration into dermis of topically treated pigs
Small skin areas (4cm?) on the dorsolateral back of young domestic pigs were treated topically with 0 5% solutions at different time intervals (1- 8 hrs) prior to drug level determination Skin flaps with the treated sites in the centre were dissected and removed. The skin flaps were spread, and heated metal blocks placed on the test sites for 1 minute to indυce separation of epidermis from the dermis. After removal of the loosened epidermal sheets, 1 mm thtck dermal sheets were prepared from the treated, de-epidermized skin with a dermatome. From these sheets 6mm punch samples (6 mm 0) were collected and analysed for test compound concentration by LC/MS The procedure described was done with careful avoidance of contamination of the dermal samples with compound attached superficially to the epidermis
The following table provides AUC values of the agents of the invention in pig dermis when applied epicutaneously in the identified compositions (n=8)
Skin PK in vivo
Example Dermis Formulation Concentration AUC (0«8h) (%] [μg*h/g]
84 1 Pig PG/EtOH 7 3 0 5 2 8 ± 1 0 68 1 PM PG/EtOH 7 3 0 5 3 7 ± 1 3
Mean ± standard error mean of eight determinations are given PG propylene glycol
Figure imgf000373_0001
EtOH. ethanol
AUC means area under the curve, and is a well known term in clinical pharmacology The AUC value describes the total uptake of the agent in a time interval
In conclusion, both examples penetrate well into pig skin in vivo after a single application, confirming in vitro data described above
Biological activity
The efficacy of the compounds of formula I and salts thereof as PI3 kinase inhibitors can be demonstrated as follows'
The kinase reaction is performed in a final volume of 50 μL per well of a half area COSTAR, 96 well plate. The final concentrations of ATP and phosphatidyl inositol in the assay are 5 μM and 6 μg/mL respectively The reaction is started by the addition of PI3 kinase, e g PI3 kinase
p110β The components of the assay are added per well as follows
• 10 μL test compound in 5% DMSO per well in columns 2-1
• Total activity is determined by addition 10 μL of 5% vol/vol DMSO in the first 4 wells of column 1 and the last 4 wells of column 12 • The background is determined by addition of 10 μM control compound to the fast 4 wells of column 1 and the first 4 wells of column 12.
• 2 mL 'Assay mix' are prepared per plate
1 912 mL of HEPES assay buffer
8.33 μL of 3 mM stock of ATP giving a final concentration of 5 μM per well
1 μL of I33P]ATP on the activity date giving 0 05 μCi per well
30 μL of 1 mg/mL Pl stock giving a final concentration of 6 μg/mL per well
5 μL of 1 M stock MgCI2 giving a final concentration of 1 mM per well » 20 μL of the assay mix are added per well.
» 2 mL Enzyme mix' are prepared per plate (x* μL PI3 kinase p110i in 2 mL of kinase buffer). The Εnzyme mix' is kept on ice during addition to the assay plates.
• 20 μl Εnzyme mix' are added/well to start the reaction
• The plate is then incubated at room temperature for 90 minutes
• The reaction is terminated by the addition of 50 L WGA-SPA bead (wheat germ agglutinin-coated Scintillation Proximity Assay beads) suspension per well
• The assay plate is sealed using TopSea!-S )heat seal for polystyrene microptates, PerkinElmer LAS (Deutschland) GmbH, Rodgau, Germany) and incubated at room temperature for at least 60 minutes
• The assay plate is then centrifuged at 1500 rpm for 2 minutes using the Jouan bench top centnfuge (Jouan lnc , Nantes, France)
• The assay plate is counted using a Packard TopCount each well being counted for 20 seconds.
* The volume of enzyme is dependent on the enzymatic activity of the batch in use
In a more preferred assay, the kinase reaction is performed in a final volume of 10 μL per well of a low volume non binding CORNING, 384 well black plate (Cat No. #3676). The final concentrations of ATP and phosphatidyl inositol (Pl) in the assay are 1 μM and 10 μg/mL respectively. The reaction Is started by the addition of ATP
The components of the assay are added per well as follows
50 nL test compounds in 90% DMSO per well, in columns 1-20, 8 concentrations (1/3 and 1/3.33 serial dilution step) in single • Low control : 50 nL of 90% DMSO in half the wells of columns 23-24 (0.45% in final).
• High control 50 nL of reference compound (e g. compound of Example 7 in WO 2006/122806) in the other half of columns 23-24 (2 5 μM in final).
• Standard • 50 nL of reference compound as just mentioned diluted as the test compounds in columns 21-22
• 20 ml 'buffer' are prepared per assay
200 μL of 1M TRIS HCI pH7 5 (10 mM in final)
60 μL of 1M MgCI2 (3 mM in final)
500 μL of 2M NaCI (50 mM in final)
100 μL of 10% CHAPS (0 05% in final)
200 μL of 10OmM DTT (1mM in final)
18.94 mL of nanopure water
• 10 mL 1Pf are prepared per assay •
200 μL of 1mg/m! L-alpha-Phosphatidylinositol (Liver Bovine, Avanti Polar Lipids Cat No. 840042C MW=909 12) prepared in 3% OctylGlucoside (10 μg/ml in final)
9 8 mL of buffer'
• 10 mL 'ATP' are prepared per assay
6.7 μL of 3 mM stock of ATP giving a final concentration of 1 μM per well
1O mL of "buffer'
• 2 5 mL of each PI3K construct are prepared per assay in 'Pl' with the following final concentration
10 nM PI3K alfa EMV B1075 25 nM beta EMV BV949 1O nM delta EMV BV1060 150 nM gamma EMV BV950
• 5 μL of 'PI/PI3K' are added per well
• 5 μl 1ATP' are added per well to start the reaction • The plates are then incubated at room temperature for 60 minutes (alfa, beta, delta) or 120 minutes (gamma)
• The reaction is terminated by the addition of 10 μL Kinase-Glo (Promega Cat No #6714)
• The assay plates are read after 10 minutes in Synergy 2 reader (BioTek, Vermont USA) with an integration time of 100 milliseconds and sensitivity set to 191
• Output The High control ts around 60'QOO counts and the Low control is 30'0OO or lower
• This luminescence assay gives a useful Z' ratio between 0.4 and 0 7
The Z1 value is a universal measurement of the robustness of an assay A Z' between 0 5 and 1 0 is considered an excellent assay
For this assay, the PI3K constructs mentioned are prepared as follows
MOLECULAR BIOLOGY
Two different constructs, BV 1052 and BV 1075, are used to generate the Pf 3 Kinase « proteins for compound screening
PI3Kα BV-1052 P85(ISH2)-GIV Iinker-p110a(D20aa)-C-term His taα
PCR products for the inter SH2 domain (iSH2) of the p85 subunit and for the p110-a subunit (with a deletion of the first 20 amino acids) are generated and fused by overlapping PCR
The iSH2 PCR product is generated from first strand cDNA using initially primers
gwG13O-pO1 (5'-CGAGAAT ATGATAGATTATATGAAGAAT-S1) (SEQ ID NO' 1) and gwG13O-pO2 (S'-TGGTTT-AATGCTGTTCATACGTTTGTCAAT-S') (SEQ ID NO 2) Subsequently in a secondary PCR reaction, Gateway (Invitrogen AG Basel, Switzerland) recombination AttB1 sites and linker sequences are added at the 5'end and 3'end of the p85 iSH2 fragment respectively, using primers
gwG130-p03 (5 - GGGACAAGTTTGTACAAAAAAGCAGGCTACGAAGGAGATATACATAT- GCGAGAATATGATAGATTATATGAAGAAT -3') (SEQ ID NO" 3) and
gwG152-pO4 (5'- TACCATAATTCCACCACCACCACCGGAAATTCCCCCTGGTTT- AATGCTGTTCATACGTTTGTCAAT-3 ) (SEQ ID NO 4)
The p110-a fragment is also generated from first strand cDNA, initially using primers gwG152-pO1 (51- CTAGTGGAATGTTTACTACCAAATGG-3') (SEQ ID NO 5) and gwG152-pO2 (51- GTTCMTG-CATGCTGTTTAATTGTGT -31) (SEQ ID NO: 6)
In a subsequent PCR reaction, linker sequence and a Histidine tag are added at the 5'end and 3'end of the p110-a fragment respectively, using primers
gw152-pO3 (δ'-GGGGGAATTTCCGGTGGTGGTGGTGGAATTATGGTAC- TAGTGGAATGTTTACTACC-AAATGGA-31) (SEQ ID NO 7) and
gwG152-pO6 (5 -AGCTCCGTGATGGTGATGGTGATGTGCTCCGTTCAATG- CATGCTGTTTAATTGTGT-3') (SEQ ID NO 8)
The p85-iSH2/p110~a fusion protein is assembled in a third PCR reaction by the overlapping linkers at the 3'end of the iSH2 fragment and the 5'end of the p110-a fragment, using the above mentioned gwG13O-pO3 pnmer and a primer containing an overlapping Histidine tag and the AttB2 recombination sequences
(5'-GGGACCACTTTGTACAAGAAAGCTGGGTTTAAGCTCCGTGATGGTGATGGTGAT- GTGCTCC-31) (SEQ ID NO' 9).
This final product is recombined in a (Invitrogen) OR reaction into the donor vector pDONR201 to generate the ORF318 entry done. This clone is verified by sequencing and used in a Gateway LR reaction to transfer the insert into the Gateway adapted pBlueBac4.5 (Invitrogen) vector for generation of the baculovirus expression vector LR410
PI3Kα BV-1075 p85(iSH2)-12 XGIv Iinker-p110a(D20aa)-C-term His tao
The construct for Baculovirus BV-1075 is generated by a three-part ligation comprised of a p85 fragment and a p110-a fragment cloned into vector pBlυeBac4 5 The p85 fragment is derived from plasmid p1661~2 digested wtth Nhe/Spe The p110-a fragment derived from LR410 (see above) as a Spel/Hindlll fragment The cloning vector pBlueBac4 5 (Invitrogen) is digested with Nhe/Hindlll This results in the construct PED 153 8
The p85 component (iSH2) is generated by PCR using ORF 318 (described above) as a template and one forward primer
KAC1028 (51- GCTAGCATGCGAGAATATGATAGATTATATGAAGAATATACC) (SEQ ID NO 10) and two reverse primers,
KAC1029 (5'- GCCTCCACCACCTCCGCCTGGTTTAATGCTGTTCATACGTTTGTC) (SEQ ID NO: 11) and
KAC1039 (5'-TACTAGTCCGCCTCCACCACCTCCGCCTCCACCACCTCCGCC)
(SEQ ID NO. 12)
The two reverse primers overlap and incorporate the 12x Gly Nnker and the N-terminal sequence of the p110a gene to the Spel site. The 12x Gly linker replaces the linker in the BV1052 construct The PCR fragment is cloned into pCR2 1 TOPO (Invitrogen). Of the resulting clones, p1661-2 ts determined to be correct This plasmid is digested with Nhe and Spel and the resulting fragment is gel-isolated and punfied for sub-cloning.
The p110-a cloning fragment is generated by enzymatic digest of clone LR410 (see above) with Spe I and Hindlll The Spel site is in the coding region of the p110a gene The resulting fragment is gel-isolated and purified for sub-cloning
The cfoning vector, pBlueBac4.5 (Invitrogen) is prepared by enzymatic digestion with Nhe and Hindlll The cut vector is purified with Qiagen (Quiagen N V, Venlo, Netherlands) column and then dephosphorylated with Calf Intestine alkaline phosphatase (CIP) (New England BioLabs. Ipswich, MA) After completion of the CIP reaction the cut vector is again column purified to generate the final vector A 3 part ligation ts performed using Roche Rapid ltgase and the vendor specifications
PI3KB BV-949 p85/iSH2H3lv Imker-p11Qb(fuil-lenQthVC-term His tag
PCR products for the inter SH2 domain (iSH2) of the p85 subunit and for the full-length p1 10- b sυbunit are generated and fused by overlapping PCR
The iSH2 PCR product is generated from first strand cDNA initially using primers
gwG130-p01 (5'-CGAGAATATGATAGATTATATGAAGAAT-S') (SEQ ID NO 1) and gwG130-p02 (5'-TGGTTT-AATGCTGTTCATACGTTTGTCAAT-3•) (SEQ ID NO 2) Subsequently, in a secondary PCR reaction Gateway (Invitrogen) recombination AttB1 sites and linker sequences are added at the 5'end and 3'end of the p85 iSH2 fragment respectively, using primers
gwG13O-pO3 (5'- GGGACAAGTTTGTACAAAAAAGCAGGCTACGAAGGAGATA- TACATATGCGAGAATATGATAGATTATATGAAGAAT -3 ) (SEQ ID NO' 3) and
gwG130-p05 (5'-ACTGAAGCATCCTCCTCCTCCTCCTCCTGGTTTAAT- GCTGTTCATACGTTTGTC-3') (SEQ ID NO 13) The p110-b fragment is also generated from first strand cDNA initially using primers gwGi30-p04 (51- ATTAAACCAGGAGGAGGAGGAGGAGGATGCTTCAGTTTCATAATGCC- TCCTGCT -31) (SEQ ID NO: 4)
which contains linker sequences and the 5'end of p110-b and
gwG130-p06 (5'-AGCTCCGTGATGGTGATGGTGATGTGCTCCAGATCTGTAGTCTTT- CCGAACTGTGTG -3') (SEQ ID NO: 14)
which contains sequences of the 3'end of p110-b fused to a Histidine tag
The p85-iSH2/p1 10-b fusion protein is assembled by an overlapping PCR a reaction of the linkers at the 3'end of the tSH2 fragment and the 5'end of the p110-b fragment, using the above mentioned gwG13O-pO3 primer and a primer containing an overlapping Histidine tag and the AttB2 recombination sequences (δ'-GGGACCACTTTGTACAAGAAAGCTGGGTTT- AAGCTCCGTGATGGTGATGGTGATGTGCTCC-S1) (SEQ ID NO 9)
This final product is recombined in a Gateway (Invitrogen) OR reaction into the donor vector pDONR201 to generate the ORF253 entry clone. This clone is verified by sequencing and used in a Gateway LR reaction to transfer the insert into the Gateway adapted pBlueBac4.5 (Invitrogen) vector for generation of the baculovirus expression vector LR280
PI3K5 BV-1060 pe5(iSH2)-Glv Imker-p110d(fuU-lenαthVC-term His taα
PCR products for the inter SH2 domain (iSH2) of the p86 subunit and for the full-length p110- d subunit are generated and fused by overlapping PCR
The iSH2 PCR product is generated from first strand cDNA using initially primers
gwG130-p01 (S'-CGAGAATATGATAGATTATATGAAGAAT-S') (SEQ ID NO' 1) and gwG130-p02 (5'-TGGm-AATGCTGTTCATACGTTTGTCAAT-S1) (SEQ ID NO. 2) Subsequently, in a secondary PCR reaction Gateway (Invitrogen) recombination AttB1 sites and linker sequences are added at the 5'end and 3'end of the p85 iSH2 fragment respectively, using primers
gwG130-p03 (5'- GGGACAAGTTTGTACAAAAAAGCAGGCTACGAAGGAGAT ATACAT- ATGCGAGAATATGATAGATTATATGAAGAAT -3') (SEQ ID NO. 3) and
gwG154-pO4 (5'- TCCTCCTCCTCCTCCTCCTGGTTTAATGCTGTTCATACGTTTGTC -3') (SEQ ID NO 15) The p110-a fragment is also generated from first strand cDNA using initially primers gwG154-pO1 {51- ATGCCCCCTGGGGTGGACTGCCCCAT -3') (SEQ ID NO 16) and gwG154-pO2 (51- CTACTG-CCTGTTGTCTTTGGACACGT -3') (SEQ ID NO. 17)
In a subsequent PCR reaction linker sequences and a Histidine tag is added at the 5'end and 3'end of the p110-d fragment respectively, using primers
gw154-pO3 (5'- ATTAAACCAGGAGGAGGAGGAGGAGGACCCCCTGGGGTGGAC- TGCCCCATGGA -31) (SEQ ID NO. 18) and gwG154-pO6 (δ'-AGCTCCGTGATGGTGAT- GGTGATGTGCT-CCCTGCCTGTTGTCTTTGGACACGTTGT -3') (SEQ ID NO. 19).
The p85-iSH2/p110-d fusion protein is assembled tn a third PCR reaction by the overlapping linkers at the 3'end of the iSH2 fragment and the 5'end of the p110-d fragment, using the above mentioned gwG130-p03 pnmer and a primer containing an overlapping Histtdine tag and the Gateway (Invitrogen) AttB2 recombination sequences (δ'-GGGACCACTTTGTA- CMGAAAGCTGGGTTT-AAGCTCCGTGATGGTGATGGTGATGTGCτcC-S') (SEQ ID NO 09)
This final product is recombined in a Gateway (Invitrogen) OR reaction into the donor vector pDONR201 to generate the ORF319 entry clone. This clone is verified by sequencing and used in a Gateway LR reaction to transfer the insert into the Gateway adapted pBlueBac4.5 (Invitrogen) vector for generation of the baculovirus expression vector LR415
PI3Kv BV-950 p110α(D144aa)-C~term His tag
Thts construct is obtained from Roger Williams lab, MRC Laboratory of Molecular Biology, Cambridge, UK (November, 2003). Description of the construct in: Pacold M. E. et a). (2000) Cell 103, 931-943.
EXPRESSION
Methods to generate recombinant baculovirus and protein for PI3K isoforms.
The pBlue-Bac4.5 (for a, b, and d isoforms) or pVL1393 (for g) plasmids containing the different PI3 kinase genes are co-transfected with BaculoGold WT genomic DNA (BD Biosciences, Franklin Lakes, NJ, USA) using methods recommended by the vendor Subsequently, the recombinant baculovirus obtained from the transfection is plaque-purified on Sf9 insect cells to yield several isolates expressing recombinant protein Positive clones are selected by anti-HIS or anti-isoform antibody western For PI3K alpha and delta isoforms, a secondary plaque-purtfication is performed on the first clonal virus stocks of PI3K Amplification of all baculovirus isolates is performed at low multiplicity of infection (moi) to generate high-titer, low passage stock for protein production The baculoviruses are designated BV1052 (σ) and BV1075 (α), BV949 (β), BV1060 (δ) and 8V950 <γ)
Protein production involves infection (passage 3 or lower) of suspended Tn5 (Trichoplusia nt) or TiniPro (Expression Systems, LLC, Woodland, CA, USA) celts in protein-free media at moi of 2-10 for 39-48 hours in 2L glass Erlenmyer flasks (110 rpm) or wave-bioreactors (22- 25rpm) Initially, 1OL working volume wave-bioreactors are seeded at a density of 3e5 cells/ml at half capacity (5L) The reactor is rocked at 15rpm during the ceH growth phase for 72 hours, supplemented with 5% oxygen mixed with air (0 2L per minute) Immediately prior to infection, the wave-reactor cultures are analyzed for density, viability and diluted to approximately 1 5e6 cell/mi 100-50OmI of high titer, low passage virus is added following 2- 4 hours of additional culture Oxygen is increased to 35% for the 39-48 hour infection period and rocking platform rpm increased to 25 Dunng infection, cells are monitored by Vtcell viability analyzer (Beckman Coulter Inc, Fullerton, CA, USA) bioprocess for viability, diameter and density Nova Bioanalyzer (NOVA Biomedical Corp., Waltham, MA1 USA) readings of various parameters and metabolites (pH, O2 saturation, glucose, etc ) are taken every 12-18 hours until harvest The wave-bioreactor cells are collected within 40 hours post infection Cells are collected by centrifugation (4 degrees C at 1500 rpm), and subsequently maintained on ice during pooling of pellets for lysis and punfication Pellet pools are made with small amounts of cold, un-supplemented Grace's media (w/o protease inhibitors)
PI3K aloha Purification Protocol For HTS (BV1052)
PI3K alpha is purified in three chromatographic steps immobilized metal affinity chromatography on a Ni Sepharose resin (GE Healthcare, belonging to General Etectnc Company, Fairfield, CT1 USA), gel filtration utilizing a Superdex 200 26/60 column (GE Healthcare), and finally a cation exchange step on a SP-XL column (GE Healthcare) All buffers are chilled to 4°C and lysis is performed chilled on ice Column fractionation is performed rapidly at room temperature
Typically frozen insect cells are lysed in a hypertonic lysis buffer and applied to a prepared IMAC column The resin is washed with 3-5 column volumes of lysis buffer followed by 3-5 column volumes wash buffer containing 45 mM imidazole, and the target protein is then eluted with a buffer containing 250 mM imidazole Fractions are analyzed by Coomasste stained SDS-PAGE gels, and fractions containing target protein are pooled and applied to a prepared GFC column Fractions from the GFC column are analyzed by Coomasste stained SDS-PAGE gels and fractions containing target protein are pooled The pool from the GFC column is diluted into a low salt buffer and applied to a prepared SP-XL column The column is washed with low salt buffer until a stable A280 baseline absorbance is achieved and elυted using a 20 column volume gradient from O mM NaCi to 500 mM NaCI. Again, fractions from the SP-XL column are analyzed by Coomassie stained SDS-PAGE gels, and fractions containing the target protein are pooled. The final pool is dialyzed into a storage buffer containing 50% glycerol and stored at -20°C The final pool is assayed for activity in a phosphomositito! kinase assay
PI3K beta Purification Protocol For HTS (BV949)
Pl 3K beta is purified in two chromatographic steps: immobilized metal affinity chromatography (IMAC) on a Ni Sepharose resin (GE Healthcare) and gel filtration (GFC) utilizing a Superdex 200 26/60 column (GE Healthcare) All buffers are chilled to 4*C and lysis is performed chilled on »ce Column fractionation is performed rapidly at room temperature.
Typically frozen insect cells are lysed in a hypertonic lysis buffer and applied to a prepared IMAC column The resin is washed with 3-5 column volumes of lysis buffer, followed by 3-5 column volumes wash buffer containing 45 mM imidazole, and the target protein is then eluted with a buffer containing 250 mM imidazole Fractions are analyzed by Coomassie stained SDS-PAGE gels, and fractions containing target protein are pooled and applied to a prepared GFC column. Fractions from the GFC column are analyzed by Coomassie stained SDS-PAGE gels, and fractions containing target protein are pooled The final pool is dialyzed into a storage buffer containing 50% glycerol and stored at -2O°C The final pool is assayed for activity in the phosphoinostttol kinase assay.
PI3K αamma Purification Protocol For HTS (BV950)
Pl 3K gamma is purified in two chromatographic steps immobilized metal affinity chromatography (IMAC) on a Ni Sepharose resin (GE Healthcare) and gel filtration (GFC) utilizing a Superdex 200 26/60 column (GE Healthcare) All buffers are chilled to 4°C and lysis is performed chilled on ice. Column fractionation is performed rapidly at room temperature Typically frozen insect cells are lysed in a hypertonic lysis buffer and applied to a prepared IMAC column. The resin is washed with 3-5 column volumes of lysis buffer, followed by 3-5 column volumes wash buffer containing 45 mM imidazole, and the target protein is then eluted with a buffer containing 250 mM imidazole Fractions are analyzed by Coomassie stained SDS-PAGE gels, and fractions containing target protein are pooled and applied to a prepared GFC column Fractions from the GFC column are analyzed by Coomassie stamed SDS-PAGE gels, and fractions containing target protein are pooled The final pool is dialyzed into a storage buffer containing 50% glycerol and stored at -20°C The final pool is assayed for activity in the phosphoinostitol kinase assay. PI3K delta Purification Protocol For HTS (BV1060)
PI3K delta is purified in three chromatographic steps: immobilized metal affinity chromatography on a Ni Sepharose resin (GE Healthcare), gel filtration utilizing a Sυperdex 200 26/60 column (GE Healthcare), and finally a anion exchange step on a Q-HP column (GE Healthcare). All buffers are chilled to 4°C and lysis is performed chilled on ice Column fractionation is performed rapidly at room temperature. Typically frozen insect cells are lysed in a hypertonic lysis buffer and applied to a prepared IMAC column The resin is washed with 3-5 column volumes of lysis buffer, followed by 3-5 column volumes wash buffer containing 45 mM imidazole, and the target protein is then eluted with a buffer containing 250 mM imidazole. Fractions are analyzed by Coomassie stained SDS-PAGE gels, and fractions containing the target protein are pooled and applied to a prepared GFC column. Fractions from the GFC column are analyzed by Coomassie stained SDS-PAGE gels, and fractions containing the target protein are pooled. The pool from the GFC column is diluted into a low salt buffer and applied to a prepared Q-HP column The column is washed with low salt buffer until a stable A280 baseline absorbance is achieved, and eluted using a 20 column volume gradient from 0 mM NaCI to 500 mM NaCI. Again, fractions from the Q-HP column are analyzed by Coomassie stained SDS-PAGE gels, and fractions containing the target protein are pooled The final pool is dialyzed into a storage buffer containing 50% glycerol and stored at -2O°C. The final pool is assayed for activity m the phosphoinostito! kinase assay.
IC50 is determined by a four parameter curve fitting routine that comes aloneg with "excel fit". A 4 Parameter logistic equation is used to calculate IC«) values (IDBS XLfit) of the percentage inhibition of each compound at 8 concentrations (usually 10, 3 0, 1 0, 0.3, 0 1 , 0.030,0.010 and 0.003 μM), Alternatively, IC50 values are calculated using idbsXUt model 204, which is a 4 parameter logistic model.
Yet alternatively, for an ATP depletion assay, compounds of the formula (I) to be tested are dissolved in DMSO and directly distributed into a white 384-well plate at 0 5 μL per well To start the reaction, 10 μL of 10 nM PI3 kinase and 5 μg/ml 1-alpha-phosphatidylinositol (Pl) are added into each well followed by 10 μL of 2 μM ATP. The reaction is performed until approx 50% of the ATP is depleted, and then stopped by the addition of 20 μL of Kinase-Glo solution (Promega Corp., Madison, Wl, USA) The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence ICs0 values are then determined Some of the compounds of formula (I) show a certain level of selectivity against the different paralogs PI3K alpha, beta, gamma and delta.
The range of activity, expressed as IC50, in these assays is preferably between 1 nM and 5000 nMt more preferably between 1 nM and about 1000 nM
Figure imgf000384_0001
-384 *•
Figure imgf000385_0001
Figure imgf000386_0001
Figure imgf000387_0001
Figure imgf000388_0001
Figure imgf000389_0001
Figure imgf000390_0001
Figure imgf000391_0001
Figure imgf000392_0001
Figure imgf000393_0001
Figure imgf000394_0001
Figure imgf000395_0001
Figure imgf000396_0001
Figure imgf000397_0001
Figure imgf000398_0001
Figure imgf000399_0001
Figure imgf000400_0001
The efficacy of the compounds of formula I and salts thereof as mTor kinase inhibitors can be demonstrated as follows
Biochemical assay for m-TOR by TR-FRET.
Assay components are purchased from Invitrogen Corporation (Carlsbad/CA, USA)' GFP- 4EBP1 (Cat No PV4759), Tb3+-α-p4EBP1 [pThr46] Antibody (Cat No. PV4757), proprietary TR-FRET dilution buffer (Cat. No. PV3574), mTOR protein (Cat. No PV4753)
50 nL of compound dilutions (final concentration of 10, 3 0, 1 0, 0 3, 0 1 , 0 03, 0 01 and 0.003 μM) are dispensed onto black 384-well low volume non-binding polystyrene (Cat No NBS#3676, Corning, Lowell/MA, USA) Then 5 μl_ of ATP (8 μM final concentration) and GFP-4EBP1 (400 nM final concentration) with 5 μl_ mTOR proteins (0 5 nM final concentration) are incubated at rt The standard reaction buffer for the TR-FRET mTOR assay contained 50 mM HEPES pH 7 5, 10 mM MnCI2, 50 mM NaCI, 1 mM EGTA, 1 mM DTT. Reactions were stopped with 10 μL of a mixture of EDTA containing the Tb3+-α- p4EBP1[pT46] detection Ab (0 5 nM) in TR-FRET dilution buffer (proprietary to IVG). Plates are read 15 mins later in a Synergy2 reader using an integration time of 0.2 seconds and a delay of 0 1 seconds. Control for the 100% inhibition of the kinase reaction is performed by replacing the mTOR kinase by the standard reaction buffer The control for the 0% inhibition is given by the solvent vehicle of the compounds (90% DMSO in H2O) A standard compound is used as a reference compound and included in all assay plates in the form of 16 dilution points in duplicate
The range of activity, expressed as IC501 in this assay is preferably between 1 nM and 5000 nM, more preferably between 1 nM and about 1000 nM
Figure imgf000401_0001
Figure imgf000402_0001
Figure imgf000403_0001
Figure imgf000404_0001
Figure imgf000405_0001
The efficacy of the compounds of the invention in blocking the activation of the PI3K/PKB pathway was demonstrated in cellular settings using a reverse protein array assay for sensitive quantification of compound of formula I mediated inhibition of PKB Ser473 phosphorylation in Rat1 cells stably transfected with activated versions of Pl3-kinase isoforms alpha, beta or delta- Ce(Is and cell culture conditions:
Rat1 cell lines stably expressing a myr-HA-tagged, constitutively active sυbunit of the catalytic PI3K class I p110 isoform α, β or δ (addition of a myπstylation signal at the N- terminus of pHO isoforms has been shown to lead to constitutive activation of PI3K and corresponding downstream signals, such as phosphorylation of PKB at Ser473) were cultivated in Dulbecco's modified Eagle's medium (DMEM high Glucose, GIBCO, cat. No 41956-039) supplemented with 10% heat inactivated fetal bovine calf serum (Amimed, cat No 2-01 F16-I), 1% L-Glutamine (Invitrogen, cat No 25030-02), 1% penicillin-streptomycin (GIBCO, cat. No 15140-114) and 10 μg/ml Puromycine (Sigma, cat. No P9620)
Compound treatment of cells and preparation of samples:
The Rat1-myr-HA-p110 alpha, beta and delta cells were trypsinized and counted with a CASY TT cell counter (Schϋrfe System GmbH, Reutlingen Germany) The cells were d/luted in fresh OMEM complete medium and 3x104ce)ls/150μl/well seeded in 96-well TPP-tissue culture plates (TPP, cat. No 92096). The pJates were incubated at 37 °C and 5% CO2 under humidified condition for at least 20 h Compound of formula I working solutions were prepared freshly as serial 8 step dilutions (vol/vol) in DMSO on the day of the experiment The working solutions were further diluted 1/500 tn eel) culture medium to get final compound concentrations of 10, 3 333, 1 111 , 0.370 0 123. 0 041 , 0.014, 0.005 μM The final DMSO concentration was kept constant at 0 2% cell culture medium containing 0 2% DMSO was used as vehicle treatment control Post incubation, the cells were treated with the serial compound dilution 50 μl of the compound medium mixture was added to the wells containing cells and 150 μl DMEM medium and incubated for 30 minutes (37 °C, 5% CO2) After 30 minutes of incubation, the medium mixture was quickly removed by aspiration For cell lysis, a mixture of 10% CLB1 CeLyA lysis buffer (Zeptosens, cat No. 9000), 90% CSBL1 CeLyA spotting buffer (Zeptosens, cat No 9020) was freshly prepared and supplemented with 1% Octyl β-D-glucopyranoside (SIGMA, cat. No 0Θ001-5G) and 1 mM Na-Crthovanadate (Sigma cat No S-6508) 50 μl of the described lysts buffer mix was added to each well, followed by 10 minutes of incubation on ice After an additional freeze-thaw cycle, another 50 μl of the lysis buffer mix without Octyl β-D-glυcopyranoside was added to the wells, and 90 μl of the cell lysate was transferred to a 96-well V-bottom plate (Fisher Scientific, cat No 6067Y), followed by a centrtfυgation step (5 mm, 1500 rpm at 19 °C in an Eppendorf 5810R centrifuge) to remove the unlysed cell debris
Spotting of the ZeptoMARK® chips: The samples were spotted onto ZeptoMARK® PWG protein micfoarray chips (Zeptosens, Witterswil. Switzerland) with the piezoelectric microdispense-based, non-contact Nano- Plotter 2 1 (GeSiM, Grosserkmannsdσrf, Germany) Each sample was spotted at 4 different sample concentrations (d1= 100%, d2= 75%, d3= 50%, d4= 25%) by diluting the cell lysate with the corresponding volume of lysis buffer mix After spotting the ZeptoMARK® protein microarrays, the chips are incubated for 1 hour at 37°C. To receive a uniform blocking result, the CeLyA blocking buffer BB1 (Zeptosens, cat No. 9040) is administered via an ultrasonic nebulizer After 20 minutes of blocking the chips are extensively πnsed with deiomzed water (MiIIt-Q quality, 18MΩ x cm) and dried in a nitrogen air flow.
ZeptoREADER signal detection and data analysis:
After the sample spotting and blocking procedure, the ZeptoMARK® chips were transferred to the ZeptoCARRIER (Zeptosens, cat. No 1100), whose six flow cells individually address the six arrays on a chfp, and washed twice with 200 μl CAB1 CeLyA assay buffer (Zeptosens, cat No 9032) The assay buffer was then aspirated and each compartment incubated with 100 μl of the primary target antibody (pAkt Ser473; CST#9271) at RT over night Post incubation, the pnmary antibody was removed, the arrays washed twice with CAB1 buffer and further incubated with 100 μl of Alexa fluor 647-labeled anti rabbit IgG Fab fragments (Invitrogen, #Z25305) for one hour at RT in the dark After incubation, the arrays were washed twice with 200 μl CAB1 buffer The fluorescence of the target-bound Fab fragments is read out on the ZeptoReader (Zeptosens, Witterswi), Switzerland) using a laser (excitation wavelength 635 nm) and a CCD camera. The fluorescence signal was assessed with exposure times of 1, 3, 5 and 10 seconds, depending on the intensity of the signal. The resulting four images taken per array are stored as 16-bit TIF files
The fluorescence images for each array were analyzed with the ZeptoVIEW Pro 2.0 software (Zeptosens, Witterswil Switzerland) and the relative fluorescence intensity for each signal was calculated. The range of activity, expressed as ICbo. in this assay is preferably between about 1 nM and about 10 μM, more preferably between about 1 nM and about 1 μM
Rat1-myr-p110 alpha
Figure imgf000407_0001
-407-
Figure imgf000408_0001
Figure imgf000409_0001
Figure imgf000410_0001
Figure imgf000411_0001
Figure imgf000412_0001
Rat1-myr-p110beta
Figure imgf000412_0002
Figure imgf000413_0001
Figure imgf000414_0001
Figure imgf000415_0001
Figure imgf000416_0001
Rat1-myr-p110 delta
Figure imgf000416_0002
Figure imgf000417_0001
Figure imgf000418_0001
Figure imgf000419_0001
Figure imgf000420_0001
Figure imgf000421_0001
The efficacy of the compounds of the invention in displaying an inhibitory effect downstream of mTORC1 complex (mTOR/raptor) was demonstrated in cellular setting using a reverse protein array assay for sensitive quantification of drug-mediated inhibition of S6 Ribosomal Protein phosphorylation Ser235/236 in TSC 1 null mouse embryo fibroblast (MEF) cells .
QeIIs and cell culture conditions,
TSC1-/- MEFs cells (provided by D Kwialkowski), were cultivated in Dυlbeccovs modified Eagle s medium (DMEM high Glucose, GI8CO, cat. No 41956-039) supplemented with 10% heat inactivated fetal bovine calf serum (Amimed, cat. No 2-01F16-I). 1% L-Glutamine (Invitrogen, cat. No 25030-02), 1% penicillin-streptomycin (GIBCO. cat No. 15140-114) at 37°C in a 5% CO2 and 95% relative humidity atmosphere incubator
Treatment of cells and preparation of samples.
The TSC 1-/- cells were trypsmized and counted with a CASY TT cell counter (Scharfe System GmbH, Reutlingen Germany) The cells were diluted in fresh DMEM complete medium and 0.75x104 cells/150μt/well seeded in 96-well TPP-tissue culture plates (TPP, cat No. 92096). The plates were incubated at 37 °C and 5% CO2 under humidified condition for at least 2Oh. Working solutions were prepared freshly as serial 8 step dilutions (vol/vol) tn DMSO on the day of the experiment The working solutions were further diluted 1/5000 in cell culture medium to get final compound concentrations of 1 , 0.3333. 0.11 11 , 0.037, 0.0123. 0.041, 0.0014, 0 005 μM. The final DMSO concentration was kept constant at 0 02% cell culture medium containing 0.02% DMSO was used as vehicle treatment control Post incubation, the cells were treated with the serial compound dilution 50 μl of the compound medium mixture was added to the wells containing cells and 150 μl DMEM medium and incubated for 60 minutes (37 °C1 5% CO2) After 60 minutes of incubation, the medium mixture was quickly removed by aspiration For cell lysis, a mixture of 10% CLB1 CeLyA lysis buffer (Zeptosens, cat No. 9000), 90% CSBL1 CeLyA spotting buffer (Zeptosens, cat No 9020) was freshly prepared and supplemented with 1% Octyl β-D-glucopyranoside (SIGMA, cat No 08001 -5G) and 1 mM Na-Orthovanadate (Sigma, cat No S-6508) 50 μl of the descπbed lysis buffer mix was added to each well, followed by 10 minutes of incubation on ice. After an additional freeze-thaw cycle, another 50 μl of the lysis buffer mix without Octyl β- D-glυcopyranoside was added to the wells, and 90 μl of the cell lysate was transferred to a 96-well V-bottom plate (Fisher Scientific, cat No 6067Y), followed by a centrifugation step (5 min, 1500 rpm at 19 °C in an Eppendorf 5810R centrifuge) to remove the unlysed ceil debris
Spotting of the ZeotoMARK® chips
The spotting of the chips follows the previous described method
ZeptoREADER signal detection and data analysts.
The signal detection and the data analysis follows the previous described method using the pS6 ribosomal protein Ser235/ 236 (CST, cat No #2211) as a primary antibody
The range of activity, expressed as IC.o. m this assay is preferably between about 0.1 nM and about 1 μM, more preferably between about 0 1 nM and about 0 5 μM
Figure imgf000422_0001
- 422-
Figure imgf000423_0001
Figure imgf000424_0001
Figure imgf000425_0001
Figure imgf000426_0001
There are also experiments to demonstrate the antitumor activity of compounds of the formula (I) in vivo.
For example, female Harlan (Indianapolis, Indiana, USA) athymic nu/nu mice with s c transplanted human glioblastoma U87MG tumors can be used to determine the anti-tumor activity of Pf 3 kinase inhibitors. On day 0, with the animals under peroral Forene® (1-chforo- 2,2,2-trifluoroethyldifluormethylether, Abbot, Wiesbaden, Germany) narcosis, a tumor fragment of approximately 25 mg is placed under the skin on the animals' left flank and the small incised wound is closed by means of suture clips When tumors reach a volume of 100 mm3, the mice are divided at random into groups of 6-8 animals and treatment commences The treatment is earned out for a 2-3 weeks period with peroral, intravenous or intra-peritoneal administration once daily (or less frequently) of a compound of formula (I) in a suitable vehicle at defined doses The tumors are measured twice a week with a slide gauge and the volume of the tumors is calculated.
As an alternative to cell line U87MG, other cell lines may also be used in the same manner, for example,
• the MDA-MB 468 breast adenocarcinoma cell line (ATCC No. HTB 132, see also In Vitro 14, 911-15 [1978J);
• the MDA-MB 231 breast carcinoma cell line (ATCC No. HTB-26, see also In Vitro 12, 331 [1976]);
• the MDA-MB 453 breast carcinoma cell line (ATCC No.HTB-131 ),
• the Colo 205 colon carcinoma cell line (ATCC No CCL 222; see also Cancer Res 38, 1345-55 (1978]),
• the DU145 prostate carcinoma cell line DU 145 (ATCC No HTB 81; see also Cancer Res 3Z, 4049-58 (1978)),
• the PC-3 prostate carcinoma cell line PC-3 (especially preferred, ATCC No. CRL 1435- see also Cancer Res 40, 524-34 [198O)) and the PC-3M prostate carcinoma cell line,
• the A549 human lung adenocarcinoma (ATCC No CCL 185- see also lnt J. Cancer 17, 62-70 [1976]),
• the NCI-H596 cell line (ATCC No. HTB 178, see also Science 246, 491-4 {1989)),
• the pancreatic cancer cell line SUIT-2 (see Tomioka et al , Cancer Res 61, 7518- 24 [2001])

Claims

What is claimed is
A compound of the formula (I)
Figure imgf000428_0001
(I), wherein
X is O or S;
Y is CH or N,
R1 is a substituted or unsubstituted 5-membered heteroaryl,
R2 is hydrogen,CrC4alkyl or d-C^alkenyl,
Ra re a substituted or unsubstituted aryl or heterocyclyl, and
R4, R5 and R6 are hydrogen, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof
2 A compound according to Claim 1 , wherein
R1 Is selected from pyrazotyl, thienyl, furyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadtazolyl, trtezolyl, imidazolyl, tetrazolyl or thiadiazolyl, each of which is independently unsubstituted or substituted with one, two or three substrtυents independently selected from the group consisting of lower alkyl, halo, halo-lower alkyl, hydroxy, carboxy, lower alkoxy, aryt-lower alkyl aryl-lower alkoxy, lower alkanoyloxy, lower alkanoyl, hydroxy-lower alkyl; alkoxy lower alkyl, hydroxy lower alkoxy, amino, mono- or di-substituted amino, cyclic ammo, ammo-lower alkyl, alkylamino-lower alkandψl, dialkylamino-lower alkandiyl, ΛΛIower alkylamino; N,N-di-k>wer alkylamino, amino lower alkoxy, lower afkanoylamino tower alkanoyl- lower alkyl-amino, benzoylamino; carbamoyl-lower alkoxy, N-lower alkylcarbamoyWower alkoxy or N,N-di~!ower alkylcarbamoyl-lower alkoxy, amidino, N- hydroxy-amidino, hydroxylamine, aikoxyamino, nitro, guanidino, amidino-lower alkyl; N-hydroxyamidino-lower alkyl, carboxy, lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl, lower alkanoyl, sulfo, lower alkanesulfonyl, sulfonamide (NH2-S(O)?-), dioxolo, phosphono (-PO=O)(OH)2), hydroxy-lower alkoxy phosphoryl or di-lower alkoxyphosphoryl, carbamoyl, mono- or di-lower alkylcarbamoyl, carbamoyl lower alkyl, sυlfamoyl, sulfamide, mono- or di-lower alkylaminosulfonyl. lower alkanesulfonylamino, lower alkanesulfonyl- lower alkyl-amino, cyano, cyano-lower alkyl, C6-Ci6 aryl, where C6-C16 aryl is unsubstituted or substituted with any of the substrtuents defined above, amino-carbonyl-fower alkyl, heterocyclyl, heterocyclyl- lower alkyl, heterocyclyl-tower alkoxy or heterocyclyl-lower alkanesυtfanyl, wherein the heterocyclyl is a substituted or unsubstituted 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, C3-Ciocycloalkyl, hydroxyCr C8cycloalkyl, heteroaryl with 4 or 6 ring atoms and 1-4 ring heteroatoms selected from O, N and S, -NR6R6, wherein R8 and R9 can be the same or different and are independently H, lower alkyl or lower cycloalkyl, or the R« and R9 can, with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, and
R3 is unsubstituted phenyl, or phenyl substituted with one or two groups independently selected from the group consisting of halo, halo-lower alkyl, hydroxyl; amino, mono or disubstituted amino, cyclic amino, ammo-lower alkyl, lower alkoxy hydroxy-lower alkyl, hydroxy lower alkoxy; lower alkyl, cyano, cyano-lower alkyl, amidino, N- hydroxyamidtno, amidino-lower alkyl, or N-hydroxyamidino-lower alkyl, sulfonyl, alkyl-substitυted sulfonyl, sulfonamide, pyrrolidinesulfonyl, lower alkyl sulfonyl amino, lower alkyl sulfonylalkandiylamino, lower alkylsulfonyl-N-lower alkylamino, [1 ,3]dioxolo, halo-substituted [1,3]dioxolo, alkoxy carbonyl, carbamoyl, substituted carbamoyl, heterocycle, heterocyclyl lower alkyl heteroaryl or heteroaryl lower alkyl, or
R3 is indolyl, 1-methyl-2,3-dihydro-1 H-indolyl 2-oxo-2,3'dihydro-1H~mdolyl, pyridyl pyrimidinyl, 1H-pyrrolo[2,3-blpyridinyl, 1 -methyl- 1H-pyrrolo[2 3-b]pyndinyl, pyrazolyl, pyrazinyl, quinolyl 1 S-Dfmethy^-oxo^.S-dihydro-1H-imidazoKδ-bjpyπdinyl, 1- ethyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo(4 5-b]pyridinyl 1-(2-methoxy-ethyl)-3- methyl-2-oxo-2,3-dihydro-1 H-imidazo(4 5-b]pyridmyl 2-Dimethylamino-3-methyl-3H- imidazo(4,5-b)pyridinyl, 2-methoxy-3-methyl~3H-tmidazo[4,5-b]pyndinyl, 3-methyl- 3H-[1 213Jtria2Olo[4,5-b)pyndinyl, 2,3-Dimethyl-3H-imidazo{415-b]pyridinyl, 3-methyl- 3H-imtdazo[4,5-b]pyπdinyl, 1 H-pyrrolo[3 2-b]pyridinyl, 1-methyl-1H-pyrrok>|:3,2- b)pyπdinyl 1-methyl-2-oxo-1 ,4-dihydro-2H-pyπdo[2,3-d][1 ,3]oxazinyl, 4-methyl-3,4- dihydro-2H-pyπdo{3,2-b][1 ,4]oxazinyl, 1 3,3-tnmethyl-2-oxo-2 3-dihydro-1H- pyrrolo[2,3-b]pyridinyl and 1 -ethyl-2-oxo-1 ,4-dihydro-2H-pyrido[3,2~d](1 ,3]oxazinyl each of these heterocycle radicals being unsubstituted or substituted by one to two radicals selected from the group consisting of halo, halo-lower alkyl, hydroxyl amino, mono or disubstituted amino, cyclic amino substituted cyclic amino, ammo-lower alkyl, alkylamino-lower alkyl, dialkylamino-loweralkyl, cycloalkylaminoalkyl, dicycloalkylaminoalkyl; alkylcycloalkytøminoaJkyl; lower alkoxy; cycfoalkoxy, lower- alkoxyalkyl: hydroxy-lower alkyl; hydroxy lower cycloalkyl; hydroxy lower alkoxy; alkoxy lower alkoxy, lower alkyl: cyano, cyano-iower alkyl, cyano lower cycloalkyl; amidino; A/-hydroxyamidino, amidino-lower alkyl, N-hydroxyamidino-lower alkyl; nitro; carboxylic acid; substituted sulfonyl; sulfonamide, alkylsulfonylamino, alkylsulfonylalkyiamino; acylamino; acyl alkyl amino; alkylcarbonylaminoalkyl, alkylaminocarbonylalkyl; aJkylcarbonyl-N-alkylamino; [1 ,3]dioxolo; substituted [1,3}dioxolo, alkoxy carbonyl, carbamoyl: substituted carbamoyl; 1 H-tetrazolyl; pyrazol' imidazole, triazole, azetidinyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, ethylpiperazinyl; triazojonyl; methylimidazolyl or morpholino, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof
3. A compound according to Claim 1 or Claim 2, wherein
R1 is unsubstituted or substituted pyrazolyl or unsubstitυted or substituted isoxazolyl, wherein said substituted pyrazolyl is substituted by one, two or three substituents and said substituted isoxazolyl is substituted by one or two substituents, wherein said substituents are independently selected from the group consisting of. halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted lower alkoxy, unsubstituted or substituted lower alkylamirto unsubstituted or substituted alkoxy lower alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted carbamoyl lower alkyl, lower mono- and di- alkyl carbamoyl lower alkyl, unsubstituted or substituted cycloaminocarbonyl lower alkyl, unsubstituted or substituted heterocydylcarbonyl lower alkyl unsubstituted or substituted hydroxyl lower aikyi, unsubstituted or substituted carboxy lower alkyl, halo-loweralkyl, hydroxycarbonyl- loweralkyl, morpholinecarbonylalkyl, hydroxy or amino, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof
4 A compound according to claim 3 or claim 4, wherein satd substituted pyrazolyl is substituted with one, two or three substituents, at least one of which ts in the alpha-position, independently selected from
halo, lower alkyl, lower alkenyl, lower alkynyl, cycloioweralkyl, hydroxy, amino, halo lower alkyl, 2-hydroxyethyl, methoxyethyl, hydroxycarbonylmethy! (HOC(O)CH?-), dialkylaminocarbonylmethyl, (methoxyethyl)(methyl)aminocarbonylmethylmethyl ((MeOEt)(Me)NC(O)CH2-), azettdinylcarbonylmethyl, morpholinecarbonylmethyl, (4- methylpiperazin-1yl)cart>onylmethyl,
and wherein said substituted isoxazolyl is substituted by one or two, same or different, unsubstitυted lower alkyl sυbstituents, at least one of which is in the alpha- position,
or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
5 A compound according to any one of Claims 1 to 4, wherein
R1 is a group selected from:
or
Figure imgf000431_0001
Figure imgf000431_0002
(A) (B)
wherein, the curved line indicates the bonding position to the rest of the molecule of formula (I) and the alpha position is shown by the atoms labeled with a * symbol, and
Rt0 is C,-C4alkyl,
R11 is hydrogen or CrC4alkyl or ftuoroCrC4alkyl,
R12 is hydrogen or CrC4alkyl,
R13 ts hydrogen or d-C4a!kyl;
R14 is Ci-C4aikyl, 2-hydroxyethyt, methoxyethyl, hydroxycarbonylmethyl (HOC(O)CHr), dimeihylaminocarbonylmethyl (Me2NC(O)CHr). ethylmethylaminocarbonylmethyl (EtMeNC(O)CH2-). (methoxyethyl)(methyl) aminocarbonyimethylmethyl ((MeOEt)(Me)NC(O)CH2-) 2-azetidin-1-yl-2-oxo-ethyl, 4- morphσlinecarbonylmethyl and (4-methylp!perazin-1yl)carbonylmethyl; and R1S is methyl or chloro,
or R1 is a group of formula (AB)
Figure imgf000432_0001
(AB)
wherein, the curved line indicates the bonding position to the rest of the molecule of formula (I) and the alpha position is shown by the atoms labeled with a * symbol, and
R1β and R17 are independently selected from same or different, unsubstituted CrC4a)kyl, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof
6 A compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof according to any preceding claim wherein R1, is selected from the group,
i .δ-dtmethyl-1H-pyrazoM-yl, 2-ethyl-2H-pyrazol-3-yl, 2-methyl-2H-pyrazol-3-yl, 2 5-dimethyl- 2H-pyrazoJ-3-yl, 1-isopropyl-3-methyl-1H-pyrazol-4-yl, 1-ethyl-3-methyl-1 H-pyrazol-4-yl, 2,4- dimethyl-2H-pyrazol-3-yl, 1,3-dimethyl-1 H-pyrazol-4-yl, 1,3,5-trimethyl-1H-ρyrazol-4-yl, 2- methyl-5-triflυoromethyl-2H-pyrazol-3-yl, 1 -hydroxycarbonyl methyl-3-methyl-pyrazol-4-yl, 1 -dimethylaminocarbonylmethyl-S-methyl-pyrazoM-yl 1 - dimethylaminocarbonylmethyl-S.S-dimethyl-pyrazoM-yl, i-diethylaminocarbonylmethyl-3- methyl-pyrazol-4-yl, 1-{2-hydroxyethyl)-3-methyl-pyrazol-4-yl, 1-(2-azetidin-1-yl-2-oxo-ethyl)- 3-methyl-1 H-pyrazol-4-yl 1-(4-morpholin)-carbonylmethyl-3-methyl-pyrazol-4-yl, 3-methyl-1- [2-(4-methyl-piperazin-1 -yl)-2-oxo-ethyl]-1 H-pyrazol-4-yl, 1 -methyl-3-chloro-pyrazol-4-yl, 1 -(2- methoxyethyl)-3 5-dimethyl-pyrazol-4-yl and i-N-ethyl-N-methylaminocarbonylmethyl-S- methyl-pyrazol-4-yl or 3,5-d(methyl-isoxazoi-4-yl
A compound according to any preceding claim wherein,
R3 is selected from phenyl, hydroxyphenyl, methoxyphenyl, 3,4-dimethoxyphenyl ethoxyphenyl, 3,4-diethoxyphenyl, iso-propoxyphenyl, methoxy ethoxy-phenyl, 3- methoxy-4-(2-methoxy ethoxy)-phenyl, fluoro-(iso-propoxy)-phenyl, 3-methoxy-4- hydroxy phenyl, fluoro-hydroxy-phenyl; hydroxy-fluoroalkyl-phenyl, 2,2-difluoro- benzo(1,3]dtoxolo; benzene sulfonamide; N.N-dimethylbenzenesulfonamide; 3- (pyrrolidine-1-sutfonyl)-phenyl; N-(phen-3-yl)-methanesulfonamide; N-methyt-N- phen-3-yl-methanesulfonamide; 3-methanesulfonylphenyl; 3- or 4-benzamide, 3- or 4-N~methyl-benzamide, 3- or 4-N,N-dimethyl-benzamide; pyrazol-phenyl; imidazol- phenyl, pyrtdyl; alkylpyπdyl; alkoxypyrtdyl; cycloaikoxypyπdyl, (haloalkoxy)pyridyl, cycloalkylalkoxypyrtdyl; alkoxyalkylpyπdyl; alkoxyalkoxypyridyi, (alkyl)(a)koxyalkoxy)pyπdyl; benzyloxyalkoxypyridyl, hydroxyalkylpyπdyl , hydroxycyctoalkylpyπdyl, hydroxyflυoroalkylpyridyl, amtnoalkylpyπdyl; alkyl-sutfonyl pyridyl' hydroxyalkoxypyrkiyl, alkoxycarbonylpyridyl; aminopyπdyl; alkylaminopyridyl; dtalkylaminopyridyl; cycloalkylaminopyridyl; (N-alkyl-N-cydoalkylamino)pyridyl; (alkyt)(ammo)ρyndyl: (halo)(amino)pyridyl, (halo)(alkylamino)pyπdyl, (halo)(dialkylamino)pyridy1; (halo)(hydroxyalkyl)pyπdyl; (alkoxy)(alkyl)pyπdyl, (alkoxy)(alkoxy)pyridyl; (alkoxy)(alkoxyalkyi)pyridyl; (alkoxy)(deuteroalkoxy- alkyl)pyridyl; (alkoxy)(hydroxyalkyl)pyridyl; (haloalkoxy)(alkyl)pyridyl, (haloalkoxy)(hydroxya!ky!)pyridyi, (alkoxyalkoxy)(hydroxyalkyl)pyridyl, (alkyl)(alkylamino)pyridyl, {alkyl)(di-alkylamino)pyridyl; cycloaminopyπdyl, cyclic ether-substituted amino-pyπdyl; hydroxy-cyctoaminopyridyl, loweralkoxy- cycfoaminopyridyl' hydroxyaikylaminopyπdyl; (a<kyl)(hydroxy)pyridyl; (hydroxyalkyi)(alkylamino)pyπdyl; (hydroxya)ky!)(amino)pyndyl, (alkoxyafkyl)(alkylamino)pyridyl, (alkoxyalkyl){am»no)pyridyl; amino-haiotoweralkyl- pyrfdyl; alkylamino-haloalkyl-pyridyl; haloalkyl-deuteroloweralkylamino-pyridyl, haloalkylpyπdinyl; cyanoalkylpyridinyl, cyanocycloalkylpyridinyl; halopyndyl; halo- alkoxy-pyπdyl; carbamoylpyrfdyl, alkyl-substituted carbamoylpyridyl; piperazinylpyrkfyl; N-alkylpiperazinylpyridyl, alkylsulfonamfdopyrrdyl, dialkylsulfonamictopyridyl, (alkylsu[fonamido)(alkyl)pyπdyl, (alky)sulfonamido)(halo)pyridyl; (alkylsulfonamidoalkyl)pyπdyl, dialkylsulfonamido(alkyl)pyridyl, 3H-tetrazol-5-yl pyπdyl; alkylcarbonylaminoalkylpyridyl, (halo)(aikylcarbonyiamino)pyridyl1 (alkoxy)(alkylcarbonylamino)pyridyl, (alkoxy)(alkylcarbonyl-N-alkylamino)pyπdyl, (alkoxy)(ni(ro)pyπdyl, (alkoxy)(cyano)pyridyl , (alkoxy)(amino)pyridyi, (alkoxy)(alkylamino)pyridy), (alkoxyalkyl)(alkylamino)pyridyl; (alkoxy)(alkylaminocarbonyl)pyridyl; (aikoxyalky!)(alkylamino)pyπdyl, (amino)(alkylaminocarbonyt)pyridyl, (amino)(alkoxyalkylaminocarbonyl)pyridyl; (alkylamino)(alky!aminocarbonyl)pyridyl, (alkoxy)(aminocarbonyl)pyridyl; <aikoxy)(hydroxycarbonyl)pyridyr morpholinylpyπdinyl; (1H-pyrazolyl)-pyridinyl, loweralkylsubstituted(1H-tmidazol-1-yi)-pyπdinyl, pyrimidmyl; di- loweralkylaminopyπmidinyl; alkoxypyrimidinyl; di-alkoxypyrimidinyl, (alkylamino)(alkoxy)pyπmtdinyl; cycloaminopyrimidinyl, aminopyrimidinyl, alkylaminopyπmidinyl; dialkylaminopyrimidinyl, 1 H -pyrrolo[2 , 3-b]py ridiny I ; 1-methyl- 1H-pyrrolo[2,3-b]pyπdinyl; pyrazinyl; pyrazolyl, hydroxyalkylpyrazolyl, 1-(2- (tetrahydro-pyran-2-yloxy)-ethyl]-1 H-pyrazolyl; quinolinyl; 2-oxo-2,3-dihydro-1 H- indol'5-yl; 1-methy!-2,3-dihydro-1H-indol-5-yi, 1H-imidazo[4,5-b)pyridtn-2(3H)-one-6- yl; 3H-imidazo(4>5-b]pyridin-6-yll (3-methyl)-3H-irnidazo[4,5~b]pyridin-6-yl; (2- methyl)-(3-methyl)-3H-imidazo[4,5-b]pyrtdin-6-yl; (2-methoxy)-(3-methyl)-3H- imidazoH.δ-bJpyπdin-β-yl, (2-dimethylamiπo)'(3-methyl)-3H-imidazo(4ι5-b]pyπdin-6- yl; 3H-[1 ,2.3]tπazolo[4,5-b)pyridin-6-yl, (3-methy!)-3H-[1.a^Jtnazoto^.S-bjpyndin-e- yl; H-pyrrok>[3,2-b)pyndin-6-yl, 1-methyl-1H-pyrrolo[3,2-b]pyridin-6'yl" 2-oxo-1 ,4- dihydro-2H-pyndo[2,3-dJ{1 ,3]oxazin-6-yr, 1-methyl-2-oxo-1,4-dthydro-2H-pyrido[2,3- d]{1 ,3]oxazin«6-yl, 3,4-dihydro-2H-pyrido[3,2-b]J1 ,4]oxazin-7-yl; 4~methyl-3,4- dihydro-2H-pyrido[3,2-b][1 ,4}oxazin-7-yl, 1 ,3.3-tπmethyl-2-oxo-2,3-dfhydro-1H- pyrrolo[2,3'b]pyridin-5-yl; 2-oxo-1 ,4-dihydfo-2H-pyrido[3,2-dH1 ,33oxazin-7-yl, 1-ethyl- 2-0X0-1 ,4-dihydro-2H-pyiϊdo[3s2-d][1 ,3]oxazin-7-y|- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
8. A compound selected from the group consisting of
8-(3,4-Dimethoxyrphenyf)-1-(1 ,S-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydrowmidazo(4,5- c]quiπolin-2-one;
δ^S^-Dimethoxy-phenyO-I^Σ-ethyl^H-pyrazol-S-yO-S-rriethyl-I .S-dihydro-imidazo^.δ- cJquinoJin-2-one;
8-(3,4-Dimethoxy-phenyl)-3-methyl-1-(2-methyl-2H-pyrazol-3-yl)-1 ,3-dihydro-irnidazo[4,5- c]qυtnolin-2-one,
8-(3,4-Dimethoxy-phenyl)-1^2,5-dimethyl-2Hφyrazol-3-yl)-3-methyl-1 l3-dthydro-imidazo[4,5- cJquinolin-2-one,
8-(3,4-Dimethoxy-phenyl)-1 -(1 -)sopropyl-3-methyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo(4,5-clquinolin-2-one,
8-(3,4-Dimethoxy-phenyl)-1-(1-ethyf-3-methyl-1 H-pyrazol-4-yl)-3-methyl-1 l3-dihydro- imidazo(4,5-c}quinolin-2-one;
8-(3,4Oimethoxy-phenyl)-1-(2>4-dfmethyl-2H-pyrazol-3-yl)-3-methyl-1 ,3-dihydro-irnidazo[4,5- c]quinolin-2-one; 8-(3,4-Dimethoxy-phenyl)- 1 -( 1 , 3-dimethyM H-pyrazo!-4-yl)-3~methyl- 1 , 3-dihydro-imidazo[4 ,5- c]quinolin-2-one,
8-(3,4-Dimethoxy-phenyl)-3-methyl-1-(1 ,3,5-tπmethyM H-pyrazol-4-yl)~1 ,3-dthydro- imidazo[4,5-c]quinolin-2~one,
1-(3-Chloro-1-methyt«1H-pyrazol-4-yl)-8-(3,4-dimethoxy-phenyl)-3-methyl-1 ,3-dihydro- imidazo{4,5-c]qufnolin-2>one,
1-(2>4-Dimethyt-2H-pyrazol-3-yl)-8-(6-methoκy-pyridin-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4 , 5-c)qυinolin-2-one,
8-(δ-Methoxy--pyπdin-3-y))--3-methyl-1-(2-methyl-2H-pyrazol-3-yl)-1 ,3-dihydro-imidazo[4,5- cJquinolin-2-one:
1'(2,5-Dimethyl-2H-pyra2θl-3-yl)-8-(6-methoxy-pyridin~3-yl)-3-nnetbyl-1 ,3-dihydro- imidazo[4,5-c}quinolin-2-one;
8-(6-Methoxy"pyridin-3-y!)-3-methyl-1-(1,3,5-trimethyl-1H-pyrazol-4-y!)-1 ,3-dihydro- imidazo[4.5-c]quinolin-2-oπe;
1 -( 1 , 3-Dimethyl-1 H-pyrazo(-4-yl)-8-(6-methoxy-pyridin-3-yl)-3-methy}- 1 , 3-dihydro- imidazo[4,5-c]quinolin-2-one,
1-(2-Ethyl-2H-pyrazol-3-yl)-8-(6-methoxy-pyridtn-3-yl)-3-methyl-1 ,3-d)hydro-imidazo[4v5- cJquinolin-2-one,
1-(1-Ethyt-3-methyl-1H-pyrazol-4-yl)-8-{6-methoxy-pyridin-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one;
I^Hsopropyl-S-rriθthyl-1H-pyrazoM-yO-δ-Cβ-methoxy-pyridin-S-yO-S-methyl-I .S-dihydro- imidazo[4,5-c)c)uinolir>-2-one1
1-(1 ,5-D}methyl-1H-pyrazol-4-yi)-8-(6-methoxy-pyridin-3-yi>-3-methyl-1 ,3-dihydro- imidazo[4,5-c]qυinolin-2-one;
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(6-ethoxy-pyridin-3-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5- c]quinolin-2-one;
δ-iδ-Ethoxy-pyndin-S-yO-S-methyl-1-lZ-methyl-S-triflυoromethyl-ΣH-pyrazol-S-ylJ-I .S-dthydro- imidazo[4,5-c]quinolin-2-one, δ^δ-Ethoxy-pyπdin-S-yO-a-methyl-HI .S.δ-trimethyMH-pyrazoM-yO-I .S-dthydro- imidazo^.δ-cjqumolin^-one,
8-(6-Ethoxy-pyridin-3-yl)-1-(2-ethyl-2H-pyrazol-3-yl)-3-methy!-1 (3-dihydro-!mida2.o[4,5- c]quino!in-2-one,
8-(6-Ethoxy-pyrtdin-3-yl)-1 -( 1 -ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro- !midazo[4,5-c]quiπolin-2-one,
1-(1 5-Dimethyl-1H-pyrazol-4-yl)-8-(6-ethoxy-pyπdtn-3-yl)-3-methyl-1 t3-dihydro-imida2θ(4 5- c]qυinohn-2-one,
8-(6-Ethoxy-pyπdin-3-yl)-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-melhyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one,
i-CS-Chloro-1-methyl-1H-pyrazoM-yO-S-fβ-ethoxy-pyridin-S-yO-S-methyl-i ^-dihydro- tmtdazo[4 ,5-cJquinolin-2-one
2-{4-[8-(6-Ethoxy»pyridin-3-yl)-3'mβthyl-2-oxo-2,3-dihydro-imidazo[4 5-c]quinolin-1-y!J-3- methyt-pyrazol-1-yl}-N,N-dimethyl-acetamide,
8^6-Ethoxy-pyridin-3-yl)-3-methyl-143-methyl-1-{2-moφfx>lin-4-yl-2-oxo-ethyl)-1H-pyrazol-4- yl]-1 ,3-dihydro-imidazol4,5-c]quiπoifn-2-one,
8-(6-Ethoxy-pyndin-3-yl)-1-[1--(2-methoxy-ethyl)-3 5-dimethyl-1H-pyrazol-4-yl]-3-methyl-1 (3- dihydro-imidazo[4,5-c]quino!in-2-one,
2-{4-{8-(6-Ethoxy-pyπdin-3-yl)-3-methyl-2-oxo-2>3-dihydro-imidazo[4,5-c]quinolin-1-yl)-3l5- dimethyl-pyrazol- 1 -yt}-N , N-dimethyl-acetamide,
8-(6-Dimethylamino-pyridin-3-yl)-1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 3- d)hydro-imidazo[4 , 5-c]quinolin-2-one ,
8-(6-Dtmethylamino-pyi idtn-3-yl)- 1 -(1 -ethyl-3-methyl-1 H-pyrazol-4-yl)-3-methyl-1 , 3-dihydro- imidazo(4 5-c)quinolin-2-onβ,
8-(6-Dimethylamino-pyπdin-3-yl)-3-methyl- 1 -( 1 , 3, 5-tπmethyl-1 H-pyrazol-4-yl)- 1 3-dthydro- imidazo[4 5-c]qumolin-2-one
8-(6-Dimethylaminθ'Pyπdtn-3-yl)-1-(1 ,5-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazol4,5-c]quinolin-2-one, 8-(6-Dimethylamino~pyridin-3-yl)>1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo{4,5-c]quinolin-2-one;
8-(6-Dimethylamino-pyriclin-3-yl)~1>(2,5<iimethyl-2H-pyrazol-3-yl)-3-methyl-1 )3-dihydro- imidazo[4,5-c]quinolin-2-one,
8-(6-Dimethylamino-pyridin-3-yl)-3-methyl-1-(2-methy!-2H-pyrazol-3-y))-1 ,3-dihydro- imidazo|4,5-c]quinolin-2-one;
8-(6-Dimethylamino-pyridin-3-yl)'1-(2-ethyl-2H-pyra2θl-3-yi)-3-methy!-1,3-dihydro- imldazo[4,5-c]quinolin-2-one,
I^S-Chloro-1-methyl-1H-pyrazoM-yO-a^β-dimethylammoψyridin-S-ylJ-S-methyl-I .S-dihydro- imidazoH.δ-cJquinolin-Σ-one,
θ-Cβ-Azetidin-1-yl-pyridin-S-yO-1-CI.S-dimethyl-I H-pyrazol^-yO-S-methyl-I.S-dihydro- imidazo[4.5-c)qυinoltn-2-one;
8-(6-Azetidin-1 -yl-pyridin-3-yl)-1 -(1 -tsopropyl-3-methyl-1 H-pyrazol-4-yl)-3-methy!-1 ,3-dttiydro- imidazo[4,5-c]quinolin-2-one;
8^2-Dimethylamirκ>φyrimidin-5-yl)-1-(iHSθpropyl-3-rnelhyl-1H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imidazo[4.5-c)quinolin-2-one;
8'(2-Dimethylamino-pyrimidin-5-y!)-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo(4,5-c]quinolin-2-one,
1 -(3'Chloro- 1 -methyl-1 H-pyrazol-4-yl)-8-(2-dimethylamino-pyrimidin-5-yl)-3-methyl- 1 , 3- dihydrθ'imidazo[4,5-c)quinolin-2-one;
Θ^Σ-Dimethylamino-pyrimidin-S-yO-i^i-ethyl-S-methyl-1H-pyrazoM-yO-S-methyl-I .S- dihydro-imidazo(4,5-c]quinolin-2-one;
1-(2,5-Dimethyl-2Hψyrazol-3-yl)-3-methyl-8-(6-methyl-pyτidin-3-yl)-1 ,3-dihydro-iiτiidazol4,5- c]quinolin-2-one;
1 -( 1 , 3-Dimethyl- 1 H-pyrazoM-yl)-3-methyl-8-(6-methyl-pyridin-3-yl)- 1 , 3-dihydro-imidazo[4 ,5- cJquinolin-2-one,
3-Methyl-1-(2-methyl-2H-pyrazol-3-yl)-8-(6-tπflυoromethyt-pyπdin-3-yl)-1 ,3-dihydro- imidazoK, 5-c]quinolin-2-one; 1-(2.5-Dimethyl-2H-pyrazol-3-yl)-3-methy{-8-(δ-trifluoromethyl-pyriciin-3-yl)-1 ,3-clihydro- imidazo[4,5-c]quinolin-2-one;
1 '(2,5-Dimethyl-2H-pyrazol-3-yi)-8-(24lυoro-pyridin-3-yl)-3-methyl'1 ,3-dihydro-imidazo[4,5- cJquinolin-2-on€,
S-Methyl-δφyridin-S-yl-I^I .S.S^rimethyl-1HφyrazoM-yO-I.S-dihydro-irnidazo^.δ-clquinoiin- 2-one;
1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-8-pyπdin-3-yl- 1 , 3-dihydrc-imidazo[4 , 5-c]quincHin-2- one;
8-(2-Fluoro-pyridin-4-yl)-3-methyl-1-(2-methyl-2H-pyrazoi-3-yl)-1 ,3-dihydro-imidazo[4,5- c]quinolin-2-one;
i-CI .S-DimethyMH-pyrazoM-ylJ-δ^S-methoxy-pyπdin-S-yO-S-methyl'I .S-dihydro- tmtdazol4 ,5-c]quinolin-2-one:
1 -(1 ,3-Dimethyl-i H-pyra2θl-4-yl)-8-(5-fluoro-6-methoxy"pyridin'3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one;
S-li-CI .S-Dimethyl-1H-pyrazoM-yO-S-methyl^-oxo-Σ.S^lihydro-I H-imidazoK.S-clquinotin-δ- yl]-pyridine-2-carboxylic acid amide;
5-(1-(1 ,3-Dtmethyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydfo-1 H-imtdazo{4,5-c]quinolin-8- yl]-pyridine-2-carboxyHc acid methylamide,
5-(3-Methyl-2-oxo-1-(1,3,5-trimethyl-1H-pyra2θl-4-yt)-2>3-dihydro-1H-imidazot4)5-c)quinolt)v 8-yl]-pyridine-2-carboxylic acid methylamjde;
5-t1-(1-lsopropy!-3-methyl-1H-pyrazol-4-yl)-3-methy!-2-oxo-2,3-dihydro-1 H-imidazc>{4,5- c]quinolin-8-yl]-pyndfne-2-carbαxy!ic acid methylamide,
1-(1-EthyW-melhyl-1H-pyrazoi-4-yl)-8-(6-hydroxymethy!-pyridfn-3-yl)-3-methyl-1,3-dihydro- imidazo|i4 , 5-c]quinolin-2-one,
1 -(1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-8-(6-hydroxymethyl-pyridin-3-yl)-3-methyl- 1 , 3-dihydro- imidazo[4 , 5-c]qυinolin-2-one ,
8-(6-Hydroxymethyl-pyridin-3-yf)-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1,3- dihydro-imidazo(4,5-c]quinolin-2-one, δ^β-Hydroxymethyl-pyπdin-S-yO-S-methyl-1-Ci .a.S-trimethyl-1H-pyrazoM-yO-i .a-dihydro- imidazo[4,5-c]quinolin-2-one,
i-CS-Chloro-1-rr^hyl-1HφyrazoM-yO-β^δΦydroxymethyl-pyπdin-a-yiJ-S-methyl-I .S-dihycIro- imidazo[4,5-c]quinolin-2-onet
1 -( 1 -Ethyl-3-methyl- 1 Hψyrazol-4-yl)-8-(2-methoxy-pyπmtdin-5-yl)-3-methyl- 1 ,3-dihydro- imidazo[4(5-c]quinohn-2-one;
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(2-methoxy-pyrimldtn-5-yl)-3-methyl-1 ,3-dthydro- imidazo[4,5-c]quinolin-2-one,
1-(3-Chtoro-iHiiethyl-1H-pyrazol-4-yl)-8-(2-methoxy-pyrirnidm-5-yI)-3-methyt-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one,
1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-[6-(2-methoxy-ethoxy)-pyridin-3-yl]-3-methyl-1,3-dihydro- imidazo{4 , 5-c]qυmdin-2-oπe ,
8-[6-(2-Benzyloxy-ethoxy)ψyridin-3-y)]-1-(1 l3-dimβthyl-1H-pyrazol-4-yl)-3-nnethyl-1 ,3-dihydro- imidazo(415-cJquinolin-2-one,
8-[6-(3-Benzyloxy-propoxy)-pyrtdin-3-yl]- 1 -( 1 , 3-dimethyl-1 H-pyrazol-4-yl)-3-methyl- 1 3- dihydro-imidazo(4,5-c]qυinolin-2-one<
8-[6-(2-Hydroxy-ethylamtno)-pyπdin-3-yl]*3-methyl-1-(2-methyl-2H-pyrazol-3-y!)-1 ,3-dihydro- irnidazo[4.5-c]quinolin-2-one,
1-(1 ,3-Dimethyl-1H-pyrazol-4-yi)-8-[6-(2-hydfoxy-ethylamino)-pyridin-3-yl]-3-methyl-1 ,3- dihydrθ'imidazo[4,5-c]quinolin-2-one,
i-CI.SOimethyl-1H-pyrazol^-ylH-CS-methanesutfonyl-pyridiri-S-yO-S-methyl-I .S-dihydro- imtdazo[4,5-c]quinolin-2-one,
8-(6-Amino-pyridHv3-yl)-1-(1 t3-dimethyl-1H-pyrazol-4'yl)-3-methyl-1 ,3-dihydro-imidazo[4,5- c]qutnolin-2-oπe,
δ-CΘ-Amino-pyπdin-S-yO-1-CI-isopropyl-S-methyl-1H-pyrazol^-yO-S-methyl-I .S-dihydro- imidazoH.S-cJqυinolin^-one;
1 -( 1 , 3-Dtmethyl- 1 H~pyrazol~4-y!)-3-methy!-8-(5-methyl-pyπdin-3-y!)- 1 , 3-dihydro-imldazo{4 , 5- c]qutnolin-2-one; 8-(6-Amino-5-trifIuonomethyl-pyr!din-3-yt)-1 -( 1 , 3-dimethyl-1 H-pyrazol-4-yi)-3-methyl- 1 ,3- dihydrcHtriidazQ[4,5-cJquinolin-2-one,
2-{4-(8-(6-Amino-5-trifluoromethyt-pyr)din-3-yi)-3-methyl-2-oxo-2,3-dihydro-imtdazo[4,5- clqυinolin-1-ylJ-S.δ-dimethyl-pyrazol-1-ylJ-N.N-dimethyl-acetamide,
8-(6-Amino-5-trifluoromethyl-pyπdin-3-yl)-3-methyl-1 -( 1 , 3, 5-tπmethyl- 1 H-pyrazol-4-yl)- 1 , 3- dihydro-imidazo[4,5-clquinolin-2-one,
8-(6-Amino-5-trifiuoromethyl-pyπdin-3-yl)-1-(1-isopropyl-3-methyl-1H-pyrazd-4-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-or>e,
8-(6-Amino-5-tnfluoromethyl-pyrtdin-3-yl)-1-(3,5-dimethyl-isoxazo)-4-yl)-3-methyl-1 3-dihydro- imidazo[4,5-cJquinolin-2-one,
8-(6-Amino-5-tπfluoromethyl-pyπdin-3-yl)-1-(2,5-dimethyl-2H-pyrazol-3-yl)-3-methyl-1 l3- dihydro-mπκdazo[4,5-c]qυtnolin-2-one,
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yi)'3-methyl-8-pyπmκiin-5-yl-1 ,3-dihydro-imidazo(4,5- c]qυinolin-2-one,
S-CS^-D^ethoxy-phenyO-i^i -ethyl-θ-methyl-1H-pyrazoM-ylJ-S-methyl-I .S-dihydro- imfdazo[4 , 5-c]qυtno(in-2-one ,
β^S^-Diethoxy-phβnyO-S-methyl-I^I .S.δ-trimethyl-1H-pyrazol^-yO-I .S-dihydro-imidazo^.S- c]quino!in-2-one,
8'(3-Ethoxy-4-methoxy-phenyl)-1-(1-ethyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-1 ,3"d!hydro- imidazo[4,5-cJqυino<in-2-one,
β-CS-Ethoxy^-methoxy-phenyO-S-methyl-1-CI .S.δ-tπmethyl-1H-pyrazoM-ylJ-i ^-dihydro- tmidazo(4,5-cJquino!in-2-one,
1-(1 t3-Dimethyl-1H-pyrazol-4-yi)-8-(3-ethoxy-4-methoxy-phenyl)-3-methyl-1 ,3-dihydro- imidazo^.δ-cjquinolin^-one,
8-(4-Ethoxy-3'methoxy-phenyl)-1-(1-ethyl-3-methyl»1H-pyrazol'4-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one,
8'{4-Ethoxy-3-methoxy-phenyl)-3-methyl-1-(1 ,3,5-tπmβthyl-1 H-pyrazol-4-yl)- 1 ,3-d«hydro- midazo[4,5-c]quinolin-2-one- 1 -(1 , 3-Dimethyl- 1 H-pyra2ol-4-yl)-8-(4-ethoxy-3-methoxy-phenyl)-3-methyl- 1 , 3-dihydro- imidazo[4 , 5-c]quinolin -2-one ,
1 -(1 ,3-DimethyM H-pyrazol-4-yl)-8-[3-methoxy-4-(2-methoxy-ethoxy)-phenyl]-3-methyl- 1 ,3- dihydro-irnidazo[4,5-c]quinolin-2-one;
1 -(I -Ethy!-3-methyl-1 H-pyrazol-4-yl)-8-[3-methoxy-4-(2-methoxy-ethoxy)-phenyl]-3-methyl- 1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one;
δ^-Hydroxy-S-methoxy-phenyO-S-methyl-i^t^S-trimethyHH-pyrazoM-yO-I .S-dihydro- imidazo[4,5-c)qυinohn-2-one;
1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4~yl)-8-(3-hydroxy~phenyl)-3-methy!-1 , 3-dihydro~imtdazo{4, 5- c]quinolin-2-one;
SKS-Hydroxy-phenyO-S-methyl-1-ii .S.S-tπmelhyl-1H-pyrazoM-yO-I .S-dihydro-imidazo^.S- c]qυinolin-2-one;
1 -(1 ,3-Dtmethyl-1 H-pyrazol-4-yl)-8-(3-fK.oro-5-hydroxy-phenyi)-3-methy!-1 ,3-dihydro- imMJazo[4,5-c]quinolin-2-one;
1-(1,3-Dimethyl-1 H-pyrazol-4-yl)-8-(3-hydroxy-5-trifluoromethyl-phenyl)-3-methyl-1 ,3-d)hydro- imidazo[4, 5-c]quinolin-2-one,
8-(2,2-Difluoro-benzo[1 ,3Jdioxol~4-yl)-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c)quinolin-2"θne;
1 -( 1 ,3-Dimethyl- 1 H-ρyrazol-4-yl)-3-methyl-8-( 1 H-ρyrrok>{2, 3-b]pyridin-5-yl)- 1 , 3-dihydro- imidazo(4,5-cJqυinolin-2-one,
1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-phenyl-1 l3-dihydro-irnidazo(4,5-c}quinolin-2-one,
S-Methyl-δrphenyl-I^I .S.δ^πmethyl-1H-pyrazoM-yO-I .S-dihydro-imidazo^.S-clquinoIin^- one;
N,N-Dimethyl-2-[3-methyl-4-(3-methyl-2-oxo-8-phenyl-2,3-dihydro-imidazo(4,5-c]qumolin-1- yl)-pyrazol-1-ylj-acβtamide;
2-(3,5Oimethyl-4-(3-methyl-2-oxo-8-pnenyi-2,3-dihydro-imidazo[4,5-c]quinolm-1 -yl)-pyrazol- 1-yl]-N,N-dimethyl-acetamide; 1 -(1 ,3-D«methyl-1 H~pyrazof~4-yl)-3-mβthyl-8-qu«nolin-3-yl-1.S-dihydro-imidazo^.S-clquinoHn-
2-one;
3-[1-{1 ,3-Din^thyl-1H-pyra2θM-yl)-3-methyl-2-oxo-2,3Hdihydro-1H-imicla2θ{4,5-c|qutnolin-8> ylJ-N-methyl-benzeπesulfonamlde,
1-(1 ,3-Dimathyl-i H-pyrazol-4-yl)-β-(3-methanesυlfonyl-phenyl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one;
4-[1-(1 l3-Dimethyl-1H-pyra2θl-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazol4,5-c]quinolin-8- yl]-benzamide,
8-(6-Cyclopropylmethoxy-pyπdin-3-yt)' 1 -( 1 , 3-dimethyl-1 H~pyrazot-4-yl)-3-methyl- 1 , 3-dihydro- imidazo(4,5-c]quinolin-2-one,
4-[1-(1,3-Dtmethyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2.3-dihydro-1H-imidazo[4,5-c]quinoiin-8- y IJ- N-methy l-benzamide ,
4'[1-(3-Chloro-1-methyl-1H-pyrazol-4-yl)-3-methyl-2-oxθ'2,3-dihydro-1H-imidazo[4,5- c]quinolin-8-yl]-N-methyl~benzamide,
1 -( 1 , 3-Dimethyl- 1 H-pyrazol^-yO-S-methyl-δ-fS-Cpyrrofidine- 1 -sulfonyl)-phenyl]-1 , 3-dihydro- imidazo[4,5-c]quinolin-2-one,
^(δ-Amino-pyridin-S-yO-1-CI .S-dimethyl-1H-pyrazoM-yO-S-methyl-I .S-dihydro-ijTiidazoH.S- cJquinolin-2-one,
e^S-Amino-pyndin-S-yO-i^i-ethyl-S-methyl-1H-pyrazoM-yO-S'methyM .S-dihydro- imidazo[4,5-c]qυinolin-2-one,
8-(5-Amino-pyridin-3-yl)- 1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro- imidazo[4,5-c)qυinolin-2-one;
S-II^I .S-Dimethyl-1H-pyrazoM-ylJ-S-methyl^-oxo^.S-dihydro-1H-imidazoH.S-cjquinolin-S- yl]-benzamide;
N-{3-[1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-3-methyl~2-oxo-2,3-dihydro-1 H-imidazo[4,5-c]quinolin- 8-yl]-phenyl}-methanesulfonamtde, 4-[1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-iiriidazo[4,5-c]quinoIin-8- yl)-N , N-dimethyl-benzamide,
1 -(1 , 3-Dimethyl-1 H-pyrazol-4-yl)-3-methy!-8-(2-oxo-2, 3-dihydro- 1 H-indol-5-y!)- 1 , 3-dihydro- imidazo(4,5-c]quinolin-2-one;
1 -< 1 ,3-Dimethyl- 1 H-pyrazcrt-4-y!)-3-methyl-8-( 1 -methyl-2, 3-dihydro- 1 H-indol-5-yl)-1 , 3-dihydro- imidazo[4,5-c]quinolin-2-one,
1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(4-pyrazol-1-yi-phenyl)-1 ,3-dihydro-imtda2θ(4,5- c]quinolirv2-one,
N , N-Dimethyl-2-{3-methyl-4-[3-methyl-2-oxo-8- (4-pyrazol- 1 -yl-phenyl)-2 , 3-dihydro- tm(dazo[4,5-c|quinolin-1-yl]-pyrazol-1-yl}-acetamide,
1 -( 1 -Ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl-8-(4-pyrazol- 1 -yl-phenyl)- 1 , 3-dihydro- imtdazo[4,5~c]qutnolin-2-one,
2-{3,5-Dimethyl-4-[3-methyl-2-oxo-8-(4-pyrazol-1-y)-phenyl)-2,3-dihydro-fmidazo[4,5- c)qυinolin-1 -yl]-pyrazol- 1 -yl)-N , N-dimethyl-acetamide,
2"{3,5-Dimethyl-4-t3-methy!-2-oxo-8-(4-pyrazol-1-yl-phenyl)-2,3-dihydro-imidazo(4,S- clquinolin-1-ylJ-pyrazol-1-ylJ-N.N-dtmethyl-acetamide,
N-Ethyl-N-rπethyl-2-{3-meltiyl-4-[3-methyl-2-oxo-8-(4-pyrazol-1-yl-phenyi)-2, 3-dihydro- imidazo[4,5-c]qυinofin-1 -yl]-pyrazoM -yl}-acetamide,
1-(1 ,3-Dimethyl-i H-pyra2θl-4-yi)-8-(2-ethoxy-pyπmidin-5-yl)'3-methyl-1 ,3-dihydro- imidazo{4,5-c)quinofin-2-one,
3'[1-(1 S-Dimethyl-1H-pyrazoM-ylJ-S-methyl^-oxo^.S-dihydro-1H-imidazo^.δ-cJquinolin-δ- ytJ-N, N-dimethyl-benzenesutf onamide ,
N.N-Dimethyl-S-p-methyl^-oxo-1-CI.S.δ-tπmethyl-1H-pyrazoM-yO^ S-dihydrO'1H- imidazo[4,5-c]quinolin-8-y1)-benzenesu!fonamide,
1-{1 3-Dimethyl-1H-pyrazol-4-yl)-8-(5-methoxymethyl-pyridin-3-yl)-3-methyl-1 , 3-dihydro- imidazo^.δ-cjqυfnohn^-one,
I^S-Chloro-1-mβthyl-1H-pyrazoM-yO-δ-CS-methoxymethyl-pyπdin-S-yO-S-nriethyl-I .S-dihydro- imidazole, 5-c]quinolin-2-one, 1 -( 1 , 3~Dimethyl-1 H-pyrazol-4-y!)-3-methyl-8-(6-propoxy-pyridin-3-yl)- 1 , 3~dihydro-imidazo[4 5- c]qυinolin-2-one,
1'(1 ,3-Dimethyl-1H-pyra2θl-4-yl)'8-(5-ethoxy-pyπdin-3-yl)-3-methyl-1 3-dihydro-imidazo[4,5- c}quirκ)lin-2-one,
2-{4-[8-(5-Ethoxy-pyridin-3-yl)-3-me(hy1-2-oxo.2,3-dihydro-imidazo[4l5-cJquinolin-1-ylJ-3- methyl-pyrazoM-yty-N.N-dimethyl-acetamide,
δ^S-Ethoxy-pyπdin-S-yO-S-methyl-i^i^ δ-tπmethyl-1H-pyrazoM'yl^i .S-dihydro- imidazo[4 , 5-c]qυtnolin-2-one ,
1-(3-Chloro-1 -methyl- 1H-pyrazol-4-y!)-8-(5-ethoxy-pyridtn-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-cJquinolin-2-one,
1-(2,4-Dimethyl-2H-pyra2θl-3-y))-8-(5-ethoxy-pyπdin-3-yi)-3-methyl-1 ,3-dihydro-imtda2o[4,5- c]quinolin-2-one,
i-CI ^-Dtmethyl-1H-pyrazol^-ylJ-β-CS-ethoxy-phenyO-S-methyl-I .S-dihydro-imidazo^.S- c]quinoHn-2-one.
1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl )-8-(5-isopropoxy-pyridin-3-yl)-3-methyl- 1 ,3-dihydro- imidazo^.δ-clqυinolin^-one,
I^S-Chlofo-1-mβthyl-I H-pyrazoM-yO-δ-lδ-isopropoxy-pyπdin-S-yO-S'methyl-I .S-dihydro- imidazo[4 5-c]qυinolin-2-one,
1-{2,4-Dimethyl-2H-pyrazol-3-yl)-8-(5-isopropoxy-pyπdln-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one,
1 -( 1 -Ethyl-3-methyl- 1 H-pyrazol-4-yl)-8-{5-isopropoxy-pyridin-3-yl)-3-methyl- 1 , 3-dihydro- imidazo[4 5-cJquino!in-2-oπe,
N-Ethyl-2-{4-(8-(5-isopropoxy-pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-tmidazo[4 5-cJqutnolin- 1 -yl]-3-methy(-pyrazol-1 -yJ}-N-methyl-acetamide
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-[5-(2-methoxy-ethoxy)-pyπdin-3-yl]-3-methy)-1 3-dihydro- imidazo^.S-cJquinolin^-one,
1-(3-Chloro-1-methyl-1H-pyrazol-4-yl)-8-{5-(2-methoxy-ethoxy)-pyridin-3-yl]-3-methyl-1 3- dihydro-imidazo[4,5-c}quiπol!n-2-one θ-Cδ-Cyclobutoxy-pyridin-a-y!)- 1 -( 1 , 3-dimethyl- 1 H«pyrazol-4-yl)-3-methyl- 1 , 3-dihydro- imidazo[4,5-c)quinolin-2-one;
2-{4-[8-(5-Cyclobutoxy-pyridin-3-yl)-3-methyt-2-oxo-2)3-dihydro-imtdazo(4l5-c]quino!in-1-ylj- S.δ-dimethyl-pyTazot-1-ylJ-N.N-dimethyl-acetamide,
δ^S-Cyclopropylmethoxy-pyridin-S-yO'l-ii.S-dimethyl-1H-pyrazol^-yO-S-methyl-I.S-dihydro- imidazo[4,5-c]quinolin-2-one,
NKS-li-CI .SOimethyl-1H-pyrazoM-yO-S-methyl-a-oxo^.S-dihydro-I H-irnidazoH.δ-φuinoltn- 8-yl)'2-methoxy-pyπdin-3-yl}-N-methyl-acetamide;
N-{5-(1-(1 ,3-Dimethyl-1H-pyrazol~4-yl)-3-methyl-2-oxo-2>3-dihydro-1H-imidazo[4)5-c)quinolin- 8-yl]-2-ethoxy-pyridin-3-yl}-N-methyl-acetamide;
N-{5-[1-(1 ,3-Dimethyl-1Hi3yra2θl^-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-im!dazo[4,5-c)quinolin- 8-yl]-2-methoxy-pyridtn-3-yl}-acetamide1
N-{5-[ 1 -( 1 , 3-D«methyt- 1 H-pyrazol-4'yl)-3-methyl-2-oxo-2 , 3-dihydro- 1 H-imidazo[4 , 5-c]quino!in- 8-yl]-2-ethoxy-pyridin-3-yl}-acetamide,
1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-8-(6-methoxy-5-nitro-pyridin-3-yl)-3-methyl- 1 , 3-dihydro- imidazoH.δ-cjquinolin^-one,
8-(1 ,3-Dimethyl-2-oxo-2,3-dihydro-1H-tmidazoi;4,5-b]pyπdin-6-yl)-1-(1 3-dimethyl-1H-pyrazol- 4-y1)'3-methyt-1 , 3-dihydro-imidazo[4 , 5-c]quinolin-2-one,
1 -{ 1 , 3-Dimethyl- 1 H-pyrazol-4-y1)-8-( 1 -ethyl-3-methyl-2-oxo-2, 3-dihydro- 1 H-imidazol4 5- bjpyndin-δ'yO-S-mβthyl-I.S-dihydro-imidazo^^-cJquinohn^-one,
1-(1 3-Dimethyl-1 H-pyrazol-4-yt)-8-(1-(2-methoxy-ethyl)-3-methyl-2-oxo-2 3-dihydro-1H- imidazo[4 , 5-bjpyπdin-6-y l]-3-methyl- 1.3-dihydro-imtdazo[4 , 5-c)qu)nolin-2-one,
8-(2-Dimethylamino-3-π>ethyl-3H-imidazo(4,5-b]pyrtdin-6-yl)-1 -(1 ,3-dimeihyl-i H-pyrazol~4-yl)- 3-methyl-1.3-dihydro-imidazo[4,5-c]quinolin-2-one,
1-(1 3-Dimβthyl-1 H-pyrazol-4-yl)-8-(2-methoxy-3-methyl-3H-imidazo[4,5-b]pyπdin-6-yl)-3- methyl- i ^-dihydro-imidazo^.S-cJquinolin^-one,
1-(1,3-Dimethyl-1H-pyrazol-4-yI)-3-methy!-8-(3-methyl-3H-[1 ,2 3]triazolo[4,5-b]pyπdin-6-yt)- 1 ,3-dihydro-im(dazo[4,5-c3quinolin-2-one, δ^a.S-Dimethyl-aH-imidazo^.δ-bJpyridin-β-yO-1-CI .S-dimethyl-1H'pyrazoM-yO-a-methyt-i .a- dihydro-imidazo[4,5-c]quinolin-2-one;
1-(1(3Oimethyl-1H-pyτazol-4-yl)-3-methyl-8-(3-methyl-3H-imidazo(4,5-b]pyπdi(>6-yl)-1,3- dihydro-imidazo{4,5-c)quinolin-2-one;
N-{5'[1 -(1 ,3-DimethyM H-pyrazol~4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c]quinolin- 8-yl)-2-methyl-pyridin-3-yl}-N-methyl-methanesulfonarnfde;
N^δ-fi-CI^-Dimethyl-1H-pyrazol^-yO-S-methyl^-oxo^.S-dihydro-1H-imidazoK.δ-clquinolin- 8-yi]-2-methyl-pyridin-3-yl}-methanesυlfonamide,
i-CI.S-Dimethyl-1H-pyrazoW-yO-e^^iH-imkJazol-Σ-yi^phenyll-S-methyl-i .a-dihydro- imidazo(4,5-c]quinolin-2-one;
1 -(1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-8-{6-(2-methyl-imidazol- 1 -yl)-pyridin-3-yl]- 1 ,3- dihydro-imidazo{4 , 5-c]qυinoltn-2-one ;
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)~3~methyl-B-(6-pyrazol-1 -yl-pyridin-3-yl)-1 ,3-dihydro- imidazo{4,5-c]quinolin-2-one;
1-(1 ,3-Dimethyl-1 H-pyrazol-4-y!)-3-methyl-8-(2-methylamino-pyπmidin-5-yl)-1,3-dihydfθ- inrtidazo[4,5-c]quinolin-2-one;
3-Methyl-8-(2-mβthylamifK>-pyrimidtn-5-yi)-1-(1 l3,5-tπmethyl-1 H-pyrazol-4-yl)-1 l3-dihydro- imtdazo[4, 5-c)qυinolin-2-one;
8-(2'Amino-pyrimidin-5-yl)- 1 -( 1 , 3-dimβthyl- 1 H-pyrazoi-4-yl)-3-methyl-1 ,3-dihydro- imidazo[4 , 5-c]quinolin-2-one;
8-(2-Amino-pyrirnidin-5-yl)-3-methyl-1-(1,3,5-trimethyl-1H-pyrazo!-4-yl)-1 ,3-dihydro- imidazot4,5-c3qυinolin-2-one;
1-(1,3-Dimethyl-1H-pyrazol-4-yi)-8-(3-isopropoxy-phenyl)-3-methyt-1 ,3-dthydro-imidazo{4,5- c]quinolin-2-one;
1-(1 3-Dimelhyl-1 H-pyrazol-4-yl)-8-(2-fluoro-3-isopropoxy-phenyl)-3-methyl-1 ,3-dihydro- imidazo^.δ-cjquinolin^-one;
I^I .S-Dimethyl-1H-pyrazoM-yO-Θ^S-isopropoxy-β-methyl-pyndin-S-yO-S-methyl-i ^-dihydro- imidazo{4,5-c]quinolirv2-one( 1 -( 1 -Ethyl-3-methyl- 1 H-pyrazol~4-yl)-8-(5-isopropoxy-6-methyl-pyπdin-3-yl)-3-fnef hyl- 1 ,3~ dihydro-<midazo[4,5-c]qutnolin-2-one;
1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-ethoxy-6-methyl-pyridin-3-yl)-3-methyl-1 ,3-dihydro- imidazo{4,5-cJqυinoiin-2-one,
8-(5-Ethoxy-6-methyl-pyridin-3-yl)- 1 -[ 1 -(2-methoxy-ethyl)-3, 5-dimethyl- 1 H-pyrazol-4-yl]-3- methyl- 1 , 3-dihydro-imidazo[4 , 5-c]qυlπolm-2-one'
2-{4-(8-(5-Ethoxy-6-methyl-pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-imidazo{4,5-c3quinotin-1- yl3-3,5-dimethyl-pyrazol-1«yl}-N,N-dimethyl-acetamide,
1 -(3-Chtoro-1 -methyl-1 H-pyrazol-4-yl)-8-[5-(2-methoxy-ethoxy)-6-methyl-pyπdin-3-yl}-3- methyl-1 , 3-dibydro-imidazo[4 , 5-c3quirK)lin-2-one,
1-(1 ,3-D<methy!-1H-pyrazol-4-yl)^-[5^2-methoxy-ethoxy)-6-rrtethyl-pyridin-3-yl]-3-mβthyl-1 ,3- dihydro-imidazo[4,5-c}quinotirv2-one,
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(5-ethylamino-6-methyl-pyridin-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-cJquinolin-2-one,
1-(3-Chloro-1-methyl-1H-pyrazol-4-yl)-8-(5^thylamino-6-methyl-pyπdin-3-yl)-3-methyl-1 ,3- dihydro-imidazo(4,5-c)c|uinolin-2-onet
8-(5-Ethylamino-6-methyl-pyridm-3-yl)-1~{1-ethyl-3'methyl-1H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imidazo[4,5"C]quinolin-2-one;
8-{5-Ethylamino-δ-methyl-pyridin-3-yl)- 1 -[ 1 -(2-methoxy-ethyl)-3, 5-dimethyl-1 H-pyrazol-4-yl)- 3-methyl-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one,
2-{4-(8-(5-Ethylamino-6-methyl-pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5- clquinoltn-1-ytJ-S.δ-dimethyl-pyrazol-i -ylJ-N.N-dimethyl-acetamide,
8-(5-Amino-6-methyl^yridin-3-y!)-1-(3-chloro-i -methyl-1 H-pyrazol-4-yl)-3-methyl-1 , 3- dihydro-imidazo[4,5-c]quinolin-2'θne,
8-(5-Amino-6-methyl-pyridin-3-yl)-1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo{4,5-c]quinolin-2-one,
δ^δ-Amino-δ-methoxy-pyπdin-S-yO-I^S-chloro-1-methyl-1H-pyrazoM-yO-S-methyl-I .S- dihydro-imidazo|4,5'C}quinolin-2-one, i-fS-Chloro-1-methyf-1H-pyrazoM-yO-S-CS-ethylamino-β-methoxy-pyridin-S-yO-S-rnθthyl-I .S- dihydro-imidazo(4 5-c]quinolin-2~one,
8-(5-Ethylamino-6-rr^thoxy^yfidtn-3-yl)-141-(2-methoxy-ethyl)-3,5-dimethyl-1H-pyrazol-4- yl)-3-methyl-1.3~dihydro-imidazo(4,5-c]quinolin-2-one;
1 -{1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(2-ethoxy-pyridin-4-yl)-3-methyl-1 ,3-dihydro-imidazo[4,5- c]quinolin-2-one;
1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(2-isopropoxy-pyridin-4-yl)-3-methyl-1 3-dihydro- imidazo(4,5-c)quinolin-2-one,
i-CI .S-Dimethyl-1H-pyrazoM-yO-δ^S-isopropoxy-β-methoxy-pyridin-S-ylJ-S-methyl-I.S- dihydro-imtdazo(4,5-cJquinolin-2-αne;
1 -(1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-ethoxy-δ-methoxy-pyr(din-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,6-c]quinolin-2-one,
8-(5-Diethylamtno-pyπdin-3-yl)-1-{1 ,3-dimethy!-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one;
1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-8-[6-(4-methyl-piperazin- 1 -yl)-pyridin-3-yl]- 1 , 3- dihydro-imidazo[4,5-c]quinolin-2-one;
HLS-Dimethyl-1H-pyrazol^-yO-S-methyl-β-Cβ-pyrrolidin-1-yl-pyridin-S-yO-i^-dihydro- tmidazo[4,5-c]qυinolin-2-one,
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-[6-(ethyl-methyl-amino)-pyridin-3-yl]-3-methyl-1 ,3-dihydro- imidazof4,5-c]qu)nol!n-2-one;
S-fβ^Ethyl-methyl-aminoJ-pyridin-S-ylJ-1-CI-isopropyl-S-methyl-I H-pyrazol^-yO-S-methyl-I .S- dthydro-imidazo[4,5-c]quinolin-2-one,
8-t6-(Ethyl-methy!-anr>mo)-pyridin-3-yl]- 1 -(1 -ethyl-3-methyl- 1 H-pyrazot-4-yl)-3-methyl~ 1 , 3- dihydro-imida2o(4,5-c}quino!in-2'One;
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(1H-pyrrolo[3,2-bJpyridin-6-yl)-1 ,3'dihydro- imidazo[4.5-cJquinolin-2-one,
5-[1-(1 ,3-Dimethyl-i H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo (4,5-c]quinolin-8- yl]-pyrtdine-2-carboxyiic actd methyl ester: {4-[8-(6'Metho>cy-pyridin-3-yl)-3-friethyl-2-oxo-2t3-dihydro-iniiclazo[4,5-c]quinolin-1-yl)-3- methyl-pyrazol-1*yl}-acettc acid;
2^4-[8-<6-Methoxy-pyridin-3-yl)-3-methyl-2-oxc>-2ι3-dihydro-imidazo[4,5-c]quinolin-1-yl)-3- methyl-pyrazoM-yl^N.N-dimethyl-acetarnide;
1 -[ 1 -(2-Hydroxy-ethyl)-3-methyl-1 H-pyrazol^4-yl]-8-(6-methoxy-pyridin-3'yl)-3-methyl-1 , 3- dihydro-imidazo[4,5-c]quinolin-2-one,
8-(6-Ethoxy-pyridin-3-yl)- 1 -( 1 -(2-hydroxy-ethyl)-3-methyl-1 H-pyrazol-4-yl]-3»methyl- 1 ,3- dihydro-imidazo[4,5'C]quinolin-2-one;
1-(1-Bhyl-3-methyl-1H-pyrazol-4-yl)-β-(6-methoxymethyl-pyridin-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinol!n'2-one;
i^i-lsopropyl-S-methyl-1H-pyrazoM-yO-δ-Cβ-methoxymethyl-pyπdin-S-yO-S-methyl-I .S- dihydro-rmidazo[4,5-c]quinolin-2-one;
1-(1 ,3-Dimβthyl-i H-pyra2Lθl-4-yl)-8-[1-(2-hydroxy-ethyl)-1 H-pyrazo)-4-yl]-3-methyl-1 ,3- dihydro-imrdazo[4,5-c]quinolin-2-one(
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)'3-methyl-8-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]"1H- pyrazo!-4-yi}-1 ,3-dihydro-imidazo[4.5-cJquinolin-2-one;
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-[6-(2-hydroxy-ethoxy)-pyπdin-3-yl]-3-methyJ-1 ,3-dihydro- imidazo{4,5-c]quinolin-2-one;
1-(1,3-Dimethyl-1Hφyrazol-4-yl)-8-[6-{3-hydroxy-propoxy)-pyπdin-3-yl]-3-methyl-1 l3-dihydro- imidazo{4,5-c]quino!in-2-one;
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(6-methoxy-pyridin-3-yi)-1,3-dihydro-imidazo[4,5- c]quinolin-2-one;
1-(1 ,3-0imethyl-1 H-pyrazol-4-yl)-8-(6-ethoxy-pyridin-3-yl)- 1 (3-dihydro-imidazot4,5-c]qυinolin- 2-one;
8-(3t4-Dimethoxy-phenyf )- 1 -( 1 ,3-dimethyl- 1 H-pyrazol-4-yt)- 1 , 3-dihydro-imidazo{4 , 5- cJquinolin-2-one;
5-[1 -( 1 -lsopropyl-3-methyl- 1 H-py razoM-yf )-3-methyl-2-oxo-2 , 3-dihydro- 1 H-imidazo{4 , 5- c]quinolin-8-yl]-pyridine-2-carboxylic acid amide; i^i-lsopropyl-S-methyl-1H-pyrazoM-yO-S-methyl-β-pyrklin^-yl-I.S-dihydroHmiclazoH.δ- c]quinolin-2-one,
1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-8-pyπd!n-2-yl- 1 , 3-dihydro-imidazo[4 ,5-cJquinolin-2- one,
1-(1 3-Dimethyl-1H-pyrazol-4-y1)-3-methy!-8-pyra2in-2-yl-1 ,3-dihydro-irnidazo[4)5-c]quinc>lin- 2-one,
1 -(1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-8-(1 -methyl-1 H-ρyrro(o[2,3-b]pyridin-5-yl)-1 ,3- dihydro-imtdazo{4,5-c]quinolin-2-one,
N-{3'[1 -(1 ,3-Dimethyl-i H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imκdazo{4,5-c}quinolin- 6-ylJ-phenylJ-N-mθthyl-methanesulfonamide,
1-(1-lsopropyl-3-methyl-1H-pyrazol-4-yl)-3'methyl-8-(6-methylamino-pyndin-3-y))-1,3- dihydro-imidazo{4 , S-clqυmolin^-orte,
1-(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-3-methyl-8-(6-methylamino-pyridin"3-yl)-1 ,3-d4hydro- imidazo[4, 5-c}quinolin-2-one,
N,N-Dirtiethyt-2-{3-m€thyl-4-[3-methyl-8-(6-methylamino-pyπdin-3-yl)'2-oxo-213-dihydrθ' imidazo[4 ,5-c]quinolin- 1 -yl]-pyrazol- 1 -yl}-acetamide
1 -(1 -Ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl-8-(6-methylamino-pyridin-3-yl)- 1 , 3-dihydro- tmidazo{4,5-c3quinotin-2-one,
I^S-Chloro-1-methyt-1H-pyrazol^-yO-S-methyl-δ^β-methylammo-pyridin-S-yO-I .S-dthydro- imidazo{4 , 5-c]quinolin-2-one,
1 -(3-Chloro- 1 -methyl- 1 H-pyrazoJ^-yO-S-methyl-δ-CS-methyl-β-methylamino-pyridin-S-yO- 1 , 3- d(hydro-tmidazo[4 5-cJqυinolin-2-oπe
N-{5-[1-(1 3-Dtmethyl-1 H-pyrazol-4-yl)-3-methy!-2-oxo-2,3-dihydro-1 H-imidazo[4,5-c]quinoJin- 8-y!)-pyπdin-3-yl}-methanesυlfonamide,
N-{5-[1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4 5-c]quinolin- 8-yl]-pyridin-3-yl}-N-methyl-methanesulfonamide,
I^I .S-Dimethyl-1H-pyrazoM'yO-δ-CS-ethylamino-pyridin-S-yO-S-methyl-I .S-dihydro- imidazo(4,5-c]quinolin-2-one, 1 -(1 ,3-DimethyM H-pyrazol-4-yf)-3-methyl-8-[6-(2H-tetrazol-5-yl).pyπdin-3-yf]-1 ,3-dihydro- ifnidazo[4,5-c]quinolin-2-one(
5-[1-(1 ,3-Dimethyl-1H-pyrazoM-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imκJazo{4,5-c]quinc>)tri-θ- yll-pyridine-2-carbonttrtle-
5-[1-(1,3-Dimethy)-1H-pyrazol-4-yl)-3-methy)-2-oxo-2,3-dihydro-1H-imidazo(4,5-c]quinolin-8- yl)-2-methoxy-nicotiπic acid,
δ-II^I .S-Dimethyl-iH-pyrazoM-yO-S-methyl^-oxo^.S-dihydro-1H-imidazoH.S-clqυinolm-β- y!)-2-methoxy-N-methyl-nicotinamκte;
S-li-li.S-Dimethyl-1H-pyrazoM-yO'S-methyl^-oxo^.S-dihydro-1H-imidazo^.δ-clquinoltn-δ- yl]-2-methoxy-nicotinamide;
1-(1 ,3-Dimethyl-1H-pyra2:ol-4-y<)-3-mβthyl-8-(6-piperazin-1-y!-pyridin-3-yl)-1 ,3-dihydro- imidazo[4,5-c]qutnolin-2-one;
8-(5-Amino-6-methoxy-pyπdin-3-yl)'1-(1 3-dimethyl-1H-pyrazol-4-yl)-3-methyH ,3-dihydro- imida2θ(4,5-c)qutno}in-2-one,
I^I .S-Dimethyl-1H-pyrazoM-yO-S-mβthyl-δ-pyπdin-S-yl-I .S-dihydro-jmidazo^.S-cjquinotine- 2-thione,
8-(3/-Dimethoxy-phenyl)-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro-irnidazo[4,5- c]qυinoltne-2-thione,
1-(1 ,3-Dtmethyl-1 H-pyrazol-4-yl)-3-methyl-8-(1-methyl-1H-pyrro)o{3,2-b]pyrκlin-6-y!)-1 ,3- dthydro-imidazo[4,5-c]quinolin-2-one,
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-ethylamino-pyridin-3-yi)-3-iTiethyl-1 ,3-dihydro- imidazo(4,5-c]quinolin-2-one;
β-(6-Ethoxy-pyrid!n-3-yl)- 1-[1-(2-methoxy-ethyl)-3-methyl-1H-pyrazo!-4-yi]-3-methyH ,3- dihydro-imfdazo^.δ-clquinolin-Σ-one;
δ^i^i .S-Dimethyl-1H-pyrazoM-yO-S-methyl-Σ-ox^^-dihydro-1H-imidazoH.S-cjquinolin-δ- yl]-2~methoxy-nicotinonrtrile;
δ-Cβ-Ethoxy-pyπdm-S-yl)- 1 -{3-methyl- 1 -[2-(4-methyl-piperazin- 1 -yl)-2-oxo-ethyl J- 1 H-pyrazol- 4-yl}«1 ,3-dihydro-)midazo[4,5-c]qυinolin-2-one; 3-Methyl-1-{3-methyl-1-j2-(4-methyl-ptperazfn-1-yl)-2-oxo-ethyl]-1H-pyrazoi-4-yl}-8-phenyl- 1 ,3-dihydro-irnidazo[4,5-c]qυinolin-2-one;
N-Ethyl-N-methyl-2-[3-methyl-4-(3-methyl-2-oxo-8-phenyl-2,3-dihydro-irnidazot4,5-c]quinolin- 1-yl)-pyrazot-1-ytJ-acetamidet
2-{4-[8-(6-Ethoxy-pyπdin-3-yl)-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-c}quinolin-1-ylJ-3- methyl-pyrazol-1-ylj-N-ethyl-N-methyl-acetamide,
N-(2-Methoxy-ethyl)-N-methy!-2-(3-methyl-4-(3-methyl-2-oxo-8-phenyl-2l3-dihydro- imidazo[4,5-c)quirκ>lin-1-yl)-pyrazol-1-yl]-acetarnide
1-[1-(2-Azetidin-1-yl-2-oxo-ethyl)-3-methyl-1H-pyrazol-4-y1l-8-(6-ethoxy-pyridin-3-y))-3- methyl-1 ,3Hdihydro-imκtøzo[4,5-c]qumc>)irt-2-one,
N , N-Diethy l-2-{3-methyl-4-(3-methy l~8-(6-methyl-pyπdin-3-yl)-2-oxo-2 , 3-dihydro-imidazo[4 , 5- c]quinolin-1-yl]-pyrazol-1-yl}-acetamide,
N'Ethyl-N-methyl^S-methyM-tS-methyl-Σ-oxo-S^-pyrrolidin-1-yl-pyπmidin-S-yO-Σ.S- dihydro-imidazo[4 , 5-c]quinolin- 1 -yl)-pyrazol- 1 -yl)-acetamidβ,
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(2-pyrroltdiri-1-yl-pyπmtdin-5-yl)-1 )3-dihydro- imidazo[4,5-cJqυinolin-2-one,
8-(5-Fluoro-6-methylamino-pyπdin-3-yl)-3-methyl-1-(1 ,3,5-tnmethyl-1 H-pyrazot-4-yl)-1 ,3- dihydro-imidazo[4,5-c)qυinolin-2-one;
1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-f luoro-6-methylamino-pyridin-3-yl)-3-methyt- 1 , 3- dihydro-imidazo[4,5-c]qυinoliiv2"θne,
8-(5-Fluoro-6-methylamtno-pyridin-3-yl)- 1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1,3-dihydro-imidazo[4,5-c]quinolin-2-one,
8-(6-Amino-5-f luoro-pyridin-3-yl)-3-methyl- 1 -( 1 , 3, 5-tπmethyl- 1 H-pyrazo)-4-yl)~1 , 3-dihydro- imidazo^.δ-ctøuinolin^-one;
8-(6-Amino-5-fluoro>pyridin-3-yl)-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c)quinotin-2-one,
8-(6-Amino-5-fluoro-pyridin-3-yl)-1-(1-isopropyt-3-methyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imidazo[4,5-c]qυinolin-2-one, 3~Methyl-8-{6-tπdeuteromethylamino-5-triflυoromethyl-pyrJdin-3-yl)-1-(1 l3,5-trinriethy{-1H- pyrazol-4-yl)-1 ,3-dihydro-imidazo[4,5'C]quinolin-2-one;
3-Methyl-8-(6-me(hy!amirw)-54rifluoromethylφyπdin-3-yl)-1-(1 ,3,5-trimethyl-1H-pyrazol-4-y1)- 1 ,3-dihydro-tmidazo[4,5-c]quinolin-2-one;
1 -(1 -lsopropyl-3-methyl-1 H-pyrazol-4-yl)-3-methyl~8-(6-methylamtno-5-triflυoromethyl-pyridin- 3-yl)-1 ,3-dihydro-imidazo[4,5-c]qυinolin-2-one;
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-3-methyl-8-(6-methy!amino-5-trifluoromethyl-pyπdin-3-yI)- 1 (3-dihydro-imidazo[4,5-c]quinolin-2-one,
^(β-Ethylamino-S-trifluoromethyl-pyridin-S-yO-S-methyl-I^I .S.δ-trimethyl-1H-pyrazol^-yl)- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one;
i-ClS-Dimethyl-1Hφyrazol^-yO-δ-CΘ-ethylamino-δ^rifluoromethyl-pyridin-S-yO-S-methyl-i ^- dihydro-imidazo(4,5-c]quinolin-2-one;
8-(5-Chloro-6-methylamino-pyridin-3-yl)-1-(1 s3-dimethyl-1H-pyrazol-4-yt)--3-methyl-1 ,3- dihydro-imida2o{4,5-c3quiπolin-2-one,
8-(5-Chloro-6-methy!amino-pyridin-3-yt)- 1 -{ 1 -ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 , 3- dihydro-imidazo[4,5-c]quinolin-2-one(
8-(5-Chloro-6-methylamino-pyridin-3-yt)- 1 -( 1 -isopropyl-3- methyl- 1 H-pyrazot-4-yl)-3-methyl- 1 ,3-dihydro-imidazo{4,5-c}quinolin-2-one;
8-(5'Chloro-6-methylamino-pyridin-3-yl)-3-methyl-1-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-1,3- dihydro-imidazo[4,5-c)quinolin-2-one;
8-(5-Chloro-6-methylamino-pyridm-3-yl)- 1 -(2 , 5-dimethyl-2H-pyrazol-3-yl)-3-methyl- 1 , 3- dihydro-imidazo[4,5~c]quirκ>lin-2-one;
δ^S-Chloro-θ-methylamino-pyridin-S-yO-I^S.S-dimethyl-isoxazol^'yO-S-methyl-I.S-dihydro- imidazo[4,5-c]qυinolin-2-one;
β^S-Chloro-e-ethylamino-pyridin-S-yO-I^I.S-dimethyl-1H-pyrazol^-yO-S-methyl-I .S-dihydro- imidazo[4,5-c)quinolin-2-one,
δ-CΘ-Amino-S-chloro-pyridin-S-yO-S-methyl-I^I .S.δ-trimethyl-1H-pyrazoM-ylJ-I .S-dihydro- imidazo[4,5-c]quinoiin-2-one, βKβ-Amtno-δ-chtoro-pyridin-S-yO-i'CI.S-dimethyl-1H-pyrazoM-yO-S'methyl-I.S-cfihydro- imidazo(4,5-c]qu!noliiv2-one,
8-(6-Amino-5-chloro-pyridin-3-yl)-1 -( 1 -ethyl-3-methyl-1 H-pyrazo!-4-yl)-3-methyl- 1 ,3-dihydro- imidazo[4,5-cjquinolin-2-one,
S^β-Amino-S-chloro-pyridin-S-yiJ-I^S.S-dimethyl-isoxazoM-yO-S-methyl'lS-dthydro- imtdazo[4t5-c)qυinolin-2-one,
β-CS-Amino-e-fluoro-pyridin-S-yO-i^i-isopropyl-S-methyl-1H-pyrazol^-yO-S-methyl-I .S- dihydro-imidazo(4,5-c]quinolin-2-one;
8-(5-Amino-6-fluoro-pyridii>3-yl)-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one;
8-(5-Amino-6-fluoro-pyridin-3-yl)-1-{2>5-dimethyl-2H-pyrazol-3-yl)-3-methyl-1 ,3-dihydro- imidazo(4,5-c]quinolin-2-one;
i-CI-Ethyl-S-methyl-I H-pyrazoM-yO-S^β-fluoro-δ-methylamino-pyπdin-S-yO-S-methyl-I .S- drhydro-imκiazot415-c]quinolin~2-one;
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(6-fluoro-5-methylamino-pyridin-3-yl)-3-methyl-1 ,3- dihydro-imidazo[4,5-clqυinolin-2~oπe1
8-(5Otmethylamino-6-fluoro-pyπdin-3-yl)-1'(1 >dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3- dihydrθ'imidazo[4,5-c]qυinolin-2-one;
8-(5-Amino-6-chloro-pyrtdin-3-yl)-1 -( 1 -isopropyl-3-methyt- 1 H-pyrazol-4-yl)-3-methyl-1 , 3- dihydrθ'imidazo[4,5-cJqutnolin-2-one,
8-(5-Amino-6-chloro-pyridin-3-yl)-1-(1 ,3-dimethyH H-pyrazol-4-yl)-3-methyl~1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one,
δ-iS-Amiπo-θ'Chloro-pyπdin-S-yO-S-methyl-I^I .S.δ-trimethyl-1H-pyrazoM-yl^i .S-dihydro- imidazo^.S-clquinoli^-one,
δ-lδ-Chloro-δ-ethylarriino-pyπdin-S-yO-S-methyl-I^I .S^-trimethyl-1H-pyrazol^-yO-I .S- dihydro-imidazo[4,5-c]quinolin-2-one;
8-{δ-Chloro-5-ethylaiτiino-pyridin-3-yl)-1-(1 l3-dimethyl-1H-pyrazo!-4-yl)-3-methyl-1 ,3-dihydro- imidazo(4,5~c]quinolm-2-one; δ^β-Chloro-δ-ethylaminoψyridin-S'yO-I^S.δ-dimethyl-isoxazoM-yO-S'methyl-I.S-dihydro- imidazo[4,5-c]quinolin-2-one,
8-(5-Ethylamino-6-flυoro-pyridirv3-yl)-3-methyl-1-(1 ,3,5-trimethyl-1H-pyrazol-4-yl)-1 ,3- dihydro-imidazo[4,5-c]qυinolin-2-one,
i-CS.δ-Dimethyl-isoxazoM-yl^S^δ-ethylamino-β-fluorO'pyridin-S-yO-S-mθthyl-I .S-dihydro- imidazo[4(5-c]cjuino!in-2-one;
1-(1 ,3-Dimethyl-1Hψyrazol^-yl)-8-(5-ethylamino-6-hydroxymethyl'pyridin-3-yl)-3-methyl-1 ,3- dihydro-imidazo(4 , 5-c]quiπolin-2-one;
8-{5-Ethylamino-6-hydroxymethyl-pyridin-3-yl)- 1 -(1 -ethyl-3-methyM H-pyrazol-4-yl)-3-methyl- 1 3~dihydrcHmidazo[4,5«c]quinolin-2-one,
β-Cδ-Ethylamino-€-hydroxyrriethyt-pyridin-S-yO-i ^i-isopropyl-S-methyl-I H-pyrazoM-yO-S- methyl-1 ,3-dihydro-imidazo[4,5-c]quiπolin-2-one;
8-(5-Ethylamino-6-hydroxym€thy)-pyridin-3-yl)-3-methyl- 1 -{ 1 , 3,5-trimethyl- 1 H-pyrazol-4-yl)- 1,3-dihydro-imidazol4,5-c]quinolin-2-one,
1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-8-(5-ethylamino-6-methoxymethyl-pyridin-3-yl)-3-methy1- 1,3-dihydro-imidazo{4,5-c]qυinoNn-2-one,
8-(5-Ethy!amino-6-methoxymethyl-pyrtdin-3-y!)-1-(1 -ethyl-3-methyl-1H-pyrazo!-4-yl)-3-methyl- I .S-dihydro-imidazo^.S-clquinolin^-one,
1 -( 1 , 3-Dimethyl- 1 H-pyrazoJ-4-yl)-8-<6-hydr oxymethyl-5-methylamino-pyπdin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one,
S-Cβ-Hydroxymethyl-S-methylamino-pyπdin-S-yO-i^i-isopropyl-S-methyl-1H-pyrazoM-yO-S- methyl-1 ,3-dihydro-irnidazo[4,5-c]quinolin-2-one;
1 -(3-Chloro-1 -methyl- 1 H-pyrazol-4-yl)-8-(5-hydroxymethyl-5-methylamino-pyridin-3-yl)-3- methyl-1 ,3-dihydro-irrndazo[4,5-c]qutnolin-2-one,
8-(6Ηydroxymethyl-5-m€thylamtno-pyridin'3-yl)-3-methyt-1-(1 (3,5-trimethyl-1H-pyrazol-4-yl)- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one,
i ^i-Ethyl-S-methyl-1H-pyrazol^-yO-β-CΘ-hydroxymethyl-S-methylamino-pyridin-S-yO-S- methyl- 1 ,3-dihydro-imidazo[4,5-cJquinolin-2-one' i-CI .S-Dimethyl-1H-pyrazol^-yO-θ-Cδ-methoxymethyl-S-methylamino-pyriclin-S-yO-S-methyl- 1,3-dihydro-imidazo(4,5~c)quinolin-2~one;
1 -(3-Ch!oro-1 -methyl-1 H-pyrazol-4-yl)-8-(6-methoxymethyl-5-methylamino-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one;
1 -( 1 -Ethyl-3-methyl- 1 H-pyrazo!-4-yl)-8-(δ-methoxymethyl-5-methylaminθ'Pyridin-3-y l)-3- methy I- 1 , 3~dihydro-tmidazo[4 ,5-c)qυinolin-2-one ,
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(6-ethyl-5-ethylamino-pyrid>n-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one;
IKI.S-Dtmethyl-1H-pyrazoM-yO-δ-Cβ-ethyl-S-isopropylaminO'Pyridin-S-yO-S-methyl-I .S- dihydro-imidazo{4,5-c]qumohn-2~one,
1 -( 1 , 3-Dimethyl- 1 H-pyrazof-4-yl)-3-methyl-8-(6-fnethy)-5-methylamino-pyridin-3-yl)- 1 ,3- dihydro-imidazo[4,5-c]qυinolin-2-one,
8-(5-Dimethylamino-6-methyl-pyridin-3-yl)-1K1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro-imidazo|4,5-c]qυinoJin-2-or>e(
i-ii ^-Dimethyl-1H-pyrazoM-yfJ-δ-JS-Cethyl-methyl-aminoJ-e-methyl-pyπdin-S-ylJ-S-methyl- 1 ,3-dihydro-imidazo{4,5-clquinolin-2-one;
8-(6-Amtno-5-ethoxymethyl-pyridin-3-yl)-1-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3- dihydro~imidazo[4,5-cjquinolin-2-one,
S^β^mino-δ-ethoxymethylφyridin-S-yiJ-1-CI-ethyl-S-methyl-1H-pyfazol^-yO-S-methyl-tS- dihydro-imidazo[4,5-c]quinolin-2-one,
S^β-Amino-δ-ethoxymethyl-pyridin-S-yO-1-CI-isopropyl-S-methyl-1H-pyrazoM-yO-S-methyt- 1 , 3-dihydro-imidazo[4 , 5-c]quinolin-2-one,
β^β-Amino-δ-ethoxymethyl-pyridin-S-yO-1-IS-chloro-1-methyl-1H-pyrazoM-ylJ-S-methyl-I .S- dihydro-imidazo[4,5-c]quinolin-2-one;
δ-Cδ-Amino-δ-ethoxymethyl-pyridin-S-yO-S-methyl-I^I .S.δ-trimethyl-1H-pyrazol^-yiJ-I.S- dihydro-imidazo[4,δ-c)quinolin-2-one,
1K1,3-Dimethyl-1H-pyrazot-4-yl)-8-(δ-ethoxymethyl-6-ethylamino-pyndin-3-yl)-3-methyl-1 ,3- dihydro-imidazo[4,5-c]quinolin-2-one, β^e-Amino-S-methoxymethyl-pyridirvS-yO-1-CI-isopropyl^-methyf-I H-pyrazoM-yO-S-methyl- 1 ,3-dihydro-imκiazo[4,δ-cJquinolin-2-one,
δ-Ce'Amino-δ-mettioxymethyl-pyridin-S-yO-1-CI-ethyl-S-methyl-1H-pyrazol-^y^S-methyf-I .S- dihydro-imidazo[4,5-c]quinolin-2-one,
δ-Cδ-Amino-S-methoxymethyl-pyridin-S-yiJ-1-tS-chloro-1-methyl-1H-pyrazol^-yO-S-methyl- 1 ,3-dihydro-imκ3azo[4,5-c)quinolin-2-one,
β-Ce-Amirrø-S-hydroxymethyl-pyridin-S-yO-i^i-isopropyl-S-methyl-1H-pyrazol^-yO-S-methyl- 1 ,3-dihydroHmidazo[4,5-c]quinolin-2-one;
8K6-Amino-5-hydroxymethyl-pyridin-3-yl)-3-methyl-1-(1,3,5-trifnethyl-1H-pyra2Ol-4-yl)-1,3- dihydro-imidazo[4,5-c]quinolin-2-one;
β-Cβ-Amino-S-hydfOxymethyl-pyridin-S-yO-I^S-chloro-i -methyl-1H-pyrazoM-yl^S-methyl-I .S- dihydrθ'imidazo[4>5-cJquinolin-2-one1
1 -( 1 -lsopropyl-3-methyl-1 H-pyrazoM-yl)-3-methyl-8-( 1 -methyl-2-oxo- 1 ,4-dihydro-2H- pyridoI∑.S-dJli .Sloxazin-β-yO-I .S-dihydro-imidazoH.δ-cJqυinolin^-one,
δ-(5-Hydroxyrr>ethyl-6-methylamino-pyndin-3-yl)-1-(1-isopropyl-3-methyl-1 H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c|quiπol!n-2-one,
δ-(5-Cyclobυtylamino-pyrid!n-3-y I)- 1 -( 1 , 3-dimethyl- 1 H-pyrazot-4-yi)-3-methy!- 1 , 3-dthydro- imidazo[4, 5-c}quinolin-2-one:
H1 ,3-Dimethyl-1H-pyrazol-4-yl)-δ-[δ-(isopropyl-methyl-amino)-pyridin-3-yl}-3-methyl-1 ,3- dihydro-irnidazo[4,5-c]qυinolin-2-one;
8>[5-(Cyclobutyl-methyl-amino)-pyridin-3-yl]-1 -(1 ,3-dimethyl-i H~pyrazol-4-yl)-3-methyl-1 ,3- dihydrθ'imidazo[4,5-c)qυinolin-2-one,
i-li.S-Dimethyl-I H-pyrazoM-yO-S-methyl-δ-CS-morpholin^-yl-pyridin-S-yO-I .S-dihydro- tmidazo[4,5-c)qυinolin-2-one;
1-(2l5-Dimethy!-2H-pyrazot-3-yi)-3-methyl-8-(δ-morphoJin-4-yl-pyridin-3-yl)-t3-dihydro- imidazo[4,5-c]quinolin-2-one,
1 -(1 -{2-Hydroxy-ethyl)-3-methyl- 1 H-pyrazot-4«yl]-3-methyl-8-(5-morpholin-4-yl-pyπdtn-3-y I)- 1 ,3-dihydro-imtdazo{4,5-c)quinolin-2-one, I^I.S-Dimethyt-1H-pyrazoM-yO-δ-tS^ethyl-methyl-aminoJ-pyridin-S-ytJ-S-methyl-I .S-dihyc.ro- imidazo[4,5-c]quinofin-2-one,
1-(1 3-Dimethyl-1 H-pyrazol-4-yl)-8-(5-isopropylamino-pyπdin-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one;
δ^δ-lsopropylamino-pyπdin-S-yO-1-ti-CS-methoxy-ethyO-S.δ-dimethyl-1H-pyrazoM-ylj-S- methyl-1 ,3-dihydro-imidazo{4,5-c]quinolin-2-onef
8-(5-Dimethylamino-pyπdin-3-yl)- 1 -( 1 , 3-dimethyl-1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro- imidazo[4,5-c)quinoJin-2-one;
δ'CS-Azetidin-1-yl-pyridin-S-yO-I^I .S-dimethyl-I H-pyrazoM-ylJ-S-methyl-I .S-dihydro- imidazoK.δ-cJquinohn^-one-
1 -(1 -Ethyl-3-methyl-1 H-pyrazol~4-yl)-3-methyl-8-(5-methylamino-pyndin-3-yl)-1 ,3-dJhydro- imidazo[4,5-c]quinolin-2-one,
1-(1-lsopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-8-(5-methylamino-pyπdin-3-yl)-1 3- dihydro-imidazo[4,5-c]quinolin-2-one,
1 -( 1 , 3-Dimethyl-1 H-pyrazol-4-yl)-8-[5-(2-fluoro-ethoxy)-pyridin-3-ylJ-3-methyl-1 , 3-dihydro- imidazoKδ-ctøuinolir^-one;
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-f5'(2-fiuoro-1-fluoromeUiyl-ethoxy)-pyπdin-3-yl]-3-methyl- 1 ,3-dihydro-imidazo{4,5-c]quinol!n-2-one;
8-(5-Diflυoromethoxy-pyriditv3-yl)- 1 -( 1 3-dimethyl- 1 H-pyτazol-4-yl)-3-methyl- 1 , 3-dihydro- imidazo[4,5-c)quinolin-2-one,
i-CI.S-Dimethyl-1H-pyrazoM-yO-β^S-m€thoxy-θ-methyl-pyπdin-S-yO-S-methyl-I .S-dihydro- imidazo[4,5-c]quinolin-2-one;
i-CI .S-Dimethyl-1H-pyrazol^-yl^β^S-hydroxy-θ-methyl-pyndin-S-yO-S-methyl-I .S-dihydro- imidazo[4 5-c)quinolin-2-one;
1-(2,5-Dimethyl-2H-pyra2θ!-3-yl)-8-(5-hydroxy-6-methyl-pyridin-3-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]qυinolin-2-one,
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(6-ethyl-5-isopropoxy-pyπdin-3-y!)-3-methyl-1 ,3-dihydro- imidazo[4,5-c)qυinolin-2-one, 1-(1 ,3-DimethyM H-pyrazol-4-yl)-8-(5-ethoxy-6-ethyl-pyπdin-3-yl)-3-methyt-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one,
1 -( 1 , 3-Dimethyl-1 H-pyrazo(-4-yi)-8-(6-ethy!-5-hydroxy-pyridin-3-yl)-3-methyl- 1 , 3-dihydro- imtdazot4 , 5-c)quinolin-2-one:
1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-(2-fIuoro-1-fluoromethyl-ethoxy)-6-methyl-pyridin-3-yl]- S-metbyl-I.S-dihydro-imidazo^.δ-ctøuinolin^-one,
1-(1 ,3-DimetbyM H-pyrazol-4-yl)-8-(6-hydroxymethyl-5nsopropoxy-pyndin-3-yl)-3-methyl-1 ,3- dihydroHmidazo(4,5-c}qυinolin-2-αnβ;
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-tsopropoxy-6-methoxymethyl-pyπdirv3-yl)-3-methyl- 1 ,3-dihydro»imidazo[4,5-c]quinolin-2-one;
1 -(1 -Ethyl-3-methyl-1 H-pyrazol-4-yl)-8-(5-isopropoxy-6-methoxymethyl-pyridin-3-yl)-3-methyl- I.S-dihydro-imk-az^.S-clquinolin^-one,
1-{1 ,3-Dimethy(-1H-pyrazol-4-y!)-8-[5-(2-fluoro-1-fluoromethyl-ethoxy>-6-hydroxymethyl- pyridin-3-yl]-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one,
1-(1 3-Dimethyl-1H-pyrazol-4-yl)-8-(6-hydroxymethyl-5-mettioxy-pyfidin-3-yO-3-methyl-1 ,3- dihydro-imidazoI4,5-c]quinolin-2-one,
8-(6-Hydroxymethyl-5-methoxy*pyridii>3-y!)-1 -(1 -isopropyl-3-methyl-1 H-pyrazol-4-yl)-3- mβthyl-1 ,3-dihydro-imidazo[4,5-c)quinoHn-2-one,
i-CS-Chloro-i -methyl-1H-pyrazoM-yO-δ-fβ^ydroxymethyl-S-methoxy-pyπdin^-yO-S-methyl- 1,3-dihydroHmidazo[4,5-c]quinolin-2-one;
1 -{ 1 3-Dimethyl- 1 H-pyrazol-4-yt)-8-(5-melhoxy-6-methoxymethyl-pyπdin-3-yl)-3-methyl- 1 ,3- dihydro-imidazo[4,5-c]quinolin-2-one,
1 -( 1 -lsopropyl-3-methyl- 1 H-pyrazol-4-yl)-8-(5-methoxy-6-methoxymethyl-pyridin-3-yl)-3- mβthyl-1 >3-dihydro-imidazot4,5-c]qυinolin-2-one;
1-(1-Ethyl-3-methyl-1Hψyrazol-4-yl)-8-(5-methoxy-6-methoxymethyl-pyπdin-3-yl)-3-methyl' 1 ,3-dihydro-imidazo[4,5-c]qυinolin-2-one;
1-(3-Chloro-1-methyl-1H-pyrazoM-yl)-8-(5-methoxy-6-methoxymethyl-pyndin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one, 1 -(3-Chloro-1 -methyl- 1 H-pyrazol-4-yl)-8-(6-ethoxymethy)-5-methoxy-pyridin-3-yl)-3-methyl- 1 , 3-dihydro*imidazo[4 , 5-cJquinolin-2-one,
1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-8-(6-ethoxymethyl-5-methoxy-pyridin-3-yl)-3-methyl- 1 ,3- dihydro-imidazo[4,5-c}quinolin-2-one,
1-(1 3-Dimethyl-1H-pyrazol-4-yl)-8K5^thoxy-6-methoxymethyl-pyridin-3-yl)-3-methy)-1,3- dihydro-imidazo[4 5-c]quinolin-2-one;
8-(5-Ethoxy-6-methoxymethyl-pyndin-3-yl)- 1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl- 1 ,3-dihydro-imidazo(4,5-c)qυinolin-2-one;
^(I .S-Dimethyl-1H-pyrazoM-ylJ-δ-iS-ethoxy-θ-tπcl€uteromethoxymethyl-pyridin-S-yO-S- methyl-1,3-dihydro-imidazo(4,5-c]qυinolin-2-Dπe,
HS-Chioro-1-methyl-I H-pyrazol^-yO-β-iδ-methoxy-θ-trideuteromethoxymethyl-pyndin-S-yl)- 3~methyM ,3-d(hydro-imidazo(4,5-c]quinolin-2-one,
^(S-ChlorO'l-methyl-1H-pyrazoM-ylVΘ-Cδ-hydfoxymethyl-β-methoxy-pyridin-S-yO-S-methyl- I .S-dihydro-imidaz^.δ-cJquinohn^-one,
1-(3-Chloro-1-methyl-1H-pyra2θl-4-yl)-8-(6-methoxy-5-methoxymethyl-pyridin-3-yl)-3-methyl- 1 ,3-dihydro-imidazo[4,5-c3quinolin-2-one;
I^I .S-Dimethyl-1H-pyrazoM-yO-δ^δ-methoxy-δ-methoxymethyl-pyπdin-S-yO-S-methyt-I .S- dihydro-imidazo{4,5-c]qυinol!n-2-one;
I^S-ChlorO'l-methyl-1H-pyrazol^-yO-β^e-methoxymethyl-pyπdin-S-yiJ-S-methyl-I .S-dihydro- imidazo[4,5-c}quinolin-2-one
8-(5,6-Dimethoxy-pyπdin-3-yl)-1-(1 ,3-dimethyHH-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo(4,5-c]quinoliiv2-one,
1 -[1 -{2-Azetidin- 1 -yl-2-oxo-ethyl)-3-methyl- 1 H-pyrazol-4-yl]-8-(5-isopropoxy-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4,5-c]qυinolin-2-one,
1-(13-Dimethyl-1H-pyrazol-4-yl)-8-(6-ethytamino-5-methoxymethyl-pyridin-3-yl)-3-met)iyl- 1 ,3-dihydro-imidazo(4,5-c)quinolin-2~one;
8-(6-Ethylamin<>5-methoxymethyl-pyπdin-3-yl)-3-methyl-1-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one, 8-(2-Dtm8thylamino-pyrimidin-5-yl)-1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-1 ,3-dihydro-imidazo[4,5- cjquinolii>2-one
S-Cδ-Amino-δ-ethyl-pyπdin-a-yO-i'CI .S-dimethyl-1H-pyrazoU-yO-S-methyl-I .S-dihydro- imidazo[4,5-c]quinolin-2-one,
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-(6-θthyt-5-nitro-pyπdin-3-yl)-3-methyl-1 ,3-dthydro- imidazo[4,5-c]quinolin-2-one,
1-(1 3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(4-methyl-3,4-dihydro-2H-pyrido[3,2- b}(1 ,4}oxa2in-7-yl)-1 3-dfhydro-imidazo[4,5-c)quinolin-2-one
8-(5-Ethylamino-6-methyl-pyridin-3-yl)- 1 -[1 -(2-hydroxy-ethyl)-3 5-dimethyl-1 H-pyrazol-4-y!]-3- methyl-1 ,3-dihydro-imidazo|4,5-c]qυinol)n-2-one,
1-[1-(2-Hydroxy-ethyl)-3-methyl-1H-pyrazoJ-4-yl]-8-(5-methoxy-6-methyl-pyridin-3-yl)-3- methyf-1 ,3-dihydro-imtdazo(4 5-c)quinolin-2-one,
8-(5-Ethoxy-6-methy!-pyndin-3-yl)-1-(1-(2-hydroxy-ethyl)-3-methyl-1H-pyrazol-4-yi]-3-methyl- 1 , 3-dihydro-imidazo[4 , 5-c]quinolin-2-one,
1-(1 3-Dimethyl-1H-pyrazol-4-yl)-8-[6-((R)-3-hydroxy-pyrrolKJin-1'yl)-pyridin-3-yl]-3-fnethyl- 1,3-dihydro-imidazo(4,5-c]quinolin-2-one,
1-(1 ,3-Dimethyl-1H-pyra2ol-4-yl)-8-(6-((S)-3-hydroxy-pyrrolKiin-1-yl)-pyndin-3-yl]-3-methyl- 1 ,3-dihydro-imidazo(4,5-c)quinoNn-2-one,
1-(1 3-Dimethyl-1H-pyrazot-4-yl)-8-[6-((R)-3-methoxy-pyrro!idin-1-yl5-pyri<.in-3-yl]-3-methyl- 1 , 3-dihydro-imidazo[4 , 5-c]quinolin-2-one
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-8-[6-((S)-3-methoxy-pyrro)idin-1-yl)-pyridin-3-yl]-3«methyl- 1 3-dihydro-imidazo[4,5-c]quinolin-2-orve,
I^I .S-Dimethyl-1H-pyrazoM-yO-S-methyl-S-lδ-Ctetrahydro-pyran^-ylaminoJ-pyridin-S'ylj-I .S- dihydro-imidazo[4,5-c]quinolin-2-one,
8-[5-(1-Hydroxy-1-methyl-ethyl)-pyridin-3-yl]-1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3- methyl-1 ,3-dihydro-imidazo(4 5-c]quinolin-2-oπe
1 -( 1 , 3-Dinnethyf- 1 H-pyrazol-4-yl)-8-[5-( 1 -hydroxy- 1 ~methyl-ethyl)-pyπdin-3-ylJ-3-methyl- 1 ,3- dihydro-imidazo[4,5-c]quinolin-2-one, 1-(3-Chioro-1-methy)-1H-pyrazol-4-yl)-8-[5^1-hydroxy-1-methyl-eihy1)-pyridin-3-yl]-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one,
1 -(1 ~Ethyl-3-methyl-1 H-pyrazol*4-yl)-8-(5-(1 -hydroxy- 1 -methyl-ethyl)-pyπdin-3-yl]-3-methyl- 1 ,3-dihydro-imida2θt4,5-c)qυinolin-2-one,
1 -( 1 , 3-Dimethyl-1 H-pyrazol-4-yl)-8-[5-( 1 -ethyl- 1 -hydroxy-propyl)-pyridin-3-yl]-3-methyl-1 , 3- dihydro-imidazo(4,5-c]quinolin-2-one;
(rac)-1 -( 1 , 3-Dimethyl- 1 H-pyrazoM-yi)-8-[5-( 1 -hydroxy-ethyl)-pyndm-3-yl]-3-methyl- 1 ,3- dihydro-tmtdazo{4 , 5~c]quinolin-2-one ,
1 -(1 ,3-Dimethyl-1 H-pyrazol-4-yl)-8-(5-(1 -hydroxy-cyciopentyO-pyridin-S-yll-S-methyl-i ,3- dfhydro-imidazo[4,5-c)qmnolin-2-one,
8-[5-(2-Fluoro-1-flυoromethyl-1 'hydroxy-ethyl)-pyf!din-3-yl]-1'(1-isopropyi-3-methyl-1 H- pyrazol-4-yl)-3-methyl- 1 , 3-dlhydro-imidazo(4, 5-c]quinotin-2-one,
2-{5-[1-(1,3-Dimethyl-1H-pyrazot-4-yl)-3-methyl-2-oxo-2,3"dihydro-1 H-imidazo[4,5-c)qυinolin- 8-yl)-pyπdfn-3-yl}-2-methyl-propionitrile)
2-{5-[1-(1-Ethyl-3-methy(-1H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5- c]quinolin-8-yll-pyπdin-3-yl}-2-methyl-prop)on)trile,
2-{5-[1-{3"Chloro-1-methyl-1H-pyrazoi-4-yl)-3-methyl-2-oxo-2)3-dihydro-1H-!midazo{4(5- c)quinolin-8-yl]-pyπdin-3-yl}-2-methyl-propion)trile,
1 -{5-[ 1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-3~methyl-2-oxo-2, 3-d)hydro- 1 H-imidazo[4, 5-cJquinolin- 8-yl]-pyπdin-3-yl}-cyclobutanecarbofntπle,
H5-{1 -(1 -Ethyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo[4.5- c)quinolin-8-yl]-pyndin-3-yl}-cyclobutanecarbonitπle,
N-{2-Chloro-5-[1-(1,3-dimethyl-1H-pyrazoM-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5- clquinolin-δ-yll-pyπdin-S-ylV-acetamide,
N-{2-Chloro-5-[1 -(1 ,3-dimethyl- 1 H-pyrazoM-yl)-3-methyl-2-oxo-2 ,3-dihydro-i H-imidazo[4 , 5- c]quinolin-8-yl]-pyπdin-3-yl}-methanesulfonamide,
2'Amino-5-|;i-(1 ,3-dimethyl-1H-pyrazo)-4-yl)-3-methyl-2-oxo-2,3-dihydro-1 H-imidazo[4>5- cJquinolin-δ-ylJ-N-methyl-nicotinamide, 2-Amino-5-[1 -( 1 -isopropy{-3-methyl-1 H-pyrazol-4-yi)-3-methyl-2-oxo-2 ,3-dihydro-1 H- imidazo[4,5-c}quinolin-8-y(l-N-methyl-nicottnamide,
2-Amino-5-{1 -(1 ,3~dimethyl-1 H-pyrazoI-4-yl)-3-metbyl-2-oxo-2,3-dihydro-1 H-im!dazo(4,5- cJquinolin-δ-ylj-N-tsopropyl-nicotinamide,
2-Amino-5-[1-(1 t3-dimethyl-1H-pyrazol-4-y1)-3-methyl-2-oxo-2,3-dihydro-1H-imidazoi4,5- c]quinolin-8-yl]-N-(2-methoxy-ethyl)-nicottnamide;
2-Amino-N-ethyl-5-{1-(1-isopropyl-3-methyl-1H-pyrazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H- imidazo(4,5-c]quinolifv8-yl)-nicotinamide;
2-{5-[ 1 -( 1 ,3-Dimethyl- 1 H-pyrazol-4-yl)-3-methyl-2-oxo-2, 3-dihydro- 1 H'imidazo[4, 5-c)quino!in- 8-yl]-pyπdin-3-y!}-N-methyl-acetamide;
1 -( 1 , 3-Dimethyl- 1 H-pyrazol«4-yl)-8-[5-{2-hydroxy- 1 , 1 -ditnethyl-ethyl)-pyπdin~3-ylJ-3-methyl- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one;
2-{5-[1 -(1 ,3-Dimethyl-1 H-pyrazoM-yl)-3-methyl-2-oxo-2,3-dihydro-1 H~imidazo[4,5-c]quinolin- 8-yl]-pyridin-3-yl}-2-methyl-propionic acid methyl ester,
8-(5-Aminomethyl-pyridin-3-yl)-1 -(1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one,
N-{5-[ 1 -( 1 , 3-Dimβthyl-1 H-pyrazol-4-yl)-3-methyl-2-oxo-2, 3-dihydro- 1 H-imidazo[4 ,5-c]qυinolirv δ-ylJ-pyπdin-S-ylmethylJ-acetamide,
8-(5-Aminomethyl-pyπdin-3-yl)-1-(1 ,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1 ,3-dihydro- imidazo(4,5-c]quinolin-2-one,
1 -( 1 , 3-DimethyM H-pyrazol-4-yl)-3-mβthyl-8-( 1 ,3, 3-trimethyl-2-oxo-2 , 3-dihydro- 1 H- pyrfθlo{2,3-b)pyridin-5-yl)-1 ,3-dihydro-imfdazo(4,5-c]quinolin-2-one,
8-(2,4-Dimethoxy-pynmidin-5-yl)-1 -( 1 -ethyl-3-methyl-1 H-pyrazol-4-yl)-3-methyl- 1 , 3-dihydro- imidazo^.δ-cjquiπolin^-one1
8-(2,4-Dimethoxy-pyrimidin*5~yl)-1-(1,3-dimethyI-1H-pyrazol-4-yl)-3-methyl-1 , 3-dihydro- imidazo[4,5-c]quinolin-2-oπe;
8-(2l4-Dimethoxy-pyrimidin-5-yl)-1-(iHSopropyl-3~methyl-1 H-pyrazo)-4-yl)-3-methyl-1 )3- dihydro-imidazo{4,5-c]quinolin-2-one 8-(2,4Oimethoxy-pyrimidin-5-yl)-1-(2,5-dimethyl-2Hψyrazol-3-yl)-3-methyl-1,3-dihydro- imidazo^.δ-cjquinoliri^-one,
1-(1 ,3-Dimethyl-1H-pyrazot-4-yl)-8-(2-ethylaniino-4-methoxy-pyrirnidin-5-yl)-3-methyl-1 ,3- dihydro-imida2θ[4,5-c]quinolin-2-one,
1-(1-Ethyl-3-methyl-1Hψyrazol-4-y1)-8-(4-methoxy'2-methylamino--pyrimldin-5-yl)-3-methyl' 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one,
1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(1-ethyl-2-oxo-1,4-dihydro-2H-pyrido[3,2-d](1 3]oxazin-7- yl)-3-methyl-1 ,3-dihydro-imidazo[4,5-c]quino)in-2-one,
δ-Cδ-Chloro-β-hydroxymethyl-pyπdtn-S-yO-1-fi ^-dimethyl-1H-pyrazoM-yO-S-methyl-I .S- dihydro-imκlazo(4)5-clquinolin-2One;
1-(1 ,3-Dimethy!-1 H-pyrazd^-yl)-8-(5-(1"methoxy-1-methyl-ethyl)-pyridin-3-ylJ-3-methyl-1 ,3- dihydro-imidazo[4,5-c]quinolin-2-one;
I^I.S-Dimethyt-1H-pyrazoM-yO-δ-tδ-CI-ethoxy-1-methyl-ethyO-pyridin-S-yll-S-methyl-I .S- dihydro-imidazo[4,5-clquinolin-2-one,
1 -( 1 -isopropyl-3-methyl- 1 H-pyrazol-4-yl)-3-methyl-8-{6-(methylamino)pyridin-3-yl)- 1 H- imidazo[4,5-c}qυinoline-2(3H)-thione,
S-fi-dS-Dimethyl-1H-pyrazoM-yO-S-methyl-a-oxo^.S-dihydro-1H-imidazo^.δ-φuinolin-δ- yi]-N-ethyl-2-mβthylamino-nicoUnamide,
N-Ethyl-2-methylamifK)-5-[3HT)ethyl-2-oxo-1-(1,3,5-trimethyl-1H-pyrazo!-4-y!)-2,3-dihydro-1H- imidazoH.δ-cIqυinotin-δ-yll-nicotinaniidβ,
1 -( 1 , 3-Dimethyl- 1 H-pyrazol-4-yl)-δ-(5-ethoxy-6-hydroxymethyl-pyridin-3-yl)-3-methyl- 1 , 3- dihydro-imidazo[4,5-c]quinolin-2'θne,
1-(1 ,3-Dimethyl-1H-pyrazol-4-yl)-δ-[6-hydroxymethyl-5-(2-methoxy-ethoxy)-pyπdin-3-yl)-3- methyl- 1 ,3-dihydro-imidazo(4,5-c]quinolii>2-one(
δ-(5-Amino-pyridin-3-yl)-1 -{1 ,3-dimethyl-1 H-pyrazol-4-yl)-3-ethyl-1 3-dihydro-imidazo[4,5- c]quinohn-2-one;
3-A!lyl-8-(5-amino-pyridin-3-yl)-1-(1 ,3-dimethyl-1H"Pyrazol-4-yj)-1 ,3-d!hydro-imidazo{4,5- c]qυinotin-2-one, N,N-Diethyl-2-{3-methy!4-{3-methyl-2-oxo-8-(2ψyrrotidin-1-yl-pyrimidin-5-yl)-2l3-clihydro- imidazo(4 ,5-c]qυ(nolin- 1 -yl]-pyrazol- 1 -yl}-acetamide,
{3-Methyl-4-[3-methyl-2-oxo-8-(2-pyrrol)d)n-1-yl-pyrimidin-5-yI)-2,3-dihydro-imidazo(4,5- c]qυino!in-1-yl}-pyrazol-1-yl}-acetic acid;
1-π-(2-Azetidin-1-yl-2-oxo-ethyl)-3-methyl-1H-pyrazol-4-yl]-3-methyl-8-(2-pyrrolidin-1-yl- pyrimtdin-5-yl)-1 ,3-dihydro-imidazo(4,5-c]quinolin-2-one;
3-Methyl-1-[3-methyl-1-(2-morpholin-4-yl-2-oxo-ethyl)-1H-pyrazo)-4-yl]-8-(2'pyrrolidin-1-yl- pyrimidin-5-yl)-1 , 3-dihydro-imidazo[4 , 5-c]quinolin~2-one;
3-Methyl-1-[3-methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)>1H-pyrazc^-4-ylJ-8-(2-pyrrolidin-1 -yl- pyπmidin-5-yl)-1 ,3-dihydro-imidazo[4,5-c)quinolin-2-one,
3-Methyl- 1 -{3-methyl- 1 -{2-(4-methyl-p«perazin- 1 -yl)-2-oxo-ethyl)- 1 H-pyra20l-4-yl}-8-(2- pyrrdidin-1-yl-pyπmidin-S-yO-I .S-dihydro-imidazoH.S-cJqυinolin-Σ-one;
1 -( 1 -lsopropyl-3-methyl- 1 H-pyrazol-4-yl)-8-(5-methoxymethyl-6-methylamino-pyridin-3-yl)-3- methyl-1 ,3-dihydro-imidazo[4.5-c]quinolin-2-one;
1 -( 1 -Ethyl-3-methyl- 1 H-pyrazol-4-y1)-8-(5-methoxymethyl-6-methylamino-pyridin-3-yl)-3- methyl- 1 , 3-dihydro-imidazo[4, S-cJquinolin-2-one;
1 -(1 3-DimethyM H-pyrazol-4-yl)-8-(5-methoxymethyf-6-methylamino-pyπdin-3-yl)-3-nr>ethyl- 1 ,3-dihydro-imidazo[4,5-c)qumolin-2-one;
1-(3^hloro-1-methyl-1 H-pyrazol-4-yl)-8-{5-methoxymethy!-6-methylamino-pyπdin-3-yl)-3- methyl-I .S-dihydro-imidazo^.δ-cJquinolin^-one,
8-(5-Methoxymethyl-6-mθthylamino-pyridin-3-yl)-3-methyl-1 -(1 ,3,5-tπmethyl-1 H-pyrazol-4-yl)- 1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one;
8-(3,4"dimethoxy-phenyl)-1-(1 ,3-dimettiyl-1 H-pyrazol-4-yl)-1 ,3-dihydro-1 ,3,5,9-tetraaza- cyclopenta[a]naphthalen-2-one;
β-CS^-Dimethoxy-phenyO-1-dS-dimethyl-1H-pyrazoM-yO-S-methyl-tS-dihydro-I .S.S.Θ- tetraaza-cyclopenta{a]naphthalen-2-oπe,
8-(3,4-Dimethoxy-phenyl)- 1 -( 1 , 3-dimethyl- 1 H-pyrazol-4-yl)-3-ethyl- 1 ,3-dihydro- 1.3,5 9- tetraaza-cyclopenta[alnaphthalen-2-one, δ^a.ΦDimethoxy-phθnyO-1-Ca.δ-dimethyl-aH-pyrazol-S-yO-tS-dihydro-I.S^.Θ-tetraaza- cyclopenta[a]naph(halen-2-one,
8-(3,4-Dimethoxy-phenyl)-1-(2,5-climethyl-2H-pyrazol-3-y})-3-methy|.1 ,3-clihydro-1.3,5,9- tetraaza-cyclopenta[a}naphthalen-2-one;
δ^S^-Dimethoxy-phenyO-1-CI-ethyl-S-methyl-I H-pyrazoM-yO-S-methyl-I .S-dihydro-I .S^.Θ- tetraaza-cyclopenta{a]naphthalen-2-one,
or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof
9. A pharmaceutical composition comprising a compound of formula (I), according to any of Claims 1 to 8, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and optionally a further therapeutic agent, together with a pharmaceutically acceptable carrier.
10 A compound of the formula (I)1 according to any one of Claims 1 to 8, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for use in the treatment of the animal or human body
1 1. Use of a compound of formula (I), according to any one of Claims 1 to 8, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for the preparation of a pharmaceutical composition for use in the treatment of a lipid and/or protein kinase dependent disease.
12 A method of treatment of a disease that responds to inhibition of a lipid and/or protein kinase, which comprises administering a prophylactically or therapeutically effective amount of a compound of formula (I) according to any one of Claims 1 to 8, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, to a warm-blooded animal in need of such treatment
13 A compound for use according to Claim 10, or the use of a compound according to claim 11 , or a method of treatment according to claim 12, wherein said use, treatment or administration is by topical application,
14 A compound for use according to Claim 10, or the use of a compound according to claim 11 , or a method of treatment according to claim 12, wherein the lipid kinase dependent disease is preferably one dependent on a Class I PI3K and the protein kinase dependent disease is preferably dependent on a Class IV PI3K, 15 A compound for use according to Claim 10, or the use of a compound according to claim 11 , or a method of treatment according to claim 12, wherein the lipid kinase dependent disease is dependent on a Class I PI3K selected from the group consisting of PI3Kalpha, PI3Kbeta, PI3Kdelta PI3Kgamma and the protein kinase dependent disease is dependent on a Class IV PI3K which is mTOR
16 A compound for use according to Claim 10, or the use of a compound according to claim 11 , or a method of treatment according to claim 12, wherein the disease is a proliferative disease, a benign or malignant tumor, a carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovanes, colon, rectum, prostate, pancreas, lung, vagina or thyroid, sarcoma, glioblastomas, multiple myeloma or gastrointestinal cancer, colon carcinoma or colorectal adenoma or a tumor of the neck or head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, lymphomas, a mammary carcinoma or a leukemia, Cowden syndrome, Lhermitte-Dudos disease or Bannayan-Zonana syndrome, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, a benign hyperproliferative sktn disorder caused by inflammation, such as psoriasis or as a result of dysregulation of fibroblasts such as skin fibrosis, scleroderma or keloids
17 A compound of the formula (I), according to any one of Claims 1 to 8, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for use, by topical administration, for the treatment of a disease selected from basal cell carcinoma, squamous cell carcinoma, actinic keratosis, a hyperproliferative skin disorder caused by inflammation, such as psoriasis or as a result of dysregulation of fibroblasts such as skin fibrosis, scleroderma or keloids.
PCT/EP2010/057719 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES WO2010139731A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
UAA201114398A UA106074C2 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
SG2011085487A SG176572A1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
MX2011012943A MX2011012943A (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES.
KR1020127000098A KR101445458B1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
AU2010255727A AU2010255727B2 (en) 2009-06-04 2010-06-02 1H-imidazo[4,5-c]quinolinone derivatives
EP10721029A EP2438064A1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
JP2012513613A JP5596137B2 (en) 2009-06-04 2010-06-02 1H-imidazo [4,5-c] quinolinone derivative
NZ596487A NZ596487A (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
BRPI1010621A BRPI1010621A2 (en) 2009-06-04 2010-06-02 imidazoquinolinones derivative, their pharmaceutical composition and their use
CN201080034616.0A CN102574845B (en) 2009-06-04 2010-06-02 1H-imidazo [4,5-c] qualone derivative
CA2763821A CA2763821A1 (en) 2009-06-04 2010-06-02 1h-imidazo[4,5-c]quinolinone derivatives
EA201101704A EA020715B1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
MA34404A MA33332B1 (en) 2009-06-04 2010-06-02 Derivatives 1h imidazo [4,5- c] quinolinone
IL216452A IL216452A0 (en) 2009-06-04 2011-11-17 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
ZA2011/08439A ZA201108439B (en) 2009-06-04 2011-11-17 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
CU2011000221A CU24064B1 (en) 2009-06-04 2011-11-30 DERIVATIVES OF 1H-IMIDAZO- [4,5-C] -QUINOLINONA
TNP2011000626A TN2011000626A1 (en) 2009-06-04 2011-12-05 1h-imidazo[4,5-c]quinolinone derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04
US61/184,141 2009-06-04

Publications (1)

Publication Number Publication Date
WO2010139731A1 true WO2010139731A1 (en) 2010-12-09

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/057719 WO2010139731A1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Country Status (30)

Country Link
US (2) US8476294B2 (en)
EP (1) EP2438064A1 (en)
JP (1) JP5596137B2 (en)
KR (1) KR101445458B1 (en)
CN (1) CN102574845B (en)
AR (1) AR076949A1 (en)
AU (1) AU2010255727B2 (en)
BR (1) BRPI1010621A2 (en)
CA (1) CA2763821A1 (en)
CL (1) CL2011003052A1 (en)
CO (1) CO6470887A2 (en)
CR (1) CR20110608A (en)
CU (1) CU24064B1 (en)
DO (1) DOP2011000373A (en)
EA (1) EA020715B1 (en)
EC (1) ECSP11011500A (en)
GE (1) GEP20156267B (en)
IL (1) IL216452A0 (en)
MA (1) MA33332B1 (en)
MX (1) MX2011012943A (en)
NI (1) NI201100209A (en)
NZ (1) NZ596487A (en)
PE (1) PE20120224A1 (en)
SG (1) SG176572A1 (en)
TN (1) TN2011000626A1 (en)
TW (1) TWI464168B (en)
UA (1) UA106074C2 (en)
UY (1) UY32682A (en)
WO (1) WO2010139731A1 (en)
ZA (1) ZA201108439B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012077031A1 (en) * 2010-12-06 2012-06-14 Piramal Life Sciences Limited Substituted imidazoquinoline derivatives
WO2012097039A1 (en) 2011-01-14 2012-07-19 Eli Lilly And Company Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
WO2014172190A1 (en) 2013-04-15 2014-10-23 E. I. Du Pont De Nemours And Company Fungicidal amides
JP2014533661A (en) * 2011-11-17 2014-12-15 山▲東▼▲軒▼竹医▲葯▼科技有限公司 Tricyclic PI3K and / or mTOR inhibitors
WO2015043398A1 (en) 2013-09-30 2015-04-02 上海璎黎药业有限公司 Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
WO2015186056A1 (en) 2014-06-03 2015-12-10 Actelion Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
WO2016155884A1 (en) * 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonyl quinolines and use thereof as atm kinase inhibitors
US20160304510A1 (en) * 2013-11-20 2016-10-20 Beijing Forelandpharma Co. Ltd. Imidazolone derivatives, pharmaceutical compositions and uses thereof
WO2017076898A1 (en) * 2015-11-05 2017-05-11 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US9856255B2 (en) 2015-09-17 2018-01-02 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10189834B2 (en) 2014-05-08 2019-01-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10899695B2 (en) 2017-02-06 2021-01-26 Idorsia Pharmaceuticals Ltd Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
US10988472B2 (en) 2016-10-13 2021-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for blocking transmission of malarial parasite
US11213517B2 (en) 2016-12-16 2022-01-04 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a T-type calcium channel blocker
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (en) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN105531348B (en) * 2013-09-11 2017-11-07 默克专利有限公司 Heterocyclic compound
US10989719B2 (en) * 2013-10-11 2021-04-27 National University Corporation Tokyo Medical And Dental University Methods for treating spinocerebellar ataxia type I using RPA1
JOP20190209A1 (en) * 2017-03-16 2019-09-12 Astrazeneca Ab Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US11919899B2 (en) 2020-09-21 2024-03-05 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097641A2 (en) * 2002-05-21 2003-11-27 Novartis Ag 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
WO2005054238A1 (en) * 2003-11-21 2005-06-16 Novartis Ag 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
WO2006122806A2 (en) * 2005-05-20 2006-11-23 Novartis Ag 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
WO2008103636A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
WO2009013305A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2546117A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
AU2005284835A1 (en) 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
AU2006311871B2 (en) 2005-11-04 2011-03-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
JP5562033B2 (en) 2006-11-20 2014-07-30 ノバルティス アーゲー 2-Methyl-2- [4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo [4,5-c] quinolin-1-yl) -phenyl]- Salt and crystalline form of propionitrile
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
US20110020338A1 (en) 2008-03-26 2011-01-27 Carlos Garcia-Echeverria 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
JP5591809B2 (en) 2008-09-30 2014-09-17 ファイザー・インク Imidazo [1,5] naphthyridine compounds, their use in medicine and compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097641A2 (en) * 2002-05-21 2003-11-27 Novartis Ag 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
WO2005054238A1 (en) * 2003-11-21 2005-06-16 Novartis Ag 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
WO2006122806A2 (en) * 2005-05-20 2006-11-23 Novartis Ag 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
WO2008103636A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
WO2009013305A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
B.T. HENNESSY ET AL.: "Exploiting the PI3K/Akt pathway for cancer drug discovery", NATURE REVIEWS, vol. 4, pages 988 - 1004
BADER ET AL., NATURE REV. CANCER, vol. 5, 2005, pages 921
CANCER CELL, vol. 9, pages 341 - 349
CANTLEY ET AL., CELL, vol. 64, 1991, pages 281
D.M. SABATINI: "mTOR and cancer: insights into a complex relationship", NATURE REVIEWS, vol. 6, pages 729 - 734
ESCOBEDO; WILLIAMS, NATURE, vol. 335, 1988, pages 85
FANTL ET AL., CELL, vol. 69, 1992, pages 413 - 423
FANTL, CELL, vol. 69, 1992, pages 413
FRUMAN ET AL., ANNU REV. BIOCHEM., vol. 67, 1998, pages 481
HENNESSEY, NATURE REV. DRUG DISC., vol. 4, 2005, pages 988 - 1004
K. LNOKI ET AL.: "Disregulation of the TSC-mTOR pathway in human disease", NATURE GENETICS, vol. 37, pages 19 - 24, XP002484968, DOI: doi:10.1038/ng1494
KANG, PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 802
KATSO ET AL., ANNU. REV. CELL DEV. BIOL., vol. 17, 2001, pages 615
KATSO ET AL., ANNU. REV. CELL DEV. BIOL., vol. 17, 2001, pages 615 - 675
PARSONS ET AL., NATURE, vol. 436, 2005, pages 792
SAMUELS ET AL., CANCER CELL, vol. 7, 2005, pages 561 - 573
SAMUELS ET AL., SCIENCE, vol. 304, 2004, pages 554
SARBASSOV ET AL., SCIENCE, vol. 307, 2005, pages 7098
STEPHENS ET AL., CELL, vol. 89, 1997, pages 105
SUIRE ET AL., CURR. BIOL., vol. 15, 2005, pages 566
VANHAESEBROECK ET AL., ANNU. REV. BIOCHEM, vol. 70, 2001, pages 535
VIVANCO; SAWYER, NATURE REV, CANCER, vol. 2, 2002, pages 489

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012077031A1 (en) * 2010-12-06 2012-06-14 Piramal Life Sciences Limited Substituted imidazoquinoline derivatives
JP2014504286A (en) * 2010-12-06 2014-02-20 ピラマル エンタープライジーズ リミテッド Substituted imidazoquinoline derivatives
WO2012097039A1 (en) 2011-01-14 2012-07-19 Eli Lilly And Company Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
US8440829B2 (en) 2011-01-14 2013-05-14 Eli Lilly And Company PI3 kinase/mTOR dual inhibitor
US8658668B2 (en) 2011-01-14 2014-02-25 Eli Lilly And Company PI3 kinase/mTOR dual inhibitor
EP2781520A4 (en) * 2011-11-17 2015-07-08 Xuanzhu Pharma Co Ltd Three-ring pi3k and/or mtor inhibitor
JP2014533661A (en) * 2011-11-17 2014-12-15 山▲東▼▲軒▼竹医▲葯▼科技有限公司 Tricyclic PI3K and / or mTOR inhibitors
US9284315B2 (en) 2011-11-17 2016-03-15 Zuanzhu Pharma Co., Ltd. Three-ring PI3K and/or mTOR inhibitor
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
WO2014172190A1 (en) 2013-04-15 2014-10-23 E. I. Du Pont De Nemours And Company Fungicidal amides
WO2015043398A1 (en) 2013-09-30 2015-04-02 上海璎黎药业有限公司 Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
US10047084B2 (en) * 2013-11-20 2018-08-14 Beijing Forelandpharma Co. Ltd. Imidazolone derivatives, pharmaceutical compositions and uses thereof
US20160304510A1 (en) * 2013-11-20 2016-10-20 Beijing Forelandpharma Co. Ltd. Imidazolone derivatives, pharmaceutical compositions and uses thereof
US10189834B2 (en) 2014-05-08 2019-01-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US9932314B2 (en) 2014-06-03 2018-04-03 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as T-type calcium channel blockers
WO2015186056A1 (en) 2014-06-03 2015-12-10 Actelion Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
US10065929B2 (en) 2014-06-03 2018-09-04 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as T-type calcium channel blockers
US10745399B2 (en) 2015-04-02 2020-08-18 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
RU2743343C2 (en) * 2015-04-02 2021-02-17 Мерк Патент Гмбх Imidazolonyl quinolines and use thereof as kinase atm inhibitors
WO2016155884A1 (en) * 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonyl quinolines and use thereof as atm kinase inhibitors
KR102652052B1 (en) 2015-04-02 2024-03-27 메르크 파텐트 게엠베하 Imidazolonyl quinolines and use thereof as atm kinase inhibitors
KR20170132323A (en) * 2015-04-02 2017-12-01 메르크 파텐트 게엠베하 Imidazolonyl quinolines and use thereof as atm kinase inhibitors
US11608338B2 (en) 2015-04-02 2023-03-21 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
AU2020204241B2 (en) * 2015-04-02 2022-11-17 Merck Patent Gmbh Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
EP3868761A1 (en) 2015-04-02 2021-08-25 Merck Patent GmbH Imidazolonylchinolines and their use as atm kinase inhibitors
US10457677B2 (en) 2015-04-02 2019-10-29 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
EP3560924A1 (en) 2015-04-02 2019-10-30 Merck Patent GmbH Imidazolonyl quinolines and their use as atm kinase inhibitors
AU2016239270B2 (en) * 2015-04-02 2020-03-26 Merck Patent Gmbh Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
US10975075B2 (en) 2015-04-02 2021-04-13 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
US10882858B2 (en) 2015-09-17 2021-01-05 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
TWI762109B (en) * 2015-09-17 2022-04-21 瑞典商阿斯特捷利康公司 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US9856255B2 (en) 2015-09-17 2018-01-02 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
TWI714631B (en) * 2015-09-17 2021-01-01 瑞典商阿斯特捷利康公司 IMIDAZO[4,5-c]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER
US11613539B2 (en) 2015-09-17 2023-03-28 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
KR102469153B1 (en) 2015-09-17 2022-11-22 아스트라제네카 아베 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
US10457679B2 (en) 2015-09-17 2019-10-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
KR20190112852A (en) * 2015-09-17 2019-10-07 아스트라제네카 아베 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
WO2017076898A1 (en) * 2015-11-05 2017-05-11 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AU2016348620B2 (en) * 2015-11-05 2019-05-02 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN108348515A (en) * 2015-11-05 2018-07-31 阿斯利康(瑞典)有限公司 Imidazo [4,5-c] quinoline-2-ketone compound and their purposes in treating cancer
US10988472B2 (en) 2016-10-13 2021-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for blocking transmission of malarial parasite
US11753408B2 (en) 2016-10-13 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for blocking transmission of malarial parasite
US11213517B2 (en) 2016-12-16 2022-01-04 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a T-type calcium channel blocker
US10899695B2 (en) 2017-02-06 2021-01-26 Idorsia Pharmaceuticals Ltd Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors

Also Published As

Publication number Publication date
CO6470887A2 (en) 2012-06-29
SG176572A1 (en) 2012-01-30
CU20110221A7 (en) 2012-03-15
BRPI1010621A2 (en) 2016-06-21
US8476294B2 (en) 2013-07-02
TN2011000626A1 (en) 2013-05-24
AU2010255727B2 (en) 2013-02-28
US20100317657A1 (en) 2010-12-16
ECSP11011500A (en) 2012-01-31
JP5596137B2 (en) 2014-09-24
NZ596487A (en) 2012-11-30
CR20110608A (en) 2012-01-16
MA33332B1 (en) 2012-06-01
TWI464168B (en) 2014-12-11
DOP2011000373A (en) 2011-12-31
CU24064B1 (en) 2014-12-26
CN102574845B (en) 2015-09-02
UY32682A (en) 2011-01-31
KR101445458B1 (en) 2014-10-07
JP2012528828A (en) 2012-11-15
UA106074C2 (en) 2014-07-25
PE20120224A1 (en) 2012-04-04
US20140005163A1 (en) 2014-01-02
AR076949A1 (en) 2011-07-20
CA2763821A1 (en) 2010-12-09
MX2011012943A (en) 2012-01-27
TW201102386A (en) 2011-01-16
CL2011003052A1 (en) 2012-08-31
EA020715B1 (en) 2015-01-30
KR20120034710A (en) 2012-04-12
NI201100209A (en) 2012-02-02
AU2010255727A1 (en) 2011-12-08
GEP20156267B (en) 2015-04-14
IL216452A0 (en) 2012-01-31
CN102574845A (en) 2012-07-11
ZA201108439B (en) 2012-08-29
EP2438064A1 (en) 2012-04-11
EA201101704A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
AU2010255727B2 (en) 1H-imidazo[4,5-c]quinolinone derivatives
US20100311714A1 (en) 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
US8188113B2 (en) Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AU2013249041B2 (en) Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an HIV infection
JP6306049B2 (en) Heterobicyclo-substituted- [1,2,4] triazolo [1,5-C] quinazoline-5-amine compounds having A2A antagonist properties
AU2018243770A1 (en) Isoquinolines as inhibitors of HPK1
AU2010249790A1 (en) Benzoxazepines based P13K/mT0R inhibitors against proliferative diseases
TWI601724B (en) Imidazo quinoline derivatives and salts thereof, preparation process and pharmaceutical use thereof
JP7357932B2 (en) Fused cyclic urea derivatives as CRHR2 antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080034616.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10721029

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010255727

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 596487

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: CR2011-000608

Country of ref document: CR

REEP Request for entry into the european phase

Ref document number: 2010721029

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010721029

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2763821

Country of ref document: CA

Ref document number: 9325/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12484

Country of ref document: GE

Ref document number: 2012513613

Country of ref document: JP

Ref document number: 002047-2011

Country of ref document: PE

Ref document number: MX/A/2011/012943

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010255727

Country of ref document: AU

Date of ref document: 20100602

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11170918

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: A201114398

Country of ref document: UA

Ref document number: 201101704

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20127000098

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1010621

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1010621

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111202